PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hahm, KB; Cho, KN; Lee, C; Im, YH; Chang, J; Choi, SG; Sorensen, PHB; Thiele, CJ; Kim, SJ				Hahm, KB; Cho, KN; Lee, C; Im, YH; Chang, J; Choi, SG; Sorensen, PHB; Thiele, CJ; Kim, SJ			Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein	NATURE GENETICS			English	Article							EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; DNA-BINDING; FUSION PROTEIN; ETS-FAMILY; EWS GENE; EXPRESSION; SEQUENCE; CANCER; CELLS	Chromosomal translocations resulting in the expression of chimaeric transcription factors are frequently observed in tumour cells(1), and have been suggested to be a common mechanism in human carcinogenesis. Ewing sarcoma and related peripheral primitive neuroectodermal tumours share recurrent translocations that fuse the gene EWSR1 (formerly EWS) from 22q-12 to FLI1 and genes encoding other ETS transcription factors(2-4) (which bind DNA through the conserved ETS domain(5,6)). It has been shown that transduction of the gene EWSR1-FLI1 (encoding EWS-FLI1 protein) can transform NIH3T3 cells, and that mutants containing a deletion in either the EWS domain or the DNA-binding domain in FLI1 lose this ability(5-8). This indicates that the EWS-FLI1 fusion protein may act as an aberrant transcription factor, but the exact mechanism of oncogenesis remains unknown. Because ETS transcription factors regulate expression of TGFBR2 (encoding the TGF-beta type II receptor, TGF-beta RII; refs 9,14), a putative tumour suppressor gene, we hypothesized that TGFBR2 may be a target of the EWS-FLI1 fusion protein. We show here that embryonic stem (ES) cell lines with the EWSR1-FLI1 fusion have reduced TGF-beta sensitivity, and that fusion-positive ES cells and primary tumours both express low or undetectable levels of TGFBR2 mRNA and protein product. Co-transfection of FLI1 and the TGFBR2 promoter induces promoter activity, whereas EWSR1-FLI1 leads to suppression of TGFBR2 promoter activity and FLI1-induced promoter activity. Introduction of EWSR1-FLI1 into cells lacking the EWSR1-FLI1 fusion suppresses TGF-beta RII expression, whereas antisense to EWSR1-FLI1 in ES cell lines positive for this gene fusion restores TGF-beta RII expression. Furthermore, introduction of normal TGF-beta RII into ES cell lines restores TGF-beta sensitivity and blocks tumorigenicity. Our results implicate TGF-beta RII as a direct target of EWS-FLI1.	NCI, Lab Cell Regulat & Carcinogenesis, DBS, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, DCS, Bethesda, MD 20892 USA; British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); BC Childrens Hospital; University of British Columbia	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, DBS, Bethesda, MD 20892 USA.							Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; CHANG J, 1998, CANCER RES, V57, P1; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; JEON IS, 1995, ONCOGENE, V10, P1229; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOME JR, 1996, P 2 EUR THERM SCI 14, V1, P15; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	20	194	201	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					222	227		10.1038/13854	http://dx.doi.org/10.1038/13854			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508522				2022-12-27	WOS:000082827500025
J	Ioshikhes, IP; Zhang, MQ				Ioshikhes, IP; Zhang, MQ			Large-scale human promoter mapping using CpG islands	NATURE GENETICS			English	Article							DNA METHYLATION; HUMAN GENOME; BIOLOGY; REGIONS; CANCER; GENES	Vertebrate genomic DNA is generally CpG depleted(1,2), possibly because methylation of cytosines at 80% of CpG dinucleotides results in their frequent mutation to thymine. and thus CpG to TpG dinucleotides(3). There are, however, genomic regions of high G+C content (CpG islands), where the occurrence of CpGs is significantly higher, close to the expected frequency, whereas the methylation concentration is significantly lower than the overall genome(4). CpG islands(5) are longer than 200 bp and have over 50% of G+C content and CpG frequency, at least 0.6 of that statistically expected. Approximately 50% of mammalian gene promoters are associated with one or more CpG islands(6). Although biologists often intuitively use CpG islands for 5' gene identification(7,8). this has not been rigorously quantified(9). We have determined the features that discriminate the promoter-associated and non-associated CpG islands. This led to an effective algorithm for large-scale promoter mapping (with 2kb resolution) with a concentration of false-positive predictions of promoters much lower than previously obtained. Using this algorithm, we correctly discriminated approximately 85% of the CpG islands within an interval (-500 to +1500) around a transcriptional start site (TSS) from those that lie further away from TSSs. We also correctly mapped approximately 93% of the promoters containing CpG islands.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Zhang, MQ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01696] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; MCLACHLAN GJ, 1994, DISCRIMINANT ANAL ST; Pedersen AG, 1999, COMPUT CHEM, V23, P191, DOI 10.1016/S0097-8485(99)00015-7; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Singer-Sam J., 1993, Experientia Supplementum (Basel), V64, P358; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; VENABLES WN, 1994, MOD APPL STAT S PLUS; Zhang M Q, 1998, Pac Symp Biocomput, P240; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919; Zhang MQ, 1997, P NATL ACAD SCI USA, V94, P565, DOI 10.1073/pnas.94.2.565	22	206	213	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					61	63		10.1038/79189	http://dx.doi.org/10.1038/79189			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973249				2022-12-27	WOS:000089078000018
J	Lewis, J; McGowan, E; Rockwood, J; Melrose, H; Nacharaju, P; Van Slegtenhorst, M; Gwinn-Hardy, K; Murphy, MP; Baker, M; Yu, X; Duff, K; Hardy, J; Corral, A; Lin, WL; Yen, SH; Dickson, DW; Davies, P; Hutton, M				Lewis, J; McGowan, E; Rockwood, J; Melrose, H; Nacharaju, P; Van Slegtenhorst, M; Gwinn-Hardy, K; Murphy, MP; Baker, M; Yu, X; Duff, K; Hardy, J; Corral, A; Lin, WL; Yen, SH; Dickson, DW; Davies, P; Hutton, M			Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein	NATURE GENETICS			English	Article							PAIRED HELICAL FILAMENTS; TRANSGENIC MICE; FRONTOTEMPORAL DEMENTIA; NEURODEGENERATIVE DISEASES; CORTICOBASAL DEGENERATION; CYTOSKELETAL PATHOLOGY; PARKINSONISM; TAUOPATHIES; MUTATIONS; MISSENSE	Neurofibrillary tangles (NFT) composed of the microtubule-associated protein tau are prominent in Alzheimer disease (AD), Pick disease, progressive supranuclear palsy (PSP) and corticobasal degeneration(1) (CBD). Mutations in the gene (Mtapt) encoding tau protein cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). thereby proving that tau dysfunction can directly result in neurodegeneration(2). Expression of human tau containing the most common(3-5) FTDP-17 mutation (P301L) results in motor and behavioural deficits in transgenic mice, with age- and gene-dose-dependent development of NFT. This phenotype occurred as early as 6.5 months in hemizygous and 4.5 months in homozygous animals. NFT and Pick-body-like neuronal lesions occurred in the amygdala, septal nuclei, pre-optic nuclei, hypothalamus, midbrain, pens, medulla, deep cerebellar nuclei and spinal cord, with tau-immunoreactive pre-tangles in the cortex, hippocampus and basal ganglia. Areas with the most NFT had reactive gliosis. Spinal cord had axonal spheroids, anterior horn cell toss and axonal degeneration in anterior spinal roots. We also saw peripheral neuropathy and skeletal muscle with neurogenic atrophy. Brain and spinal cord contained insoluble tau that co-migrated with insoluble tau from AD and FTDP-17 brains. The phenotype of mice expressing P301L mutant tau mimics features of human tauopathies and provides a model for investigating the pathogenesis of diseases with NFT.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY USA	Mayo Clinic; Yeshiva University; Albert Einstein College of Medicine	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Duff, Karen EK/C-2510-2009; Gwinn, Katrina A/C-2508-2009; Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423; Duff, Karen/0000-0002-6177-868X; Gwinn, Katrina/0000-0002-8277-651X; Dickson, Dennis W/0000-0001-7189-7917	PHS HHS [P01, R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; FEANY MB, 1995, AM J PATHOL, V146, P1388; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5287; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; HUTTON M, 1999, NEUROSCI NEWS, V2, P73; Ikonomovic MD, 1997, J NEUROPATH EXP NEUR, V56, P1018, DOI 10.1097/00005072-199709000-00007; IQBAL K, 1991, NEUROBIOL AGING, V12, P357, DOI 10.1016/0197-4580(91)90022-C; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jicha GA, 1999, J NEUROSCI RES, V55, P713, DOI 10.1002/(SICI)1097-4547(19990315)55:6<713::AID-JNR6>3.0.CO;2-G; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Mirra SS, 1999, J NEUROPATH EXP NEUR, V58, P335, DOI 10.1097/00005072-199904000-00004; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Trojanowski JQ, 1999, BRAIN PATHOL, V9, P733	23	1017	1086	2	70	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					402	405		10.1038/78078	http://dx.doi.org/10.1038/78078			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932182				2022-12-27	WOS:000088615000013
J	Bulman, MP; Kusumi, K; Frayling, TM; McKeown, C; Garrett, C; Lander, ES; Krumlauf, R; Hattersley, AT; Ellard, S; Turnpenny, PD				Bulman, MP; Kusumi, K; Frayling, TM; McKeown, C; Garrett, C; Lander, ES; Krumlauf, R; Hattersley, AT; Ellard, S; Turnpenny, PD			Mutations in the human Delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis	NATURE GENETICS			English	Article							EPIDERMAL GROWTH-FACTOR; ALAGILLE-SYNDROME; NOTCH-GENE; DROSOPHILA; EXPRESSION; SEGMENTATION; BOUNDARIES; PATTERN; COMPLEX; ENCODES	Spondylocostal dysostosis (SD, MIM 277300) is a group of vertebral malsegmentation syndromes with reduced stature resulting from axial skeletal defects. SD is characterized by mu[tiple hemivertebrae, rib fusions and deletions with a non-progressive kyphoscoliosis. Cases may be sporadic or familial, with both autosomal dominant and autosomal recessive modes of inheritance reported(1). Autosomal recessive SD maps to a 7.8cM interval on chromosome 19q13.1-q13.3 (ref, 2) that is homologous with a mouse region containing a gene encoding the Notch ligand delta-like 3 (DII3). DII3 is mutated(3) in the Xray-induced mouse mutant pudgy (pu), causing a variety of vertebrocostal defects similar to SD phenotypes. Here we have cloned and sequenced human DLL3 to evaluate it as a candidate gene for SD and identified mutations in three autosomal recessive SD families. Two of the mutations predict truncations within conserved extracellular domains. The third is a missense mutation in a highly conserved glycine residue of the fifth epidermal growth factor (EGF) repeat, which has revealed an important functional role for this domain. These represent the first mutations in a human Delta homologue, thus highlighting the critical role of the Notch signalling pathway and its components in patterning the mammalian axial skeleton.	Royal Devon & Exeter Hosp, Clin Genet, Exeter EX2 5DW, Devon, England; Sch Postgrad Med & Hlth Sci, Exeter, Devon, England; Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England; Birmingham Womens Hosp, Clin Genet Unit, Birmingham, W Midlands, England; Northwick Pk & St Marks Trust, Kennedy Galton Ctr, Harrow, Middx, England; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Exeter; University of Exeter; MRC National Institute for Medical Research; Birmingham Women's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute	Turnpenny, PD (corresponding author), Royal Devon & Exeter Hosp, Clin Genet, Barrack Rd, Exeter EX2 5DW, Devon, England.		Krumlauf, Robb/AAH-5012-2019; Kusumi, Kenro/J-2626-2012	Krumlauf, Robb/0000-0001-9102-7927; Kusumi, Kenro/0000-0002-1458-4540; Ellard, Sian/0000-0002-7620-5526; Hattersley, Andrew/0000-0001-5620-473X; Frayling, Timothy/0000-0001-8362-2603				ArtavanisTsakonas S, 1997, NAT GENET, V16, P212, DOI 10.1038/ng0797-212; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BONAIME JL, 1978, PEDIATRIE, V33, P173; CASAMASSIMA AC, 1981, AM J MED GENET, V8, P117, DOI 10.1002/ajmg.1320080114; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DELGOFFE C, 1982, ANN PEDIATR-PARIS, V29, P135; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Mortier GR, 1996, AM J MED GENET, V61, P310, DOI 10.1002/(SICI)1096-8628(19960202)61:4<310::AID-AJMG3>3.0.CO;2-Y; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; SIMPSON JM, 1995, J MED GENET, V32, P633, DOI 10.1136/jmg.32.8.633; THOMAS U, 1991, DEVELOPMENT, V111, P749; TURNPENNY PD, 1991, J MED GENET, V28, P27, DOI 10.1136/jmg.28.1.27; Turnpenny PD, 1999, AM J HUM GENET, V65, P175, DOI 10.1086/302464; WEINMASTER G, 1991, DEVELOPMENT, V113, P931; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	30	300	316	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					438	441		10.1038/74307	http://dx.doi.org/10.1038/74307			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742114				2022-12-27	WOS:000086192800029
J	Kaji, K; Oda, S; Shikano, T; Ohnuki, T; Uematsu, Y; Sakagami, J; Tada, N; Miyazaki, S; Kudo, A				Kaji, K; Oda, S; Shikano, T; Ohnuki, T; Uematsu, Y; Sakagami, J; Tada, N; Miyazaki, S; Kudo, A			The gamete fusion process is defective in eggs of Cd9-deficient mice	NATURE GENETICS			English	Article							MOUSE EGG; CA2+ OSCILLATIONS; STEM-CELLS; FERTILIZATION; CD9; SPERM; CALCIUM; PROTEIN; ACTIVATION; COMPLEXES	The cell-surface molecule Cd9, a member of the transmembrane-4 superfamily(1), interacts with the integrin family(2) and other membrane proteins(3-5), and is postulated to participate in cell migration and adhesion(6-8). Expression of Cd9 enhances membrane fusion between muscle cells(9) and promotes viral infection in some cells(10,11). Fertilization also involves membrane fusion, between gametes. In mammals, the sperm binds to microvilli on the egg surface, and sperm-egg membrane fusion first occurs around the equatorial region of the sperm head(12). The fused membrane is then disrupted, and the sperm nucleus as well as the cytoplasm is incorporated into the egg. Cd9 is expressed on the plasma membrane of the mouse egg, and an anti-Cd9 monoclonal antibody inhibits sperm-egg surface interactions(13). We generated Cd9(-/-) mice and found that homozygous mutant females were infertile. Sperm-egg binding was normal, but sperm-egg fusion was almost entirely inhibited in eggs from Cd9(-/-) females. Intracellular Ca2+ oscillations, which signal fertilization, were absent in almost all mutant eggs; in rare cases, a response occurred after a long time period. In normal animals, Cd9 molecules were expressed on the egg microvilli and became densely concentrated at the sperm attachment site. Thus, our results show that Cd9 is important in the gamete fusion process at fertilization.	Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 227, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo, Japan; Taisho Pharmaceut Co Ltd, Med Res Labs, Omiya, Saitama, Japan; Natl Inst Physiol Sci, Dept Mol Physiol, Lab Intracellular Metab, Okazaki, Aichi 444, Japan	Tokyo Institute of Technology; Tokyo Women's Medical University; Taisho Pharmaceutical Holdings Co Ltd; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Kudo, A (corresponding author), Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 227, Japan.		Kudo, Akira/C-7340-2015	Kudo, Akira/0000-0001-6289-3391				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BEGG DA, 1978, J CELL BIOL, V79, P846, DOI 10.1083/jcb.79.3.846; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Chen KK, 1930, MEDICINE, V9, P1, DOI 10.1097/00005792-193002000-00001; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Horvath G, 1998, J BIOL CHEM, V273, P30537, DOI 10.1074/jbc.273.46.30537; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Lawrence Y, 1997, DEVELOPMENT, V124, P233; Loffler S, 1997, J VIROL, V71, P42; LONGO FJ, 1985, AM J ANAT, V174, P303, DOI 10.1002/aja.1001740310; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nakano Y, 1997, MOL HUM REPROD, V3, P1087, DOI 10.1093/molehr/3.12.1087; PHILLIPS DM, 1985, AM J ANAT, V174, P357, DOI 10.1002/aja.1001740314; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Slupsky JR, 1997, EUR J BIOCHEM, V244, P168, DOI 10.1111/j.1432-1033.1997.00168.x; Swann K, 1997, BIOESSAYS, V19, P371, DOI 10.1002/bies.950190504; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TALBOT P, 1982, FERTIL STERIL, V37, P240; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; Willett B, 1997, J GEN VIROL, V78, P611, DOI 10.1099/0022-1317-78-3-611; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yanagimachi R., 1994, P189	29	369	389	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					279	282		10.1038/73502	http://dx.doi.org/10.1038/73502			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700183				2022-12-27	WOS:000085590600020
J	Munroe, RJ; Bergstrom, RA; Zheng, QY; Libby, B; Smith, R; John, SWM; Schimenti, KJ; Browning, VL; Schimenti, JC				Munroe, RJ; Bergstrom, RA; Zheng, QY; Libby, B; Smith, R; John, SWM; Schimenti, KJ; Browning, VL; Schimenti, JC			Mouse mutants from chemically mutagenized embryonic stem cells	NATURE GENETICS			English	Article							ETHYL METHANESULFONATE; HPRT LOCUS; MICE; MUTATIONS; SPECTRUM	The drive to characterize functions of human genes on a global scale has stimulated interest in large-scale generation of mouse mutants. Conventional germ-cell mutagenesis with N-ethyl-N-nitrosourea (ENU) is compromised by an inability to monitor mutation efficiency, strain(1) and interlocus(2) variation in mutation induction, and extensive husbandry requirements. To overcome these obstacles and develop new methods for generating mouse mutants, we devised protocols to generate germline chimaeric mice from embryonic stem (ES) cells heavily mutagenized with ethylmethanesulphonate (EMS). Germline chimaeras were derived from cultures that underwent a mutation rate of up to 1 in 1,200 at the Hprt locus (encoding hypoxanthine guanine phosphoribosyl transferase). The spectrum of mutations induced by EMS and the frameshift mutagen ICR191 was consistent with that observed in other mammalian cells. Chimaeras derived from ES cells treated with EMS transmitted mutations affecting several processes, including limb development, hair growth, hearing and gametogenesis. This technology affords several advantages over traditional mutagenesis, including the ability to conduct shortened breeding schemes and to screen for mutant phenotypes directly in ES cells or their differentiated derivatives.	Jackson Lab, Bar Harbor, ME 04609 USA; Howard Hughes Med Inst, Bar Harbor, ME USA	Jackson Laboratory; Howard Hughes Medical Institute	Schimenti, JC (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Zheng, Qing/C-1731-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007065] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008441] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004301, R01DC005827, R03DC004376] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [CA34196, P30 CA034196, P30 CA034196-159007] Funding Source: Medline; NICHD NIH HHS [HD07065, F32 HD008441, T32 HD007065, F32 HD008441-02] Funding Source: Medline; NIDCD NIH HHS [R01 DC005827, R01 DC004301-01, R03 DC004376-01A1, R01 DC004301, R01 DC005827-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM045415-12, R01 GM045415, GM45415] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODE VC, 1984, GENETICS, V108, P457; Chen YJ, 2000, NAT GENET, V24, P314, DOI 10.1038/73557; HSIE AW, 1975, SOMAT CELL GENET, V1, P247, DOI 10.1007/BF01538449; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLUNGLAND A, 1995, CARCINOGENESIS, V16, P1281, DOI 10.1093/carcin/16.6.1281; Rinchik EM, 1999, GENETICS, V152, P373; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SMITH RS, 1994, LAB ANIM SCI, V44, P551; SOLIS RR, 1995, NATURE, V378, P720; TAFT SA, 1994, ENVIRON MOL MUTAGEN, V23, P96, DOI 10.1002/em.2850230204; You Y, 1997, NAT GENET, V15, P285, DOI 10.1038/ng0397-285; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	13	105	110	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					318	321		10.1038/73563	http://dx.doi.org/10.1038/73563			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700192	Green Accepted			2022-12-27	WOS:000085590600029
J	Lipkin, SM; Wang, V; Jacoby, R; Banerjee-Basu, S; Baxevanis, AD; Lynch, HT; Elliott, RM; Collins, FS				Lipkin, SM; Wang, V; Jacoby, R; Banerjee-Basu, S; Baxevanis, AD; Lynch, HT; Elliott, RM; Collins, FS			MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-TUMOR SUSCEPTIBILITY; MICE DEFICIENT; MUTATION; MOUSE; PMS2; DATABASE; TISSUES; CELLS; MSH6	DNA mismatch repair is important because of its role in maintaining genomic integrity and its association with hereditary non-polyposis colon cancer (HNPCC). To identify new human mismatch repair proteins, we probed nuclear extracts with the conserved carboxy-terminal MLH1 interaction domain. Here we describe the cloning and complete genomic sequence of MLH3, which encodes a new DNA mismatch repair protein that interacts with MLH1. MLH3 is more similar to mismatch repair proteins from yeast, plants, worms and bacteria than to any known mammalian protein, suggesting that its conserved sequence may confer unique functions in mice and humans. Cells in culture stably expressing a dominant-negative MLH3 protein exhibit microsatellite instability. MIh3 is highly expressed in gastrointestinal epithelium and physically maps to the mouse complex trait locus colon cancer susceptibility I (Ccs1). Although we were unable to identify a mutation in the protein-coding region of MIh3 in the susceptible mouse strain, colon tumours from congenic Ccs1 mice exhibit microsatellite instability. Functional redundancy among MIh3, Pms1 and Pms2 may explain why neither Pms1 nor Pms2 mutant mice develop colon cancer, and why PMS1 and PMS2 mutations are only rarely found in HNPCC families.	NIH, Natl Ctr Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD 20892 USA; NIH, Natl Ctr Human Genome Res Inst, Genome Technol Branch, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Med, Div Gastroenterol, Madison, WI USA; New York State Dept Hlth, Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Wisconsin System; University of Wisconsin Madison; Roswell Park Cancer Institute; Creighton University	Collins, FS (corresponding author), NIH, Natl Ctr Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD 20892 USA.	fc23a@nih.gov	wang, vicky/AAO-6474-2020	Baxevanis, Andy/0000-0002-5370-0014	NATIONAL CANCER INSTITUTE [R01CA062225] Funding Source: NIH RePORTER; NCI NIH HHS [CA62225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; Dayhoff M., 1978, ATLAS PROTEIN SEQUEN; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; EDELMANN W, IN PRESS CANC RES; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; EVANS JT, 1977, CANCER RES, V37, P134; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Glaab WE, 1998, J BIOL CHEM, V273, P26662, DOI 10.1074/jbc.273.41.26662; HAWN MT, 1995, CANCER RES, V55, P3721; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kolodner RD, 1999, CANCER RES, V59, P5068; Kondo E, 1999, J BIOCHEM-TOKYO, V125, P818; LANDER ES, 1989, GENETICS, V121, P185; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; LYNCH HT, 1994, ANTICANCER RES, V14, P1617; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; NAKAGAWA T, IN PRESS P NATL ACAD; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Risinger JI, 1998, CANCER RES, V58, P2978; RYAN J, 1987, JNCI-J NATL CANCER I, V79, P135; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	49	234	257	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					27	35		10.1038/71643	http://dx.doi.org/10.1038/71643			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615123				2022-12-27	WOS:000084609200011
J	Arikawa-Hirasawa, E; Watanabe, H; Takami, H; Hassell, JR; Yamada, Y				Arikawa-Hirasawa, E; Watanabe, H; Takami, H; Hassell, JR; Yamada, Y			Perlecan is essential for cartilage and cephalic development	NATURE GENETICS			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; FACTOR RECEPTOR 3; DYSPLASIA TYPE-I; THANATOPHORIC DYSPLASIA; EXPRESSION; ACTIVATION; MUTATIONS; SKELETAL; MEMBRANE		Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Shriners Hosp Crippled Children, Tampa, FL 33612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, Y (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov						ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; Aszodi A, 1998, J MOL MED-JMM, V76, P238, DOI 10.1007/s001090050214; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Delezoide AL, 1997, HUM MOL GENET, V6, P1899, DOI 10.1093/hmg/6.11.1899; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; Harris MJ, 1997, TERATOLOGY, V56, P177, DOI 10.1002/(SICI)1096-9926(199709)56:3<177::AID-TERA1>3.0.CO;2-Z; HORTON WA, 1988, BONE, V9, P53, DOI 10.1016/8756-3282(88)90027-0; Horton William A., 1997, Current Opinion in Pediatrics, V9, P437, DOI 10.1097/00008480-199708000-00021; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; MORRISSKAY G, 1991, J CRAN GENET DEV BIO, V11, P181; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; ORNOY A, 1985, AM J MED GENET, V21, P613, DOI 10.1002/ajmg.1320210402; Peters PWJ, 1977, METHODS PRENATAL TOX, P153; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Weber M, 1998, J PEDIATR ORTHOP B, V7, P1, DOI 10.1097/01202412-199801000-00001; Wilcox WR, 1998, AM J MED GENET, V78, P274, DOI 10.1002/(SICI)1096-8628(19980707)78:3<274::AID-AJMG14>3.0.CO;2-C	30	395	409	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					354	358		10.1038/15537	http://dx.doi.org/10.1038/15537			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545953				2022-12-27	WOS:000083792200028
J	Goedecke, W; Eijpe, M; Offenberg, HH; van Aalderen, M; Heyting, C				Goedecke, W; Eijpe, M; Offenberg, HH; van Aalderen, M; Heyting, C			Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis	NATURE GENETICS			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; SYNAPTONEMAL COMPLEXES; MEIOTIC RECOMBINATION; INITIATION SITE; BUDDING YEAST; DNA; REPAIR; IDENTIFICATION	Double-strand DNA breaks (DSBs) pose a major threat to living cells, and several mechanisms for repairing these lesions have evolved. Eukaryotes can process DSBs by homologous recombination (HR) or non-homologous end joining(1,2) (NHEJ). NHEJ connects DNA ends irrespective of their sequence, and it predominates in mitotic cells, particularly during G1 (ref. 3). HR requires interaction of the broken DNA molecule with an intact homologous copy, and allows restoration of the original DNA sequence. HR is active during G2 of the mitotic cycle(3) and predominates during meiosis, when the cell creates DSBs (ref. 4), which must be repaired by HR to ensure proper chromosome segregation. How the cell controls the choice between the two repair pathways is not understood. We demonstrate here a physical interaction between mammalian Ku70, which is essential for NHEJ (ref. 5), and Mre11, which functions both in NHEJ and meiotic HR (refs 2,6). Moreover, we show that irradiated cells deficient for Ku70 are incapable of targeting Mre11 to subnuclear foci that may represent DNA-repair complexes(7). Nevertheless, Ku70 and Mre11 were differentially expressed during meiosis. In the mouse testis, Mre11 and Ku70 co-localized in nuclei of somatic cells and in the XY bivalent. In early meiotic prophase, however, when meiotic recombination is most probably initiated(8), Mre11 was abundant, whereas Ku70 was not detectable. We propose that Ku70 acts as a switch between the two DSB repair pathways. When present, Ku70 destines DSBs for NHEJ by binding to DNA ends and attracting other factors for NHEJ, including Mre11; when absent, it allows participation of DNA ends and Mre11 in the meiotic HR pathway.	Agr Univ Wageningen, Genet Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Heyting, C (corresponding author), Agr Univ Wageningen, Genet Lab, Dreijenlaan 2, NL-6703 HA Wageningen, Netherlands.	Christa.Heyting@molcelgen.el.wau.nl						Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Golemis E A, 1997, Methods Mol Biol, V63, P197; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; OAKBERG EF, 1971, ANAT REC, V169, P515, DOI 10.1002/ar.1091690305; Offenberg HH, 1998, NUCLEIC ACIDS RES, V26, P2572, DOI 10.1093/nar/26.11.2572; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2	31	186	187	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					194	198		10.1038/13821	http://dx.doi.org/10.1038/13821			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508516				2022-12-27	WOS:000082827500019
J	Schafer, K; Braun, T				Schafer, K; Braun, T			Early specification of limb muscle precursor cells by the homeobox gene Lbx1h	NATURE GENETICS			English	Article							CONNECTIVE-TISSUE; PROGENITOR CELLS; CHICK LIMB; EXPRESSION; PAX-3; MOUSE; MIGRATION; MUSCULATURE; EMBRYO	During vertebrate embryogenesis, myogenic precursor cells of limb muscles delaminate from the ventro-lateral edge of the semitic dermomyotome and migrate to the limb buds, where they congregate into dorsal and ventral muscle masses(1,2). It has been proposed that the surrounding connective tissue controls muscle pattern formation in limbs(3-5). Regulatory molecules such as receptor tyrosine kinases like c-Met (ref. 6) and those encoded by homeobox-containing genes, including c-Met (ref. 6), Tbx1 (ref. 7), Mox2 (ref. 8), Six1 and Six2 (ref. 9), Pitx2, Pax3 (refs 10,11) and Lbx1h (refs 12,13), are expressed in migrating limb precursor cells. The role of these genes in the patterning of limb muscles is unknown, although mutation of Pax3 or Met causes disruption of limb muscle development at an initial step, disturbing the epithelial-to-mesenchymal transition of the semitic epithelium(6,10,11). No limb muscle cells form in these mutants, and the early loss of myogenic precursor cells prevented an analysis of later functions of these genes during limb muscle development(14). Based on quail-chick chimaera studies(3,15), it was assumed that a cell-autonomous contribution of myogenic cells to the formation of individual limb muscles is negligible, and that an instructive role of limb mesenchyme is critical in this process. Here we show that Lbx1h determines migratory routes of muscle precursor cells in a cell-autonomous manner, thereby leading to the formation of distinct limb muscle patterns. Inactivation of Lbx1h, which is specifically expressed in migrating muscle precursor cells(12,13) , led to a lack of extensor muscles in forelimbs and an absence of muscles in hindlimbs. The defect was caused by the failure of all muscle precursor cells of hindlimbs and of precursor cells of extensor muscles of forelimbs to migrate to their corresponding muscle anlagen. Our results demonstrate that Lbx1h is a key regulator of muscle precursor cell migration and is required for the acquisition of dorsal identities of forelimb muscles.	Univ Halle Wittenberg, Inst Physiol Chem, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg	Braun, T (corresponding author), Univ Halle Wittenberg, Inst Physiol Chem, Hollystr 1, D-06097 Halle, Germany.	Thomas.Braun@medizin.uni-halle.de	Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804				Bancroft JD, 1990, THEORY PRACTICE HIST; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BrandSaberi B, 1996, INT J DEV BIOL, V40, P411; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUTLER J, 1988, DEVELOPMENT, V102, P763; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CHEVALLIER A, 1982, ROUX ARCH DEV BIOL, V191, P277, DOI 10.1007/BF00848416; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Daston G, 1996, DEVELOPMENT, V122, P1017; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; GOULDING M, 1994, DEVELOPMENT, V120, P957; Isaac A, 1998, DEVELOPMENT, V125, P1867; JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5; MARTIN P, 1990, International Journal of Developmental Biology, V34, P323; MAUGER A, 1983, J EMBRYOL EXP MORPH, V76, P199; Mennerich D, 1998, MECH DEVELOP, V73, P147, DOI 10.1016/S0925-4773(98)00046-X; OLIVER G, 1995, DEVELOPMENT, V121, P693; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; Zweigerdt R, 1997, DEV BIOL, V192, P172, DOI 10.1006/dbio.1997.8759	21	140	144	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					213	216		10.1038/13843	http://dx.doi.org/10.1038/13843			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508520				2022-12-27	WOS:000082827500023
J	Engelender, S; Kaminsky, Z; Guo, X; Sharp, AH; Amaravi, RK; Kleiderlein, JJ; Margolis, RL; Troncoso, JC; Lanahan, AA; Worley, PF; Dawson, VL; Dawson, TM; Ross, CA				Engelender, S; Kaminsky, Z; Guo, X; Sharp, AH; Amaravi, RK; Kleiderlein, JJ; Margolis, RL; Troncoso, JC; Lanahan, AA; Worley, PF; Dawson, VL; Dawson, TM; Ross, CA			Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions	NATURE GENETICS			English	Article							PARKINSONS-DISEASE; LEWY BODIES; ALZHEIMERS-DISEASE; PROTEIN; BRAIN; IDENTIFICATION; COMPONENT; PATHOLOGY; DEMENTIA; MUTATION	Parkinson disease (PD) is a neurodegenerative disease characterized by tremor, bradykinesia, rigidity and postural instability. Post-mortem examination shows loss of neurons and Lewy bodies, which are cytoplasmic eosinophilic inclusions, in the substantia nigra and other brain regions(1,2). A few families have PD caused by mutations (A53T or A30P) in the gene SNCA (encoding alpha-synuclein; refs 3-5). alpha-synuclein is present in Lewy bodies of patients with sporadic PD (refs 6,7), suggesting that alpha-synuclein may be involved in the pathogenesis of PD. It is unknown how alpha-synuclein contributes to the cellular and biochemical mechanisms of PD, and its normal functions and biochemical properties are poorly understood(8-10). To determine the protein-interaction partners of alpha-synuclein, we performed a yeast two-hybrid screen. We identified a novel interacting protein, which we term synphilin-1 (encoded by the gene SNCAIP). We found that alpha-synuclein interacts in vivo with synphilin-1 in neurons. Co-transfection of both proteins (but not control proteins) in HEK 293 cells yields cytoplasmic eosinophilic inclusions.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Program Cellular & Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ross, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA.		Ross, Christopher A/H-8395-2013; Dawson, Valina/Y-9757-2019	Engelender, Simone/0000-0001-7401-6855; Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377, P50NS016375, P01NS016375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38377, NS16375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DAWSON VL, 1993, J NEUROSCI, V13, P2651; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Heintz N, 1997, NAT GENET, V16, P325, DOI 10.1038/ng0897-325; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; Nussbaum RL, 1997, HUM MOL GENET, V6, P1687, DOI 10.1093/hmg/6.10.1687; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6	30	403	425	2	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					110	114		10.1038/8820	http://dx.doi.org/10.1038/8820			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319874				2022-12-27	WOS:000080096300035
J	Shinkura, R; Kitada, K; Matsuda, F; Tashiro, K; Ikuta, K; Suzuki, M; Kogishi, K; Serikawa, T; Honjo, T				Shinkura, R; Kitada, K; Matsuda, F; Tashiro, K; Ikuta, K; Suzuki, M; Kogishi, K; Serikawa, T; Honjo, T			Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase	NATURE GENETICS			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; TUMOR-NECROSIS-FACTOR; PERIPHERAL LYMPHOID ORGANS; ALY MUTANT MICE; DEFICIENT MICE; CELL-DEATH; ALPHA; ORGANOGENESIS; ORGANIZATION; EXPRESSION	The alymphoplasia (aly) mutation of mouse is autosomal recessive and characterized by the systemic absence of lymph nodes (LN) and Peyer's patches (PP) and disorganized splenic and thymic structures with immunodeficiency(1-3). Although recent reports have shown that the interaction between lymphotoxin (LT) and the LT beta-receptor (Lt beta r, encoded by Ltbr) provides a critical signal for LN genesis in mice(4-10), the aly locus on chromosome 11 (ref, 11) is distinct from those for LT and its receptor. We found that the aly allele carries a point mutation causing an amino acid substitution in the carboxy-terminal interaction domain of Nf-kappa b-inducing kinase(12,13) (Nik, encoded by the gene Nik). Transgenic complementation with wild-type Nik restored the normal structures of LN, PP, spleen and thymus, and the normal immune response in aly/aly mice. In addition, the aly mutation in a kinase domain-truncated Nik abolished its dominant-negative effect on Nf-kappa b activation induced by an excess of Lt beta r. Our observations agree with previous reports that Lt beta r-deficient mice showed defects in LN genesis(4) and that Nik is a common mediator of Nf-kappa b activation by the tumour necrosis factor (TNF) receptor family(12,13). Nik is able to interact with members of the TRAF family (Traf1, 2, 3, 5 and 6; ref. 13), suggesting it acts downstream of TRAF-associating receptor signalling pathways, including Tnfr (ref. 12), Cd40 (refs 14,15), Cd30 (refs 16,17) and Lt beta r (refs 18-21). The phenotypes of aly/aly mice are more severe than those of Ltbr(-/-) mice, however, indicating involvement of Nik in signal transduction mediated by other receptors.	Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Inst Lab Anim, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8620976, Japan	Kyoto University; Kyoto University; Kyoto University; Kumamoto University	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.		Honjo, Tasuku/N-4470-2016; Matsuda, Fumihiko/B-9893-2009	Ikuta, Koichi/0000-0003-1319-1021				BANKS TA, 1995, J IMMUNOL, V155, P1685; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KOSCO MH, 1992, J IMMUNOL, V148, P2331; Krajewska M, 1998, AM J PATHOL, V152, P1549; KURAMOTO T, 1994, INT IMMUNOL, V6, P991, DOI 10.1093/intimm/6.7.991; KVIST S, 1983, EMBO J, V2, P245, DOI 10.1002/j.1460-2075.1983.tb01413.x; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shinkura R, 1996, INT IMMUNOL, V8, P1067, DOI 10.1093/intimm/8.7.1067; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460	28	380	388	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					74	77		10.1038/8780	http://dx.doi.org/10.1038/8780			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319865				2022-12-27	WOS:000080096300026
J	Terauchi, Y; Tsuji, Y; Satoh, S; Minoura, H; Murakami, K; Okuno, A; Inukai, K; Asano, T; Kaburagi, Y; Ueki, K; Nakajima, H; Hanafusa, T; Matsuzawa, Y; Sekihara, H; Yin, YX; Barrett, JC; Oda, H; Ishikawa, T; Akanuma, Y; Komuro, I; Suzuki, M; Yamamura, K; Kodama, T; Suzuki, H; Koyasu, S; Aizawa, S; Tobe, K; Fukui, Y; Yazaki, Y; Kadowaki, T				Terauchi, Y; Tsuji, Y; Satoh, S; Minoura, H; Murakami, K; Okuno, A; Inukai, K; Asano, T; Kaburagi, Y; Ueki, K; Nakajima, H; Hanafusa, T; Matsuzawa, Y; Sekihara, H; Yin, YX; Barrett, JC; Oda, H; Ishikawa, T; Akanuma, Y; Komuro, I; Suzuki, M; Yamamura, K; Kodama, T; Suzuki, H; Koyasu, S; Aizawa, S; Tobe, K; Fukui, Y; Yazaki, Y; Kadowaki, T			Increased insulin sensitivity and hypoglycaemia in mice lacking the P85 alpha subunit of phosphoinositide 3-kinase	NATURE GENETICS			English	Article							RECEPTOR TYROSINE KINASES; RAT ADIPOSE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; PROTEIN; SUBSTRATE-1; TRANSLOCATION	The hallmark of type 2 diabetes, the most common metabolic disorder, is a defect in insulin-stimulated glucose transport in peripheral tissues. Although a role for phosphoinositide-3-kinase (PI3K) activity in insulin-stimulated glucose transport and glucose transporter isoform 4 (Glut4) translocation has been suggested in vitro(1,2), its role in vive and the molecular link between activation of PI3K and translocation has not yet been elucidated. To determine the role of PI3K in glucose homeostasis, we generated mice with a targeted disruption of the gene encoding the p85 alpha regulatory subunit of PI3K (Pik3r1; refs 3-5). Pik3r1(-/-) mice showed increased insulin sensitivity and hypoglycaemia due to increased glucose transport in skeletal muscle and adipocytes. Insulin-stimulated PI3K activity associated with insulin receptor substrates (IRSs) was mediated via full-length p85 alpha in wild-type mice, but via the p50 alpha alternative splicing isoform of the same gene(6,7) in Pik3r1(-/-) mice. This isoform switch was associated with an increase in insulin-induced generation of phosphatidylinositol(3, 4, 5)triphosphate (PtdIns(3, 4, 5)P-3) in Pik3r1(-/-) adipocytes and facilitation of Glut4 translocation from the law-density microsome (LDM) fraction to the plasma membrane (PM). This mechanism seems to be responsible for the phenotype of Pik3r1(-/-) mice, namely increased glucose transport and hypoglycaemia. Our work provides the first direct evidence that PI3K and its regulatory subunit have a role in glucose homeostasis in vive.	Univ Tokyo, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, Dept Pathol, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Tokyo 1138655, Japan; Univ Tokyo, Dept Appl Biol Chem, Biol Chem Lab, Tokyo 1138655, Japan; Osaka Univ, Dept Internal Med 2, Suita, Osaka 565, Japan; Yokohama City Univ, Dept Internal Med, Yokohama, Kanagawa 236, Japan; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo 100, Japan; Kumamoto Univ, Sch Med, Lab Transgen Technol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Dev Genet, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 860, Japan; Keio Univ, Sch Med, Dept Immunol, Tokyo 160, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Osaka University; Yokohama City University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Asahi Life Foundation; Kumamoto University; Kumamoto University; Kumamoto University; Keio University	Kadowaki, T (corresponding author), Univ Tokyo, Dept Internal Med, Tokyo 1138655, Japan.		Koyasu, Shigeo/J-5583-2015; Suzuki, Harumi/L-1271-2013; Terauchi, Yasuo/AAO-4347-2020; Fukui, Yasuhisa/E-8806-2010	Koyasu, Shigeo/0000-0001-9585-3038; Suzuki, Harumi/0000-0003-3616-9361; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; HARANO Y, 1981, J CLIN ENDOCR METAB, V52, P982, DOI 10.1210/jcem-52-5-982; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KADOWAKI T, 1996, ENDOCR J, V43, P533; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	28	326	336	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					230	235		10.1038/6023	http://dx.doi.org/10.1038/6023			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988280				2022-12-27	WOS:000078399500030
J	Ali, RR; Sarra, GM; Stephens, C; de Alwis, M; Bainbridge, JWB; Munro, PM; Fauser, S; Reichell, MB; Kinnon, C; Hunt, DM; Bhattacharya, SS; Thrasher, AJ				Ali, RR; Sarra, GM; Stephens, C; de Alwis, M; Bainbridge, JWB; Munro, PM; Fauser, S; Reichell, MB; Kinnon, C; Hunt, DM; Bhattacharya, SS; Thrasher, AJ			Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy	NATURE GENETICS			English	Article							RDS MUTANT MICE; RETINITIS-PIGMENTOSA; RESCUE; MOUSE; AMPLICONS; VECTOR; ROM-1; DEATH	The gene Prph2 encodes a photoreceptor-specific membrane glycoprotein(1), peripherin-2 (also known as peripherin/rds), which is inserted into the rims of photoreceptor outer segment discs in a complex with rom-1 (ref. 2). The complex is necessary for the stabilization of the discs, which are renewed constantly throughout life, and which contain the visual pigments necessary for photon capture(3). Mutations in Prph2 have been shown to result in a variety of photoreceptor dystrophies, including autosomal dominant retinitis pigmentosa and macular dystrophy(4). A common feature of these diseases is the loss of photoreceptor function, also seen in the retinal degeneration slow (rds or prph2(Rd2/Rd2)) mouse, which is homozygous for a null mutation in Prph2. It is characterized by a complete failure to develop photoreceptor discs and outer segments(5), downregulation of rhodopsin(6,7) and apoptotic loss of photoreceptor cells(8,9). The electroretinograms (ERGs) of Prph2(Rd2/Rd2) mice have greatly diminished a-wave and b-wave amplitudes, which decline to virtually undetectable concentrations by two months(10). Subretinal injection of recombinant adeno-associated virus (AAV) encoding a Prph2 transgene results in stable generation of outer segment structures and formation of new stacks of discs containing both perpherin-2 and rhodopsin, which in many cases are morphologically similar to normal outer segments. Moreover, the re-establishment of the structural integrity of the photoreceptor layer also results in electrophysiological correction. These studies demonstrate for the first time that a complex ultrastructural cell defect can be corrected both morphologically and functionally by in vivo gene transfer.	UCL, Inst Ophthalmol, Dept Mol Genet, London, England; UCL, Inst Child Hlth, Mol Immunol Unit, London, England; Univ Tubingen, Hosp Eye, Tubingen, Germany; Univ Leipzig, Hosp Eye, D-7010 Leipzig, Germany	University of London; University College London; University of London; University College London; Eberhard Karls University of Tubingen; Leipzig University	Ali, RR (corresponding author), UCL, Inst Ophthalmol, Dept Mol Genet, Mortimer St, London, England.	r.ali@ucl.ac.uk	Kinnon, Christine/A-1585-2010; Hunt, David M/K-6024-2012; Bhattacharya, Shom/N-2926-2016	Hunt, David M/0000-0002-9264-3948; Bhattacharya, Shom/0000-0002-1601-6344; Bainbridge, James/0000-0003-1318-8201; Ali, Robin/0000-0003-3126-6517				Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boursnell MEG, 1997, J INFECT DIS, V175, P16, DOI 10.1093/infdis/175.1.16; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; HILLENKAMP F, 1975, APPL PHYS, V8, P341, DOI 10.1007/BF00898368; Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967; MOLDAY RS, 1994, PROG RETIN EYE RES, V13, P271, DOI 10.1016/1350-9462(94)90013-2; NIR I, 1990, EXP EYE RES, V51, P257, DOI 10.1016/0014-4835(90)90022-M; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; REUTER JH, 1984, NEUROSCI LETT, V48, P231, DOI 10.1016/0304-3940(84)90024-7; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; SHALKEN JJ, 1985, BIOCHIM BIOPHYS ACTA, V839, P122; Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; Zhang XL, 1999, HUM GENE THER, V10, P2527, DOI 10.1089/10430349950016861; Zhang XL, 1998, J GEN VIROL, V79, P125, DOI 10.1099/0022-1317-79-1-125	18	256	277	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					306	310		10.1038/77068	http://dx.doi.org/10.1038/77068			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888879				2022-12-27	WOS:000087920900019
J	Zhu, XD; Kuster, B; Mann, M; Petrini, JHJ; de Lange, T				Zhu, XD; Kuster, B; Mann, M; Petrini, JHJ; de Lange, T			Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres	NATURE GENETICS			English	Article							STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; PROTEIN COMPLEX; 2 PATHWAYS; END; MRE11; IDENTIFICATION; RECOMBINATION; MAINTENANCE	Telomeres allow cells to distinguish natural chromosome ends from damaged DNA and protect the ends from degradation and fusion. In human cells, telomere protection depends on the TTAGGG repeat binding factor, TRF2 (refs 1-4), which has been proposed to remodel telomeres into large duplex loops(5) (t-loops). Here we show by nanoelectrospray tandem mass spectrometry that RAD50 protein is present in TRF2 immunocomplexes. Protein blotting showed that a small fraction of RAD50, MRE11 and the third component of the MRE11 double-strand break (DSB) repair complex, the Nijmegen breakage syndrome protein (NBS1), is associated with TRF2. Indirect immunofluorescence demonstrated the presence of RAD50 and MRE11 at interphase telomeres. NBS1 was associated with TRF2 and telomeres in S phase, but not in G1 or G2. Although the MRE11 complex accumulated in irradiation-induced foci (IRIFs) in response to gamma-irradiation, TRF2 did not relocate to IRIFs and irradiation did not affect the association of TRF2 with the MRE11 complex, arguing against a role for TRF2 in TSB repair. Instead, we propose that the MRE11 complex functions at telomeres. possibly by modulating t-loop formation.	Rockefeller Univ, New York, NY 10021 USA; Univ So Denmark, Prot Interact Lab, Odense, Denmark; Univ Wisconsin, Sch Med, Genet Lab, Madison, WI USA	Rockefeller University; University of Southern Denmark; University of Wisconsin System; University of Wisconsin Madison	de Lange, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011; Mann, Matthias/A-3454-2013; Kuster, Bernhard/Q-6031-2016	de Lange, Titia/0000-0002-9267-367X; Mann, Matthias/0000-0003-1292-4799; Kuster, Bernhard/0000-0002-9094-1677; Zhu, Xu-Dong/0000-0003-1859-3134	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM059413, R01GM056888, R01GM049046, R01GM059413, R37GM049046] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49046, GM59413, GM56888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HARLEY CB, 1995, TELOMERES, P247; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Le S, 1999, GENETICS, V152, P143; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yeager TR, 1999, CANCER RES, V59, P4175	33	481	502	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					347	352		10.1038/77139	http://dx.doi.org/10.1038/77139			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888888				2022-12-27	WOS:000087920900028
J	Gayther, SA; Batley, SJ; Linger, L; Bannister, A; Thorpe, K; Chin, SF; Daigo, Y; Russell, P; Wilson, A; Sowter, HM; Delhanty, JDA; Ponder, BAJ; Kouzarides, T; Caldas, C				Gayther, SA; Batley, SJ; Linger, L; Bannister, A; Thorpe, K; Chin, SF; Daigo, Y; Russell, P; Wilson, A; Sowter, HM; Delhanty, JDA; Ponder, BAJ; Kouzarides, T; Caldas, C			Mutations truncating the EP300 acetylase in human cancers	NATURE GENETICS			English	Article							E1A-ASSOCIATED PROTEIN P300; COACTIVATORS P300; CBP; GENE; P53; BINDING; FAMILY	The EP300 protein is a histone acetyltransferase(1.2) that regulates transcription via chromatin remodelling(3) and is important in the processes of cell proliferation(4) and differentiation(5). EP300 acetylation of TP53 in response to DNA damage regulates its DNA-binding and transcription functions(6-9). A role for EP300 in cancer has been implied by the fact that it is targeted by viral oncoproteins, it is fused to MLL in leukaemia and two missense sequence alterations in EP300 were identified in epithelial malignancies(10-13). Nevertheless, direct demonstration of the role of EP300 in tumorigenesis by inactivating mutations in human cancers has been lacking. Here we describe EP300 mutations, which predict a truncated protein, in 6 (3%) of 193 epithelial cancers analysed. Of these six mutations, two were in primary tumours (a colorectal cancer and a breast cancer) and four were in cancer cell lines (colorectal, breast and pancreatic). In addition, we identified a somatic in-frame insertion in a primary breast cancer and missense alterations in a primary colorectal cancer and two cell lines (breast and pancreatic). Inactivation of the second allele was demonstrated in five of six cases with truncating mutations and in two other cases. Our data show that EP300 is mutated in epithelial cancers and provide the first evidence that it behaves as a classical tumour-suppressor gene.	Univ Cambridge, Dept Oncol, Cambridge, England; Univ Cambridge, Dept Pathol, Cambridge, England; Univ Cambridge, Strangeways Res Labs, Cambridge, England; Univ Cambridge, Canbridge Inst Med Res, Wellcome Trust Ctr Study Mol Mechanisms Dis, Cambridge, England; Univ Cambridge, Wellcome CRC Inst, Cambridge, England; Derby City Gen Hosp, Oncol Res Lab, Derby, England; Univ Cambridge, Rosie Hosp, Dept Obstet & Gynaecol, Cambridge, England; UCL, London Sch Med, Dept Obstet & Gynaecol, London, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Nottingham; University of Cambridge; University of London; University College London	Caldas, C (corresponding author), Univ Cambridge, Dept Oncol, Cambridge, England.	cc234@cam.ac.uk	Thorpe, Karen/N-1159-2017; Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008	Thorpe, Karen/0000-0001-8927-4064; Caldas, Carlos/0000-0003-3547-1489; Kouzarides, Tony/0000-0002-8918-4162; Bannister, Andrew/0000-0002-6312-4436; chin, suet-feung/0000-0001-5697-1082; Daigo, Yataro/0000-0002-0915-3025				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CALDAS C, 1994, NAT GENET, V8, P410, DOI 10.1038/ng1294-410c; Foster KA, 1996, CANCER RES, V56, P3622; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	18	458	492	3	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					300	303		10.1038/73536	http://dx.doi.org/10.1038/73536			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700188				2022-12-27	WOS:000085590600025
J	Li, BJ; Boast, S; de los Santos, K; Schieren, I; Quiroz, M; Teitelbaum, SL; Tondravi, MM; Goff, SP				Li, BJ; Boast, S; de los Santos, K; Schieren, I; Quiroz, M; Teitelbaum, SL; Tondravi, MM; Goff, SP			Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation	NATURE GENETICS			English	Article							C-ABL; CLEIDOCRANIAL DYSPLASIA; BONE; DIFFERENTIATION; MOUSE; CELLS; GENE; EXPRESSION; MUTATION; CBFA1	The c-Abl protein is a non-receptor tyrosine kinase involved in many aspects of mammalian development. c-Abl kinase is widely expressed, but high levels are found in hyaline cartilage in the adult, bone tissue in newborn mice, and osteoblasts and associated neovasculature at sites of endochondrial ossification in the fetus(1,2). Mice homozygous for mutations in the gene encoding c-Abl (Abl) display increased perinatal mortality, reduced fertility, foreshortened crania and defects in the maturation of B cells in bone marrow(3,4). Here we demonstrate that Abl(-/-) mice are also osteoporotic. The long bones of mutant mice contain thinner cortical bone and reduced trabecular bone volume. The osteoporotic phenotype is not due to accelerated bone turnover-both the number and activity of osteoclasts are similar to those of control littermates-but rather to dysfunctional osteoblasts. In addition, the rate of mineral apposition in the mutant animals is reduced. Osteoblasts from both stromal and calvarial explants showed delayed maturation in vitro as measured by expression of alkaline phosphatase (ALP), induction of mRNA encoding osteocalcin and mineral deposition.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63130 USA; Amer Red Cross, Dept Tissue Biol, Rockville, MD USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Washington University (WUSTL); American Red Cross	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA.	goff@cuccfa.ccc.columbia.edu	Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044089, R01AR032788] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32788, AR44089] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; Cook HC, 1974, MANUAL HISTOLOGICAL; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Moursi AM, 1996, J CELL SCI, V109, P1369; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; ONeill AJ, 1997, J PATHOL, V183, P325, DOI 10.1002/(SICI)1096-9896(199711)183:3<325::AID-PATH941>3.0.CO;2-A; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN M, 1988, CIBA F SYMP, V136, P42; QUARLES LD, 1992, J BONE MINER RES, V7, P683; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; STEIN CA, 1990, PRINCIPLES PRACT ONC, V4, P1; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x	22	125	131	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					304	308		10.1038/73542	http://dx.doi.org/10.1038/73542			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700189				2022-12-27	WOS:000085590600026
J	Galvin, KM; Donovan, MJ; Lynch, CA; Meyer, RI; Paul, RJ; Lorenz, JN; Fairchild-Huntress, V; Dixon, KL; Dunmore, JH; Gimbrone, MA; Falb, D; Huszar, D				Galvin, KM; Donovan, MJ; Lynch, CA; Meyer, RI; Paul, RJ; Lorenz, JN; Fairchild-Huntress, V; Dixon, KL; Dunmore, JH; Gimbrone, MA; Falb, D; Huszar, D			A role for Smad6 in development and homeostasis of the cardiovascular system	NATURE GENETICS			English	Article							TGF-BETA; FAMILY MEMBERS; MESSENGER-RNA; GENE; EXPRESSION; BONE; ENDOTHELIUM; INDUCTION; LACZ	Smad proteins are intracellular mediators of signalling initiated by Tgf-beta superfamily ligands (Tgf-beta s, activins and bone morphogenetic proteins (Bmps)). Smads 1, 2, 3, 5 and 8 are activated upon phosphorylation by specific type I receptors, and associate with the common partner Smad4 to trigger transcriptional responses(1). The inhibitory Smads (6 and 7) are transcriptionally induced in cultured cells treated with Tgf-beta superfamily ligands, and downregulate signalling in in vitro assays(2-7). Gene disruption in mice has begun to reveal specific developmental and physiological functions of the signal-transducing Smads. Here we explore the role of an inhibitory Smad in vivo by targeted mutation of Madh6 (which encodes the Smad6 protein). Targeted insertion of a LacZ reporter demonstrated that Smad6 expression is largely restricted to the heart and blood vessels, and that Madh6 mutants have multiple cardiovascular abnormalities. Hyperplasia of the cardiac valves and outflow tract septation defects indicate a function for Smad6 in the regulation of endocardial cushion transformation. The role of Smad6 in the homeostasis of the adult cardiovascular system is indicated by the development of aortic ossification and elevated broad pressure in viable mutants. These defects highlight the importance of Smad6 in the tissue-specific modulation of Tgf-beta superfamily signalling pathways in vivo.	Millennium Pharmaceut, Cambridge, MA USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH USA; Brigham & Womens Hosp, Div Vasc Res, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Galvin, KM (corresponding author), Millennium Pharmaceut, Cambridge, MA USA.							Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BOSTROM K, 1995, AM J CARDIOL, V75, pB88, DOI 10.1016/0002-9149(95)80020-S; BRADLEY A, 1987, TERATOCARCINOMAS EMB; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; COHEN RA, 1988, J PHARMACOL EXP THER, V244, P550; Dudley AT, 1997, DEV DYNAM, V208, P349; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; HUANG JX, 1995, ANN NY ACAD SCI, V752, P317, DOI 10.1111/j.1749-6632.1995.tb17441.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Lalli J, 1997, CIRC RES, V80, P506, DOI 10.1161/01.RES.80.4.506; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MILLAN FA, 1991, DEVELOPMENT, V111, P131; Moore CS, 1998, DEV DYNAM, V212, P548, DOI 10.1002/(SICI)1097-0177(199808)212:4<548::AID-AJA8>3.0.CO;2-H; Perrella MA, 1998, MINER ELECTROL METAB, V24, P136, DOI 10.1159/000057361; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314	22	375	394	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					171	174		10.1038/72835	http://dx.doi.org/10.1038/72835			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655064				2022-12-27	WOS:000085104600019
J	Hollander, MC; Sheikh, MS; Bulavin, DV; Lundgren, K; Augeri-Henmueller, L; Shehee, R; Molinaro, TA; Kim, KE; Tolosa, E; Ashwell, JD; Rosenberg, MP; Zhan, QM; Fernandez-Salguero, PM; Morgan, WF; Deng, CX; Fornace, AJ				Hollander, MC; Sheikh, MS; Bulavin, DV; Lundgren, K; Augeri-Henmueller, L; Shehee, R; Molinaro, TA; Kim, KE; Tolosa, E; Ashwell, JD; Rosenberg, MP; Zhan, QM; Fernandez-Salguero, PM; Morgan, WF; Deng, CX; Fornace, AJ			Genomic instability in Gadd45a-deficient mice	NATURE GENETICS			English	Article							CELL-CYCLE ARREST; P53-DEFICIENT MICE; P53; GADD45; DEFICIENT; PROTEIN; P21	Gadd45a-null mice generated by gene targeting exhibited several of the phenotypes characteristic of p53-deficient mice, including genomic instability, increased radiation carcinogenesis and a low frequency of exencephaly. Genomic instability was exemplified by aneuploidy, chromosome aberrations, gene amplification and centrosome amplification, and was accompanied by abnormalities in mitosis, cytokinesis and growth control. Unequal segregation of chromosomes due to multiple spindle poles during mitosis occurred in several Gadd45a(-/-) cell lineages and may contribute to the aneuploidy. Our results indicate that Gadd45a is one component of the p53 pathway that contributes to the maintenance of genomic stability.	NCI, Gene Response Sect, DBS, Bethesda, MD 20892 USA; Glaxo Wellcome Res & Dev Inc, Res Triangle Pk, NC 27709 USA; NCI, Lab Immune Cell Biol, DBS, Bethesda, MD 20892 USA; NCI, Lab Metab, DBS, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; NIDDKD, Genet Dev & Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Fornace, AJ (corresponding author), NCI, Gene Response Sect, DBS, Bethesda, MD 20892 USA.		Fernandez-Salguero, Pedro M./J-8437-2014; deng, chuxia/N-6713-2016; Tolosa, Eva/S-3454-2016; Fornace, Albert/A-7407-2008	Fernandez-Salguero, Pedro M./0000-0003-2839-5027; Fornace, Albert/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrier F, 1999, MOL CELL BIOL, V19, P1673; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Kamien R, 1997, MUSIC THEOR SPECTRUM, V19, P1, DOI 10.1525/mts.1997.19.1.02a00010; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NELSONREES WA, 1980, CYTOGENET CELL GENET, V27, P216, DOI 10.1159/000131490; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takeshi K, 1998, JPN QUART, V45, P4; WANG X, IN PRESS J BIOL CHEM; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	30	426	441	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					176	184		10.1038/13802	http://dx.doi.org/10.1038/13802			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508513				2022-12-27	WOS:000082827500016
J	Phimister, B				Phimister, B			Having a go at the hepatitis B virus	NATURE GENETICS			English	Editorial Material																		Larkin J, 1999, NAT MED, V5, P907, DOI 10.1038/11347	1	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					318	318		10.1038/11880	http://dx.doi.org/10.1038/11880			1	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431228	Bronze			2022-12-27	WOS:000081772500004
J	Aminoff, M; Carter, JE; Chadwick, RB; Johnson, C; Grasbeck, R; Abdelaal, MA; Broch, H; Jenner, LB; Verroust, PJ; Moestrup, SK; de la Chapelle, A; Krahe, R				Aminoff, M; Carter, JE; Chadwick, RB; Johnson, C; Grasbeck, R; Abdelaal, MA; Broch, H; Jenner, LB; Verroust, PJ; Moestrup, SK; de la Chapelle, A; Krahe, R			Mutations in CUBN, encoding the intrinsic factor-vitamin B-12 receptor, cubilin, cause hereditary megaloblastic anaemia 1	NATURE GENETICS			English	Article							IMERSLUND-GRASBECK SYNDROME; HUMAN GENOME; MALABSORPTION; PROTEIN; MAP; ENDOCYTOSIS; DOMAIN	Megaloblastic anaemia 1 (MGA1, OMIM 261100) is a rare, autosomal recessive disorder characterized by juvenile megaloblastic: anaemia, as well as neurological symptoms that may be the only manifestations(1,2). At the cellular level, MGA1 is characterized by selective intestinal vitamin B-12 (B-12, cobalamin) malabsorption-2. MGA1 occurs worldwide, but its prevalence is higher in several Middle Eastern countries(3-6) and Norway(1,7), and highest in Finlands (0.8/100,000). We previously mapped the MGA1 locus by linkage analysis in Finnish and Norwegian families to a 6-cM region on chromosome 10p12.1 (ref. 8). A functional candidate gene encoding the intrinsic factor (IF)-B-12 receptor, cubilin, was recently cloned(9,10); the human homologue, CUBN, was mapped to the same region(10). We have now refined the MGA1 region by linkage disequilibrium (LD) mapping, fine-mapped CUBN and identified two independent disease-specific CUBN mutations in 17 Finnish MGA1 families. Our genetic and molecular data indicate that mutations in CUBN cause MGA1.	Ohio State Univ, Div Human Canc Genet, Dept Immunol & Med Microbiol, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Helsinki, Dept Med Genet, Folkhalsan Inst Genet, FIN-00280 Helsinki, Finland; Minerva Fdn, Inst Med Res, FIN-00250 Helsinki, Finland; Natl Guard King Khalid Hosp, Dept Pathol, Jeddah 21423, Saudi Arabia; Vestfold Cent Hosp, Dept Pediat, N-3103 Tonesberg, Norway; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark; Hop Tenon, INSERM U 489, F-75020 Paris, France; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Helsinki; King Saud University; King Khalid University Hospital; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Aarhus University	Krahe, R (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Immunol & Med Microbiol, Ctr Comprehens Canc, Columbus, OH 43210 USA.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019; Jenner, Lasse/H-1584-2017	Moestrup, Søren Kragh/0000-0003-3862-2107; Jenner, Lasse/0000-0003-3917-8853	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELAAL MA, 1991, ACTA PAEDIATR SCAND, V80, P1109; ALTAY C, 1995, PEDIATR HEMAT ONCOL, V12, P19, DOI 10.3109/08880019509029524; AMINOFF M, 1995, AM J HUM GENET, V57, P824; BENBASSA.I, 1969, ISRAEL J MED SCI, V5, P62; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BROCH H, 1984, ACTA PAEDIATR SCAND, V73, P248, DOI 10.1111/j.1651-2227.1984.tb09937.x; BURMAN JF, 1985, GUT, V26, P311, DOI 10.1136/gut.26.3.311; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dugue B, 1998, J PEDIATR GASTR NUTR, V26, P21, DOI 10.1097/00005176-199801000-00004; FURUHJELM U, 1973, SCAND J HAEMATOL, V11, P27; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; Grasbeck R, 1997, ACTA BIOCHIM POL, V44, P725; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Imerslund O, 1960, ACTA PAEDIATR, V49, P208; Ismail EAR, 1997, ACTA PAEDIATR, V86, P424, DOI 10.1111/j.1651-2227.1997.tb09035.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kozyraki R, 1998, BLOOD, V91, P3593; KRAULIS P, 1991, J APP CRYST A, V47, P110; MACKENZI.IL, 1972, NEW ENGL J MED, V286, P1021, DOI 10.1056/NEJM197205112861902; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; MOESTRUP SK, IN PRESS CHEM BIOCH; PHELPS RS, 1995, BIOTECHNIQUES, V19, P984; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; SAHALI D, 1992, AM J PATHOL, V140, P33	30	186	189	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					309	313		10.1038/6831	http://dx.doi.org/10.1038/6831			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080186				2022-12-27	WOS:000078977900027
J	Bonne, G; Di Barletta, MR; Varnous, S; Becane, HM; Hammouda, EH; Merlini, L; Muntoni, F; Greenberg, CR; Gary, F; Urtizberea, JA; Duboc, D; Fardeau, M; Toniolo, D; Schwartz, K				Bonne, G; Di Barletta, MR; Varnous, S; Becane, HM; Hammouda, EH; Merlini, L; Muntoni, F; Greenberg, CR; Gary, F; Urtizberea, JA; Duboc, D; Fardeau, M; Toniolo, D; Schwartz, K			Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy	NATURE GENETICS			English	Article							INTERMEDIATE FILAMENT PROTEINS; CHROMATIN BINDING-SITE; NUCLEAR-ENVELOPE; IDENTIFICATION; MEMBRANE; DOMAIN; CDNA; CARDIOMYOPATHY; ORGANIZATION; LOCALIZATION	Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and a cardiomyopathy with conduction blocks which is life-threatening(1). Two modes of inheritance exist, X-linked (OMIM 310300) and autosomal dominant (EDMD-AD; OMIM 181350). EDMD-AD is clinically identical to the X-linked forms of the disease(2-4). Mutations in EMD, the gene encoding emerin, are responsible for the X-linked form(5,6). We have mapped the locus for EDMD-AD to an 8-cM interval on chromosome 1q11-q23 in a large French pedigree, and found that the EMD phenotype in four other small families was potentially linked to this locus. This region contains the lamin A/C gene (LMNA), a candidate gene encoding two proteins of the nuclear lamina, lamins A and C, produced by alternative splicing(7,8). We identified four mutations in LMNA that co-segregate with the disease phenotype in the five families: one nonsense mutation and three missense mutations. These results are the first identification of mutations in a component of the nuclear lamina as a cause of inherited muscle disorder. Together with mutations in EMD (refs 5,6), they underscore the potential importance of the nuclear envelope components in the pathogenesis of neuromuscular disorders.	Grp Hosp Pitie Salpetriere, INSERM UR153, F-75651 Paris 13, France; Grp Hosp Pitie Salpetriere, Inst Myol, F-75651 Paris 13, France; CNR, IGBE CNR, Ist Genet Biochim & Evoluz, I-27100 Pavia, Italy; Ist Ortoped Rizzoli, Neuromuscular Lab, I-40136 Bologna, Italy; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Paediat, London W12 0NN, England; Ctr Hlth Sci, Winnipeg, MB, Canada; Genethon, F-91002 Evry, France; Hop Cochin, Serv Cardiol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Ortopedico Rizzoli; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Schwartz, K (corresponding author), Grp Hosp Pitie Salpetriere, INSERM UR153, Batiment Babinski,47 Bld de Hop, F-75651 Paris 13, France.	gbonne@myologie.infobiogen.fr; mroumane@myologie.infobiogen.fr	Toniolo, Daniela/AAE-2969-2019; Merlini, Luciano/N-6478-2019; Bonne, Gisèle/G-3121-2013	Toniolo, Daniela/0000-0001-9545-6032; Merlini, Luciano/0000-0002-1108-1198; Bonne, Gisèle/0000-0002-2516-3258	Telethon [E.0297] Funding Source: Medline	Telethon(Fondazione Telethon)		BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Cartegni L, 1997, HUM MOL GENET, V6, P2257, DOI 10.1093/hmg/6.13.2257; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EMERY AEH, 1989, J MED GENET, V26, P637, DOI 10.1136/jmg.26.10.637; FENICHEL GM, 1982, NEUROLOGY, V32, P1399, DOI 10.1212/WNL.32.12.1399; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GUILLY MN, 1990, EXP CELL RES, V189, P145, DOI 10.1016/0014-4827(90)90267-E; GUILLY MN, 1987, EMBO J, V6, P3795, DOI 10.1002/j.1460-2075.1987.tb02715.x; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; LIN F, 1993, J BIOL CHEM, V268, P16321; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MILLER RG, 1985, NEUROLOGY, V35, P1230, DOI 10.1212/WNL.35.8.1230; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; ROBER RA, 1990, J CELL SCI, V95, P587; SPEER MC, 1992, AM J HUM GENET, V50, P1211; Squarzoni S, 1998, NEUROMUSCULAR DISORD, V8, P338, DOI 10.1016/S0960-8966(98)00031-5; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Van Der Kooi A. J., 1996, Annals of Neurology, V39, P636, DOI 10.1002/ana.410390513; vanderKooi AJ, 1997, AM J HUM GENET, V60, P891; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; Wydner KL, 1996, GENOMICS, V32, P474, DOI 10.1006/geno.1996.0146; Yates JRW, 1997, NEUROMUSCULAR DISORD, V7, P67, DOI 10.1016/S0960-8966(96)00403-8	28	956	992	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					285	288		10.1038/6799	http://dx.doi.org/10.1038/6799			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080180				2022-12-27	WOS:000078977900021
J	Kirschner, LS; Carney, JA; Pack, SD; Taymans, SE; Giatzakis, C; Cho, YS; Cho-Chung, YS; Stratakis, CA				Kirschner, LS; Carney, JA; Pack, SD; Taymans, SE; Giatzakis, C; Cho, YS; Cho-Chung, YS; Stratakis, CA			Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex	NATURE GENETICS			English	Article							SPOTTY SKIN PIGMENTATION; ENDOCRINE OVERACTIVITY; ACTIVATING MUTATIONS; CARDIAC MYXOMAS; RI-ALPHA; SCHWANNOMAS; DIAGNOSIS; DISEASE; TUMORS; MICE	Carney complex (CNC) is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and psammomatous melanotic schwannomas(1-5). CNC is inherited as an autosomal dominant trait and the genes responsible have been mapped to 2p16 and 17q22-24 (refs 6,7). Because of its similarities to the McCune-Albright syndrome(5,8) and other features, such as paradoxical responses to endocrine signals(9), genes implicated in cyclic nucleotide-dependent signalling have been considered candidates for causing CNC (ref. 10). In CNC families mapping to 17q. we detected loss of heterozygosity (LOH) in the vicinity of the gene (PRKAR1A) encoding protein kinase A regulatory subunit 1-alpha (Rl alpha), including a polymorphic site within its 5' region. We subsequently identified three unrelated kindreds with an identical mutation in the coding region of PRKAR1A. Analysis of additional cases revealed the same mutation in a sporadic case of CNC, and different mutations in three other families, including one with isolated inherited cardiac myxomas. Analysis of PKA activity in CNC tumours demonstrated a decreased basal activity, but an increase in cAMP-stimulated activity compared with non-CNC tumours, We conclude that germline mutations in PRKAR1A, an apparent tumour-suppressor gene, are responsible for the CNC phenotype in a subset of patients with this disease.	NICHHD, Unit Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA; Mayo Clin, Emeritus Staff, Dept Lab Med & Pathol, Rochester, MN USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Stratakis, CA (corresponding author), NICHHD, Unit Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA.	stratakc@ccl.nichd.nih.gov	Pack, Svetlana D./C-2020-2014; Stratakis, Constantine/AAP-4745-2020	Pack, Svetlana D./0000-0003-3256-6626; /0000-0002-6224-6685	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000642, ZIAHD000642] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BEEBE SJ, 1984, J BIOL CHEM, V259, P3539; CARNEY JA, 1995, SEMIN DERMATOL, V14, P90, DOI 10.1016/S1085-5629(05)80003-3; CARNEY JA, 1986, MAYO CLIN PROC, V61, P165, DOI 10.1016/S0025-6196(12)61843-6; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DANOFF A, 1987, ARCH INTERN MED, V147, P443, DOI 10.1001/archinte.147.3.443; DeMarco L, 1996, HUM GENET, V98, P185, DOI 10.1007/s004390050187; Jones AC, 1999, CLIN CHEM, V45, P1133; KUO JF, 1970, BIOCHIM BIOPHYS ACTA, V212, P79, DOI 10.1016/0005-2744(70)90180-4; LIEBLER GA, 1976, J THORAC CARDIOV SUR, V71, P605; O'Donovan MC, 1998, GENOMICS, V52, P44, DOI 10.1006/geno.1998.5411; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Schoenberg-Fejzo M, 1999, AM J HUM GENET, V65, pA444; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; Stratakis CA, 1998, AM J MED GENET, V80, P183, DOI 10.1002/(SICI)1096-8628(19981102)80:2<183::AID-AJMG19>3.0.CO;2-I; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, ANN INTERN MED, V131, P585, DOI 10.7326/0003-4819-131-8-199910190-00006; Stratakis CA, 1998, J CLIN ENDOCR METAB, V83, P2972, DOI 10.1210/jc.83.8.2972; Stratakis CA, 1996, J CLIN ENDOCR METAB, V81, P3607, DOI 10.1210/jc.81.10.3607; Stratakis CA, 1999, AM J HUM GENET, V65, pA447; Stratakis CA, 2000, FRONT BIOSCI-LANDMRK, V5, pD353, DOI 10.2741/Stratakis; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	28	768	794	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					89	92		10.1038/79238	http://dx.doi.org/10.1038/79238			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973256				2022-12-27	WOS:000089078000025
J	Verpy, E; Leibovici, M; Zwaenepoel, I; Liu, XZ; Gal, A; Salem, N; Mansour, A; Blanchard, S; Kobayashi, I; Keats, BJB; Slim, R; Petit, C				Verpy, E; Leibovici, M; Zwaenepoel, I; Liu, XZ; Gal, A; Salem, N; Mansour, A; Blanchard, S; Kobayashi, I; Keats, BJB; Slim, R; Petit, C			A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C	NATURE GENETICS			English	Article							MYOSIN-VIIA; DEAFNESS; REGION; GENE; IDENTIFICATION; TRANSCRIPTION; LOCALIZATION; MODULES; SYSTEM; SITES	Usher syndrome type 1 (USH1) is an autosomal recessive sensory defect involving congenital profound sensorineural deafness, vestibular dysfunction and blindness (due to progressive retinitis pigmentosa)(1). Six different USH1 loci have been reported. So far, only MYO7A (USH1B), encoding myosin VIIA (ref. 2), has been identified as a gene whose mutation causes the disease. Here, we report a gene underlying USH1C (MIM 276904), a USH1 subtype described in a population of Acadian descendants from Louisiana(3) and in a Lebanese family(4). We identified this gene (USH1C), encoding a PDZ-domain-containing protein, harmonin, in a subtracted mouse cDNA library derived from inner ear sensory areas. In patients we found a splice-site mutation, a frameshift mutation and the expansion of an intronic variable number of tandem repeat (VNTR). We showed that, in the mouse inner ear, only the sensory hair cells express harmonin. The inner ear Ush1c transcripts predicted several harmonin isoforms, some containing an additional coiled-coil domain and a proline- and serine-rich region. As several of these transcripts were absent from the eye, we propose that USH1C also underlies the DFNB18 form of isolated deafness.	Inst Pasteur, CNRS URA 1968, Unite Genet Deficits Sensoriels, Paris 15, France; Virginia Commonwealth Univ, Coll Med, Dept Human Genet, Richmond, VA USA; Virginia Commonwealth Univ, Coll Med, Dept Otolaryngol, Richmond, VA USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Humangenet, D-2000 Hamburg, Germany; Univ St Joseph, Fac Med, Unite Genet Med, Beirut, Lebanon; Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon; Hokkaido Univ, Sch Med, Dept Pediat, Sapporo, Hokkaido 060, Japan; Louisiana State Univ, Hlth Sci Ctr, Dept Biometry & Genet, New Orleans, LA USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Virginia Commonwealth University; Virginia Commonwealth University; University of Hamburg; Saint Joseph University Beirut; American University of Beirut; American University of Beirut; Hokkaido University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Petit, C (corresponding author), Inst Pasteur, CNRS URA 1968, Unite Genet Deficits Sensoriels, Paris 15, France.	cpetit@pasteur.fr	Kobayashi, Ichiro/G-8638-2012; Slim, Rima/J-4104-2019; Leibovici, Michel/ABB-6745-2020	Slim, Rima/0000-0002-4060-2159; Petit, Christine/0000-0002-9069-002X	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002530, R03DC004530] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC02530, R03 DC04530] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bitner-Glindzicz M, 2000, NAT GENET, V26, P56, DOI 10.1038/79178; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; DeAngelis MM, 1998, BBA-MOL BASIS DIS, V1407, P84, DOI 10.1016/S0925-4439(98)00025-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Higgins MJ, 1998, GENOME RES, V8, P57, DOI 10.1101/gr.8.1.57; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; Kimberling W J, 1995, J Am Acad Audiol, V6, P63; Kobayashi I, 1999, GASTROENTEROLOGY, V117, P823, DOI 10.1016/S0016-5085(99)70340-9; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; Saouda M, 1998, HUM GENET, V103, P193, DOI 10.1007/s004390050806; Scanlan MJ, 1999, BBA-GENE STRUCT EXPR, V1445, P39, DOI 10.1016/S0167-4781(99)00033-0; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; Steel KP, 1995, ANNU REV GENET, V29, P675; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	31	349	361	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					51	55		10.1038/79171	http://dx.doi.org/10.1038/79171			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973247				2022-12-27	WOS:000089078000016
J	Li, H; Li, SH; Johnston, H; Shelbourne, PF; Li, XJ				Li, H; Li, SH; Johnston, H; Shelbourne, PF; Li, XJ			Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity	NATURE GENETICS			English	Article							INTRANUCLEAR INCLUSIONS; PROJECTION NEURONS; TRANSGENIC MICE; DISEASE; PROTEIN; LOCALIZATION; APOPTOSIS; MUTATION; RECEPTOR; NUCLEAR	Huntington disease (HD) is caused by expansion of a glutamine repeat in the amino-terminal region of huntingtin. Despite its widespread expression, mutant huntingtin induces selective neuronal loss in striatal neurons. Here we report that, in mutant mice expressing HD repeats, the production and aggregation of N-terminal huntingtin fragments preferentially occur in HD-affected neurons and their processes and axonal terminals. N-terminal fragments of mutant huntingtin form aggregates and induce neuritic degeneration in cultured striatal neurons. N-terminal mutant huntingtin also binds to synaptic vesicles and inhibits their glutamate uptake in vitro. The specific processing and accumulation of toxic fragments of N-terminal huntingtin in HD-affected striatal neurons, especially in their neuronal processes and axonal terminals, may contribute to the selective neuropathology of HD.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Mol Genet, Glasgow, Lanark, Scotland; Tongi Med Univ, Dept Histol & Embryol, Wuhan, Peoples R China	Emory University; University of Glasgow; Huazhong University of Science & Technology	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu						ALBIN RL, 1992, ANN NEUROL, V31, P425, DOI 10.1002/ana.410310412; ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BEAL MF, 1994, NEUROBIOL AGING, V15, P275; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ivkovic S, 1999, J NEUROSCI, V19, P5409; KISH PE, 1989, METHOD ENZYMOL, V174, P9; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Shelbourne PF, 1999, HUM MOL GENET, V8, P763, DOI 10.1093/hmg/8.5.763; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; Xia ZG, 1996, J NEUROSCI, V16, P5425	25	241	253	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					385	389		10.1038/78054	http://dx.doi.org/10.1038/78054			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932179				2022-12-27	WOS:000088615000010
J	Galloway, SM; McNatty, KP; Cambridge, LM; Laitinen, MPE; Juengel, JL; Jokiranta, TS; McLaren, RJ; Luiro, K; Dodds, KG; Montgomery, GW; Beattie, AE; Davis, GH; Ritvos, O				Galloway, SM; McNatty, KP; Cambridge, LM; Laitinen, MPE; Juengel, JL; Jokiranta, TS; McLaren, RJ; Luiro, K; Dodds, KG; Montgomery, GW; Beattie, AE; Davis, GH; Ritvos, O			Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner	NATURE GENETICS			English	Article							DIFFERENTIATION FACTOR-9; X-CHROMOSOME; MESSENGER-RNA; 3-DIMENSIONAL STRUCTURE; HOMOLOG GDF-9B; SHEEP OVARY; FACTOR-BETA; FOLLICLES; FECX(1); EWES	Multiple ovulations are uncommon in humans, cattle and many breeds of sheep. Pituitary gonadotrophins and as yet unidentified ovarian factors precisely regulate follicular development so that, normally, only one follicle is selected to ovulate. The Inverdale (FecX(I)) sheep, however, carries a naturally occurring X-linked mutation that causes increased ovulation rate and twin and triplet births in heterozygotes (FecX(I)/FecX(+); ref. 1). but primary ovarian failure in homozygotes (FecX(I)/FecX(I); ref. 2). Germcell development, formation of the follicle and the earliest stages of follicular growth are normal in FecX(I)/FecX(I) sheep, but follicular development beyond the primary stage is impaired(3,4). A second family unrelated to the Inverdale sheep also has the same X-linked phenotype(5) (Hanna, FecX(H)). Crossing FecX(I) with FecXH animals produces FecX(I)/FecX(H) infertile females phenotypically indistinguishable from FecX(I)/FecX(I) females(6). We report here that the FecX(I) locus maps to an orthologous chromosomal region syntenic to human Xp11.2-11.4, which contains BMP15, encoding bone morphogenetic protein 15 (also known as growth differentiation factor 9B (GDF9B)). Whereas BMP15 is a member of the transforming growth factor beta (TGF beta) superfamily and is specifically expressed in oocytes, its function is unknown(7-9). We show that independent germline point mutations exist in FecX(I) and FecX(H) carriers. These findings establish that BMP15 is essential for female fertility and that natural mutations in an ovary-derived factor can cause both increased ovulation rate and infertility phenotypes in a dosage-sensitive manner.	AgRes, Mol Biol Unit, Dunedin, New Zealand; Univ Otago, Dept Biochem, Ctr Gene Res, Dunedin, New Zealand; AgRes, Wallaceville Anim Res Ctr, Upper Hutt, New Zealand; Biomedicum Helsinki, Programme Dev & Reprod Biol, Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland; AgRes, Invermay Agr Ctr, Mosgiel, New Zealand	AgResearch - New Zealand; University of Otago; AgResearch - New Zealand; University of Helsinki; University of Helsinki; AgResearch - New Zealand	Galloway, SM (corresponding author), AgRes, Mol Biol Unit, Dunedin, New Zealand.		Montgomery, Grant W/B-7148-2008; Jokiranta, T. Sakari/F-1906-2011; Ritvos, Olli/GWC-2442-2022	Montgomery, Grant W/0000-0002-4140-8139; Dodds, Ken/0000-0002-9347-6379; Juengel, Jennifer/0000-0002-2717-7311; Luiro, Kaisu/0000-0003-0736-2891; Ritvos, Olli/0000-0001-7017-6931				Aaltonen J, 1999, J CLIN ENDOCR METAB, V84, P2744, DOI 10.1210/jc.84.8.2744; Bodensteiner KJ, 2000, BIOL REPROD, V62, P1479, DOI 10.1095/biolreprod62.6.1479; BRAWTAL R, 1993, BIOL REPROD, V49, P895, DOI 10.1095/biolreprod49.5.895; Cambridge LM, 1997, ANIM GENET, V28, P457, DOI 10.1111/j.1365-2052.1997.tb03295.x; DAVIES AH, 1994, EUR J VASCULAR SURG, V8, P249, DOI 10.1016/S0950-821X(05)80138-0; Davies KP, 1996, ANIM GENET, V27, P382, DOI 10.1111/j.1365-2052.1996.tb00998.x; DAVIS GH, 1992, BIOL REPROD, V46, P636, DOI 10.1095/biolreprod46.4.636; DAVIS GH, 1991, BIOL REPROD, V44, P620, DOI 10.1095/biolreprod44.4.620; DAVIS R, 1995, PSYCHOLOGIST, V8, P55; Davison RM, 1999, CLIN ENDOCRINOL, V51, P673, DOI 10.1046/j.1365-2265.1999.00926.x; DOLLING CHS, 1996, MENDELIAN INHERITANC, P7; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Galloway SM, 1996, GENOME RES, V6, P667, DOI 10.1101/gr.6.8.667; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HANRAHAN V, 1994, ANIM GENET, V25, P287, DOI 10.1111/j.1365-2052.1994.tb00212.x; Hayashi M, 1999, ENDOCRINOLOGY, V140, P1236, DOI 10.1210/en.140.3.1236; HENDERSON KM, 1988, J REPROD FERTIL, V84, P187, DOI 10.1530/jrf.0.0840187; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Jaatinen R, 1999, MOL CELL ENDOCRINOL, V156, P189, DOI 10.1016/S0303-7207(99)00100-8; JOKIRANTA TS, 1995, FEBS LETT, V376, P31, DOI 10.1016/0014-5793(95)01239-7; Juengel JL, 1997, J REPROD FERTIL, V110, P291, DOI 10.1530/jrf.0.1100291; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; Lundy T, 1999, J REPROD FERTIL, V115, P251, DOI 10.1530/jrf.0.1150251; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; SHACKELL GH, 1993, BIOL REPROD, V48, P1150, DOI 10.1095/biolreprod48.5.1150; Smith P, 1997, BIOL REPROD, V57, P1183, DOI 10.1095/biolreprod57.5.1183; TISDALL DJ, 1994, J MOL ENDOCRINOL, V12, P181, DOI 10.1677/jme.0.0120181	30	773	887	2	72	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					279	283		10.1038/77033	http://dx.doi.org/10.1038/77033			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888873				2022-12-27	WOS:000087920900013
J	Ewing, B; Green, P				Ewing, B; Green, P			Analysis of expressed sequence tags indicates 35,000 human genes	NATURE GENETICS			English	Article							HUMAN GENOME; CPG ISLANDS	The number of protein-coding genes in an organism provides a useful first measure of its molecular complexity. Single-celled prokaryotes and eukaryotes typically have a few thousand genes; for example. Escherichia coli(1) has 4,300 and Saccharomyces cerevisiae(2) has 6.000. Evolution of multicellularity appears to have been accompanied by a several-fold increase in gene number, the invertebrates Caenorhabditis elegans(3) and Drosophila melanogaster(4) having 19,000 and 13,600 genes, respectively. Here we estimate the number of human genes by comparing a set of human expressed sequence tag (EST) contigs with human chromosome 22 and with a non-redundant set of mRNA sequences. The two comparisons give mutually consistent estimates of approximately 35,000 genes, substantially lower than most previous estimates. Evolution of the increased physiological complexity of vertebrates may therefore have depended more on the combinatorial diversification of regulatory networks or alternative splicing than on a substantial increase in gene number.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Green, P (corresponding author), Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA.	phg@u.washington.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bernardi G, 1995, ANNU REV GENET, V29, P445, DOI 10.1146/annurev.ge.29.120195.002305; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Dickson D, 1999, NATURE, V401, P311, DOI 10.1038/43722; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEWIN B, 1990, GENES, V4, P466; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626	19	264	298	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					232	234		10.1038/76115	http://dx.doi.org/10.1038/76115			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835644				2022-12-27	WOS:000087459200028
J	Gripp, KW; Wotton, D; Edwards, MC; Roessler, E; Ades, L; Meinecke, P; Richieri-Costa, A; Zackai, EH; Massague, J; Muenke, M; Elledge, SJ				Gripp, KW; Wotton, D; Edwards, MC; Roessler, E; Ades, L; Meinecke, P; Richieri-Costa, A; Zackai, EH; Massague, J; Muenke, M; Elledge, SJ			Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination	NATURE GENETICS			English	Article							BRAIN; GENE; PROTEINS; HEDGEHOG; LAYER	Holoprosencephaly (HPE) is the most common structural defect of the developing forebrain in humans (1 in 250 conceptuses, 1 in 16,000 live-born infants(1-3)). HPE is aetiologically heterogeneous, with both environmental and genetic causes(4,5). So far, three human HPE genes are known: SHH at chromosome region 7q36 (ref. 6); ZIC2 at 13q32 (ref. 7); and SIX3 at 2p21 (ref. 8). In animal models, genes in the Nodal signalling pathway, such as those mutated in the zebrafish mutants cyclops (refs 9,10), squint (ref. Il)and one-eyed pinhead (oep: ref. 12), cause HPE. Mice heterozygous for null alleles of both Nodal and Smad2 have cyclopia(13) Here we describe the involvement of the TO-interacting factor (TGIF), a homeodomain protein, in human HPE. We mapped TGIF to the HPE minimal critical region in 18p11.3. Heterozygous mutations in individuals with HPE affect the transcriptional repression domain of TGIF, the DNA-binding domain or the domain that interacts with SMAD2. (The latter is an effector in the signalling path-way of the neural axis developmental factor NODAL, a member of the transforming growth factor-beta (TGF-beta) family.) Several of these mutations cause a loss of TGIF function. Thus, TGIF links the NODAL signalling pathway to the bifurcation of the human forebrain and the establishment of ventral midline structures.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Genet & Neurol, Philadelphia, PA 19104 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Natl Human Genome Res Inst, Dept Mol & Human Genet, NIH, Bethesda, MD USA; Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD USA; Royal Alexandra Hosp Children, Parramatta, Australia; Altonauer Kinderkrankenhaus, Hamburg, Germany; Univ Sao Paulo, Sao Paulo, Brazil	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Baylor College of Medicine; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Universidade de Sao Paulo	Muenke, M (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.		Ades, lionel/T-6882-2019; Richieri-Costa, Antonio/B-2514-2013	Muenke, Maximilian/0000-0002-7719-6545; Massague, Joan/0000-0001-9324-8408; Wotton, David/0000-0002-4652-5350				BARR M, 1983, J PEDIATR-US, V102, P565, DOI 10.1016/S0022-3476(83)80185-1; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bertolino E, 1996, DEV DYNAM, V205, P410, DOI 10.1002/(SICI)1097-0177(199604)205:4<410::AID-AJA5>3.0.CO;2-L; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Edwards MC, 1997, GENETICS, V147, P1063; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Golden JA, 1998, J NEUROPATH EXP NEUR, V57, P991, DOI 10.1097/00005072-199811000-00001; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Liu F, 1998, NAT GENET, V20, P325, DOI 10.1038/3793; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Ming JE, 1998, CLIN GENET, V53, P155; MUENKE M, IN PRESS METABOLIC M; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Roessler E, 1998, J INHERIT METAB DIS, V21, P481, DOI 10.1023/A:1005406719292; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; VARLET I, 1997, CURR OPIN GENE DEV, V7, P518; Wallis DE, 1999, NAT GENET, V22, P196, DOI 10.1038/9718; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	24	305	318	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					205	208		10.1038/76074	http://dx.doi.org/10.1038/76074			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835638				2022-12-27	WOS:000087459200022
J	Bouck, JB; Metzker, ML; Gibbs, RA				Bouck, JB; Metzker, ML; Gibbs, RA			Shotgun sample sequence comparisons between mouse and human genomes	NATURE GENETICS			English	Article							ELEMENTS; PROTEIN; REGION; SCALE	A mixed 'clone-by-clone' and 'whole-genome shotgun' strategy will be used to determine the genomic sequence of the mouse. This method will allow a phase of rapid annotation of the contemporaneous human sequence draft, through whole-genome 'sample sequence comparisons'.	Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Bouck, JB (corresponding author), Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA.	jbouck@bcm.tmc.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG002139] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG02139] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; [Anonymous], 1999, SCIENCE, V285, P1493; Ansari-Lari MA, 1998, GENOME RES, V8, P29; Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012; Blaxter M, 1999, SCIENCE, V283, P2103; Bouck J, 1998, GENOME RES, V8, P1074, DOI 10.1101/gr.8.10.1074; BOUCK J, IN PRESS BIOINFORMAT; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; C. elegans Sequencing Consortium, 1999, SCIENCE, V283, P35; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; KOOP BF, 1992, GENOMICS, V13, P1209, DOI 10.1016/0888-7543(92)90039-U; Metzker ML, 1996, SCIENCE, V271, P1420, DOI 10.1126/science.271.5254.1420; Myers MP, 1997, NUCLEIC ACIDS RES, V25, P4710, DOI 10.1093/nar/25.23.4710; Oeltjen JC, 1997, GENOME RES, V7, P315, DOI 10.1101/gr.7.4.315; PENNISI E, SCIENCE, V287, P1179; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; Tunnicliffe GRR, 2000, MAMM GENOME, V11, P213, DOI 10.1007/s003350010039	22	18	22	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					31	33		10.1038/75563	http://dx.doi.org/10.1038/75563			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802652				2022-12-27	WOS:000086884000012
J	Pellegata, NS; Dieguez-Lucena, JL; Joensuu, T; Lau, S; Montgomery, KT; Krahe, R; Kivela, T; Kucherlapati, R; Forsius, H; de la Chapelle, A				Pellegata, NS; Dieguez-Lucena, JL; Joensuu, T; Lau, S; Montgomery, KT; Krahe, R; Kivela, T; Kucherlapati, R; Forsius, H; de la Chapelle, A			Mutations in KERA, encoding keratocan, cause cornea plana	NATURE GENETICS			English	Article							HUMAN DECORIN GENE; SULFATE PROTEOGLYCAN; GENOMIC DNA; HUMAN DSPG3; CONGENITA; CHROMOSOME-12; ORGANIZATION; EXPRESSION; CLONING; REGION	Specialized collagens and small leucine-rich proteoglycans (SLRPs) interact to produce the transparent corneal structure(1) In cornea plana, the forward convex curvature is flattened, leading to a decrease in refraction(2). A more severe, recessively inherited form (CNA2; MIM 217300) and a milder, dominantly inherited form (CNA1; MIM 121400) exist. CNA2 is a rare disorder with a worldwide distribution, but a high prevalence in the Finnish population(3). The gene mutated in CNA2 was assigned by linkage analysis to 12q (refs 4,5), where there is a cluster of several SLRP genes(6-9). We cloned two additional SLRP genes highly expressed in cornea: KERA (encoding keratocan) in 12q and OGN (encoding osteoglycin) in 9q. Here we report mutations in KERA in 47 CNA2 patients: 46 Finnish patients are homozygous for a founder missense mutation, leading to the substitution of a highly conserved amino acid; and one American patient is homozygous for a mutation leading to a premature stop codon that truncates the KERA protein. Our data establish that mutations in KERA cause CNA2. CNA1 patients had no mutations in these proteoglycan genes.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Folkhalsan Inst Genet, Helsinki, Finland; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Univ Helsinki Hosp, Dept Ophthalmol, Helsinki, Finland	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Yeshiva University; Albert Einstein College of Medicine; University of Helsinki; Helsinki University Central Hospital	de la Chapelle, A (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA.		Joensuu, Tarja/F-3059-2011; Kucherlapati, Raju/ABC-8807-2021; Kivelä, Tero/C-9241-2009; Pellegata, Natalia S/I-1256-2012	Kivelä, Tero/0000-0003-1198-4394; Pellegata, Natalia S/0000-0002-8000-7784	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058] Funding Source: Medline; PHS HHS [NG1763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Deere M, 1999, GENOME RES, V9, P449; Deere M, 1996, GENOMICS, V38, P399, DOI 10.1006/geno.1996.0643; ERIKSSON AW, 1973, CLIN GENET, V4, P301; Forsius H, 1998, ACTA OPHTHALMOL SCAN, V76, P196, DOI 10.1034/j.1600-0420.1998.760215.x; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Griffith M, 1999, SCIENCE, V286, P2169, DOI 10.1126/science.286.5447.2169; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Hocking AM, 1998, MATRIX BIOL, V17, P1; Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; MIANO JM, 1999, MOL BIOL VASCULAR DI, P25; SiglerVillanueva A, 1997, OPHTHALMIC GENET, V18, P55, DOI 10.3109/13816819709057116; SPENCER WH, 1996, OPHTHALMIC PATHOLOGY, P159; Tahvanainen E, 1996, J MED GENET, V33, P116, DOI 10.1136/jmg.33.2.116; TAHVANAINEN E, 1995, GENOMICS, V26, P290, DOI 10.1016/0888-7543(95)80213-6; Tahvanainen E, 1996, GENOME RES, V6, P249, DOI 10.1101/gr.6.4.249; Tahvanainen E, 1995, GENOMICS, V30, P409, DOI 10.1006/geno.1995.1258; Tasheva ES, 1999, DNA SEQUENCE, V10, P67, DOI 10.3109/10425179909033939; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRALSTAD RL, 1974, J CELL BIOL, V62, P815; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; WILSON FM, 1994, CORNEA, P539	26	117	124	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					91	95		10.1038/75664	http://dx.doi.org/10.1038/75664			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802664				2022-12-27	WOS:000086884000024
J	Vrana, PB; Fossella, JA; Matteson, P; del Rio, T; O'Neill, MJ; Tilghman, SM				Vrana, PB; Fossella, JA; Matteson, P; del Rio, T; O'Neill, MJ; Tilghman, SM			Genetic and epigenetic incompatibilities underlie hybrid dysgenesis in Peromyscus	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; PLACENTAL DEVELOPMENT; IMPRINTED GENE; HALDANES RULE; MOUSE; LOCUS; GROWTH; MAP	Crosses between the two North American rodent species Peromyscus polionotus (PO) and Peromyscus maniculatus (BW) yield parent-of-origin effects on both embryonic and placental growth(1,2). The two species are approximately the same size, but a female BW crossed with a male PO produces offspring that are smaller than either parent. In the reciprocal cross, the offspring are oversized and typically die before birth. Rare survivors are exclusively female, consistent with Haldane's rule, which states that in instances of hybrid sterility or inviability, the heterogametic sex tends to be more severely affected(3). To understand these sex- and parent-of-origin-specific patterns of overgrowth, we analysed reciprocal backcrosses. Our studies reveal that hybrid inviability is partially due to a maternally expressed X-linked PO locus and an imprinted paternally expressed autosomal BW locus. In addition, the hybrids display skewing of X-chromosome inactivation in favour of the expression of the BW X chromosome. The most severe overgrowth is accompanied by widespread relaxation of imprinting of mostly paternally expressed genes. Both genetic and epigenetic mechanisms underlie hybrid inviability in Peromyscus and hence have a role in the establishment and maintenance of reproductive isolation barriers in mammals.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051460] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; CATTANACH BM, 1970, GENET RES, V15, P183, DOI 10.1017/S0016672300001518; CATTANACH BM, 1972, GENET RES, V19, P229, DOI 10.1017/S001667230001449X; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COYNE JA, 1989, EVOLUTION, V43, P362, DOI [10.2307/2409213, 10.1111/j.1558-5646.1989.tb04233.x]; DARVASI A, 1995, GENETICS, V141, P1199; DAWSON WD, 1965, EVOLUTION, V19, P44, DOI 10.2307/2406294; Dawson WD, 1999, MAMM GENOME, V10, P730, DOI 10.1007/s003359901080; Dobzhansky T., 1937; Gray A. P., 1972, MAMMALIAN HYBRIDS; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Li YH, 1998, NAT GENET, V20, P309, DOI 10.1038/3129; Lyons LA, 1997, NAT GENET, V15, P47, DOI 10.1038/ng0197-47; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Muller HJ, 1942, BIOL S, V6, P71; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; ROGERS JF, 1970, J REPROD FERTIL, V21, P255; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; TURELLI M, 1995, GENETICS, V140, P389; Vrana PB, 1998, NAT GENET, V20, P362, DOI 10.1038/3833; Zechner U, 1996, NAT GENET, V12, P398, DOI 10.1038/ng0496-398; Zeng LW, 1996, GENETICS, V143, P603	30	133	137	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					120	124		10.1038/75518	http://dx.doi.org/10.1038/75518			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802670				2022-12-27	WOS:000086884000030
J	Ross, DT; Scherf, U; Eisen, MB; Perou, CM; Rees, C; Spellman, P; Iyer, V; Jeffrey, SS; Van de Rijn, M; Waltham, M; Pergamenschikov, A; Lee, JCE; Lashkari, D; Shalon, D; Myers, TG; Weinstein, JN; Botstein, D; Brown, PO				Ross, DT; Scherf, U; Eisen, MB; Perou, CM; Rees, C; Spellman, P; Iyer, V; Jeffrey, SS; Van de Rijn, M; Waltham, M; Pergamenschikov, A; Lee, JCE; Lashkari, D; Shalon, D; Myers, TG; Weinstein, JN; Botstein, D; Brown, PO			Systematic variation in gene expression patterns in human cancer cell lines	NATURE GENETICS			English	Article							ANTICANCER DRUG SCREEN; MOLECULAR PHARMACOLOGY; EPITHELIAL-CELLS; BREAST; DIFFERENTIATION; ESTABLISHMENT; PROTEINS; ADHESION; DISPLAY; DISEASE	We used cDNA microarrays to explore the variation in expression of approximately 8,000 unique genes among the 60 cell lines used in the National Cancer Institute's screen for anti-cancer drugs. Classification of the cell lines based solely on the observed patterns of gene expression revealed a correspondence to the ostensible origins of the tumours from which the cell lines were derived. The consistent relationship between the gene expression patterns and the tissue of origin allowed us to recognize outliers whose previous classification appeared incorrect. Specific features of the gene expression patterns appeared to be related to physiological properties of the cell lines, such as their doubling time in culture, drug metabolism or the interferon response. Comparison of gene expression patterns in the cell lines to those observed in normal breast tissue or in breast tumour specimens revealed features of the expression patterns in the tumours that had recognizable counterparts in specific cell lines, reflecting the tumour, stromal and inflammatory components of the tumour tissue. These results provided a novel molecular characterization of this important group of human cell lines and their relationships to tumours in vivo.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Incyte Pharmaceut, Fremont, CA USA; Genometrix Inc, The Woodlands, TX USA; NCI, Informat Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diagnosis,NIH, Rockville, MD USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Incyte; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.		Waltham, Mark/A-1728-2009; Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247; Shalon, Tidhar Dari/0000-0003-2646-6215; Jeffrey, Stefanie/0000-0003-4478-2764; Myers, Timothy Gene/0000-0002-7059-5906; van de Rijn, Matt/0000-0002-1909-9739; Weinstein, John/0000-0001-9401-6908; Eisen, Michael/0000-0002-7528-738X	NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NCI NIH HHS [CA 077097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; BRINKLEY BR, 1980, CANCER RES, V40, P3118; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; COWIN P, 1996, CURR OPIN CELL BIOL, V8, P244; Davies JA, 1997, BIOESSAYS, V19, P699, DOI 10.1002/bies.950190810; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hartigan J., 1975, CLUSTERING ALGORITHM; HELMLEKOLB C, 1993, PFLUG ARCH EUR J PHY, V425, P34, DOI 10.1007/BF00374501; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371-199807000-00001; Khan J, 1998, CANCER RES, V58, P5009; Lincecum JM, 1998, J CELL BIOCHEM, V70, P22, DOI 10.1002/(SICI)1097-4644(19980701)70:1<22::AID-JCB3>3.0.CO;2-5; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Moscow JA, 1997, CANCER CHEMOTHER BIO, V17, P139; Myers TG, 1997, ELECTROPHORESIS, V18, P647, DOI 10.1002/elps.1150180351; NESLAND JM, 1988, PATHOL RES PRACT, V183, P214, DOI 10.1016/S0344-0338(88)80048-7; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; RUTKA JT, 1987, ACTA NEUROPATHOL, V75, P92, DOI 10.1007/BF00686798; RUTKA JT, 1986, CANCER RES, V46, P5893; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sgroi DC, 1999, CANCER RES, V59, P5656; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SMITH HS, 1986, ANN NY ACAD SCI, V464, P288, DOI 10.1111/j.1749-6632.1986.tb16010.x; Sokal RR, 1963, PRINCIPLES NUMERICAL; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; VANOSDOL WW, 1994, J NATL CANCER I, V86, P1853, DOI 10.1093/jnci/86.24.1853; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	44	1648	1767	1	89	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					227	235		10.1038/73432	http://dx.doi.org/10.1038/73432			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700174	Green Submitted			2022-12-27	WOS:000085590600011
J	Zemni, R; Bienvenu, T; Vinet, MC; Sefiani, A; Carrie, A; Billuart, P; McDonell, N; Couvert, P; Francis, F; Chafey, P; Fauchereau, F; Friocourt, G; des Portes, V; Cardona, A; Frints, S; Meindl, A; Brandau, O; Ronce, N; Moraine, C; van Bokhoven, H; Ropers, HH; Sudbrak, R; Kahn, A; Fryns, JP; Beldjord, R; Chelly, J				Zemni, R; Bienvenu, T; Vinet, MC; Sefiani, A; Carrie, A; Billuart, P; McDonell, N; Couvert, P; Francis, F; Chafey, P; Fauchereau, F; Friocourt, G; des Portes, V; Cardona, A; Frints, S; Meindl, A; Brandau, O; Ronce, N; Moraine, C; van Bokhoven, H; Ropers, HH; Sudbrak, R; Kahn, A; Fryns, JP; Beldjord, R; Chelly, J			A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation	NATURE GENETICS			English	Article							MEMORY; SUPERFAMILY	X-linked forms of mental retardation (MR) affect approximately 1 in 600 males and are likely to be highly heterogeneous(1-3) They can be categorized into syndromic (MRXS) and nonspecific (MRX) forms. In MRX forms, affected patients have no distinctive clinical or biochemical features. At least five MRX genes have been identified by positional cloning, but each accounts for only 0.5%-1.0% of MRX cases(4,5). Here we show that the gene TM4SF2 at Xp11.4 is inactivated by the X breakpoint of an X;2 balanced translocation in a patient with MR. Further investigation led to identification of TM4SF2 mutations in 2 of 33 other MRX families. RNA in site hybridization showed that TM4SF2 is highly expressed in the central nervous system, including the cerebral cortex and hippocampus. TM4SF2 encodes a member of the tetraspanin family of proteins, which are known to contribute in molecular complexes including beta-l integrins(6-8). We speculate that through this interaction, TM4SF2 might have a role in the control of neurite outgrowth.	CHU Cochin, ICGM, INSERM, U129, Paris, France; Natl Inst Hyg, Rabat, Morocco; Inst Pasteur, Lab Technol Cellulaire, Paris, France; Clin Genet Univ, UZ Gasthuisberg, Ctr Human Genet, Louvain, Belgium; Univ Munich, Abt Med Genet, Munich, Germany; Ctr Hosp Tours, Serv Genet, Hop Bretonneau, Tours, France; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Mol Genet, Abt Lehrach, Berlin, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven; University Hospital Leuven; University of Munich; CHU Tours; Radboud University Nijmegen; Max Planck Society	Chelly, J (corresponding author), CHU Cochin, ICGM, INSERM, U129, Paris, France.		van Bokhoven, Hans/D-8764-2012; Bokhoven, J.H.L.M. van van/H-8015-2014; Sudbrak, Ralf/HHZ-8821-2022; Francis, Fiona/B-5854-2016; Chelly, Jamel/J-7528-2015; Billuart, Pierre/K-3832-2017; Friocourt-Masse, Gaelle/M-8916-2017; Glover, Vivette/M-2711-2016	Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Chelly, Jamel/0000-0002-0939-8719; Billuart, Pierre/0000-0003-1913-1687; Glover, Vivette/0000-0001-6543-1651; Francis, Fiona/0000-0001-8542-7537; Friocourt, Gaelle/0000-0001-6681-7644; Couvert, Philippe/0000-0002-7607-2057; Frints, Suzanna G.M./0000-0002-5027-8364				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; Chelly J, 1999, HUM MOL GENET, V8, P1833, DOI 10.1093/hmg/8.10.1833; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CrumeyrolleArias M, 1996, HISTOCHEM J, V28, P801, DOI 10.1007/BF02272153; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; EMI N, 1993, IMMUNOGENETICS, V37, P193; FERNANDEZ E, 1993, PCR METH APPL, V3, P122; GLASS IA, 1991, J MED GENET, V28, P361, DOI 10.1136/jmg.28.6.361; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HELMER ME, 1998, CURR OPIN CELL BIOL, V10, P578; HERBST DS, 1980, AM J MED GENET, V7, P461, DOI 10.1002/ajmg.1320070407; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MANDEL JL, 1994, AM J MED GENET, V51, P550, DOI 10.1002/ajmg.1320510452; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; RUBENSTEIN E, 1993, GUIDEBOOK EXTRACELLU, P20; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9	21	187	193	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					167	170		10.1038/72829	http://dx.doi.org/10.1038/72829			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655063				2022-12-27	WOS:000085104600018
J	Hsieh-Li, HM; Chang, JG; Jong, YJ; Wu, MH; Wang, NM; Tsai, CH; Li, H				Hsieh-Li, HM; Chang, JG; Jong, YJ; Wu, MH; Wang, NM; Tsai, CH; Li, H			A mouse model for spinal muscular atrophy	NATURE GENETICS			English	Article							SURVIVAL MOTOR-NEURON; SMN PROTEIN; DETERMINING GENE; IDENTIFICATION; DISEASE; CELLS; TISSUES	The survival motor neuron gene is present in humans in a telomeric copy, SMN1, and several centromeric copies, SMN2. Homozygous mutation of SMN1 is associated with proximal spinal muscular atrophy (SMA), a severe motor neuron disease characterized by early childhood onset of progressive muscle weakness(1-5). To understand the functional role of SMN1 in SMA, we produced mouse lines deficient for mouse Smn and transgenic mouse lines that expressed human SMN2. Smn(-/-) mice died during the peri-implantation stage. In contrast, transgenic mice harbouring SMN2 in the Smn(-/-) background showed pathological changes in the spinal cord and skeletal muscles similar tho those of SMA patients. The severity of the pathological changes in these mice correlated with the amount of SMN protein that contained the region encoded by exon 7. Our results demonstrate that SMN2 can partially compensate for lack of SMN1, The variable phenotypes of Smn(-/-)SMN2 mice reflect those seen in SMA patients, providing a mouse model for this disease.	Acad Sinica, Inst Mol Biol, Taipei, Taiwan; China Med Coll Hosp, Dept Med Res, Taichung, Taiwan; Kaohsiung Med Univ, Dept Pediat, Kaohsiung, Taiwan; Kaohsiung Med Univ, Dept Clin Lab, Kaohsiung, Taiwan	Academia Sinica - Taiwan; China Medical University Taiwan; Kaohsiung Medical University; Kaohsiung Medical University	Li, H (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.		Jong, Yuh-Jyh/B-8782-2009; Chang, Jan-Gowth/C-9544-2009					Bergin A, 1997, GENE, V204, P47, DOI 10.1016/S0378-1119(97)00510-6; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Burlet P, 1998, HUM MOL GENET, V7, P1927, DOI 10.1093/hmg/7.12.1927; Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886; Chang JG, 1997, HUM GENET, V100, P577, DOI 10.1007/s004390050555; CHOU SM, 1978, ACTA NEUROPATHOL, V41, P45, DOI 10.1007/BF00689556; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DIMITAR K, 1998, NAT GENET, V20, P230; DUBOWLTZ V, 1995, MUSCLE DISORDERS CHI; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HENDREY J, 1995, DEV BIOL, V172, P253, DOI 10.1006/dbio.1995.0020; Hogan B, 1994, MANIPULATING MOUSE E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; La Bella V, 1998, EUR J NEUROSCI, V10, P2913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li H, 1996, EMBO J, V15, P714, DOI 10.1002/j.1460-2075.1996.tb00407.x; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Parsons DW, 1998, AM J HUM GENET, V63, P1712, DOI 10.1086/302160; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; vanderSteege G, 1996, AM J HUM GENET, V59, P834; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	30	548	572	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					66	70		10.1038/71709	http://dx.doi.org/10.1038/71709			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615130				2022-12-27	WOS:000084609200018
J	Harrison, KA; Thaler, J; Pfaff, SL; Gu, H; Kehrl, JH				Harrison, KA; Thaler, J; Pfaff, SL; Gu, H; Kehrl, JH			Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice	NATURE GENETICS			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; HOMEOBOX GENE; BETA-CELLS; DIFFERENTIATION; REVEALS; REQUIREMENT; MESENCHYME; INTESTINE; NOTOCHORD; PDX-1	In most mammals the pancreas develops from the foregut endoderm as ventral and dorsal buds. These buds fuse and develop into a complex organ composed of endocrine, exocrine and ductal components(1,2). This developmental process depends upon an integrated network of transcription factors. Gene targeting experiments have revealed critical roles for Pdx1, lsl1, Pax4, Pax6 and Nkx2-2 (refs 3-10). The homeobox gene HLXB9 (encoding HB9) is prominently expressed in adult human pancreas(11), although its role in pancreas development and function is unknown. To facilitate its study, we isolated the mouse HLXB9 orthologue, Hlxb9. During mouse development, the dorsal and ventral pancreatic buds and mature beta-cells in the islets of Langerhans express Hlxb9. In mice homologous for a null mutation of Hlxb9, the dorsal lobe of the pancreas fails to develop. The remnant Hlxb9(-/-) pancreas has small islets of Langerhans with reduced numbers of insulin-producing p-cells. Hlxb9(-/-) beta-cells express low levels of the glucose transporter Glut2 and homeodomain factor Nkx 6-1. Thus, Hlxb9 is key to normal pancreas development and function.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Salk Institute	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	jkehrl@niaid.nih.gov	Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000737, Z01AI000719] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; BAUBONIS W, 1993, NUCLEIC ACIDS RES, V21, P2025, DOI 10.1093/nar/21.9.2025; Githens Sherwood, 1993, P21; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kim SK, 1997, DEVELOPMENT, V124, P4243; Offield MF, 1996, DEVELOPMENT, V122, P983; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Ross AJ, 1998, NAT GENET, V20, P358, DOI 10.1038/3828; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; THALER J, IN PRESS NEURON; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	26	275	294	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					71	75		10.1038/12674	http://dx.doi.org/10.1038/12674			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471502				2022-12-27	WOS:000082337300019
J	Delpire, E; Lu, JM; England, R; Dull, C; Thorne, T				Delpire, E; Lu, JM; England, R; Dull, C; Thorne, T			Deafness and imbalance associated with inactivation of the secretory Ma-K-2Cl co-transporter	NATURE GENETICS			English	Article							K-CL COTRANSPORTER; INNER-EAR; NA-K-2CL COTRANSPORTER; MOLECULAR-CLONING; LOOP DIURETICS; LOCALIZATION; CELLS; GENE; EXPRESSION; MUTATION	Deaf ness can result from a variety of gene defects'. Some genes involved in the physiology of hearing encode membrane transporters that regulate the ionic composition of the fluid bathing the inner ear. The endolymph is an extracellular fluid with an atypical composition that resembles the intracellular milieu, high in K+ and low in Na+. Recent studies have emphasized the prominent role of K+ channels in endolymph secretion(2-4) and mechanical transduction(5). Coupled electroneutral transport of Na+, K+ and Cl- is: mediated by two isoforms of the. Na-K-2Cl cotransporter:the absorptive isoform BSC1 (also called NKCC2, encoded by SIc12a1 in mouse) that is exclusively expressed in kidney;- and BSC2/NKCC1 (encoded by SIc12a2 in mouse).: the secretory isoform which has a wider pattern of expression including epithelia, muscle cells; neurons, and red blood cells(6,7). These Eo-transporters: share 57% homology at the amino acid level(8-11) and are pharmacologically inhibited by loop diuretics. There is functional(12-14) and histochemical(15-17) evidence for the presence of the secretory isoform of the Na-K-2Cl co-transporter in gerbil. rat and rabbit inner ear. We disrupted mouse SIc12a2 and report here that SIc12a2(-/-) mice are deaf and exhibit classic shaker/waltzer behaviour, indicative of inner-ear defects. We localized the co-transporter to key secreting epithelia of the mouse inner ear and-show that absence of functional co-transporter leads to structural damages in the inner ear consistent with a decrease in endolymph secretion.	Vanderbilt Univ, Med Ctr, Anesthesiol Res Div, Labs Cellular & Mol Physiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Delpire, E (corresponding author), Vanderbilt Univ, Med Ctr, Anesthesiol Res Div, Labs Cellular & Mol Physiol, Nashville, TN 37232 USA.							Alvarez-Leefmans F.J., 1998, PRESYNAPTIC INHIBITI, P50; Belal A Jr, 1980, Am J Otolaryngol, V1, P275, DOI 10.1016/S0196-0709(80)80030-5; COOPERMAN LB, 1973, AM HEART J, V85, P831, DOI 10.1016/0002-8703(73)90434-1; Crouch JJ, 1997, J HISTOCHEM CYTOCHEM, V45, P773, DOI 10.1177/002215549704500601; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Deol M S, 1968, J Med Genet, V5, P137, DOI 10.1136/jmg.5.2.137; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Goto S, 1997, BRAIN RES, V765, P324, DOI 10.1016/S0006-8993(97)00679-3; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Ikeda K, 1997, HEARING RES, V107, P1, DOI 10.1016/S0378-5955(97)00009-9; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; MARCUS DC, 1987, HEARING RES, V30, P55, DOI 10.1016/0378-5955(87)90183-3; MARCUS NY, 1987, AM J PHYSIOL, V253, pF613, DOI 10.1152/ajprenal.1987.253.4.F613; Mizuta K, 1997, HEARING RES, V106, P154, DOI 10.1016/S0378-5955(97)00010-5; Mount DB, 1998, J EXP BIOL, V201, P2091; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Randall J, 1997, AM J PHYSIOL-CELL PH, V273, pC1267, DOI 10.1152/ajpcell.1997.273.4.C1267; ROSE BD, 1991, KIDNEY INT, V39, P336, DOI 10.1038/ki.1991.43; RYBAK LP, 1993, OTOLARYNG CLIN N AM, V26, P829; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; SHIGA N, 1995, BBA-BIOMEMBRANES, V1240, P48, DOI 10.1016/0005-2736(95)00175-1; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANGEMANN P, 1995, HEARING RES, V84, P19, DOI 10.1016/0378-5955(95)00009-S	30	307	328	1	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					192	195		10.1038/9713	http://dx.doi.org/10.1038/9713			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369265				2022-12-27	WOS:000080680900028
J	Lanford, PJ; Lan, Y; Jiang, RL; Lindsell, C; Weinmaster, G; Gridley, T; Kelley, MW				Lanford, PJ; Lan, Y; Jiang, RL; Lindsell, C; Weinmaster, G; Gridley, T; Kelley, MW			Notch signalling pathway mediates hair cell development in mammalian cochlea	NATURE GENETICS			English	Article							NEUROGENIC GENE-DELTA; DROSOPHILA; HOMOLOG; EMBRYOGENESIS; JAGGED2; LIGAND; CORTI	The mammalian cochlea contains an invariant mosaic of sensory hair cells and non-sensory supporting cells reminiscent of invertebrate structures such as the compound eye in Drosophila melanogaster(1,2). The sensory epithelium in the mammalian cochlea (the organ of Corti) contains four rows of mechanosensory hair cells: a single row of inner hair cells and three rows of outer hair cells. Each hair cell is separated from the next by an interceding supporting cell, forming an invariant and alternating mosaic that extends the length of the cochlear duct(1). Previous results suggest that determination of cell fates in the cochlear mosaic occurs via inhibitory interactions between adjacent progenitor cells(3-5) (lateral inhibition). Cells populating the cochlear epithelium appear to constitute a developmental equivalence group in which developing hair cells suppress differentiation in their immediate neighbours through lateral inhibition(6). These interactions may be mediated through the Notch signalling pathway, a molecular mechanism that is involved in the determination of a variety of cell fates(7-9) Here we show that genes encoding the receptor protein Notch1 and its ligand, lagged 2, are expressed in alternating cell types in the developing sensory epithelium. In addition, genetic deletion of Jag2 results in a significant increase in sensory hair cells, presumably as a result of a decrease in Notch activation. These results provide direct evidence for Notch-mediated lateral inhibition in a mammalian system and support a role for Notch in the development of the cochlear mosaic.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20007 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90024 USA	Georgetown University; Jackson Laboratory; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kelley, MW (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	kelleym2@gunet.georgetown.edu		Jiang, Rulang/0000-0001-7842-4696	PHS HHS [K02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adam J, 1998, DEVELOPMENT, V125, P4645; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BASLER K, 1991, BIOESSAYS, V13, P621, DOI 10.1002/bies.950131202; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CORWIN JT, 1991, CIBA F SYMP, V160, P103; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; Dornseifer P, 1997, MECH DEVELOP, V63, P159, DOI 10.1016/S0925-4773(97)00037-3; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Haddon C, 1998, DEVELOPMENT, V125, P4637; Haddon C, 1998, DEVELOPMENT, V125, P359; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P123; KELLEY MW, 1995, J NEUROSCI, V15, P3013; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Kopan R, 1997, TRENDS GENET, V13, P465, DOI 10.1016/S0168-9525(97)01318-8; LEWIS J, 1991, CIBA F SYMP, V160, P25, DOI 10.4171/RMI/104; Lewis J, 1996, CURR OPIN NEUROBIOL, V6, P3, DOI 10.1016/S0959-4388(96)80002-X; Lim D., 1992, DEV AUDITORY VESTIBU, P33; LIM DJ, 1985, ACTA OTO-LARYNGOL, P1; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; NADOL JB, 1988, HEARING RES, V34, P253, DOI 10.1016/0378-5955(88)90006-8; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINSTABL C, 1992, J CLIN MONITOR, V8, P116, DOI 10.1007/BF01617429; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	30	369	390	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					289	292		10.1038/6804	http://dx.doi.org/10.1038/6804			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080181				2022-12-27	WOS:000078977900022
J	Battey, J; Jordan, E; Cox, D; Dove, W				Battey, J; Jordan, E; Cox, D; Dove, W			An action plan for mouse genomics	NATURE GENETICS			English	Editorial Material								The mouse has become the leading animal model for studying biological processes in mammals. Creation of additional genomic and genetic resources will make the mouse an even more useful model for the research community. On the basis of recommendations from the scientific community, the National Institutes of Health (NIH) plans to support grants to generate a 'working draft' sequence of the mouse genome by 2003, systematic mutagenesis and phenotyping centres, repositories for mouse strain maintenance, distribution and cryopreservation and training fellowships in mouse pathobiology.	Natl Inst Deafness & Other Commun Disorders, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison	Battey, J (corresponding author), Natl Inst Deafness & Other Commun Disorders, NIH Bldg 31,9000 Rockville Pike, Bethesda, MD 20892 USA.								0	78	80	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					73	75		10.1038/5012	http://dx.doi.org/10.1038/5012			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916794				2022-12-27	WOS:000077960700012
J	Bowtell, DDL				Bowtell, DDL			Options available - from start to finish - for obtaining expression data by microarray	NATURE GENETICS			English	Review							3 ABUNDANCE CLASSES; GENE-EXPRESSION; DNA MICROARRAY; MESSENGER-RNA; HYBRIDIZATION; GENOME; CANCER; SCALE; PATTERNS; PROTEOME	The excitement surrounding microarray technology has been tempered by the limited ability of the general biomedical research community to gain access to it. Given that the hardware required for exploitation of the technology is becoming increasingly available, it is an appropriate moment to review options, be they commercially or publically available. Here, we provide a snapshot of the rapidly changing field of microarray-based RNA expression analysis and consider the components and procedures for putting together a complete system.	Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	Peter Maccallum Cancer Center	Bowtell, DDL (corresponding author), Peter MacCallum Canc Inst, Locked Bag 1,A Beckett St, Melbourne, Vic 3000, Australia.		Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; CALE KA, 1999, NAT GENET, V21, P38; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; DRMANAC R, 1994, SCIENCE, V163, P596; Drmanac S, 1998, NAT BIOTECHNOL, V16, P54, DOI 10.1038/nbt0198-54; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Ermolaeva O, 1998, NAT GENET, V20, P19, DOI 10.1038/1670; FRIEMERT C, 1989, Methods in Molecular and Cellular Biology, V1, P143; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; HASTIE ND, 1976, CELL, V9, P761, DOI 10.1016/0092-8674(76)90139-2; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; KAHN P, 1995, SCIENCE, V270, P369, DOI 10.1126/science.270.5235.369; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Pietu G, 1996, GENOME RES, V6, P492, DOI 10.1101/gr.6.6.492; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schutze K, 1998, NAT BIOTECHNOL, V16, P737, DOI 10.1038/nbt0898-737; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	36	342	471	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			25	32		10.1038/4455	http://dx.doi.org/10.1038/4455			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915497				2022-12-27	WOS:000078008200008
J	Robertson, KD; Ait-Si-Ali, S; Yokochi, T; Wade, PA; Jones, PL; Wolffe, AP				Robertson, KD; Ait-Si-Ali, S; Yokochi, T; Wade, PA; Jones, PL; Wolffe, AP			DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters	NATURE GENETICS			English	Article							DNA METHYLTRANSFERASE GENE; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; IMMUNODEFICIENCY SYNDROME; CYTOSINE METHYLATION; REPLICATION; MUTATIONS; MECP2	Methylation of CpG islands is associated with transcriptional silencing and the formation of nuclease-resistant chromatin structures enriched in hypoacetylated histones(1-3). Methyl-CpG-binding proteins, such as MeCP2, provide a link between methylated DNA and hypoacetylated histones by recruiting histone deacetylase(4,5), but the mechanisms establishing the methylation patterns themselves are unknown. Whether DNA methylation is always causal for the assembly of repressive chromatin or whether features of transcriptionally silent chromatin might target methyltransferase remains unresolved. Mammalian DNA methyltransferases show little sequence specificity in vitro, yet methylation can be targeted in vivo within chromosomes to repetitive elements(6,7), centromeress(8-10) and imprinted loci(11). This targeting is frequently disrupted in tumour cells, resulting in the improper silencing of tumour-suppressor genes associated with CpG islands(1,2). Here we show that the predominant mammalian DNA methyltransferase, DNMT1, co-purifies with the retinoblastoma (Rb) tumour suppressor gene product, E2F1. and HDAC1 and that DNMT1 cooperates with Rb to repress transcription from promoters containing E2F-binding sites. These results establish a link between DNA methylation, histone deacetylase and sequence-specific DNA binding activity, as well as a growth-regulatory pathway that is disrupted in nearly all cancer cells.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wolffe, AP (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA USA.	awolffe@sangamo.com	Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X; Robertson, Keith/0000-0002-7508-3328	DIVISION OF BASIC SCIENCES - NCI [Z01BC010420] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; ISSA JP, 1997, LEUKEMIA S1, V11, P7; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Luff B, 1999, MOL CELL, V3, P505, DOI 10.1016/S1097-2765(00)80478-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Roberts J.D., 1991, CONCEPT MAGNETIC RES, V3, P27, DOI [DOI 10.1002/cmr.1820030104, 10.1002/cmr.1820030104, DOI 10.1002/CMR.1820030104]; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	28	744	789	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					338	342		10.1038/77124	http://dx.doi.org/10.1038/77124			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888886				2022-12-27	WOS:000087920900026
J	Taillon-Miller, P; Bauer-Sardina, I; Saccone, NL; Putzel, J; Laitinen, T; Cao, A; Kere, J; Pilia, G; Rice, JP; Kwok, PY				Taillon-Miller, P; Bauer-Sardina, I; Saccone, NL; Putzel, J; Laitinen, T; Cao, A; Kere, J; Pilia, G; Rice, JP; Kwok, PY			Juxtaposed regions of extensive and minimal linkage disequilibrium in human Xq25 and Xq28	NATURE GENETICS			English	Article							GAMETIC DISEQUILIBRIUM; GENOME; GENE; POPULATION	Linkage disequilibrium (LD). or the non-random association of alleles. is poorly understood in the human genome(1). Population genetic theory suggests that LD is determined by the age of the markers, population history, recombination rate, selection and genetic drift(2). Despite the uncertainties in determining the relative contributions of these factors, some groups have argued that LD is a simple function of distance between markers(3,4). Disease-gene mapping studies and a simulation study gave differing predictions on the degree of LD in isolated and general populations(5,6). In view of the discrepancies between theory and experimental observations, we constructed a high-density SNP map of the Xq25-Xq28 region(7) and analysed the male genotypes and haplotypes across this region for LD in three populations. The populations included an outbred European sample (CEPH males) and isolated population samples from Finland and Sardinia. We found two extended regions of strong LD bracketed by regions with no evidence for LD in all three samples. Haplotype analysis showed a paucity of haplotypes in regions of strong LD. Our results suggest that, in this region of the X chromosome. LD is not a monotonic function of the distance between markers, but is more a property of the particular location in the human genome.	Washington Univ, Div Dermatol, St Louis, MO 63130 USA; Washington Univ, Dept Psychiat, St Louis, MO 63130 USA; Univ Cagliari, CNR, IRTAM, Cagliari, Sardinia, Italy; Univ Helsinki, Finnish Genome Ctr, Helsinki, Finland	Washington University (WUSTL); Washington University (WUSTL); Consiglio Nazionale delle Ricerche (CNR); University of Cagliari; University of Helsinki	Kwok, PY (corresponding author), Washington Univ, Div Dermatol, St Louis, MO 63130 USA.		Kere, Juha/A-9179-2008; Kwok, Pui-Yan/F-7725-2014; Kere, Juha/AAX-9117-2021	Kere, Juha/0000-0003-1974-0271; Kwok, Pui-Yan/0000-0002-5087-3059; Kere, Juha/0000-0003-1974-0271	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000835, R01HG001439, P50HG000201] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01HG1439, P50HG00835, P50HG00201] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		CAO A, 1994, BLOOD REV, V8, P1, DOI 10.1016/0268-960X(94)90002-7; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Hartl D., 1989, PRINCIPLES POPULATIO; HEDRICK PW, 1987, GENETICS, V117, P331; HOGLUND P, 1995, AM J HUM GENET, V57, P95; Huttley GA, 1999, GENETICS, V152, P1711; JORDE LB, 1993, AM J HUM GENET, V53, P1038; JORDE LB, 1994, AM J HUM GENET, V54, P884; KERE J, 1994, HUM GENET, V93, P162, DOI 10.1007/BF00210603; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; KWOK PY, 1992, GENOMICS, V13, P935, DOI 10.1016/0888-7543(92)90004-C; KWOK PY, 1994, GENOMICS, V23, P138, DOI 10.1006/geno.1994.1469; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; LEWONTIN RC, 1988, GENETICS, V120, P849; TAHVANAINEN E, 1994, P NATL ACAD SCI USA, V91, P7267, DOI 10.1073/pnas.91.15.7267; Taillon-Miller P, 1999, GENOME RES, V9, P499; Taillon-Miller P, 2000, GENOMICS, V65, P195, DOI 10.1006/geno.2000.6165; TaillonMiller P, 1997, GENOMICS, V46, P307, DOI 10.1006/geno.1997.5042; WATKINS WS, 1994, AM J HUM GENET, V55, P348	21	205	214	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					324	328		10.1038/77100	http://dx.doi.org/10.1038/77100			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888883				2022-12-27	WOS:000087920900023
J	Bignell, GR; Warren, W; Seal, S; Takahashi, M; Rapley, E; Barfoot, R; Green, H; Brown, C; Biggs, PJ; Lakhani, SR; Jones, C; Hansen, J; Blair, E; Hofmann, B; Siebert, R; Turner, G; Evans, DG; Schrander-Stumpel, C; Beemer, FA; van den Ouweland, A; Halley, D; Delpech, B; Cleveland, MG; Leigh, I; Leisti, J; Rasmussen, S; Wallace, MR; Fenske, C; Banerjee, P; Oiso, N; Chaggar, R; Merrett, S; Leonard, N; Huber, M; Hohl, D; Chapman, P; Burn, J; Swift, S; Smith, A; Ashworth, A; Stratton, MR				Bignell, GR; Warren, W; Seal, S; Takahashi, M; Rapley, E; Barfoot, R; Green, H; Brown, C; Biggs, PJ; Lakhani, SR; Jones, C; Hansen, J; Blair, E; Hofmann, B; Siebert, R; Turner, G; Evans, DG; Schrander-Stumpel, C; Beemer, FA; van den Ouweland, A; Halley, D; Delpech, B; Cleveland, MG; Leigh, I; Leisti, J; Rasmussen, S; Wallace, MR; Fenske, C; Banerjee, P; Oiso, N; Chaggar, R; Merrett, S; Leonard, N; Huber, M; Hohl, D; Chapman, P; Burn, J; Swift, S; Smith, A; Ashworth, A; Stratton, MR			Identification of the familial cylindromatosis tumour-suppressor gene	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; DYNACTIN COMPLEX; DNA FRAGMENTS; CLIP-170; CYLD1; PROTEINS; SPINDLE; CELLS	Familial cylindromatosis is an autosomal dominant genetic predisposition to multiple tumours of the skin appendages. The susceptibility gene (CYLD) has previously been localized to chromosome 16q and has the genetic attributes of a tumour-suppressor gene (recessive oncogene). Here we have identified CYLD by detecting germline mutations in 21 cylindromatosis families and somatic mutations in 1 sporadic and 5 familial cylindromas. All mutations predict truncation or absence of the encoded protein. CYLD encodes three cytoskeletal-associated-protein-glycine-conserved (CAP-GLY) domains, which are found in proteins that coordinate the attachment of organelles to microtubules. CYLD also has sequence homology to the catalytic domain of ubiquitin carboxy-terminal hydrolases (UCH).	Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; UCL, Royal Free & Univ Coll, Sch Med, Dept Histopathol, London, England; OHSU, Dept Surg, Portland, OR USA; Oxford Radcliffe Hosp Trust, Dept Clin Genet, Oxford, England; Univ Dusseldorf, Hautklin Med Einrichtungen, D-4000 Dusseldorf, Germany; Univ Kiel, Dept Human Genet, Kiel, Germany; Dept Clin Genet, Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England; St Marys Hosp, Cent Manchester Healthcare NHS Trust, Reg Genet Serv, Manchester, Lancs, England; Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands; Univ Utrecht, Med Ctr, Dept Med Genet, Utrecht, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Ctr Henri Becquerel, Oncol Mol Lab, UPRES EA 2122, Grp Rech Inflammat & Canc, F-76038 Rouen, France; Univ Iowa, Dept Dermatol, Iowa City, IA USA; St Bartholomews & Royal London Sch Med & Dent, Ctr Cutaneous Res, London, England; Oulu Univ, Cent Hosp, Dept Clin Genet, SF-90220 Oulu, Finland; Univ Florida, Coll Med, Div Genet, Gainesville, FL USA; St George Hosp, Sch Med, Dept Med Genet, London, England; Osaka City Univ, Sch Med, Dept Dermatol, Abeno Ku, Osaka 545, Japan; Ludwig Inst Canc Res, London W1P 8BT, England; Royal Victoria Infirm, Dept Histopathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Hop Beaumont, CHUV, Serv Dermatol, Lausanne, Switzerland; Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; UCL Medical School; Oregon Health & Science University; Heinrich Heine University Dusseldorf; University of Kiel; University of Manchester; Maastricht University; Maastricht University Medical Centre (MUMC); Utrecht University; Erasmus University Rotterdam; UNICANCER; Centre Henri Becquerel; University of Iowa; University of London; Queen Mary University London; University of Oulu; State University System of Florida; University of Florida; St Georges University London; Osaka Metropolitan University; Ludwig Institute for Cancer Research; Newcastle University - UK; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Newcastle University - UK	Stratton, MR (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England.	mikes@icr.ac.uk	Biggs, Patrick Jon/H-3355-2014; Hohl, Daniel M/N-7554-2016; Huber, Marcel/M-8822-2016; Jones, Chris/ABE-6059-2021; Evans, D Gareth/AAB-4308-2022; Siebert, Reiner/A-8049-2010; Oiso, Naoki/H-6540-2019; Lakhani, Sunil R/I-1970-2018	Biggs, Patrick Jon/0000-0002-0285-4101; Huber, Marcel/0000-0003-3821-2378; Jones, Chris/0000-0001-8118-2296; Evans, D Gareth/0000-0002-8482-5784; Oiso, Naoki/0000-0001-5593-6496; Lakhani, Sunil R/0000-0003-4067-2760; Takahashi, Meiko/0000-0002-8344-5472; Burn, John/0000-0002-9823-2322				Abenoza P, 1990, NEOPLASMS ECCRINE DI; Antonarakis SE, 1998, HUM MUTAT, V11, P1; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BIGGS PJ, 1995, NAT GENET, V11, P441, DOI 10.1038/ng1295-441; Biggs PJ, 1996, ONCOGENE, V12, P1375; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Chase DS, 1998, J MED GENET, V35, P413, DOI 10.1136/jmg.35.5.413; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; GERRETSEN AL, 1995, J AM ACAD DERMATOL, V33, P199, DOI 10.1016/0190-9622(95)90234-1; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RIEHEMANN K, 1993, TRENDS BIOCHEM SCI, V18, P82, DOI 10.1016/0968-0004(93)90159-K; Takahashi M, 2000, HUM GENET, V106, P58, DOI 10.1007/s004399900227; Thomson SAM, 1999, HUM GENET, V105, P171, DOI 10.1007/s004399900077; VANBALKOM IDC, 1994, J MED GENET, V31, P321, DOI 10.1136/jmg.31.4.321; Verhoef S, 1998, J MED GENET, V35, P841, DOI 10.1136/jmg.35.10.841; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153	27	541	561	4	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					160	165		10.1038/76006	http://dx.doi.org/10.1038/76006			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835629				2022-12-27	WOS:000087459200013
J	Gangloff, S; Soustelle, C; Fabre, F				Gangloff, S; Soustelle, C; Fabre, F			Homologous recombination is responsible for cell death in the absence of the Sgs1 and Srs2 helicases	NATURE GENETICS			English	Article							WERNERS-SYNDROME GENES; STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; BLOOMS-SYNDROME; DNA HELICASE; YEAST SGS1; MUTATIONS; RAD51; ALLELE; SEQUENCE	DNA helicases are involved in many aspects of DNA metabolism, including transcription, replication, recombination and repair. In the yeast Saccharomyces cerevisiae, the absence of the Sgs1 helicase results in genomic instability and accelerated ageing(1-4). In human cells, mutations in orthologues of SGS1 lead to Bloom (BS). Werner (WS) or Rothmund-Thomson (RTS) syndromes, which are rare, autosomal recessive diseases characterized by genetic instability associated with cancer predisposition(5-7). Although data concerning these human diseases are accumulating, there is still no clear idea of the function of the proteins involved. Here we show that sgs1 Delta mutants are deficient in DNA repair and are defective for induced recombination events that involve homologous chromosomes. The role of homologous recombination is further evidenced in haploid cells in which both Sgs1p and Srs2p are absent. Yeast SRS2 encodes another DNA helicase involved in the maintenance of genome integrity(8-10). Our data suggest that some defects observed in BS. WS or RTS are the consequence of unrestrained recombination.	CEA, UMR 217 CNRS, DSV, DRR,LERA, F-92265 Fontenay Aux Roses, France	CEA	Gangloff, S (corresponding author), CEA, UMR 217 CNRS, DSV, DRR,LERA, F-92265 Fontenay Aux Roses, France.	Serge.Gangloff@cea.fr; Francis.Fabre@cea.fr	Gangloff, Serge/B-2758-2008	Gangloff, Serge/0000-0003-1333-6091				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Chanet R, 1996, MOL CELL BIOL, V16, P4782; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; KAYTOR MD, 1995, GENETICS, V140, P1441; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MILNE GT, 1995, GENETICS, V139, P1189; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; Rothstein R, 2000, GENE DEV, V14, P1; SCHILD D, 1995, GENETICS, V140, P115; SHERMAN F, 1991, P21; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith J, 1999, GENETICS, V151, P447; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Watt PM, 1996, GENETICS, V144, P935; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	26	303	306	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					192	194		10.1038/76055	http://dx.doi.org/10.1038/76055			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835635				2022-12-27	WOS:000087459200019
J	Smith, SJ; Cases, S; Jensen, DR; Chen, HC; Sande, E; Tow, B; Sanan, DA; Raber, J; Eckel, RH; Farese, RV				Smith, SJ; Cases, S; Jensen, DR; Chen, HC; Sande, E; Tow, B; Sanan, DA; Raber, J; Eckel, RH; Farese, RV			Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat	NATURE GENETICS			English	Article							CHOLESTEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; DIABETES-MELLITUS; LEPTIN; GENE; LIPODYSTROPHY; ENZYMES; FAT	Triglycerides (or triacylglycerols) represent the major form of stored energy in eukaryotes. Triglyceride synthesis has been assumed to occur primarily through acyl CoA:diacylglycerol transferase (Dgat), a microsomal enzyme that catalyses the final and only committed step in the glycerol phosphate pathway(1-3). Therefore, Dgat has been considered necessary for adipose tissue formation and essential for survival. Here we show that Dgat-deficient (Dgat(-/-)) mice are viable and can still synthesize triglycerides, Moreover, these mice are lean and resistant to diet-induced obesity. The obesity resistance involves increased energy expenditure and increased activity. Dgat deficiency also alters triglyceride metabolism in other tissues, including the mammary gland, where lactation is defective in Dgat(-/-) females. Our findings indicate that multiple mechanisms exist for triglyceride synthesis and suggest that the selective inhibition of Dgat-mediated triglyceride synthesis may be useful for treating obesity.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Neurol, San Francisco, CA 94141 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Chen, Hubert/0000-0002-7599-7218				BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; ERICKSON SK, 1980, J LIPID RES, V21, P930; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; MAHLEY RW, 1995, J LIPID RES, V36, P839; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; [No title captured]	19	670	753	1	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					87	90		10.1038/75651	http://dx.doi.org/10.1038/75651			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802663				2022-12-27	WOS:000086884000023
J	Yant, SR; Meuse, L; Chiu, W; Ivics, Z; Izsvak, Z; Kay, MA				Yant, SR; Meuse, L; Chiu, W; Ivics, Z; Izsvak, Z; Kay, MA			Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system	NATURE GENETICS			English	Article							MEDIATED GENE-TRANSFER; ADENOASSOCIATED VIRUS; MARINER TRANSPOSASE; FACTOR-IX; IN-VITRO; HEMOPHILIA-B; HUMAN ALPHA-1-ANTITRYPSIN; RECOMBINANT ADENOVIRUSES; IMMUNE-RESPONSES; MOUSE-LIVER	The development of non-viral gene-transfer technologies that can support stable chromosomal integration and persistent gene expression in vivo is desirable. Here we describe the successful use of transposon technology for the nonhomologous insertion of foreign genes into the genomes of adult mammals using naked DNA. We show that the Sleeping Beauty transposase can efficiently insert transposon DNA into the mouse genome in approximately 5-6% of transfected mouse liver cells. Chromosomal transposition resulted in long-term expression (>5 months) of human blood coagulation factor IX at levels that were therapeutic in a mouse model of haemophilia B. Our results establish DNA-mediated transposition as a new genetic tool for mammals, and provide new strategies to improve existing non-viral and viral vectors for human gene therapy applications.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Max Delbruck Ctr Mol Med, Berlin, Germany	Stanford University; Stanford University; University of Washington; University of Washington Seattle; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kay, MA (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.	markay@stanford.edu	Wilson, Matthew H/K-3193-2013	Kay, Mark/0000-0002-2799-2615; Yant, Stephen R,/0000-0002-4444-7483	NIDDK NIH HHS [DK49022] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALINO SF, 1994, BIOCHEM BIOPH RES CO, V204, P1023, DOI 10.1006/bbrc.1994.2565; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; Choate KA, 1997, HUM GENE THER, V8, P1659, DOI 10.1089/hum.1997.8.14-1659; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Gordon Erlinda M., 1994, Current Opinion in Biotechnology, V5, P611, DOI 10.1016/0958-1669(94)90083-3; Hartl DL, 1997, TRENDS GENET, V13, P197, DOI 10.1016/S0168-9525(97)01087-1; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; Kay MA, 1997, P NATL ACAD SCI USA, V94, P4686, DOI 10.1073/pnas.94.9.4686; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; Kovesdi I, 1997, CURR OPIN BIOTECH, V8, P583, DOI 10.1016/S0958-1669(97)80033-X; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lampe DJ, 1998, GENETICS, V149, P179; Latchman David S., 1994, Molecular Biotechnology, V2, P179, DOI 10.1007/BF02824809; Li K, 1997, J MOL CELL CARDIOL, V29, P1499, DOI 10.1006/jmcc.1997.0389; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Lin HF, 1997, BLOOD, V90, P3962, DOI 10.1182/blood.V90.10.3962; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Lohe AR, 1997, P NATL ACAD SCI USA, V94, P1293, DOI 10.1073/pnas.94.4.1293; Lohe AR, 1996, GENETICS, V144, P1087; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Miao CH, 2000, J VIROL, V74, P3793, DOI 10.1128/JVI.74.8.3793-3803.2000; Mumper RJ, 1996, PHARMACEUT RES, V13, P701, DOI 10.1023/A:1016039330870; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Rabinowitz JE, 1998, CURR OPIN BIOTECH, V9, P470, DOI 10.1016/S0958-1669(98)80031-1; Raz E, 1998, CURR BIOL, V8, P82, DOI 10.1016/S0960-9822(98)70038-7; REINER AP, 1995, METABOLIC MOL BASIS; Rutledge EA, 1997, J VIROL, V71, P8429, DOI 10.1128/JVI.71.11.8429-8436.1997; Schouten GJ, 1998, NUCLEIC ACIDS RES, V26, P3013, DOI 10.1093/nar/26.12.3013; Sherman A, 1998, NAT BIOTECHNOL, V16, P1050, DOI 10.1038/3497; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; Yew NS, 1997, HUM GENE THER, V8, P575, DOI 10.1089/hum.1997.8.5-575; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zhang LN, 1998, NUCLEIC ACIDS RES, V26, P3687, DOI 10.1093/nar/26.16.3687; Zhu JD, 1999, HUM GENE THER, V10, P113, DOI 10.1089/10430349950019246	50	403	444	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					35	41		10.1038/75568	http://dx.doi.org/10.1038/75568			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802653				2022-12-27	WOS:000086884000013
J	Shackleton, S; Lloyd, DJ; Jackson, SNJ; Evans, R; Niermeijer, MF; Singh, BM; Schmidt, H; Brabant, G; Kumar, S; Durrington, PN; Gregory, S; O'Rahilly, S; Trembath, RC				Shackleton, S; Lloyd, DJ; Jackson, SNJ; Evans, R; Niermeijer, MF; Singh, BM; Schmidt, H; Brabant, G; Kumar, S; Durrington, PN; Gregory, S; O'Rahilly, S; Trembath, RC			LMNA, encoding lamin A/C, is mutated in partial lipodystrophy	NATURE GENETICS			English	Article							INTERMEDIATE FILAMENT PROTEINS; FAMILIAL PARTIAL LIPODYSTROPHY; GENE; HOMOLOGY	The lipodystrophies are a group of disorders characterized by the absence or reduction of subcutaneous adipose tissue. Partial lipodystrophy (PLD; MIM 151660) is an inherited condition in which a regional (trunk and limbs) loss of fat occurs during the peri-pubertal phase(1,2). Additionally, variable degrees of resistance to insulin action, together with a hyperlipidaemic state, may occur and simulate the metabolic features commonly associated with predisposition to atherosclerotic disease(3). The PLD locus has been mapped to chromosome 1q with no evidence of genetic heterogeneity(4). We, and others, have refined the location to a 5.3-cM interval between markers D1S305 and D1S1600 (refs 5,6). Through a positional cloning approach we have identified five different missense mutations in LMNA among ten kindreds and three individuals with PLD. The protein product of LMNA is lamin AIC, which is a component of the nuclear envelope. Heterozygous mutations in LMNA have recently been identified in kindreds with the variant form of muscular dystrophy (MD) known as autosomal dominant Emery-Dreifuss MD (EDMD-AD; ref. 7) and dilated cardiomyopathy and conduction-system diseases (CMD1A). As LMNA is ubiquitously expressed, the finding of site-specific amino acid substitutions in PLD, EDMD-AD and CMD1A reveals distinct functional domains of the lamin A/C protein required for the maintenance and integrity of different cell types.	Univ Leicester, Dept Med, Div Med Genet, Leicester, Leics, England; Univ Leicester, Dept Genet, Div Med Genet, Leicester, Leics, England; Sanger Ctr, Cambridge, England; Erasmus Univ, Dept Clin Genet, Rotterdam, Netherlands; Acad Hosp Dijkzigt, NL-3000 DR Rotterdam, Netherlands; New Cross Hosp, Ctr Diabet, Wolverhampton, England; 4 Med Klin mS Gastroenterol, Hepatol & Endokrinol, Berlin, Germany; Med Hsch Hannover, Abt Klin Endokrinol, Hannover, Germany; Univ Birmingham, Brimingham Heartlands Hosp, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge, England	University of Leicester; University of Leicester; Wellcome Trust Sanger Institute; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; New Cross Hospital; Hannover Medical School; Heart of England NHS Foundation Trust; University of Birmingham; University of Manchester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Trembath, RC (corresponding author), Univ Leicester, Dept Med, Div Med Genet, Leicester, Leics, England.		O'Rahilly, Stephen/ABF-6509-2020; kumar, sudhesh/D-6945-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Gregory, Simon/0000-0002-7805-1743; kumar, sudhesh/0000-0003-4326-5941; Trembath, Richard/0000-0003-0550-3400; Lloyd, David/0000-0001-5924-0672				Anderson JL, 1999, AM J MED GENET, V82, P161, DOI 10.1002/(SICI)1096-8628(19990115)82:2<161::AID-AJMG12>3.3.CO;2-S; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; Coyle B, 1996, NAT GENET, V12, P421, DOI 10.1038/ng0496-421; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Garg A, 1999, J CLIN ENDOCR METAB, V84, P170, DOI 10.1210/jc.84.1.170; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; Jackson SNJ, 1997, QJM-INT J MED, V90, P27; Jackson SNJ, 1998, AM J HUM GENET, V63, P534, DOI 10.1086/301971; KOBBERLING J, 1986, J MED GENET, V23, P120, DOI 10.1136/jmg.23.2.120; LIN F, 1993, J BIOL CHEM, V268, P16321; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Peters JM, 1998, NAT GENET, V18, P292, DOI 10.1038/ng0398-292; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; WOLIN SL, 1987, EMBO J, V6, P3809, DOI 10.1002/j.1460-2075.1987.tb02717.x	21	530	554	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					153	156		10.1038/72807	http://dx.doi.org/10.1038/72807			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655060				2022-12-27	WOS:000085104600015
J	Gedeon, AK; Colley, A; Jamieson, R; Thompson, EM; Rogers, J; Sillence, D; Tiller, GE; Mulley, JC; Gecz, J				Gedeon, AK; Colley, A; Jamieson, R; Thompson, EM; Rogers, J; Sillence, D; Tiller, GE; Mulley, JC; Gecz, J			Identification of the gene (SEDL) causing X-linked spondyloepiphyseal dysplasia tarda	NATURE GENETICS			English	Article							PROTEIN; LINKAGE; CHROMOSOME; CLONING; ENCODES; DXS16; XP22; MAP	Spondyloepiphyseal dysplasia tarda (SEDL; MIM 313400) is an X-linked recessive osteochondrodysplasia that occurs in approximately two of every one million people(1). This progressive skeletal disorder which manifests in childhood is characterized by disproportionate short stature with short neck and trunk, barrel chest and absence of systemic complications(2-4). Distinctive radiological signs are platyspondyly with hump-shaped central and posterior portions, narrow disc spaces, and mild to moderate epiphyseal dysplasia. The latter usually leads to premature secondary osteoarthritis often requiring hip arthroplasty(3-5), Obligate female carriers are generally clinically and radiographically indistinguishable from the general population(4,5), although some cases have phenotypic changes consistent with expression of the gene defect(2,4,6,7). The SEDL gene has been localized to Xp22 (refs 8,9) in the approximately 2-Mb interval between DXS16 and DXS987 (ref, 10). Here we confirm and refine this localization to an interval of less than 170 kb by critical recombination events at DXS16 and AFMa124wc1 in two families. In one candidate gene we detected three dinucleotide deletions in three Australian families which effect frameshifts causing premature stop codons. The gene designated SEDL is transcribed as a 2.8-kb transcript in many tissues including fetal cartilage. SEDL encodes a 140 amino acid protein with a putative role in endoplasmic reticulum (ER)-to-Golgi vesicular transport.	Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia; Liverpool Hlth Serv, Dept Clin Genet, Liverpool, NSW 2170, Australia; New Childrens Hosp, Dept Clin Genet, Sydney, NSW, Australia; Womens & Childrens Hosp, Ctr Med Genet, S Australian Clin Genet Serv, Adelaide, SA 5006, Australia; Victorian Clin Genet Serv, Melbourne, Vic, Australia; Vanderbilt Univ, Sch Med, Dept Pediat, Div Med Genet, Nashville, TN 37232 USA; Univ Adelaide, Dept Paediat, Adelaide, SA, Australia	Womens & Childrens Hospital Australia; University of Sydney; Womens & Childrens Hospital Australia; Vanderbilt University; University of Adelaide	Gecz, J (corresponding author), Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia.	jgecz@mad.adelaide.edu.au	Jamieson, Robyn/M-5161-2019; Gecz, Jozef/X-3469-2019; Gedeon, Agi/G-7890-2011	Jamieson, Robyn/0000-0002-7285-0253; Gecz, Jozef/0000-0002-7884-6861; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR045477] Funding Source: NIH RePORTER; NIAMS NIH HHS [R55 AR45477] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BANNERMAN RM, 1971, J MED GENET, V8, P291, DOI 10.1136/jmg.8.3.291; CHANG YPC, 1994, HUM MOL GENET, V3, P1029, DOI 10.1093/hmg/3.6.1029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Davies JP, 1997, GENOMICS, V41, P131, DOI 10.1006/geno.1997.4644; de Conciliis L, 1998, GENOMICS, V51, P243, DOI 10.1006/geno.1998.5348; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FERRERO GB, 1995, HUM MOL GENET, V4, P1821, DOI 10.1093/hmg/4.10.1821; GOTTESMAN GS, 1996, J BONE MINER RES  S1, V11, pS252; HARPER PS, 1973, BRIT J RADIOL, V46, P676, DOI 10.1259/0007-1285-46-549-676; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEUERTZ S, 1993, GENOMICS, V18, P100, DOI 10.1006/geno.1993.1431; HEUERTZ S, 1995, HUM GENET, V96, P407, DOI 10.1007/BF00191797; ICETON JA, 1986, J BONE JOINT SURG BR, V68, P616, DOI 10.1302/0301-620X.68B4.3733841; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MacKenzie JJ, 1996, J MED GENET, V33, P823, DOI 10.1136/jmg.33.10.823; Narayanan V, 1998, AM J MED GENET, V78, P165, DOI 10.1002/(SICI)1096-8628(19980630)78:2<165::AID-AJMG13>3.0.CO;2-L; ROSSI G, 1995, MOL BIOL CELL, V6, P1769, DOI 10.1091/mbc.6.12.1769; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; SZPIROTAPIA S, 1988, HUM GENET, V81, P61, DOI 10.1007/BF00283731; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Whyte MP, 1999, MEDICINE, V78, P9, DOI 10.1097/00005792-199901000-00002; WYNNEDAVIES R, 1985, J BONE JOINT SURG BR, V67, P133, DOI 10.1302/0301-620X.67B1.3155744	23	142	167	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					400	404		10.1038/11976	http://dx.doi.org/10.1038/11976			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431248				2022-12-27	WOS:000081772500026
J	Derry, JMJ; Gormally, E; Means, GD; Zhao, W; Meindl, A; Kelley, RI; Boyd, Y; Herman, GE				Derry, JMJ; Gormally, E; Means, GD; Zhao, W; Meindl, A; Kelley, RI; Boyd, Y; Herman, GE			Mutations in a Delta(8)-Delta(7) sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata	NATURE GENETICS			English	Article							PEROXISOMAL ENZYME DEFICIENCY; LEMLI-OPITZ-SYNDROME; CHOLESTEROL-BIOSYNTHESIS; BINDING-PROTEIN; VITAMIN-D; INHIBITION	Tattered (Td) is an X-linked, semi-dominant mouse mutation associated with prenatal male lethality(1). Heterozygous females are small and at 4-5 days of age develop patches of hyperkeratotic skin where no hair grows, resulting in a striping of the coat in adults(2). Craniofacial anomalies and twisted toes have also been observed in some affected females(3,4). A potential second allele of Td has also been described(5). The phenotype of Td is similar to that seen in heterozygous females with human X-linked dominant chondrodysplasia punctata (CDPX2, alternatively known as X-linked dominant Conradi-Hunermann-Happle syndrome) as well as another X-linked, semi-dominant mouse mutation, bare patches (Bpa). The Bpa gene has recently been identified(6) and encodes a protein with homology to 3 beta-hydroxysteroid dehydrogenases that functions in one of the later steps of cholesterol biosynthesis. CDPX2 patients display skin defects including linear or whorled atrophic and pigmentary lesions, striated hyperkeratosis, coarse lusterless hair and alopecia, cataracts and skeletal abnormalities including short stature, rhizomelic shortening of the limbs, epiphyseal stippling and craniofacial defects (MIM 302960). We have now identified the defect in Td mice as a single amino acid substitution in the Delta(8)-Delta(7) sterol isomerase emopamil binding protein (Ebp; encoded by Ebp in mouse) and identified alterations in human EBP in seven unrelated CDPX2 patients.	Immunex Res & Dev Corp, Seattle, WA 98101 USA; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; Ohio State Univ, Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; LMU, Kinderpolklin, Abt Med Genet, Munich, Germany; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Ohio State University; Research Institute at Nationwide Children's Hospital; Ohio State University; University of Munich; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University	Derry, JMJ (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.				NINDS NIH HHS [R01 NS34953] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034953] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLAIR HJ, 1994, MOUSE GENOME, V92, P511; CATTANACH BM, 1982, MOUSE NEWS LETT, V66, P61; Cho SY, 1998, MOL CELLS, V8, P233; CLAYTON PT, 1989, J INHERIT METAB DIS, V12, P358, DOI 10.1007/BF03335422; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HOLMES RD, 1987, NEW ENGL J MED, V316, P1608; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kelley RI, 1998, AM J HUM GENET, V63, P322, DOI 10.1086/301987; Kelley RI, 1999, AM J MED GENET, V83, P213, DOI 10.1002/(SICI)1096-8628(19990319)83:3<213::AID-AJMG15>3.0.CO;2-C; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; Labit-Le Bouteiller C, 1998, EUR J BIOCHEM, V256, P342, DOI 10.1046/j.1432-1327.1998.2560342.x; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; MERRELL K, 1995, MAMM GENOME, V6, P291, DOI 10.1007/BF00352419; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RASBERRY C, 1995, MOUSE GENOME, V93, P1028; Seo KW, 1997, MAMM GENOME, V8, P578, DOI 10.1007/s003359900507; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; TRAUPE H, 1992, HUM GENET, V89, P659, DOI 10.1007/BF00221958; Uwechue IC, 1996, GENOMICS, V37, P238, DOI 10.1006/geno.1996.0549; UWECHUE IC, 1997, THESIS U OXFORD; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	24	180	187	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					286	290		10.1038/10350	http://dx.doi.org/10.1038/10350			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391218				2022-12-27	WOS:000081125900023
J	Kobayashi, K; Sinasac, DS; Iijima, M; Boright, AP; Begum, L; Lee, JR; Yasuda, T; Ikeda, S; Hirano, R; Terazono, H; Crackower, MA; Kondo, I; Tsui, LC; Scherer, SW; Saheki, T				Kobayashi, K; Sinasac, DS; Iijima, M; Boright, AP; Begum, L; Lee, JR; Yasuda, T; Ikeda, S; Hirano, R; Terazono, H; Crackower, MA; Kondo, I; Tsui, LC; Scherer, SW; Saheki, T			The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein	NATURE GENETICS			English	Article							ORTHOTOPIC LIVER-TRANSPLANTATION; SECRETORY TRYPSIN-INHIBITOR; ARGININOSUCCINATE SYNTHETASE; CLASSICAL CITRULLINEMIA; MESSENGER-RNA; UREA CYCLE; MUTATIONS; CLONING; CALCIUM; DNA	Citrullinaemia (CTLN) is an autosomal recessive disease caused by deficiency of argininosuccinate synthetase (ASS). Adultonset type II citrullinaemia (CTLN2) is characterized by a liverspecific ASS deficiency with no abnormalities in hepatic ASS mRNA or the gene ASS (refs 1-17). CTLN2 patients (1/100.000 in Japan(13)) suffer from a disturbance of consciousness and coma, and most die with cerebral edema within a few years of onset. CTLN2 differs from classical citrullinaemia (CTLN1, OMIM 215700) in that CTLN1 is neonatal or infantile in onset, with ASS enzyme defects (in all tissues) arising due to mutations in ASS on chromosome 9q34 (refs 18-21). We collected 118 CTLN2 families, and localized the CTLN2 locus to chromosome 7q21.3 by homozygosity mapping analysis of individuals from 18 consanguineous unions. Using positional cloning we identified a novel gene, SLC5A13, and found five different DNA sequence alterations that account for mutations in all consanguineous patients examined. SLC25A13 encodes a 3.4-kb transcript expressed most abundantly in liver. The protein encoded by SLC25A13, named citrin, is bipartite in structure, containing a mitochondrial carrier motif and four EF-hand domains, suggesting it is a calcium-dependent mitochondrial solute transporter with a role in urea cycle function.	Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 890820, Japan; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Yagi Clin, Aira 8995400, Japan; Ehime Univ, Sch Med, Dept Hyg, Shigenobu, Ehime 7910295, Japan	Kagoshima University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ehime University	Kobayashi, K (corresponding author), Kagoshima Univ, Fac Med, Dept Biochem, 8-35-1 Sakuragaoka, Kagoshima 890820, Japan.		Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; Sinasac, David/0000-0002-3749-5989				Crackower MA, 1999, GENOMICS, V55, P257, DOI 10.1006/geno.1998.5665; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Hegele RA, 1997, J CLIN ENDOCR METAB, V82, P3373, DOI 10.1210/jc.82.10.3373; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; IMAMURA Y, 1987, CLIN CHIM ACTA, V164, P201, DOI 10.1016/0009-8981(87)90071-4; Kakinoki H, 1997, HUM MUTAT, V9, P250, DOI 10.1002/(SICI)1098-1004(1997)9:3<250::AID-HUMU6>3.3.CO;2-K; Kawamoto S, 1997, CLIN TRANSPLANT, V11, P453; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOBAYASHI K, 1986, AM J HUM GENET, V38, P667; KOBAYASHI K, 1995, FEBS LETT, V372, P69, DOI 10.1016/0014-5793(95)00948-9; KOBAYASHI K, 1994, AM J HUM GENET, V55, P1103; KOBAYASHI K, 1995, HUM GENET, V96, P454; Kobayashi K, 1997, HEPATOLOGY, V25, P1160, DOI 10.1002/hep.510250519; KOBAYASHI K, 1993, AM J HUM GENET, V53, P1024; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; SAHEKI T, 1982, CLIN CHIM ACTA, V118, P93; SAHEKI T, 1987, CLIN CHIM ACTA, V170, P297, DOI 10.1016/0009-8981(87)90140-9; SAHEKI T, 1987, REV PHYSIOL BIOCH P, V108, P21, DOI 10.1007/BFb0034071; SAHEKI T, 1981, CLIN CHIM ACTA, V109, P325, DOI 10.1016/0009-8981(81)90318-1; Saheki T, 1983, ADV EXP MED BIOL, V153, P63; SAHEKI T, 1985, GUANIDINES, P149; Sameshima Y., 1986, J CLIN BIOCHEM NUTR, V1, P129; SASE M, 1985, HUM GENET, V69, P130, DOI 10.1007/BF00293282; TODO S, 1992, HEPATOLOGY, V15, P419, DOI 10.1002/hep.1840150311; YAGI Y, 1988, AM J CLIN PATHOL, V89, P735, DOI 10.1093/ajcp/89.6.735; Yazaki M, 1996, TRANSPLANTATION, V62, P1679, DOI 10.1097/00007890-199612150-00027	30	310	356	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					159	163		10.1038/9667	http://dx.doi.org/10.1038/9667			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369257				2022-12-27	WOS:000080680900020
J	Fleck, O; Lehmann, E; Schar, P; Kohli, J				Fleck, O; Lehmann, E; Schar, P; Kohli, J			Involvement of nucleotide-excision repair in msh2 pms1-independent mismatch repair	NATURE GENETICS			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; RECOMBINATION; GENE; DNA; PROTEIN; YEAST; MUTATIONS; SPECTRUM; SEQUENCE	Nucleotide-excision repair (NER) and mismatch repair (MMR) are prominent examples of highly conserved DNA repair systems which recognize and replace damaged and/or mispaired nucleotides in DNA. In humans, inheritable defects in components of the NER system are associated with severe diseases such as xeroderma pigmentosum (XP) and Cockayne syndrome(1) (CS), whereas inactivation of MMR is accompanied by predisposition to certain types of cancer(2). In Schizosaccharomyces pombe, the msh2- and pms1-dependent long-patch MMR system efficiently corrects small insertion/deletion leaps and all base-base mismatches, except C/C, Up to 70% of OC mismatches generated in recombination intermediates, and to a lesser extent also other base-base mismatches, are thought to undergo correction by a minor, short-patch excision repair system(3,4). We identify here the NER genes rhp 14, swi10 and rad16 as components of this repair pathway and show that they act independently of msh2 and pms1.	Univ Bern, Inst Gen Microbiol, CH-3012 Bern, Switzerland; Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland	University of Bern; University of Zurich	Fleck, O (corresponding author), Univ Bern, Inst Gen Microbiol, Baltzer Str 4, CH-3012 Bern, Switzerland.	fleck@imb.unibe.ch	Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147; Fleck, Oliver/0000-0003-0550-6513				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; CARPENTER ATC, 1982, P NATL ACAD SCI-BIOL, V79, P5961, DOI 10.1073/pnas.79.19.5961; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; GUTZ H, 1994, HDB GENETICS SCHIZOS, P395; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MONTELONE BA, 1994, YEAST, V10, P13, DOI 10.1002/yea.320100103; MONTELONE BA, 1992, MUTAT RES, V267, P55, DOI 10.1016/0027-5107(92)90110-N; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; Rudolph C, 1999, MOL CELL BIOL, V19, P241; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAR P, 1994, EMBO J, V13, P5212, DOI 10.1002/j.1460-2075.1994.tb06852.x; SCHAR P, 1993, GENETICS, V133, P825; SCHAR P, 1993, GENETICS, V133, P815; Schar P, 1997, GENETICS, V146, P1275; SCHAR P, 1998, NUCL ACID M, V12, P199; SEKELSKY JJ, 1995, GENETICS, V141, P619; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4	20	64	68	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					314	317		10.1038/6838	http://dx.doi.org/10.1038/6838			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080187				2022-12-27	WOS:000078977900028
J	Herbert, A; Rich, A				Herbert, A; Rich, A			RNA processing and the evolution of eukaryotes	NATURE GENETICS			English	Article							HEPATITIS-DELTA VIRUS; DOUBLE-STRAND BREAKS; RECEPTOR CHANNELS; MESSENGER-RNA; TRANSPOSABLE ELEMENTS; REVERSE-TRANSCRIPTASE; MOLECULAR-BIOLOGY; MAMMALIAN-CELLS; NUCLEOLAR RNAS; DNA-POLYMERASE	In eukaryotes, RNA processing events, including alternative splicing and RNA editing, can generate many different messages from a single gene. As a consequence, the RNA pool, which we refer to here as the 'ribotype', has a different information content from the genotype and can vary as circumstances change. The outcome of a single RNA processing event often regulates the outcome of another, giving rise to networks that affect the composition and expression of a particular ribotype. Successful ribotypes are determined by natural selection, and can be incorporated into the genome over time by reverse transcription. Eukaryotic evolution is therefore influenced by the alternate ways in which RNAs are processed and the continual interplay between RNA and DNA.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Herbert, A (corresponding author), MIT, Dept Biol, Room 38-233, Cambridge, MA 02139 USA.	alan@mit.edu	Herbert, Alan/AAY-4286-2020	Herbert, Alan/0000-0002-0093-1572				ALLAUDEEN HS, 1978, PHARMACOL THER PT A, V2, P447, DOI 10.1016/0362-5478(78)90002-5; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; BASS BL, 1993, RNA WORLD, P383; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; Britten RJ, 1997, GENE, V205, P177, DOI 10.1016/S0378-1119(97)00399-5; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; CRICK F, 1970, NATURE, V227, P561, DOI 10.1038/227561a0; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; Gebauer F, 1998, RNA, V4, P142; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Herbert A, 1996, TRENDS GENET, V12, P6, DOI 10.1016/0168-9525(96)81375-8; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; Kidwell MG, 1997, P NATL ACAD SCI USA, V94, P7704, DOI 10.1073/pnas.94.15.7704; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; Kren BT, 1996, FASEB J, V10, P559, DOI 10.1096/fasebj.10.5.8621056; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LEE R, 1993, CELL, V75, P643; LEWIN B, 1980, GENE EXPRESSION EUKA, P728; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Ma JY, 1997, J BIOL CHEM, V272, P672; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MURNANE JP, 1995, NUCLEIC ACIDS RES, V23, P2837, DOI 10.1093/nar/23.15.2837; Patton DE, 1997, NEURON, V19, P711, DOI 10.1016/S0896-6273(00)80383-9; Petschek JP, 1997, GENE, V204, P267, DOI 10.1016/S0378-1119(97)00465-4; Polson AG, 1996, NATURE, V380, P454; Poole AM, 1998, J MOL EVOL, V46, P1, DOI 10.1007/PL00006275; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11858; SIMPSON L, 1997, EUKARYOTIC MRNA PROC, P335; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG YC, 1997, EUKARYOTIC MRNA PROC, P242; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	57	58	64	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					265	269		10.1038/6780	http://dx.doi.org/10.1038/6780			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080177				2022-12-27	WOS:000078977900018
J	Sakuntabhai, A; Ruiz-Perez, V; Carter, S; Jacobsen, N; Burge, S; Monk, S; Smith, M; Munro, CS; O'Donovan, M; Craddock, N; Kucherlapati, R; Rees, JL; Owen, M; Lathrop, GM; Monaco, AP; Strachan, T; Hovnanian, A				Sakuntabhai, A; Ruiz-Perez, V; Carter, S; Jacobsen, N; Burge, S; Monk, S; Smith, M; Munro, CS; O'Donovan, M; Craddock, N; Kucherlapati, R; Rees, JL; Owen, M; Lathrop, GM; Monaco, AP; Strachan, T; Hovnanian, A			Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease	NATURE GENETICS			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM STORES; PLASMA-MEMBRANE; ATPASE FAMILY; GENE; LOCALIZATION; CELLS; CA-2+-ATPASE; DESMOSOMES; DEPENDENCE	Darier disease (DD) is an autosomal-dominant skin disorder characterized by loss of adhesion between epidermal cells (acantholysis) and abnormal keratinization. Recently we constructed a 2.4-Mb, Pi-derived artificial chromosome contig spanning the DD candidate region on chromosome 12q23-24.1. After screening several genes that mapped to this region, we identified mutations in the ATP2A2 gene, which encodes the sarco/endoplasmic reticulum Ca2+-ATPase type 2 isoform (SERCA2) and is highly expressed in keratinocytes. Thirteen mutations were identified, including frameshift deletions. in-frame deletions or insertions, splice-site mutations and non-conservative missense mutations in functional domains. Our results demonstrate that mutations in ATP2A2 cause DD and disclose a role for this pump in a Ca2+-signalling pathway regulating cell-to-cell adhesion and differentiation of the epidermis.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Newcastle Univ, Dept Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Cardiff Univ, Dept Psychol Med, Cardiff CF4 4XN, S Glam, Wales; Churchill Hosp, Dept Dermatol, Oxford OX3 7LJ, England; So Gen Hosp, Dept Dermatol, Glasgow G51 4TF, Lanark, Scotland; Univ Birmingham, Dept Psychiat, Birmingham B15 2QZ, W Midlands, England; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Newcastle Univ, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Oxford; Wellcome Centre for Human Genetics; Newcastle University - UK; Cardiff University; University of Oxford; University of Glasgow; University of Birmingham; Yeshiva University; Albert Einstein College of Medicine; Newcastle University - UK	Hovnanian, A (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	tom.strachan@ncl.ac.uk; alain.hovanian@well.ox.ac.uk	Hovnanian, Alain/I-4711-2017; Ruiz-Perez, Victor L/K-6066-2014; Kucherlapati, Raju/ABC-8807-2021; Monaco, Anthony P/A-4495-2010; O'Donovan, Michael C/P-7005-2018	Hovnanian, Alain/0000-0003-3412-7512; Ruiz-Perez, Victor L/0000-0003-0635-3619; Monaco, Anthony P/0000-0001-7480-3197; O'Donovan, Michael C/0000-0001-7073-2379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baba-Aissa F, 1998, MOL CHEM NEUROPATHOL, V33, P199, DOI 10.1007/BF02815182; BASHIR R, 1993, HUM MOL GENET, V2, P1937, DOI 10.1093/hmg/2.11.1937; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Burdett IDJ, 1998, MICRON, V29, P309, DOI 10.1016/S0968-4328(98)00015-8; BURGE S, 1994, BRIT J DERMATOL, V131, P153; BURGE SM, 1991, BRIT J DERMATOL, V124, P242, DOI 10.1111/j.1365-2133.1991.tb00568.x; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARTER SA, 1994, GENOMICS, V24, P378, DOI 10.1006/geno.1994.1632; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CRADDOCK N, 1993, HUM MOL GENET, V2, P1941, DOI 10.1093/hmg/2.11.1941; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; GROVER RW, 1970, ARCH DERMATOL, V101, P426, DOI 10.1001/archderm.101.4.426; Hailey H, 1939, ARCH DERMATOL SYPH, V39, P679, DOI 10.1001/archderm.1939.01480220064005; IKEDA S, 1994, J INVEST DERMATOL, V103, P478, DOI 10.1111/1523-1747.ep12395577; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, J BIOL CHEM, V266, P17067; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MacLennan DH, 1998, ACTA PHYSIOL SCAND, V163, P55; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAQUAT LE, 1995, RNA, V1, P453; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; Monk S, 1998, AM J HUM GENET, V62, P890, DOI 10.1086/301794; MUNRO CS, 1992, BRIT J DERMATOL, V127, P126, DOI 10.1111/j.1365-2133.1992.tb08044.x; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; PARFITT E, 1994, HUM MOL GENET, V3, P35, DOI 10.1093/hmg/3.1.35; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; Wakem P, 1996, J INVEST DERMATOL, V106, P365, DOI 10.1111/1523-1747.ep12343145; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211	41	523	552	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					271	277		10.1038/6784	http://dx.doi.org/10.1038/6784			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080178				2022-12-27	WOS:000078977900019
J	Marra, M; Hillier, L; Kucaba, T; Allen, M; Barstead, R; Beck, C; Blistain, A; Bonaldo, M; Bowers, Y; Bowles, L; Cardenas, M; Chamberlain, A; Chappell, J; Clifton, S; Favello, A; Geisel, S; Gibbons, M; Harvey, N; Hill, F; Jackson, Y; Kohn, S; Lennon, G; Mardis, E; Martin, J; Mila, L; McCann, R; Morales, R; Pape, D; Person, B; Prange, C; Ritter, E; Soares, M; Schurk, R; Shin, T; Steptoe, M; Swaller, T; Theising, B; Underwood, K; Wylie, T; Yount, T; Wilson, R; Waterston, R				Marra, M; Hillier, L; Kucaba, T; Allen, M; Barstead, R; Beck, C; Blistain, A; Bonaldo, M; Bowers, Y; Bowles, L; Cardenas, M; Chamberlain, A; Chappell, J; Clifton, S; Favello, A; Geisel, S; Gibbons, M; Harvey, N; Hill, F; Jackson, Y; Kohn, S; Lennon, G; Mardis, E; Martin, J; Mila, L; McCann, R; Morales, R; Pape, D; Person, B; Prange, C; Ritter, E; Soares, M; Schurk, R; Shin, T; Steptoe, M; Swaller, T; Theising, B; Underwood, K; Wylie, T; Yount, T; Wilson, R; Waterston, R			An encyclopedia of mouse genes	NATURE GENETICS			English	Article							EXPRESSED SEQUENCE TAGS; CAENORHABDITIS-ELEGANS; HUMAN GENOME; CDNA LIBRARY; MUTAGENESIS; DISCOVERY; FAMILIES; RICE; MAP	The laboratory mouse is the premier model system for studies of mammalian development due to the powerful classical genetic analysis(1) possible (see also the Jackson Laboratory web site, http://www.jax.org/) and the ever-expanding collection of molecular tools(2,3). To enhance the utility of the mouse system, we initiated a program to generate a large database of expressed sequence tags (ESTs) that can provide rapid access to genes(4-16). Of particular significance was the possibility that cDNA libraries could be prepared from very early stages of development, a situation unrealized in human EST projects(7,12). We report here the development of a comprehensive database of ESTs for the mouse. The project, initiated in March 1996, has focused on 5' end sequences from directionally cloned, oligo-dT primed cDNA libraries. As of 23 October 1998, 352,040 sequences had been generated, annotated and deposited in dbEST, where they comprised 93% of the total ESTs available for mouse. EST data are versatile and have been applied to gene identification(17), comparative sequence analysis(18,19), comparative gene mapping and candidate disease gene identification(20), genome sequence annotation(21,22), microarray development(23) and the development of gene-based map resources(24).	Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Iowa, Iowa City, IA 52242 USA; Univ Calif Lawrence Livermore Natl Lab, IMAGE Consortium, Biol & Biotechnol Res Program, Livermore, CA 94550 USA; Genelogic Inc, Genom, Gaithersburg, MD 20878 USA	Washington University (WUSTL); Oklahoma Medical Research Foundation; University of Iowa; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Marra, M (corresponding author), Washington Univ, Genome Sequencing Ctr, 4444 Forest Pk Blvd, St Louis, MO 63108 USA.		Marra, Marco A/B-5987-2008; Mardis, Elaine/W-2202-2019; Lennon, Greg/T-4717-2019; Wilson, Richard K./AAF-4139-2019	Marra, Marco A/0000-0001-7146-7175; Wilson, Richard K./0000-0002-1992-1358				ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; Bailey LC, 1998, GENOME RES, V8, P362, DOI 10.1101/gr.8.4.362; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Brown SDM, 1996, TRENDS GENET, V12, P433, DOI 10.1016/0168-9525(96)30094-2; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Jiang J, 1998, GENOME RES, V8, P268, DOI 10.1101/gr.8.3.268; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Makalowski W, 1996, GENOME RES, V6, P846, DOI 10.1101/gr.6.9.846; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; Nelson PS, 1998, GENOMICS, V47, P12, DOI 10.1006/geno.1997.5035; PUTNEY SD, 1983, NATURE, V302, P718, DOI 10.1038/302718a0; Sasaki N, 1998, GENOMICS, V49, P167, DOI 10.1006/geno.1998.5209; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; Scharf JM, 1998, NAT GENET, V20, P83, DOI 10.1038/1753; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; Sutherland HF, 1998, GENOMICS, V52, P37, DOI 10.1006/geno.1998.5414; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Yamamoto K, 1997, PLANT MOL BIOL, V35, P135, DOI 10.1023/A:1005735322577; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	30	95	98	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					191	194		10.1038/5976	http://dx.doi.org/10.1038/5976			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988271				2022-12-27	WOS:000078399500021
J	Aitman, TJ; Glazier, AM; Wallace, CA; Cooper, LD; Norsworthy, PJ; Wahid, FN; Al-Majali, KM; Trembling, PM; Mann, CJ; Shoulders, CC; Graf, D; St Lezin, E; Kurtz, TW; Kren, V; Pravenec, M; Ibrahimi, A; Abumrad, NA; Stanton, LW; Scott, J				Aitman, TJ; Glazier, AM; Wallace, CA; Cooper, LD; Norsworthy, PJ; Wahid, FN; Al-Majali, KM; Trembling, PM; Mann, CJ; Shoulders, CC; Graf, D; St Lezin, E; Kurtz, TW; Kren, V; Pravenec, M; Ibrahimi, A; Abumrad, NA; Stanton, LW; Scott, J			Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats	NATURE GENETICS			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; QUANTITATIVE TRAIT LOCI; RECOMBINANT INBRED STRAINS; BLOOD-PRESSURE; LIPOLYSIS; MAP; CHROMOSOMES; LIPOPROTEIN; EXPRESSION; OBESITY	The human insulin-resistance syndromes, type 2 diabetes, obesity, combined hyperlipidaemia and essential hypertension, are complex disorders whose genetic basis is unknown. The spontaneously hypertensive rat (SHR) is insulin resistant and a model of these human syndromes. Quantitative trait loci (QTLs) for SHR defects in glucose and fatty acid metabolism, hypertriglyceridaemia and hypertension map to a single locus on rat chromosome 4. Here we combine use of cDNA microarrays, congenic mapping and radiation hybrid (RH) mapping to identify a defective SHR gene, Cd36 (also known as Fat, as it encodes fatty acid translocase), at the peak of linkage to these QTLs. SHR Cd36 cDNA contains multiple sequence variants, caused by unequal genomic recombination of a duplicated ancestral gene. The encoded protein product is undetectable in SHR adipocyte plasma membrane. Transgenic mice overexpressing Cd36 have reduced blood lipids. We conclude that Cd36 deficiency underlies insulin resistance, defective fatty acid metabolism and hypertriglyceridaemia in SHR and may be important in the pathogenesis of human insulin-resistance syndromes.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Clin Sci Ctr,Mol Med Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Natl Heart & Lung Inst, London W12 0NN, England; Charles Univ Prague, Fac Med 1, Dept Biol, Prague 12800 2, Czech Republic; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague 4, Czech Republic; SUNY Stony Brook, Stony Brook, NY 11733 USA; Scios Inc, Sunnyvale, CA 94086 USA	Imperial College London; Imperial College London; Charles University Prague; University of California System; University of California San Francisco; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Scios	Aitman, TJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Clin Sci Ctr,Mol Med Grp, London W12 0NN, England.	taitman@ic.ac.uk	Pravenec, Michal/B-1666-2012; Graf, Daniel/H-1214-2011	Pravenec, Michal/0000-0001-9197-5871; Graf, Daniel/0000-0003-1163-8117; Aitman, Timothy/0000-0002-7875-4502; Ibrahimi, Azeddine/0000-0003-3226-3836; Norsworthy, Penny/0000-0002-5572-8491; Trembling, Paul/0000-0002-5016-4607	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL56028] Funding Source: Medline; NIDDK NIH HHS [DK33301] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, IN PRESS J LIPID RES; Aitman TJ, 1997, ARTERIOSCL THROM VAS, V17, P748, DOI 10.1161/01.ATV.17.4.748; Aitman TJ, 1997, NAT GENET, V16, P197, DOI 10.1038/ng0697-197; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; Bougneres P, 1997, J CLIN INVEST, V99, P2568, DOI 10.1172/JCI119444; Calvo D, 1998, J LIPID RES, V39, P777; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Curtis BR, 1996, TRANSFUSION, V36, P331, DOI 10.1046/j.1537-2995.1996.36496226147.x; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GOLDMUNTZ EA, 1995, MAMM GENOME, V6, P459, DOI 10.1007/BF00360654; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; Hwang EH, 1998, J NUCL MED, V39, P1681; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; IRITANI N, 1977, ATHEROSCLEROSIS, V28, P217, DOI 10.1016/0021-9150(77)90171-X; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; Kovacs P, 1998, ARCH BIOCHEM BIOPHYS, V354, P139, DOI 10.1006/abbi.1998.0686; KUNZ HW, 1978, J IMMUNOGENET, V5, P365; LANGE K, 1995, GENOME RES, V5, P136, DOI 10.1101/gr.5.2.136; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LIFTON RP, 1995, J CLIN INVEST, V95, P1040; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NATHAN DM, 1997, LANCET S1, V350, P1; Pravenec M, 1996, MAMM GENOME, V7, P117, DOI 10.1007/s003359900031; Pravenec M, 1997, MAMM GENOME, V8, P387, DOI 10.1007/s003359900452; PRAVENEC M, 1995, J CLIN INVEST, V96, P1973, DOI 10.1172/JCI118244; Qu XQ, 1997, AM J HYPERTENS, V10, P1053, DOI 10.1016/S0895-7061(97)00273-2; RANDLE PJ, 1963, LANCET, V1, P785; RAO RH, 1993, DIABETES, V42, P1364, DOI 10.2337/diabetes.42.9.1364; REAVEN GM, 1989, DIABETES, V38, P1155, DOI 10.2337/diabetes.38.9.1155; Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REYNISDOTTIR S, 1995, J CLIN INVEST, V95, P2161, DOI 10.1172/JCI117905; REYNISDOTTIR S, 1994, J CLIN INVEST, V93, P2590, DOI 10.1172/JCI117271; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; SAMANI NJ, 1993, J CLIN INVEST, V92, P1099, DOI 10.1172/JCI116616; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; URWIJITAROON Y, 1995, TRANSFUSION, V35, P868, DOI 10.1046/j.1537-2995.1995.351096026370.x; Watanabe Kenichi, 1997, Kaku Igaku, V34, P1125	49	610	633	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					76	83		10.1038/5013	http://dx.doi.org/10.1038/5013			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916795				2022-12-27	WOS:000077960700013
J	Huynh, DP; Figueroa, K; Hoang, N; Pulst, SM				Huynh, DP; Figueroa, K; Hoang, N; Pulst, SM			Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human	NATURE GENETICS			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; MACHADO-JOSEPH DISEASE; TRANSGENIC MICE; EXPANDED POLYGLUTAMINE; HUNTINGTONS-DISEASE; CAG REPEAT; PURKINJE-CELL; SPINOCEREBELLAR ATAXIA-2; TRINUCLEOTIDE REPEAT; ALZHEIMERS-DISEASE	Instability of CAG DNA trinucleotide repeats is the mutational mechanism for several neurodegenerative diseases resulting in the expansion of a polyglutamine (polyQ) tract. Proteins with long polyQ tracts have an increased tendency to aggregate, often as truncated fragments forming ubiquitinated intranuclear inclusion bodies. We examined whether similar features define spinocerebellar ataxia type 2 (SCA2) pathogenesis using cultured cells, human brains and transgenic mouse lines. In SCA2 brains, we found cytoplasmic, but not nuclear, microaggregates. Mice expressing ataxin-2 with Q58 showed progressive functional deficits accompanied by loss of the Purkinje cell dendritic arbor and finally loss of Purkinje cells. Despite similar functional deficits and anatomical changes observed in ataxin-1[Q80] transgenic lines, ataxin-2[Q58] remained cytoplasmic without detectable ubiquitination.	Univ Calif Los Angeles, Sch Med, CSMC Burns & Allen Res Inst, Rose Moss Lab Parkinsons & Neurodegenerat Dis, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Neurol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pulst, SM (corresponding author), Univ Calif Los Angeles, Sch Med, CSMC Burns & Allen Res Inst, Rose Moss Lab Parkinsons & Neurodegenerat Dis, Los Angeles, CA 90024 USA.	Pulst@CSHS.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033123] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS33123] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Clark HB, 1997, J NEUROSCI, V17, P7385; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Huynh DP, 1999, ANN NEUROL, V45, P232, DOI 10.1002/1531-8249(199902)45:2<232::AID-ANA14>3.0.CO;2-7; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Ishikawa K, 1999, HUM MOL GENET, V8, P1185, DOI 10.1093/hmg/8.7.1185; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kim M, 1999, J NEUROSCI, V19, P964; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOEPPEN AH, 1991, J NEUROPATH EXP NEUR, V50, P505, DOI 10.1097/00005072-199107000-00010; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Koyano S, 1999, NEUROSCI LETT, V273, P117, DOI 10.1016/S0304-3940(99)00656-4; Kuemmerle S, 1999, ANN NEUROL, V46, P842; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Nechiporuk T, 1998, HUM MOL GENET, V7, P1301, DOI 10.1093/hmg/7.8.1301; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Trottier Y, 1998, NEUROBIOL DIS, V5, P335, DOI 10.1006/nbdi.1998.0208; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; Vig PJS, 1998, NEUROLOGY, V50, P106, DOI 10.1212/WNL.50.1.106; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	48	228	237	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					44	50		10.1038/79162	http://dx.doi.org/10.1038/79162			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973246				2022-12-27	WOS:000089078000015
J	de Angelis, MH; Flaswinkel, H; Fuchs, H; Rathkolb, B; Soewarto, D; Marschall, S; Heffner, S; Pargent, W; Wuensch, K; Jung, M; Reis, A; Richter, T; Alessandrini, F; Jakob, T; Fuchs, E; Kolb, H; Kremmer, E; Schaeble, K; Rollinski, B; Roscher, A; Peters, C; Meitinger, T; Strom, T; Steckler, T; Holsboer, F; Klopstock, T; Gekeler, F; Schindewolf, C; Jung, T; Avraham, K; Behrendt, H; Ring, J; Zimmer, A; Schughart, K; Pfeffer, K; Wolf, E; Balling, R				de Angelis, MH; Flaswinkel, H; Fuchs, H; Rathkolb, B; Soewarto, D; Marschall, S; Heffner, S; Pargent, W; Wuensch, K; Jung, M; Reis, A; Richter, T; Alessandrini, F; Jakob, T; Fuchs, E; Kolb, H; Kremmer, E; Schaeble, K; Rollinski, B; Roscher, A; Peters, C; Meitinger, T; Strom, T; Steckler, T; Holsboer, F; Klopstock, T; Gekeler, F; Schindewolf, C; Jung, T; Avraham, K; Behrendt, H; Ring, J; Zimmer, A; Schughart, K; Pfeffer, K; Wolf, E; Balling, R			Genome-wide, large-scale production of mutant mice by ENU mutagenesis	NATURE GENETICS			English	Article							MOUSE; SPERMATOZOA	In the post-genome era, the mouse will have a major role as a model system for functional genome analysis. This requires a large number of mutants similar to the collections available from other model organisms such as Drosophila melanogaster and Caenorhabditis elegans. Here we report on a systematic, genome-wide, mutagenesis screen in mice. As part of the German Human Genome Project, we have undertaken a large-scale ENU-mutagenesis screen for dominant mutations and a limited screen for recessive mutations'. In screening over 14,000 mice for a large number of clinically relevant parameters, we recovered 182 mouse mutants for a variety of phenotypes. In addition, 247 variant mouse mutants are currently in genetic confirmation testing and will result in additional new mutant lines. This mutagenesis screen, along with the screen described in the accompanying paper(2), leads to a significant increase in the number of mouse models(3) available to the scientific community. Our mutant lines are freely accessible to non-commercial users (for information, see http://www.gsf.de/ieg/groups/enu-mouse.html).	GSF, Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany; GSF, Res Ctr Environm & Hlth, Inst Pathol, Neuherberg, Germany; GSF, Res Ctr Environm & Hlth, Inst Immunol, Neuherberg, Germany; GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; Univ Munich, Gene Ctr, Inst Mol Anim Breeding, Munich, Germany; Ingenium Pharmaceut AG, Martinsried, Germany; Max Delbrueck Ctr, Mol Genet & Mikrosatellitenzentrum, Berlin, Germany; GSF Munich, TUM, Div Environm Dermatol & Allergol, Munich, Germany; Clin Harlaching, Inst Clin Chem, Munich, Germany; Dr Von Haunerschen Kinderspital, Kinderklin, Abt Klin Chem Biochem & Stoffwechsel, Munich, Germany; Dr Von Haunerschen Kinderspital, Kinderpoliklin, Munich, Germany; Univ Klin Freiburg, Freiburg, Germany; Univ Munich, Klinikum Grosshadern, Dept Neurobiol, Munich, Germany; Univ Munich, Kinderklin, Abt Med Genet, Munich, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Bundesamt Strahlenschutz, Inst Strahlenhyg, Oberschleissheim, Germany; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, Tel Aviv, Israel; NIMH, Genet Lab, Bethesda, MD USA; Transgene SA, Strasbourg, France	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Munchen Klinik; University of Munich; University of Munich; University of Freiburg; University of Munich; University of Munich; Max Planck Society; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Transgene SA	de Angelis, MH (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany.	hrabe@gsf.de	Balling, Rudi/E-9680-2010; de Angelis, Martin Hrabe/F-5531-2012; Reis, André/D-2309-2009; Zimmer, Andreas/B-8357-2009; Meitinger, Thomas/O-1318-2015; Fuchs, Helmut/M-7347-2014; Ring, Johannes/GLN-4341-2022; Steckler, Thomas/AAF-3975-2020; Jakob, Thilo/J-1621-2012; Rathkolb, Birgit/F-7041-2013	Balling, Rudi/0000-0003-2902-5650; de Angelis, Martin Hrabe/0000-0002-7898-2353; Reis, André/0000-0002-6301-6363; Fuchs, Helmut/0000-0002-5143-2677; Ring, Johannes/0000-0001-8236-3152; Schughart, Klaus/0000-0002-6824-7523; Meitinger, Thomas/0000-0002-8838-8403; Pfeffer, Klaus/0000-0002-5652-6330; Wolf, Eckhard/0000-0002-0430-9510; Avraham, Karen B/0000-0002-4913-251X				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Brown SDM, 1996, TRENDS GENET, V12, P433, DOI 10.1016/0168-9525(96)30094-2; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; Graw J, 1999, GENOMICS, V62, P67, DOI 10.1006/geno.1999.5974; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; Marschall S, 1999, TRENDS GENET, V15, P128, DOI 10.1016/S0168-9525(99)01715-1; Marschall S, 1999, MAMM GENOME, V10, P773, DOI 10.1007/s003359901090; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Nolan PM, 1997, METHODS, V13, P379, DOI 10.1006/meth.1997.0545; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5918; Spickett GP, 1997, IMMUNOL TODAY, V18, P325, DOI 10.1016/S0167-5699(97)01086-4; WHYTE MP, 1979, MEDICINE, V58, P329, DOI 10.1097/00005792-197909000-00001	13	518	527	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					444	447		10.1038/78146	http://dx.doi.org/10.1038/78146			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932192				2022-12-27	WOS:000088615000023
J	Svensson, EC; Huggins, GS; Lin, H; Clendenin, C; Jiang, F; Tufts, R; Dardik, FB; Leiden, JM				Svensson, EC; Huggins, GS; Lin, H; Clendenin, C; Jiang, F; Tufts, R; Dardik, FB; Leiden, JM			A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR GATA-4; HEART TUBE FORMATION; ATRIOVENTRICULAR JUNCTION; VENTRAL MORPHOGENESIS; NF-ATC; MOUSE; TRISOMY-16; COFACTOR; NKX2-5; VALVE	Tricuspid atresia (TA) is a common form of congenital heart disease, accounting for 1-3% of congenital cardiac disorders(1). TA is characterized by the congenital agenesis of the tricuspid valve connecting the right atrium to the right ventricle and both an atrial septal defect (ASD) and a ventricular septal defect(2) (VSD). Some patients also have pulmonic stenosis. persistence of a left-sided superior vena cava or transposition of the great arteries. Most cases of TA are sporadic, but familiar occurrences with disease in multiple siblings have been reported(3-5). Gata4 is a zinc-finger transcription factor with a role in early cardiac development. Gata4-deficient mice fail to form a ventral heart tube and die of circulatory failure at embryonic day (E) 8.5 (refs 6,7). Zfpm2 (also known as Fog-2) is a multi-zinc-finger protein that is co-expressed with Gata4 in the developing heart beginning at E8.5 (refs 8-10). Zfpm2 interacts specifically with the N-terminal zinc finger of Gata4 and represses Gata4-dependent transcription(8-10). Here we use targeted mutagenesis to explore the role of Zfpm2 in normal cardiac development. Zfpm2-deficient mice died of congestive heart failure at E13 with a syndrome of tricuspid atresia that includes an absent tricuspid valve, a large ASD, a VSD, an elongated left ventricular outflow tract, rightward displacement of the aortic valve and pulmonic stenosis. These mice also display hypoplasia of the compact zone of the left ventricle. Our findings indicate the importance of Zfpm2 in the normal looping and septation of the heart and suggest a genetic basis for the syndrome of tricuspid atresia.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Chicago	Leiden, JM (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003667, R01HL054592] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54592, HL03667, R01 HL054592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RH, 1998, CARDIOVASC RES, V39, P155, DOI 10.1016/S0008-6363(98)00037-6; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Bonnet D, 1999, J MED GENET, V36, P349; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; GELB BD, 1991, AM J MED GENET, V40, P471, DOI 10.1002/ajmg.1320400420; KUMAR A, 1994, PEDIATR CARDIOL, V15, P201, DOI 10.1007/BF00800676; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAMERS WH, 1995, CIRCULATION, V91, P111, DOI 10.1161/01.CIR.91.1.111; Lee RY, 1997, CIRC RES, V80, P757; Lin AE, 1998, J MED GENET, V35, P1055, DOI 10.1136/jmg.35.12.1055; Lu JR, 1999, MOL CELL BIOL, V19, P4495; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; RAO PS, 1980, AM HEART J, V99, P799, DOI 10.1016/0002-8703(80)90632-8; SADE RM, 1990, PEDIATR CLIN N AM, V37, P151; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; SUJANSKY E, 1993, AM J MED GENET, V47, P512, DOI 10.1002/ajmg.1320470415; SVENSSON E, IN PRESS J BIOL CHEM; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Webb S, 1997, CARDIOVASC RES, V34, P515, DOI 10.1016/S0008-6363(97)00064-3; Webb S, 1999, CIRC RES, V84, P897; Webb S, 1998, CIRC RES, V82, P645, DOI 10.1161/01.RES.82.6.645	28	138	142	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					353	356		10.1038/77146	http://dx.doi.org/10.1038/77146			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888889				2022-12-27	WOS:000087920900029
J	Le Saux, O; Urban, Z; Tschuch, C; Csiszar, K; Bacchelli, B; Quaglino, D; Pasquali-Ronchetti, I; Pope, FM; Richards, A; Terry, S; Bercovitch, L; de Paepe, A; Boyd, CD				Le Saux, O; Urban, Z; Tschuch, C; Csiszar, K; Bacchelli, B; Quaglino, D; Pasquali-Ronchetti, I; Pope, FM; Richards, A; Terry, S; Bercovitch, L; de Paepe, A; Boyd, CD			Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum	NATURE GENETICS			English	Article							CHROMOSOME 16P13.1; BETA-THALASSEMIA; EXPRESSION; DISEASE; MAPS	Pseudoxanthoma elasticum (PXE) is a heritable disorder characterized by calcification of elastic fibres in skin, arteries and retina that results in dermal lesions with associated laxity and loss of elasticity, arterial insufficiency and retinal haemorrhages leading to macular degefieration(1-5). PXE is usually found as a sporadic disorder, but examples of both autosomal recessive and autosomal dominant forms of PXE have been observed(6). Partial manifestations of the PXE phenotype have also been described in presumed carriers in PXE families(7,8). Linkage of both dominant and recessive forms of PXE to a 5-cM domain on chromosome 16013.1 has been reported (refs 8,9). We have refined this locus to an 820-kb region containing 6 candidate genes(10). Here we report the exclusion of five of these genes and the identification of the first mutations responsible for the development of PXE in a gene encoding a protein associated with multidrug resistance (ABCC6).	Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Univ Modena, Dept Biomed Sci, Modena, Italy; Univ Wales Hosp, Inst Med Genet, MRC, Connect Tissue Genet Grp, Cardiff CF4 4XN, S Glam, Wales; Univ Cambridge, Dept Pathol, MRC, Connect Tissue Genet Grp, Cambridge CB2 1QP, England; PXE Int Inc, Sharon, MA USA; Brown Univ, Dept Dermatol, Providence, RI 02912 USA; Univ Hosp, Univ Ziekenhuis, Ctr Med Genet, Ghent, Belgium	University of Hawaii System; Universita di Modena e Reggio Emilia; Cardiff University; University of Cambridge; Brown University; Ghent University; Ghent University Hospital	Boyd, CD (corresponding author), Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA.		Le Saux, Olivier/P-4668-2017; Urban, Zsolt/B-1977-2008; Urban, Zsolt/A-2018-2013; Quaglino, Daniela/A-9381-2010	Le Saux, Olivier/0000-0002-5605-3617; Urban, Zsolt/0000-0003-3890-1843; Quaglino, Daniela/0000-0002-4302-5078	NCRR NIH HHS [RR03061] Funding Source: Medline; NEI NIH HHS [EY13019] Funding Source: Medline; NHLBI NIH HHS [HL50665] Funding Source: Medline; Telethon [E.0696] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013019] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050665] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aessopos A, 1998, ANGIOLOGY, V49, P137, DOI 10.1177/000331979804900206; Bacchelli B, 1999, MODERN PATHOL, V12, P1112; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Belinsky MG, 1999, BRIT J CANCER, V80, P1342, DOI 10.1038/sj.bjc.6690527; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Jones PM, 1998, J MEMBRANE BIOL, V166, P133, DOI 10.1007/s002329900455; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 1999, GENOMICS, V62, P1, DOI 10.1006/geno.1999.5925; LEBWOHL M, 1993, NEW ENGL J MED, V329, P1237, DOI 10.1056/NEJM199310213291705; MENDELSOHN G, 1978, ARCH PATHOL LAB MED, V102, P298; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; Neldner K H, 1988, Clin Dermatol, V6, P1; Nikko AP, 1996, AM J DERMATOPATH, V18, P396, DOI 10.1097/00000372-199608000-00011; Ong-ajyooth L, 1998, NEPHRON, V78, P156, DOI 10.1159/000044904; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POPE FM, 1975, BRIT J DERMATOL, V92, P493; Sapadin AN, 1998, J AM ACAD DERMATOL, V39, P338, DOI 10.1016/S0190-9622(98)70385-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Struk B, 1997, HUM MOL GENET, V6, P1823, DOI 10.1093/hmg/6.11.1823; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Urban Z, 1999, HUM GENET, V104, P135, DOI 10.1007/s004390050926; vanSoest S, 1997, GENOME RES, V7, P830, DOI 10.1101/gr.7.8.830; Weenink AC, 1996, NETH J MED, V49, P24, DOI 10.1016/0300-2977(95)00079-8; Wilton SD, 1998, HUM MUTAT, V11, P252, DOI 10.1002/(SICI)1098-1004(1998)11:3<252::AID-HUMU11>3.3.CO;2-Z; YAP EY, 1992, RETINA-J RET VIT DIS, V12, P315, DOI 10.1097/00006982-199212040-00004	26	400	416	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					223	227		10.1038/76102	http://dx.doi.org/10.1038/76102			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835642				2022-12-27	WOS:000087459200026
J	van den Boogaard, MJH; Dorland, M; Beemer, FA; van Amstel, HKP				van den Boogaard, MJH; Dorland, M; Beemer, FA; van Amstel, HKP			MSX1 mutation is associated with orofacial clefting and tooth agenesis in humans	NATURE GENETICS			English	Article							PALATE; LIP; PREVALENCE		Univ Utrecht, Med Ctr, Dept Med Genet, Utrecht, Netherlands	Utrecht University	van den Boogaard, MJH (corresponding author), Univ Utrecht, Med Ctr, Dept Med Genet, Utrecht, Netherlands.							Christensen K, 1996, AM J HUM GENET, V58, P182; Croen LA, 1998, AM J MED GENET, V79, P42, DOI 10.1002/(SICI)1096-8628(19980827)79:1<42::AID-AJMG11>3.0.CO;2-M; FITZPATRICK D, 1993, J CRAN GENET DEV BIO, V13, P230; FRASER FC, 1970, AM J HUM GENET, V22, P336; HEWITT JE, 1991, GENOMICS, V11, P670, DOI 10.1016/0888-7543(91)90074-O; Hu GZ, 1998, MOL CELL BIOL, V18, P6044, DOI 10.1128/MCB.18.10.6044; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; Murray JC, 1997, CLEFT PALATE-CRAN J, V34, P7, DOI 10.1597/1545-1569(1997)034<0007:CAESOC>2.3.CO;2; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schutte BC, 1999, HUM MOL GENET, V8, P1853, DOI 10.1093/hmg/8.10.1853; Tolarova MM, 1998, AM J MED GENET, V75, P126; VANDERAS AP, 1987, CLEFT PALATE J, V24, P216; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224	15	421	430	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					342	343		10.1038/74155	http://dx.doi.org/10.1038/74155			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742093				2022-12-27	WOS:000086192800009
J	Nichols, KE; Crispino, JD; Poncz, M; White, JG; Orkin, SH; Maris, JM; Weiss, MJ				Nichols, KE; Crispino, JD; Poncz, M; White, JG; Orkin, SH; Maris, JM; Weiss, MJ			Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR GATA-1; FINGER PROTEIN; CELLS; FOG; DIFFERENTIATION; PRECURSORS; MATURATION; EXPRESSION; COFACTOR; LACKING	Haematopoietic development is regulated by nuclear protein complexes that coordinate lineage-specific patterns of gene expression. Targeted mutagenesis in embryonic stem cells and mice has revealed roles for the X-linked gene Gata1 in erythrocyte and megakaryocyte differentiation(1-4), GATA-1 is the founding member of a family of DNA-binding proteins that recognize the motif WGATAR through a conserved multifunctional domain consisting of two C4-type zinc fingers(5-8). Here we describe a family with X-linked dyserythropoietic anaemia and thrombocytopenia due to a substitution of methionine for valine at amino acid 205 of GATA-1. This highly conserved valine is necessary for interaction of the amino-terminal zinc finger of GATA-1 with its essential cofactor, FOG-1 (for friend of GATA-1; refs 9-12). We show that the V205M mutation abrogates the interaction between Gata-1 and Fog-1, inhibiting the ability of Gata-1 to rescue erythroid differentiation in an erythroid cell line deficient for Gata-1 (G1E). Our findings underscore the importance of FOG-1:Gata-1 associations in both megakaryocyte and erythroid development, and suggest that other X-linked anaemias or thrombocytopenias may be caused by defects in GATA1.	Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Minnesota, Dept Lab Med, Minneapolis, MN 55455 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; Harvard Univ, Childrens Hosp, Sch Med, Div Hematol & Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Weiss, MJ (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA.		Weiss, Mitchell J/A-1245-2013; Nichols, Kim/E-9353-2016; Nichols, Kim/AAP-8592-2020; Weiss, Mitchell J/W-9814-2018	Nichols, Kim/0000-0002-5581-6555; Nichols, Kim/0000-0002-5581-6555; Weiss, Mitchell J/0000-0003-2460-3036; Crispino, John/0000-0002-8182-8306	NCI NIH HHS [R01 CA78545] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NIAID NIH HHS [AI K11AI01331-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078545] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; HUTSON JM, 1994, REPROD FERT DEVELOP, V6, P151, DOI 10.1071/RD9940151; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; MARTINEZCARRION M, 1986, COENZYMES COFACTOR B, V1, P1; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; THOMPSON AR, 1977, BLOOD, V50, P303; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Viger RS, 1998, DEVELOPMENT, V125, P2665; Vyas P, 1999, BLOOD, V93, P2867; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WEISS TG, 1994, ETHICS INT AFF, V8, P1; Weissberg RP, 1997, ISS CHILDR FAM LIVES, V8, P1; White JG, 1998, SEMIN THROMB HEMOST, V24, P163, DOI 10.1055/s-2007-995836; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	27	384	392	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					266	270		10.1038/73480	http://dx.doi.org/10.1038/73480			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700180				2022-12-27	WOS:000085590600017
J	Bach, I; Rodriguez-Esteban, C; Carriere, C; Bhushan, A; Krones, A; Rose, DW; Glass, CK; Andersen, B; Belmonte, JCI; Rosenfeld, MG				Bach, I; Rodriguez-Esteban, C; Carriere, C; Bhushan, A; Krones, A; Rose, DW; Glass, CK; Andersen, B; Belmonte, JCI; Rosenfeld, MG			RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex	NATURE GENETICS			English	Article							VERTEBRATE LIMB; SONIC HEDGEHOG; RING FINGER; ZINC-FINGER; N-COR; PROTEIN; DOMAIN; REPRESSION; INITIATION; INDUCTION	LIM domains(1) are required for both inhibitory effects on LIM homeodomain transcription factors and synergistic transcriptional activation events(1-4). The inhibitory actions of the LIM domain can often be overcome by the LIM co-regulator known as CLIM2, LDB1 and NLI (referred to hereafter as CLIM2; refs 2-4). The association of the CLIM cofactors with LIM domains does not, however, improve the DNA-binding ability of LIM homeodomain proteins(4,5). suggesting the action of a LIM-associated inhibitor factor. Here we present evidence that LIM domains are capable of binding a novel RING-H2 zinc-finger protein, Rlim (for RING finger LIM domain-binding protein), which acts as a negative co-regulator via the recruitment of the Sin3A/histone deacetylase corepressor complex. A corepressor function of RLIM is also suggested by in vivo studies of chick wing development. Overexpression of the gene Rnf12, encoding Rlim, results in phenotypes similar to those observed after inhibition of the LIM homeodomain factor LHX2, which is required for the formation of distal structures along the proximodistal axis, or by overexpression of dominant-negative CLIM1. We conclude that Rlim is a novel corepressor that recruits histone deacetylase-containing complexes to the LIM domain.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Eukaryot Regulatory Biol Program, La Jolla, CA 92093 USA; Salk Inst Biol Sci, Gene Express Lab, San Diego, CA 92186 USA; Salk Inst Biol Sci, Clayton Fdn, San Diego, CA 92186 USA; Univ Calif San Diego, Whittier Diabet Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Hamburg, Ctr Mol Neurobiol, D-20246 Hamburg, Germany	Howard Hughes Medical Institute; University of California System; University of California San Diego; Salk Institute; Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Hamburg	Bach, I (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Eukaryot Regulatory Biol Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ingolf.bach@zmnh.uni-hamburg.de; belmonte@salk.edu; mrosenfeld@ucsd.edu	Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002080, R01AR044882] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02080, AR044882] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Rodriguez-Esteban C, 1998, DEVELOPMENT, V125, P3925; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Toyama R, 1998, MECH DEVELOP, V71, P197, DOI 10.1016/S0925-4773(97)00202-5; Tranque P, 1996, P NATL ACAD SCI USA, V93, P3105, DOI 10.1073/pnas.93.7.3105; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0	28	120	124	1	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					394	399		10.1038/11970	http://dx.doi.org/10.1038/11970			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431247				2022-12-27	WOS:000081772500025
J	Brooks-Wilson, A; Marcil, M; Clee, SM; Zhang, LH; Roomp, K; van Dam, M; Yu, L; Brewer, C; Collins, JA; Molhuizen, HOF; Loubser, O; Ouelette, BFF; Fichter, K; Ashbourne-Excoffon, KJD; Sensen, CW; Scherer, S; Mott, S; Denis, M; Martindale, D; Frohlich, J; Morgan, K; Koop, B; Pimstone, S; Kastelein, JJP; Genest, J; Hayden, MR				Brooks-Wilson, A; Marcil, M; Clee, SM; Zhang, LH; Roomp, K; van Dam, M; Yu, L; Brewer, C; Collins, JA; Molhuizen, HOF; Loubser, O; Ouelette, BFF; Fichter, K; Ashbourne-Excoffon, KJD; Sensen, CW; Scherer, S; Mott, S; Denis, M; Martindale, D; Frohlich, J; Morgan, K; Koop, B; Pimstone, S; Kastelein, JJP; Genest, J; Hayden, MR			Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency	NATURE GENETICS			English	Article							CORONARY HEART-DISEASE; MULTILOCUS LINKAGE ANALYSIS; HDL CHOLESTEROL LEVELS; GENE ABCR; PHOSPHOLIPASE-C; ARTERY DISEASE; FIBROBLASTS; EFFLUX; COMPUTATIONS; TRANSPORTERS	Genes have a major role in the control of high-density lipoprotein (HDL) cholesterol (HDL-C) levels. Here we have identified two Tangier disease (TD) families, confirmed 9q31 linkage and refined the disease locus to a limited genomic region containing the gene encoding the ATP-binding cassette transporter (ABC1). Familiar HDL deficiency (FHA) is a more frequent cause of low HDL levels. On the basis of independent linkage and meiotic recombinants, we localized the FHA locus to the same genomic region as the TD locus, Mutations in ABC1 were detected in both TD and FHA, indicating that TD and FHA are allelic. This indicates that the protein encoded by ABC1 is a key gatekeeper influencing intracellular cholesterol transport, hence we have named it cholesterol efflux regulatory protein (CERP).	Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Xenon Biores Inc, NRC Innovat Ctr, Vancouver, BC V6T 1W5, Canada; Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Clin Res Inst Montreal, Cardiovasc Genet Lab, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Victoria, Ctr Environm Hlth, Dept Biol, Victoria, BC V8W 3N5, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; National Research Council Canada; University of Amsterdam; Academic Medical Center Amsterdam; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; McGill University; International Business Machines (IBM); National Research Council Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Victoria; University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Hayden, Michael R/D-8581-2011; Clee, Susanne/AAC-4278-2020; van Dam, Marjel/AFT-3071-2022; Clee, Susanne/F-7312-2010; Koop, Ben F./A-8151-2008; Collins, Jennifer/AAE-1895-2020; Ouellette, Francis/G-1684-2010; Sensen, Christoph W./C-1798-2013; Kastelein, John/AAF-7950-2020; Scherer, Stephen W./B-3785-2013; Excoffon, Katherine/ABC-5037-2021; Brooks-Wilson, Angela/E-9399-2012	Hayden, Michael R/0000-0001-5159-1419; Clee, Susanne/0000-0001-7946-688X; Koop, Ben F./0000-0003-0045-5200; Sensen, Christoph W./0000-0001-9604-8962; Scherer, Stephen W./0000-0002-8326-1999; Excoffon, Katherine/0000-0003-3945-0298; Brooks-Wilson, Angela/0000-0003-1009-6408; van Dam, Marjel/0000-0001-9802-7516; Ouellette, B. F. Francis/0000-0003-4676-675X				Allikmets R, 1998, GENE, V215, P111, DOI 10.1016/S0378-1119(98)00269-8; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; Baxevanis AD, 1998, METHOD BIOCHEM ANAL, V39, P98; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; DROBNIK W, 1995, ARTERIOSCL THROM VAS, V15, P1369, DOI 10.1161/01.ATV.15.9.1369; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FREDRICKSON D, 1961, ANN INTERN MED, V55, P1016, DOI 10.7326/0003-4819-55-6-1016; FROHLICH J, 1987, CLIN INVEST MED, V10, P377; GARTNER J, 1992, NAT GENET, V1, P23; Genest J, 1999, J INVEST MED, V47, P31; GENEST J, 1993, ARTERIOSCLER THROMB, V13, P1728, DOI 10.1161/01.ATV.13.12.1728; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; KANNEL WB, 1983, AM J CARDIOL, V52, pB9, DOI 10.1016/0002-9149(83)90649-5; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATHROP GM, 1986, GENET EPIDEMIOL, V3, P39, DOI 10.1002/gepi.1370030105; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MARCIL M, 1995, ARTERIOSCL THROM VAS, V15, P1015, DOI 10.1161/01.ATV.15.8.1015; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROWEN L, 1994, AUTOMATED DNA SEQUEN; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Schuler GD, 1998, METHOD BIOCHEM ANAL, V39, P145; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; TALMUD P, 1982, GENET EPIDEMIOL, V45, P161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	50	1437	1496	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					336	345		10.1038/11905	http://dx.doi.org/10.1038/11905			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431236				2022-12-27	WOS:000081772500014
J	Braverman, N; Lin, P; Moebius, FF; Obie, C; Moser, A; Glossmann, H; Wilcox, WR; Rimoin, DL; Smith, M; Kratz, L; Kelley, RI; Valle, D				Braverman, N; Lin, P; Moebius, FF; Obie, C; Moser, A; Glossmann, H; Wilcox, WR; Rimoin, DL; Smith, M; Kratz, L; Kelley, RI; Valle, D			Mutations in the gene encoding 3 beta-hydroxysteroid-Delta(8),Delta(7)-isomerase cause X-linked dominant Conradi-Hunermann syndrome	NATURE GENETICS			English	Article							LEMLI-OPITZ-SYNDROME; ANTAGONIST BINDING-PROTEIN; CHONDRODYSPLASIA PUNCTATA; DISRUPTION; REDUCTASE; RECEPTOR; YEAST; LIVER	X-linked dominant Conradi-Hunermann syndrome (CDPX2; MIM 302960) is one of a group of disorders with aberrant punctate calcification in cartilage, or chondrodysplasia punctata (CDP). This is most prominent around the vertebral column, pelvis and long bones in CPDX2. Additionally, CDPX2 patients may have asymmetric rhizomesomelia, sectorial cataracts, patchy alopecia, ichthyosis and atrophoderma(1). The phenotype in CDPX2 females ranges from stillborn to mildly affected individuals identified in adulthood. CDPX2 is presumed lethal in males, although a few affected males have been reported(2,3). We found increased 8(9)-cholestenol and 8-dehydrocholesterol in tissue samples from seven female probands with CDPX2 (ref. 4). This pattern of accumulated cholesterol intermediates suggested a deficiency of 3 beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (sterol-Delta(8)-isomerase), which catalyses an intermediate step in the conversion of lanosterol to cholesterol(4). A candidate gene encoding a sterol-Delta(8)-isomerase (EBP) has been identified and mapped to Xp11.22-p11.23 (refs 5,6). Using SSCP analysis and sequencing of genomic DNA, we found EBP mutations in all probands. We confirmed the functional significance of two missense alleles by expressing them in a sterol-Delta(8)-isomerase-deficient yeast strain. Our results indicate that defects in sterol-Delta(8)-isomerase cause CDPX2 and suggest a role for sterols in bone development.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Inst Biochem Pharmacol, Innsbruck, Austria; Univ Calif Los Angeles, Burns & Allen Cedars Sinai Res Inst, Dept Pediat, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Irvine	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.		Glossmann, Hartmut/AAL-9790-2020	glossmann, hartmut h./0000-0002-7392-3266; Braverman, Nancy/0000-0003-1621-5164	NCRR NIH HHS [RR00052, RR00722] Funding Source: Medline; NICHD NIH HHS [P01HD10981] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; BJORKHEM I, 1987, J LIPID RES, V28, P1137; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BRODY LC, 1992, J BIOL CHEM, V267, P3302; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Derry JMJ, 1999, NAT GENET, V22, P286, DOI 10.1038/10350; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HAPPLE R, 1995, AM J MED GENET, V57, P493, DOI 10.1002/ajmg.1320570327; HAPPLE R, 1979, HUM GENET, V53, P65, DOI 10.1007/BF00289453; HERMAN GE, 1990, GENOMICS, V7, P307, DOI 10.1016/0888-7543(90)90162-N; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kelley RI, 1999, AM J MED GENET, V83, P213, DOI 10.1002/(SICI)1096-8628(19990319)83:3<213::AID-AJMG15>3.0.CO;2-C; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; MOEBIUS FF, 1994, J BIOL CHEM, V269, P29314; Moebius FF, 1999, BIOCHEMISTRY-US, V38, P1119, DOI 10.1021/bi981804i; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; SUTPHEN R, 1995, AM J MED GENET, V57, P489, DOI 10.1002/ajmg.1320570326; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205	25	200	205	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					291	294		10.1038/10357	http://dx.doi.org/10.1038/10357			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391219				2022-12-27	WOS:000081125900024
J	Steinborn, R; Schinogl, P; Zakhartchenko, V; Achmann, R; Schernthaner, W; Stojkovic, M; Wolf, E; Muller, M; Brem, G				Steinborn, R; Schinogl, P; Zakhartchenko, V; Achmann, R; Schernthaner, W; Stojkovic, M; Wolf, E; Muller, M; Brem, G			Mitochondrial DNA heteroplasmy in cloned cattle produced by fetal and adult cell cloning	NATURE GENETICS			English	Article							NUCLEI; FIBROBLASTS; SHEEP; MICE		Univ Vet Med, Inst Genet & Anim Breeding, Vienna, Austria; Ludwig Boltzmann Inst Immuno Cyto & Mol Genet, Vienna, Austria; Inst Agrobiotechnol, Dept Biotechnol Anim Prod, Tulln, Austria; Univ Munich, Gene Ctr, Dept Mol Anim Breeding & Genet, Munich, Germany	University of Veterinary Medicine Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Munich	Steinborn, R (corresponding author), Univ Vet Med, Inst Genet & Anim Breeding, Vienna, Austria.	Ralf.Steinborn@vu-wien.ac.at		Zakhartchenko, Valeri/0000-0002-5974-9759; Muller, Mathias/0000-0002-7879-3552; Stojkovic, Miodrag/0000-0001-7526-6573; Wolf, Eckhard/0000-0002-0430-9510				Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Hiendleder S, 1999, MOL REPROD DEV, V54, P24, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;24::AID-MRD4&gt;3.0.CO;2-S; Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; PLANTE Y, 1992, THERIOGENOLOGY, V38, P887; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Steinborn R, 1998, FEBS LETT, V426, P357, DOI 10.1016/S0014-5793(98)00351-2; Steinborn R, 1998, FEBS LETT, V426, P352, DOI 10.1016/S0014-5793(98)00350-0; Sutovsky P, 1999, NATURE, V402, P371, DOI 10.1038/46466; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zakhartchenko V, 1999, MOL REPROD DEV, V54, P264, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;264::AID-MRD7&gt;3.0.CO;2-Y; Zakhartchenko V, 1999, J REPROD FERTIL, V115, P325, DOI 10.1530/jrf.0.1150325	14	134	141	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					255	257		10.1038/77000	http://dx.doi.org/10.1038/77000			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888867				2022-12-27	WOS:000087920900008
J	Sun, X; Lewandoski, M; Meyers, EN; Liu, YH; Maxson, RE; Martin, GR				Sun, X; Lewandoski, M; Meyers, EN; Liu, YH; Maxson, RE; Martin, GR			Conditional inactivation of Fgf4 reveals complexity of signalling during limb bud development	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; VERTEBRATE LIMB; SONIC-HEDGEHOG; FEEDBACK LOOP; MEDIATED RECOMBINATION; GENE-FUNCTION; MOUSE; EXPRESSION; GROWTH; OUTGROWTH	Development of the vertebrate limb bud depends on reciprocal interactions between the zone of polarizing activity (ZPA) and the apical ectodermal ridge(1) (AER). Sonic hedgehog (SHH) and fibroblast growth factors (FGFs) are key signalling molecules produced in the ZPA and AER, respectively(1,2). Experiments in chicks suggested that SHH expression in the ZPA is maintained by FGF4 expression in the AER, acid vice versa(3,4), providing a molecular mechanism for coordinating the activities of these two signalling centres. This SHH/FGF4 feedback loop model is supported by genetic evidence showing that Fgf4 expression is not maintained in Shh(-/-) mouse limbs(5). We report here that Shh expression is maintained and limb formation is normal when Fgf4 is inactivated in mouse limbs, thus contradicting the model. We also found that maintenance of Fgf9 and Fgf17 expression is dependent on Shh, whereas Fgf8 expression is not. We discuss a model in which no individual Fgf expressed in the AER (AER-Fgf) is solely necessary to maintain Shh expression, but, instead, the combined activities of two or more AER-Fgfs function in a positive feedback loop with Shh to control limb development.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA; USC Norris Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southern California	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.			Lewandoski, Mark/0000-0002-1066-3735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012450] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD34380, HD01216] Funding Source: Medline; NIDCR NIH HHS [R01 DE12450] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bellusci S, 1997, DEVELOPMENT, V124, P4867; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Colvin JS, 1999, DEV DYNAM, V216, P72; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; JONES CM, 1991, DEVELOPMENT, V111, P531; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LIU YH, 1994, MECH DEVELOP, V48, P187, DOI 10.1016/0925-4773(94)90059-0; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; LYONS KM, 1990, DEVELOPMENT, V109, P833; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Maruoka Y, 1998, MECH DEVELOP, V74, P175, DOI 10.1016/S0925-4773(98)00061-6; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Minowada G, 1999, DEVELOPMENT, V126, P4465; Moon AM, 2000, DEVELOPMENT, V127, P989; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; XU J, IN PRESS DEVELOPMENT; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	30	236	251	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					83	86		10.1038/75644	http://dx.doi.org/10.1038/75644			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802662				2022-12-27	WOS:000086884000022
J	Esnault, C; Maestre, J; Heidmann, T				Esnault, C; Maestre, J; Heidmann, T			Human LINE retrotransposons generate processed pseudogenes	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPOSABLE ELEMENTS; INDICATOR GENE; RNA; GENOME; CELLS; INFECTION; TRANSPOSITION; PARTICLES; SEQUENCE	Long interspersed elements (LINEs) are endogenous mobile genetic elements(1-4) that have dispersed and accumulated in the genomes of higher eukaryotes via germline transposition, with up to 100,000 copies in mammalian genomes. In humans, LINEs are the major source of insertional mutagenesis, being involved in both germinal and somatic mutant phenotypes(4). Here we show that the human LINE retrotransposons, which transpose through the reverse transcription of their own transcript(2), can also mobilize transcribed DNA not associated with a LIME sequence by a process involving the diversion of the LINE enzymatic machinery by the corresponding mRNA transcripts. This results in the 'retroposition' of the transcribed gene and the formation of new copies that disclose features characteristic of the widespread and naturally occurring processed pseudogenes: loss of intron and promoter, acquisition of a poly(A) 3' end and presence of target-site duplications of varying length(5,6). We further show-by introducing deletions within either coding sequence of the human LINE-that both ORFs are necessary for the formation of the processed pseudogenes, and that retroviral-like elements are not able to produce similar structures in the same assay. Our results strengthen the unique versatility of LINEs as genome modellers.	Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, Rue Camille Desmoulins, Villejuif, France.							Boeke J. D., 1997, P343; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CARLTON MBL, 1995, MAMM GENOME, V6, P90, DOI 10.1007/BF00303250; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DORNBURG R, 1990, MOL CELL BIOL, V10, P68, DOI 10.1128/MCB.10.1.68; Eickbush T, 1999, SCIENCE, V283, P1465, DOI 10.1126/science.283.5407.1465; FINNEGAN DJ, 1989, MOBILE DNA, P503; Gabriel A, 1998, TRENDS GENET, V14, P220, DOI 10.1016/S0168-9525(98)01474-7; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; LEVINE KL, 1990, MOL CELL BIOL, V10, P1891, DOI 10.1128/MCB.10.5.1891; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Sandmeyer S, 1998, GENOME RES, V8, P416, DOI 10.1101/gr.8.5.416; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; Weiss RA, 1997, NATURE, V390, P235, DOI 10.1038/36740	30	608	625	1	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					363	367		10.1038/74184	http://dx.doi.org/10.1038/74184			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742098				2022-12-27	WOS:000086192800013
J	Gibbons, RJ; McDowell, TL; Raman, S; O'Rourke, DM; Garrick, D; Ayyub, H; Higgs, DR				Gibbons, RJ; McDowell, TL; Raman, S; O'Rourke, DM; Garrick, D; Ayyub, H; Higgs, DR			Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation	NATURE GENETICS			English	Article							SEQUENCES; REGION	A goal of molecular genetics is to understand the relationship between basic nuclear processes, epigenetic changes and the numerous proteins that orchestrate these effects. One such protein, ATRX, contains a highly conserved plant homeodomain (PHD)-like domain, present in many chromatin-associated proteins, and a carboxy-terminal domain which identifies it as a member of the SNF2 family of helicase/ATPases(1,2). Mutations in ATRX give rise to characteristic developmental abnormalities including severe mental retardation, facial dysmorphism, urogenital abnormalities and alpha-thalassaemia(1). This circumstantial evidence suggests that ATRX may act as a transcriptional regulator through an effect on chromatin. We have recently shown that ATRX is localized to pericentromeric heterochromatin during interphase and mitosis, suggesting that ATRX might exert other chromatin-mediated effects in the nucleus. Moreover, at metaphase, some ATRX is localized at or close to the ribosomal DNA (rDNA) arrays on the short arms of human acrocentric chromosomes(3). Here we show that mutations in ATRX give rise to changes in the pattern of methylation of several highly repeated sequences including the rDNA arrays, a Y-specific satellite and subtelomeric repeats. Our findings provide a potential link between the processes of chromatin remodelling, DNA methylation and gene expression in mammalian development.	John Radcliffe Hosp, Inst Mol Med, MRC Mol Haematol, Oxford OX3 9DU, England; Univ Oxford, Nuffield Dept Clin Lab, Oxford, England	University of Oxford; University of Oxford	Higgs, DR (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC Mol Haematol, Oxford OX3 9DU, England.		GARRICK, David/O-5734-2019; Garrick, David/F-1728-2017	GARRICK, David/0000-0001-7422-7986; Garrick, David/0000-0001-7422-7986				BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; COOKE HJ, 1982, CHROMOSOMA, V87, P491, DOI 10.1007/BF00333470; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; FROMMER M, 1984, NUCLEIC ACIDS RES, V12, P2887, DOI 10.1093/nar/12.6.2887; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Goenechea L. G., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P841; Jacobsen SE, 1999, CURR BIOL, V9, pR617, DOI 10.1016/S0960-9822(99)80388-1; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; Kakutani T, 1999, GENETICS, V151, P831; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; TASSERONDEJONG JG, 1988, GENE, V74, P147, DOI 10.1016/0378-1119(88)90272-7; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	20	391	407	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					368	371		10.1038/74191	http://dx.doi.org/10.1038/74191			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742099				2022-12-27	WOS:000086192800014
J	Satokata, I; Ma, L; Ohshima, H; Bei, M; Woo, I; Nishizawa, K; Maeda, T; Takano, Y; Uchiyama, M; Heaney, S; Peters, H; Tang, ZQ; Maxson, R; Maas, R				Satokata, I; Ma, L; Ohshima, H; Bei, M; Woo, I; Nishizawa, K; Maeda, T; Takano, Y; Uchiyama, M; Heaney, S; Peters, H; Tang, ZQ; Maxson, R; Maas, R			Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation	NATURE GENETICS			English	Article							PARIETAL FORAMINA; TOOTH DEVELOPMENT; INDIAN HEDGEHOG; HOMEODOMAIN; GENE; CRANIOSYNOSTOSIS; EXPRESSION; MUTATION; FAMILY; FETAL	The composite structure of the mammalian skull, which forms predominantly via intramembranous ossification, requires precise pre- and post-natal growth regulation of individual calvarial elements. Disturbances of this process frequently cause severe clinical manifestations in humans. Enhanced DNA binding by a mutant MSX2 homeodomain results in a gain of function and produces craniosynostosis in humans(1,2). Here we show that Msx2-deficient mice have defects of skull ossification and persistent calvarial foramen, This phenotype results from defective proliferation of osteoprogenitors at the osteogenic front during calvarial morphogenesis, and closely resembles that associated with human MSX2 haploinsufficiency in parietal foramina(3) (PFM), Msx2(-/-) mice also have defects in endochondral bone formation. In the axial and appendicular skeleton, post-natal deficits in Pth/Pthrp receptor (Pthr) signalling and in expression of marker genes for bone differentiation indicate that Msx2 is required for both chondrogenesis and osteogenesis, Consistent with phenotypes associated with PFM, Msx2-mutant mice also display defective tooth, hair follicle and mammary gland development, and seizures, the latter accompanied by abnormal development of the cerebellum. Most Msx2-mutant phenotypes, including calvarial defects, are enhanced by genetic combination with Msx1 loss of function, indicating that Msx gene dosage can modify expression of the PFM phenotype. Our results provide a developmental basis for PFM and demonstrate that Msx2 is essential at multiple sites during organogenesis.	Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Norris Canc Ctr, Los Angeles, CA USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Niigata Univ, Sch Med, Dept Pediat, Asahimachi, Japan; Niigata Univ, Fac Dent, Dept Oral Anat, Niigata, Japan; Tokyo Med & Dent Univ, Fac Dent, Dept Oral Anat, Tokyo, Japan	University of Southern California; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Niigata University; Niigata University; Tokyo Medical & Dental University (TMDU)	Maas, R (corresponding author), Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.		Ohshima, Hayato/AAW-5545-2020	Ohshima, Hayato/0000-0001-8571-9900	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011697] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE11697] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; Bei M, 1998, DEVELOPMENT, V125, P4325; Chrzanowska K, 1998, AM J MED GENET, V78, P401, DOI 10.1002/(SICI)1096-8628(19980806)78:5<401::AID-AJMG1>3.0.CO;2-O; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KITE WC, 1961, NEUROLOGY, V11, P345, DOI 10.1097/00132985-196104000-00010; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LITTLE BB, 1990, AM J MED GENET, V35, P453, DOI 10.1002/ajmg.1320350402; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; McKusick V.A., 1998, MENDELIAN INHERITANC; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; PREIS S, 1995, ACTA PAEDIATR, V84, P701, DOI 10.1111/j.1651-2227.1995.tb13735.x; REGINELLI AD, 1995, DEVELOPMENT, V121, P1065; Sakakura T., 1987, The mammary gland. Development, regulation, and function., P37; SAKAKURA Y, 1989, AM J ANAT, V184, P287, DOI 10.1002/aja.1001840404; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722	29	584	603	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					391	395		10.1038/74231	http://dx.doi.org/10.1038/74231			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742104				2022-12-27	WOS:000086192800019
J	Marth, GT; Korf, I; Yandell, MD; Yeh, RT; Gu, ZJ; Zakeri, H; Stitziel, NO; Hillier, L; Kwok, PY; Gish, WR				Marth, GT; Korf, I; Yandell, MD; Yeh, RT; Gu, ZJ; Zakeri, H; Stitziel, NO; Hillier, L; Kwok, PY; Gish, WR			A general approach to single-nucleotide polymorphism discovery	NATURE GENETICS			English	Article							EXPRESSED SEQUENCE TAGS; HUMAN-GENOME	Single-nucleotide polymorphisms (SNPs) are the most abundant form of human genetic variation and a resource for mapping complex genetic traits'. The large volume of data produced by high-throughput sequencing projects is a rich and largely untapped source of SNPs (refs 2-5). We present here a unified approach to the discovery of variations in genetic sequence data of arbitrary DNA sources. We propose to use the rapidly emerging genomic: sequence(6,7) as a template on which to layer often unmapped, fragmentary sequence data(8-11) and to use base quality values(12) to discern true allelic variations from sequencing errors. By taking advantage of the genomic sequence we are able to use simpler yet more accurate methods for sequence organization: fragment clustering, paralogue identification and multiple alignment. We analyse these sequences with a novel, Bayesian inference engine, POLYBAYES, to calculate the probability that a given site is polymorphic. Rigorous treatment of base quality permits completely automated evaluation of the full length of all sequences, without limitations on alignment depth. We demonstrate this approach by accurate SNP predictions in human ESTs aligned to finished and working-draft quality genomic sequences, a data set representative of the typical challenges of sequence-based SNP discovery.	Washington Univ, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63110 USA; Washington Univ, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Marth, GT (corresponding author), Washington Univ, Dept Genet, St Louis, MO 63110 USA.		Kwok, Pui-Yan/F-7725-2014; Stitziel, Nathan/AAL-8413-2021; Gish, Warren/C-8123-2012	Kwok, Pui-Yan/0000-0002-5087-3059; Stitziel, Nathan/0000-0002-4963-8211; 	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001720, P50HG001458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284] Funding Source: NIH RePORTER; NHGRI NIH HHS [P50HG01458, R01HG1720] Funding Source: Medline; NIAMS NIH HHS [T32AR07284] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aaronson JS, 1996, GENOME RES, V6, P829, DOI 10.1101/gr.6.9.829; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; Bayes T., 1764, PHILOS T ROY SOC LON, V53, P370, DOI [10.1098/rstl.1763.0053, DOI 10.1098/RSTL.1763.0053]; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Durbin R, 1998, GENOME RES, V8, P161, DOI 10.1101/gr.8.3.161; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KWOK PY, 1994, GENOMICS, V23, P138, DOI 10.1006/geno.1994.1469; Marra M, 1996, GENOME RES, V6, P1118, DOI 10.1101/gr.6.11.1118; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Picoult-Newberg L, 1999, GENOME RES, V9, P167; *SANG CTR WASH U G, 1998, GENOME RES, V8, P1097; Taillon-Miller P, 1998, GENOME RES, V8, P748, DOI 10.1101/gr.8.7.748; TaillonMiller P, 1997, GENOMICS, V46, P307, DOI 10.1006/geno.1997.5042; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	23	370	436	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					452	456		10.1038/70570	http://dx.doi.org/10.1038/70570			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581034				2022-12-27	WOS:000084023900023
J	Warrick, JM; Chan, HYE; Gray-Board, GL; Chai, YH; Paulson, HL; Bonini, NM				Warrick, JM; Chan, HYE; Gray-Board, GL; Chai, YH; Paulson, HL; Bonini, NM			Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70	NATURE GENETICS			English	Article							MACHADO-JOSEPH DISEASE; NEURONAL INTRANUCLEAR INCLUSIONS; EXPANDED POLYGLUTAMINE; SPINOCEREBELLAR ATAXIA; PROTEIN; AGGREGATION; HUNTINGTIN; LOCALIZATION; DEGENERATION; EXPRESSION	At least eight inherited human neurodegenerative diseases are caused by expansion of a polyglutamine domain within the respective proteins(1,2). This confers dominant toxicity on the proteins, leading to dysfunction and loss of neurons. Expanded polyglutamine proteins form aggregates, including nuclear inclusions (NI), within neurons, possibly due to misfolding of the proteins(3-5). MI are ubiquitinated and sequester molecular chaperone proteins and proteasome components(6-9), suggesting that disease pathogenesis includes activation of cellular stress pathways to help refold, disaggregate or degrade the mutant disease proteins. Overexpression of specific chaperone proteins reduces polyglutamine aggregation in transfected cells(7-9), but whether this alters toxicity is unknown. Using a Drosophila melanogaster model of polyglutamine disease(10), we show that directed expression of the molecular chaperone HSP70 suppresses polyglutamine-induced neurodegeneration in vivo. Suppression by HSP70 occurred without a visible effect on NI formation, indicating that polyglutamine toxicity can be dissociated from formation of large aggregates. Our studies indicate that HSP70 or related molecular chaperones may provide a means of treating these and other neurodegenerative diseases associated with abnormal protein conformation and toxicity.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Iowa City, IA USA	University of Pennsylvania; University of Iowa	Bonini, NM (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.		Chan, Edwin/A-9478-2011	Chan, Edwin/0000-0003-4307-474X				BRAND AH, 1993, DEVELOPMENT, V118, P401; CAHI Y, IN PRESS J NEUROSCI; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; LANDSBURU P, 1997, NEURON, V19, P1151; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; RANUM LPW, 1995, AM J HUM GENET, V57, P603; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wolff Tanya, 1993, P1277	29	665	693	0	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					425	428		10.1038/70532	http://dx.doi.org/10.1038/70532			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581028				2022-12-27	WOS:000084023900017
J	Debrauwere, H; Buard, J; Tessier, J; Aubert, D; Vergnaud, G; Nicolas, A				Debrauwere, H; Buard, J; Tessier, J; Aubert, D; Vergnaud, G; Nicolas, A			Meiotic instability of human minisatellite CEB1 in yeast requires DNA double-strand breaks	NATURE GENETICS			English	Article							COMPLEX RECOMBINATION EVENTS; SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; MISMATCH REPAIR; INITIATION SITE; MUTATION; MEIOSIS; SEQUENCE; SIZE		Inst Curie, CNRS, UMR 144, Sect Rech, F-75231 Paris, France; Inst Biol, Nantes, France; Univ Paris Sud, Inst Genet & Microbiol, Orsay, France; Ctr Etud Bouchet, F-91710 Vert Le Petit, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay	Nicolas, A (corresponding author), Inst Curie, CNRS, UMR 144, Sect Rech, F-75231 Paris, France.		Vergnaud, Gilles/P-1304-2015; Vergnaud, Gilles/AAC-1162-2020	Vergnaud, Gilles/0000-0003-0913-194X; Vergnaud, Gilles/0000-0003-0913-194X				ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Appelgren H, 1997, MOL GEN GENET, V256, P7, DOI 10.1007/s004380050540; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bois P, 1997, HUM MOL GENET, V6, P1565, DOI 10.1093/hmg/6.9.1565; Borde V, 1999, MOL CELL BIOL, V19, P4832; Buard J, 1998, EMBO J, V17, P3495, DOI 10.1093/emboj/17.12.3495; BUARD J, 1994, EMBO J, V13, P3203, DOI 10.1002/j.1460-2075.1994.tb06619.x; DEMASSY B, 1993, EMBO J, V12, P1459, DOI 10.1002/j.1460-2075.1993.tb05789.x; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KEENEY S, IN PRESS GENOMICS; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KLAPHOLZ S, 1980, GENETICS, V96, P567; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROCCO V, 1992, P NATL ACAD SCI USA, V89, P12068, DOI 10.1073/pnas.89.24.12068; ROMANIENKO PJ, IN PRESS GENOMICS; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tamaki K, 1999, HUM MOL GENET, V8, P879, DOI 10.1093/hmg/8.5.879; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297	30	53	54	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					367	371		10.1038/15557	http://dx.doi.org/10.1038/15557			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545956				2022-12-27	WOS:000083792200031
J	Huang, LP; Kuo, YM; Gitschier, J				Huang, LP; Kuo, YM; Gitschier, J			The pallid gene encodes a novel, syntaxin 13-interacting protein involved in platelet storage pool deficiency	NATURE GENETICS			English	Article							HERMANSKY-PUDLAK-SYNDROME; CHEDIAK-HIGASHI-SYNDROME; PALE EAR EP; MUTATION ANALYSIS; MOUSE; COMPLEX; DISTINCT; AP-3; IDENTIFICATION; EXPRESSION		Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gitschier, J (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.							Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Gwynn B, 1997, GENOMICS, V42, P532, DOI 10.1006/geno.1997.4764; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; James P, 1996, GENETICS, V144, P1425; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; LYON MF, 1989, GENETIC VARIANTS STR, P274; MARTORANA PA, 1993, LAB INVEST, V68, P233; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; NOVAK EK, 1984, BLOOD, V63, P536; NOVAK EK, 1979, GENETICS, V92, P189; O'Donohue MF, 1998, BIOTECHNIQUES, V24, P910, DOI 10.2144/98246bm01; Oh J, 1998, AM J HUM GENET, V62, P593, DOI 10.1086/301757; Ooi CE, 1997, EMBO J, V16, P4508; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Roberts E, 1931, SCIENCE, V74, P569, DOI 10.1126/science.74.1927.569; ROBINSON PJ, 1981, IMMUNOGENETICS, V14, P449, DOI 10.1007/BF00373326; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; THERIAULT LL, 1970, DEV BIOL, V23, P261, DOI 10.1016/0012-1606(70)90098-9; White R. A., 1997, Mouse Genome, V95, P492; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; Zuberi AR, 1996, GENOMICS, V33, P75, DOI 10.1006/geno.1996.0161	28	144	147	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					329	332		10.1038/15507	http://dx.doi.org/10.1038/15507			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610180				2022-12-27	WOS:000083792200023
J	Segre, JA; Bauer, C; Fuchs, E				Segre, JA; Bauer, C; Fuchs, E			Klf4 is a transcription factor required for establishing the barrier function of the skin	NATURE GENETICS			English	Article							ZINC-FINGER PROTEIN; KRUPPEL-LIKE FACTOR; EPIDERMAL-KERATINOCYTES; STRATUM-CORNEUM; ACID RECEPTOR; MICE LACKING; GENE; DIFFERENTIATION; EXPRESSION; ENVELOPES	Located at the interface between body and environment, the epidermis must protect the body against toxic agents and dehydration, and protect itself against physical and mechanical stresses(1-4). Acquired just before birth and at the last stage of epidermal differentiation, the skin's proteinaceous/lipid barrier creates a surface seal essential for protecting animals against microbial infections and dehydration. We show here that Kruppel-like factor 4 (Klf4, encoded by the gene Klf4), highly expressed in the differentiating layers of epidermis, is both vital to and selective for barrier acquisition. Klf4(-/-) mice die shortly after birth due to loss of skin barrier function, as measured by penetration of external dyes and rapid loss of body fluids. The defect was not corrected by grafting of Klf4(-/-) skin onto nude mice. Loss of the barrier occurs without morphological and biochemical alterations to the well-known structural features of epidermis that are essential for mechanical integrity. Instead, late-stage differentiation structures are selectively perturbed, including the cornified envelope, a likely scaffold for lipid organization. Using suppressive subtractive hybridization, we identified three transcripts encoding cornified envelope proteins with altered expression in the absence of Klf4. Sprr2a is one, and is the only epidermal gene whose promoter is known to possess a functional Klf4 binding site. Our studies provide new insights into transcriptional governance of barrier function, and pave the way for unravelling the molecular events that orchestrate this essential process.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Fuchs, Elaine/G-1565-2016		NIAMS NIH HHS [AR31737] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; DOWNING DT, 1992, J LIPID RES, V33, P301; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MICHEL S, 1988, J INVEST DERMATOL, V91, P11, DOI 10.1111/1523-1747.ep12463281; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WICKETT RR, 1995, SKIN PHARMACOL, V8, P179; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	30	611	634	2	55	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					356	360		10.1038/11926	http://dx.doi.org/10.1038/11926			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431239				2022-12-27	WOS:000081772500017
J	Van Etten, WJ; Steen, RG; Nguyen, H; Castle, AB; Slonim, DK; Ge, B; Nusbaum, C; Schuler, GD; Lander, ES; Hudson, TJ				Van Etten, WJ; Steen, RG; Nguyen, H; Castle, AB; Slonim, DK; Ge, B; Nusbaum, C; Schuler, GD; Lander, ES; Hudson, TJ			Radiation hybrid map of the mouse genome	NATURE GENETICS			English	Article								Radiation hybrid (RH) maps are a useful tool for genome analysis, providing a direct method for localizing genes and anchoring physical maps and genomic sequence along chromosomes, The construction of a comprehensive RH map for the human genome(1) has resulted in gene maps reflecting the location of more than 30,000 human genes(2,3). Here we report the first comprehensive RH map of the mouse genome. The map contains 2,486 loci screened against an RH panel of 93 cell lines(4). Most loci (93%) are simple sequence length polymorphisms (SSLPs) taken from the mouse genetic map, thereby providing direct integration between these two key maps, We performed RH mapping by a new and efficient approach in which we replaced traditional gel- or hybridization-based assays by a homogeneous 5'-nuclease assay(5) involving a single common probe for all genetic markers. The map provides essentially complete connectivity and coverage across the genome, and good resolution for ordering loci, with 1 centiRay (cR) corresponding to an average of approximately 100 kb, The RH map, together with an accompanying World-Wide Web server, makes it possible for any investigator to rapidly localize sequences in the mouse genome. Together with the previously constructed genetic map(6) and a YAC-based physical map reported in a companion paper(7), the fundamental maps required for mouse genomics are now available.	MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02142 USA; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02142 USA.			Slonim, Donna/0000-0003-3357-437X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001806] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01806] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Slonim D, 1997, J COMPUT BIOL, V4, P487, DOI 10.1089/cmb.1997.4.487	10	93	100	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					384	387		10.1038/11962	http://dx.doi.org/10.1038/11962			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431245				2022-12-27	WOS:000081772500023
J	Yang, XW; Wynder, C; Doughty, ML; Heintz, N				Yang, XW; Wynder, C; Doughty, ML; Heintz, N			BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin	NATURE GENETICS			English	Article							HOMOLOGOUS RECOMBINATION; MOUSE CEREBELLUM; FINGER PROTEINS; FOLIAL PATTERN; ZINC FINGERS; DROSOPHILA; MICE; IDENTIFICATION; EXPRESSION; MUTATIONS	Geneticanalysis in mice has most commonly employed two general strategies: phenotypic screens for spontaneous or induced mutations and genotypic analysis using homologous recombination or gene trapping to produce deletion or insertion mutants. Here we use bacterial artificial chromosome (BAC)-mediated gene-dosage analysis in transgenic mice to reveal novel genetic functions that are not evident from conventional loss-of-function mutations. We demonstrate a role for the zinc-finger transcription factor Zipro1 (formerly Ru49 and Zfp38) in the proliferation of granule cell precursors in the developing cerebellum, and document the contribution of this process to the final stages of cerebellar morphogenesis. We also show that Zipro I is expressed in skin, and increased Zipro1 dosage results in a hair-loss phenotype associated with increased epithelial cell proliferation and abnormal hair follicle development.	Howard Hughes Med Inst, Mol Biol Lab, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Heintz, N (corresponding author), Howard Hughes Med Inst, Mol Biol Lab, 1230 York Ave,Box 260, New York, NY 10021 USA.	heintz@rockvax.rockefeller.edu	Pillay, Nischalan/F-9536-2012		NIGMS NIH HHS [GM07739] Funding Source: Medline; DS NIH HHS [NINDS 30532] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DS NIH HHS		Alder J, 1996, NEURON, V17, P389, DOI 10.1016/S0896-6273(00)80172-5; ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOWDHURY K, 1992, MECH DEVELOP, V39, P129, DOI 10.1016/0925-4773(92)90040-Q; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Helms AW, 1998, DEVELOPMENT, V125, P919; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; LAUDER JM, 1974, BRAIN RES, V76, P33, DOI 10.1016/0006-8993(74)90511-3; Levine K, 1995, Prog Cell Cycle Res, V1, P101; MARES V, 1970, BRAIN RES, V23, P343, DOI 10.1016/0006-8993(70)90061-2; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; NEUMANN PE, 1990, BRAIN RES, V524, P85, DOI 10.1016/0006-8993(90)90495-W; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Perrimon N, 1998, P NATL ACAD SCI USA, V95, P9716, DOI 10.1073/pnas.95.17.9716; ROBERTS PA, 1982, GENETICS, V102, P75; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; SOUTHERN PJ, 1982, J MOL APPL GENET, V4, P321; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; Sundberg JP, 1996, J INVEST DERMATOL, V106, P368, DOI 10.1111/1523-1747.ep12343152; Thompson CC, 1996, J NEUROSCI, V16, P7832; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang XW, 1996, DEVELOPMENT, V122, P555	50	99	102	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					327	335		10.1038/11896	http://dx.doi.org/10.1038/11896			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431235				2022-12-27	WOS:000081772500013
J	Siegfried, Z; Eden, S; Mendelsohn, M; Feng, X; Tsuberi, BZ; Cedar, H				Siegfried, Z; Eden, S; Mendelsohn, M; Feng, X; Tsuberi, BZ; Cedar, H			DNA methylation represses transcription in vivo	NATURE GENETICS			English	Article							CELL-SPECIFIC DEMETHYLATION; GLOBIN GENE-EXPRESSION; CYTOSINE METHYLATION; CPG ISLAND; ACTIVATION; BINDING; SITES	DNA in somatic tissue is characterized by a bimodal pattern of methylation, which is established in the animal through a series of developmental events'. In the mouse blastula, most DNA is unmethylated, but after implantation a wave of de novo methylation modifies most of the genome, excluding the majority of Cpt islands, which are mainly associated with housekeeping genes. This genomic methylation pattern is broadly maintained during the life of the organism by maintenance methylation, and generally correlates with gene expression. Experiments both in vitro(3-5) and in vivo(6-9) indicate that methylation inhibits transcription, It has not yet been possible, however, to determine the role of DNA methylation on specific. sequences during normal development Cis-acting regulatory elements and trans-acting factors appear to be involved in both stage- and tissue-specific demethylation processes(10,11). Spl-like elements have a key role in protecting the CpG island of Aprt (encoding adenine phosphoribosyl transferase) from de novo methylation, and when these elements are specifically mutated, the Aprf CpG island becomes methylated genome, in transgenic mice(12,13) . We have now characterized an embryo-specific element,ment from the CpG island sequence upstream of Aprt that can protect itself from de novo methylation in transgenic mice as well as reduce methylation of flanking sequences. We placed this element on a removable cassette adjacent to a human HBB (encoding P-globin) reporter and generated a transgene whose methylation pattern can be switched in vivo. Analysis of globin transcription in this system showed that methylation in cis inhibits gt,ne expression in a variety of tissues, indicating that DNA modification may serve as a global genomic repressor.	Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Columbia Univ, Sch Med, Ctr Neurobiol & Behav, New York, NY 10032 USA	Hebrew University of Jerusalem; Columbia University	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem, IL-91120 Jerusalem, Israel.	cedar@md2.huji.ac.il						BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HOGAN B, 1986, MANIPULATING MOUSE E, P92; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	28	273	280	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					203	206		10.1038/9727	http://dx.doi.org/10.1038/9727			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369268				2022-12-27	WOS:000080680900031
J	Yamamoto, H; Simon, A; Eriksson, U; Harris, E; Berson, EL; Dryja, TP				Yamamoto, H; Simon, A; Eriksson, U; Harris, E; Berson, EL; Dryja, TP			Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus	NATURE GENETICS			English	Article								The:metabolic pathways that produce Il-cis retinal are important for vision because this retinoid is the chromophore residing in rhodopsin and the tone opsins. The all-trans retinal that is generated after cone and rod photopigments absorb photons of light is recycled back to 11-cis retinal by the retinal pigment epithelium and Muller cells: of the retina. Several of the enzymes involved have:recently been purified and molecularly cloned (1-3);:here we focus on Il-cis retinol dehydrogenase (encoded by the gene RDH5; chromosome 12q13-14; ref. 4), the first cloned enzyme in this pathway. This microsomal enzyme is abundant in the retinal pigment epithelium(5), where it has been proposed to catalyse the conversion of Il-cis retinol to Il-cis retinal. We evaluated patients with hereditary retinal diseases featuring subretinal spots (retinitis punctata albescens and fundus albipunctatus) and patients with typical dominant or recessive retinitis pigmentosa for mutations in RDH5. Mutations were found only in two unrelated patients, both with fundus albipunctatus; they segregated with disease in the respective families. Recombinant mutant Il-cis retinol dehydrogenases had reduced activity compared with recombinant enzyme with wild-type sequence. Our results suggest that mutant alleles in RDH5 are a cause of fundus albipunctatus, a rare form of stationary night blindness characterized by a delay in the regeneration of cone and rod photopigments.	Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenat, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ocular Mol Genet Inst, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA; Ludwig Inst Canc Res, S-10401 Stockholm, Sweden	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Ludwig Institute for Cancer Research	Dryja, TP (corresponding author), Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenat, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.	dryja@helix.mgh.harvard.edu		Simon, Andras/0000-0002-1018-1891	NEI NIH HHS [EY00169, EY08683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000169, R01EY008683, R37EY000169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERSON EL, 1968, ARCH OPHTHALMOL-CHIC, V80, P58; BERSON EL, 1976, T AM ACAD OPHTHALMOL, V81, pO659; Carr RE, 1974, DOC OPHTHALMOL P SER, V9, P193; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARMOR MF, 1976, DOC OPHTHAL P SERIES, V13, P227; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; RIPPS H, 1982, INVEST OPHTH VIS SCI, V23, P588; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; Simon A, 1999, J CELL SCI, V112, P549; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023	16	210	226	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					188	191		10.1038/9707	http://dx.doi.org/10.1038/9707			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369264				2022-12-27	WOS:000080680900027
J	Buetow, KH; Edmonson, MN; Cassidy, AB				Buetow, KH; Edmonson, MN; Cassidy, AB			Reliable identification of large numbers of candidate SNPs from public EST data	NATURE GENETICS			English	Article							EXPRESSED SEQUENCE TAGS	High-resolution genetic analysis of the human genome promises to provide insight into common disease susceptibility. To perform such analysis will require a collection of high-throughput, high-density analysis reagents. We have developed a polymorphism detection system that uses public-domain sequence data. This detection system is called the single nucleotide polyrmorphism pipeline (SNPpipeline). The analytic core of the SNPpipeline is composed of three components: PHRED, PHRAP and DEMIGLACE. PHRED and PHRAP are components of a sequence analysis suite developed to perform the semi-automated analysis required for large-scale genomes(1,2) (provided courtesy of P. Green). Using these informatics tools, which examine redundant raw expressed sequence tag (EST) data, we have identified more than 3,000 candidate single-nucleotide polyrmorphisms (SNPs). Empiric validation studies of a set of 192 candidates indicate that 82% identify variation in a sample of ten Centre d'Etudes Polymorphism Humain (CEPH) individuals. Our results suggest that existing sequence resources may serve as a valuable source for identifying genetic variation.	NCI, Lab Populat Genet, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center	Buetow, KH (corresponding author), NCI, Lab Populat Genet, NIH, Bethesda, MD 20892 USA.							Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; JIN L, 1990, MOL BIOL EVOL, V7, P82; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Sokal RR, 1963, PRINCIPLES NUMERICAL; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	8	207	234	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					323	325		10.1038/6851	http://dx.doi.org/10.1038/6851			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080189				2022-12-27	WOS:000078977900030
J	Vulpe, CD; Kuo, YM; Murphy, TL; Cowley, L; Askwith, C; Libina, N; Gitschier, J; Anderson, GJ				Vulpe, CD; Kuo, YM; Murphy, TL; Cowley, L; Askwith, C; Libina, N; Gitschier, J; Anderson, GJ			Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; FET3 GENE; FERROXIDASE; EXPRESSION; YEAST	Iron is essential for many cellular functions; consequently, disturbances of iron homeostasis, leading to either iron deficiency or iron overload, can have significant clinical consequences. Despite the clinical prevalence of these disorders, the mechanism by which dietary iron is absorbed into the body is poorly understood. We have identified a key component in intestinal iron transport by study of the sex-linked anaemia (s/a) mouse, which has a block in intestinal iron transport(1). Mice carrying the sla mutation develop moderate to severe microcytic hypochromic anaemia(1). Although these mice take up iron from the intestinal lumen into mature epithelial cells normally(2), the subsequent exit of iron into the circulation is diminished(3). As a result, iron accumulates in enterocytes and is lost during turnover of the intestinal epithelium(4). Biochemical studies have failed to identify the underlying difference between s/a and normal mice, therefore, we used a genetic approach to identify the gene mutant in sla mice. We describe here a novel gene, Heph, encoding a transmembrane-bound ceruloplasmin homologue that is mutant in the sla mouse and highly expressed in intestine. We suggest that the hephaestin protein is a multicopper ferroxidase necessary for iron egress from intestinal enterocytes into the circulation and that it is an important link between copper and iron metabolism in mammals.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Queensland, Joint Clin Sci Program, Brisbane, Qld, Australia; Queensland Inst Med Res, Clin Sci Unit, Brisbane, Qld, Australia; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Queensland; QIMR Berghofer Medical Research Institute; Utah System of Higher Education; University of Utah	Gitschier, J (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.		Vulpe, Chris/AAF-9170-2020; Anderson, Gregory J/G-4148-2013	Vulpe, Chris/0000-0001-5134-8929; Anderson, Gregory J/0000-0002-8814-5866				Anderson GJ, 1998, GENOMICS, V48, P34, DOI 10.1006/geno.1997.5138; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BANNERMAN RM, 1976, FED PROC, V35, P2281; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; Bothwell TH., IRON METABOLISM MAN, P256; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; Danks DM, 1989, METABOLIC BASIS INHE, P1411; Davis LG, 1986, BASIC METHODS MOL BI, P42; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; EDWARDS JA, 1977, J LAB CLIN MED, V90, P68; FALCONER DS, 1962, GENET RES, V3, P248, DOI 10.1017/S0016672300035035; GREWAL MS, 1962, GENET RES, V3, P238, DOI 10.1017/S0016672300035023; HALLIDAY JW, 1992, IRON HUMAN DISEASE, P131; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Kuo YM, 1997, HUM MOL GENET, V6, P1043, DOI 10.1093/hmg/6.7.1043; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Logan JI, 1996, J NEUROL NEUROSUR PS, V61, P431, DOI 10.1136/jnnp.61.5.431; Lombard M, 1997, GUT, V40, P435, DOI 10.1136/gut.40.4.435; MANIS J, 1970, NATURE, V227, P385, DOI 10.1038/227385a0; Skinke B, 1994, IRON METABOLISM HLTH, P151; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552	23	829	857	2	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					195	199		10.1038/5979	http://dx.doi.org/10.1038/5979			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988272				2022-12-27	WOS:000078399500022
J	Yang, YL; Guo, L; Xu, SA; Holland, CA; Kitamura, T; Hunter, K; Cunningham, JM				Yang, YL; Guo, L; Xu, SA; Holland, CA; Kitamura, T; Hunter, K; Cunningham, JM			Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1	NATURE GENETICS			English	Article							MURINE LEUKEMIA-VIRUS; ENVELOPE GLYCOPROTEINS; CELLULAR RECEPTOR; PROTEIN; LEUKEMOGENESIS; CHROMOSOME-1; BINDING; SUSCEPTIBILITY; CONSTRUCTION; RETROVIRUSES	The onset of leukaemia caused by type C retroviruses (MLV) in mice is accelerated by the emergence of recombinant polytropic or mink cell focus-forming (MCF) viruses(1-4). Susceptibility to infection by polytropic/MCF and also by closely related xenotropic MLV has been mapped to Rmc1 on mouse chromosome 1 (refs 5-7). To identify this gene, we introduced an expression cDNA library prepared from mouse NIH3T3 fibroblasts into nonpermissive hamster cells and screened these cells for acquired susceptibility to MCF viruses encoding beta-galactosidase and G418 resistance. From hamster cell clones identified in the screen, we recovered a mouse cDNA that maps to Rmc1 and confers MCF MLV infection when expressed in nonpermissive cell lines. It encodes a membrane protein related to Syg1p (suppressor of yeast G alpha deletion; ref. 8), The receptor-binding domain of the MCF MLV envelope protein binds specifically to Xenopus laevis oocytes that express mouse Syg1, suggesting it functions as a receptor that mediates virus entry. We also obtained the cDNA encoding human SYG1. When expressed in hamster cells, it establishes infectivity by MCF MLV as well as xenotropic MLV, which do not infect laboratory mice.	Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Natl Med Ctr, Ctr Virol Immunol & Infect Dis Res, Washington, DC 20010 USA; Univ Tokyo, Inst Med Sci, Tokyo 108, Japan; Fox Chase Canc Ctr, Dept Mol Biol, Philadelphia, PA 19111 USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Children's National Health System; University of Tokyo; Fox Chase Cancer Center	Cunningham, JM (corresponding author), Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.		Kitamura, Toshio/AAA-2071-2021		NCI NIH HHS [2R01CA/AI61246-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS RM, 1992, P NATL ACAD SCI USA, V89, P8981, DOI 10.1073/pnas.89.19.8981; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CHESEBRO B, 1985, VIROLOGY, V141, P119, DOI 10.1016/0042-6822(85)90188-6; Davey RA, 1997, J VIROL, V71, P8096, DOI 10.1128/JVI.71.11.8096-8102.1997; Fan H, 1997, TRENDS MICROBIOL, V5, P74, DOI 10.1016/S0966-842X(96)10076-7; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; FLUBACHER MM, 1994, J VIROL, V68, P7709, DOI 10.1128/JVI.68.12.7709-7716.1994; HERR W, 1984, J VIROL, V50, P155, DOI 10.1128/JVI.50.1.155-162.1984; HUNTER K, 1991, SOMAT CELL MOLEC GEN, V17, P169, DOI 10.1007/BF01232974; HUNTER KW, 1994, MAMM GENOME, V5, P597, DOI 10.1007/BF00411453; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KOZAK CA, 1983, J VIROL, V48, P300, DOI 10.1128/JVI.48.1.300-303.1983; KOZAK CA, 1985, J VIROL, V55, P690, DOI 10.1128/JVI.55.3.690-695.1985; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; Loiler SA, 1997, J VIROL, V71, P4825, DOI 10.1128/JVI.71.6.4825-4828.1997; Lyu MS, 1996, J VIROL, V70, P830, DOI 10.1128/JVI.70.2.830-833.1996; OTT D, 1992, J VIROL, V66, P4632, DOI 10.1128/JVI.66.8.4632-4638.1992; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RUSCETTI S, 1981, J EXP MED, V154, P907, DOI 10.1084/jem.154.3.907; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; STOYE JP, 1991, J VIROL, V65, P1273, DOI 10.1128/JVI.65.3.1273-1285.1991; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0	26	118	120	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					216	219		10.1038/6005	http://dx.doi.org/10.1038/6005			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988277				2022-12-27	WOS:000078399500027
J	Morales, CP; Holt, SE; Ouellette, M; Kaur, KJ; Yan, Y; Wilson, KS; White, MA; Wright, WE; Shay, JW				Morales, CP; Holt, SE; Ouellette, M; Kaur, KJ; Yan, Y; Wilson, KS; White, MA; Wright, WE; Shay, JW			Absence of cancer-associated changes in human fibroblasts immortalized with telomerase	NATURE GENETICS			English	Article							CELL-CYCLE REGULATION; EPITHELIAL-CELLS; DNA-DAMAGE; GENE; P53; SENESCENCE; DISRUPTION; CULTURE; PROTEIN	The ectopic expression of telomerase(1-2) in normal human cells results in an extended lifespan(3-4), indicating that telomere shortening regulates the timing of cellular senescence, As telomerase expression is a hallmark of cancer, we investigated the long-term effects of forced expression of human telomerase catalytic component (hTERT) in normal human fibroblasts. In vitro growth requirements, cell-cycle checkpoints and karyotypic stability in telomerase-expressing cells are similar to those of untransfected controls. In addition, co-expression of telomerase, the viral oncoproteins HPV16 E6/E7 (which inactivate p53 and pRB) and oncogenic HRAS does not result in growth in soft agar, Thus, although ectopic expression of telomerase in human fibroblasts is sufficient for immortalization, it does not result in changes typically associated with malignant transformation.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, Richmond, VA 23298 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Virginia Commonwealth University	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	shay@utsw.swmed.edu	Gagneja, Kanwalinderjit K/K-3204-2017; Shay, Jerry W/F-7878-2011	Gagneja, Kanwalinderjit K/0000-0001-7844-8583; 	NCI NIH HHS [CA71443] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERCROMBIE M, 1970, IN VITRO CELL DEV B, V6, P128; BENN PA, 1976, AM J HUM GENET, V28, P465; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gustashaw Karen M., 1997, P259; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, INT J ONCOL, V8, P263; Honda T, 1996, MUTAT RES-FUND MOL M, V354, P15, DOI 10.1016/0027-5107(96)00003-6; KASTAN MB, 1991, CANCER RES, V51, P6304; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NOWELL PC, 1987, DEV RECOGNITION TRAN, P1; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SAKSELA E, 1963, P NATL ACAD SCI USA, V50, P390, DOI 10.1073/pnas.50.2.390; SCHER CD, 1971, EXP CELL RES, V68, P479, DOI 10.1016/0014-4827(71)90181-9; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	29	643	679	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					115	118		10.1038/5063	http://dx.doi.org/10.1038/5063			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916803				2022-12-27	WOS:000077960700021
J	Slavotinek, AM; Stone, EM; Mykytyn, K; Heckenlively, JR; Green, JS; Heon, E; Musarella, MA; Parfrey, PS; Sheffield, VC; Biesecker, LG				Slavotinek, AM; Stone, EM; Mykytyn, K; Heckenlively, JR; Green, JS; Heon, E; Musarella, MA; Parfrey, PS; Sheffield, VC; Biesecker, LG			Mutations in MKKS cause Bardet-Biedl syndrome	NATURE GENETICS			English	Article							SYNDROME LOCUS; LINKAGE		Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; Harbor UCLA Med Ctr, Dept Ophthalmol, Torrance, CA 90509 USA; Mem Univ St Johns, Fac Med, St Johns, NF, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Vis Sci Res Program, Toronto, ON M5S 1A1, Canada; Long Isl Coll Hosp, Brooklyn, NY 11201 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Memorial University Newfoundland; University of Toronto; University of Toronto; Long Island College Hospital	Sheffield, VC (corresponding author), Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.		Slavotinek, Anne/AAK-6794-2020	Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835	NATIONAL EYE INSTITUTE [R01EY011298] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000009] Funding Source: NIH RePORTER; NEI NIH HHS [EY11298] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Beales PL, 1999, J MED GENET, V36, P437; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; David A, 1999, J MED GENET, V36, P599; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; MCKUSICK VA, 1978, AM J HUM GENET, V30, P105; MCKUSICK VA, 1964, JAMA-J AM MED ASSOC, V189, P813; Rosenberg MJ, 2000, AM J HUM GENET, V66, P419, DOI 10.1086/302743; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Stone DL, 1998, HUM MOL GENET, V7, P475, DOI 10.1093/hmg/7.3.475; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301	14	206	212	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					15	16		10.1038/79116	http://dx.doi.org/10.1038/79116			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973238				2022-12-27	WOS:000089078000008
J	Afzal, AR; Rajab, A; Fenske, CD; Oldridge, M; Elanko, N; Ternes-Pereira, E; Tuysuz, B; Murday, VA; Patton, MA; Wilkie, AOM; Jeffery, S				Afzal, AR; Rajab, A; Fenske, CD; Oldridge, M; Elanko, N; Ternes-Pereira, E; Tuysuz, B; Murday, VA; Patton, MA; Wilkie, AOM; Jeffery, S			Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2	NATURE GENETICS			English	Article							X-LINKED AGAMMAGLOBULINEMIA; FETAL FACE SYNDROME; LIGNEOUS CONJUNCTIVITIS; PLASMINOGEN GENE; TYROSINE; DISEASE; DISRUPTION; FAMILY; DOMAIN; CDMP1	The autosomal recessive form of Robinow syndrome (RRS; MIM 268310) is a severe skeletal dysplasia with generalized limb bone shortening, segmental defects of the spine, brachydactyly and a dysmorphic facial appearance(1-3). We previously mapped the gene mutated in RRS to chromosome 9q22 (ref. 4), a region that overlaps the locus for autosomal dominant brachydactyly type B (refs 5,6). The recent identification of ROR2, encoding an orphan receptor tyrosine kinase, as the gene mutated in brachydactyly type B (BDB1; ref. 7) and the mesomelic dwarfing in mice homozygous for a lacZ and/or a neo insertion into Ror2 (refs 8.9) made this gene a candidate for RRS. Here we report homozygous missense mutations in both intracellular and extracellular domains of ROR2 in affected individuals from 3 unrelated consanguineous families, and a nonsense mutation that removes the tyrosine kinase domain and all subsequent 3' regions of the gene in 14 patients from 7 families from Oman. The nature of these mutations suggests that RRS is caused by loss of ROR2 activity. The identification of mutations in three distinct domains (containing Frizzled-like, kringle and tyrosine kinase motifs) indicates that these are all essential for ROR2 function.	Univ London St Georges Hosp, Sch Med, Med Genet Unit, London, England; Minist Hlth, DGHA, Med Genet Unit, Muscat, Oman; John Radcliffe Hosp, Inst Mol Med, Oxford, England; Univ Fed Santa Catarina, Dept Clin Med, Florianopolis, SC, Brazil; Univ Istanbul, Cerrahpasa Med Fac, Dept Paediat, Istanbul, Turkey	St Georges University London; University of Oxford; Universidade Federal de Santa Catarina (UFSC); Istanbul University; Istanbul University - Cerrahpasa	Jeffery, S (corresponding author), Univ London St Georges Hosp, Sch Med, Med Genet Unit, London, England.		Tüysüz, Beyhan/AAN-4858-2020; Wilkie, Andrew/AAC-3820-2020	Wilkie, Andrew/0000-0002-2972-5481; Tuysuz, Beyhan/0000-0002-9620-5021				Afzal AR, 2000, HUM GENET, V106, P351, DOI 10.1007/s004390051049; Aksit S, 1997, CLIN GENET, V52, P226; Castellino FJ, 1997, CIBA F SYMP, V212, P46; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gherardi E, 1997, CIBA F SYMP, V212, P24; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; Kantaputra PN, 1999, AM J MED GENET, V84, P1, DOI 10.1002/(SICI)1096-8628(19990507)84:1<1::AID-AJMG1>3.0.CO;2-C; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Oldridge M, 1999, AM J HUM GENET, V64, P578, DOI 10.1086/302255; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Robinow M, 1993, Clin Dysmorphol, V2, P189; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Schuster V, 1999, BLOOD, V93, P3457, DOI 10.1182/blood.V93.10.3457.410k03_3457_3466; Soliman AT, 1998, METABOLISM, V47, P1337, DOI 10.1016/S0026-0495(98)90301-8; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; TEEBI AS, 1990, AM J MED GENET, V35, P64, DOI 10.1002/ajmg.1320350112; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P51, DOI 10.1093/hmg/4.1.51; WADIA RS, 1978, J MED GENET, V15, P123, DOI 10.1136/jmg.15.2.123; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3	30	227	240	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					419	422		10.1038/78107	http://dx.doi.org/10.1038/78107			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932186				2022-12-27	WOS:000088615000017
J	Nolan, PM; Peters, J; Strivens, M; Rogers, D; Hagan, J; Spurr, N; Gray, IC; Vizor, L; Brooker, D; Whitehill, E; Washbourne, R; Hough, T; Greenaway, S; Hewitt, M; Liu, XH; McCormack, S; Pickford, K; Selley, R; Wells, C; Tymowska-Lalanne, Z; Roby, P; Glenister, P; Thornton, C; Thaung, C; Stevenson, JA; Arkell, R; Mburu, P; Hardisty, R; Kiernan, A; Erven, H; Steel, KP; Voegeling, S; Guenet, JL; Nickols, C; Sadri, R; Naase, M; Isaacs, A; Davies, K; Browne, M; Fisher, EMC; Martin, J; Rastan, S; Brown, SDM; Hunter, J				Nolan, PM; Peters, J; Strivens, M; Rogers, D; Hagan, J; Spurr, N; Gray, IC; Vizor, L; Brooker, D; Whitehill, E; Washbourne, R; Hough, T; Greenaway, S; Hewitt, M; Liu, XH; McCormack, S; Pickford, K; Selley, R; Wells, C; Tymowska-Lalanne, Z; Roby, P; Glenister, P; Thornton, C; Thaung, C; Stevenson, JA; Arkell, R; Mburu, P; Hardisty, R; Kiernan, A; Erven, H; Steel, KP; Voegeling, S; Guenet, JL; Nickols, C; Sadri, R; Naase, M; Isaacs, A; Davies, K; Browne, M; Fisher, EMC; Martin, J; Rastan, S; Brown, SDM; Hunter, J			A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse	NATURE GENETICS			English	Article							MUTATIONS; MODELS; MICE	As the human genome project approaches completion, the challenge for mammalian geneticists is to develop approaches for the systematic determination of mammalian gene function. Mouse mutagenesis will be a key element of studies of gene function(1-3). Phenotype-driven approaches using the chemical mutagen ethylnitrosourea(4-6) (ENU) represent a potentially efficient route for the generation of large numbers of mutant mice that can be screened for novel phenotypes. The advantage of this approach is that, in assessing gene function, no a priori assumptions are made about the genes involved in any pathway. Phenotype-driven mutagenesis is thus an effective method for the identification of novel genes and pathways(1,2). We have undertaken a genome-wide, phenotype-driven screen for dominant mutations in the mouse. We generated and screened over 26,000 mice, and recovered some 500 new mouse mutants. Our work along with the programme reported in the accompanying paper(7), has led to a substantial increase in the mouse mutant resource and represents a first step towards systematic studies of gene function in mammalian genetics.	MRC, Mammalian Genet Unit, Harwell, Berks, England; Mouse Genome Ctr, Harwell, Berks, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow, Essex, England; SmithKline Beecham Pharmaceut, Dept Biotechnol & Genet, Harlow, Essex, England; MRC, Inst Hearing Res, Nottingham, England; Inst Pasteur, Paris, France; Univ London Queen Mary & Westfield Coll, Dept Morbid Anat, London, England; Univ Oxford, Dept Human Anat & Genet, Oxford, England; Univ London Imperial Coll Sci Technol & Med, Dept Neurogenet, London, England; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland	GlaxoSmithKline; GlaxoSmithKline; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; Queen Mary University London; University of Oxford; Imperial College London; University of Edinburgh	Brown, SDM (corresponding author), MRC, Mammalian Genet Unit, Harwell, Berks, England.		arkell, ruth m/D-1525-2009; Nolan, Patrick/W-3918-2019; Thaung, Caroline/C-2180-2008; Arkell, Ruth/AAR-8471-2021; Fisher, Elizabeth MC/C-2168-2008; Wells, Christine A/A-5071-2010	arkell, ruth m/0000-0002-6213-7323; Nolan, Patrick/0000-0001-5550-0334; Thaung, Caroline/0000-0002-8318-046X; Arkell, Ruth/0000-0002-6213-7323; Fisher, Elizabeth MC/0000-0003-2850-9936; Wells, Christine A/0000-0003-3133-3628				Brown SDM, 1996, TRENDS GENET, V12, P433, DOI 10.1016/0168-9525(96)30094-2; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; CANDY CJ, 1997, J REPROD FERTIL, V110, P1; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; *MED RES COUNC, 1993, MED RES COUNC RESP U; Nolan PM, 1997, METHODS, V13, P379, DOI 10.1006/meth.1997.0545; NOLAN PM, 1995, GENETICS, V140, P245; Rinchik EM, 1999, GENETICS, V152, P373; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5918; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; Thornton CE, 1999, MAMM GENOME, V10, P987, DOI 10.1007/s003359901145	15	476	496	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					440	443		10.1038/78140	http://dx.doi.org/10.1038/78140			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932191				2022-12-27	WOS:000088615000022
J	Wei, J; Hemmings, GP				Wei, J; Hemmings, GP			The NOTCH4 locus is associated with susceptibility to schizophrenia	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; GENE		Schizophrenia Assoc Great Britain, Inst Biol Psychiat, Bangor, Gwynedd, Wales		Wei, J (corresponding author), Schizophrenia Assoc Great Britain, Inst Biol Psychiat, Bangor, Gwynedd, Wales.			Wei, Jun/0000-0002-2916-4944				FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; Levinson DF, 1996, AM J MED GENET, V67, P580; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; SCHWAB SG, 1995, NAT GENET, V11, P325, DOI 10.1038/ng1195-325; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Spielman RS, 1996, AM J HUM GENET, V59, P983; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; STRAUB RE, 1995, NAT GENET, V11, P235; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WANG SB, 1995, NAT GENET, V10, P41, DOI 10.1038/ng0595-41	11	134	147	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					376	377		10.1038/78044	http://dx.doi.org/10.1038/78044			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932176				2022-12-27	WOS:000088615000008
J	Sundin, OH; Yang, JM; Li, YY; Zhu, DP; Hurd, JN; Mitchell, TN; Silva, ED; Maumenee, IH				Sundin, OH; Yang, JM; Li, YY; Zhu, DP; Hurd, JN; Mitchell, TN; Silva, ED; Maumenee, IH			Genetic basis of total colourblindness among the Pingelapese islanders	NATURE GENETICS			English	Article							GATED CATION CHANNEL; ALPHA-SUBUNIT; BETA-SUBUNIT; ACHROMATOPSIA; PHOTORECEPTORS; MUTATIONS; DATABASE; LOCUS	Complete achromatopsia is a rare, autosomal recessive disorder characterized by photophobia, low visual acuity. nystagmus and a total inability to distinguish colours. In this disease, cone photoreceptors. the retinal sensory neurons mediating colour vision, seem viable but fail to generate an electrical response to light(1,2). Achromatopsia, or rod monochromatism, was first mapped to 2p11-2q12 (MIM 216900; ref. 3), where it is associated with missense mutations in CNGA3 (ref. 4). CNGA3 encodes the a-subunit of the cone cyclic nucleotide-gated cation channel, which generates the light-evoked electrical responses of cone photoreceptors(5-7). A second locus at 8q21-q22 has been identified among the Pingelapese islanders of Micronesia(8,9), who have a high incidence of recessive achromatopsia(10,11) (MIM 262300). Here we narrow the achromatopsia locus to 1.4 cM and show that Pingelapese achromatopsia segregates with a missense mutation at a highly conserved site in CNGB3. a new gene that encodes the beta-subunit of the cone cyclic nucleotide-gated cation channel. Two independent frameshift deletions establish that achromatopsia is the null phenotype of CNGB3. Combined with earlier findings, our results demonstrate that both alpha- and beta-subunits of the cGMP-gated channel are essential for phototransduction in all three classes of cones.	Johns Hopkins Univ, Sch Med, Lab Dev Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Ctr Hereditary Eye Dis, Dept Ophthalmol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Genet & Mol Biol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sundin, OH (corresponding author), Johns Hopkins Univ, Sch Med, Lab Dev Genet, Baltimore, MD 21218 USA.			Silva, Eduardo/0000-0002-2739-9854	NEI NIH HHS [R01-EY10813] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010813] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arbour NC, 1997, HUM MOL GENET, V6, P689, DOI 10.1093/hmg/6.5.689; Ardell MD, 1996, FEBS LETT, V389, P213, DOI 10.1016/0014-5793(96)00588-1; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRODY JA, 1970, LANCET, V1, P1253; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HURD JN, 1977, THESIS U HAWAII; HUSSELS IE, 1972, AM J HUM GENET, V24, P304; Kohl S, 1998, NAT GENET, V19, P257, DOI 10.1038/935; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; Krill A. E., 1977, HEREDITARY RETINAL C; Milunsky A, 1999, CLIN GENET, V56, P82, DOI 10.1034/j.1399-0004.1999.560112.x; MORTON NE, 1972, AM J HUM GENET, V24, P277; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Ott J., 1999, ANAL HUMAN GENETIC L; SHARPE LT, 1990, NIGHT VISION BASIC C; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; Winick JD, 1999, AM J HUM GENET, V64, P1679, DOI 10.1086/302423; Wissinger B, 1997, EUR J NEUROSCI, V9, P2512, DOI 10.1111/j.1460-9568.1997.tb01680.x; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	23	168	176	0	124	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					289	293		10.1038/77162	http://dx.doi.org/10.1038/77162			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888875				2022-12-27	WOS:000087920900015
J	Berry, V; Francis, P; Kaushal, S; Moore, A; Bhattacharya, S				Berry, V; Francis, P; Kaushal, S; Moore, A; Bhattacharya, S			Missense mutations in MIP underlie autosomal dominant 'polymorphic' and lamellar cataracts linked to 12q	NATURE GENETICS			English	Article							ZONULAR PULVERULENT CATARACT; FAMILY		Inst Ophthalmol, Dept Mol Genet, London, England; Moorfields Eye Hosp, London, England; Addenbrookes Hosp, Cambridge, England	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Bhattacharya, S (corresponding author), Inst Ophthalmol, Dept Mol Genet, London, England.		Bhattacharya, Shom/N-2926-2016	Bhattacharya, Shom/0000-0002-1601-6344				Daniels G, 1999, BLOOD REV, V13, P14, DOI 10.1016/S0268-960X(99)90020-6; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Echevarria M, 1998, J PHYSIOL BIOCHEM, V54, P107; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; Ionides A, 1999, BRIT J OPHTHALMOL, V83, P802, DOI 10.1136/bjo.83.7.802; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Lambert SR, 1996, SURV OPHTHALMOL, V40, P427, DOI 10.1016/S0039-6257(96)82011-X; Lee MD, 1997, MEDICINE, V76, P141, DOI 10.1097/00005792-199705000-00001; Mackay D, 1997, AM J HUM GENET, V60, P1474, DOI 10.1086/515468; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825	14	221	236	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					15	17		10.1038/75538	http://dx.doi.org/10.1038/75538			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802646				2022-12-27	WOS:000086884000008
J	Marin, MC; Jost, CA; Brooks, LA; Irwin, MS; O'Nions, J; Tidy, JA; James, N; McGregor, JM; Harwood, CA; Yulug, IG; Vousden, KH; Allday, MJ; Gusterson, B; Ikawa, S; Hinds, PW; Crook, T; Kaelin, WG				Marin, MC; Jost, CA; Brooks, LA; Irwin, MS; O'Nions, J; Tidy, JA; James, N; McGregor, JM; Harwood, CA; Yulug, IG; Vousden, KH; Allday, MJ; Gusterson, B; Ikawa, S; Hinds, PW; Crook, T; Kaelin, WG			A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	NATURE GENETICS			English	Article							HUMAN LUNG-CANCER; CERVICAL-CANCER; CELL-LINES; WILD-TYPE; GENE; MUTATIONS; P73; SUPPRESSION; GROWTH; RISK	The p73 protein, a homologue of the tumour-suppressor protein p53, can activate p53-responsive promoters and induce apoptosis in p53-deficient cells. Here we report that some tumour-derived p53 mutants can bind to and inactivate p73. The binding of such mutants is influenced by whether TP53 (encoding p53) codon 72, by virtue of a common polymorphism in the human population, encodes Arg or Pro. The ability of mutant p53 to bind p73, neutralize p73-induced apoptosis and transform cells in cooperation with EJ-Ras was enhanced when codon 72 encoded Arg. We found that the Arg-containing allele was preferentially mutated and retained in squamous cell tumours arising in Arg/Pro germline heterozygotes. Thus, inactivation of p53 family members may contribute to the biological properties of a subset of p53 mutants, and a polymorphic residue within p53 affects mutant behaviour.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; London Sch Hyg & Trop Med, London WC1, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, London SW3 6JB, England; Univ Sheffield, No Gen Hosp, Dept Gynecol Oncol, Sheffield S5 7AU, S Yorkshire, England; Univ Birmingham, CRC, Inst Canc Studies, Birmingham, W Midlands, England; Ctr Cutaneous Res, London, England; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA; St Marys Hosp, Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London, England; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 980, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Northern General Hospital; University of Sheffield; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Imperial College London; Ludwig Institute for Cancer Research; Tohoku University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Marin, Maria C/G-1040-2010; 井川, 俊太郎/L-5911-2015; Marín Vieira, María del Carmen/B-8108-2015; gusterson, barry a/D-3752-2009	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X; Harwood, Catherine/0000-0002-1375-0965; Yulug, Isik/0000-0002-7577-2502				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Helland A, 1998, NATURE, V396, P530, DOI 10.1038/25034; Hildesheim A, 1998, NATURE, V396, P531, DOI 10.1038/25040; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JIN XM, 1995, CARCINOGENESIS, V16, P2205, DOI 10.1093/carcin/16.9.2205; JONES M, 1992, GENE CHROMOSOME CANC, V1, P89; Josefsson AM, 1998, NATURE, V396, P531, DOI 10.1038/25037; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAWAJIRI K, 1993, CARCINOGENESIS, V14, P1085, DOI 10.1093/carcin/14.6.1085; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lanham S, 1998, LANCET, V352, P1631, DOI 10.1016/S0140-6736(05)61083-5; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; MCGREGOR J, 1997, ONCOGENE, V14, P1737; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Minaguchi T, 1998, CANCER RES, V58, P4585; Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORFY K, 1994, EMBO J, V13, P3496; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SHAULSKY G, 1991, CANCER RES, V51, P5232; Storey A, 1998, NATURE, V396, P532, DOI 10.1038/25043; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B	49	450	460	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					47	54		10.1038/75586	http://dx.doi.org/10.1038/75586			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802655				2022-12-27	WOS:000086884000015
J	Ruiz-Perez, VL; Ide, SE; Strom, TM; Lorenz, B; Wilson, D; Woods, K; King, L; Francomano, C; Freisinger, P; Spranger, S; Marino, B; Dallapiccola, B; Wright, M; Meitinger, T; Polymeropoulos, MH; Goodship, J				Ruiz-Perez, VL; Ide, SE; Strom, TM; Lorenz, B; Wilson, D; Woods, K; King, L; Francomano, C; Freisinger, P; Spranger, S; Marino, B; Dallapiccola, B; Wright, M; Meitinger, T; Polymeropoulos, MH; Goodship, J			Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrodental dysostosis	NATURE GENETICS			English	Article							REGION	Ellis-van Creveld syndrome (EvC, MIM 225500) is an autosomal recessive skeletal dysplasia characterized by short limbs, short ribs, postaxial polydactyly and dysplastic nails and teeth(1,2). Congenital cardiac defects, most commonly a defect of primary atrial septation producing a common atrium, occur in 60% of affected individuals. The disease was mapped to chromosome 4p16 in nine Amish subpedigrees and single pedigrees from Mexico, Ecuador and Brazil(3). Weyers acrodental dysostosis (MIM 193530), an autosomal dominant disorder with a similar but milder phenotype, has been mapped in a single pedigree to an area including the EvC critical region(4). We have identified a new gene (EVC), encoding a 992-amino-acid protein, that is mutated in individuals with EvC. We identified a splice-donor change in an Amish pedigree and six truncating mutations and a single amino acid deletion in seven pedigrees. The heterozygous carriers of these mutations did not manifest features of EvC. We found two heterozygous missense mutations associated with a phenotype, one in a man with Weyers acrodental dysostosis and another in a father and his daughter, who both have the heart defect characteristic of EvC and polydactyly, but not short stature. We suggest that EvC and Weyers acrodental dysostosis are allelic: conditions.	Univ Newcastle Upon Tyne, Sch Biochem & Genet, Human Genet Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Novartis Pharmaceut Corp, Pharmacogenet Div, Gaithersburg, MD USA; Univ Munich, Klinikum Innenstadt, Abt Med Genet, D-8000 Munich, Germany; Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD USA; George Washington Univ, Grad Genet Program GWIBS, Washington, DC USA; Tech Univ Munich, Kinderklin, D-8000 Munich, Germany; Univ Bremen, Ctr Human Genet, Bremen, Germany; Osped Pediat Bambino Gesu, Rome, Italy; Univ La Sapienza, CSS Mendel Inst, Rome, Italy	Newcastle University - UK; Novartis; University of Munich; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); George Washington University; Technical University of Munich; University of Bremen; IRCCS Bambino Gesu; IRCCS Casa Sollievo Della Sofferenza; Istituto CSS Mendel; Sapienza University Rome	Goodship, J (corresponding author), Univ Newcastle Upon Tyne, Sch Biochem & Genet, Human Genet Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Meitinger, Thomas/O-1318-2015; Ruiz-Perez, Victor L/K-6066-2014; Wilson, David/A-6264-2010; Dallapiccola, Bruno/K-8692-2016	Ruiz-Perez, Victor L/0000-0003-0635-3619; Wilson, David/0000-0001-8779-2060; Dallapiccola, Bruno/0000-0002-5031-1013; Woods-Townsend, Kathryn/0000-0003-3376-6988; Meitinger, Thomas/0000-0002-8838-8403				Bullen P., 1997, MOL GENETICS EARLY H, P27; DIGILIO MC, 1995, HUM GENET, V96, P251, DOI 10.1007/BF00207395; ELLIS RICHARD W. B., 1940, ARCH DIS CHILDHOOD [LONDON], V15, P65; Hanley NA, 1999, MECH DEVELOP, V87, P175, DOI 10.1016/S0925-4773(99)00123-9; HILL RD, 1977, J MED GENET, V14, P33, DOI 10.1136/jmg.14.1.33; Howard TD, 1997, AM J HUM GENET, V61, P1405, DOI 10.1086/301643; Ide SE, 1996, HUM GENET, V98, P572, DOI 10.1007/s004390050261; ISHIDA Y, 1994, GENOMICS, V22, P302, DOI 10.1006/geno.1994.1388; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; MCKUSICK VA, 1964, B JOHNS HOPKINS HOSP, V115, P306; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Polymeropoulos MH, 1996, GENOMICS, V35, P1, DOI 10.1006/geno.1996.0315; SPRANGER S, 1995, CLIN GENET, V47, P217; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Wilson GM, 1999, MOL CELL BIOL, V19, P4056	15	208	217	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					283	286		10.1038/73508	http://dx.doi.org/10.1038/73508			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700184				2022-12-27	WOS:000085590600021
J	Hu, ZL; Bonifas, JM; Beech, J; Bench, G; Shigihara, T; Ogawa, H; Ikeda, S; Mauro, T; Epstein, EH				Hu, ZL; Bonifas, JM; Beech, J; Bench, G; Shigihara, T; Ogawa, H; Ikeda, S; Mauro, T; Epstein, EH			Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease	NATURE GENETICS			English	Article							YEAST SECRETORY PATHWAY; IDENTIFICATION; GENE; CHROMOSOME; RETICULUM; GOLGI; PMR1; DIFFERENTIATION; TRANSPORT; PEMPHIGUS	Hailey-Hailey disease (HHD, MIM 16960) is inherited in an autosomal dominant manner and characterized by persistent blisters and erosions of the skin(1). Impaired intercellular adhesion and epidermal blistering also occur in individuals with pemphigus (which is due to autoantibodies directed against desmosomal proteins) and in patients with Darier disease (DD, MIM 124200), which is caused by mutations in a gene encoding a sarco/endoplasmic reticulum (ER)-Golgi calcium pump(2). We report here the identification of mutations in ATP2C1, encoding the human homologue of an ATP-powered pump that sequesters calcium into the Golgi in yeast, in 21 HHD kindreds. Regulation of cytoplasmic calcium is impaired in cultured keratinocytes from HHD patients, and the normal epidermal calcium gradient is attenuated in vivo in HHD patients. Our findings not only provide an understanding of the molecular basis of HHD, but also underscore the importance of calcium control to the functioning of stratified squamous epithelia.	San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Dermatol, VA Med Ctr, San Francisco, CA 94143 USA; Univ Calif Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA; Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 113, Japan	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Juntendo University	Epstein, EH (corresponding author), San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA.			Bench, Graham/0000-0002-1969-6867; hu, zhilan/0000-0003-2925-5595	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043119, R29AR044341] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43119, AR44341] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amagai M, 1996, J INVEST DERMATOL, V107, P539, DOI 10.1111/1523-1747.ep12582796; Amar LS, 1999, CELL ADHES COMMUN, V7, P125, DOI 10.3109/15419069909034396; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; BERTELLI A, 1994, DRUG EXP CLIN RES, V20, P7; BUNSE T, 1991, ACTA DERM-VENEREOL, V71, P287; BURGE SM, 1992, BRIT J DERMATOL, V126, P275, DOI 10.1111/j.1365-2133.1992.tb00658.x; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; Christiano AM, 1997, HUM MUTAT, V10, P408, DOI 10.1002/(SICI)1098-1004(1997)10:5<408::AID-HUMU12>3.0.CO;2-3; Elias PM, 1998, J INVEST DERMATOL, V110, P399, DOI 10.1046/j.1523-1747.1998.00151.x; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; IKEDA S, 1994, HUM MOL GENET, V3, P1147, DOI 10.1093/hmg/3.7.1147; IKEDA S, 1991, J INVEST DERMATOL, V97, P644, DOI 10.1111/1523-1747.ep12483596; KAUFMAN RJ, 1994, BIOCHEMISTRY-US, V33, P9813, DOI 10.1021/bi00199a001; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; Mauro T, 1997, J INVEST DERMATOL, V108, P864, DOI 10.1111/1523-1747.ep12292585; ODA K, 1992, J BIOL CHEM, V267, P17465; PELUSO AM, 1995, GENOMICS, V30, P77; RESING KA, 1993, J BIOL CHEM, V268, P25139; Richards L, 1995, STUDIES QUALITATIVE, V5, P105; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sorin A, 1997, J BIOL CHEM, V272, P9895; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453	27	393	427	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					61	65		10.1038/71701	http://dx.doi.org/10.1038/71701			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615129				2022-12-27	WOS:000084609200017
J	Sidow, A; Bulotsky, MS; Kerrebrock, AW; Birren, BW; Altshuler, D; Jaenisch, R; Johnson, KR; Lander, ES				Sidow, A; Bulotsky, MS; Kerrebrock, AW; Birren, BW; Altshuler, D; Jaenisch, R; Johnson, KR; Lander, ES			A novel member of the F-box/WD40 gene family, encoding dactylin, is disrupted in the mouse dactylaplasia mutant	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; F-BOX; UBIQUITIN-LIGASE; LIMB; PROTEOLYSIS; MUTATION; COMPLEX; LOCUS; RNA	Early outgrowth of the vertebrate embryonic limb requires signalling by the apical ectodermal ridge (AER) to the progress zone (PZ), which in response proliferates and lays down the pattern of the presumptive limb in a proximal to distal progression(1). Signals from the PZ maintain the AER until the anlagen for the distal phalanges have been formed(2). The semidominant mouse mutant dactylaplasia (Dac) disrupts the maintenance of the AER, leading to truncation of distal structures of the developing footplate, or autopod(3-5). Adult Dac homozygotes thus lack hands and feet except for malformed single digits, whereas heterozygotes lack phalanges of the three middle digits. Dac resembles the human autosomal dominant split hand/foot malformation (SHFM) diseases. One of these, SHFM3, maps to chromosome 10q24 (refs 6,7), which is syntenic to the Dac region on chromosome 19, and may disrupt the orthologue of Dac. We report here the positional cloning of Dac and show that it belongs to the F-box/WD40 gene family, which encodes adapters that target specific proteins for destruction by presenting them to the ubiquitination machinery(8). In conjuction with recent biochemical studies(9-12), this report demonstrates the importance of this gene family in vertebrate embryonic development.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Jackson Laboratory	Sidow, A (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, R248B, Stanford, CA 94305 USA.		Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107				Altabef M, 1997, DEVELOPMENT, V124, P4547; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CHAI CK, 1981, J HERED, V72, P234, DOI 10.1093/oxfordjournals.jhered.a109486; Crackower M, 1998, DEV BIOL, V201, P78, DOI 10.1006/dbio.1998.8938; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; Ji W, 1994, PCR Methods Appl, V4, P109; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Loomis CA, 1998, DEVELOPMENT, V125, P1137; LYONS KM, 1990, DEVELOPMENT, V109, P833; McKusick V.A., 1998, MENDELIAN INHERITANC; Michaud JL, 1997, DEVELOPMENT, V124, P1453; NUNES ME, 1995, HUM MOL GENET, V4, P2165, DOI 10.1093/hmg/4.11.2165; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAUNDERS JW, 1963, DEV BIOL, V7, P64, DOI 10.1016/0012-1606(63)90107-6; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WOLF DA, IN PRESS CURR BIOL; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	80	83	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					104	107		10.1038/12709	http://dx.doi.org/10.1038/12709			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471509				2022-12-27	WOS:000082337300026
J	Bowles, J; Cooper, L; Berkman, J; Koopman, P				Bowles, J; Cooper, L; Berkman, J; Koopman, P			Sry requires a CAG repeat domain for male sex determination in Mus musculus	NATURE GENETICS			English	Article							DETERMINING REGION; DETERMINING GENE; DNA; MOUSE; MICE; REVERSAL; PROTEINS; EXPRESSION; EVOLUTION; LOCUS	SRY, the mammalian Y-chromosomal sex-determining gene(1-3) encodes a protein characterized by a DNA-binding and -bending domain referred to as the HMG box(4,5). Despite the pivotal role of this gene, only the HMG box region has been conserved through evolution(6,7), suggesting that SRY function depends solely on the HMG box and therefore acts as an architectural transcription factors. In mice (genus Mus) Sry also includes a large CAG trinucleotide repeat region encoding a carboxy-terminal glutamine-rich domain that acts as a transcriptional trans-activator in vitro(9). The absence of this or any other potential trans-activating domain in other mammals(1,9), however, has raised doubts as to its biological relevance. To test directly whether the glutamine-rich region is required for Sry function in vivo, we created truncation mutations of the Mus musculus musculus Sry gene and tested their ability to induce testis formation in XX embryos using a transgenic mouse assay. Sry constructs that encode proteins lacking the glutamine-rich region were unable to effect male sex determination, in contrast to their wild-type counterparts. We conclude that the glutamine-rich repeat domain of the mouse Sry protein has an essential role in sex determination in vivo, and that Sry may act via a fundamentally different biochemical mechanism in mice compared with other mammals.	Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia	University of Queensland	Koopman, P (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia.	p.koopman@cmcb.uq.edu.au	Koopman, Peter A/C-9416-2009; Bowles, Josephine/AAG-4903-2020; Bowles, Josephine/B-6583-2013	Koopman, Peter A/0000-0001-6939-0914; Bowles, Josephine/0000-0003-2867-7438; Bowles, Josephine/0000-0003-2867-7438				Albrecht KH, 1997, GENETICS, V147, P1267; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Eicher EM, 1995, PHILOS T R SOC B, V350, P263, DOI 10.1098/rstb.1995.0160; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; LATCHMAN DS, 1998, EUKARYOTIC TRANSCRIP; Lau YFC, 1998, CYTOGENET CELL GENET, V80, P128, DOI 10.1159/000014968; MANN JR, 1993, METHOD ENZYMOL, V225, P771; MILLER KE, 1995, MAMM GENOME, V6, P206, DOI 10.1007/BF00293015; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	30	105	108	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					405	408		10.1038/11981	http://dx.doi.org/10.1038/11981			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431249				2022-12-27	WOS:000081772500027
J	Waisfisz, Q; Morgan, NV; Savino, M; de Winter, JP; van Berkel, CGM; Hoatlin, ME; Ianzano, L; Gibson, RA; Arwert, F; Savoia, A; Mathew, CG; Pronk, JC; Joenje, H				Waisfisz, Q; Morgan, NV; Savino, M; de Winter, JP; van Berkel, CGM; Hoatlin, ME; Ianzano, L; Gibson, RA; Arwert, F; Savoia, A; Mathew, CG; Pronk, JC; Joenje, H			Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism	NATURE GENETICS			English	Article							GROUP-A; SALMONELLA-TYPHIMURIUM; ALKYLATING-AGENTS; GENETIC-DEFECT; ANEMIA; MUTATIONS; HISD3052; LOCUS; CELLS	Somatic mosaicism due to reversion of a pathogenic allele to wild type has been described in several autosomal recessive disorders(1-6), The best known mechanism involves intragenic mitotic recombination or gene conversion in compound heterozygous patients, whereby one allele serves to restore the wild-type sequence in the other. Here we document for the first time functional correction of a pathogenic microdeletion, microinsertion and missense mutation in homozygous Fanconi anaemia(7) (FA) patients resulting from compensatory secondary sequence alterations in cis, The frameshift mutation 1615delG in FANCA was compensated by two additional single base-pair deletions (1637delA and 1641delT); another FANCA frameshift mutation, 3559insG, was compensated by 3580insCGCTG; and a missense mutation in FANCC (1749T-->G, Leu496Arg) was altered by 1748C-->T, creating a cysteine codon. Although in all three cases the predicted proteins were different from wild type, their cDNAs complemented the characteristic hypersensitivity of FA cells to crosslinking agents, thus establishing a functional correction to wild type.	Free Univ Amsterdam, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; UMDS, Guys Hosp, Kings & St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England; Osped CSS, IRCCS, Serv Genet Med, I-71013 San Giovanni Rotondo, Italy; Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA	Vrije Universiteit Amsterdam; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; IRCCS Casa Sollievo Della Sofferenza; Oregon Health & Science University	Joenje, H (corresponding author), Free Univ Amsterdam, Dept Clin Genet & Human Genet, Vander Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Mathew, Christopher G/G-3434-2015; Savoia, Anna/B-6463-2014; Morgan, Neil V/A-5475-2009; Savoia, Anna/AIC-4560-2022	Mathew, Christopher G/0000-0003-4178-1838; Savoia, Anna/0000-0002-2407-2696; Morgan, Neil V/0000-0001-6433-5692; Savoia, Anna/0000-0002-2407-2696; Gibson, Rachel/0000-0002-1338-1290; Waisfisz, Quinten/0000-0002-7384-9182	NHLBI NIH HHS [HL56045] Funding Source: Medline; Telethon [E.0688] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056045, R01HL056045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ariga T, 1998, BLOOD, V92, P699, DOI 10.1182/blood.V92.2.699; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; DeMarini DM, 1998, GENETICS, V149, P17; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; Gibson RA, 1996, HUM MUTAT, V8, P140, DOI 10.1002/(SICI)1098-1004(1996)8:2<140::AID-HUMU6>3.0.CO;2-F; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOATLIN ME, 1987, J VIROL, V61, P144; ISHIDA R, 1982, CANCER RES, V42, P4000; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Jonkman MF, 1997, CELL, V88, P543, DOI 10.1016/S0092-8674(00)81894-2; Kruyt FAE, 1997, BLOOD, V90, P3288, DOI 10.1182/blood.V90.9.3288; Kruyt FAE, 1996, BLOOD, V87, P938, DOI 10.1182/blood.V87.3.938.bloodjournal873938; KVITTINGEN EA, 1994, J CLIN INVEST, V94, P1657, DOI 10.1172/JCI117509; KWEE ML, 1983, HUM GENET, V64, P384, DOI 10.1007/BF00292372; Lo Ten Foe J R, 1997, EUR J HUM GENET, V5, P137; OHARA SM, 1991, MUTAT RES, V247, P45, DOI 10.1016/0027-5107(91)90032-J; Savino M, 1997, AM J HUM GENET, V61, P1246, DOI 10.1086/301632; Savoia A, 1996, HUM GENET, V97, P599; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; von Borstel RC, 1998, GENETICS, V148, P1647; Wijker M, 1999, EUR J HUM GENET, V7, P52, DOI 10.1038/sj.ejhg.5200248; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	24	156	159	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					379	383		10.1038/11956	http://dx.doi.org/10.1038/11956			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431244				2022-12-27	WOS:000081772500022
J	Tavazoie, S; Hughes, JD; Campbell, MJ; Cho, RJ; Church, GM				Tavazoie, S; Hughes, JD; Campbell, MJ; Cho, RJ; Church, GM			Systematic determination of genetic network architecture	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BINDING-SITES; GENOME; YEAST; EXPRESSION; TRANSCRIPTION; HYBRIDIZATION; METABOLISM; PROMOTERS	Technologies to measure whole-genome mRNA abundances(1-3) and methods to organize and display such data(4-10) are emerging as valuable tools for systems-level exploration of transcriptional regulatory networks. For instance, it has been shown that mRNA data from 118 genes, measured at several time points in the developing hindbrain of mice, can be hierarchically clustered into various patterns (or 'waves') whose members tend to participate in common processes(5). We have previously shown that hierarchical clustering can group together genes whose cis-regulatory elements are bound by the same proteins in vivo(6). Hierarchical clustering has also been used to organize genes into hierarchical dendograms on the basis of their expression across multiple growth conditions(7). The application of Fourier analysis to synchronized yeast mRNA expression data has identified cell-cycle periodic genes, many of which have expected cis-regulatory elements(8). Here we apply a systematic set of statistical algorithms, based on whole-genome mRNA data, partitional clustering and motif discovery, to identify transcriptional regulatory sub-networks in yeast-without any a priori knowledge of their structure or any assumptions about their dynamics. This approach uncovered new regulons (sets of co-regulated genes) and their putative cis-regulatory elements. We used statistical characterization of known regulons and motifs to derive criteria by which we infer the biological significance of newly discovered regulons and motifs. Our approach holds promise for the rapid elucidation of genetic network architecture in sequenced organisms in which little biology is known.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Grad Program Biophys, Boston, MA 02115 USA; Mol Applicat Grp, Palo Alto, CA 94303 USA; Stanford Univ, Med Ctr, Dept Genet, Palo Alto, CA 94304 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Stanford University	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	church@salt2.med.harvard.edu	Yang, Chen/G-1379-2010; Cho, Raymond/AAO-8125-2020	Cho, Raymond/0000-0001-6090-6603; church, george/0000-0001-6232-9969				BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Everitt B., 1974, CLUSTER ANAL, P122; Hartigan J.A., 1975, CLUSTERING ALGORITHM; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Planta RJ, 1995, BIOCHEM CELL BIOL, V73, P825, DOI 10.1139/o95-090; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	24	1746	1834	0	92	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1999	22	3					281	285		10.1038/10343	http://dx.doi.org/10.1038/10343			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391217				2022-12-27	WOS:000081125900022
J	Miettinen, PJ; Chin, JR; Shum, L; Slavkin, HC; Shuler, CF; Derynck, R; Werb, Z				Miettinen, PJ; Chin, JR; Shum, L; Slavkin, HC; Shuler, CF; Derynck, R; Werb, Z			Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure	NATURE GENETICS			English	Article							FACTOR-ALPHA-GENE; CLEFT-PALATE; EGF RECEPTOR; MICE LACKING; ORGAN-CULTURE; MOUSE; LIP; ASSOCIATION; DEFECTS; MORPHOGENESIS	Craniofacial malformations are among the most frequent congenital birth defects in humans; cleft palate, that is inadequate fusion of the palatal shelves, occurs with an annual incidence of 1 in 700 to 1 in 1,000 live births among individuals of European descent(1). The secondary palate arises as bilateral outgrowths from the maxillary processes(2), and its formation depends on the coordinated development of craniofacial structures including the Meckel's cartilage and the mandible(3). Cleft lip and palate syndromes in humans are associated with polymorphisms in the gene (TGFA) encoding transforming growth factor-alpha (TGF-alpha), an epidermal growth factor receptor (EGFR) ligand made by most epithelia(1,4). Here we have characterized craniofacial develop ment in Egfr-deficient (Egfr(-/-)) mice. Newborn Egfr(-/-) mice have facial mediolateral defects including narrow, elongated snouts, underdeveloped lower jaw and a high incidence of cleft palate. Palatal shelf explants from Egfr(-/-) mice fused, but frequently had residual epithelium in the midline. In addition, morphogenesis of Meckel's cartilage was deficient in cultured mandibular processes from Egfr(-/-) embryos. The secretion of matrix metalloproteinases (MMPs) was diminished in Egfr(-/-) explants, consistent with the ability of EGF to increase MMP secretion and with the decreased MMP expression caused by inhibition of Egfr sig nailing in wild-type explants. Accordingly, inactivation of MMPs in wild-type explants phenocopied the defective morphology of Meckel's cartilage seen in Egfr(-/-) explants. Our results indicate that EGFR signalling is necessary for normal craniofacial development and that its role is mediated in part by its downstream targets, the MMPs, and may explain the genetic correlation of human cleft palate with polymorphisms in TGFA.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; NIAMSD, Craniofacial Dev Sect, NIH, Bethesda, MD 20892 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90025 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Southern California	Miettinen, PJ (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland.	paivi.miettinen@helsinki.fi			NCI NIH HHS [CA54826] Funding Source: Medline; NIAMS NIH HHS [AR41114] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041114, Z01AR041114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBOTT BD, 1987, J CRAN GENET DEV BIO, V7, P219; Abbott BD, 1995, TOXICOLOGY, V105, P365, DOI 10.1016/0300-483X(95)03234-7; ARDINGER HH, 1989, AM J HUM GENET, V45, P348; CHENEVIXTRENCH G, 1992, AM J HUM GENET, V51, P1377; Chin JR, 1997, DEVELOPMENT, V124, P1519; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; CHUNG CS, 1968, AM J HUM GENET, V20, P44; Diehl SR, 1997, P NATL ACAD SCI USA, V94, P5231, DOI 10.1073/pnas.94.10.5231; DIXON MJ, 1992, ARCH ORAL BIOL, V37, P395, DOI 10.1016/0003-9969(92)90024-3; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Iamaroon A, 1996, J DENT RES, V75, P1534, DOI 10.1177/00220345960750080301; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mitchell LE, 1997, GENET EPIDEMIOL, V14, P231; NEEL JV, 1958, AM J HUM GENET, V10, P398; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SEEGMILLER RE, 1977, J EMBRYOL EXP MORPH, V38, P227; Sheehan D.C., 1980, THEORY PRACTICE HIST; SHIANG R, 1993, AM J HUM GENET, V53, P836; SHULER C F, 1991, International Journal of Developmental Biology, V35, P463; SHULER CF, 1995, CRIT REV ORAL BIOL M, V6, P202, DOI 10.1177/10454411950060030301; SHUM L, 1993, DEVELOPMENT, V118, P903; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; van der Zee E, 1998, J PERIODONTAL RES, V33, P65; WILSON JB, 1993, CELL GROWTH DIFFER, V4, P67	28	204	218	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					69	73		10.1038/8773	http://dx.doi.org/10.1038/8773			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319864				2022-12-27	WOS:000080096300025
J	Corda, Y; Schramke, V; Longhese, MP; Smokvina, T; Paciotti, V; Brevet, V; Gilson, E; Geli, V				Corda, Y; Schramke, V; Longhese, MP; Smokvina, T; Paciotti, V; Brevet, V; Gilson, E; Geli, V			Interaction between Set1p and checkpoint protein Mec3p in DNA repair and telomere functions	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; GROUP GENE ENHANCER; BUDDING YEAST; TRITHORAX; LENGTH; DAMAGE; REPLICATION; SIR4	The yeast protein Set1p, inactivation of which alleviates telomeric position effect (TPE), contains a conserved SET domain present in chromosomal proteins involved in epigenetic control of transcription(1-2). Mec3p is required for efficient DNA-damage-dependent checkpoints at G1/S, intra-S and G2/M (refs 3-7). We show here that the SET domain of Set1p interacts with Mec3p. Deletion of SET1 increases the viability of mec3 Delta mutants after DNA damage (in a process that is mostly independent of Rad53p kinase, which has a central role in checkpoint control(8-9)) but does not significantly affect cell-cycle progression. Deletion of MEC3 enhances TPE and attenuates the set1 Delta-induced silencing defect. Furthermore, restoration of TPE in a set1 Delta mutant by overexpression of the isolated SET domain requires Mec3p. Finally, deletion of MEC3 results in telomere elongation, whereas cells with deletions of both SET1 and MEC3 do not have elongated telomeres. Our findings indicate that interactions between SET1 and MEC3 have a role in DNA repair and telomere function.	CNRS, Lab Ingn & Dynam Syst Macromol, F-13402 Marseille 20, France; Univ Milan, Dipartimento Genet & Biol Micorganismi, I-20133 Milan, Italy; Ecole Normale Super Lyon, CNRS, UMR 8510, Biol Cellulaire & Mol Lab, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); University of Milan; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Geli, V (corresponding author), CNRS, Lab Ingn & Dynam Syst Macromol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Pia, Maria/AAK-2693-2020	Longhese, Maria Pia/0000-0003-1726-2034				Adams AK, 1996, MOL CELL BIOL, V16, P4614; Allen JB, 1994, GENE DEV, V8, P2416; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Fairhead C, 1996, YEAST, V12, P1439; GOLEMIS EA, 1990, CURRENT PROTOCOLS MO, V27, P1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; LONGHESE MP, 1996, MOL CELL BIOL, V16, P3225; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748	30	87	93	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					204	208		10.1038/5991	http://dx.doi.org/10.1038/5991			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988274				2022-12-27	WOS:000078399500024
J	Southern, E; Mir, K; Shchepinov, M				Southern, E; Mir, K; Shchepinov, M			Molecular interactions on microarrays	NATURE GENETICS			English	Review							OLIGONUCLEOTIDE ARRAYS; GLASS SUPPORTS; NUCLEIC-ACIDS; DNA PROBES; HYBRIDIZATION; GENE; POLYMORPHISMS; DIAGNOSTICS; LIBRARIES; SEQUENCES	The structural features of nucleic acid probes tethered to a solid support and the molecular basis of their interaction with targets in solution have direct implications of the hybridization process. We discuss how arrays of oligonucleotides provide powerful tools to study the molecular basis of these interactions on a scale which is impossible using conventional analysis.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Southern, E (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ems@bioch.ox.ac.uk						BIRNSTIEL M, 1968, NATURE, V219, P454, DOI 10.1038/219454a0; Blanchard AP, 1996, BIOSENS BIOELECTRON, V11, P687, DOI 10.1016/0956-5663(96)83302-1; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Fotin AV, 1998, NUCLEIC ACIDS RES, V26, P1515, DOI 10.1093/nar/26.6.1515; GILLESPIE D, 1965, J MOL BIOL, V12, P829, DOI 10.1016/S0022-2836(65)80331-X; Gray DE, 1997, LANGMUIR, V13, P2833, DOI 10.1021/la962139m; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Livshits MA, 1996, BIOPHYS J, V71, P2795, DOI 10.1016/S0006-3495(96)79473-0; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; MASKOS U, 1993, NUCLEIC ACIDS RES, V21, P2267, DOI 10.1093/nar/21.9.2267; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1675, DOI 10.1093/nar/20.7.1675; MASKOS U, 1993, NUCLEIC ACIDS RES, V21, P4663, DOI 10.1093/nar/21.20.4663; MATSON RS, 1995, ANAL BIOCHEM, V224, P110, DOI 10.1006/abio.1995.1014; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; MIR KU, 1995, THESIS OXFORD U; NICKERSON DA, 1990, P NATL ACAD SCI USA, V87, P8923, DOI 10.1073/pnas.87.22.8923; NIKIFOROV TT, 1994, NUCLEIC ACIDS RES, V22, P4167, DOI 10.1093/nar/22.20.4167; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; RITOSSA F, 1971, P NATL ACAD SCI USA, V68, P1580, DOI 10.1073/pnas.68.7.1580; Shchepinov MS, 1997, NUCLEIC ACIDS RES, V25, P1155, DOI 10.1093/nar/25.6.1155; Shchepinov MS, 1997, NUCLEIC ACIDS RES, V25, P4447, DOI 10.1093/nar/25.22.4447; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WILLIAMS JC, 1994, NUCLEIC ACIDS RES, V22, P1365, DOI 10.1093/nar/22.8.1365; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	36	635	707	0	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21			S			5	9		10.1038/4429	http://dx.doi.org/10.1038/4429			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915493				2022-12-27	WOS:000078008200004
J	Halford, MM; Armes, J; Buchert, M; Meskenaite, V; Grail, D; Hibbs, ML; Wilks, AF; Farlie, PG; Newgreen, DF; Hovens, CM; Stacker, SA				Halford, MM; Armes, J; Buchert, M; Meskenaite, V; Grail, D; Hibbs, ML; Wilks, AF; Farlie, PG; Newgreen, DF; Hovens, CM; Stacker, SA			Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk	NATURE GENETICS			English	Article							INVERSUS SYNDROME BPES; TYROSINE KINASE FAMILY; BLEPHAROPHIMOSIS; EXPRESSION; PTOSIS; DUPLICATION; SELECTION; DELETION; DOMAINS; TARGETS	Secondary palate formation is a complex process that is frequently disturbed in mammals, resulting in the birth defect cleft palate(1,2). Gene targeting has identified components of cytokine/growth factor signalling systems such as Tgf-alpha/Egfr, Eph receptors B2 and B3 (Ephb2 and Ephb3, respectively), Tgf-beta 2, Tgf-beta 3 and activin-beta A (ref. 3) as regulators of secondary palate development, Here we demonstrate that the mouse orphan receptor 'related to tyrosine kinases' (Ryk) is essential for normal development and morphogenesis of craniofacial structures including the secondary palate. Ryk belongs to a subclass of catalytically inactive, but otherwise distantly related, receptor protein tyrosine kinases(4-6) (RTKs). Mice homozygous for a null allele of Ryk have a distinctive craniofacial appearance, shortened limbs and postnatal mortality due to feeding and respiratory complications associated with a complete cleft of the secondary palate. Consistent with cleft palate phenocopy in Ephb2/Ephb3-deficient mice(7) and the role of a Drosophila melanogaster Ryk orthologue, Derailed, in the transduction of repulsive axon pathfinding cues(8,9), our biochemical data implicate Ryk in signalling mediated by Eph receptors and the cell-junction-associated Af-6 (also known as Afadin), Our findings highlight the importance of signal crosstalk between members of different RTK subfamilies.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Victorian Breast Canc Res Consortium, E Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Dept Pathol, E Melbourne, Vic, Australia; Royal Melbourne Hosp, Dept Surg, Melbourne, Vic, Australia; Univ Zurich, ETH Zurich, Inst Neuroinformat, Zurich, Switzerland; Royal Childrens Hosp, Murdoch Inst, Parkville, Vic 3052, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Royal Melbourne Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic, Australia.		Armes, Jane/D-6396-2012; Buchert, Michael/Z-1777-2019; Hibbs, Margaret L/D-7013-2011; Wilks, Andrew F/R-5542-2019	Armes, Jane/0000-0002-2215-0347; Buchert, Michael/0000-0003-2672-0148; Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273; Wilks, Andrew F/0000-0002-8554-2399; Hovens, Christopher/0000-0002-0610-1289				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; BOHME B, 1993, ONCOGENE, V82, P857; Bonkowsky JL, 1999, NATURE, V402, P540, DOI 10.1038/990122; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CIOSSEK T, 1995, ONCOGENE, V10, P97; FEAR C, 1979, ARCH DIS CHILD, V54, P135, DOI 10.1136/adc.54.2.135; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Francis-West P, 1998, MECH DEVELOP, V75, P3, DOI 10.1016/S0925-4773(98)00082-3; FRYNS JP, 1995, CLIN GENET, V48, P111; FUJITA H, 1992, AM J MED GENET, V44, P434, DOI 10.1002/ajmg.1320440409; Gorlin RJ, 1990, PLAST RECONSTR SURG; Halford MM, 1999, J BIOL CHEM, V274, P7379, DOI 10.1074/jbc.274.11.7379; Hockley D, 1998, JAVA REP, V3, P6; Hogan B, 1994, MANIPULATING MOUSE E; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; ISHIKIRIYAMA S, 1994, AM J MED GENET, V52, P245, DOI 10.1002/ajmg.1320520228; JEWETT T, 1993, AM J MED GENET, V47, P1147, DOI 10.1002/ajmg.1320470802; Kamitori K, 1999, DEV BRAIN RES, V114, P149, DOI 10.1016/S0165-3806(99)00033-4; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; ROSENFELD W, 1981, AM J MED GENET, V10, P187, DOI 10.1002/ajmg.1320100212; SALAZAR D, 1979, AM J DIS CHILD, V133, P1006, DOI 10.1001/archpedi.1979.02130100030005; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Simon AF, 1998, MECH DEVELOP, V76, P45, DOI 10.1016/S0925-4773(98)00104-X; STACKER SA, 1993, ONCOGENE, V8, P1347; WILLIAMSON RA, 1981, AM J MED GENET, V9, P105, DOI 10.1002/ajmg.1320090204	30	137	142	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					414	418		10.1038/78099	http://dx.doi.org/10.1038/78099			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932185				2022-12-27	WOS:000088615000016
J	Ferdinandusse, S; Denis, S; Clayton, PT; Graham, A; Rees, JE; Allen, JT; McLean, BN; Brown, AY; Vreken, P; Waterham, HR; Wanders, RJA				Ferdinandusse, S; Denis, S; Clayton, PT; Graham, A; Rees, JE; Allen, JT; McLean, BN; Brown, AY; Vreken, P; Waterham, HR; Wanders, RJA			Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy	NATURE GENETICS			English	Article							BETA-OXIDATION; REFSUM-DISEASE; HUMAN LIVER; RAT-LIVER; ACID; OXIDASE; PURIFICATION; ESTERS; BILE	Sensory motor neuropathy is associated with various inherited disorders including Charcot-Marie-Tooth disease(1,2), X-linked adrenoleukodystrophy/adrenomyeloneuropathy(3) and Refsum disease(4). In the latter two, the neuropathy is thought to result from the accumulation of specific: fatty acids. We describe here three patients with elevated plasma concentrations of pristanic acid (a branched-chain fatty acid) and C27-bile-acid intermediates. Two of the patients suffered from adult-onset sensory motor neuropathy. One patient also had pigmentary retinopathy, suggesting Refsum disease, whereas the other patient had upper motor neuron signs in the legs, suggesting adrenomyeloneuropathy. The third patient was a child without neuropathy. In all three patients we discovered a deficiency of alpha-methylacyl-CoA racemase (AMACR). This enzyme is responsible for the conversion of pristanoyl-CoA and C27-bile acyl-CoAs to their (S)-stereoisomers(,)(5,6) which are the only stereoisomers that can be degraded via peroxisomal beta-oxidation(7,8). Sequence analysis of AMACR cDNA from the patients identified two different mutations that are likely to cause disease, based on analysis in Escherichia coli. Our findings have implications for the diagnosis of adult-onset neuropathies of unknown aetiology.	Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Inst Child Hlth, Biochem Unit, London, England; Southmead Hosp, Biochem Genet Unit, Bristol, Avon, England; Royal Cornwall Hosp, Treliske, Truro, England	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of London; University College London; Southmead Hospital; Royal Cornwall Hospital	Wanders, RJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Clayton, Peter T/C-1523-2008	Ferdinandusse, Sacha/0000-0002-7738-5709; Clayton, Peter/0000-0001-7592-4302				ACKMAN RG, 1967, LIPIDS, V2, P357, DOI 10.1007/BF02531848; BATTA AK, 1983, J LIPID RES, V24, P94; Croes K, 1999, J LIPID RES, V40, P601; Dubois-Dalcq M, 1999, TRENDS NEUROSCI, V22, P4, DOI 10.1016/S0166-2236(98)01319-8; HUNGERBUHLER JP, 1985, EUR NEUROL, V24, P153, DOI 10.1159/000115788; IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7; Ikegawa S, 1998, STEROIDS, V63, P603, DOI 10.1016/S0039-128X(98)00070-1; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Moser AB, 1999, NEUROCHEM RES, V24, P187, DOI 10.1023/A:1022549618333; Murakami T, 1996, MEDICINE, V75, P233, DOI 10.1097/00005792-199609000-00001; Pedersen JI, 1996, BIOCHEM BIOPH RES CO, V224, P37, DOI 10.1006/bbrc.1996.0981; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; Schmitz W, 1997, BIOCHEM J, V326, P883, DOI 10.1042/bj3260883; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; Sequeira JSS, 1998, J INHERIT METAB DIS, V21, P149, DOI 10.1023/A:1005395709826; Steinberg D., 1995, METABOLIC MOL BASES, P2351; VANELDERE JR, 1987, EUR J CLIN INVEST, V17, P386; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; VanVeldhoven PP, 1997, BBA-LIPID LIPID MET, V1347, P62, DOI 10.1016/S0005-2760(97)00053-2; Vreken P, 1998, J CHROMATOGR B, V713, P281, DOI 10.1016/S0378-4347(98)00186-8; Wanders RJA, 1995, J INHERIT METAB DIS, V18, P113, DOI 10.1007/BF00711434; Warner LE, 1999, ANNU REV MED, V50, P263, DOI 10.1146/annurev.med.50.1.263	24	185	196	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					188	191		10.1038/72861	http://dx.doi.org/10.1038/72861			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655068				2022-12-27	WOS:000085104600023
J	Kim, SH; Kaminker, P; Campisi, J				Kim, SH; Kaminker, P; Campisi, J			TIN2, a new regulator of telomere length in human cells	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; REPLICATIVE SENESCENCE; CHROMOSOME STABILITY; RETROVIRAL VECTORS; HUMAN FIBROBLASTS; GENE-TRANSFER; RAP1 PROTEIN; LIFE-SPAN; IN-VITRO; YEAST	Telomeres are DNA-protein structures that cap linear chromosomes and are essential for maintaining genomic stability and cell phenotype. We identified a novel human telomere-associated protein, TIN2, by interaction cloning using the telomeric DNA-binding-protein TRF1 as a bait. TIN2 interacted with TRF1 in vitro and in cells, and colocalized with TRF1 in nuclei and metaphase chromosomes. A mutant TIN2 that lacks amino-terminal sequences effects elongated human telomeres in a telomerase-dependent manner. Our findings suggest that TRF1 is insufficient for control of telomere length in human cells, and that TIN2 is an essential mediator of TRF1 function.	Lawrence Berkeley Natl Lab, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Campisi, J (corresponding author), Lawrence Berkeley Natl Lab, Dept Cell & Mol Biol, Berkeley, CA 94720 USA.	jcampisi@lbl.gov			NATIONAL INSTITUTE ON AGING [R01AG009909, T32AG000266, R37AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG009909, T32 AG000266, AG00266, AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi Judith, 1996, P121; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; FINER MH, 1994, BLOOD, V83, P43; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; James P, 1996, GENETICS, V144, P1425; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Sambrook J, 1989, MOL CLONING; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	47	407	432	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					405	412		10.1038/70508	http://dx.doi.org/10.1038/70508			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581025	Green Published, Green Accepted			2022-12-27	WOS:000084023900014
J	Ranta, S; Zhang, YH; Ross, B; Lonka, L; Takkunen, E; Messer, A; Sharp, J; Wheeler, R; Kusumi, K; Mole, S; Liu, WC; Soares, MB; Bonaldo, MD; Hirvasniemi, A; de la Chapelle, A; Gilliam, TC; Lehesjoki, AE				Ranta, S; Zhang, YH; Ross, B; Lonka, L; Takkunen, E; Messer, A; Sharp, J; Wheeler, R; Kusumi, K; Mole, S; Liu, WC; Soares, MB; Bonaldo, MD; Hirvasniemi, A; de la Chapelle, A; Gilliam, TC; Lehesjoki, AE			The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8	NATURE GENETICS			English	Article							NORTHERN EPILEPSY SYNDROME; PROTEIN; MOUSE; DEGENERATION; CHILDHOOD; DISEASE; MODEL	The neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of progressive neurodegenerative disorders characterized by the accumulation of autofluorescent lipopigment in various tissues(1). Progressive epilepsy with mental retardation (EPMR, MIM 600143) was recently recognized as a new NCL subtype(2) (CLN8), It is an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation(3). Here we report the positional cloning of a novel gene, CLN8, which is mutated in EPMR. It encodes a putative transmembrane protein. EPMR patients were homozygous for a missense mutation (70C-->G, R24G) that was not found in homozygosity in 433 controls. We also cloned the mouse Cln8 sequence. It displays 82% nucleotide identity with CLN8, conservation of the codon harbouring the human mutation and is localized to the same region as the motor neuron degeneration mouse, mnd, a naturally occurring mouse NCL (ref. 4). In mnd/mnd mice, we identified a homozygous 1-bp insertion (267-268insC, codon 90) predicting a frameshift and a truncated protein. Our data demonstrate that mutations in these orthologous genes underlie NCL phenotypes in human and mouse, and represent the first description of the molecular basis of a naturally occurring animal model for NCL.	Folkhalsan Inst Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Columbia Univ, Dept Psychiat, New York, NY USA; Columbia Univ, Dept Genet & Dev, New York, NY USA; Columbia Univ, Columbia Genome Ctr, New York, NY USA; New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY USA; UCL, Dept Paediat, Royal Free & Univ Coll Med Sch, London, England; Cambridge Ctr Mol Recognit, Whitehead Inst Biomed Res, Cambridge, MA USA; Univ Iowa, Iowa City, IA USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; Columbia University; Columbia University; Columbia University; State University of New York (SUNY) System; Wadsworth Center; University of London; University College London; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Iowa; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ranta, S (corresponding author), Folkhalsan Inst Genet, Helsinki, Finland.	susanna.ranta@helsinki.fi	Ranta, Susanna/C-6149-2016; Kusumi, Kenro/J-2626-2012; Mole, Sara/C-2024-2008	Kusumi, Kenro/0000-0002-1458-4540; Mole, Sara/0000-0003-4385-4957; Jaaskelainen, Elina/0000-0002-2880-3206	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029110] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29110] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BONALDO MD, 1994, HUM MOL GENET, V3, P1663; BRONSON RT, 1993, ANN NEUROL, V33, P381, DOI 10.1002/ana.410330408; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Haltia M, 1999, BIOM HLTH R, V33, P117; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HIRVASNIEMI A, 1995, EPILEPSIA, V36, P792, DOI 10.1111/j.1528-1157.1995.tb01616.x; HIRVASNIEMI A, 1994, J MED GENET, V31, P177, DOI 10.1136/jmg.31.3.177; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MESSER A, 1993, NEUROMUSCULAR DISORD, V3, P129, DOI 10.1016/0960-8966(93)90004-4; MESSER A, 1987, J NEUROGENET, V4, P201, DOI 10.3109/01677068709102341; MESSER A, 1993, EXP EYE RES, V57, P637, DOI 10.1006/exer.1993.1169; MESSER A, 1986, J NEUROGENET, V3, P345, DOI 10.3109/01677068609106858; MESSER A, 1995, AM J MED GENET, V57, P361, DOI 10.1002/ajmg.1320570251; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PARDO CA, 1994, AM J PATHOL, V144, P829; Porter JC, 1997, MOL CELL NEUROSCI, V9, P185, DOI 10.1006/mcne.1997.0617; Ranta S, 1997, GENOME RES, V7, P887, DOI 10.1101/gr.7.9.887; ROST B, 1995, PROTEIN SCI, V4, P521; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802	25	221	226	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					233	236		10.1038/13868	http://dx.doi.org/10.1038/13868			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508524				2022-12-27	WOS:000082827500027
J	Pearce, DA; Ferea, T; Nosel, SA; Das, B; Sherman, F				Pearce, DA; Ferea, T; Nosel, SA; Das, B; Sherman, F			Action of BTN1, the yeast orthologue of the gene mutated in Batten disease	NATURE GENETICS			English	Article							MITOCHONDRIAL ATP SYNTHASE; NEURONAL CEROID-LIPOFUSCINOSIS; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; SUBUNIT-C; MEMBRANE; PROTEIN; EXPRESSION; STORAGE; MUTANTS	Neuronal ceroid-lipofuscinoses (NCL) are autosomal recessive disorders that form the most common group of progressive neurodegenerative diseases in children, with an incidence as high as 1 in 12,500 live births, and with approximately 440,000 carriers in the United States(1,2). Disease progression is characterized by a decline in mental abilities, increased severity of untreatable seizures, blindness, loss of motor skills and premature death. The CLN3 gene, which is responsible for Batten disease, has been positionally cloned(3). The yeast gene, denoted BTN1, encodes a non-essential protein that is 39% identical and 59% similar to human CLN3 (ref. 4). Strains lacking Btn1p, btn1-Delta, are resistant to D-(-)-threo-2-amino-1-[p-nitrophenyl]-1,3-propanediol (ANP) in a pH-dependent manner(5). This phenotype was complemented by expression of human CLN3, demonstrating that yeast Btn1p and human CLN3 share the same function(5). Here, we report that btn1-Delta yeast strains have an abnormally acidic vacuolar pH in the early phases of growth. Furthermore, DNA microarray analysis of BTN1 and btn1-Delta strains revealed differential expression of two genes, with at least one, HSP30, involved in pH control. Because Btn1p is located in the vacuole, we suggest that Batten disease is caused by a defect in vacuolar (lysosomal) pH control. Our findings draw parallels between fundamental biological processes in yeast and previously observed characteristics of neurodegeneration in humans.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	University of Rochester; Stanford University	Pearce, DA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.		Das, Biswadip/AAN-6505-2021	Das, Biswadip/0000-0002-2839-2048	NCI NIH HHS [CA 36856] Funding Source: Medline; NINDS NIH HHS [R01 NS36610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE P, 1992, AM J MED GENET, V42, P549, DOI 10.1002/ajmg.1320420426; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; Croopnick JB, 1998, BIOCHEM BIOPH RES CO, V250, P335, DOI 10.1006/bbrc.1998.9272; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; GOEBEL HH, 1995, J CHILD NEUROL, V10, P424, DOI 10.1177/088307389501000602; HALL NA, 1991, BIOCHEM J, V275, P269, DOI 10.1042/bj2750269; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; HEMENWAY CS, 1995, GENETICS, V141, P833; Jarvela I, 1998, HUM MOL GENET, V7, P85, DOI 10.1093/hmg/7.1.85; KOENIG H, 1964, J NEUROPATH EXP NEUR, V23, P191; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MORANO KA, 1994, J CELL SCI, V107, P2813; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pearce DA, 1998, P NATL ACAD SCI USA, V95, P6915, DOI 10.1073/pnas.95.12.6915; Pearce DA, 1997, YEAST, V13, P691, DOI 10.1002/(SICI)1097-0061(19970630)13:8<691::AID-YEA123>3.0.CO;2-D; Pearce DA, 1999, MOL GENET METAB, V66, P320, DOI 10.1006/mgme.1999.2819; Pearce DA, 1999, MOL GENET METAB, V66, P314, DOI 10.1006/mgme.1999.2820; Piper PW, 1997, CELL STRESS CHAPERON, V2, P12, DOI 10.1379/1466-1268(1997)002<0012:HTIPMH>2.3.CO;2; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	26	147	152	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					55	58		10.1038/8861	http://dx.doi.org/10.1038/8861			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319861				2022-12-27	WOS:000080096300022
J	Elchebly, M; Wagner, J; Kennedy, TE; Lanctot, C; Michaliszyn, E; Itie, A; Drouin, J; Tremblay, ML				Elchebly, M; Wagner, J; Kennedy, TE; Lanctot, C; Michaliszyn, E; Itie, A; Drouin, J; Tremblay, ML			Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma	NATURE GENETICS			English	Article							MOTOR AXON GUIDANCE; GENE; LAR; DROSOPHILA; EXPRESSION; SYSTEM; RAT	Protein tyrosine phosphatase sigma (PTP-sigma, encoded by the Ptprs gene) is a member of the LAR subfamily of receptor-like protein tyrosine phosphatases that is highly expressed during mammalian embryonic development in the germinal cell layer lining the lateral ventricles of the developing brain, dorsal root ganglia, Rathke's pouch, olfactory epithelium, retina and developing lung and heart(1-4). On the basis of its expression and homology with the Drosophila melanogaster orthologues DPTP99 and DPTP100A (refs 5,6), which have roles in the targeting of axonal growth cones, we hypothesized that PTP-sigma may also have a modulating function in cell-cell interactions, as well as in axon guidance during mammalian embryogenesis, To investigate its function in vivo, we generated Ptprs-deficient mice. The resulting Ptprs(-/-) animals display retarded growth, increased neonatal mortality, hyposmia and hypofecundity. Anatomical and histological analyses showed a decrease in overall brain size with a severe depletion of luteinizing hormone-releasing hormone (LHRH)immunoreactive cells in Ptprs(-/-) hypothalamus. Ptprs(-/-) mice have an enlarged intermediate pituitary lobe, but smaller anterior and posterior lobes, These results suggest that tyrosine phosphorylation-dependent signalling pathways regulated by PTP-sigma influence the proliferation and/or adhesiveness of various cell types in the developing hypothalamo-pituitary axis.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Inst Rech Clin Montreal, Montreal, PQ M2W 1R7, Canada	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Tremblay, ML (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.			Drouin, Jacques/0000-0001-8226-5691				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Deiss V, 1997, PHYSIOL BEHAV, V61, P209, DOI 10.1016/S0031-9384(96)00402-7; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Kim H, 1996, AM J PHYSIOL-LUNG C, V270, pL566, DOI 10.1152/ajplung.1996.270.4.L566; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; OGRADY P, 1994, J BIOL CHEM, V269, P25193; RUGARLI EI, 1993, NAT GENET, V4, P19, DOI 10.1038/ng0593-19; SAHIN M, 1993, J NEUROSCI, V13, P4968; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; UETANI N, 1997, KINASES PHOSPHATASES, P313; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WANG H, 1995, J NEUROSCI RES, V41, P297, DOI 10.1002/jnr.490410303; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	16	131	135	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					330	333		10.1038/6859	http://dx.doi.org/10.1038/6859			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080191				2022-12-27	WOS:000078977900032
J	Irby, RB; Mao, WG; Coppola, D; Kang, J; Loubeau, JM; Trudeau, W; Karl, R; Fujita, DJ; Jove, R; Yeatman, TJ				Irby, RB; Mao, WG; Coppola, D; Kang, J; Loubeau, JM; Trudeau, W; Karl, R; Fujita, DJ; Jove, R; Yeatman, TJ			Activating SRC mutation in a subset of advanced human colon cancers	NATURE GENETICS			English	Article							PROTEIN-KINASE ACTIVITY; C-SRC; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; SARCOMA VIRUS; PP60C-SRC; CARCINOMA; ONCOGENES; MUTANTS; REGION	The discovery of Rous sarcoma virus (RSV) led to the identification of cellular Src (c-Src), a non-receptor tyrosine kinase, which has since been implicated in the development of numerous human cancers(1-4). c-Src has been found to be highly activated in colon cancers, particularly in those metastatic to the liver(5-11) Studies of the mechanism of c-Src regulation have suggested that c-Src kinase activity is downregulated by phosphorylation of a critical carboxy-terminal tyrosine (Tyr 530 in human c-Src, equivalent to Tyr 527 in chicken Src) and have implied the existence of activating mutations in this C-terminal regulatory region(12-18). We report here the identification of a truncating mutation in SRC at codon 531 in 12% of cases of advanced human colon cancer tested and demonstrate that the mutation is activating, transforming, tumorigenic and promotes metastasis. These results provide, for the first time, genetic evidence that activating SRC mutations may have a role in the malignant progression of human colon cancer.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ Calgary, Med Ctr, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Calgary	Yeatman, TJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Surg, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA055652, K11CA065512] Funding Source: NIH RePORTER; NCI NIH HHS [CA65512, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; Guo Z, 1997, NAT BIOTECHNOL, V15, P331, DOI 10.1038/nbt0497-331; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TALAMONTI MA, 1991, J CLIN INVEST, V91, P53; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	28	414	431	3	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					187	190		10.1038/5971	http://dx.doi.org/10.1038/5971			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988270				2022-12-27	WOS:000078399500020
J	Jones, PA; Laird, PW				Jones, PA; Laird, PW			Cancer epigenetics comes of age	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR GENE; CPG-RICH ISLANDS; DNA METHYLATION; CHROMOSOME INACTIVATION; DENOVO METHYLATION; COLORECTAL-CANCER; WILMS-TUMOR; CELL-LINES; BINDING; HYPERMETHYLATION	The discovery of numerous hypermethylated promoters of tumour-suppressor genes, along with a better understanding of gene-silencing mechanisms, has moved DNA methylation from obscurity to recognition as an alternative mechanism of tumour-suppressor inactivation in cancer. Epigenetic events can also facilitate genetic damage, as illustrated by the increased mutagenicity of 5-methylcytosine and the silencing of the MLH1 mismatch repair gene by DNA methylation in colorectal tumours. We review here current mechanistic understanding of the role of DNA methylation in malignant transformation, and suggest Knudson's two-hit hypothesis should now be expanded to include epigenetic mechanisms of gene inactivation.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA.	jones_p@froggy.hsc.usc.edu; laird_p@froggy.hsc.usc.edu	DeMeester, Tom R/A-4333-2009; Laird, Peter W/G-8683-2012	Laird, Peter W/0000-0001-9117-3641	NCI NIH HHS [R35 CA 49758, R01 CA075090, R01 CA 75090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075090, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 1997, CANCER RES, V57, P3370; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; Batova A, 1997, CANCER RES, V57, P832; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Cunningham JM, 1998, CANCER RES, V58, P3455; FEINBERG AP, 1988, CANCER RES, V48, P1159; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Gonzalgo ML, 1997, CANCER RES, V57, P594; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; GRANT M, 1992, NAT GENET, V2, P161, DOI 10.1038/ng1092-161; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Huang THM, 1997, CANCER RES, V57, P1030; Hussain SP, 1998, CANCER RES, V58, P4023; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jones PA, 1996, CANCER RES, V56, P2463; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, IN PRESS TRENDS GENE; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LARSEN F, 1993, HUM MOL GENET, V2, P775, DOI 10.1093/hmg/2.6.775; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LUBBERT M, 1997, BLOOD S, V90, pA582; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Myohanen SK, 1998, CANCER RES, V58, P591; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NORRIS DP, 1991, MAMM GENOME, V1, P78, DOI 10.1007/BF02443782; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Prowse AH, 1997, AM J HUM GENET, V60, P765; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Rein T, 1998, NUCLEIC ACIDS RES, V26, P2255, DOI 10.1093/nar/26.10.2255; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; SAKAI T, 1991, AM J HUM GENET, V48, P880; SILVERMAN LR, 1998, P AN M AM SOC CLIN, V17, pA14; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Toyota Minoru, 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P95; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; YANG AS, 1996, EPIGENETIC MECH GENE, P77; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Yeivin A, 1993, EXS, V64, P523; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387	74	1892	2043	6	336	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					163	167		10.1038/5947	http://dx.doi.org/10.1038/5947			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988266				2022-12-27	WOS:000078399500016
J	Rossi, FMV; Guicherit, OM; Spicher, A; Kringstein, AM; Fatyol, K; Blakely, BT; Blau, HM				Rossi, FMV; Guicherit, OM; Spicher, A; Kringstein, AM; Fatyol, K; Blakely, BT; Blau, HM			Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16	NATURE GENETICS			English	Article							MAMMALIAN-CELLS; GENE-EXPRESSION; ANTIBIOTIC-RESISTANCE; RETROVIRAL VECTORS; PRIMARY MYOBLASTS; TET REPRESSOR; COMPLEX; SYSTEM; PROMOTERS; DESIGN	Continuous regulation is required to maintain a given cell state(1,2) or to allow it to change in response to the environment(3,4). Studies of the mechanisms underlying such regulation have often been hindered by the inability to control gene expression at will. Among the inducible systems available for regulating gene expression in eukaryotes(5-8), the tetracycline (tet) regulatable system has distinct advantages(9-11). It is highly specific, non-toxic and non-eukaryotic, and consequently does not have pleiotropic effects on host cell genes. Previously this system also had drawbacks, as it did not extinguish gene expression completely, precluding the study of toxic or growth-inhibitory gene products. We report here the development of a facile reversible tetracycline-inducible retroviral system (designated RetroTet-ART) in which activators and repressors together are expressed in cells. Gene expression can now be actively repressed in the absence of tet and induced in the presence of tet, as we have engineered distinct dimerization domains that allow co-expression of homodimeric tet-regulated transactivators and transrepressors in the same cells, without the formation of non-functional heterodimers. Using this system, we show that growth arrest by the cell cycle inhibitor p16 is reversible and dependent on its continuous expression.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Rossi, Fabio MV/B-5587-2013	Rossi, Fabio MV/0000-0002-0368-2620	NCI NIH HHS [CA59717] Funding Source: Medline; NIA NIH HHS [AG09521] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA059717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Dupin E, 1998, CURR TOP DEV BIOL, V36, P1; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GALBRAITH DW, IN PRESS METH CELL B; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kringstein AM, 1998, P NATL ACAD SCI USA, V95, P13670, DOI 10.1073/pnas.95.23.13670; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Poulos NE, 1996, CANCER RES, V56, P1719; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPICHER A, 1994, DEV BIOL, V164, P72, DOI 10.1006/dbio.1994.1181; Springer ML, 1997, SOMAT CELL MOLEC GEN, V23, P203, DOI 10.1007/BF02721371; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; ZHAO J, 1992, MICROBIOL IMMUNOL, V36, P1051, DOI 10.1111/j.1348-0421.1992.tb02109.x	31	91	97	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					389	393		10.1038/3871	http://dx.doi.org/10.1038/3871			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843215				2022-12-27	WOS:000077199600030
J	Rodriguez, I; Greer, CA; Mok, MY; Mombaerts, P				Rodriguez, I; Greer, CA; Mok, MY; Mombaerts, P			A putative pheromone receptor gene expressed in human olfactory mucosa	NATURE GENETICS			English	Article							VOMERONASAL ORGAN; MULTIGENE FAMILY; MAMMALS		Rockefeller Univ, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA	Rockefeller University; Yale University	Mombaerts, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	peter@mail.rockefeller.edu		rodriguez, ivan/0000-0002-6468-0565				Dorries KM, 1997, BRAIN BEHAV EVOLUT, V49, P53, DOI 10.1159/000112981; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HUDSON R, 1986, PHYSIOL BEHAV, V37, P123, DOI 10.1016/0031-9384(86)90394-X; Humphrey T, 1940, J COMP NEUROL, V73, P431, DOI 10.1002/cne.900730305; Johnston RE, 1998, ANN NY ACAD SCI, V855, P333, DOI 10.1111/j.1749-6632.1998.tb10592.x; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1999, CURR OPIN GENET DEV, V9, P315, DOI 10.1016/S0959-437X(99)80047-1; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Saito H, 1998, MOL BRAIN RES, V60, P215, DOI 10.1016/S0169-328X(98)00183-1; STENSAAS LJ, 1991, J STEROID BIOCHEM, V39, P553, DOI 10.1016/0960-0760(91)90252-Z; Stern K, 1998, NATURE, V392, P177, DOI 10.1038/32408	14	166	177	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					18	19		10.1038/79124	http://dx.doi.org/10.1038/79124			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973240				2022-12-27	WOS:000089078000010
J	van Bokhoven, H; Celli, J; Kayserili, H; van Beusekom, E; Balci, S; Brussel, W; Skovby, F; Kerr, B; Percin, EF; Akarsu, N; Brunner, HG				van Bokhoven, H; Celli, J; Kayserili, H; van Beusekom, E; Balci, S; Brussel, W; Skovby, F; Kerr, B; Percin, EF; Akarsu, N; Brunner, HG			Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome	NATURE GENETICS			English	Article							GROWTH-FACTOR RECEPTOR-3; NERVOUS-SYSTEM; DOMAIN; FAMILY; CRANIOSYNOSTOSIS; EXPRESSION; DYSPLASIA; FEATURES	Robinow syndrome is a short-limbed dwarfism characterized by abnormal morphogenesis of the face and external genitalia, and vertebral segmentation(1,2). The recessive form of Robinow syndrome (RRS; OMIM 268310). particularly frequent in Turkey(3-6), has a high incidence of abnormalities of the vertebral column such as hemivertebrae and rib fusions. which is not seen in the dominant form. Some patients have cardiac malformations or facial clefting. We have mapped a gene for RRS to 9q21-q23 in 11 families. Haplotype sharing was observed between three families from Turkey, which localized the gene to a 4.9-cM interval. The gene ROR2, which encodes an orphan membrane-bound tyrosine kinase, maps to this region. Heterozygous (presumed gain of function) mutations in ROR2 were previously shown to cause dominant brachydactyly type B (BDB; ref. 7). In contrast, Ror2(-/-) mice have a short-limbed phenotype that is more reminiscent of the mesomelic shortening observed in RRS. We detected several homozygous ROR2 mutations in our cohort of RRS patients that are located upstream from those previously found in BDB. The ROR2 mutations present in RRS result in premature stop codons and predict nonfunctional proteins.	Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Istanbul Univ, Istanbul Fac Med, Div Med Genet, Dept Pediat, Istanbul, Turkey; Hacettepe Univ, Inst Child Hlth, Div Clin Genet, Ankara, Turkey; Rijnstate Hosp, Dept Pediat, Arnhem, Netherlands; Rigshosp, Dept Clin Genet, Copenhagen, Denmark; Royal Manchester Childrens Hosp, Reg Genet Serv, Manchester, Lancs, England; Cumhuriye Univ, Dept Med Biol & Genet, Sivas, Turkey	Radboud University Nijmegen; Istanbul University; Hacettepe University; Rijnstate Hospital; Rigshospitalet; University of Copenhagen; Royal Manchester Children's Hospital; Cumhuriyet University	Brunner, HG (corresponding author), Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.	h.brunner@antrg.azn.nl	van Bokhoven, Hans/D-8764-2012; Bokhoven, J.H.L.M. van van/H-8015-2014; Kayserili, Hülya/AAA-5593-2021; Percin, Ferda E/H-6850-2016; Akarsu, Nurten/E-9758-2013; van Beusekom, Ellen/AAF-2687-2019; Brunner, Han/C-9928-2013	Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Kayserili, Hülya/0000-0003-0376-499X; Percin, Ferda E/0000-0001-9317-8155; Akarsu, Nurten/0000-0001-5432-0032; 				Aksit S, 1997, CLIN GENET, V52, P226; Atalay S, 1993, Clin Dysmorphol, V2, P208; Balci S, 1993, Clin Dysmorphol, V2, P199; Balci S, 1998, AM J MED GENET, V79, P27, DOI 10.1002/(SICI)1096-8628(19980827)79:1<27::AID-AJMG7>3.0.CO;2-F; Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; BUTLER MG, 1987, CLIN GENET, V31, P77; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KREMER H, 1994, HUM MOL GENET, V3, P299, DOI 10.1093/hmg/3.2.299; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; ROBINOW M, 1969, AM J DIS CHILD, V117, P645, DOI 10.1001/archpedi.1969.02100030647005; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	30	203	213	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					423	426		10.1038/78113	http://dx.doi.org/10.1038/78113			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932187				2022-12-27	WOS:000088615000018
J	Anson-Cartwright, L; Dawson, K; Holmyard, D; Fisher, SJ; Lazzarini, RA; Cross, JC				Anson-Cartwright, L; Dawson, K; Holmyard, D; Fisher, SJ; Lazzarini, RA; Cross, JC			The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta	NATURE GENETICS			English	Article							TRANSCRIPTION FACTORS; MOUSE; DROSOPHILA; DIFFERENTIATION; EXPRESSION; GENE; IMPLANTATION; SWITCH; GCM1	Trophoblast cells of the placenta are established at the blastocyst stage and differentiate into specialized subtypes after implantation(1,2). In mice, the outer layer of the placenta consists of trophoblast giant cells that invade the uterus and promote maternal blood flow to the implantation site by producing cytokines with angiogenic(3) and vasodilatory(4) actions. The innermost layer, called the labyrinth, consists of branched villi that provide a large surface area for nutrient transport and are composed of trophoblast cells and underlying mesodermal cells derived from the allantois. The chorioallantoic villi develop after embryonic day (E) 8.5 through extensive folding and branching of an initially flat sheet of trophoblast cells, the chorionic plate, in response to contact with the allantois. We show here that Gcm1. encoding the transcription factor glial cells missing-1 (Gcm1). is expressed in small clusters of chorionic trophoblast cells at the flat chorionic plate stage and at sites of chorioallantoic folding and extension when morphogenesis begins. Mutation of Gcm1 in mice causes a complete block to branching of the chorioallantoic interface, resulting in embryonic mortality by E10 due to the absence of the placental labyrinth. In addition, chorionic trophoblast cells in Gcm1-deficient placentas do not fuse to form syncytiotrophoblast. Abnormal development of placental villi is frequently associated with fetal death and intrauterine growth restriction in humans, and our studies provide the earliest molecular insight into this aspect of placental development.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA; Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY USA; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; University of Toronto; University of Toronto	Cross, JC (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Genes & Dev Res Grp, Calgary, AB, Canada.		Cross, James/F-4814-2011; Cross, James/AAU-2973-2020	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378				Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BECKER M, 1995, CREATIVITY RES J, V8, P219, DOI 10.1207/s15326934crj0803_2; Bernardoni R, 1998, DEVELOPMENT, V125, P3189; Bernardoni R, 1997, DEV BIOL, V191, P118; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, IN PRESS SEMIN CELL; Cross JC, 1996, FETAL MATERNAL MED R, V8, P57, DOI DOI 10.1017/S0965539500001492; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HERNANDE.D, 1974, CELL TISSUE RES, V148, P381; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; Jacquemin P, 1998, DEV DYNAM, V212, P423, DOI 10.1002/(SICI)1097-0177(199807)212:3<423::AID-AJA10>3.0.CO;2-1; Janatpour MJ, 1999, DEV GENET, V25, P146, DOI 10.1002/(SICI)1520-6408(1999)25:2<146::AID-DVG9>3.0.CO;2-K; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Wurst W., 1993, Gene targeting: a practical approach., P33; Yotsumoto S, 1998, DEV BIOL, V203, P264, DOI 10.1006/dbio.1998.9073	30	312	322	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					311	314		10.1038/77076	http://dx.doi.org/10.1038/77076			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888880				2022-12-27	WOS:000087920900020
J	Avela, K; Lipsanen-Nyman, M; Idanheimo, N; Seemanova, E; Rosengren, S; Makela, TP; Perheentupa, J; de la Chapelle, A; Lehesjoki, AE				Avela, K; Lipsanen-Nyman, M; Idanheimo, N; Seemanova, E; Rosengren, S; Makela, TP; Perheentupa, J; de la Chapelle, A; Lehesjoki, AE			Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism	NATURE GENETICS			English	Article							NUCLEAR RECEPTORS; WILMS-TUMOR; IN-VIVO; FINGER; EXPRESSION; DOMAIN; IDENTIFICATION; MUTATIONS; PRODUCT; DISEASE	Mulibrey nanism (for muscle-liver-brain-eye nanism, MUL; MIM 253250) is an autosomal recessive disorder that involves several tissues of mesodermal origin, implying a defect in a highly pleiotropic gene(1). Characteristic features include severe growth failure of prenatal onset and constrictive pericardium with consequent hepatomegaly(1-3). In addition, muscle hypotonia, J-shaped sella turcica, yellowish dots in the ocular fundi, typical dysmorphic features and hypoplasia of various endocrine glands causing hormonal deficiency are (1-3). About 4% of RAUL patients develop Wilms' common tumour(2,4,5). MUL is enriched in the Finnish population, but is rare elsewhere(1-3). We previously assigned MUL to chromosome 17q22-q23 and constructed a physical contig over the critical MUL region(6,7). The region has now been further refined by haplotype analysis and new positional candidate genes have been localized. We identified a gene with four independent MUL-associated mutations that all cause a frameshift and predict a truncated protein. MUL is ubiquitously expressed and encodes a new member of the RINC-B-box-Coiled-coil (RBCC) family of zinc-finger proteins(8-10), whose members are involved in diverse cellular functions such as developmental patterning and oncogenesis.	Folkhalsan Inst Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Hosp Children & Adolescents, FIN-00014 Helsinki, Finland; Charles Univ, Sch Med 2, Inst Biol & Med Genet, Prague, Czech Republic; Univ Connecticut, Sch Med, Farmington, CT USA; Univ Helsinki, Bioctr, FIN-00014 Helsinki, Finland; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; University of Helsinki; Charles University Prague; University of Connecticut; University of Helsinki; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Avela, K (corresponding author), Folkhalsan Inst Genet, Helsinki, Finland.		makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Lipsanen-Nyman, Marita/0000-0003-4959-2310	NCI NIH HHS [P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Avela K, 1997, AM J HUM GENET, V60, P896; Bernot A, 1997, NAT GENET, V17, P25; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1993, FEBS LETT, V335, P255, DOI 10.1016/0014-5793(93)80741-C; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; COOPER DN, 1991, HUM GENET, V87, P409; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dow MR, 1998, GENETICS, V150, P119; LAPUNZINA P, 1995, AM J MED GENET, V55, P349, DOI 10.1002/ajmg.1320550320; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LIPSANENNYMAN M, 1986, THESIS U HELSINKI; Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Paavola P, 1999, GENOME RES, V9, P267; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; PERHEENTUPA J, 1973, LANCET, V2, P351, DOI 10.1016/S0140-6736(73)93193-0; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Seemanova E, 1999, AM J MED GENET, V85, P76, DOI 10.1002/(SICI)1096-8628(19990702)85:1<76::AID-AJMG12>3.0.CO;2-Z; SIMILA S, 1980, CLIN GENET, V17, P29; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	31	124	127	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					298	301		10.1038/77053	http://dx.doi.org/10.1038/77053			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888877				2022-12-27	WOS:000087920900017
J	Ferguson, JN; Young, LJ; Hearn, EF; Matzuk, MM; Insel, TR; Winslow, JT				Ferguson, JN; Young, LJ; Hearn, EF; Matzuk, MM; Insel, TR; Winslow, JT			Social amnesia in mice lacking the oxytocin gene	NATURE GENETICS			English	Article							OLFACTORY-BULB; NEUROHYPOPHYSEAL PEPTIDES; MATERNAL-BEHAVIOR; MALE-MOUSE; RECOGNITION; RATS; MEMORY; VASOPRESSIN; MODULATION; LESIONS	The development of social familiarity in rodents depends predominantly on olfactory cues and can critically influence reproductive success(1,2). Researchers have operationally defined this memory by a reliable decrease in olfactory investigation in repeated or prolonged encounters with a conspecific(3-6). Brain oxytocin (OT) and vasopressin (AVP) seem to modulate a range of social behaviour from parental care to mate guarding(7). Pharmacological studies indicate that AVP administration may enhance social memory(8-10), whereas OT administration may either inhibit or facilitate social memory depending on dose, route or paradigm(1,11-13). We found that male mice mutant for the oxytocin gene (Oxt(-/-)) failed to develop social memory, whereas wild-type (Oxt(+/+)) mice showed intact social memory. Measurement of both olfactory foraging and olfactory habituation tasks indicated that olfactory detection of non-social stimuli is intact in Oxt(-/-) mice. Spatial memory and behavioural inhibition measured in a Morris water-maze, Y-maze. or habituation of an acoustic startle also seemed intact. Treatment with OT but not AVP rescued social memory in Oxt(-/-) mice, and treatment with an OT antagonist produced a social amnesia-like effect in Oxt(+/+) mice. Our data indicate that OT is necessary for the normal development of social memory in mice and support the hypothesis that social memory has a neural basis distinct from other forms of memory.	Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Ctr Behav Neurosci, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA	Emory University; Emory University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Winslow, JT (corresponding author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Ctr Behav Neurosci, Atlanta, GA 30322 USA.		Young, Larry/HGE-5031-2022		NCRR NIH HHS [RR0016] Funding Source: Medline; NICHD NIH HHS [HD33438] Funding Source: Medline; PHS HHS [R01M56538-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033438] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD033438] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENELLI A, 1995, NEUROPEPTIDES, V28, P251, DOI 10.1016/0143-4179(95)90029-2; Contarino A, 1999, BRAIN RES, V835, P1, DOI 10.1016/S0006-8993(98)01158-5; DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192; Dantzer R, 1998, PROG BRAIN RES, V119, P409; Dluzen DE, 1998, NEUROSCI LETT, V254, P161, DOI 10.1016/S0304-3940(98)00691-0; DLUZEN DE, 1993, BRAIN RES, V609, P98, DOI 10.1016/0006-8993(93)90860-P; Engelmann M, 1998, BEHAV BRAIN RES, V90, P89, DOI 10.1016/S0166-4328(97)00084-3; Engelmann M, 1996, NEUROSCI BIOBEHAV R, V20, P341, DOI 10.1016/0149-7634(95)00059-3; GHEUSI G, 1994, BEHAV PROCESS, V33, P59, DOI 10.1016/0376-6357(94)90060-4; Insel TR, 1998, ADV EXP MED BIOL, V449, P215; JIRIKOWSKI GF, 1991, CELL TISSUE RES, V266, P399, DOI 10.1007/BF00318196; Kendrick KM, 1997, BRAIN RES BULL, V44, P383, DOI 10.1016/S0361-9230(97)00218-9; Keverne EB, 1996, J PHYSIOLOGY-PARIS, V90, P399, DOI 10.1016/S0928-4257(97)87929-6; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Kubota Y, 1996, MOL CELL ENDOCRINOL, V124, P25, DOI 10.1016/S0303-7207(96)03923-8; LEVY F, 1995, BRAIN RES, V669, P197, DOI 10.1016/0006-8993(94)01236-B; MENCIOWSZALEK T, 1992, BEHAV NEURAL BIOL, V57, P205, DOI 10.1016/0163-1047(92)90164-Y; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; PAOLINI AG, 1993, NEUROSCIENCE, V57, P717, DOI 10.1016/0306-4522(93)90017-A; Paolini AG, 1996, BEHAV BRAIN RES, V81, P223, DOI 10.1016/S0166-4328(96)89082-6; Popik P, 1991, Eur Neuropsychopharmacol, V1, P555, DOI 10.1016/0924-977X(91)90010-R; POPIK P, 1992, BEHAV PHARMACOL, V3, P351; Popik P, 1998, PROG BRAIN RES, V119, P415; POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591; POPIK P, 1991, NEUROPEPTIDES, V18, P23, DOI 10.1016/0143-4179(91)90159-G; POPIK P, 1993, EUR NEUROPSYCHOPHARM, V30, P200; Smith CP, 1997, J PHARMACOL EXP THER, V280, P710; THOR DH, 1981, ANIM LEARN BEHAV, V9, P28; WINSLOW JT, 1995, PSYCHOPHARMACOLOGY, V121, P164, DOI 10.1007/BF02245626; Yu GZ, 1996, NEUROSCIENCE, V72, P1083, DOI 10.1016/0306-4522(95)00600-1	30	772	789	2	119	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					284	288		10.1038/77040	http://dx.doi.org/10.1038/77040			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888874				2022-12-27	WOS:000087920900014
J	Escayg, A; MacDonald, BT; Meisler, MH; Baulac, S; Huberfeld, G; An-Gourfinkel, I; Brice, A; LeGuern, E; Moulard, B; Chaigne, D; Buresi, C; Malafosse, A				Escayg, A; MacDonald, BT; Meisler, MH; Baulac, S; Huberfeld, G; An-Gourfinkel, I; Brice, A; LeGuern, E; Moulard, B; Chaigne, D; Buresi, C; Malafosse, A			Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2	NATURE GENETICS			English	Article							GENERALIZED EPILEPSY; FEBRILE SEIZURES		Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Hop La Pitie Salpetriere, INSERM, U289, Paris, France; Hop La Pitie Salpetriere, Ctr Epilepsie, Paris, France; Genethon, Evry, France; Hop Univ Geneve, Div Neuropsychiat, Chene Bourg, Switzerland; Clin St Odile, Strasbourg, France	University of Michigan System; University of Michigan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Geneva	Meisler, MH (corresponding author), Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.		brice, alexis/AAE-8275-2019; Baulac, Stéphanie/O-2099-2016; Brice, Alexis/A-2170-2009	brice, alexis/0000-0002-0941-3990; Baulac, Stéphanie/0000-0001-6430-4693; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34509] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baulac S, 1999, AM J HUM GENET, V65, P1078, DOI 10.1086/302593; Bulman DE, 1997, HUM MOL GENET, V6, P1679, DOI 10.1093/hmg/6.10.1679; Catterall W A, 1999, Adv Neurol, V79, P441; ESCAYG A, IN PRESS AM J HUM GE; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; LEHMANNHORN F, 1999, PHYSIOL REV, V79, P137; Lopes-Cendes I, 2000, AM J HUM GENET, V66, P698, DOI 10.1086/302768; Moulard B, 1999, AM J HUM GENET, V65, P1396, DOI 10.1086/302621; NODA M, 1987, J RECEPTOR RES, V7, P467, DOI 10.3109/10799898709054998; Peiffer A, 1999, ANN NEUROL, V46, P671, DOI 10.1002/1531-8249(199910)46:4<671::AID-ANA20>3.0.CO;2-5; Plummer NW, 1999, GENOMICS, V57, P323, DOI 10.1006/geno.1998.5735; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Smith RD, 1998, J NEUROSCI, V18, P811; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wattanasirichaigoon D, 1999, AM J MED GENET, V86, P470, DOI 10.1002/(SICI)1096-8628(19991029)86:5<470::AID-AJMG13>3.0.CO;2-Y	15	758	799	1	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					343	345		10.1038/74159	http://dx.doi.org/10.1038/74159			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742094				2022-12-27	WOS:000086192800010
J	Moseley, ML; Schut, LJ; Bird, TD; Day, JW; Ranum, LPW				Moseley, ML; Schut, LJ; Bird, TD; Day, JW; Ranum, LPW			Large, expanded repeats in SCA8 are not confined to patients with cerebellar ataxia - Reply	NATURE GENETICS			English	Letter									Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Dept Vet Affairs Med Ctr, Seattle, WA USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Ranum, LPW (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.							Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; Moseley ML, 1999, AM J HUM GENET, V65, pA462; Stevanin G, 2000, NAT GENET, V24, P213, DOI 10.1038/73408; Worth PF, 2000, NAT GENET, V24, P214, DOI 10.1038/73411	5	11	11	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					215	215		10.1038/73415	http://dx.doi.org/10.1038/73415			1	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700169	Bronze			2022-12-27	WOS:000085590600008
J	Matsuo, K; Owens, JM; Tonko, M; Elliott, C; Chambers, TJ; Wagner, EF				Matsuo, K; Owens, JM; Tonko, M; Elliott, C; Chambers, TJ; Wagner, EF			Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation	NATURE GENETICS			English	Article							TERMINAL TRANSACTIVATION DOMAIN; ACTIVATION DOMAINS; BINDING PROTEIN; CELL-GROWTH; FRA-1 GENE; TRANSFORMATION; LIGAND; CYTOKINE; REQUIRES; MOUSE	Osteoclasts are bone-resorbing cells derived from haematopoietic precursors of the monocyte-macrophage lineage. Mice lacking Fos (encoding c-Fos) develop osteopetrosis due to an early differentiation block in the osteoclast lineage(1-3), c-Fos is a component of the dimeric transcription factor activator protein-1 (Ap-1), which is composed mainly of Fos (c-Fos, FosB, Fra-1 and Fra-2) and Jun proteins (c-Jun, JunB and JunD). Unlike Fra-1 (encoded by Fos/1), c-Fos contains transactivation domains required for oncogenesis and cellular transformation(4-6). The mechanism by which c-Fos exerts its specific function in osteoclast differentiation is not understood. Here we show by retroviral-gene transfer that all four Fos proteins, hut not the Jun proteins, rescue the differentiation block in vitro. Structure-function analysis demonstrated that the major carboxy-terminal transactivation domains of c-Fos and FosB are dispensable and that Fra-1 (which lacks transactivation domains(4,7)) has the highest rescue activity. Moreover, a transgene expressing Fra-1 rescues the osteopetrosis of c-fos-mutant mice in vivo. The osteoclast differentiation factor Rankl (also known as TRANCE, CUE and OPGL; refs 8-11) induces transcription of Fos/1 in a c-fos-dependent manner, thereby establishing a link between Rank signalling and the expression of Ap-1 proteins in osteoclast differentiation.	Res Inst Mol Pathol, A-1030 Vienna, Austria; St George Hosp, Sch Med, Dept Histopathol, London, England	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); St Georges University London	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Matsuo, Koichi/K-5695-2012; Elliott, Candace/F-1860-2011	Matsuo, Koichi/0000-0002-1490-8955; Elliott, Candace/0000-0002-9174-0244; Wagner, Erwin F/0000-0001-7872-0196				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LIVAK KJ, 1995, PCR METH APPL, V4, P357; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; WANG SJ, 1992, J OPT SOC AM B, V9, P360, DOI 10.1364/JOSAB.9.000360; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	30	266	276	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					184	187		10.1038/72855	http://dx.doi.org/10.1038/72855			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655067				2022-12-27	WOS:000085104600022
J	Jensen, J; Pedersen, EE; Galante, P; Hald, J; Heller, RS; Ishibashi, M; Kageyama, R; Guillemot, F; Serup, P; Madsen, OD				Jensen, J; Pedersen, EE; Galante, P; Hald, J; Heller, RS; Ishibashi, M; Kageyama, R; Guillemot, F; Serup, P; Madsen, OD			Control sf endodermal endocrine development by Hes-1	NATURE GENETICS			English	Article							HELIX TRANSCRIPTION FACTOR; EPITHELIAL-MESENCHYMAL INTERACTIONS; ACHAETE-SCUTE HOMOLOG-1; SEX DETERMINATION; NERVOUS-SYSTEM; BETA-CELLS; DIFFERENTIATION; DROSOPHILA; GENE; PANCREAS	Development of endocrine cells in the endoderm involves Atonal and Achaete/Scute-related basic helix-loop-helix (bHLH) proteins. These proteins also serve as neuronal determination and differentiation factors, and are antagonized by the Notch pathway partly acting through Hairy and Enhancer-of-split (HES)-type proteins. Here we show that mice deficient in Hes1 (encoding Hes-1) display severe pancreatic hypoplasia caused by depletion of pancreatic epithelial precursors due to accelerated differentiation of post-mitotic endocrine cells expressing glucagon. Moreover, upregulation of several bHLH components is associated with precocious and excessive differentiation of multiple endocrine cell types in the developing stomach and gut, showing that Hes-1 operates as a general negative regulator of endodermal endocrine differentiation.	Hagedorn Res Lab, Dept Dev Biol, Gentofte, Denmark; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Strasbourg, France	Novo Nordisk; Hagedorn Research Institute; Kyoto University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Madsen, OD (corresponding author), Hagedorn Res Lab, Dept Dev Biol, Gentofte, Denmark.	ODM@Novo.dk	Serup, Palle/A-7407-2011; Madsen, Ole D./A-7415-2011; Guillemot, Francois/AAV-1482-2021; Heller, R.Scott/A-7279-2008	Serup, Palle/0000-0002-0858-590X; Madsen, Ole D./0000-0002-2753-5203; Jensen, Jan/0000-0003-0657-4032	NIDDK NIH HHS [DK-55284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BARBASH DA, 1995, GENETICS, V141, P1451; Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Cau E, 1997, DEVELOPMENT, V124, P1611; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DESHPANDE G, 1995, MOL CELL BIOL, V15, P4430; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HOGAN B, 1994, MANIPULATING MOUSE E, P303; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JENSEN J, IN PRESS DIABETES; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Larsson LI, 1998, MECH DEVELOP, V79, P153, DOI 10.1016/S0925-4773(98)00182-8; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Offield MF, 1996, DEVELOPMENT, V122, P983; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; Pabst O, 1997, DEV DYNAM, V209, P29; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; Robb L, 1998, DEV DYNAM, V213, P105, DOI 10.1002/(SICI)1097-0177(199809)213:1<105::AID-AJA10>3.0.CO;2-1; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Valsecchi V, 1997, MECH DEVELOP, V69, P203, DOI 10.1016/S0925-4773(97)00146-9; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5	48	866	898	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					36	44		10.1038/71657	http://dx.doi.org/10.1038/71657			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615124				2022-12-27	WOS:000084609200012
J	Fisher, S; Halpern, ME				Fisher, S; Halpern, ME			Patterning the zebrafish axial skeleton requires early chordin function	NATURE GENETICS			English	Article							BONE MORPHOGENETIC PROTEINS; SONIC HEDGEHOG; EMBRYO; GENE; ORGANIZER; MICE; MSX2; EXPRESSION; INDUCTION; DOMAINS	Members of the bone morphogenetic protein (BMP) family actively promote ventral cell fates, such as epidermis and blood, in the vertebrate gastrula. More dorsally, the organizer region counteracts BMP signalling through secretion of BMP-binding antagonists chordin and noggin, allowing dorsally derived tissues such as neurectoderm and semitic muscle to develop(1). BMPs also function in skeletal development and regeneration of bone following injury(2). Noggin antagonism is thought to prevent osteogenesis at sites of joint formation(3), whereas chordin has not yet been implicated in skeletogenesis. Analyses of zebrafish mutants have confirmed the action of chordin (chd) in opposing ventralizing signals at gastrulation(4-6). Some ventralized mutants recover and develop into fertile adults, thereby revealing a requirement for chd function for the later processes of fin and caudal skeletal patterning. We observe in mutants the misexpression of genes encoding BMPs and putative downstream genes, and ectopic sclerotomal cells. Through injections of chd mRNA into the early embryo, we restored wild-type gene expression patterns, and the resultant fish, although genotypically mutant, developed normal axial skeletons and fins. Our results demonstrate that chordin function during gastrulation is important for the correct morphogenesis of the adult zebrafish skeleton.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Fisher, S (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001851] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01851-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; Ashe HL, 1999, NATURE, V398, P427, DOI 10.1038/18892; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Connors SA, 1999, DEVELOPMENT, V126, P3119; Fisher S, 1997, DEVELOPMENT, V124, P1301; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JOLY JS, 1993, DEVELOPMENT, V119, P1261; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Maeda R, 1997, DEVELOPMENT, V124, P2553; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Miller-Bertaglio V, 1999, DEV BIOL, V214, P72, DOI 10.1006/dbio.1999.9384; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; MonsoroBurq AH, 1996, DEVELOPMENT, V122, P3607; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Teillet MA, 1998, DEVELOPMENT, V125, P2019; Thomsen GH, 1997, TRENDS GENET, V13, P209, DOI 10.1016/S0168-9525(97)01117-7; Westerfield M, 1995, ZEBRAFISH BOOK; Winograd J, 1997, HUM MOL GENET, V6, P369, DOI 10.1093/hmg/6.3.369	30	82	82	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					442	446		10.1038/70557	http://dx.doi.org/10.1038/70557			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581032				2022-12-27	WOS:000084023900021
J	Papadopoulou, LC; Sue, CM; Davidson, MM; Tanji, K; Nishino, I; Sadlock, JE; Krishna, S; Walker, W; Selby, J; Glerum, DM; Van Coster, R; Lyon, G; Scalais, E; Lebel, R; Kaplan, P; Shanske, S; De Vivo, DC; Bonilla, E; Hirano, M; DiMauro, S; Schon, EA				Papadopoulou, LC; Sue, CM; Davidson, MM; Tanji, K; Nishino, I; Sadlock, JE; Krishna, S; Walker, W; Selby, J; Glerum, DM; Van Coster, R; Lyon, G; Scalais, E; Lebel, R; Kaplan, P; Shanske, S; De Vivo, DC; Bonilla, E; Hirano, M; DiMauro, S; Schon, EA			Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene	NATURE GENETICS			English	Article							CYTOCHROME-C-OXIDASE; MITOCHONDRIAL COPPER RECRUITMENT; SACCHAROMYCES-CEREVISIAE; SUBUNIT-II; FUNCTIONAL COMPLEMENTATION; MOLECULAR ANALYSIS; LEIGHS SYNDROME; NUCLEAR; PROTEIN; ACCUMULATION		Columbia Univ, Dept Neurol, New York, NY 10027 USA; Aristotle Univ Thessaloniki, Dept Pharmaceut Sci, Thessaloniki, Macedonia, Greece; Columbia Univ, Dept Pediat, New York, NY USA; Columbia Univ, Dept Pathol, New York, NY USA; Columbia Univ, Dept Genet & Dev, New York, NY USA; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada; State Univ Ghent Hosp, Kinderklin C Hoopt, Ghent, Belgium; Clin St Vincent, Liege, Belgium; Genet Serv Inc, Glen Ellyn, IL USA; Childrens Hosp Philadelphia, Div Metab, Philadelphia, PA 19104 USA	Columbia University; Aristotle University of Thessaloniki; Columbia University; Columbia University; Columbia University; University of Alberta; Ghent University; Ghent University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Schon, EA (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10027 USA.		Glerum, Moira/AHD-3271-2022; Nishino, Ichizo/G-2676-2010	Nishino, Ichizo/0000-0001-9452-112X; Hirano, Michio/0000-0002-7070-7402	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, R01NS028828, R01NS032527, P50NS011766] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32527, NS28828, NS11766] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams PL, 1997, ANN NEUROL, V41, P268, DOI 10.1002/ana.410410219; Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209; DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; DIMAURO S, 1994, MITOCHONDRIAL DISORD, P91; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; LOMBES A, 1991, NEUROLOGY, V41, P491, DOI 10.1212/WNL.41.4.491; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MERANTE F, 1993, AM J HUM GENET, V53, P481; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580; PREISS T, 1993, J BIOL CHEM, V268, P10659; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2; TAANMAN JW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P155, DOI 10.1016/0925-4439(92)90095-5; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	29	447	450	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					333	337						5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545952				2022-12-27	WOS:000083792200024
J	Hurvitz, JR; Suwairi, WM; Van Hul, W; El-Shanti, H; Superti-Furga, A; Roudier, J; Holderbaum, D; Pauli, RM; Herd, JK; Van Hul, E; Rezai-Delui, H; Legius, E; Le Merrer, M; Al-Alami, J; Bahabri, SA; Warman, ML				Hurvitz, JR; Suwairi, WM; Van Hul, W; El-Shanti, H; Superti-Furga, A; Roudier, J; Holderbaum, D; Pauli, RM; Herd, JK; Van Hul, E; Rezai-Delui, H; Legius, E; Le Merrer, M; Al-Alami, J; Bahabri, SA; Warman, ML			Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia	NATURE GENETICS			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; CHILDHOOD PPAC; CYR61; EXPRESSION; PRODUCT; CELLS; MOUSE; DISORDER; IDENTIFICATION	Members of the CCN (for CTGF; cyr61/cef10, nov) gene family encode cysteine-rich secreted proteins with roles in cell growth and differentiation(1). Cell-specific and tissue-specific differences in the expression and function of different CCN family members suggest they have non-redundant roles. Using a positional-candidate approach, we found that mutations in the CCN family member WISP3 are associated with the autosomal recessive skeletal disorder progressive pseudorheumatoid dysplasia (PPD; MIM 208230). PPD is an autosomal recessive disorder that may be initially misdiagnosed as juvenile rheumatoid arthritis(2-5). Its population incidence has been estimated at 1 per million in the United Kingdom(4), but it is likely to be higher in the Middle East and Gulf States(6). Affected individuals are asymptomatic in early childhood(2, 3). Signs and symptoms of disease typically develop between three and eight years of age. Clinically and radiographically, patients experience continued cartilage loss and destructive bone changes as they age(2-7), in several instances necessitating joint replacement surgery by the third decade of life. Extraskeletal manifestations have not been reported in PPD. Cartilage appears to he the primary affected tissue, and in one patient, a biopsy of the iliac crest revealed abnormal nests of chondrocytes and loss of normal cell columnar organization in growth zones(5). We have identified nine different WISP3 mutations in unrelated, affected individuals, indicating that the gene is essential for normal post-natal skeletal growth and cartilage homeostasis.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Div Rheumatol, Cleveland, OH 44106 USA; Royal Mil Hosp, Dept Pediat, Riyadh, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia; Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Jordan Univ Sci & Technol, Dept Pediat, Irbid, Jordan; Jordan Univ Sci & Technol, Dept Med Lab Sci, Irbid, Jordan; Jordan Univ Sci & Technol, Dept Biochem, Irbid, Jordan; Univ Zurich, Dept Pediat, Div Mol Pediat, Zurich, Switzerland; Univ Mediterranee, INSERM E9940, Marseille, France; Univ Wisconsin, Childrens Hosp, Div Genet, Madison, WI 53706 USA; E Tennessee State Univ, James H Quillen Coll Med, Dept Pediat, Johnson City, TN 37614 USA; Mashad Univ, Ghaen Hosp, Dept Radiol, Mashad, Iran; Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; Hop Necker Enfants Malad, Dept Genet, Paris, France; Hop Necker Enfants Malad, INSERM U393, Paris, France	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Prince Sultan Military Medical City; King Faisal Specialist Hospital & Research Center; University of Antwerp; Jordan University of Science & Technology; Jordan University of Science & Technology; Jordan University of Science & Technology; University of Zurich; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Children's Hospital of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; East Tennessee State University; Universite Catholique Louvain; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Warman, ML (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.		superti-furga, andrea/E-9162-2015; Legius, Eric/H-1735-2011; roudier, jean/A-8654-2011; El-Shanti, Hatem/O-5990-2014; EL-SHANTI, HATEM/Q-4932-2016	superti-furga, andrea/0000-0002-3543-7531; roudier, jean/0000-0001-5435-8567; El-Shanti, Hatem/0000-0001-6230-8316; EL-SHANTI, HATEM/0000-0001-6230-8316; Van Hul, Wim/0000-0002-5065-7858	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043827] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43827] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Carrel L, 1996, HUM MOL GENET, V5, P391, DOI 10.1093/hmg/5.3.391; Dale TC, 1998, BIOCHEM J, V329, P209; El-Shanti H, 1998, EUR J HUM GENET, V6, P251, DOI 10.1038/sj.ejhg.5200187; ElShanti HE, 1997, J MED GENET, V34, P559, DOI 10.1136/jmg.34.7.559; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fischer J, 1998, HUM GENET, V103, P60, DOI 10.1007/s004390050784; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KOZLOWSKI K, 1986, Australasian Radiology, V30, P244, DOI 10.1111/j.1440-1673.1986.tb01748.x; LEGIUS E, 1993, CLIN GENET, V44, P152; Martinerie C, 1996, ONCOGENE, V12, P1479; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Parr BA, 1998, DEV BIOL, V202, P228, DOI 10.1006/dbio.1998.9007; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; REZAIDELUI H, 1994, SKELETAL RADIOL, V23, P411; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Schutze N, 1998, ENDOCRINOLOGY, V139, P1761, DOI 10.1210/en.139.4.1761; SPRANGER J, 1983, EUR J PEDIATR, V140, P34, DOI 10.1007/BF00661902; TEEBI AS, 1986, J MED GENET, V23, P189, DOI 10.1136/jmg.23.2.189-a; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; WYNNEDAVIES R, 1982, J BONE JOINT SURG BR, V64, P442, DOI 10.1302/0301-620X.64B4.6807993; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	33	200	219	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					94	98		10.1038/12699	http://dx.doi.org/10.1038/12699			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471507				2022-12-27	WOS:000082337300024
J	Halushka, MK; Fan, JB; Bentley, K; Hsie, L; Shen, NP; Weder, A; Cooper, R; Lipshutz, R; Chakravarti, A				Halushka, MK; Fan, JB; Bentley, K; Hsie, L; Shen, NP; Weder, A; Cooper, R; Lipshutz, R; Chakravarti, A			Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis	NATURE GENETICS			English	Article							HUMAN-GENOME; ESSENTIAL-HYPERTENSION; LINKAGE; RECOMBINATION; DIVERSITY; GENETICS; DISEASES; CLUSTER; GLOBIN; ARRAYS	Sequence variation in human genes is largely confined to single-nucleotide polymorphisms (SNPs) and is valuable in tests of association with common diseases and pharmacogenetic traits. We performed a systematic and comprehensive survey of molecular variation to assess the nature, pattern and frequency of SNPs in 75 candidate human genes for blood-pressure homeostasis and hypertension. We assayed 28 Mb(190 kb in 148 alleles) of genomic sequence, comprising the 5' and 3' untranslated regions (UTRs), introns and coding sequence of these genes, for sequence differences in individuals of African and Northern European descent using high-density variant detection arrays (VDAs). We identified 874 candidate human SNPs, of which 22% were confirmed by DNA sequencing to reveal a discordancy rate of 21% for VDA detection. The SNPs detected have an average minor allele frequency of 11%, and 387 are within the coding sequence (cSNPs). Of all cSNPs, 54% lead to a predicted change in the protein sequence, implying a high level of human protein diversity. These protein-altering SNPs are 38% of the total number of such SNPs expected, are more likely to be population-specific and are rarer in the human population, directly demonstrating the effects of natural selection on human genes. Overall, the degree of nucleotide polymorphism across these human genes, and orthologous great ape sequences, is highly variable and is correlated with the effects of functional conservation on gene sequences.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Loyola Univ, Med Ctr, Dept Epidemiol, Maywood, IL 60153 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Affymetrix; University of Michigan System; University of Michigan; Loyola University Chicago	Chakravarti, A (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.			Halushka, Marc/0000-0002-7112-7389	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL054466] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001847] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG01847] Funding Source: Medline; NHLBI NIH HHS [U10 HL54466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHAKRAVARTI A, 1984, P NATL ACAD SCI-BIOL, V81, P6085, DOI 10.1073/pnas.81.19.6085; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Chakravarti A, 1998, NAT GENET, V19, P216, DOI 10.1038/885; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; CHARLESWORTH B, 1993, GENETICS, V134, P1289; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Harding RM, 1997, AM J HUM GENET, V60, P772; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; HARRIS H, 1966, PROC R SOC SER B-BIO, V164, P298, DOI 10.1098/rspb.1966.0032; HARRIS H, 1972, ANN HUM GENET, V36, P9, DOI 10.1111/j.1469-1809.1972.tb00578.x; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JORDE LB, 1994, AM J HUM GENET, V54, P884; Kaplan NM, 1994, CLIN HYPERTENSION; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; KURTZ TW, 1993, AM J MED, V94, P77, DOI 10.1016/0002-9343(93)90124-8; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, GENETICS, V129, P513; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MOCKRIN SC, 1996, MOL GENETICS GENE TH; Nachman MW, 1998, GENETICS, V150, P1133; Nei M., 1987, MOL EVOLUTIONARY GEN; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WARD R, 1990, HYPERTENSION PATHOPH, P81; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626	44	799	938	0	68	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					239	247		10.1038/10297	http://dx.doi.org/10.1038/10297			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391210				2022-12-27	WOS:000081125900015
J	Nef, S; Parada, LF				Nef, S; Parada, LF			Cryptorchidism in mice mutant for Insl3	NATURE GENETICS			English	Article							TESTICULAR DESCENT; HORMONAL-CONTROL; CELLS; GUBERNACULUM; EXPRESSION; RECEPTOR; NEURONS; TESTES; MOUSE; GENE	Impaired testicular descent (cryptorchidism) is one of the most frequent congenital abnormalities in humans, involving 2% of male births'. Cryptorchidism can result in infertility and increases risk for development of germ-cell tumours. Testicular descent from abdomen to scrotum occurs in two distinct phases: the trans-abdominal phase and the inguino-scrotal phase(1-3). Currently, little is known about the factors that regulate the trans-abdominal phase of testicular descent. Leydig insulin-like hormone (Insl3) is a member of the insulin hormone superfamily(4) expressed in the developing testis(5). We show here that mice mutant for Insl(3) are viable, but exhibit bilateral cryptorchidism due to developmental abnormalities of the gubernaculum, resulting in abnormal spermatogenesis and infertility. Female homozygotes have impaired fertility associated with deregulation of the oestrus cycle. These findings reveal roles for lnsl(3) in the development of the urogenital tract and in female fertility. lnsl(3) may act as a hormone to regulate the growth and differentiation of the gubernaculum, thereby mediating intra-abdominal testicular descent.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Nef, Serge/AAV-6445-2020; Parada, luis F/B-9400-2014	Nef, Serge/0000-0001-5462-0676; 				ADHAM IM, 1993, J BIOL CHEM, V268, P26668; BERKOWITZ GS, 1993, PEDIATRICS, V92, P44; GRIFFITHS AL, 1993, INT J ANDROL, V16, P380, DOI 10.1111/j.1365-2605.1993.tb01365.x; HUSMANN DA, 1995, UROLOGY, V46, P267, DOI 10.1016/S0090-4295(99)80207-6; HUTSON JM, 1994, REPROD FERT DEVELOP, V6, P151, DOI 10.1071/RD9940151; HUTSON JM, 1985, LANCET, V2, P419; Liebl DJ, 1997, J NEUROSCI, V17, P9113; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nef S, 1997, P NATL ACAD SCI USA, V94, P4766, DOI 10.1073/pnas.94.9.4766; NISHIMUNE Y, 1978, FERTIL STERIL, V29, P95; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RESKO JA, 1973, ENDOCRINOLOGY, V93, P156, DOI 10.1210/endo-93-1-156; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; Shono T, 1996, INT J ANDROL, V19, P263, DOI 10.1111/j.1365-2605.1996.tb00474.x; Thomson AA, 1997, DEVELOPMENT, V124, P2431; Tsuji M, 1998, J STEROID BIOCHEM, V67, P113, DOI 10.1016/S0960-0760(98)00079-X; VISSER JH, 1995, J UROLOGY, V153, P516, DOI 10.1097/00005392-199502000-00074; VONFENTENER VJM, 1988, ENDOCRINOLOGY, V123, P2868; WENSING CJG, 1988, HORM RES, V30, P144, DOI 10.1159/000181051; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; WILSON JD, 1983, AUST J BIOL SCI, V36, P101; Zarrow MX, 1964, EXPT ENDOCRINOLOGY S; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmermann S, 1997, MOL REPROD DEV, V47, P30, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;30::AID-MRD5&gt;3.0.CO;2-R; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	26	548	573	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					295	299		10.1038/10364	http://dx.doi.org/10.1038/10364			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391220				2022-12-27	WOS:000081125900025
J	Houten, SM; Kuis, W; Duran, M; de Koning, TJ; van Royen-Kerkhof, A; Romeijn, GJ; Frenkel, J; Dorland, L; de Barse, MMJ; Huijbers, WAR; Rijkers, GT; Waterham, HR; Wanders, RJA; Poll-The, BT				Houten, SM; Kuis, W; Duran, M; de Koning, TJ; van Royen-Kerkhof, A; Romeijn, GJ; Frenkel, J; Dorland, L; de Barse, MMJ; Huijbers, WAR; Rijkers, GT; Waterham, HR; Wanders, RJA; Poll-The, BT			Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome	NATURE GENETICS			English	Article							ACIDURIA; IDENTIFICATION; CHOLESTEROL; DEFICIENCY	Hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM 260920) is an autosomal recessive disorder characterized by recurrent episodes of fever associated with lymphadenopathy, arthralgia, gastrointestinal dismay and skin rash(1,) (2). Diagnostic hallmark of HIDS is a constitutively elevated level of serum immunoglobulin D (IgD), although patients have been reported with normal IgD levels'. To determine the underlying defect in HIDS, we analysed urine of several patients and discovered increased concentrations of mevalonic acid during severe episodes of fever, but not between crises. Subsequent analysis of cells from four unrelated HIDS patients revealed reduced activities of mevalonate kinase (MK; encoded by the gene MVK), a key enzyme of isoprenoid biosynthesis. Sequence analysis of MVK cDNA from the patients identified three different mutations, one of which was common to all patients. Expression of the mutant cDNAs in Escherichia coli showed that all three mutations affect the activity of the encoded proteins. Moreover, immunoblot analysis demonstrated a deficiency of MK protein in patient fibroblasts, indicating a protein-destabilizing effect of the mutations.	Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Metab Disorders, Utrecht, Netherlands; Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Immunol, Utrecht, Netherlands; Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Gen Pediat, Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Beatrix Hosp, Gorinchem, Netherlands	Utrecht University; Utrecht University; Utrecht University; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Waterham, HR (corresponding author), Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Metab Disorders, Utrecht, Netherlands.	h.r.waterham@amc.uva.nl; b.pollthe@wkz.azu.nl	Rijkers, Ger/R-7236-2019; Houten, Sander/Y-3599-2019; De Koning, Tom J/AAE-1323-2020; Rijkers, Ger/AAW-6143-2020	Rijkers, Ger/0000-0001-6948-6123; Houten, Sander/0000-0002-6167-9147; De Koning, Tom J/0000-0001-5609-1309; Poll-The, Bwee Tien/0000-0002-8118-5419				BIARDI L, 1994, J BIOL CHEM, V269, P1197; Centola M, 1998, HUM MOL GENET, V7, P1581, DOI 10.1093/hmg/7.10.1581; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hinson DD, 1997, J BIOL CHEM, V272, P26756, DOI 10.1074/jbc.272.42.26756; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; HOFFMANN GF, 1992, J INHERIT METAB DIS, V15, P738, DOI 10.1007/BF01800016; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7; Lindenthal B, 1996, J LIPID RES, V37, P2193; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; VANDERMEER JWM, 1984, LANCET, V1, P1087	13	367	377	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					175	177		10.1038/9691	http://dx.doi.org/10.1038/9691			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369261				2022-12-27	WOS:000080680900024
J	Lander, ES				Lander, ES			Array of hope	NATURE GENETICS			English	Article									MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.							Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194	18	420	472	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			3	4		10.1038/4427	http://dx.doi.org/10.1038/4427			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915492				2022-12-27	WOS:000078008200003
J	Vingsbo-Lundberg, C; Nordquist, N; Olofsson, P; Sundvall, M; Saxne, T; Pettersson, U; Holmdahl, R				Vingsbo-Lundberg, C; Nordquist, N; Olofsson, P; Sundvall, M; Saxne, T; Pettersson, U; Holmdahl, R			Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats	NATURE GENETICS			English	Article							BB RAT; SUSCEPTIBILITY	Rheumatoid arthritis (RA) is a chronic and genetically complex inflammatory disorder that leads to erosive destruction of peripheral joints(1-5). The use of animal models mimicking RA, such as pristane-induced arthritis (PIA) in rats, should facilitate its genetic analysis. Pristane is a non-immunogenic synthetic oil that, after a single subcutaneous injection into DA rats, induces arthritis restricted to peripheral joints with a chronic relapsing disease course(6). To identify genes involved in the control of chronic arthritis, we made crosses between susceptible DA rats and resistant E3 rats and analysed the progeny with microsatellite markers covering the entire rat genome. Our results show that different arthritis phenotypes are associated with different chromosomal loci. Loci on chromosomes 4 and 6 (Pia2 and Pia3) influence arthritis onset, whereas a locus on chromosome 12 (Pia4) is associated with severity and joint erosion. We found that chronicity is associated with a different set of loci, one on chromosome 4 and the other on chromosome 14 (Pia5, Pia6). These findings demonstrate for the first time that different phases of a chronic self-perpetuative disease which mimics RA are associated with distinct sets of genes.	Univ Lund, Dept Cell & Mol Biol, Sect Med Inflammat Res, Lund, Sweden; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden; Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Res, Lund, Sweden; Univ Lund, Dept Rheumatol, Lund, Sweden	Lund University; Uppsala University; Lund University; Lund University	Holmdahl, R (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Med Inflammat Res, Lund, Sweden.	rikard.holmdahl@inflam.lu.se	Holmdahl, Rikard/AAI-7682-2020; Nordquist, Niklas/B-9334-2011	Nordquist, Niklas/0000-0002-3864-937X; Olofsson, Peter/0000-0003-4849-8541				GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; Holmdahl R, 1998, HUMAN GENOME METHODS, P215; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINCOLN S, 1992, MAPPING GENES CONTRO; Lincoln S, 1992, CONSTRUCING GENETIC, V3rd; Lorentzen JC, 1998, P NATL ACAD SCI USA, V95, P6383, DOI 10.1073/pnas.95.11.6383; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PETTERSSON A, 1995, J AUTOIMMUN, V8, P493, DOI 10.1016/0896-8411(95)90004-7; Remmers EF, 1996, NAT GENET, V14, P82, DOI 10.1038/ng0996-82; SILMAN AJ, 1993, BRIT J RHEUMATOL, V32, P903; Vingsbo C, 1996, AM J PATHOL, V149, P1675; Vingsbo-Lundberg C, 1998, ARTHRITIS RHEUM, V41, P544, DOI 10.1002/1529-0131(199803)41:3<544::AID-ART21>3.0.CO;2-#; WORDSWORTH P, 1992, AM J HUM GENET, V51, P585; WORDSWORTH P, 1991, ANN RHEUM DIS, V50, P343, DOI 10.1136/ard.50.6.343	17	141	147	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					401	404		10.1038/3887	http://dx.doi.org/10.1038/3887			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843218	Green Published			2022-12-27	WOS:000077199600033
J	Xu, X; Peng, M; Fang, Z; Xu, XP				Xu, X; Peng, M; Fang, Z; Xu, XP			The direction of microsatellite mutations is dependent upon allele length	NATURE GENETICS			English	Article							REPEAT LOCI; INSTABILITY; FREQUENCIES; EVOLUTION; MODEL; YEAST; SIZE	Microsatellites, comprising tandemly repeated short nucleotide sequences, are ubiquitous in eukaryotic: genomes. Mutations within microsatellites are frequent, altering their overall length by insertion or deletion of a small number of repeat units, with a rate as high as 10(-3) in humans(1). Despite their high mutability, stable allele frequency distributions are typically observed for microsatellites in humans as well as other primates(2,3), although the mechanism maintaining these stable distributions remains unclear. Previous studies have suggested that microsatellite mutations occur more frequently in longer alleles and favour expansion(4-8). Generalizing these results has been hindered because the sample sizes were small, only a small subset of alleles for any marker was studied and the direction of mutation (expansion or contraction) was not rigorously determined. Here we examine 236 mutations at 122 tetranucleotide repeat markers and find that the rate of contraction mutations increases exponentially with allele size. whereas the rate of expansion mutations is constant across the entire allele distribution. The overall rate of expansion mutations does not differ from that of contractions. Our findings offer an explanation for the stationary allele distribution of microsatellites.	Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA; Anhui Med Univ, Inst Biomed, Hefei, Anhui, Peoples R China	Harvard University; Harvard T.H. Chan School of Public Health; Anhui Medical University	Xu, X (corresponding author), Harvard Univ, Sch Publ Hlth, Program Populat Genet, 665 Huntington Ave, Boston, MA 02115 USA.		Xu, Xin/A-1687-2016	Xu, Xin/0000-0002-6324-5211				Amos W, 1996, NAT GENET, V13, P390, DOI 10.1038/ng0896-390; Brinkmann B, 1998, AM J HUM GENET, V62, P1408, DOI 10.1086/301869; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; GARZA JC, 1995, MOL BIOL EVOL, V12, P594; Goldstein DB, 1997, J HERED, V88, P335, DOI 10.1093/oxfordjournals.jhered.a023114; Horvath S, 1998, AM J HUM GENET, V63, P1886, DOI 10.1086/302137; Kimmel M, 1996, THEOR POPUL BIOL, V50, P345, DOI 10.1006/tpbi.1996.0035; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Twerdi CD, 1999, P NATL ACAD SCI USA, V96, P2875, DOI 10.1073/pnas.96.6.2875; VALDES AM, 1993, GENETICS, V133, P737; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; Wierdl M, 1997, GENETICS, V146, P769; Xu XP, 1999, AM J HUM GENET, V64, P1694, DOI 10.1086/302405; ZHIVOTOVSKY LA, 1995, P NATL ACAD SCI USA, V92, P11549, DOI 10.1073/pnas.92.25.11549	17	280	304	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					396	399		10.1038/74238	http://dx.doi.org/10.1038/74238			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742105				2022-12-27	WOS:000086192800020
J	Oldridge, M; Fortuna, AM; Maringa, M; Propping, P; Mansour, S; Pollitt, C; DeChiara, TM; Kimble, RB; Valenzuela, DM; Yancopoulos, GD; Wilkie, AOM				Oldridge, M; Fortuna, AM; Maringa, M; Propping, P; Mansour, S; Pollitt, C; DeChiara, TM; Kimble, RB; Valenzuela, DM; Yancopoulos, GD; Wilkie, AOM			Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B	NATURE GENETICS			English	Article							MAP; FAMILY; FGFR2	Inherited limb malformations provide a valuable resource for the identification of genes involved in limb development(1,2). Brachydactyly type B (BDB), an autosomal dominant disorder, is the most severe of the brachydactylies(3) and characterized by terminal deficiency of the fingers and toes. In the typical form of BDB, the thumbs and big toes are spared, sometimes with broadening or partial duplication(4-8). The BDB1 locus was previously mapped to chromosome 9q22 within an interval of 7.5 cM (refs 9, 10). Here we describe mutations in ROR2, which encodes the orphan receptor tyrosine kinase ROR2 (ref. 11), in three unrelated families with BDB1. We identified distinct heterozygous mutations (2 nonsense, 1 frameshift) within a 7-amino-acid segment of the 943-amino-acid protein, all of which predict truncation of the intracellular portion of the protein immediately after the tyrosine kinase domain. The localized nature of these mutations suggests that they confer a specific gain of function. We obtained further evidence for this by demonstrating that two patients heterozygous for 9q22 deletions including ROR2 do not exhibit BDB. Expression of the mouse orthologue, Ror2, early in limb development indicates that BDB arises as a primary defect of skeletal patterning.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Inst Med Genet, Porto, Portugal; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Univ London St Georges Hosp, Sch Med, SW Thames Reg Genet Serv, London SW17 0RE, England; Royal Victoria Infirm, No Reg Genet Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Oxford; University of Bonn; St Georges University London; Newcastle University - UK; Regeneron	Wilkie, AOM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.		Wilkie, Andrew/AAC-3820-2020	Wilkie, Andrew/0000-0002-2972-5481; Fortuna, Ana/0000-0002-1296-5366				AFZAL AR, IN PRESS HUM GENET; BATTLE HI, 1973, ANN HUM GENET, V36, P415, DOI 10.1111/j.1469-1809.1973.tb00605.x; Blair IP, 1998, GENOMICS, V51, P277, DOI 10.1006/geno.1998.5373; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; DEGENHARDT KH, 1954, Z MENSCHLICHE VERERB, V32, P227; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FITCH N, 1979, J MED GENET, V16, P36, DOI 10.1136/jmg.16.1.36; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; Houlston R S, 1994, Clin Dysmorphol, V3, P224; Innis JW, 1998, CLIN GENET, V53, P337; MacARTHUR J. W., 1932, HUMAN BIOL, V4, P179; MALLOCH JD, 1957, ANN HUM GENET, V22, P36, DOI 10.1111/j.1469-1809.1957.tb01297.x; Manouvrier-Hanu S, 1999, TRENDS GENET, V15, P409, DOI 10.1016/S0168-9525(99)01823-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 1997, HUM MOL GENET, V6, P137, DOI 10.1093/hmg/6.1.137; Oldridge M, 1999, AM J HUM GENET, V64, P578, DOI 10.1086/302255; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	23	161	181	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					275	278		10.1038/73495	http://dx.doi.org/10.1038/73495			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700182				2022-12-27	WOS:000085590600019
J	Su, H; Wang, XH; Bradley, A				Su, H; Wang, XH; Bradley, A			Nested chromosomal deletions induced with retroviral vectors in mice	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; GENETIC-MAP; MOUSE; SCREEN	Chromosomal deletions, especially nested deletions, are major genetic tools in diploid organisms that facilitate the functional analysis of large chromosomal regions and allow the rapid localization of mutations to specific genetic intervals. In mice, well-characterized overlapping deletions are only available at a few chromosomal loci(1,2), partly due to drawbacks of existing methods. Here we exploit the random integration of a retrovirus to generate high-resolution sets of nested deletions around defined loci in embryonic stem (ES) cells, with sizes extending from a few kilobases to several megabases. This approach expands the application of Cre-loxP-based chromosome engineering(3) because it not only allows the construction of hundreds of overlapping deletions, but also provides molecular entry points to regions based on the retroviral tags. Our approach can be extended to any region of the mouse genome.	Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Bradley, A (corresponding author), Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839				Abuin A, 1996, MOL CELL BIOL, V16, P1851; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Bridges CB, 1917, GENETICS, V2, P445; Cai WW, 1998, GENOMICS, V54, P387, DOI 10.1006/geno.1998.5620; CATTANACH BM, 1993, NAT GENET, V3, P56, DOI 10.1038/ng0193-56; DALBY B, 1995, GENETICS, V139, P757; DIETRICH W, 1992, GENETICS, V131, P423; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; Kushi A, 1998, MAMM GENOME, V9, P269, DOI 10.1007/s003359900747; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; Liu PT, 1998, GENETICS, V150, P1155; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; OCHMAN H, 1988, GENETICS, V120, P621; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Rinchik E.M., 1990, GENOME ANAL, P121; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; Thomas JW, 1998, P NATL ACAD SCI USA, V95, P1114, DOI 10.1073/pnas.95.3.1114; You Y, 1997, NAT GENET, V15, P285, DOI 10.1038/ng0397-285; ZHANG HB, 1994, MOL CELL BIOL, V14, P2404, DOI 10.1128/MCB.14.4.2404; ZHENG B, IN PRESS MOL CELL BI	24	45	51	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					92	95		10.1038/71756	http://dx.doi.org/10.1038/71756			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615136				2022-12-27	WOS:000084609200024
J	Wiles, MV; Vauti, F; Otte, J; Fuchtbauer, EM; Ruiz, P; Fuchtbauer, A; Arnold, HH; Lehrach, H; Metz, T; von Melchner, H; Wurstz, W				Wiles, MV; Vauti, F; Otte, J; Fuchtbauer, EM; Ruiz, P; Fuchtbauer, A; Arnold, HH; Lehrach, H; Metz, T; von Melchner, H; Wurstz, W			Establishment of a gene-trap sequence tag library to generate mutant mice from embryonic stem cells	NATURE GENETICS			English	Letter							DEVELOPMENTALLY-REGULATED GENES; DISRUPTION; REPORTER; VECTORS; SCREEN		GSF, Nat Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany; Max Planck Inst Mol Genet, Berlin, Germany; Goethe Univ Frankfurt, Sch Med, Lap Mol Hematol, Frankfurt, Germany; Max Planck Inst Immunobiol, Dept Dev Biol, D-7800 Freiburg, Germany; Univ Aarhus, Inst Mol & Struct Biol, Aarhus, Denmark; TU Braunschweig, Dept Cell & Mol Biol, Inst Biochem & Biotechnol, Braunschweig, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Goethe University Frankfurt; Max Planck Society; Aarhus University; Braunschweig University of Technology; Max Planck Society	Wurstz, W (corresponding author), GSF, Nat Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany.	wurst@mpipsykl.mpg.de	Noppinger, Patricia Ruiz/AAH-1753-2019; Ruiz Noppinger, Patricia/D-6418-2014	Noppinger, Patricia Ruiz/0000-0001-5617-8965; Ruiz Noppinger, Patricia/0000-0001-5617-8965; wiles, michael/0000-0002-3620-8386; Vauti, Franz/0000-0003-0275-1433; Wurst, Wolfgang/0000-0003-4422-7410				Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; HILL DP, 1993, METHOD ENZYMOL, V225, P664; NIWA H, 1993, J BIOCHEM-TOKYO, V113, P343, DOI 10.1093/oxfordjournals.jbchem.a124049; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; Salminen M, 1998, DEV DYNAM, V212, P326, DOI 10.1002/(SICI)1097-0177(199806)212:2<326::AID-AJA17>3.0.CO;2-1; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; WURST W, 1995, GENETICS, V139, P889; YOSHIDA M, 1995, TRANSGENIC RES, V4, P277, DOI 10.1007/BF01969122; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	14	111	122	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					13	14		10.1038/71622	http://dx.doi.org/10.1038/71622			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615117				2022-12-27	WOS:000084609200006
J	Horwitz, M; Benson, KF; Person, RE; Aprikyan, AG; Dale, DC				Horwitz, M; Benson, KF; Person, RE; Aprikyan, AG; Dale, DC			Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis	NATURE GENETICS			English	Article							CELLS; SPECIFICITY; THROMBIN; COMPLEX; GENE	Human cyclic haematopoiesis (cyclic neutropenia, MIM 162800) is an autosomal dominant disease in which blood-cell production from the bone marrow oscillates with 21-day periodicity(1,2). Circulating neutrophils vary between almost normal numbers and zero. During intervals of neutropenia, affected individuals are at risk for opportunistic infection(3). Monocytes, platelets, lymphocytes and reticulocytes also cycle with the same frequency. Here we use a genome-wide screen and positional cloning to map the locus to chromosome 19p13.3. We identified 7 different single-base substitutions in the gene (ELA2) encoding neutrophil elastase (EC 3.4.21.37, also known as leukocyte elastase, elastase 2 and medullasin), a serine protease of neutrophil and monocyte granules, on unique haplotypes in 13 of 13 families as well as a new mutation in a sporadic case. Neutrophil elastase (a 240-aa mature protein predominantly found in neutrophil granules(4)) is the target for protease inhibition by alpha(1)-antitrypsin, and its unopposed release destroys tissue at sites of inflammation. We hypothesize that a perturbed interaction between neutrophil elastase and serpins or other substrates may regulate mechanisms governing the clock-like timing of haematopoiesis.	Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Horwitz, M (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA.			Horwitz, Marshall/0000-0002-1683-1680	NIDDK NIH HHS [DK18951] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018951] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Berger SP, 1996, J AM SOC NEPHROL, V7, P694; BIETH JG, 1998, HDB PROTEOLYTIC ENZY, P54; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Cregge RJ, 1998, J MED CHEM, V41, P2461, DOI 10.1021/jm970812e; DALE DC, 1988, BLOOD REV, V2, P178, DOI 10.1016/0268-960X(88)90023-9; Fasman KH, 1997, NUCLEIC ACIDS RES, V25, P72, DOI 10.1093/nar/25.1.72; Haurie C, 1998, BLOOD, V92, P2629, DOI 10.1182/blood.V92.8.2629.420a35_2629_2640; Hung SH, 1998, PROTEIN ENG, V11, P669, DOI 10.1093/protein/11.8.669; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; Palmer SE, 1996, AM J MED GENET, V66, P413, DOI 10.1002/(SICI)1096-8628(19961230)66:4<413::AID-AJMG5>3.0.CO;2-L; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A	23	317	327	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					433	436		10.1038/70544	http://dx.doi.org/10.1038/70544			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581030				2022-12-27	WOS:000084023900019
J	Madsen, LS; Andersson, EC; Jansson, L; Krogsgaard, M; Andersen, CB; Engberg, J; Strominger, JL; Svejgaard, A; Hjorth, JP; Holmdahl, R; Wucherpfennig, KW; Fugger, L				Madsen, LS; Andersson, EC; Jansson, L; Krogsgaard, M; Andersen, CB; Engberg, J; Strominger, JL; Svejgaard, A; Hjorth, JP; Holmdahl, R; Wucherpfennig, KW; Fugger, L			A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor	NATURE GENETICS			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BASIC-PROTEIN PEPTIDE; TRANSGENIC MICE; MYELIN; SUSCEPTIBILITY; EXPRESSION; COMPLEX; SCREEN; LOCI; CD4		Aarhus Univ Hosp, Skejby Sygehus, Dept Clin Immunol, DK-8000 Aarhus, Denmark; Rigshosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Aarhus Univ, Inst Mol & Struct Biol, Aarhus, Denmark; Univ Lund, Sect Med Inflammat Res, Lund, Sweden; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Aarhus University; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Royal Danish School of Pharmacy; Harvard University; Aarhus University; Lund University; Harvard University; Dana-Farber Cancer Institute	Fugger, L (corresponding author), Aarhus Univ Hosp, Skejby Sygehus, Dept Clin Immunol, DK-8000 Aarhus, Denmark.		Holmdahl, Rikard/AAI-7682-2020					Coraddu F, 1998, NEUROGENETICS, V2, P24, DOI 10.1007/s100480050048; Ebers GC, 1998, SEMIN NEUROL, V18, P295, DOI 10.1055/s-2008-1040880; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; FOGDELL A, 1995, TISSUE ANTIGENS, V46, P333, DOI 10.1111/j.1399-0039.1995.tb02503.x; Fugger L, 1996, EUR J IMMUNOL, V26, P928, DOI 10.1002/eji.1830260431; FUGGER L, 1994, P NATL ACAD SCI USA, V91, P6151, DOI 10.1073/pnas.91.13.6151; Goverman J, 1999, IMMUNOL REV, V169, P147, DOI 10.1111/j.1600-065X.1999.tb01313.x; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; Haines JL, 1998, HUM MOL GENET, V7, P1229, DOI 10.1093/hmg/7.8.1229; JANSSON L, 1991, EUR J IMMUNOL, V21, P693, DOI 10.1002/eji.1830210323; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOUSKOFF V, 1993, J IMMUNOL METHODS, V166, P287, DOI 10.1016/0022-1759(93)90370-M; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; Noseworthy JH, 1999, NATURE, V399, pA40, DOI 10.1038/399a040; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Pearson CI, 1997, J EXP MED, V185, P583, DOI 10.1084/jem.185.4.583; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; Sawcer S, 1998, CURR OPIN IMMUNOL, V10, P697, DOI 10.1016/S0952-7915(98)80091-5; Smith A, 1998, PHARM SCI TECHNOL TO, V1, P188, DOI 10.1016/S1461-5347(98)00057-1; Spurkland A, 1997, TISSUE ANTIGENS, V50, P15, DOI 10.1111/j.1399-0039.1997.tb02828.x; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; SUNDVALL M, 1995, NAT GENET, V10, P313, DOI 10.1038/ng0795-313; Van de Keere F, 1998, J EXP MED, V188, P1875, DOI 10.1084/jem.188.10.1875; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	30	252	273	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					343	347		10.1038/15525	http://dx.doi.org/10.1038/15525			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610182				2022-12-27	WOS:000083792200026
J	Morgan, HD; Sutherland, HGE; Martin, DIK; Whitelaw, E				Morgan, HD; Sutherland, HGE; Martin, DIK; Whitelaw, E			Epigenetic inheritance at the agouti locus in the mouse	NATURE GENETICS			English	Article							GENE-EXPRESSION; MOLECULAR-BASIS; METHYLATION; MICE; PHENOTYPE; MUTATIONS; MITOSIS; MEIOSIS; ALLELE		Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Sydney; University of Edinburgh; Fred Hutchinson Cancer Center	Whitelaw, E (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.			Sutherland, Heidi/0000-0002-8512-1498				ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; Argeson AC, 1996, GENETICS, V142, P557; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; BELAYEV DK, 1981, J HERED, V72, P267; BRINK RA, 1956, GENETICS, V41, P872; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Chen YR, 1996, GENETICS, V144, P265; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; FEDEROFF NV, 1988, GENETICS, V120, P559; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HOLLICK JB, 1995, GENETICS, V141, P709; JABLONKA E, 1992, J THEOR BIOL, V158, P245, DOI 10.1016/S0022-5193(05)80722-2; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; MARTINEZ AR, 1994, GYNECOL ENDOCRINOL, V8, P1, DOI 10.3109/09513599409028450; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MONK M, 1995, DEV GENET, V17, P188, DOI 10.1002/dvg.1020170303; PERRY WL, 1994, BIOESSAYS, V16, P705, DOI 10.1002/bies.950161002; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WOLFF GL, 1978, GENETICS, V88, P529; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949	25	991	1027	2	167	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					314	318		10.1038/15490	http://dx.doi.org/10.1038/15490			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545949				2022-12-27	WOS:000083792200020
J	Persons, DA; Paulson, RF; Loyd, MR; Herley, MT; Bodner, SM; Bernstein, A; Correll, PH; Ney, PA				Persons, DA; Paulson, RF; Loyd, MR; Herley, MT; Bodner, SM; Bernstein, A; Correll, PH; Ney, PA			Fv2 encodes a truncated form of the Stk receptor tyrosine kinase	NATURE GENETICS			English	Article							FRIEND-LEUKEMIA VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; FV-2 GENE-ACTION; PROGENITOR CELLS; CELLULAR SITE; ERYTHROLEUKEMIA; GLYCOPROTEIN; GP55; MICE; ONCOGENE	The Friend virus susceptibility 2 (Fv2) locus encodes a dominant host factor that confers susceptibility to Friend virus-induced erythroleukaemia in mice. We mapped Fv2 to a 1.0-Mb interval that also contained the gene (Ron) encoding the stem cell kinase receptor (Stk). A truncated form of Stk (Sf-stk), which was the most abundant form of Stk in Fv2-sensitive (Fv2(ss)) erythroid cells, was not expressed in Fv2 resistant (Fv2(rr)) cells. Enforced expression of Sf-stk conferred susceptibility to Friend disease, whereas targeted disruption of Ron caused resistance. We conclude that the Fv2 locus encodes Ron, and that a naturally expressed, truncated form of Stk confers susceptibility to Friend virus-induced erythroleukaemia.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Ney, PA (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	paul.ney@stjude.org			NATIONAL CANCER INSTITUTE [R01CA084214, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084214-02, R01 CA084214, R01 CA084214-03, R01 CA084214-01, R01 CA084214-04, P30 CA21765, R01 CA084214-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AMANUMA H, 1983, P NATL ACAD SCI-BIOL, V80, P3913, DOI 10.1073/pnas.80.13.3913; AXELRAD A, 1969, CAN CANC C, V8, P313; AXELRAD AA, 1964, VIROLOGY, V24, P513, DOI 10.1016/0042-6822(64)90199-0; BEHRINGER RR, 1989, EXP HEMATOL, V17, P330; BEHRINGER RR, 1985, CELL, V40, P441, DOI 10.1016/0092-8674(85)90158-8; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENNETT M, 1968, SCIENCE, V162, P564, DOI 10.1126/science.162.3853.564; BERGER SA, 1985, P NATL ACAD SCI USA, V82, P6913, DOI 10.1073/pnas.82.20.6913; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Blake JA, 1998, NUCLEIC ACIDS RES, V26, P130, DOI 10.1093/nar/26.1.130; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHESEBRO B, 1978, J IMMUNOL, V120, P1081; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; Correll Pamela H., 1997, Genes and Function, V1, P69; DIETRICH W, 1992, GENETICS, V131, P423; ELIOTT RW, 1978, ELECTROPHORESIS, P261; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GEIB RW, 1987, VIRUS RES, V8, P327, DOI 10.1016/0168-1702(87)90005-0; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOATLIN ME, 1995, J VIROL, V69, P856, DOI 10.1128/JVI.69.2.856-863.1995; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KAI K, 1986, VIROLOGY, V150, P509, DOI 10.1016/0042-6822(86)90315-6; KOZAK CA, 1985, J VIROL, V55, P281, DOI 10.1128/JVI.55.2.281-285.1985; KUMAR V, 1978, J NATL CANCER I, V61, P1117; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LILLY F, 1970, J NATL CANCER I, V45, P163; MAGER D, 1981, MOL CELL BIOL, V1, P721, DOI 10.1128/MCB.1.8.721; Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766; METCALF D, 1959, CANCER RES, V19, P52; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Paulson RF, 1998, MAMM GENOME, V9, P381, DOI 10.1007/s003359900774; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Riberdy JM, 1999, J VIROL, V73, P1453, DOI 10.1128/JVI.73.2.1453-1459.1999; Santoro MM, 1997, MOL CELL BIOL, V17, P1758; SHIBUYA T, 1982, NATURE, V296, P577, DOI 10.1038/296577a0; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STEEVES RA, 1975, J NATL CANCER I, V54, P289, DOI 10.1093/jnci/54.2.289; STEEVES RA, 1968, NATURE, V218, P372, DOI 10.1038/218372a0; SUZUKI S, 1980, CELL, V19, P225, DOI 10.1016/0092-8674(80)90404-3; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; VANDERGAAG HC, 1990, VIROLOGY, V177, P837, DOI 10.1016/0042-6822(90)90561-5; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Wei MH, 1996, CANCER RES, V56, P1487; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034	50	124	128	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					159	165		10.1038/13787	http://dx.doi.org/10.1038/13787			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508511				2022-12-27	WOS:000082827500014
J	Liu, PT; Wakamiya, M; Shea, MJ; Albrecht, U; Behringer, RR; Bradley, A				Liu, PT; Wakamiya, M; Shea, MJ; Albrecht, U; Behringer, RR; Bradley, A			Requirement for Wnt3 in vertebrate axis formation	NATURE GENETICS			English	Article							ANTERIOR PRIMITIVE ENDODERM; EMBRYONIC AXIS; MOUSE EMBRYO; EXPRESSION; XENOPUS; GENES; NEUROECTODERM	Several studies have implicated Wnt signalling in primary axis formation during vertebrate embryogenesis, yet no Wnt protein has been shown to be essential for this process(1-3), In the mouse, primitive streak formation is the first overt morphological sign of the anterior-posterior axis, Here we show that Wnt3 is expressed before gastrulation in the proximal epiblast of the egg cylinder, then is restricted to the posterior proximal epiblast and its associated visceral endoderm and subsequently to the primitive streak and mesoderm, Wnt3(-/-) mice develop a normal egg cylinder but do not form a primitive streak, mesoderm or The epiblast continues to proliferate in an undifferentiated state that lacks anterior-posterior neural patterning, but anterior visceral endoderm markers are expressed and correctly positioned. Our results suggest that regional patterning of the visceral endoderm is independent of primitive streak formation, but the subsequent establishment of anterior-posterior neural pattern in the ectoderm is dependent on derivatives of the primitive streak. These studies provide genetic proof for the requirement of Wnt3 in primary axis formation in the mouse.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Albrecht, Urs/A-9831-2011	Albrecht, Urs/0000-0002-0663-8676; Bradley, Allan/0000-0002-2349-8839				ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; KRAUSS S, 1992, DEVELOPMENT, V116, P249; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Liu PT, 1998, GENETICS, V150, P1155; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; PARR BA, 1993, DEVELOPMENT, V119, P247; Popperl H, 1997, DEVELOPMENT, V124, P2997; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; TAM PPL, IN PRESS CURR TOPICS; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949; ZHENG Z, 1997, CELL, V90, P181	27	651	678	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					361	365		10.1038/11932	http://dx.doi.org/10.1038/11932			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431240				2022-12-27	WOS:000081772500018
J	Coffee, B; Zhang, FP; Warren, ST; Reines, D				Coffee, B; Zhang, FP; Warren, ST; Reines, D			Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells	NATURE GENETICS			English	Article							REPRESS TRANSCRIPTION; DNA METHYLATION; GENE; REGION; DEACETYLASE; EXPRESSION; PROMOTER; YEAST; REACTIVATION; NUCLEOSOME	Mutation of FMR1 results in fragile X mental retardation(1). The most common FMR1 mutation is expansion of a CGG repeat tract at the 5' end of FMR1 (refs 2-4), which leads to cytosine methylation and transcriptional silencing(5,6). Both DNA methylation and histone deacetylation have been associated with transcriptional inactivity(7-9). The finding that the methyl cytosine-binding protein MeCP2 binds to histone deacetylases and represses transcription in vivo(10,11) supports a model in which MeCP2 recruits histone deacetylases to methylated DNA, resulting in histone deacetylation, chromatin condensation and transcriptional silencing(12). Here we demonstrate that the 5' end of FMR1 is associated with acetylated histones H3 and H4 in cells from normal individuals, but acetylation is reduced in cells from fragile X patients. Treatment of fragile X cells with 5-aza-2'-deoxycytidine (5-aza-dC) resulted in reassociation of acetylated histones H3 and H4 with FMR1 and transcriptional reactivation, whereas treatment with trichostatin A (TSA) led to almost complete acetylated histone H4 and little acetylated histone H3 reassociation with FMR1, as well as no detectable transcription. Our results represent the first description of loss of histone acetylation at a specific locus in human disease, and advance understanding of the mechanism of FMR1 transcriptional silencing.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA	Emory University; Emory University; Howard Hughes Medical Institute; Emory University; Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.		excellency, Your/R-2357-2019; Warren, Stephen T/A-2498-2012	excellency, Your/0000-0003-0832-6243; 	NICHD NIH HHS [HD35576] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD035576] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Ammerpohl O, 1998, NUCLEIC ACIDS RES, V26, P5256, DOI 10.1093/nar/26.23.5256; ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; Drouin R, 1997, HUM MOL GENET, V6, P2051, DOI 10.1093/hmg/6.12.2051; Eberhart DE, 1996, SOMAT CELL MOLEC GEN, V22, P435, DOI 10.1007/BF02369435; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; Schwemmle S, 1997, AM J HUM GENET, V60, P1354, DOI 10.1086/515456; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	30	254	258	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					98	101		10.1038/8807	http://dx.doi.org/10.1038/8807			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319871				2022-12-27	WOS:000080096300032
J	Debouck, C; Goodfellow, PN				Debouck, C; Goodfellow, PN			DNA microarrays in drug discovery and development	NATURE GENETICS			English	Review							EXPRESSION; GENES	DNA microarrays can be used to measure the expression patterns of thousands:of genes: in p8rallel, generating clues to gene function that can help to identify appropriate targets for therapeutic intervention. They:can also be used to monitor changes in gene expression in response to drug treatments. Were, we discuss the-different ways in which microarray analysis is likely to affect drug discovery.	SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Debouck, C (corresponding author), SmithKline Beecham Pharmaceut, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERSIDIS A, 1998, NAT BIOTECHNOL, V16, P393; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; Pietu G, 1996, GENOME RES, V6, P492, DOI 10.1101/gr.6.6.492; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Smith R D, 1994, Curr Opin Nephrol Hypertens, V3, P112, DOI 10.1097/00041552-199401000-00016; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480	19	544	595	2	54	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			48	50		10.1038/4475	http://dx.doi.org/10.1038/4475			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915501				2022-12-27	WOS:000078008200012
J	Khanna, KK; Keating, KE; Kozlov, S; Scott, S; Gatei, M; Hobson, K; Taya, Y; Gabrielli, B; Chan, D; Lees-Miller, SP; Lavin, MF				Khanna, KK; Keating, KE; Kozlov, S; Scott, S; Gatei, M; Hobson, K; Taya, Y; Gabrielli, B; Chan, D; Lees-Miller, SP; Lavin, MF			ATM associates with and phosphorylates p53: mapping the region of interaction	NATURE GENETICS			English	Article							ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; PROTEIN; KINASE; PRODUCT; DOMAIN; GENE	The human genetic disorder ataxia-telangiectasia (AT) is characterized by immunodeficiency. progressive cerebellar ataxia. radiosensitivity, cell cycle checkpoint defects and cancer predisposition(1). The gene mutated in this syndrome, ATM (for AT mutated), encodes a protein containing a phosphatidyl-inositol 3-kinase (PI-3 kinase)-like domain(2,3). ATM also contains a proline-rich region(4) and a leucine zipper(2,5), both of which implicate this protein in signal transduction. The proline-rich region has been shown to bind to the SH3 domain of c-Abl, which facilitates its phosphorylation and activation by ATM (refs 4,6). Previous results have demonstrated that AT cells are defective in the G1/S checkpoint activated after radiation damage and that this defect is attributable to a defective p53 signal transduction pathway(7,8). We report here direct interaction between ATM and p53 involving two regions in ATM. one at the amino terminus and the other at the carboxy terminus, corresponding to the PI-3 kinase domain. Recombinant ATM protein phosphorylates p53 on serine 15 near the N terminus. Furthermore, ectopic expression of ATM in AT cells restores normal ionizing radiation (IR)-induced phosphorylation of p53, whereas expression of ATM antisense RNA in control cells abrogates the rapid IR-induced phosphorylation of p53 on serine 15. These results demonstrate that ATM can bind p53 directly and is responsible for its serine 15 phosphorylation. thereby contributing to the activation and stabilization of p53 during the IR-induced DNA damage response.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Dept Pathol, Brisbane, Qld 4029, Australia; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Univ Calgary, Calgary, AB T2N 1N4, Canada; PO Royal Brisbane Hosp, Queensland Inst Med Res, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; National Cancer Center - Japan; University of Calgary; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Dept Pathol, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Lavin, Martin F/F-5961-2014; Chan, Doris/O-1227-2014; Khanna, Kum Kum/I-1747-2013; Gabrielli, Brian G/B-3655-2011; Kozlov, Sergei/M-2067-2014; Kozlov, Sergei/T-9779-2019; Hobson, Keith/Q-9306-2019	Lavin, Martin F/0000-0002-5940-4769; Chan, Doris/0000-0002-4990-986X; Gabrielli, Brian G/0000-0003-3933-1651; Kozlov, Sergei/0000-0001-6183-7339; Khanna, Kum Kum/0000-0001-8650-5381				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	20	382	401	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1998	20	4					398	400		10.1038/3882	http://dx.doi.org/10.1038/3882			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843217				2022-12-27	WOS:000077199600032
J	Suzuki, K; Hu, D; Bustos, T; Zlotogora, J; Richieri-Costa, A; Helms, JA; Spritz, RA				Suzuki, K; Hu, D; Bustos, T; Zlotogora, J; Richieri-Costa, A; Helms, JA; Spritz, RA			Mutations of PVRL1, encoding a cell-cell adhesion molecule/herpesvirus receptor, in cleft lip/palate-ectodermal dysplasia	NATURE GENETICS			English	Article							POLIOVIRUS RECEPTOR; NUCLEOTIDE-SEQUENCE; MENTAL-RETARDATION; BINDING PROTEIN; PALATE; LIP; GENE; ASSOCIATION; FAMILIES; HOMOLOG	Cleft lip, with:or without cleft palate (CL/P), is one of the most common birth defects, occurring in 0.4 to 2.0 per 1,000 infants born alive(1). Approximately 70% of CL/P cases are non-syndromic (MIM 119530), but CL/P also occurs in many single-gene syndromes, each affecting a protein critical for orofacial development. Here we describe positional cloning of the gene responsible for an autosomal recessive CL/P-ectodermal dysplasia (ED) syndrome (CLPED1; previously ED4; ref. 2), which we identify as PVRL1, encoding nectin-1, an immunoglobulin (Ig)-related transmembrane cell-cell adhesion molecule that is part of the NAP cell adhesion system(3-6). Nectin-1 is also the principal cell surface receptor for cr-herpesviruses (HveC; ref. 7), and the high frequency of CLPED1 on Margarita island in the Caribbean Sea might result from resistance of heterozygotes to infection by these viruses.	Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA USA; Cent Univ Venezuela, Ctr Nacl Genet Humana & Expt, Caracas, Venezuela; Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel; USP, HRAC, Dept Genet, Bauru, SP, Brazil	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco; University of Central Venezuela; Hebrew University of Jerusalem; Universidade de Sao Paulo	Spritz, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA.		Richieri-Costa, Antonio/B-2514-2013	Zlotogora, Joel/0000-0001-6293-2979	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012462, R29DE012462] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01079] Funding Source: Medline; NIDCR NIH HHS [DE12462] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amos C, 1996, AM J HUM GENET, V59, P743; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BUSTOS T, 1991, AM J MED GENET, V41, P398, DOI 10.1002/ajmg.1320410403; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Helms JA, 1997, DEV BIOL, V187, P25, DOI 10.1006/dbio.1997.8589; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Lee ST, 1995, MOL CELLS, V5, P668; LEONHARDT EA, 1994, GENOMICS, V19, P130, DOI 10.1006/geno.1994.1022; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; OGUR G, 1988, J MED GENET, V25, P37, DOI 10.1136/jmg.25.1.37; RODINI ESO, 1990, AM J MED GENET, V36, P473, DOI 10.1002/ajmg.1320360420; Schollmeyer P, 1990, APMIS Suppl, V19, P54; Schutte BC, 1999, HUM MOL GENET, V8, P1853, DOI 10.1093/hmg/8.10.1853; STEIN J, 1995, AM J HUM GENET, V57, P257; Suzuki K, 1998, AM J HUM GENET, V63, P1102, DOI 10.1086/302072; TAKAHASHI K, 1999, J CELL BIOL, V139, P517; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Wyszynski DF, 1997, HUM GENET, V99, P22; ZLOTOGORA J, 1988, J MED GENET, V25, P503, DOI 10.1136/jmg.25.7.503; ZLOTOGORA J, 1994, J MED GENET, V31, P957, DOI 10.1136/jmg.31.12.957; ZLOTOGORA J, 1987, J MED GENET, V24, P291, DOI 10.1136/jmg.24.5.291	30	247	256	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					427	430		10.1038/78119	http://dx.doi.org/10.1038/78119			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932188				2022-12-27	WOS:000088615000019
J	Frattini, A; Orchard, PJ; Sobacchi, C; Giliani, S; Abinun, M; Mattsson, JP; Keeling, DJ; Andersson, AK; Wallbrandt, P; Zecca, L; Notarangelo, LD; Vezzoni, P; Villa, A				Frattini, A; Orchard, PJ; Sobacchi, C; Giliani, S; Abinun, M; Mattsson, JP; Keeling, DJ; Andersson, AK; Wallbrandt, P; Zecca, L; Notarangelo, LD; Vezzoni, P; Villa, A			Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis	NATURE GENETICS			English	Article							MEDIATED EXTRACELLULAR ACIDIFICATION; OSTEOCLASTIC BONE-RESORPTION; MEMBRANE-PROTEIN; LEADS; MICE; OSTEOSCLEROSIS; MUTATION; TIRC7; GENE	Osteopetrosis includes a group of inherited diseases in which inadequate bone resorption is caused by osteoclast dysfunction. Although molecular defects have been described for many animal models of osteopetrosis. the gene responsible for most cases of the severe human form of the disease (infantile malignant osteopetrosis) is unknown. Infantile malignant autosomal recessive osteopetrosis (MIM 259700) is a severe bone disease with a fatal outcome, generally within the first decade of life. Osteoclasts are present in normal or elevated numbers in individuals affected by autosomal recessive osteopetrosis(1), suggesting that the defect is not in osteoclast differentiation, but in a gene involved in the functional capacity of mature osteoclasts. Some of the mouse mutants have a decreased number of osteoclasts. which suggests that the defect directly interferes with osteoclast differentiation(2,3). In other mutants, it is the function of the osteoclast that seems to be affected, as they show normal or elevated numbers of non-functioning osteoclasts(2,4-6). Here we show that TCIRG1, encoding the osteoclast-specific 116-kD subunit of the vacuolar proton pump, is mutated in five of nine patients with a diagnosis of infantile malignant osteopetrosis. Our data indicate that mutations in TCIRG1 are a frequent cause of autosomal recessive osteopetrosis in humans.	CNR, Ist Tecnol Biomed Avanzate, Segrate, Italy; Univ Minnesota, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA; Univ Brescia, Pediat Clin, Ist Med Mol Angelo Nocivelli, I-25121 Brescia, Italy; Newcastle Gen Hosp, Dept Pediat Immunol & Infect Dis, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; AstraZeneca R&D, Dept Cell Biol & Biochem, Molndal, Sweden; AstraZeneca R&D, Dept Biol Mol, Molndal, Sweden	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Minnesota System; University of Minnesota Twin Cities; University of Brescia; Newcastle General Hospital; AstraZeneca; AstraZeneca	Vezzoni, P (corresponding author), CNR, Ist Tecnol Biomed Avanzate, Segrate, Italy.	vezzoni@itba.mi.cnr.it	SOBACCHI, CRISTINA/J-9345-2018; Frattini, Annalisa/B-7684-2015; Notarangelo, Luigi D/F-9718-2016; Vezzoni, Paolo/K-3197-2018; Vezzoni, Paolo/R-3416-2019; Giliani, Silvia/AAX-8843-2020	SOBACCHI, CRISTINA/0000-0002-2684-7184; Frattini, Annalisa/0000-0002-1166-3091; Notarangelo, Luigi D/0000-0002-8335-0262; Giliani, Silvia/0000-0001-8137-4642; Villa, Anna/0000-0003-4428-9013; Vezzoni, Paolo/0000-0002-6382-3923	Telethon [E.0917] Funding Source: Medline	Telethon(Fondazione Telethon)		BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Eapen M, 1998, BONE MARROW TRANSPL, V22, P941, DOI 10.1038/sj.bmt.1701474; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GERRITSEN EJA, 1994, PEDIATRICS, V93, P247; Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407; Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Maquat LE, 1996, AM J HUM GENET, V59, P279; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074-7613(00)80634-2; Vaananen HK, 2000, J CELL SCI, V113, P377; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8	20	512	539	2	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					343	346		10.1038/77131	http://dx.doi.org/10.1038/77131			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888887				2022-12-27	WOS:000087920900027
J	Stone, DL; Slavotinek, R; Bouffard, GG; Banerjee-Basu, S; Baxevanis, AD; Barr, M; Biesecker, LG				Stone, DL; Slavotinek, R; Bouffard, GG; Banerjee-Basu, S; Baxevanis, AD; Barr, M; Biesecker, LG			Mutation of a gene encoding a putative chaperonin causes McKusick-Kaufman syndrome	NATURE GENETICS			English	Article							CCT	McKusick-Kaufman syndrome (MKKS, MIM 236700) is a human developmental anomaly syndrome comprising hydrometrocolpos (HMC), postaxial polydactyly (PAP) and congenital heart disease(1,2) (CHD). MKKS has been mapped in the Old Order Amish population to 20p12, between D20S162 and D20S894 (ref. 3). Here we describe the identification of a gene mutated in MKKS. We analysed the approximately 450-kb candidate region by sample sequencing, which revealed the presence of several known genes and EST clusters. We evaluated candidate transcripts by northern-blot analysis of adult and fetal tissues. We selected one transcript with widespread expression, MKKS, for analysis in a patient from the Amish pedigree and a sporadic, non-Amish case. The Old Order Amish patient was found to be homozygous for an allele that had two missense substitutions and the non-Amish patient was a compound heterozygote for a frameshift mutation predicting premature protein truncation and a distinct missense mutation. The MKKS predicted protein shows amino acid similarity to the chaperonin family of proteins, suggesting a role for protein processing in limb, cardiac and reproductive system development. We believe that this is the first description of a human disorder caused by mutations affecting a putative chaperonin molecule.	Natl Human Genome Res Inst, Genet Dis Res Branch, NIH, Bethesda, MD USA; NIH Intramural Sequencing Ctr, Gaithersburg, MD USA; Univ Michigan, Med Ctr, NIH,NHGRI, Genome Technol Branch, Ann Arbor, MI USA; Univ Michigan, Med Ctr, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Obstet, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Biesecker, LG (corresponding author), Natl Human Genome Res Inst, Genet Dis Res Branch, NIH, Bethesda, MD USA.	leslieb@helix.nih.gov	Biesecker, Leslie/AAG-2526-2021	Baxevanis, Andy/0000-0002-5370-0014	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000009] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Agarwala R, 1998, GENOME RES, V8, P211, DOI 10.1101/gr.8.3.211; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; David A, 1999, J MED GENET, V36, P599; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; KAUFMAN R L, 1972, Birth Defects Original Article Series, V8, P85; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; MCKUSICK VA, 1964, JAMA-J AM MED ASSOC, V189, P813; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROSENBERG MJ, IN PRESS AM J HUM GE; Slavotinek AM, 1999, AM J HUM GENET, V65, pA36; Stone DL, 1998, HUM MOL GENET, V7, P475, DOI 10.1093/hmg/7.3.475; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WILSON RK, 1997, ANAL DNA; ZHAO ND, 1994, GENE, V145, P313	20	151	158	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					79	82		10.1038/75637	http://dx.doi.org/10.1038/75637			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802661				2022-12-27	WOS:000086884000021
J	Chen, YJ; Yee, D; Dains, K; Chatterjee, A; Cavalcoli, J; Schneider, E; Om, J; Woychik, RP; Magnuson, T				Chen, YJ; Yee, D; Dains, K; Chatterjee, A; Cavalcoli, J; Schneider, E; Om, J; Woychik, RP; Magnuson, T			Genotype-based screen for ENU-induced mutations in mouse embryonic stem cells	NATURE GENETICS			English	Article							ETHYL-N-NITROSOUREA; HPRT GENE; ETHYLNITROSOUREA; MUTAGENESIS; LOCUS; DNA; REPAIR; ALKYLTRANSFERASE; SPERMATOGONIA; INDUCTION	The ability to generate mutations is a prerequisite to functional genetic analysis. Despite a long history of using mice as a model system for genetic analysis, the scientific community has not generated a comprehensive collection of multiple alleles for most mouse genes. The chemical mutagen of choice for mouse has been N-ethyl-N-nitrosourea (ENU). an alkylating agent that mainly causes base substitutions in DNA, and therefore allows for recovery of complete and partial loss-, as well as gain-, of-function alleles', Specific locus tests designed to detect recessive mutations showed that ENU is the most efficient mutagen in mouse with an approximate mutation rate of 1 in 1,000 gametes(2,3). In fact, several genome-wide(4-7) and region-specific(8-10) screens based on phenotypes have been carried out. The anticipation of the completion of the human and mouse genome projects, however, now emphasizes genotype-driven genetics-from sequence to mutants. To take advantage of the mutagenicity of ENU and its ability to create allelic series of mutations, we have developed a complementary approach to generating mutations using mouse embryonic stem (ES) cells. We show that a high mutation frequency can be achieved and that modulating DNA-repair activities can enhance this frequency. The treated cells retain germline competency, thereby rendering this approach applicable for efficient generation of an allelic series of mutations pivotal to a fine-tuned dissection of biological pathways.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Parke Davis Lab Mol Genet, Alameda, CA USA	Case Western Reserve University; Pfizer	Magnuson, T (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				BRONSTEIN SM, 1991, CANCER RES, V51, P5188; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; DOUGLAS GR, 1995, P NATL ACAD SCI USA, V92, P7485, DOI 10.1073/pnas.92.16.7485; FAVOR J, 1991, MUTAT RES, V249, P293, DOI 10.1016/0027-5107(91)90003-7; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; JANSEN JG, 1994, MUTAGENESIS, V9, P417, DOI 10.1093/mutage/9.5.417; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; JUSTICE MJ, 1986, GENET RES, V47, P187, DOI 10.1017/S0016672300023119; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; Munroe RJ, 2000, NAT GENET, V24, P318, DOI 10.1038/73563; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Rinchik EM, 1999, GENETICS, V152, P373; RUSSELL LB, 1990, BANBURY REPORT, V34, P271; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SHEDLOVSKY A, 1988, P NATL ACAD SCI USA, V85, P180, DOI 10.1073/pnas.85.1.180; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Tong HH, 1997, ENVIRON MOL MUTAGEN, V29, P168; Veld CWOH, 1997, MUTAGENESIS, V12, P417, DOI 10.1093/mutage/12.6.417; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	23	107	114	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					314	317		10.1038/73557	http://dx.doi.org/10.1038/73557			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700191				2022-12-27	WOS:000085590600028
J	Nadeau, JH; Singer, JB; Matin, A; Lander, ES				Nadeau, JH; Singer, JB; Matin, A; Lander, ES			Analysing complex genetic traits with chromosome substitution strains	NATURE GENETICS			English	Editorial Material							HUMAN-DISEASE; MOUSE MODELS; MICE; POPULATION; GENOME	Many valuable animal models of human disease are known and new models are continually being generated in existing inbred strains(1,2). Some disease models are simple mendelian traits, but most have a polygenic basis. The current approach to identifying quantitative trait loci (QTLs) that underlie such traits is to localize them in crosses, construct congenic strains carrying individual QTLs, and finally map and clone the genes. This process is time-consuming and expensive, requiring the genotyping of large crosses and many generations of breeding. Here we describe a different approach in which a panel of chromosome substitution strains (CSSs) is used for QTL mapping. Each of these strains has a single chromosome from the donor strain substituting for the corresponding chromosome in the host strain. We discuss the construction, applications and advantages of CSSs compared with conventional crosses for detecting and analysing QTLs, including those that have weak phenotypic effects.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA USA	Case Western Reserve University; University Hospitals of Cleveland; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Nadeau, JH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.	jhn4@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA075056] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012305] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [F32HG000195] Funding Source: NIH RePORTER; NCI NIH HHS [CA75056] Funding Source: Medline; NCRR NIH HHS [RR12305] Funding Source: Medline; NHGRI NIH HHS [F32 HG00195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bedell MA, 1997, GENE DEV, V11, P11, DOI 10.1101/gad.11.1.11; Bedell MA, 1997, GENE DEV, V11, P1, DOI 10.1101/gad.11.1.1; Collin GB, 1996, MAMM GENOME, V7, P68, DOI 10.1007/s003359900017; DARVASI A, 1995, GENETICS, V141, P1199; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gould KA, 1996, GENETICS, V144, P1769; HUDGINS CC, 1985, J IMMUNOL, V134, P3849; LANDER ES, 1989, GENETICS, V121, P185; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; SCRIBNER CL, 1988, CLIN IMMUNOL IMMUNOP, V49, P133, DOI 10.1016/0090-1229(88)90102-X; SNELL GD, 1948, J GENET, V49, P87, DOI 10.1007/BF02986826; Steen RG, 1999, GENOME RES, V9, pAP1; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Wakeland E, 1997, IMMUNOL TODAY, V18, P472, DOI 10.1016/S0167-5699(97)01126-2; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WATERS NS, 1994, BEHAV BRAIN RES, V63, P195, DOI 10.1016/0166-4328(94)90091-4	18	342	361	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					221	225		10.1038/73427	http://dx.doi.org/10.1038/73427			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700173				2022-12-27	WOS:000085590600010
J	Satoh, S; Daigo, Y; Furukawa, Y; Kato, T; Miwa, N; Nishiwaki, T; Kawasoe, T; Ishiguro, H; Fujita, M; Tokino, T; Sasaki, Y; Imaoka, S; Murata, M; Shimano, T; Yamaoka, Y; Nakamura, Y				Satoh, S; Daigo, Y; Furukawa, Y; Kato, T; Miwa, N; Nishiwaki, T; Kawasoe, T; Ishiguro, H; Fujita, M; Tokino, T; Sasaki, Y; Imaoka, S; Murata, M; Shimano, T; Yamaoka, Y; Nakamura, Y			AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1	NATURE GENETICS			English	Article							BETA-CATENIN GENE; TUMOR-SUPPRESSOR; APC; ACTIVATION; ADENOVIRUS; APOPTOSIS; PATHWAY; EXON-3	The Wnt signalling pathway is essential for development and organogenesis(1-3). Wnt signalling stabilizes beta-catenin, which accumulates in the cytoplasm, binds to T-cell factor (TCF; also known as lymphocyte enhancer-binding factor, LEF) and then upregulates downstream genes(4-6). Mutations in CTNNB1 (encoding beta-catenin) or ape (adenomatous polyposis coli) have been reported in human neoplasms including colon cancers and hepatocellular carcinomas(7-13) (HCCs), Because HCCs tend to show accumulation of beta-catenin more often than mutations in CTNNB1, we looked for mutations in AXIN1, encoding a key factor for Wnt signalling, in 6 HCC cell lines and 100 primary HCCs. Among the 4 cell lines and 87 HCCs in which we did not detect CTNNB1 mutations, we identified AXIN1 mutations in 3 cell lines and 6 mutations in 5 of the primary HCCs. In cell lines containing mutations in either gene, we observed increased DNA binding of TCF associated with beta-catenin in nuclei. Adenovirus mediated gene transfer of wild-type AXIN1 induced apoptosis in hepatocellular and colorectal cancer cells that had accumulated beta-catenin as a consequence of either APC, CTNNB1 or AXIN1 mutation, suggesting that axin may be an effective therapeutic molecule for suppressing growth of hepatocellular and colorectal cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan; Municipal Ikeda Hosp, Osaka, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Kyoto, Japan	University of Tokyo; Sapporo Medical University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan.		Tokino, Takashi/AAI-9887-2021	Daigo, Yataro/0000-0002-0915-3025				Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DING SF, 1993, CANCER DETECT PREV, V17, P405; Fukuchi T, 1998, CANCER RES, V58, P3526; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Iwao K, 1998, CANCER RES, V58, P1021; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nakamura Y, 1997, NAT MED, V3, P499, DOI 10.1038/nm0597-499; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Voeller HJ, 1998, CANCER RES, V58, P2520; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zurawel RH, 1998, CANCER RES, V58, P896	28	839	891	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					245	250		10.1038/73448	http://dx.doi.org/10.1038/73448			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700176				2022-12-27	WOS:000085590600013
J	Engert, JC; Berube, P; Mercier, J; Dore, C; Lepage, P; Ge, B; Bouchard, JP; Mathieu, J; Melancon, SB; Schalling, M; Lander, ES; Morgan, K; Hudson, TJ; Richter, A				Engert, JC; Berube, P; Mercier, J; Dore, C; Lepage, P; Ge, B; Bouchard, JP; Mathieu, J; Melancon, SB; Schalling, M; Lander, ES; Morgan, K; Hudson, TJ; Richter, A			ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF	NATURE GENETICS			English	Article							DISEQUILIBRIUM; LINKAGE; CHAPERONE; POPULATIONS; FREQUENCY; DISORDERS; SAGUENAY; FINLAND; ALLELE; BASE	Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS or SACS) is an early onset neurodegenerative disease with high prevalence (carrier frequency 1/22) in the Charlevoix-Saguenay-Lac-Saint-Jean (CSLSJ) region of Quebec. We previously mapped the gene responsible for ARSACS to chromosome 13q11 and identified two ancestral haplotypes. Here we report the cloning of this gene, SAGS, which encodes the protein sacsin. The ORF of SAGS is 11,487 bp and is encoded by a single gigantic exon spanning 12,794 bp. This exon is the largest to be identified in any vertebrate organism. The ORF is conserved in human and mouse. The putative protein contains three large segments with sequence similarity to each other and to the predicted protein of an Arabidopsis thaliana ORF. The presence of heat-shock domains suggests a function for sacsin in chaperone-mediated protein folding. SAGS is expressed in a variety of tissues, including the central nervous system. We identified two SAGS mutations in ARSACS families that lead to protein truncation, consistent with haplotype analysis.	Univ Montreal, Hop St Justine, Gen Med Serv, Dept Pediat, Montreal, PQ H3T 1C5, Canada; McGill Univ, Montreal Genome Ctr, Hlth Ctr Res Inst, Montreal, PQ, Canada; Hop Enfants Jesus, Serv Neurol, Quebec City, PQ G1J 1Z4, Canada; Hop Chicoutimi, Serv Neurol, Chicoutimi, PQ, Canada; Karolinska Inst, Neurogen Unit, Dept Mol Med, Stockholm, Sweden; MIT, Whitehead Inst Biomed Res, Cambridge, MA USA; McGill Univ, Dept Human Genet & Med, Montreal, PQ, Canada	Universite de Montreal; McGill University; Laval University; Karolinska Institutet; Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University	Richter, A (corresponding author), Univ Montreal, Hop St Justine, Gen Med Serv, Dept Pediat, Montreal, PQ H3T 1C5, Canada.	thudson@genome.wi.mit.edu; richtera@ere.umontreal.ca	Schalling, Martin/F-1518-2015	Schalling, Martin/0000-0001-5011-2922; Berube, Pierre/0000-0002-1008-192X; Engert, James/0000-0001-8411-4790; Hudson, Thomas/0000-0002-1376-4849				Austerlitz F, 1998, P NATL ACAD SCI USA, V95, P15140, DOI 10.1073/pnas.95.25.15140; Austerlitz F, 1999, GENET EPIDEMIOL, V16, P2, DOI 10.1002/(SICI)1098-2272(1999)16:1<2::AID-GEPI2>3.0.CO;2-9; Birren Bruce, 1999, P241; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bonfield JK, 1996, DNA SEQUENCE, V6, P109, DOI 10.3109/10425179609010197; Bouchard JP, 1998, NEUROMUSCULAR DISORD, V8, P474, DOI 10.1016/S0960-8966(98)00055-8; Bouchard JP., 1991, HDB CLIN NEUROLOGY H, V60, P451; Boysen C, 1997, BIOTECHNIQUES, V23, P978, DOI 10.2144/97236bm01; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Charbonneau H., 1987, HIST ATLAS CANADA, V1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; DEBRAEKELEER M, 1995, ANN HUM BIOL, V22, P111, DOI 10.1080/03014469500003772; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; DICKIE MM, 1965, MOUSE NEWS LETT, V32, P45; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Engert JC, 1999, GENOMICS, V62, P156, DOI 10.1006/geno.1999.6003; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Graham J, 1998, AM J HUM GENET, V63, P1517, DOI 10.1086/302102; GRAHAM J, 1998, THESIS U WASHINGTON; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Heyer E, 1999, HUM BIOL, V71, P99; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KNOPPERS BM, 1991, CAN MED ASSOC J, V144, P128; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; McNally EM, 1996, AM J HUM GENET, V59, P1040; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter A, 1999, AM J HUM GENET, V64, P768, DOI 10.1086/302274; SCHALLING M, 1991, NEUROSCIENCE, V41, P753, DOI 10.1016/0306-4522(91)90365-U; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Thompson EA, 1997, AM J HUM GENET, V60, P197; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WEEKS DE, 1995, AM J HUM GENET, V56, P1506	42	286	298	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					120	125		10.1038/72769	http://dx.doi.org/10.1038/72769			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655055				2022-12-27	WOS:000085104600010
J	Hicks, GG; Singh, N; Nashabi, A; Mai, S; Bozek, G; Klewes, L; Arapovic, D; White, EK; Koury, MJ; Oltz, EM; Van Kaer, L; Ruley, HE				Hicks, GG; Singh, N; Nashabi, A; Mai, S; Bozek, G; Klewes, L; Arapovic, D; White, EK; Koury, MJ; Oltz, EM; Van Kaer, L; Ruley, HE			Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death	NATURE GENETICS			English	Article							HUMAN MYELOID-LEUKEMIA; C-ABL; ATAXIA-TELANGIECTASIA; TLS; PROTEIN; CELLS; ATM; TLS/FUS; ERG; DNA	The gene FUS (also known as TLS (for translocated in liposarcoma) and hnRNP P-2) is translocated with the gene encoding the transcription factor ERG-1 in human myeloid leukaemias(1-3) Although the functions of wild-type FUS are unknown, the protein contains an RNA-recognition motif and is a component of nuclear riboprotein complexes(4,5). FUS resembles a transcription factor in that it binds DNA. contributes a transcriptional activation domain to the FUS-ERG oncoprotein and interacts with several transcription factors in vitro(6-8). TO better understand FUS function in vivo, we examined the consequences of disrupting Fus in mice. Our results indicate that Fus is essential for viability of neonatal animals, influences lymphocyte development in a non-cell-intrinsic manner, has an intrinsic role in the proliferative responses of B cells to specific mitogenic stimuli and is required for the maintenance of genomic stability. The involvement of a nuclear riboprotein in these processes in vivo indicates that Fus is important in genome maintenance.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Winnipeg, MB, Canada; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Dept Vet Affairs, Nashville, TN USA	University of Manitoba; Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Hicks, GG (corresponding author), Manitoba Inst Cell Biol, 100 Olivia St, Winnipeg, MB R3E 0V9, Canada.		Van Kaer, Luc/H-1033-2015; Mai, Sabine/E-5667-2017	Van Kaer, Luc/0000-0001-5275-2309; Mai, Sabine/0000-0002-5797-2201; Hicks, Geoffrey/0000-0003-4688-2312	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013166] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000684] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA42014] Funding Source: Medline; NCRR NIH HHS [R01RR13166] Funding Source: Medline; NHGRI NIH HHS [R01HG00684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; CALVIO C, 1995, RNA, V1, P724; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; HIYOSHI M, 1995, CLIN LAB HAEMATOL, V17, P243; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Singh N, 1999, J IMMUNOL, V163, P2373; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	30	220	226	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					175	179		10.1038/72842	http://dx.doi.org/10.1038/72842			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655065				2022-12-27	WOS:000085104600020
J	Nowak, KJ; Wattanasirichaigoon, D; Goebel, HH; Wilce, M; Pelin, K; Donner, K; Jacob, RL; Hubner, C; Oexle, K; Anderson, JR; Verity, CM; North, KN; Iannaccone, ST; Muller, CR; Nurnberg, P; Muntoni, F; Sewry, C; Hughes, I; Sutphen, R; Lacson, AG; Swoboda, KJ; Vigneron, J; Wallgren-Pettersson, C; Beggs, AH; Laing, NG				Nowak, KJ; Wattanasirichaigoon, D; Goebel, HH; Wilce, M; Pelin, K; Donner, K; Jacob, RL; Hubner, C; Oexle, K; Anderson, JR; Verity, CM; North, KN; Iannaccone, ST; Muller, CR; Nurnberg, P; Muntoni, F; Sewry, C; Hughes, I; Sutphen, R; Lacson, AG; Swoboda, KJ; Vigneron, J; Wallgren-Pettersson, C; Beggs, AH; Laing, NG			Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy	NATURE GENETICS			English	Article							MISSENSE MUTATIONS; DNASE-I; CARDIOMYOPATHY; SEQUENCE; COMPLEX	Muscle contraction results from the force generated between the thin filament protein actin and the thick filament protein myosin, which causes the thick and thin muscle filaments to slide past each other(1). There are skeletal muscle, cardiac muscle, smooth muscle and non-muscle isoforms of both actin and myosin(2). Inherited diseases in humans have been associated with defects in cardiac actin (dilated cardiomyopathy(3) and hypertrophic cardiomyopathy(4)), cardiac myosin (hypertrophic cardiomyopathy(5)) and non-muscle myosin (deafness(6)). Here we report that mutations in the human skeletal muscle cr-actin gene(2) (ACTA1) are associated with two different muscle diseases, 'congenital myopathy with excess of thin myofilaments' (actin myopathy(7)) and nemaline myopathy(8). Both diseases are characterized by structural abnormalities of the muscle fibres and variable degrees of muscle weakness. We have identified 15 different missense mutations resulting in 14 different amino acid changes. The missense mutations in ACTA1 are distributed throughout all six coding exons(2), and some involve known functional domains of actin(9). Approximately half of the patients died within their first year, but two female patients have survived into their thirties and have children. We identified dominant mutations in all but 1 of 14 families, with the missense mutations being single and heterozygous. The only family showing dominant inheritance comprised a 33-year-old affected mother and her two affected and two unaffected children. In another family, the clinically unaffected father is a somatic mosaic for the mutation seen in both of his affected children. We identified recessive mutations in one family in which the two affected siblings had heterozygous mutations in two different exons, one paternally and the other maternally inherited. We also identified de novo mutations in seven sporadic probands for which it was possible to analyse parental DNA.	Univ Western Australia, Queen Elizabeth II Med Ctr, Australian Neuromuscular Res Inst, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; Murdoch Univ, Dept Vet & Biomed Sci, Murdoch, WA 6150, Australia; Harvard Univ, Childrens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA; Univ Mainz, Dept Neuropathol, D-6500 Mainz, Germany; Univ Western Australia, Crystallog Ctr, Perth, WA 6009, Australia; Univ Western Australia, Dept Pharmacol, Perth, WA 6009, Australia; Univ Helsinki, Folkhalsan Inst Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Royal Perth Hosp, Dept Neuropathol, Perth, WA, Australia; Humboldt Univ, Dept Neuropaediat, Berlin, Germany; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Child Dev Ctr, Cambridge, England; Royal Alexandra Hosp Children, Neurogenet Res Unit, Sydney, NSW, Australia; Univ Texas, SW Med Ctr, Texas Scottish Rite Hosp Children, Dallas, TX USA; Univ Wurzburg, Dept Human Genet, D-8700 Wurzburg, Germany; Humboldt Univ, Inst Med Genet, Charite Med Sch, Berlin, Germany; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Paediat & Neonatal Med, London, England; Royal Manchester Childrens Hosp, Dept Paediat Neurol, Manchester M27 1HA, Lancs, England; Univ S Florida, Sch Med, All Childrens Hosp, Tampa, FL 33620 USA; Univ S Florida, Sch Med, Dept Pediat, Tampa, FL 33620 USA; Univ S Florida, Sch Med, Dept Pathol, Tampa, FL 33620 USA; Serv Matern Reg A Pinard, Nancy, France; Univ Helsinki, Folkhalsan Dept Med Genet, Helsinki, Finland	University of Western Australia; Murdoch University; Harvard University; Boston Children's Hospital; Harvard Medical School; Johannes Gutenberg University of Mainz; University of Western Australia; University of Western Australia; University of Helsinki; University of Helsinki; Royal Perth Hospital; University of Western Australia; Humboldt University of Berlin; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Texas Scottish Rite Hospital for Children; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Imperial College London; Royal Manchester Children's Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Helsinki	Laing, NG (corresponding author), Univ Western Australia, Queen Elizabeth II Med Ctr, Australian Neuromuscular Res Inst, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia.		; North, Kathryn/K-6476-2012	Donner, Kati/0000-0001-9190-4336; Pelin, Katarina/0000-0002-7040-7266; Swoboda, Kathryn/0000-0002-4593-6342; Beggs, Alan/0000-0001-8818-0568; Oexle, Konrad/0000-0001-7447-2252; North, Kathryn/0000-0003-0841-8009; Laing, Nigel/0000-0001-5111-3732				AKKARI PA, 1994, CYTOGENET CELL GENET, V65, P265, DOI 10.1159/000133644; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Craig R, 1994, MYOLOGY, P134; DIETZEN CJ, 1993, MUSCLE NERVE, V16, P328; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; DRUMMOND DR, 1992, EUR J BIOCHEM, V209, P171, DOI 10.1111/j.1432-1033.1992.tb17274.x; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Goebel HH, 1997, NEUROMUSCULAR DISORD, V7, P160, DOI 10.1016/S0960-8966(97)00441-0; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAING NG, 1995, CURR OPIN NEUROL, V8, P391, DOI 10.1097/00019052-199510000-00012; LAING NG, 1995, NAT GENET, V9, P75, DOI 10.1038/ng0195-75; Lammens M, 1997, NEUROPEDIATRICS, V28, P116, DOI 10.1055/s-2007-973683; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; North KN, 1997, J MED GENET, V34, P705, DOI 10.1136/jmg.34.9.705; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; SAKAI Y, 1990, J BIOCHEM-TOKYO, V107, P499, DOI 10.1093/oxfordjournals.jbchem.a123074; SHETERLINE P, 1999, ACTIN, P1; TAN P, 1997, NEUROMUSCULAR DISORD, V7, P427; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; WALLGRENPETTERS.C, 1998, INHERITED NEUROMUSCU, P247; WALLGRENPETTERSSON C, 1989, J NEUROL SCI, V89, P1, DOI 10.1016/0022-510X(89)90002-6; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WERTMAN KF, 1992, GENETICS, V132, P337	30	292	299	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					208	212		10.1038/13837	http://dx.doi.org/10.1038/13837			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508519				2022-12-27	WOS:000082827500022
J	Feliubadalo, L; Font, M; Purroy, J; Rousaud, F; Estivill, X; Nunes, V; Golomb, E; Centola, M; Aksentijevich, I; Kreiss, Y; Goldman, B; Pras, M; Kastner, DL; Pras, E; Gasparini, P; Bisceglia, L; Beccia, E; Gallucci, M; de Sanctis, L; Ponzone, A; Rizzoni, GF; Zelante, L; Bassi, MT; George, AL; Manzoni, M; De Grandi, A; Riboni, M; Endsley, JK; Ballabio, A; Borsani, G; Reig, N; Fernandez, E; Estevez, R; Pineda, M; Torrents, D; Camps, M; Lloberas, J; Zorzano, A; Palacin, M				Feliubadalo, L; Font, M; Purroy, J; Rousaud, F; Estivill, X; Nunes, V; Golomb, E; Centola, M; Aksentijevich, I; Kreiss, Y; Goldman, B; Pras, M; Kastner, DL; Pras, E; Gasparini, P; Bisceglia, L; Beccia, E; Gallucci, M; de Sanctis, L; Ponzone, A; Rizzoni, GF; Zelante, L; Bassi, MT; George, AL; Manzoni, M; De Grandi, A; Riboni, M; Endsley, JK; Ballabio, A; Borsani, G; Reig, N; Fernandez, E; Estevez, R; Pineda, M; Torrents, D; Camps, M; Lloberas, J; Zorzano, A; Palacin, M		Int Cystinuria Consortium	Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b(o,+)AT) of rBAT	NATURE GENETICS			English	Article							AMINO-ACID-TRANSPORT; EXPRESSION CLONING; SLC3A1 GENE; IDENTIFICATION; LOCALIZATION; KIDNEY; SYSTEM	Cystinuria (MIM 220100) is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids. Mutations in SLC3A1, encoding rBAT, cause cystinuria type I (ref. 1), but not other types of cystinuria (ref. 2). A gene whose mutation causes non-type I cystinuria has been mapped by linkage analysis to 19q12-13.1 (refs 3,4). We have identified a new transcript, encoding a protein (b(o,+)AT, for b(o,+) amino acid transporter) belonging to a family of light subunits of amino acid transporters, expressed in kidney, liver, small intestine and placenta, and localized its gene (SLC7A9) to the non-type I cystinuria 19q locus. Co-transfection of b(o,+)AT and rBAT brings the latter to the plasma membrane, and results in the uptake of L-arginine in COS cells. We have found SLC7A9 mutations in Libyan-Jews, North American, Italian and Spanish non-type I cystinuria patients. The Libyan Jewish patients are homozygous for a founder missense mutation (V170M) that abolishes b(o,+)AT amino-acid uptake activity when co-transfected with rBAT in COS cells. We identified four missense mutations (G105R, A182T, G195R and C295R) and two frameshift (520insT and 596delTG) mutations in other patients. Our data establish that mutations in SLC7A9 cause non-type I cystinuria, and suggest that b(o,+)AT is the light subunit of rBAT.	Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, E-08028 Barcelona, Spain; Hosp Duran & Reynals, Ctr Genet Med & Mol IRO, E-08907 Barcelona, Spain; Fdn Puigvert, Serv Nefrol IUNA, E-08025 Barcelona, Spain; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; NIAMSD, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Inst Human Genet, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med F, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Heller Inst Med Sci, IL-52621 Tel Hashomer, Israel; IRCCS, Med Genet Serv, Hosp CSS, San Giovanni Rotondo, Italy; IRCCS, Div Urol, Hosp CSS, San Giovanni Rotondo, Italy; Hosp Cristo Re, Div Urol, Rome, Italy; Univ Turin, Dept Pediat, I-10124 Turin, Italy; Hosp Bambino Gesu, Div Pediat Nephrol, Rome, Italy; Telethon Inst Genet & Med, I-20132 Milan, Italy; Vanderbilt Univ, Dept Med, Div Med Genet, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Univ Barcelona, Dept Fisiol Biol Macrophage, Fac Biol, E-08028 Barcelona, Spain	University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Fundacio Puigvert; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo Della Sofferenza; University of Turin; IRCCS Bambino Gesu; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Vanderbilt University; Vanderbilt University; University of Barcelona	Palacin, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Estivill, Xavier/E-2957-2012; Palacín, Manuel/G-9786-2015; Bisceglia, Luigi/B-8720-2017; Feliubadalo, Lidia/G-4577-2016; Riu, Marta Pineda/I-1497-2015; Lloberas, Jorge/D-4303-2014; De Sanctis, Luisa/AAC-6902-2022; Borsani, Giuseppe/B-1709-2010; Wilson, Matthew H/K-3193-2013; Aksentijevich, Ivona/AAF-1335-2019; Estivill, Xavier/A-3125-2013; Zorzano, Antonio/R-5479-2018; Bassi, Maria Teresa T/A-3517-2014; Nunes, Virginia/AAD-1014-2019; Nunes, Virginia/D-4356-2014; Gasparini, Paolo/B-6173-2014; Camps Camprubi, Marta/F-6557-2016; Torrents, David/G-5785-2015; Gallucci, Michele/K-9600-2016; Estevez, Raul/D-8610-2015	Bisceglia, Luigi/0000-0001-5367-8518; Feliubadalo, Lidia/0000-0002-1736-0112; Riu, Marta Pineda/0000-0002-5403-5845; Lloberas, Jorge/0000-0001-7075-4201; Borsani, Giuseppe/0000-0003-0110-1148; Estivill, Xavier/0000-0002-0723-2256; Bassi, Maria Teresa T/0000-0002-8236-1197; Nunes, Virginia/0000-0002-5747-9310; Nunes, Virginia/0000-0002-5747-9310; Camps Camprubi, Marta/0000-0001-5392-1792; Gasparini, Paolo/0000-0002-0859-0856; Torrents, David/0000-0002-6086-9037; Gallucci, Michele/0000-0002-3637-6531; DE SANCTIS, Luisa/0000-0003-2113-6196; Estevez, Raul/0000-0003-1579-650X; BALLABIO, Andrea/0000-0003-1381-4604; Palacin, Manuel/0000-0002-8670-293X	Telethon [E.0556, TGM97000, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; Bisceglia L, 1997, AM J HUM GENET, V60, P611; BISCEGLIA L, 1994, HUM MUTAT, V4, P136, DOI 10.1002/humu.1380040208; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; FELIUBADALO L, IN PRESS GENOMICS; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GOODYER PR, 1993, J PEDIATR-US, V122, P568, DOI 10.1016/S0022-3476(05)83537-1; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Pras E, 1998, AM J MED GENET, V80, P173, DOI 10.1002/(SICI)1096-8628(19981102)80:2<173::AID-AJMG16>3.0.CO;2-S; PRAS E, IN PRESS GENOMICS; Sambrook J., 2002, MOL CLONING LAB MANU; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Wartenfeld R, 1997, AM J HUM GENET, V60, P617	29	254	259	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					52	57		10.1038/12652	http://dx.doi.org/10.1038/12652			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471498				2022-12-27	WOS:000082337300015
J	Ng, HH; Zhang, Y; Hendrich, B; Johnson, CA; Turner, BM; Erdjument-Bromage, H; Tempst, P; Reinberg, D; Bird, A				Ng, HH; Zhang, Y; Hendrich, B; Johnson, CA; Turner, BM; Erdjument-Bromage, H; Tempst, P; Reinberg, D; Bird, A			MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex	NATURE GENETICS			English	Article							CPG BINDING-PROTEIN; DNA METHYLATION; CHROMOSOMAL PROTEIN; TRICHOSTATIN-A; IDENTIFICATION; LOCALIZATION; ACETYLATION; COMPONENT	Mammalian DNA is methylated at many CpG dinucleotides. The biological consequences of methylation are mediated by a family of methyl-CpG binding proteins(1-4). The best characterized family member is MeCP2, a transcriptional repressor that recruits histone deacetylases(5-7). Our report concerns MBD2, which can bind methylated DNA in vivo and in vitro(4) and has been reported to actively demethylate DNA (ref. 8). As DNA methylation causes gene silencing, the MBD2 demethylase is a candidate transcriptional activator. Using specific antibodies, however, we find here that MBD2 in Hela cells is associated with histone deacetylase (HDAC) in the MeCP1 repressor complex(1,9). An affinity-purified HDAC1 corepressor complex(10,11) also contains MBD2, suggesting that MeCP1 corresponds to a fraction of this complex. Exogenous MBD2 represses transcription in a transient assay, and repression can he relieved by the deacetylase inhibitor trichostatin A (TSA; ref. 12). in our hands, MBDZ does not demethylate DNA. Our data suggest that Hela cells, which lack the known methylation-dependent repressor MeCP2, use an alternative pathway involving MBD2 to silence methylated genes.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Edinburgh; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Birmingham; Memorial Sloan Kettering Cancer Center	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.		Ng, Huck Hui/A-1135-2009; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Johnson, Colin/0000-0002-2979-8234; Bird, Adrian/0000-0002-8600-0372; Zhang, Yi/0000-0002-2789-0811; Reinberg, Danny/0000-0003-4288-2016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; WHITE DA, IN PRESS METHODS; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang BG, 1997, DYN CONTIN DISCRET I, V3, P89; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	24	708	742	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					58	61		10.1038/12659	http://dx.doi.org/10.1038/12659			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471499	Green Published			2022-12-27	WOS:000082337300016
J	Xu, X; Toselli, PA; Russell, LD; Seldin, DC				Xu, X; Toselli, PA; Russell, LD; Seldin, DC			Globozoospermia in mice lacking the casein kinase II alpha ' catalytic subunit	NATURE GENETICS			English	Article							HEADED HUMAN SPERMATOZOA; DEFICIENT MICE; SPERMATOGENESIS; SPERMIOGENESIS; MANCHETTE; NUCLEAR; CELLS; GENE	Protein kinase casein kinase II (Ck2) is a cyclic-AMP and calcium-independent serine-threonine kinase that is composed of two catalytic subunits (alpha and alpha') and two regulatory beta-subunits. Ck2 is not a casein kinase in vivo, but over 100 substrates are known(1). The highly conserved amino acid sequences of its subunits(2, 3) and their broad expression suggest that Ck2 may have a fundamental role in cell function. Ck2 has been implicated in DNA replication, regulation of basal and inducible transcription, translation and control of metabolism. The Ck2 alpha and Ck2 alpha' isoforms (products of the genes Csnk2a1 and Csnk2a2, respectively) are highly homologous, but the reason for their redundancy and evolutionary conservation is unknown. We find here that Csnk2a2 is preferentially expressed in late stages of spermatogenesis, and male mice in which Csnk2a2 has been disrupted are infertile, with oligospermia and globozoospermia ('round-headed' spermatozoa). This is the first demonstration of a unique role for a Ck2 isoform in development. The primary spermatogenic defect in Csnk2a2(-/-) testis is a specific abnormality of anterior head shaping of elongating spermatids; this is the first defined gene that regulates sperm head morphogenesis. As the germ cells differentiate, they are capable of undergoing chromatin condensation, although many abnormal cells are deleted through apoptosis or Sertoli cell phagocytosis. The few that survive to populate the epididymis exhibit head abnormalities similar to those described in human globozoospermia, thus Csnk2a2 may be a candidate gene for these inherited syndromes.	Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Boston Medical Center; Boston University; Southern Illinois University System; Southern Illinois University	Seldin, DC (corresponding author), Boston Med Ctr, Dept Med, Boston, MA 02118 USA.	dseldin@med-med1.bu.edu		Seldin, David C/0000-0003-0168-2333				Baccetti B, 1996, J SUBMICR CYTOL PATH, V28, P587; BACCETTI B, 1977, ANDROLOGIA, V9, P255; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; CASTELLANI L, 1978, ARCH ANDROLOGY, V1, P291, DOI 10.3109/01485017808988349; CHESTER N, 1995, J BIOL CHEM, V270, P7501, DOI 10.1074/jbc.270.13.7501; COLE A, 1988, BIOL REPROD, V38, P385, DOI 10.1095/biolreprod38.2.385; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; ESCALIER D, 1990, International Journal of Developmental Biology, V34, P287; FAWCETT DW, 1971, DEV BIOL, V26, P220, DOI 10.1016/0012-1606(71)90124-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Mudgal P, 1998, MOL REPROD DEV, V50, P178, DOI 10.1002/(SICI)1098-2795(199806)50:2&lt;178::AID-MRD8&gt;3.0.CO;2-H; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Rubes J, 1998, FERTIL STERIL, V70, P715, DOI 10.1016/S0015-0282(98)00261-1; RUSSELL LD, 1991, AM J ANAT, V192, P97, DOI 10.1002/aja.1001920202; Russo R. O., 1990, Journal of Sustainable Agriculture, V1, P19, DOI 10.1300/J064v01n02_04; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINGH G, 1992, INT J FERTIL, V37, P99; Tawfic S, 1999, J CELL BIOCHEM, V72, P242; TOPPARI J, 1988, CYTOMETRY, V9, P456, DOI 10.1002/cyto.990090509; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TOSELLI P, 1994, LIFE SCI, V55, P621, DOI 10.1016/0024-3205(94)00488-9; VONBERNHARDI R, 1990, ANDROLOGIA, V22, P12; Ward WS, 1999, BIOL REPROD, V60, P702, DOI 10.1095/biolreprod60.3.702; Xu X, 1998, GENOMICS, V48, P79, DOI 10.1006/geno.1997.5154	26	298	314	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					118	121		10.1038/12729	http://dx.doi.org/10.1038/12729			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471512				2022-12-27	WOS:000082337300029
J	Labay, V; Raz, T; Baron, D; Mandel, H; Williams, H; Barrett, T; Szargel, R; McDonald, L; Shalata, A; Nosaka, K; Gregory, S; Cohen, N				Labay, V; Raz, T; Baron, D; Mandel, H; Williams, H; Barrett, T; Szargel, R; McDonald, L; Shalata, A; Nosaka, K; Gregory, S; Cohen, N			Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness	NATURE GENETICS			English	Article							ANEMIA SYNDROME; HUMAN GENOME; TRANSPORT; GENE	Thiamine-responsive megaloblastic anaemia (TRMA), also known as Rogers syndrome, is an early onset, autosomal recessive disorder defined by the occurrence megaloblastic anaemia, diabetes mellitus and sensorineural deafness. responding in varying degrees to thiamine treatment(1,2) (MIM 249270). We have previously narrowed the TRMA locus from a 16-cM to a 4-cM interval on chromosomal region 1q23.3 (refs 3,4) and this region has been further refined to a 1.4-cM interval(5). Previous studies have suggested that deficiency in,a high-affinity thiamine transporter may cause this disorder(6,7). Here we identify the TRMA gene by positional cloning. We assembled a P1-derived artificial chromosome (PAC) contig spanning the TRMA candidate region. This clarified the order of genetic markers across the TRMA locus, provided 9 new polymorphic markers and narrowed the locus to an approximately 400-kb region. Mutations in a new gene, SLC19A2, encoding a putative transmembrane protein homologous to the reduced folate carrier protein(8,9), were found in all affected individuals in six TRMA families, suggesting that a defective thiamine transporter protein (THTR-1) may underlie the TRMA syndrome.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Genet, Tamkin Human Mol Genet Res Fac, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pediat, Rambam Med Ctr, IL-31096 Haifa, Israel; Sanger Ctr, Cambridge, England; Univ Birmingham, Dept Pediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Kyoto Prefectural Univ Med, Kyoto, Japan	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Wellcome Trust Sanger Institute; University of Birmingham; Kyoto Prefectural University of Medicine	Cohen, N (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Genet, Tamkin Human Mol Genet Res Fac, POB 9649, IL-31096 Haifa, Israel.		Barrett, Timothy/F-1682-2010	Barrett, Timothy/0000-0002-6873-0750; Gregory, Simon/0000-0002-7805-1743	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banikazemi M, 1999, MOL GENET METAB, V66, P193, DOI 10.1006/mgme.1998.2799; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; Gyapay Gabor, 1996, Methods (Orlando), V9, P91, DOI 10.1006/meth.1996.0012; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; MANDEL H, 1984, NEW ENGL J MED, V311, P836, DOI 10.1056/NEJM198409273111307; Neufeld EJ, 1997, AM J HUM GENET, V61, P1335, DOI 10.1086/301642; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Raz T, 1998, HUM GENET, V103, P455, DOI 10.1007/s004390050850; RINDI G, 1994, J INHERIT METAB DIS, V17, P667, DOI 10.1007/BF00712009; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468	17	198	202	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					300	304		10.1038/10372	http://dx.doi.org/10.1038/10372			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391221				2022-12-27	WOS:000081125900026
J	Camacho, JA; Obie, C; Biery, B; Goodman, BK; Hu, CA; Almashanu, S; Steel, G; Casey, R; Lambert, M; Mitchell, GA; Valle, D				Camacho, JA; Obie, C; Biery, B; Goodman, BK; Hu, CA; Almashanu, S; Steel, G; Casey, R; Lambert, M; Mitchell, GA; Valle, D			Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter	NATURE GENETICS			English	Article							RAT-LIVER MITOCHONDRIA; ARGININE-BIOSYNTHESIS; PHOSPHATE SYNTHETASE; CARRIER PROTEINS; HHH SYNDROME; IDENTIFICATION; CITRULLINE; QUEBEC; PURIFICATION; MEMBRANE	Neurospora crassa ARG13 and Saccharomyces cerevisiae ARG11 I en code mitochondrial carrier family (MCF) proteins that transport ornithine across the mitochondrial inner membrane,. We used their sequences to identify EST candidates that partially encode orthologous mammalian transporters. We thereby identified such a gene (ORNT1) that maps to 13q14 and whose expression, similar to that of other urea cycle (UC) components, was high in liver and varied with changes in dietary protein. ORNT1 expression, restores ornithine metabolism in fibroblasts from patients with hyperammonaemia-hyperornithinaemia-homocitrullinuria (HHH) syndrome. In a survey of 11 HHH probands, we identified 3 ORNT1 mutant alleles that account for 21 of 22 possible mutant ORNT1 genes in our patients: F188 Delta which is common in French-Canadian HHH patients and encodes an unstable protein; E180K, which encodes a stable, properly targeted protein that is inactive; and a 13q14 microdeletion. Our results show that ORNT1 encodes the mitochondrial ornithine transporter involved in UC function and is defective in HHH syndrome.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynaecol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21218 USA; Univ Saskatchewan, Dept Pediat, Saskatoon, SK, Canada; Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; University of Saskatchewan; Universite de Montreal	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [C06EY007414] Funding Source: NIH RePORTER; NEI NIH HHS [EY07414] Funding Source: Medline; NICHD NIH HHS [HD24061] Funding Source: Medline; NIGMS NIH HHS [GM07471] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bouchard JP, 1998, NEUROMUSCULAR DISORD, V8, P474, DOI 10.1016/S0960-8966(98)00055-8; BRADFORD NM, 1980, FEBS LETT, V113, P294, DOI 10.1016/0014-5793(80)80612-0; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BRODY LC, 1992, J BIOL CHEM, V267, P330; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; Carter KC, 1998, EUR J HUM GENET, V6, P61, DOI 10.1038/sj.ejhg.5200153; Cayanis E, 1998, GENOMICS, V47, P26, DOI 10.1006/geno.1997.5087; CHARBONNEAU H, 1987, NAISSANCE POPULATION; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; Crabeel M, 1996, J BIOL CHEM, V271, P25011, DOI 10.1074/jbc.271.40.25011; DEBRAEKELEER M, 1991, HUM HERED, V41, P168, DOI 10.1159/000153996; FELL V, 1974, AM J DIS CHILD, V127, P752, DOI 10.1001/archpedi.1974.02110240138023; GAMBLE JG, 1973, J BIOL CHEM, V248, P610; GATFIELD PD, 1975, PEDIATR RES, V9, P488, DOI 10.1203/00006450-197505000-00006; Haust MD, 1996, PATHOL RES PRACT, V192, P271, DOI 10.1016/S0344-0338(96)80230-5; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Huizing M, 1997, AM J HUM GENET, V61, P1239, DOI 10.1086/301628; INDIVERI C, 1994, BBA-BIOENERGETICS, V1188, P293, DOI 10.1016/0005-2728(94)90048-5; Indiveri C, 1998, BIOCHEM BIOPH RES CO, V249, P589, DOI 10.1006/bbrc.1998.9197; INDIVERI C, 1992, EUR J BIOCHEM, V207, P449, DOI 10.1111/j.1432-1033.1992.tb17070.x; Indiveri C, 1997, BIOCHEM J, V327, P349, DOI 10.1042/bj3270349; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kramer R, 1996, KIDNEY INT, V49, P947, DOI 10.1038/ki.1996.133; LEMAY JF, 1992, J PEDIATR-US, V121, P725, DOI 10.1016/S0022-3476(05)81900-6; Liu QY, 1996, GENETICS, V143, P1163; MERANTE F, 1993, AM J HUM GENET, V53, P481; METOKI K, 1984, J INHERIT METAB DIS, V7, P9, DOI 10.1007/BF01805611; MITCHELL GA, METABOLIC MOL BASES; MORIN C, 1993, AM J HUM GENET, V53, P488; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MOUALIJ B, 1997, YEAST, V13, P573; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; PASSARELLA S, 1990, EUR J BIOCHEM, V193, P221, DOI 10.1111/j.1432-1033.1990.tb19326.x; POWERSLEE SG, 1987, J BIOL CHEM, V262, P15683; SCHIMKE RT, 1962, J BIOL CHEM, V237, P459; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; SHIH VE, 1992, PRENATAL DIAG, V12, P717, DOI 10.1002/pd.1970120905; SHIH VE, 1982, CLIN CHIM ACTA, V118, P149, DOI 10.1016/0009-8981(82)90002-X; SHIH VE, 1969, AM J DIS CHILD, V117, P83, DOI 10.1001/archpedi.1969.02100030085009; SIMELL O, 1985, PEDIATR RES, V19, P1283, DOI 10.1203/00006450-198512000-00016; SMITH L, 1992, J PEDIATR GASTR NUTR, V15, P431, DOI 10.1097/00005176-199211000-00011; VALLINA JRP, 1995, PHARM SCI, V1, P185; VICI CD, 1987, PEDIATR RES, V22, P364, DOI 10.1203/00006450-198709000-00025; Vohl MC, 1997, CLIN GENET, V52, P1, DOI 10.1111/j.1399-0004.1997.tb02506.x; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x; YOKOTA S, 1986, HISTOCHEM J, V18, P451, DOI 10.1007/BF01675338; Zammarchi E, 1997, J PEDIATR-US, V131, P440, DOI 10.1016/S0022-3476(97)80072-8	53	140	150	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					151	158		10.1038/9658	http://dx.doi.org/10.1038/9658			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369256				2022-12-27	WOS:000080680900019
J	Watanabe, TK; Bihoreau, MT; McCarthy, LC; Kiguwa, SL; Hishigaki, H; Tsuji, A; Browne, J; Yamasaki, Y; Mizoguchi-Miyakita, A; Oga, K; Ono, T; Okuno, S; Kanemoto, N; Takahashi, E; Tomita, K; Hayashi, H; Adachi, M; Webber, C; Davis, M; Kiel, S; Knights, C; Smith, A; Critcher, R; Miller, J; Thangarajah, T; Day, PJR; Hudson, JR; Irie, Y; Takagi, T; Nakamura, Y; Goodfellow, PN; Lathrop, GM; Tanigami, A; James, MR				Watanabe, TK; Bihoreau, MT; McCarthy, LC; Kiguwa, SL; Hishigaki, H; Tsuji, A; Browne, J; Yamasaki, Y; Mizoguchi-Miyakita, A; Oga, K; Ono, T; Okuno, S; Kanemoto, N; Takahashi, E; Tomita, K; Hayashi, H; Adachi, M; Webber, C; Davis, M; Kiel, S; Knights, C; Smith, A; Critcher, R; Miller, J; Thangarajah, T; Day, PJR; Hudson, JR; Irie, Y; Takagi, T; Nakamura, Y; Goodfellow, PN; Lathrop, GM; Tanigami, A; James, MR			A radiation hybrid map of the rat genome containing 5,255 markers	NATURE GENETICS			English	Article							GENETIC-LINKAGE MAP; SPONTANEOUSLY HYPERTENSIVE RAT; ARTIFICIAL CHROMOSOME LIBRARY; DEPENDENT DIABETES-MELLITUS; BLOOD-PRESSURE; LABORATORY RAT; MOUSE GENOME; GK RAT; CONSTRUCTION; NORVEGICUS	A whole-genome radiation hybrid (RH) panel was used to construct a high-resolution map of the rat genome based on microsatellite and gene markers. These include 3,019 new microsatellite markers described here for the first time and 1,714 microsatellite markers with known genetic locations, allowing comparison and integration of maps from different sources. A robust RH framework map containing 1,030 positions ordered with odds of at least 1,000:1 has been defined as a tool for mapping these markers, and for future RH mapping in the rat, More than 500 genes which have been mapped in mouse and/or human were localized with respect to the rat RH framework, allowing the construction of detailed rat-mouse and rat-human comparative maps and illustrating the power of the RH approach for comparative mapping.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Otsuka Pharmaceut Co Ltd, Otsuka GEN Res Inst, Tokushima 7710192, Japan; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Res Genet Inc, Huntsville, AL 35801 USA; Univ Tokyo, Inst Med Sci, Mol Med Lab, Minato Ku, Tokyo 108, Japan	University of Oxford; Wellcome Centre for Human Genetics; Otsuka Pharmaceutical; University of Cambridge; University of Tokyo	Tanigami, A (corresponding author), Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		TSUJI, Atsushi B/I-9922-2019	TSUJI, Atsushi B/0000-0003-2726-288X; Webber, Caleb/0000-0001-8063-7674; Kanemoto, Naohide/0000-0002-8689-0133	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersson L, 1996, MAMM GENOME, V7, P717, DOI 10.1007/s003359900222; Bihoreau MT, 1997, GENOME RES, V7, P434, DOI 10.1101/gr.7.5.434; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; Brown DM, 1996, NAT GENET, V12, P44, DOI 10.1038/ng0196-44; Brown DM, 1998, MAMM GENOME, V9, P521, DOI 10.1007/s003359900812; Cai L, 1997, GENOMICS, V39, P385, DOI 10.1006/geno.1996.4494; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; CATZELLIS FM, 1933, MAMMAL PHYLOGENY, P159; COLLINS DW, 1994, GENOMICS, V20, P386, DOI 10.1006/geno.1994.1192; DAY INM, 1995, BIOTECHNIQUES, V19, P830; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Galli J, 1996, NAT GENET, V12, P31, DOI 10.1038/ng0196-31; Gauguier D, 1996, NAT GENET, V12, P38, DOI 10.1038/ng0196-38; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; James MR, 1997, TRENDS GENET, V13, P171, DOI 10.1016/S0168-9525(97)01130-X; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kanemoto N, 1998, MAMM GENOME, V9, P419, DOI 10.1007/s003359900789; Kermarrec N, 1996, GENOMICS, V31, P111, DOI 10.1006/geno.1996.0016; KONDO Y, 1993, MAMM GENOME, V4, P571, DOI 10.1007/BF00361387; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Millwood IY, 1997, GENOMICS, V40, P253, DOI 10.1006/geno.1996.4555; Moisan MP, 1996, NAT GENET, V14, P471, DOI 10.1038/ng1296-471; Nabika T, 1997, MAMM GENOME, V8, P215, DOI 10.1007/s003359900392; Nadeau JH, 1998, MAMM GENOME, V9, P491, DOI 10.1007/s003359900806; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; Ohno S., 1967, SEX CHROMOSOMES SEX; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; Remmers EF, 1996, NAT GENET, V14, P82, DOI 10.1038/ng0996-82; Scalzi JM, 1998, GENOMICS, V47, P44, DOI 10.1006/geno.1997.5090; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332; Yang YP, 1998, GENOME RES, V8, P731, DOI 10.1101/gr.8.7.731	44	214	217	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					27	36		10.1038/8737	http://dx.doi.org/10.1038/8737			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319858				2022-12-27	WOS:000080096300019
J	Wallace, MJ; Batt, J; Fladd, CA; Henderson, JT; Skarnes, W; Rotin, D				Wallace, MJ; Batt, J; Fladd, CA; Henderson, JT; Skarnes, W; Rotin, D			Neuronal defects and posterior pituitary hypoplasia in mice lacking the receptor tyrosine phosphatase PTP sigma	NATURE GENETICS			English	Article							MOTOR AXON GUIDANCE; NERVOUS-SYSTEM; EXPRESSION; RAT; DROSOPHILA	The LAR-family protein tyrosine phosphatase sigma (PTP sigma, encoded by the gene Ptprs) consists of a cell adhesion-like extracellular domain composed of immunoglobulin and fibronectin type-ill repeats, a single transmembrane domain and two intracellular catalytic domains(1,2). It was previously shown to be expressed in neuronal and lung epithelial tissues in a developmentally regulated manner(2-8). To study the role of PTP sigma in mouse development, we inactivated Ptprs by gene targeting, All Ptprs(+/-) mice developed normally, whereas 60% of Ptprs(-/-) mice died within 48 hours after birth. The surviving Ptprs(-/-) mice demonstrated stunted growth, developmental delays and severe neurological defects including spastic movements, tremor, ataxic gait abnormal limb flexion and defective proprioception. Histopathology of brain sections revealed reduction and hypocellularity of the posterior pituitary of Ptptrs(-/-) mice, as well as a reduction of approximately 50-75%, in the number of choline acetyl transferase-positive cells in the forebrain. Moreover peripheral nerve electrophysiological analysis revealed slower conduction velocity in Ptprs(-/-) mice relative to wild-type or heterozygous animals, associated with an increased proportion of slowly conducting, small-diameter myelinated fibres and relative hypomyelination. By approximately three weeks of age, most remaining Ptprs(-/-) mice died from a wasting syndrome with atrophic intestinal villi, These results suggest that PTP sigma has a role in neuronal and epithelial development in mice.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Programme Lung Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Berkeley	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.on.ca	Fladd, Christopher/G-2422-2013	Fladd, Christopher/0000-0002-3521-1479; Wallace, Megan/0000-0001-5785-5120				BOURBON JR, 1996, PULMONARY SURFACTANT, P257; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; FERRIERE G, 1985, MUSCLE NERVE, V8, P697, DOI 10.1002/mus.880080812; Haworth K, 1998, MOL CELL NEUROSCI, V12, P93, DOI 10.1006/mcne.1998.0707; Henderson JT, 1996, J NEUROSCI, V16, P7574; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; JACOBOWITZ DM, 1997, CHEMOARCHITECTONIC A; Kim H, 1996, AM J PHYSIOL-LUNG C, V270, pL566, DOI 10.1152/ajplung.1996.270.4.L566; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Oliver J., 1983, HDB VET NEUROLOGIC D, P19; OUVRIER RA, 1987, MUSCLE NERVE, V10, P47, DOI 10.1002/mus.880100110; PITKANEN O, 1997, ANN MED, V30, P134; ROBERTSON A, 1993, ACTA NEUROPATHOL, V86, P163, DOI 10.1007/BF00334883; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; SAHIN M, 1993, J NEUROSCI, V13, P4968; SCHAAPVEID RQJ, 1995, DEV BIOL, V188, P134; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SMORTO MP, 1979, CLIN ELECTRONEUROGRA, P19; Sommer L, 1997, DEV DYNAM, V208, P48, DOI 10.1002/(SICI)1097-0177(199701)208:1<48::AID-AJA5>3.0.CO;2-1; STOKER AW, 1995, DEVELOPMENT, V121, P1833; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WANG H, 1995, J NEUROSCI RES, V41, P297, DOI 10.1002/jnr.490410303; YAN H, 1993, J BIOL CHEM, V268, P24880; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	28	111	113	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					334	338		10.1038/6866	http://dx.doi.org/10.1038/6866			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080192				2022-12-27	WOS:000078977900033
J	Liang, F; Holt, I; Pertea, G; Karamycheva, S; Salzberg, SL; Quackenbush, J				Liang, F; Holt, I; Pertea, G; Karamycheva, S; Salzberg, SL; Quackenbush, J			Gene Index analysis of the human genome estimates approximately 120,000 genes	NATURE GENETICS			English	Article							DNA-SEQUENCE	Although sequencing of the human genome will soon be completed, gene identification and annotation remains a challenge. Early estimates suggested that there might be 60,000-100,000 (ref. 1) human genes, but recent analyses of the available data from EST sequencing projects have estimated as few as 45,000 (ref. 2) or as many as 140,000 (ref. 3) distinct genes. The Chromosome 22 Sequencing Consortium estimated a minimum of 45,000 genes based on their annotation of the complete chromosome, although their data suggests there may be additional genes(4). The nearly 2,000,000 human ESTs in dbEST provide an important resource for gene identification and genome annotation, but these single-pass sequences must be carefully analysed to remove contaminating sequences, including those from genomic DNA. spurious transcription, and vector and bacterial sequences. We have developed a highly refined and rigorously tested protocol for cleaning, clustering and assembling EST sequences to produce high-fidelity consensus sequences for the represented genes (F.L. et al.. manuscript submitted) and used this to create the TIGR Gene Indices(5)-databases of expressed genes for human, mouse, rat and other species (http://www.tigr.org/tdb/tgi.html). Using highly refined and tested algorithms for EST analysis, we have arrived at two independent estimates indicating the human genome contains approximately 120,000 genes.	Inst Genom Res, Rockville, MD USA	J. Craig Venter Institute	Quackenbush, J (corresponding author), Inst Genom Res, Rockville, MD USA.	johnq@tigr.org	Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Quackenbush, John/0000-0002-2702-5879				Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; GREEN P, 1999, BRIDGING GAP SEQUENC; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; SCOTT R, 1999, 11 INT GEN SEQ AN C	9	208	222	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					239	240		10.1038/76126	http://dx.doi.org/10.1038/76126			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835646				2022-12-27	WOS:000087459200030
J	Klesert, TR; Cho, DH; Clark, JI; Maylie, J; Adelman, J; Snider, L; Yuen, EC; Soriano, P; Tapscott, SJ				Klesert, TR; Cho, DH; Clark, JI; Maylie, J; Adelman, J; Snider, L; Yuen, EC; Soriano, P; Tapscott, SJ			Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy	NATURE GENETICS			English	Article							HOMEODOMAIN-ENCODING GENE; CTG REPEAT; LENS OPACIFICATION; REDUCES EXPRESSION; PROTEIN; LOCUS; EXPANSION; FAMILY; INHIBITION; MUTATION	Expansion of a CTG trinucleotide repeat in the 3' UTR of the gene DMPK at the DM1 locus on chromosome 19 causes myotonic dystrophy(1-3), a dominantly inherited disease characterized by skeletal muscle dystrophy and myotonia, cataracts and cardiac conduction defects. Targeted deletion of Dm15, the mouse orthologue of human DMPK, produced mice with a mild myopathy(4,5) and cardiac conduction abnormalities(6), but without other features of myotonic dystrophy, such as myotonia and cataracts. We, and others, have demonstrated that repeat expansion decreases expression of the adjacent gene SIX5 (refs 7,8), which encodes a homeodomain transcription factor, To determine whether SIX5 deficiency contributes to the myotonic dystrophy phenotype, we disrupted mouse Six5 by replacing the first exon with a beta-galactosidase reporter. Six5-mutant mice showed reporter expression in multiple tissues, including the developing lens. Homozygous mutant mice had no apparent abnormalities of skeletal muscle function, but developed lenticular opacities at a higher rate than controls. Our results suggest that SIX5 deficiency contributes to the cataract phenotype in myotonic dystrophy, and that myotonic dystrophy represents a multigenic disorder.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pharmacol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Tapscott, SJ (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, 1124 Columbia St, Seattle, WA 98104 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Tapscott, Stephen/0000-0002-0319-0968	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045203] Funding Source: NIH RePORTER; NEI NIH HHS [EY04542, R01 EY004542] Funding Source: Medline; NIAMS NIH HHS [AR45203] Funding Source: Medline; NICHD NIH HHS [HD 24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; BEHRENS MI, 1994, MUSCLE NERVE, V17, P1264, DOI 10.1002/mus.880171104; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Clark JI, 1996, EXP EYE RES, V62, P75, DOI 10.1006/exer.1996.0009; Damiani E, 1996, NEUROMUSCULAR DISORD, V6, P33, DOI 10.1016/0960-8966(95)00016-X; Day JW, 1999, NEUROMUSCULAR DISORD, V9, P19, DOI 10.1016/S0960-8966(98)00094-7; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Groenen P, 1998, BIOESSAYS, V20, P901, DOI 10.1002/(SICI)1521-1878(199811)20:11<901::AID-BIES5>3.0.CO;2-0; Harris S, 1996, HUM MOL GENET, V5, P1417, DOI 10.1093/hmg/5.Supplement_1.1417; Heath SK, 1997, HUM MOL GENET, V6, P651, DOI 10.1093/hmg/6.5.651; HIRAOKA T, 1995, INVEST OPHTH VIS SCI, V36, P2550; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Korade-Mirnics Z, 1998, NUCLEIC ACIDS RES, V26, P1363, DOI 10.1093/nar/26.6.1363; Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Ramirez BU, 1996, CELL MOL NEUROBIOL, V16, P39, DOI 10.1007/BF02578385; Ranum LPW, 1998, NAT GENET, V19, P196, DOI 10.1038/570; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Winchester CL, 1999, HUM MOL GENET, V8, P481, DOI 10.1093/hmg/8.3.481	30	172	183	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					105	109		10.1038/75490	http://dx.doi.org/10.1038/75490			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802667				2022-12-27	WOS:000086884000027
J	Satoda, M; Zhao, F; Diaz, GA; Burn, J; Goodship, J; Davidson, HR; Pierpont, MEM; Gelb, BD				Satoda, M; Zhao, F; Diaz, GA; Burn, J; Goodship, J; Davidson, HR; Pierpont, MEM; Gelb, BD			Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR AP-2; NEURAL CREST CELLS; PERSISTENT TRUNCUS ARTERIOSUS; CARDIAC MALFORMATION; MICE; MOUSE; HEART; EXPRESSION; AP-2-BETA; EMBRYOGENESIS	Char syndrome is an autosomal dominant trait characterized by patent ductus arteriosus, facial dysmorphism and hand anomalies. Using a positional candidacy strategy, we mapped TFAP2B, encoding a transcription factor expressed in neural crest cells, to the Char syndrome critical region and identified missense mutations altering conserved residues in two affected families. Mutant TFAP2B proteins dimerized properly in vitro, but showed abnormal binding to TFAP2 target sequence. Dimerization of both mutants with normal TFAP2B adversely affected transactivation, demonstrating a dominant-negative mechanism. Our work shows that TFAP2B has a role in ductal, facial and limb development and suggests that Char syndrome results from derangement of neural-crest-cell derivatives.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Newcastle Univ, Sch Biochem & Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Duncan Guthrie Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland; Univ Minneapolis, Dept Pediat, Minneapolis, MN USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Newcastle University - UK	Gelb, BD (corresponding author), Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.	gelbb01@doc.mssm.edu	Diaz, George/AAF-6199-2021	Burn, John/0000-0002-9823-2322; Satoda, Masahiko/0000-0003-0804-860X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038018, K24HD001294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01294, HD38018] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Char F, 1978, Birth Defects Orig Artic Ser, V14, P303; Conway SJ, 1997, DEVELOPMENT, V124, P505; DAVIDSON HR, 1993, J MED GENET, V30, P503, DOI 10.1136/jmg.30.6.503; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Ewart JL, 1997, DEVELOPMENT, V124, P1281; FRANZ T, 1989, ANAT EMBRYOL, V180, P457, DOI 10.1007/BF00305120; FUKIISHI Y, 1992, CELL TISSUE RES, V268, P1, DOI 10.1007/BF00338048; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; Lens XM, 1997, GENOMICS, V41, P463, DOI 10.1006/geno.1997.4671; Li YH, 1997, CHINESE J CHEM, V15, P21; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; MULLINS CE, 1998, SCI PRACTICE PEDIAT, P1181; NISHIBATAKE M, 1987, CIRCULATION, V75, P255, DOI 10.1161/01.CIR.75.1.255; NORA JJ, 1988, AM J MED GENET, V29, P137, DOI 10.1002/ajmg.1320290117; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Satoda M, 1999, CIRCULATION, V99, P3036, DOI 10.1161/01.CIR.99.23.3036; Sullivan R, 1998, DEV BIOL, V204, P224, DOI 10.1006/dbio.1998.9089; WALDO KL, 1993, ANAT RECORD, V237, P385, DOI 10.1002/ar.1092370312; Waldo KL, 1999, DEV BIOL, V208, P307, DOI 10.1006/dbio.1999.9219; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wilson GN, 1998, AM J MED GENET, V76, P297, DOI 10.1002/(SICI)1096-8628(19980401)76:4<297::AID-AJMG4>3.0.CO;2-N; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; ZETTERQVIST P, 1972, CLIN GENETIC STUDY C	32	177	184	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					42	46		10.1038/75578	http://dx.doi.org/10.1038/75578			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802654				2022-12-27	WOS:000086884000014
J	Blume-Jensen, P; Jiang, GQ; Hyman, R; Lee, KF; O'Gorman, S; Hunter, T				Blume-Jensen, P; Jiang, GQ; Hyman, R; Lee, KF; O'Gorman, S; Hunter, T			Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3 '-kinase is essential for male fertility	NATURE GENETICS			English	Article							PRIMORDIAL GERM-CELLS; PROTEIN-KINASE-C; KIT RECEPTOR; CULTURE; LIGAND; EXPRESSION; MOUSE; SPERMATOGONIA; SEQUENCES; SURVIVAL	The c-kit-encoded transmembrane tyrosine kinase receptor for stem cell factor (Kit/SCF-R) is required for normal haema-topoiesis, melanogenesis and gametogenesis(1-3). However, the roles of individual Kit/SCF-R-induced signalling pathways in the control of developmental processes in the intact animal are completely unknown. To examine the function of SCF-induced phosphatidylinositol (PI) 3'-kinase activation in vivo, we employed the Cre-IoxP system(4) to mutate the codon for Tyr719. the PI 3'-kinase binding site in Kit/SCF-R. to Phe in the genome of mice by homologous recombination. Homozygous (Y719F/Y719F) mutant mice are viable. The mutation completely disrupted PI 3'-kinase binding to Kit/SCF-R and reduced SCF-induced PI 3'-kinase-dependent activation of Akt by 90%. The mutation induced a gender- and tissue-specific defect. Although there are no haematopoietic or pigmentation defects in homozygous mutant mice, males are sterile due to a block in spermatogenesis. with initially decreased proliferation and subsequent extensive apoptosis occurring at the spermatogonial stem-cell level. In contrast, female homozygotes are fully Fertile. This is the first report so far demonstrating the role of an individual signalling pathway downstream of Kit/SCF-R in the intact animal. It provides the first in vivo model for male sterility caused by a discrete signalling pathway defect affecting early germ cells.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Canc Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute; Salk Institute; Salk Institute	Blume-Jensen, P (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BESMER P, 1993, DEVELOPMENT, P125; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; COOKE JE, 1993, METHOD ENZYMOL, V225, P37; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; Heuchel R, 1999, P NATL ACAD SCI USA, V96, P11410, DOI 10.1073/pnas.96.20.11410; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; Metzger D, 1999, CURR OPIN BIOTECH, V10, P470, DOI 10.1016/S0958-1669(99)00012-9; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; SERVE H, 1994, J BIOL CHEM, V269, P6026; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	30	249	269	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					157	162		10.1038/72814	http://dx.doi.org/10.1038/72814			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655061				2022-12-27	WOS:000085104600016
J	O'Hagan, RC; Schreiber-Agus, N; Chen, K; David, G; Engelman, JA; Schwab, R; Alland, L; Thomson, C; Ronning, DR; Sacchettini, JC; Meltzer, P; DePinho, RA				O'Hagan, RC; Schreiber-Agus, N; Chen, K; David, G; Engelman, JA; Schwab, R; Alland, L; Thomson, C; Ronning, DR; Sacchettini, JC; Meltzer, P; DePinho, RA			Gene-target recognition among members of the Myc superfamily and implications for oncogenesis	NATURE GENETICS			English	Article							C-MYC; DNA-BINDING; REPRESSES TRANSCRIPTION; CELL-GROWTH; IN-VIVO; MAX; PROTEIN; DOMAIN; DIFFERENTIATION; NETWORK	Myc and Mad family proteins regulate multiple biological processes through their capacity to influence gene expression directly. Here we show that the basic regions of Myc and Mad proteins are not functionally equivalent in oncogenesis, have separable E-box-binding activities and engage both common and distinct gene targets. Our data support the view that the opposing biological actions of Myc and Mxi1 extend beyond reciprocal regulation of common gene targets. Identification of differentially regulated gene targets provides a framework for understanding the mechanism through which the Myc superfamily governs the growth, proliferation and survival of normal and neoplastic cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University College Station; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			Ronning, Donald/0000-0003-2583-8849; DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NEI NIH HHS [R01EY09300] Funding Source: Medline; NICHD NIH HHS [R01HD28317] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chiorini JA, 1999, J BIOL CHEM, V274, P4195, DOI 10.1074/jbc.274.7.4195; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeRisi J, 1996, NAT GENET, V14, P457; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Ferre d'Amare AR, 1993, NATURE, V363, P38; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khan J, 1998, CANCER RES, V58, P5009; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; [No title captured]	37	121	125	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					113	119		10.1038/72761	http://dx.doi.org/10.1038/72761			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655054				2022-12-27	WOS:000085104600009
J	Weijer, C; Goldsand, G; Emanuel, EJ				Weijer, C; Goldsand, G; Emanuel, EJ			Protecting communities in research: current guidelines and limits of extrapolation	NATURE GENETICS			English	Editorial Material							ETHICS	As genetic research increasingly focuses on communities, there have been calls for extending research protections to them. We critically examine guidelines developed to protect aboriginal communities and consider their applicability to other communities. These guidelines are based on a model of researcher-community partnership and span the phases of a research project, from protocol development to publication. The complete list of 23 protections may apply to those few non-aboriginal communities, such as the Amish, that are highly cohesive. Although some protections may be applicable to less-cohesive communities, such as Ashkenazi Jews, analysis suggests substantial problems in extending these guidelines in tote beyond the aboriginal communities for which they were developed.	Dalhousie Univ, Dept Bioeth, Halifax, NS, Canada; Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada; NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	Dalhousie University; University of Toronto; National Institutes of Health (NIH) - USA	Weijer, C (corresponding author), Dalhousie Univ, Dept Bioeth, Halifax, NS, Canada.	Charles.Weijer@dal.ca	Weijer, Charles/ABC-5433-2020	Weijer, Charles/0000-0002-5510-1074				*AB HLTH RES ETH C, 1989, IN B; *AB HLTH RES ETH C, 1998, ETH CONS HLTH REL RE; American Anthropological Association, 1997, COD ETH; American Indian Law Center, 1994, MOD TRIB RES COD; American Public Health Association, 1984, NAT ARCT HLTH SCI PO; APPELBAUM P, 1987, INFORMED CONSENT LEG; *ASS CAN U NO STUD, 1982, ETH PRINC COND RE; *AUSTR NAT HLTH ME, 1991, GUID ETH MATT AB TOR; *CAN ROYAL COMM AB, 1993, INT RES PLAN; *CAN TRIC WORK GRO, 1996, COD COND RES INV HUM; *CAN TRIC WORK GRO, 1997, COD COND RES INV HUM; Council for International Organizations of Medical Sciences, 1991, INT GUID ETH REV EP; Freedman Benjamin, 1987, IRB, V9, P7, DOI 10.2307/3563623; *IN CIRC C, 1994, P C NO FOR POL CAN; *INT ARCT RES POL, 1995, ARCT RES US, V9, P56; *KAHN SCH DIAB PRE, 1996, COD RES ETH; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lehrman S, 1997, NATURE, V389, P322, DOI 10.1038/38579; Levine Carol, 1991, IRB, V13, P1; Levine R. J., 1982, HUMAN EXPT MED ETHIC, P16; LEVINE ROBERT J., 1988, ETHICS REGULATION CL, V2nd; Macaulay AC, 1998, CAN J PUBLIC HEALTH, V89, P105, DOI 10.1007/BF03404399; MADDOCKS I, 1992, MED J AUSTRALIA, V157, P553, DOI 10.5694/j.1326-5377.1992.tb137356.x; MCCARTHY C, 1993, ETHIDS RES HUMAN SUB, P208; *MED RES COUNC CAN, 1998, TRIC POL STAT ETH CO; *MENZ SCH HLTH RES, 1989, HLTH RES GUID AB COM; *NAT COMM PROT HUM, 1979, OPRR REP, P1; National Bioethics Advisory Commission, 1999, RES INV HUM BIOL MAT; Protection of Human Subjects, 1996, FED REGISTER, V61, P51497; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Weijer C, 1999, CAMB Q HEALTHC ETHIC, V8, P501, DOI 10.1017/S0963180199004120; Weiss K M, 1997, Houst Law Rev, V33, P1431	32	120	122	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					275	280		10.1038/15455	http://dx.doi.org/10.1038/15455			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545946				2022-12-27	WOS:000083792200014
J	Xu, PX; Adams, J; Peters, H; Brown, MC; Heaney, S; Maas, R				Xu, PX; Adams, J; Peters, H; Brown, MC; Heaney, S; Maas, R			Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia	NATURE GENETICS			English	Article							BRANCHIOOTORENAL BOR SYNDROME; RECEPTOR TYROSINE KINASE; C-RET PROTOONCOGENE; EYES ABSENT; DEVELOPMENTAL DEFECTS; VARIABLE EXPRESSIVITY; MULTIPLE STEPS; GENE; PAX2; MUTATION	Haploinsufficiency for human EYA1, a homologue of the Drosophila melanogaster gene eyes absent (eya), results in the dominantly inherited disorders branchio-oto-renal (BOR) syndrome(1-3) and branchio-oto (BO) syndrome(4), which are characterized by craniofacial abnormalities and hearing loss with (BOR) or without (BO) kidney defects. To understand the developmental pathogenesis of organs affected in these syndromes, we inactivated the gene Eya1 in mice. Eya1 heterozygotes show renal abnormalities and a conductive hearing loss similar to BOR syndrome, whereas Eya1 homozygotes lack ears and kidneys due to defective inductive tissue interactions and apoptotic regression of the organ primordia. Inner ear development in Eya1 homozygotes arrests at the otic vesicle stage and all components of the inner ear and specific cranial sensory ganglia fail to form. In the kidney, Eya1 homozygosity results in an absence of ureteric bud outgrowth and a subsequent failure of metanephric induction. Gdnf expression, which is required to direct ureteric bud outgrowth via activation of the c-ret Rtk (refs 5-8), is not detected in Eya1(-/-) metanephric mesenchyme. In Eya1(-/-) ear and kidney development, Six but not Pax expression is Eya1 dependent, similar to a genetic pathway elucidated in the Drosophila eye imaginal disc. Our results indicate that Eya1 controls critical early inductive signalling events involved in ear and kidney formation and integrate Eya1 into the genetic regulatory cascade controlling kidney formation upstream of Gdnf. In addition, our results suggest that an evolutionarily conserved Pax-Eya-Six regulatory hierarchy is used in mammalian ear and kidney development.	Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Maas, R (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.				NEI NIH HHS [F32 EY006869, R01 EY10123] Funding Source: Medline; NIDCR NIH HHS [R01 DE11697] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006869, R01EY010123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011697] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abdelhak S, 1997, HUM MOL GENET, V6, P2247, DOI 10.1093/hmg/6.13.2247; Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Borycki AG, 1999, DEVELOPMENT, V126, P1665; CHEN A, 1995, AM J MED GENET, V58, P365, DOI 10.1002/ajmg.1320580413; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; FRASER FC, 1980, AM J MED GENET, V7, P341, DOI 10.1002/ajmg.1320070316; Halder G, 1998, DEVELOPMENT, V125, P2181; HEIMLER A, 1986, AM J MED GENET, V25, P15, DOI 10.1002/ajmg.1320250104; Johnson KR, 1999, HUM MOL GENET, V8, P645, DOI 10.1093/hmg/8.4.645; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KONIG R, 1994, EUR J PEDIATR, V153, P446, DOI 10.1007/s004310050171; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kumar S, 1998, HUM MUTAT, V11, P443, DOI 10.1002/(SICI)1098-1004(1998)11:6<443::AID-HUMU4>3.3.CO;2-J; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; OLIVER G, 1995, DEVELOPMENT, V121, P693; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Petersen J, 1998, INTERNET WORLD, V9, P12; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Torres M, 1995, DEVELOPMENT, V121, P4057; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Vincent C, 1997, EUR J HUM GENET, V5, P242, DOI 10.1159/000484770; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; Xu PX, 1997, DEVELOPMENT, V124, P219	29	498	512	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					113	117		10.1038/12722	http://dx.doi.org/10.1038/12722			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471511				2022-12-27	WOS:000082337300028
J	Mozo, T; Dewar, K; Dunn, P; Ecker, JR; Fischer, S; Kloska, S; Lehrach, H; Marra, M; Martienssen, R; Meier-Ewert, S; Altmann, T				Mozo, T; Dewar, K; Dunn, P; Ecker, JR; Fischer, S; Kloska, S; Lehrach, H; Marra, M; Martienssen, R; Meier-Ewert, S; Altmann, T			A complete BAC-based physical map of the Arabidopsis thaliana genome	NATURE GENETICS			English	Article							RECOMBINANT INBRED LINES; LIBRARY; CONSTRUCTION; CHROMOSOME-2; SEQUENCE; REGIONS; MARKERS; CONTIG; CLONES; PLANT	Arabidopsis thaliana is a small flowering plant that serves as the major model system in plant molecular genetics'. The efforts of many scientists have produced genetic maps that provide extensive coverage of the genome (http://genome-www.stanford.edulArabidopsis/maps.html). Recently, detailed YAC, BAG, P1 and cosmid-based physical maps (that is, representations of genomic regions as sets of overlapping clones of corresponding libraries) have been established that extend over wide genomic areas ranging from several hundreds of kilobases(2,3) to entire chromosome(4-9). These maps provide an entry to gain deeper insight into the A. thaliana genome structure. A. thaliana has been chosen as the subject of the first large-scale project intended to determine the full genome sequence of a plant(10). This sequencing project, together with the increasing interest in map-based gene cloning, has highlighted the requirement for a complete and accurate physical map of this plant species. To supply the scientific community with a high-quality resource, we present here a complete physical map of A. thaliana using essentially the IGF BAC library(11) The map consists of 27 contigs that cover the entire genome, except for the presumptive centromeric regions, nucleolar organization regions (NOR) and telomeric areas. This is the first reported map of a complex organism based entirely on BAC clones and it represents the most homogeneous and complete physical map established to date for any plant genome. Furthermore, the analysis performed here serves as a model for an efficient physical mapping procedure using BAC clones that can be applied to other complex genomes.	Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany; MIT, Ctr Genome Res, Whitehead Inst, Cambridge, MA 02141 USA; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; GPC Aktiengesell, D-82152 Martinsried, Germany	Max Planck Society; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Pennsylvania; Max Planck Society; Washington University (WUSTL); Cold Spring Harbor Laboratory	Altmann, T (corresponding author), Max Planck Inst Mol Pflanzenphysiol, Karl Liebknecht Str 25, D-14476 Golm, Germany.	altmann@mpimp-golm.mpg.de	Ecker, Joseph R/B-9144-2008; Marra, Marco A/B-5987-2008	Ecker, Joseph R/0000-0001-5799-5895; Marra, Marco A/0000-0001-7146-7175; Altmann, Thomas/0000-0002-3759-360X				Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; Kotani H, 1997, DNA Res, V4, P371, DOI 10.1093/dnares/4.6.371; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Liu YG, 1996, PLANT J, V10, P733, DOI 10.1046/j.1365-313X.1996.10040733.x; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Murata M, 1997, PLANT J, V12, P31, DOI 10.1046/j.1365-313X.1997.12010031.x; PALAZZOLO MJ, 1991, P NATL ACAD SCI USA, V88, P8034, DOI 10.1073/pnas.88.18.8034; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; Sato S, 1998, DNA Res, V5, P163, DOI 10.1093/dnares/5.3.163; Schmidt R, 1997, PLANT J, V11, P563, DOI 10.1046/j.1365-313X.1997.11030563.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; Wang ML, 1997, PLANT J, V12, P711, DOI 10.1046/j.1365-313X.1997.00711.x; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	25	109	129	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1999	22	3					271	275		10.1038/10334	http://dx.doi.org/10.1038/10334			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391215				2022-12-27	WOS:000081125900020
J	Zhong, J; Peters, AHFM; Lee, K; Braun, RE				Zhong, J; Peters, AHFM; Lee, K; Braun, RE			A double-stranded RNA binding protein required for activation of repressed messages in mammalian germ cells	NATURE GENETICS			English	Article							MESSENGER-RNA; MOUSE; MICE; SPERMATOGENESIS; LOCALIZATION; PROTAMINE	Chromatin packaging in mammalian spermatozoa requires an ordered replacement of the somatic histones by two classes of spermatid-specific basic proteins, the transition proteins and the protamines(1). Temporal expression of transition proteins and protamines during spermatid differentiation is under translational control, and premature translation of protamine 1 leads to precocious nuclear condensation and sterility(2). We have previously suggested that the double-stranded (ds) RNA binding protein Prbp (encoded by the gene Tarbp2) functions as a translational regulator during mouse spermatogenesis(3). Here we show that Prbp is required for proper translational activation of the mRNAs encoding the protamines. We generated mice that carry a targeted disruption of Tarbp2 and determined that they were sterile and severely oligospermic. Using immunohistological analysis, we determined that the endogenous Prm2 mRNA and a reporter mRNA carrying protamine 1 translational-control elements were translated in a mosaic pattern. We showed that failure to synthesize the protamines resulted in delayed replacement of the transition proteins and subsequent failure of spermiation. The timing of Prbp expression suggests that it may function as a chaperone in the assembly of specific translationally regulated ribonucleoprotein particles.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Braun, RE (corresponding author), Univ Washington, Dept Genet, Box 357360,1959 NE Pacific, Seattle, WA 98195 USA.			Peters, Antoine/0000-0002-0311-1887	NICHD NIH HHS [U54 HD12629, HD27215] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027215, U54HD012629] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; BRAUN RE, 1990, ENZYME, V44, P120, DOI 10.1159/000468752; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CATIGNOL A, 1993, MOL CELL BIOL, V13, P2193; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; FAJARDO MA, 1994, DEV BIOL, V166, P643, DOI 10.1006/dbio.1994.1344; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; Lee K, 1996, MOL CELL BIOL, V16, P3023; Meistrich ML, 1993, MOL BIOL MALE REPROD, P67; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHUMACHER JM, 1995, BIOL REPROD, V52, P1274, DOI 10.1095/biolreprod52.6.1274; STANKER LH, 1993, MOL IMMUNOL, V30, P1633, DOI 10.1016/0161-5890(93)90436-F; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979	17	134	148	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					171	174		10.1038/9684	http://dx.doi.org/10.1038/9684			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369260	Green Published			2022-12-27	WOS:000080680900023
J	Chang, B; Smith, RS; Hawes, NL; Anderson, MG; Zabaleta, A; Savinova, O; Roderick, TH; Heckenlively, JR; Davisson, MT; John, SWM				Chang, B; Smith, RS; Hawes, NL; Anderson, MG; Zabaleta, A; Savinova, O; Roderick, TH; Heckenlively, JR; Davisson, MT; John, SWM			Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice	NATURE GENETICS			English	Article							PIGMENT DISPERSION SYNDROME; TYROSINASE-RELATED PROTEIN; MOUSE MUTATION; WILD-TYPE; GENE; BROWN; MAPS	Glaucomas are a major cause of blindness'. Visual loss typically involves retinal ganglion cell death and optic nerve atrophy subsequent to a pathologic elevation of intraocular pressure (IOP). Some human glaucomas are associated with anterior segment abnormalities such as pigment dispersion syndrome (PDS) and iris atrophy with associated synechiae(2). The primary causes of these abnormalities are unknown, and their aetiology is poorly understood. We recently characterized a mouse strain (DBA/2J) that develops glaucoma subsequent to anterior segment changes including pigment dispersion and iris atrophy(3). Using crosses between mouse strains DBA/2J (D2) and C57BL/6J (B6), we now show there are two chromosomal regions that contribute to the anterior segment changes and glaucoma. Progeny homozygous for the D2 allele of one locus on chromosome 6 (called ipd) develop an iris pigment dispersion phenotype similar to human PDS, ipd resides on a region of mouse chromosome 6 with conserved synteny to a region of human chromosome 7q that is associated with human PDS (ref. 4), Progeny homozygous for the D2 allele of a different locus on chromosome 4 (called isa) develop an iris stromal atrophy phenotype (ISA). The Tyrp1 gene is a candidate for isa and likely causes ISA via a mechanism involving pigment production. Progeny homozygous for the D2 alleles of both ipd and isa develop an earlier onset and more severe disease involving pigment dispersion and iris stromal atrophy.	Jackson Lab, Bar Harbor, ME 04609 USA; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jules Stein Eye Inst, Torrance, CA USA; Tufts Univ, Sch Med, Boston, MA USA	Jackson Laboratory; Howard Hughes Medical Institute; Tufts University	John, SWM (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Anderson, Michael/B-4580-2009	Anderson, Michael/0000-0001-5730-6105; Chang, Bo/0000-0001-8259-7290	NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007758] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196] Funding Source: Medline; NEI NIH HHS [EY07758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andersen JS, 1997, ARCH OPHTHALMOL-CHIC, V115, P384, DOI 10.1001/archopht.1997.01100150386012; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BLUM J V, 1962, Trans Am Acad Ophthalmol Otolaryngol, V66, P493; FARRAR SM, 1989, AM J OPHTHALMOL, V108, P223, DOI 10.1016/0002-9394(89)90110-4; FRANKKAMENETZKI SG, 1925, KLIN MONATSBL AUGENH, V74, P133; HEON E, 1995, HUM MOL GENET, V4, P485, DOI 10.1093/hmg/4.3.485; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JAMPOL LM, 1974, AM J OPHTHALMOL, V77, P353, DOI 10.1016/0002-9394(74)90741-7; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; Manga P, 1997, AM J HUM GENET, V61, P1095, DOI 10.1086/301603; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; MIGLIAZZO CV, 1986, OPHTHALMOLOGY, V93, P1528; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; RICHTER CU, 1986, ARCH OPHTHALMOL-CHIC, V104, P211, DOI 10.1001/archopht.1986.01050140065021; RITCH R, 1993, AM J OPHTHALMOL, V115, P707, DOI 10.1016/S0002-9394(14)73635-9; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SHIBAHARA S, 1992, PIGM CELL RES, V2, P93; Shields M B, 1983, Trans Am Ophthalmol Soc, V81, P736; Shields M. B., 1996, GLAUCOMAS, P957; SHIELDS MB, 1979, OPHTHALMOLOGY, V86, P1533; SHIELDS MB, 1979, SURV OPHTHALMOL, V24, P3, DOI 10.1016/0039-6257(79)90143-7; SHIELDS MB, 1997, CHANDLER GRANTS GLAU, P319; Spencer W.H., 1996, OPHTHALMIC PATHOLOGY; SPENCER WH, 1996, OPHTHALMIC PATHOLOGY, P438; ZDARSKY E, 1990, GENETICS, V126, P443	28	215	221	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					405	409		10.1038/7741	http://dx.doi.org/10.1038/7741			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192392				2022-12-27	WOS:000079439700023
J	Gogos, JA; Santha, M; Takacs, Z; Beck, KD; Luine, V; Lucas, LR; Nadler, JV; Karayiorgou, M				Gogos, JA; Santha, M; Takacs, Z; Beck, KD; Luine, V; Lucas, LR; Nadler, JV; Karayiorgou, M			The gene encoding proline dehydrogenase modulates sensorimotor gating in mice	NATURE GENETICS			English	Article							DROSOPHILA-MELANOGASTER; GLUTAMATE; INHIBITION; HABITUATION; OXIDASE; BRAIN; GABA	Hemizygous cryptic deletions of the q11 band of human chromosome 22 have been associated with a number of psychiatric and behavioural phenotypes, including schizophrenial(1-3). Here we report the isolation and characterization of PRODH, a human homologue of Drosophila melanogaster sluggish-A (sIgA), which encodes proline dehydrogenase responsible for the behavioural phenotype of the sIgA mutant(4). PRODH is localized at chromosome 22q11 in a region deleted in some psychiatric patients. We also isolated the mouse homologue of sIgA (Prodh), identified a mutation in this gene in the Pro/Re hyperprolinaemic mouse strain and found that these mice have a deficit in sensorimotor gating accompanied by regional neurochemical alterations in the brain. Sensorimotor gating is a neural filtering process that allows attention to be focused on a given stimulus, and is affected in patients with neuropsychiatric disorders(5). Furthermore, several lines of evidence suggest that proline may serve as a modulator of synaptic transmission in the mammalian brain. Our observations, in conjunction with the chromosomal location of PRODH, suggest a potential involvement of this gene in the 22q11-associated psychiatric and behavioural phenotypes.	Rockefeller Univ, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; CUNY Hunter Coll, New York, NY 10021 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Rockefeller University; Columbia University; City University of New York (CUNY) System; Hunter College (CUNY); Duke University	Karayiorgou, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	karayin@rockvax.rockefeller.edu	Santha, Miklos/F-4772-2013					Bassett AS, 1998, AM J MED GENET, V81, P328, DOI 10.1002/(SICI)1096-8628(19980710)81:4<328::AID-AJMG10>3.3.CO;2-8; BLAKE RL, 1972, SCIENCE, V176, P809, DOI 10.1126/science.176.4036.809; BLAKE RL, 1972, BIOCHEM J, V129, P987, DOI 10.1042/bj1290987; Campbell HD, 1997, HUM GENET, V101, P69, DOI 10.1007/s004390050589; Carlson C, 1997, AM J HUM GENET, V61, P620, DOI 10.1086/515508; Chaouloff F, 1997, BEHAV BRAIN RES, V85, P27, DOI 10.1016/S0166-4328(96)00160-X; Cohen SM, 1997, BRAIN RES, V769, P333, DOI 10.1016/S0006-8993(97)00721-X; Cohen SM, 1997, BRAIN RES, V761, P271, DOI 10.1016/S0006-8993(97)00352-1; CREESE I, 1973, BRAIN RES, V55, P369, DOI 10.1016/0006-8993(73)90302-8; CRUSIO WE, 1989, BEHAV BRAIN RES, V32, P75, DOI 10.1016/S0166-4328(89)80074-9; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; GEYER MA, 1982, PSYCHOPHYSIOLOGY, V19, P1, DOI 10.1111/j.1469-8986.1982.tb02589.x; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; HAYWARD DC, 1993, P NATL ACAD SCI USA, V90, P2979, DOI 10.1073/pnas.90.7.2979; Inoue H, 1996, BIOL PHARM BULL, V19, P163; Jaeken J, 1996, J INHERIT METAB DIS, V19, P275, DOI 10.1007/BF01799254; JOHNSON JL, 1984, BRAIN RES, V323, P247, DOI 10.1016/0006-8993(84)90295-6; KANWAR YS, 1975, BIOMEDICINE, V22, P209; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; Lucas LR, 1998, EUR J NEUROSCI, V10, P3153, DOI 10.1046/j.1460-9568.1998.00321.x; Luine VN, 1997, BRAIN RES, V747, P165, DOI 10.1016/S0006-8993(96)01255-3; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Renick SE, 1999, J NEUROSCI, V19, P21, DOI 10.1523/JNEUROSCI.19-01-00021.1999; Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326; Valle, 1995, METABOLIC MOL BASES, P1125; WANG SS, 1987, MOL CELL BIOL, V7, P4431, DOI 10.1128/MCB.7.12.4431; Yan WL, 1998, AM J MED GENET, V81, P41, DOI 10.1002/(SICI)1096-8628(19980207)81:1<41::AID-AJMG8>3.0.CO;2-Q; YONEDA Y, 1982, J NEUROCHEM, V38, P1686, DOI 10.1111/j.1471-4159.1982.tb06650.x	30	213	225	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1999	21	4					434	439		10.1038/7777	http://dx.doi.org/10.1038/7777			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192398				2022-12-27	WOS:000079439700029
J	Nutt, SL; Vambrie, S; Steinlein, P; Kozmik, Z; Rolink, A; Weith, A; Busslinger, M				Nutt, SL; Vambrie, S; Steinlein, P; Kozmik, Z; Rolink, A; Weith, A; Busslinger, M			Independent regulation of the two Pax5 alleles during B-cell development	NATURE GENETICS			English	Article							MATERNAL-SPECIFIC METHYLATION; LYMPHOCYTES-B; BONE-MARROW; IGF2R LOCUS; IGH LOCUS; GENE; MOUSE; INACTIVATION; CONSERVATION; EXPRESSION	The developmental control genes of the Pax family are frequently associated with mouse mutants and human disease syndromes(1-3). The function of these transcription factors is sensitive to gene dosage, as mutation of one allele(1-3) or a modest increase in gene number(4) results in phenotypic abnormalities. Pax5 has an important role in B-cell and midbrain development(5-7). By following the expression of individual Pax5 alleles at the single-cell level, we demonstrate here that Pax5 is subject to allele-specific regulation during B-lymphopoiesis. Pax5 is predominantly transcribed from only one allele in early progenitors and mature B cells, whereas it switches to a biallelic transcription mode in immature B cells. The allele-specific regulation of Pax5 is stochastic, reversible, independent of parental origin and correlates with synchronous replication, in contrast with imprinted(8,9) and other monoallelically expressed genes(10,11). As a consequence, B-lymphoid tissues are mosaics with respect to the transcribed Pax5 allele, and thus mutation of one allele in heterozygous mice results in deletion of the cell population expressing the mutant allele due to loss of Pax5 function at the single-cell level. Similar allele-specific regulation may be a common mechanism causing the haploinsufficiency and frequent association of other Pax genes with human disease.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Basel Inst Immunol, CH-4005 Basel, Switzerland; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Busslinger, M (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	Busslinger@nt.imp.univie.ac.at	Kozmik, Zbynek/G-3581-2014; Nutt, Stephen L/C-9256-2013; Busslinger, Meinrad J./J-1249-2016; Kozmik, Zbynek/I-8807-2014	Nutt, Stephen L/0000-0002-0020-6637; Busslinger, Meinrad J./0000-0002-9111-9351; Kozmik, Zbynek/0000-0002-5850-2105				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Ghia P, 1996, J EXP MED, V184, P2217, DOI 10.1084/jem.184.6.2217; Held W, 1998, EUR J IMMUNOL, V28, P2407, DOI 10.1002/(SICI)1521-4141(199808)28:08&lt;2407::AID-IMMU2407&gt;3.0.CO;2-D; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	30	118	118	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1999	21	4					390	395		10.1038/7720	http://dx.doi.org/10.1038/7720			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192389				2022-12-27	WOS:000079439700020
J	Gong, YQ; Krakow, D; Marcelino, J; Wilkin, D; Chitayat, D; Babul-Hirji, R; Hudgins, L; Cremers, CW; Cremers, FPM; Brunner, HG; Reinker, K; Rimoin, DL; Cohn, DH; Goodman, FR; Reardon, W; Patton, M; Francomano, CA; Warman, ML				Gong, YQ; Krakow, D; Marcelino, J; Wilkin, D; Chitayat, D; Babul-Hirji, R; Hudgins, L; Cremers, CW; Cremers, FPM; Brunner, HG; Reinker, K; Rimoin, DL; Cohn, DH; Goodman, FR; Reardon, W; Patton, M; Francomano, CA; Warman, ML			Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis	NATURE GENETICS			English	Article							DELETION DEL(17) Q21.3Q23; SPEMANN ORGANIZER; XENOPUS; FOLLISTATIN; BINDING; PROTEIN; BMP-4; CDMP1	The secreted polypeptide noggin (encoded by the Nog gene) binds and inactivates members of the transforming growth factor beta superfamily of signalling proteins (TGF beta-FMs), such as BMP4 (ref. 1). By diffusing through extracellular matrices more efficiently than TGF beta-FMs, noggin may have a principal role in creating morphogenic gradients2. During mouse embryogenesis, Nog is expressed at multiple sites(3), including developing bones(4,5). Nog(-/-) mice die at birth from multiple defects that include bony fusion of the appendicular skeleton(3,4). We have identified five dominant human NOG mutations in unrelated families segregating proximal symphalangism (SYM1; OMIM 185800) and a de novo mutation in a patient with unaffected parents. We also found a dominant NOG mutation in a family segregating multiple synostoses syndrome (SYNS1; OMIM 186500); both SYM1 and SYNS1 have multiple joint fusion as their principal feature(6,7). All seven NOG mutations alter evolutionarily conserved amino CI acid residues. The findings reported here confirm that NOG is essential for joint formation and suggest that NOG requirements during skeletogenesis differ between species and between specific skeletal elements within species.	Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Shandong Med Univ, Dept Genet, Jinan, Peoples R China; Cedars Sinai Med Ctr, Ahmanson Dept Pediat, Steven Spielberg Pediat Res Ctr, Burns & Allen Cedars Sinai Res Inst, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Obstet, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Gynecol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD USA; Hosp Sick Children, Div Genet, Toronto, ON M5G 1X8, Canada; Childrens Hosp & Med Ctr, Div Med Genet, Washington, DC USA; Univ Nijmegen, Dept Otorhinolaryngol, Nijmegen, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands; Shriners Hosp Crippled Children, Dept Orthoped, Honolulu, HI USA; Inst Child Hlth, Mothercare Unit Clin Genet & Fetal Med, London, England; St George Hosp, Sch Med, London, England	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Shandong University; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's National Health System; Radboud University Nijmegen; Radboud University Nijmegen; University of London; University College London; St Georges University London	Warman, ML (corresponding author), Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA.		Reinker, Kent/R-5231-2019; Cremers, Frans/A-5625-2014; Brunner, Han/C-9928-2013; Cremers, C.W.R.J./L-4254-2015	Cremers, Frans/0000-0002-4954-5592; Reardon, Willie/0000-0001-7329-9179	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001205, P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043827] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-43827] Funding Source: Medline; NICHD NIH HHS [HD-22657, HD-01205] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; CREMERS C, 1985, ARCH OTOLARYNGOL, V111, P765; DALLAPICCOLA B, 1993, CLIN GENET, V43, P54, DOI 10.1111/j.1399-0004.1993.tb04452.x; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; ENSINK RJH, IN PRESS AM J OTOL; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; KHALIFA MM, 1993, CLIN GENET, V44, P258; Krakow D, 1998, AM J HUM GENET, V63, P120, DOI 10.1086/301921; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PARK JP, 1992, CLIN GENET, V41, P54; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; POLYMEROPOULOS MH, 1995, GENOMICS, V27, P225, DOI 10.1006/geno.1995.1035; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STORM EE, 1994, NATURE, V368, P693; STRASBURGER AK, 1965, B JOHNS HOPKINS HOSP, V117, P108; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; VALENZUELA DM, 1995, J NEUROSCI, V15, P6077; WITTA SE, 1995, DEVELOPMENT, V121, P721; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	24	240	260	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					302	304		10.1038/6821	http://dx.doi.org/10.1038/6821			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080184				2022-12-27	WOS:000078977900025
J	Cole, KA; Krizman, DB; Emmert-Buck, MR				Cole, KA; Krizman, DB; Emmert-Buck, MR			The genetics of cancer - a 3D model	NATURE GENETICS			English	Review							PROSTATIC INTRAEPITHELIAL NEOPLASIA; LASER CAPTURE MICRODISSECTION; ALLELIC LOSS; INVASIVE ADENOCARCINOMA; EXPRESSION PATTERNS; CHROMOSOME 8P12-21; PROGRESSION; CELLS; CDNA; MICROARRAY	Gene expression microarrays hold great promise for studies of human disease states. There are significant technical issues specific to utilizing clinical tissue samples which have yet to be rigorously addressed and completely overcome. Precise, quantitative measurement of gene expression profiles:from specific cell populations is at hand, offering the scientific community the first comprehensive View of the in vivo molecular anatomy of normal cells and their diseased counterparts. Here. we propose a model-for integrating-in three dimensions-expression data obtained using the microarray.	NCI, Pathol Lab, Pathogenet Unit, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; NCI, Canc Genome Anat Project, Off Director, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cole, KA (corresponding author), NCI, Pathol Lab, Pathogenet Unit, Bldg 10, Bethesda, MD 20892 USA.	mbuck@helix.nih.gov	Cole, Kristina/M-3922-2015					Abbott A, 1996, NATURE, V379, P392; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bostwick DG, 1997, VIRCHOWS ARCH, V430, P1, DOI 10.1007/BF01008010; Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W; BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I; Bostwick DG, 1996, EUR UROL, V30, P145; Bova GS, 1996, WORLD J UROL, V14, P338; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Ching J, 1996, BIOCONJUGATE CHEM, V7, P525, DOI 10.1021/bc9600426; Chuaqui RF, 1997, UROLOGY, V50, P302, DOI 10.1016/S0090-4295(97)00194-5; DENG G, 1996, SCIENCE, V20, P2057; DeRisi J, 1996, NAT GENET, V14, P457; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Eberwine J, 1996, BIOTECHNIQUES, V20, P584; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Epstein J I, 1996, Oncology (Williston Park), V10, P527; GIOMETTI CS, 1997, ELECTROPHORESIS, V16, P1187; Hayward SW, 1998, INT J ONCOL, V13, P35; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P1908; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; Kallajoki M, 1998, PROSTATE, V35, P263, DOI 10.1002/(SICI)1097-0045(19980601)35:4<263::AID-PROS5>3.0.CO;2-H; KLIMECKI WT, 1994, BIOTECHNIQUES, V16, P1021; Krizman DB, 1996, CANCER RES, V56, P5380; Kuwata H, 1998, BIOCHEM BIOPH RES CO, V245, P764, DOI 10.1006/bbrc.1998.8466; Lalani EN, 1997, SEMIN CANCER BIOL, V8, P53, DOI 10.1006/scbi.1997.0052; Latil A, 1998, VIRCHOWS ARCH, V432, P389, DOI 10.1007/s004280050183; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MCCOY K, 1988, J CELL BIOL, V106, P1879, DOI 10.1083/jcb.106.6.1879; Murphy G P, 1994, Scand J Urol Nephrol Suppl, V162, P7; NOWAK R, 1995, SCIENCE, V270, P368, DOI 10.1126/science.270.5235.368; Pettaway C A, 1998, Tech Urol, V4, P35; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Suzuki H, 1998, CANCER RES, V58, P204; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vocke CD, 1996, CANCER RES, V56, P2411; WILTSHIRE RN, 1995, CANCER RES, V55, P3954; Zhuang ZP, 1996, CANCER RES, V56, P1961	47	111	129	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21			S			38	41		10.1038/4466	http://dx.doi.org/10.1038/4466			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915499				2022-12-27	WOS:000078008200010
J	Liu, L; Dilworth, D; Gao, LZ; Monzon, J; Summers, A; Lassam, N; Hogg, D				Liu, L; Dilworth, D; Gao, LZ; Monzon, J; Summers, A; Lassam, N; Hogg, D			Mutation of the CDKN2A 5 ' UTR creates an aberrant initiation codon and predisposes to melanoma	NATURE GENETICS			English	Article							CUTANEOUS MALIGNANT-MELANOMA; FAMILIAL MELANOMA; DYSPLASTIC NEVI; GENETIC-HETEROGENEITY; P16; EXPRESSION; LOCUS; MLM	Approximately 8-12% Of melanoma is inherited in an autosomal dominant fashion with variable penetrance(1-8). A chromosome 9p21 locus has been linked to this disease in 50-80% of affected families(5-7,9). CDKN2A (also known as P16, INK4, p16(INK4A) and MTS1) is allelic to this locus and encodes a cdk4/cdk6 kinase inhibitor that constrains cells from progressing through the G1 restriction point(10-12). Although germline CDKN2A coding mutations cosegregate with melanoma in 25-60% of families predisposed to the disease(8,9,13-19), there remains a number of mutation-negative families that demonstrate linkage of inherited melanoma to 9p21 markers(9). We show here that a subset of these kindreds possess a G-->T transversion at base -34 of CDKN2A, designated G-34T. This mutation gives rise to a novel AUG translation initiation codon that decreases translation from the wild-type AUG. The G-34T mutation is not seen in controls, segregates with melanoma in families and, on the basis of haplotyping studies, probably arose from a common founder in the United Kingdom. Characterization of this and other CDKN2A non-coding mutations should have an impact on current efforts to identify susceptible melanoma-prone families and individuals.	Univ Toronto, Dept Clin Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto	Hogg, D (corresponding author), Univ Toronto, Dept Clin Sci, 100 Coll St, Toronto, ON, Canada.							BALE SJ, 1986, AM J HUM GENET, V38, P188; BERGENHEM NCH, 1992, P NATL ACAD SCI USA, V89, P8798, DOI 10.1073/pnas.89.18.8798; BERGER EG, 1994, TRANSFUS CLIN BIOL, V1, P103, DOI 10.1016/S1246-7820(94)80004-9; Borg A, 1996, CANCER RES, V56, P2497; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1994, J NATL CANCER I, V86, P1385, DOI 10.1093/jnci/86.18.1385; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; Hogg D, 1998, J Cutan Med Surg, V2, P172; Hollmann P, 1989, Tierarztl Prax, V17, P1; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LIU L, 1995, ONCOGENE, V11, P405; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845	25	199	206	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					128	132		10.1038/5082	http://dx.doi.org/10.1038/5082			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916806				2022-12-27	WOS:000077960700024
J	Altshuler, D; Hirschhorn, JN; Klannemark, M; Lindgren, CM; Vohl, MC; Nemesh, J; Lane, CR; Schaffner, SF; Bolk, S; Brewer, C; Tuomi, T; Gaudet, D; Hudson, TJ; Daly, M; Groop, L; Lander, ES				Altshuler, D; Hirschhorn, JN; Klannemark, M; Lindgren, CM; Vohl, MC; Nemesh, J; Lane, CR; Schaffner, SF; Bolk, S; Brewer, C; Tuomi, T; Gaudet, D; Hudson, TJ; Daly, M; Groop, L; Lander, ES			The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes	NATURE GENETICS			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; MISSENSE MUTATION; SULFONYLUREA RECEPTOR; GENE; MELLITUS; NIDDM; RESISTANCE; SUBSTITUTION; OBESITY; DISEQUILIBRIUM	Genetic association studies are viewed as problematic and plagued by irreproducibility(1). Many associations have been reported for type 2 diabetes(2-17), but none have been confirmed in multiple samples and with comprehensive controls. We evaluated 16 published genetic associations to type 2 diabetes and related sub-phenotypes using a family-based design to control for population stratification, and replication samples to increase power. We were able to confirm only one association, that of the common Pro12Ala polymorphism in peroxisome proliferator-activated receptor-gamma (PPAR gamma) with type 2 diabetes. By analysing over 3.000 individuals, we found a modest (1.25-fold) but significant (P=0.002) increase in diabetes risk associated with the more common proline allele (similar to 85% frequency). Moreover. our results resolve a controversy about common variation in PPAR gamma. An initial study found a threefold effect(12). but four of five subsequent publications(18-22) failed to confirm the association. All six studies are consistent with the odds ratio we describe. The data implicate inherited variation in PPAR gamma in the pathogenesis of type 2 diabetes. Because the risk allele occurs at such high frequency, its modest effect translates into a large population attributable risk-influencing as much as 25% of type 2 diabetes in the general population.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Lund Univ, Malmo Univ Hosp, Wallenberg Lab, Dept Endocrinol, Malmo, Sweden; McGill Univ, Ctr Hlth, Res Inst, Montreal Genome Ctr, Montreal, PQ, Canada; Univ Helsinki, Cent Hosp, Dept Internal Med, Helsinki, Finland; Chicoutimi Hosp, Chicoutimi, PQ, Canada; MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Lund University; Skane University Hospital; McGill University; University of Helsinki; Helsinki University Central Hospital; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lander@genome.wi.mit.edu	Daly, Mark J/B-2453-2017; Vohl, Marie-Claude/AAQ-1378-2021; Schaffner, Stephen F/D-1189-2011; Altshuler, David M/A-4476-2009	Daly, Mark J/0000-0002-0949-8752; Altshuler, David M/0000-0002-7250-4107; Schaffner, Stephen/0000-0001-6699-3568; Tuomi, Tiinamaija/0000-0002-8306-6202; Lindgren, Cecilia/0000-0002-4903-9374; Vohl, Marie-Claude/0000-0002-7017-5848	Wellcome Trust [090532] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Allison DB, 1997, AM J HUM GENET, V60, P676; ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Boehnke M, 1998, AM J HUM GENET, V62, P950, DOI 10.1086/301787; Chen XN, 1999, GENOME RES, V9, P492; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Clement K, 2000, INT J OBESITY, V24, P391, DOI 10.1038/sj.ijo.0801191; Day CP, 1998, DIABETOLOGIA, V41, P430, DOI 10.1007/s001250050926; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; Groop L, 1996, DIABETES, V45, P1585, DOI 10.2337/diabetes.45.11.1585; HAGER J, 1995, NAT GENET, V9, P299, DOI 10.1038/ng0395-299; Hani EH, 1998, DIABETOLOGIA, V41, P1511, DOI 10.1007/s001250051098; Hara K, 2000, BIOCHEM BIOPH RES CO, V271, P212, DOI 10.1006/bbrc.2000.2605; Hegele RA, 1997, J CLIN ENDOCR METAB, V82, P3373, DOI 10.1210/jc.82.10.3373; Huxtable SJ, 2000, DIABETES, V49, P126, DOI 10.2337/diabetes.49.1.126; Inoue H, 1996, DIABETES, V45, P825, DOI 10.2337/diabetes.45.6.825; Ishiyama-Shigemoto S, 1999, DIABETOLOGIA, V42, P98, DOI 10.1007/s001250051120; KAN M, 1995, DIABETES, V44, P1081, DOI 10.2337/diabetes.44.9.1081; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Mancini FP, 1999, DIABETES, V48, P1466, DOI 10.2337/diabetes.48.7.1466; Masugi J, 2000, BIOCHEM BIOPH RES CO, V268, P178, DOI 10.1006/bbrc.2000.2096; Meirhaeghe A, 2000, INT J OBESITY, V24, P195, DOI 10.1038/sj.ijo.0801112; Ringel J, 1999, BIOCHEM BIOPH RES CO, V254, P450, DOI 10.1006/bbrc.1998.9962; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Sakagashira S, 1996, DIABETES, V45, P1279, DOI 10.2337/diabetes.45.9.1279; Shaw JA, 1999, DIABETES CARE, V22, P399, DOI 10.2337/diacare.22.3.399; Shimomura H, 1997, DIABETOLOGIA, V40, P947, DOI 10.1007/s001250050772; Sigal RJ, 1996, J CLIN ENDOCR METAB, V81, P1657, DOI 10.1210/jc.81.4.1657; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; 't Hart LM, 1999, J CLIN ENDOCR METAB, V84, P1002, DOI 10.1210/jc.84.3.1002; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; 1999, NATURE GENET, V22, P1	38	1411	1473	0	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					76	80		10.1038/79216	http://dx.doi.org/10.1038/79216			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973253				2022-12-27	WOS:000089078000022
J	Kinoshita, A; Saito, T; Tomita, H; Makita, Y; Yoshida, K; Ghadami, M; Yamada, K; Kondo, S; Ikegawa, S; Nishimura, G; Fukushima, Y; Nakagomi, T; Saito, H; Sugimoto, T; Kamegaya, M; Hisa, K; Murray, JC; Taniguchi, N; Niikawa, N; Yoshiura, K				Kinoshita, A; Saito, T; Tomita, H; Makita, Y; Yoshida, K; Ghadami, M; Yamada, K; Kondo, S; Ikegawa, S; Nishimura, G; Fukushima, Y; Nakagomi, T; Saito, H; Sugimoto, T; Kamegaya, M; Hisa, K; Murray, JC; Taniguchi, N; Niikawa, N; Yoshiura, K			Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA		Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan; Osaka Univ, Fac Med, Dept Biochem, Osaka, Japan; Asahikawa Med Coll, Dept Pediat, Asahikawa, Hokkaido 078, Japan; Asahikawa Med Coll, Dept Publ Hlth, Asahikawa, Hokkaido 078, Japan; Shinshu Univ, Sch Med, Dept Internal Med 3, Nagano, Japan; Shinshu Univ, Sch Med, Dept Med Genet, Nagano, Japan; Shinshu Univ, Sch Med, Div Clin & Mol Genet, Nagano, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo, Japan; Dokkyo Univ, Sch Med, Dept Radiol, Mibu, Tochigi, Japan; Asahigawa Ryoikuen Childrens Hosp Physically Disa, Okayama, Japan; Akita Univ, Sch Med, Dept Orthoped Surg, Akita 010, Japan; Kansal Univ Otokoyama Hosp, Dept Pediat, Kyoto, Japan; Chiba Childrens Hosp, Div Orthoped Surg, Chiba, Japan; Natl Chushin Matsumoto Hosp, Dept Orthoped Surg, Nagano, Japan; Univ Iowa, Dept Pediat & Biol Sci, Iowa City, IA USA	Nagasaki University; Osaka University; Asahikawa Medical College; Asahikawa Medical College; Shinshu University; Shinshu University; Shinshu University; University of Tokyo; Dokkyo Medical University; Akita University; Kansai University; Chiba Children's Hospital; University of Iowa	Kinoshita, A (corresponding author), Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan.		Ikegawa, Shiro/N-6895-2015; Saito, Takashi/G-2563-2015; Taniguchi, Naoyuki/I-4182-2014	Ikegawa, Shiro/0000-0003-0316-2147; Saito, Takashi/0000-0002-9659-9251; Taniguchi, Naoyuki/0000-0001-5889-5968; Tomita, Hiroaki/0000-0003-2628-880X				Ballock R. T., 1993, GROWTH FACTORS PRACT, P85; BURT DW, 1992, DNA CELL BIOL, V11, P497, DOI 10.1089/dna.1992.11.497; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281, DOI 10.1007/BF01570787; Ghadami M, 2000, AM J HUM GENET, V66, P143, DOI 10.1086/302728; Janssens K, 2000, J MED GENET, V37, P245, DOI 10.1136/jmg.37.4.245; Makita Y, 2000, AM J MED GENET, V91, P153, DOI 10.1002/(SICI)1096-8628(20000313)91:2<153::AID-AJMG15>3.0.CO;2-U; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Syrris P, 1998, CLIN SCI, V95, P659, DOI 10.1042/cs0950659; Vaughn SP, 2000, GENOMICS, V66, P119, DOI 10.1006/geno.2000.6192	12	177	188	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					19	20		10.1038/79128	http://dx.doi.org/10.1038/79128			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973241				2022-12-27	WOS:000089078000011
J	Brown, CW; Houston-Hawkins, DE; Woodruff, TK; Matzuk, MM				Brown, CW; Houston-Hawkins, DE; Woodruff, TK; Matzuk, MM			Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions	NATURE GENETICS			English	Article							DEFICIENT MICE; MESSENGER-RNA; ALPHA-INHIBIN; EXPRESSION; RECEPTOR; DEFECTS; RAT; OVEREXPRESSION; PROLIFERATION; REPRODUCTION	The activins (dimers of beta A or beta B subunits, encoded by the genes Inhba and Inhbb, respectively) are TGF-beta superfamily members that have roles in reproduction and devetopment(1-3). Whereas mice homozygous for the Inhba-null allele demonstrate disruption of whisker, palate and tooth development, leading to neonatal lethality(4,5), homozygous Inhbb-null mice are viable, fertile and have eye defects(6,7). To determine if these phenotypes were due to spatiotemporal expression differences of the ligands or disruption of specific ligand-receptor interactions, we replaced the region of Inhba encoding the mature protein with Inhbb, creating the allele Inhba(tm2Zuk) thereafter designated Inhba(BK)). Although the craniofacial phenotypes of the Inhba-null mutation were rescued by the InhbaBK allele, somatic, testicular, genital and hair growth were grossly affected and influenced by the dosage and bioactivity of the allele. Thus, functional compensation within the TGF-beta superfamily can occur if the replacement gene is expressed appropriately. The novel phenotypes in these mice further illustrate the usefulness of insertion strategies for defining protein function.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Northwestern University	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.			Woodruff, Teresa/0000-0002-1197-3399	NICHD NIH HHS [HD32067, HD27823, HD01156] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD032067] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823, K08HD001156] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONIPILLAI I, 1995, MOL CELL ENDOCRINOL, V107, P99, DOI 10.1016/0303-7207(94)03430-2; BOITANI C, 1995, ENDOCRINOLOGY, V136, P5438, DOI 10.1210/en.136.12.5438; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bunn HF, 1999, BLOOD, V93, P1787, DOI 10.1182/blood.V93.6.1787.406a34_1787_1789; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; DEWINTER JP, 1992, MOL CELL ENDOCRINOL, V83, pR1, DOI 10.1016/0303-7207(92)90201-G; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; FENG ZM, 1993, ENDOCRINOLOGY, V132, P2593, DOI 10.1210/en.132.6.2593; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; KLUIN PM, 1984, ANAT EMBRYOL, V169, P73, DOI 10.1007/BF00300588; LAU AL, 1997, INHIBIN ACTIVIN FOLL, P220; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SCHREWE H, 1994, MECH DEVELOP, V47, P43, DOI 10.1016/0925-4773(94)90094-9; TRUDEAU VL, 1994, BIOCHEM BIOPH RES CO, V203, P105, DOI 10.1006/bbrc.1994.2155; Vale Wylie, 1994, P1861; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414	26	163	169	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					453	457		10.1038/78161	http://dx.doi.org/10.1038/78161			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932194				2022-12-27	WOS:000088615000025
J	Camaschella, C; Roetto, A; Cali, A; De Gobbi, M; Garozzo, G; Carella, M; Majorano, N; Totaro, A; Gasparini, P				Camaschella, C; Roetto, A; Cali, A; De Gobbi, M; Garozzo, G; Carella, M; Majorano, N; Totaro, A; Gasparini, P			The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22	NATURE GENETICS			English	Article							HEREDITARY HEMOCHROMATOSIS; TRANSFERRIN RECEPTOR; HLA-H; JUVENILE		IRCCS Osped CSS, Serv Genet Med, Foggia, Italy; Azienda Osped Civile M Paterno Arezzo, Serv Immunoematol & Med Trasfus, Ragusa, Italy; Univ Turin, Azienda Osped S Luigi, Dipartimento Sci Clin & Biol, Orbassano Torino, Italy	Civile M.P. Arezzo Hospital; University of Turin	Gasparini, P (corresponding author), IRCCS Osped CSS, Serv Genet Med, Foggia, Italy.		Camaschella, Clara/A-3289-2015; Gasparini, Paolo/B-6173-2014; Roetto, Antonella/K-4731-2016; De Gobbi, Marco/E-8136-2013; Carella, Massimo/A-2804-2014	Carella, Massimo/0000-0002-6830-6829; Gasparini, Paolo/0000-0002-0859-0856; ROETTO, Antonella/0000-0003-1188-7375; De Gobbi, Marco/0000-0003-4261-7642	Telethon [E.0679] Funding Source: Medline	Telethon(Fondazione Telethon)		Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509; Carella M, 1997, AM J HUM GENET, V60, P828; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Glockner G, 1998, GENOME RES, V8, P1060; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Pietrangelo A, 1999, NEW ENGL J MED, V341, P725, DOI 10.1056/NEJM199909023411003; Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1; Robson KJH, 1997, GUT, V41, P841; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379	15	629	661	3	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					14	15		10.1038/75534	http://dx.doi.org/10.1038/75534			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802645				2022-12-27	WOS:000086884000007
J	Coste, SC; Kesterson, RA; Heldwein, KA; Stevens, SL; Heard, AD; Hollis, JH; Murray, SE; Hill, JK; Pantely, GA; Hohimer, AR; Hatton, DC; Phillips, TJ; Finn, DA; Low, MJ; Rittenberg, MB; Stenzel, P; Stenzel-Poore, MP				Coste, SC; Kesterson, RA; Heldwein, KA; Stevens, SL; Heard, AD; Hollis, JH; Murray, SE; Hill, JK; Pantely, GA; Hohimer, AR; Hatton, DC; Phillips, TJ; Finn, DA; Low, MJ; Rittenberg, MB; Stenzel, P; Stenzel-Poore, MP			Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2	NATURE GENETICS			English	Article							CARDIAC MYOCYTES; FOOD-INTAKE; EXPRESSION; UROCORTIN; CELLS; NEUROPEPTIDE; PEPTIDE; ANXIETY; HEART; RATS	The actions of corticotropin-releasing hormone (Crh), a mediator of endocrine(1) and behavioural responses to stress(2), and the related hormone urocortin(3) (Ucn) are coordinated by two receptors, Crhr1 (encoded by Crhr) and Crhr2 (refs 4,5). These receptors may exhibit distinct functions due to unique tissue distribution(6) and pharmacology(4,5). Crhr-null mice have defined central functions for Crhr1 in anxiety and neuroendocrine stress responses(7,8). Here we generate Crhr2(-/-) mice and show that Crhr2 supplies regulatory features to the hypothalamic-pituitary-adrenal axis (HPA) stress response. Although initiation of the stress response appears to be normal. Crhr2(-/-) mice show early termination of adrenocorticotropic hormone (Acth) release, suggesting that Crhr2 is involved in maintaining HPA drive. Crhr2 also appears to modify the recovery phase of the HPA response, as corticosterone levels remain elevated 90 minutes after stress in Crhr2(-/-) mice. In addition, stress-coping behaviours associated with dearousal are reduced in Crhr2(-/-) mice. We also demonstrate that Crhr2 is essential for sustained feeding suppression (hypophagia) induced by Ucn. Feeding is initially suppressed in Crhr2(-/-) mice following Ucn, but Crhr2(-/-) mice recover more rapidly and completely than do wild-type mice. In addition to central nervous system effects, we found that, in contrast to wild-type mice, Crhr2(-/-) mice fail to show the enhanced cardiac performance or reduced blood pressure associated with systemic Ucn, suggesting that Crhr2 mediates these peripheral haemodynamic effects. Moreover, Crhr2(-/-) mice have elevated basal blood pressure, demonstrating that Crhr2(-/-) participates in cardiovascular homeostasis. Our results identify specific responses in the brain and periphery that involve Crhr2.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Obstet & Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Congenital Heart Res Ctr, Portland, OR 97201 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN USA; Vet Affairs Med Ctr, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Stenzel-Poore, MP (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.			Murray, Susan/0000-0002-6470-3827; Low, Malcolm/0000-0002-9900-3708	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055512, R29HL045043, R01HL045043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55512, HL45043] Funding Source: Medline; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Fentzke RC, 1997, J AM SOC ECHOCARDIOG, V10, P915, DOI 10.1016/S0894-7317(97)80008-9; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GRUNT M, 1992, HORM METAB RES, V24, P56, DOI 10.1055/s-2007-1003255; Gu GB, 1999, J NEUROSCI, V19, P3213; Heldwein KA, 1996, ENDOCRINOLOGY, V137, P3631, DOI 10.1210/en.137.9.3631; Liebsch G, 1999, J PSYCHIAT RES, V33, P153, DOI 10.1016/S0022-3956(98)80047-2; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; MIYAKODA G, 1987, J BIOCHEM-TOKYO, V102, P211, DOI 10.1093/oxfordjournals.jbchem.a122034; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; ONO N, 1985, P NATL ACAD SCI USA, V82, P3528, DOI 10.1073/pnas.82.10.3528; OVERTON JM, 1991, J AUTONOM NERV SYST, V35, P43, DOI 10.1016/0165-1838(91)90037-4; PARKES D, 1993, MOL ENDOCRINOL, V7, P1357, DOI 10.1210/me.7.10.1357; Parkes DG, 1997, AM J PHYSIOL-HEART C, V272, pH2115, DOI 10.1152/ajpheart.1997.272.5.H2115; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; SPRUIJT BM, 1992, PHYSIOL REV, V72, P825, DOI 10.1152/physrev.1992.72.3.825; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; SUTTON RE, 1982, J NEUROSCI, V10, P176; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; Wagoner LE, 1996, CIRCULATION, V93, P111, DOI 10.1161/01.CIR.93.1.111; WARLTIER DC, 1992, ANESTH ANALG, V75, pS17; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378	29	500	512	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					403	409		10.1038/74255	http://dx.doi.org/10.1038/74255			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742107				2022-12-27	WOS:000086192800022
J	Wilkie, AOM; Tang, ZQ; Elanko, N; Walsh, S; Twigg, SRF; Hurst, JA; Wall, SA; Chrzanowska, KH; Maxson, RE				Wilkie, AOM; Tang, ZQ; Elanko, N; Walsh, S; Twigg, SRF; Hurst, JA; Wall, SA; Chrzanowska, KH; Maxson, RE			Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification	NATURE GENETICS			English	Article							FORAMINA PARIETALIA PERMAGNA; SELECTIVE TOOTH AGENESIS; DNA-BINDING SPECIFICITY; MOLECULAR-BASIS; HOMEODOMAIN; FAMILY; CRANIOSYNOSTOSIS; MUTATION	The genetic analysis of congenital skull malformations provides insight into normal mechanisms of calvarial osteogenesis(1). Enlarged parietal foramina (PFM) are oval defects of the parietal bones caused by deficient ossification around the parietal notch, which is normally obliterated during the fifth fetal month(2), PFM are usually asymptomatic, but may be associated with headache, scalp defects and structural or vascular malformations of the brain(3,4). Inheritance is frequently autosomal dominant, but no causative mutations have been identified in non-syndromic cases. We describe here heterozygous mutations of the homeobox gene MSX2 (located on 5q34-q35) in three unrelated families with PFM. One is a deletion of approximately 206 kb including the entire gene and the others are intragenic mutations of the DNA-binding homeodomain (RK159-160del and R172H) that predict disruption of critical intramolecular and DNA contacts. Mouse Msx2 protein with either of the homeodomain mutations exhibited more than 85% reduction in binding to an optimal Msx2 DNA-binding site. Our findings contrast with the only described MSX2 homeodomain mutation(5) (P148H), associated with craniosynostosis, that binds with enhanced affinity to the same target(6). This demonstrates that MSX2 dosage is critical for human skull development and suggests that PFM and craniosynostosis result, respectively, from loss and gain of activity in an MSX2-mediated pathway of calvarial osteogenic differentiation.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Dept Clin Genet, Oxford, England; Radcliffe Infirm, Craniofacial Unit, Oxford OX2 6HE, England; Univ So Calif, Norris Hosp, Sch Med, Los Angeles, CA 90089 USA; Childrens Mem Hlth Inst, Dept Med Genet, Warsaw, Poland	University of Oxford; Radcliffe Infirmary; University of Southern California; Children's Memorial Health Institute	Wilkie, AOM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.		Wilkie, Andrew/AAC-3820-2020; Twigg, Stephen/AAU-1135-2021	Wilkie, Andrew/0000-0002-2972-5481; Twigg, Stephen/0000-0001-5024-049X; Chrzanowska, Krystyna/0000-0003-3888-0624				Bartsch H, 1996, EUR J CANCER PREV, V5, P11, DOI 10.1097/00008469-199609001-00003; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CLARKE ND, 1995, PROTEIN SCI, V4, P2269, DOI 10.1002/pro.5560041104; CURRARINO G, 1976, AM J ROENTGENOL, V127, P487, DOI 10.2214/ajr.127.3.487; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GOLABI M, 1984, AM J DIS CHILD, V138, P596, DOI 10.1001/archpedi.1984.02140440080022; Gripp KW, 1999, AM J MED GENET, V82, P170, DOI 10.1002/(SICI)1096-8628(19990115)82:2<170::AID-AJMG14>3.0.CO;2-X; HODGKINSON JE, 1993, BIOCHIM BIOPHYS ACTA, V1174, P11, DOI 10.1016/0167-4781(93)90086-S; Hu GZ, 1998, MOL CELL BIOL, V18, P6044, DOI 10.1128/MCB.18.10.6044; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; ISAAC VE, 1995, BIOCHEMISTRY-US, V34, P7127, DOI 10.1021/bi00021a026; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Jaju RJ, 1999, BLOOD, V94, P773; Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122; Kutilek S, 1997, J PAEDIATR CHILD H, V33, P168, DOI 10.1111/j.1440-1754.1997.tb01023.x; Li H, 1997, PROTEIN SCI, V6, P956, DOI 10.1002/pro.5560060502; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; PANG D, 1982, NEUROSURGERY, V11, P33, DOI 10.1227/00006123-198207010-00007; PREIS S, 1995, ACTA PAEDIATR, V84, P701, DOI 10.1111/j.1651-2227.1995.tb13735.x; SALAMANCA A, 1994, PRENATAL DIAG, V14, P766, DOI 10.1002/pd.1970140820; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Stankiewicz P, 1998, EUR J HUM GENET, V6, P61; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; WILKIE AOM, 1995, J MED GENET, V32, P174, DOI 10.1136/jmg.32.3.174; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Wuyts W, 1999, EUR J HUM GENET, V7, P579, DOI 10.1038/sj.ejhg.5200339	31	214	222	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					387	390		10.1038/74224	http://dx.doi.org/10.1038/74224			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742103				2022-12-27	WOS:000086192800018
J	Moreira, ES; Wiltshire, TJ; Faulkner, G; Nilforoushan, A; Vainzof, M; Suzuki, OT; Valle, G; Reeves, R; Zatz, M; Passos-Bueno, MR; Jenne, DE				Moreira, ES; Wiltshire, TJ; Faulkner, G; Nilforoushan, A; Vainzof, M; Suzuki, OT; Valle, G; Reeves, R; Zatz, M; Passos-Bueno, MR; Jenne, DE			Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin	NATURE GENETICS			English	Article							DELTA-SARCOGLYCAN GENE; BETA-SARCOGLYCAN; MISSENSE MUTATIONS; GAMMA-SARCOGLYCAN; LINKAGE ANALYSIS; SKELETAL-MUSCLE; COMPLEX; LGMD2F; MAPS; FORM	Autosomal recessive limb-girdle muscular dystrophies (AR LGMDs) are a genetically heterogeneous group of disorders that affect mainly the proximal musculature(1). There are eight genetically distinct forms of AR LGMD, LGMD 2A-H (refs 2-10), and the genetic lesions underlying these forms, except for LGMD 2G and 2H, have been identified. LGMD 2A and LGMD 2B are caused by mutations in the genes encoding calpain 3 (ref. 11) and dysferlin(12). respectively, and are usually associated with a mild phenotype(11-13). Mutations in the genes encoding gamma- (ref. 14), alpha- (ref. 5), beta- (refs 6,7) and delta (ref. 15)-sarcoglycans are responsible for LGMD 2C to 2F, respectively. Sarcoglycans, together with sarcospan, dystroglycans, syntrophins and dystrobrevin, constitute the dystrophin-glycoprotein complex(16,17) (DGC). Patients with LGMD 2C-F predominantly have a severe clinical course(4-8.13-15.18-20). The LGMD 2C locus maps to a 3-cM interval in 17q11-12 in two Brazilian families with a relatively mild form of AR LGMD (ref. 9). To positionally clone the LGMD 2G gene, we constructed a physical map of the 17q11-12 region and refined its localization to an interval of 1.2 Mb. The gene encoding telethonin, a sarcomeric protein, lies within this candidate region. We have found that mutations in the telethonin gene cause LGMD 2C, identifying a new molecular mechanism for AR LGMD.	Univ Sao Paulo, Inst Biociencias, Ctr Estudos Genoma Humano, Sao Paulo, Brazil; Univ Sao Paulo, Inst Biociencias, Dept Biol, Sao Paulo, Brazil; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Int Ctr Genet Engn & Biotechnol, Trieste, Italy; Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany; FMUSP, Dept Neurol, Sao Paulo, Brazil; Univ Padua, CRIBI, Padua, Italy	Universidade de Sao Paulo; Universidade de Sao Paulo; Johns Hopkins University; International Center for Genetic Engineering & Biotechnology (ICGEB); Max Planck Society; Universidade de Sao Paulo; University of Padua	Passos-Bueno, MR (corresponding author), Univ Sao Paulo, Inst Biociencias, Ctr Estudos Genoma Humano, Sao Paulo, Brazil.	passos@usp.br	Vainzof, Mariz/Q-4787-2019; Jenne, Dieter Erich/AAP-1414-2020; Moreira, Eloisa/K-9155-2014; Vainzof, Mariz/J-7150-2012; Zatz, Mayana/M-5338-2015; Passos-Bueno, Maria Rita/I-6796-2016	Vainzof, Mariz/0000-0002-2797-0782; Vainzof, Mariz/0000-0002-2797-0782; Zatz, Mayana/0000-0003-3970-8025; Passos-Bueno, Maria Rita/0000-0002-9248-3008; VALLE, GIORGIO/0000-0003-4377-5685	Telethon [1023] Funding Source: Medline	Telethon(Fondazione Telethon)		Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; Bonnemann CG, 1996, HUM MOL GENET, V5, P1953, DOI 10.1093/hmg/5.12.1953; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; McNally EM, 1996, HUM MOL GENET, V5, P1841, DOI 10.1093/hmg/5.11.1841; Moreira ES, 1998, J MED GENET, V35, P951, DOI 10.1136/jmg.35.11.951; Moreira ES, 1997, AM J HUM GENET, V61, P151, DOI 10.1086/513889; Mues A, 1998, FEBS LETT, V428, P111, DOI 10.1016/S0014-5793(98)00501-8; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Passos-Bueno MR, 1999, AM J MED GENET, V82, P392, DOI 10.1002/(SICI)1096-8628(19990219)82:5<392::AID-AJMG7>3.0.CO;2-0; PassosBueno MR, 1996, HUM MOL GENET, V5, P815, DOI 10.1093/hmg/5.6.815; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Vainzof M, 1996, HUM MOL GENET, V5, P1963, DOI 10.1093/hmg/5.12.1963; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; WALTON J, 1988, DISORDERS VOLUNTARY, P519; Weiler T, 1998, AM J HUM GENET, V63, P140, DOI 10.1086/301925; ZATZ M, 1996, HDB MUSCLE DIS, P245	30	229	238	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					163	166		10.1038/72822	http://dx.doi.org/10.1038/72822			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655062				2022-12-27	WOS:000085104600017
J	Fuks, F; Burgers, WA; Brehm, A; Hughes-Davies, L; Kouzarides, T				Fuks, F; Burgers, WA; Brehm, A; Hughes-Davies, L; Kouzarides, T			DNA methyltransferase Dnmt1 associates with histone deacetylase activity	NATURE GENETICS			English	Article							REPRESS TRANSCRIPTION; TRICHOSTATIN-A; METHYLATION; ACETYLATION; PROTEINS; COMPONENT; INTERACTS; DOMAINS; COMPLEX; MOTIF	The DNA methyltransferase Dnmt1 is responsible for cytosine methylation in mammals and has a role in gene silencing(1-4) DNA methylation represses genes partly by recruitment of the methyl-CpG-binding protein MeCP2, which in turn recruits a histone deacetylase activity(5,6). Here we show that Dnmt1 is itself associated with histone deacetylase activity in vivo. Consistent with this association, we find that one of the known histone deacetylases, HDAC1, has the ability to bind Dnmt1 and can purify methyltransferase activity from nuclear extracts. We have identified a transcriptional repression domain in Dnmt1 that functions, at least partly, by recruiting histone deacetylase activity and shows homology to the repressor domain of the trithorax-related protein HRX (also known as MLL and ALL-1). Our data show a more direct connection between DNA methylation and histone deacetylation than was previously considered. We suggest that the process of DNA methylation, mediated by Dnmt1, may depend on or generate an altered chromatin state via histone deacetylase activity.	Univ Cambridge, Wellcome CRC Inst, Cambridge, England; Univ Cambridge, Dept Pathol, Cambridge, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Cambridge, England.			Kouzarides, Tony/0000-0002-8918-4162; Burgers, Wendy/0000-0003-3396-9398				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	29	749	774	0	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					88	91		10.1038/71750	http://dx.doi.org/10.1038/71750			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615135				2022-12-27	WOS:000084609200023
J	Wyllie, FS; Jones, CJ; Skinner, JW; Haughton, MF; Wallis, C; Wynford-Thomas, D; Faragher, RGA; Kipling, D				Wyllie, FS; Jones, CJ; Skinner, JW; Haughton, MF; Wallis, C; Wynford-Thomas, D; Faragher, RGA; Kipling, D			Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts	NATURE GENETICS			English	Article							LIFE-SPAN; DISSOCIATION; GENE		Brighton Univ, Sch Pharm & Biomol Sci, Brighton, E Sussex, England; Cardiff Univ, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales	University of Brighton; Cardiff University	Faragher, RGA (corresponding author), Brighton Univ, Sch Pharm & Biomol Sci, Crockroft Bldg, Brighton, E Sussex, England.	rgaf@bton.ac.uk		Faragher, Richard/0000-0001-8366-9014				Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bennett SE, 1999, ALFRED BENZON SYMP S, V44, P214; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Kirkwood TBL., 1999, TIME OUR LIVES; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5	15	251	266	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					16	17		10.1038/71630	http://dx.doi.org/10.1038/71630			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615119				2022-12-27	WOS:000084609200008
J	Murphy, M				Murphy, M			Delayed early embryonic lethality following disruption of the murine cyclin A2 gene (vol 15, pg 83, 1997)	NATURE GENETICS			English	Correction																		Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83	1	24	25	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					481	481		10.1038/70612	http://dx.doi.org/10.1038/70612			1	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581041	Bronze			2022-12-27	WOS:000084023900030
J	van der Vlag, J; Otte, AP				van der Vlag, J; Otte, AP			Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation	NATURE GENETICS			English	Article							EXTRA SEX COMBS; GROUP GENE; COMPLEXES; DROSOPHILA; REGULATOR; IDENTIFICATION; EXPRESSION; HOMOLOGS; PRODUCT; CLONING	Polycomb-group (PcG) proteins form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations(1-3) Components of PcG complexes and their mutual interactions have been identified and analysed through extensive genetic and biochemical analyses. Molecular mechanisms underlying PcG-mediated repression of gene activity, however, have remained largely unknown. Previously we reported the existence of two distinct human PcG protein complexes(4). The EED/EZH protein complex contains the embryonic ectoderm development(4-8) (EED) and enhancer of zeste 2 (EZH2; refs 9,10) PcG proteins. The HPC/HPH PcG complex contains the human polycomb 2 (HPC2; ref. 11), human polyhomeotic(12) (HPH), BMI1 (ref. 13) and RING1 (refs 14,15) proteins. Here we show that EED (refs 4-8) interacts, both in vitro and in vivo, with histone deacetylase (HDAC) proteins(16,17). This interaction is highly specific because the HDAC proteins do not interact with other vertebrate PcG proteins. We further find that histone deacetylation activity co-immunoprecipitates with the EED protein. Finally, the histone deacetylase inhibitor trichostatin A (ref. 17) relieves transcriptional repression mediated by EED, but not by HPC2, a human homologue of polycomb(11). Our data indicate that PcG-mediated repression of gene activity involves histone deacetylation. This mechanistic link between two distinct, global gene repression systems is accomplished through the interaction of HDAC proteins with a particular PcG protein, EED.	Univ Amsterdam, Bioctr, EC Slater Inst Biochem Res, Amsterdam, Netherlands	University of Amsterdam	Otte, AP (corresponding author), Univ Amsterdam, Bioctr, EC Slater Inst Biochem Res, Kruislaan 403, Amsterdam, Netherlands.		Van der Vlag, Johan/E-4636-2010	Van der Vlag, Johan/0000-0001-7843-5918				Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Monahan SJ, 1998, VIROLOGY, V241, P122, DOI 10.1006/viro.1997.8953; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Strouboulis J, 1999, MOL CELL BIOL, V19, P3958; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	29	427	438	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					474	478		10.1038/70602	http://dx.doi.org/10.1038/70602			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581039				2022-12-27	WOS:000084023900028
J	Verheijen, FW; Verbeek, E; Aula, N; Beerens, CEMT; Havelaar, AC; Joosse, M; Peltonen, L; Aula, P; Galjaard, H; van der Spek, PJ; Mancini, GMS				Verheijen, FW; Verbeek, E; Aula, N; Beerens, CEMT; Havelaar, AC; Joosse, M; Peltonen, L; Aula, P; Galjaard, H; van der Spek, PJ; Mancini, GMS			A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases	NATURE GENETICS			English	Article							SALLA DISEASE; LYSOSOMAL MEMBRANE; MOLECULAR-CLONING; INFANTILE-FORM; PHYSICAL MAP; LOCUS; MONOSACCHARIDES; EXPRESSION; DATABASE; DISORDER	Sialic acid storage diseases (SASD, MIM 269920) are autosomal recessive neurodegenerative disorders that may present as a severe infantile form (ISSD) or a slowly progressive adult form, which is prevalent in Finland(1,2) (Salla disease). The main symptoms are hypotonia, cerebellar ataxia and mental retardation; visceromegaly and coarse features are also present in infantile cases(3). Progressive cerebellar atrophy and dysmyelination have been documented by magnetic resonance imaging (ref. 4). Enlarged lysosomes are seen on electron microscopic studies and patients excrete large amounts of free sialic acid in urine. A H+/anionic sugar symporter mechanism for sialic acid and glucuronic acid(5) is impaired in lysosomal membranes from Salla and ISSD patients(6). The locus for Salla disease was assigned to a region of approximately 200 kb on chromosome 6q14-q15 in a linkage study using Finnish families(7,8). Salla disease and ISSD were further shown to be allelic disorders(9). A physical map with PZ and PAC clones was constructed to cover the 200-kb area flanked by the loci D6S280 and D6S1622, providing the basis for precise physical positioning of the gene(10). Here we describe a new gene, SLC17A5(also known as AST), encoding a protein (sialin) with a predicted transport function that belongs to a family of anion/cation symporters (ACS). Mle found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins. Our observations suggest that mutations in SLC17A5 are the primary cause of lysosomal sialic acid storage diseases.	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Acad Hosp, Erasmus Med Ctr Rotterdam, Rotterdam, Netherlands; Natl Publ Hlth Inst, Dept Human Mol Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; NV Organon, Akzo Nobel, NL-5340 BH Oss, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Finland National Institute for Health & Welfare; University of Helsinki; AkzoNobel; Merck & Company	Verheijen, FW (corresponding author), Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AULA P, 1979, ARCH NEUROL-CHICAGO, V36, P88, DOI 10.1001/archneur.1979.00500380058006; BERRA B, 1995, AM J MED GENET, V58, P24, DOI 10.1002/ajmg.1320580107; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CAMERON PD, 1990, ARCH DIS CHILD, V65, P314, DOI 10.1136/adc.65.3.314; CHONG SS, 1993, GENOMICS, V18, P355, DOI 10.1006/geno.1993.1476; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; HAATAJA L, 1994, AM J HUM GENET, V54, P1042; HAATAJA L, 1994, NEUROPEDIATRICS, V25, P1; Havelaar AC, 1998, J BIOL CHEM, V273, P34568, DOI 10.1074/jbc.273.51.34568; Havelaar AC, 1999, FEBS LETT, V446, P65, DOI 10.1016/S0014-5793(99)00187-8; Lemyre E, 1999, AM J MED GENET, V82, P385, DOI 10.1002/(SICI)1096-8628(19990219)82:5<385::AID-AJMG6>3.3.CO;2-V; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Leppanen P, 1996, GENOMICS, V37, P62, DOI 10.1006/geno.1996.0521; MANCINI GMS, 1992, P NATL ACAD SCI USA, V89, P6609, DOI 10.1073/pnas.89.14.6609; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1991, J CLIN INVEST, V87, P1329, DOI 10.1172/JCI115136; Ni BH, 1996, J NEUROCHEM, V66, P2227; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Peltonen L, 1997, ANN MED, V29, P553, DOI 10.3109/07853899709007481; Sambrook J., 2002, MOL CLONING LAB MANU; Schlemper RJ, 1996, EUR J GASTROEN HEPAT, V8, P33, DOI 10.1097/00042737-199601000-00007; SCHLEUTKER J, 1995, AM J HUM GENET, V57, P893; SCHLEUTKER J, 1995, GENOMICS, V27, P286, DOI 10.1006/geno.1995.1044; STEVENSON RE, 1983, PEDIATRICS, V72, P441; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	30	189	198	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					462	465		10.1038/70585	http://dx.doi.org/10.1038/70585			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581036				2022-12-27	WOS:000084023900025
J	Song, WJ; Sullivan, MG; Legare, RD; Hutchings, S; Tan, XL; Kufrin, D; Ratajczak, J; Resende, IC; Haworth, C; Hock, R; Loh, M; Felix, C; Roy, DC; Busque, L; Kurnit, D; Willman, C; Gewirtz, AM; Speck, NA; Bushweller, JH; Li, FP; Gardiner, K; Poncz, M; Maris, JM; Gilliland, DG				Song, WJ; Sullivan, MG; Legare, RD; Hutchings, S; Tan, XL; Kufrin, D; Ratajczak, J; Resende, IC; Haworth, C; Hock, R; Loh, M; Felix, C; Roy, DC; Busque, L; Kurnit, D; Willman, C; Gewirtz, AM; Speck, NA; Bushweller, JH; Li, FP; Gardiner, K; Poncz, M; Maris, JM; Gilliland, DG			Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia	NATURE GENETICS			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLATELET DISORDER; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATIONS; DEFINITIVE HEMATOPOIESIS; FUSION TRANSCRIPT; GENE; AML1; T(12-21)	Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Brown Univ, Women & Infants Hosp, Program Womens Oncol, Providence, RI USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Leicester Royal Infirm, Leicester, Leics, England; St Vincent Hosp, Childrens Ctr Canc & Blood Dis, Indianapolis, IN USA; Univ Montreal, Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H3C 3J7, Canada; Univ Michigan, Med Ctr, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Ctr Canc, Albuquerque, NM 87131 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03756 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA; Eleanor Roosevelt Inst, Denver, CO USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Brown University; Women & Infants Hospital Rhode Island; University of Pennsylvania; University of Pennsylvania; University of Leicester; Universite de Montreal; Universite de Montreal; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of New Mexico; University of New Mexico; Dartmouth College; University of Virginia; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.			Bushweller, John/0000-0002-5386-1758; Roy, Denis-Claude/0000-0002-5921-1692	NATIONAL CANCER INSTITUTE [R01CA078545, R01CA081932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039536] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81932, R01 CA78545] Funding Source: Medline; NIAID NIH HHS [R29 AI39536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akamatsu Y, 1997, GENE, V185, P111, DOI 10.1016/S0378-1119(96)00644-0; Arepally G, 1998, BLOOD, V92, P2600, DOI 10.1182/blood.V92.7.2600; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BERARDI MJ, IN PRESS STRUCTURE; BUSQUE L, 1993, BLOOD, V82, P337; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOWTON SB, 1985, BLOOD, V65, P557; ERICKSON P, 1992, BLOOD, V80, P1825; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALE RE, 1994, BLOOD, V83, P2899, DOI 10.1182/blood.V83.10.2899.2899; GERRARD JM, 1991, BRIT J HAEMATOL, V79, P246, DOI 10.1111/j.1365-2141.1991.tb04529.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ho CY, 1996, BLOOD, V87, P5218, DOI 10.1182/blood.V87.12.5218.bloodjournal87125218; Horwitz M, 1997, AM J HUM GENET, V61, P873, DOI 10.1086/514894; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Knudson AG, 1997, J CLIN ONCOL, V15, P3280, DOI 10.1200/JCO.1997.15.10.3280; Kowalska MA, 1999, BRIT J HAEMATOL, V104, P220, DOI 10.1046/j.1365-2141.1999.01169.x; Legare RD, 1997, LEUKEMIA, V11, P2111, DOI 10.1038/sj.leu.2400852; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Loh ML, 1998, BLOOD, V92, P4792, DOI 10.1182/blood.V92.12.4792.424k30_4792_4797; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Ratajczak MZ, 1998, BLOOD, V91, P353, DOI 10.1182/blood.V91.1.353.353_353_359; Ratajczak MZ, 1997, BRIT J HAEMATOL, V99, P228, DOI 10.1046/j.1365-2141.1997.3563170.x; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Rowley JD, 1998, J LAB CLIN MED, V132, P244, DOI 10.1016/S0022-2143(98)90036-1; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1999, LEUKEMIA, V13, P19, DOI 10.1038/sj.leu.2401257; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Speck NA, 1999, CANCER RES, V59, p1789S; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEINBERG RA, 1989, CANCER RES, V49, P3713; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	49	829	852	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					166	175		10.1038/13793	http://dx.doi.org/10.1038/13793			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508512				2022-12-27	WOS:000082827500015
J	Cargill, M; Altshuler, D; Ireland, J; Sklar, P; Ardlie, K; Patil, N; Lane, CR; Lim, EP; Kalyanaraman, N; Nemesh, J; Ziaugra, L; Friedland, L; Rolfe, A; Warrington, J; Lipshutz, R; Daley, GQ; Lander, ES				Cargill, M; Altshuler, D; Ireland, J; Sklar, P; Ardlie, K; Patil, N; Lane, CR; Lim, EP; Kalyanaraman, N; Nemesh, J; Ziaugra, L; Friedland, L; Rolfe, A; Warrington, J; Lipshutz, R; Daley, GQ; Lander, ES			Characterization of single-nucleotide polymorphisms in coding regions of human genes	NATURE GENETICS			English	Article							HUMAN LIPOPROTEIN-LIPASE; SEQUENCE VARIATION; HUMAN GENOME; ALLELE; DIVERSITY; MUTATION; DISEASE	A major goal in human genetics is to understand the role of common genetic variants in susceptibility to common diseases. This will require characterizing the nature of gene variation in human populations, assembling an extensive catalogue of single-nucleotide polymorphisms (SNPs) in candidate genes and performing association studies for particular diseases. At present, our knowledge of human gene variation remains rudimentary. Here we describe a systematic survey of SNPs in the coding regions of human genes. We identified SNPs in 106 genes relevant to cardiovascular disease, endocrinology and neuropsychiatry by screening an average of 114 independent alleles using 2 independent screening methods. To ensure high accuracy, all reported SNPs were confirmed by DNA sequencing. We identified 560 SNPs, including 392 coding-region SNPs (cSNPs) divided roughly equally between those causing synonymous and non-synonymous changes. We observed different rates of polymorphism among classes of sites within genes (non-coding, degenerate and non-degenerate) as well as between genes. The cSNPs most likely to influence disease, those that alter the amino acid sequence of the encoded protein, are found at a lower rate and with lower allele frequencies than silent substitutions. This likely reflects selection acting against deleterious alleles during human evolution. The lower allele frequency of missense cSNPs has implications for the compilation of a comprehensive catalogue, as well as for the subsequent application to disease association.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Affymetrix; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 1 Kendall Sq,Bldg 300, Cambridge, MA 02139 USA.		Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107				AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Harding RM, 1997, AM J HUM GENET, V60, P772; HARRIS H, 1975, PRINCIPLES BIOCH GEN; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, GENETICS, V129, P513; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; Nachman MW, 1998, GENETICS, V150, P1133; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; TAJIMA F, 1989, GENETICS, V123, P585; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WATTERSON GA, 1977, THEOR POPUL BIOL, V11, P141, DOI 10.1016/0040-5809(77)90023-5; Wayne ML, 1998, TRENDS ECOL EVOL, V13, P236, DOI 10.1016/S0169-5347(98)01360-3; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Zietkiewicz E, 1997, GENE, V205, P161	32	1430	1606	0	122	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					231	238		10.1038/10290	http://dx.doi.org/10.1038/10290			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391209				2022-12-27	WOS:000081125900014
J	Giaever, G; Shoemaker, DD; Jones, TW; Liang, H; Winzeler, EA; Astromoff, A; Davis, RW				Giaever, G; Shoemaker, DD; Jones, TW; Liang, H; Winzeler, EA; Astromoff, A; Davis, RW			Genomic profiling of drug sensitivities via induced haploinsufficiency	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; GENES; EXPRESSION	Lowering the dosage of a single gene from two copies to one copy in diploid yeast results in a heterozygote that is sensitized to any drug that acts on the product of this gene. This haploinsufficient phenotype thereby identifies the gene product of the heterozygous locus as the likely drug target. We exploited this finding in a genomic approach to drug-target identification. Genome sequence information was used to generate molecularly tagged heterozygous yeast strains that were pooled, grown competitively in drug and analysed for drug sensitivity using high-density oligonucleotide arrays. Individual heterozygous strain analysis verified six known drug targets. Parallel analysis identified the known target and two hypersensitive loci in a mixed culture of 233 strains in the presence of the drug tunicamycin, Our discovery that both drug target and hypersensitive loci exhibit drug-induced haploinsufficiency may have important consequences in pharmacogenomics and variable drug toxicity observed in human populations.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Rosetta Inpharmat, Kirkland, WA 98034 USA; Stanford DNA Sequencing & Technol Ctr, Palo Alto, CA 94394 USA	Stanford University; Merck & Company; Stanford University	Giaever, G (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	ggiaever@cmgm.stanford.edu	Winzeler, Elizabeth/AAP-6752-2020	Winzeler, Elizabeth/0000-0002-4049-2113	PHS HHS [H600198] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baganz F, 1997, YEAST, V13, P1563, DOI 10.1002/(SICI)1097-0061(199712)13:16<1563::AID-YEA240>3.3.CO;2-Y; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; Karim FD, 1996, GENETICS, V143, P315; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; Launhardt H, 1998, YEAST, V14, P935, DOI 10.1002/(SICI)1097-0061(199807)14:10<935::AID-YEA289>3.0.CO;2-9; LINDSLEY DL, 1972, GENETICS, V71, P157; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; RINE J, 1991, METHOD ENZYMOL, V194, P239; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; RITTBERG DAH, 1989, BIOCHEM CELL BIOL, V67, P352, DOI 10.1139/o89-055; Rose MD., 1990, METHODS YEAST GENETI; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STEARNS T, 1990, GENETICS, V124, P251; TURI TG, 1992, J BIOL CHEM, V267, P2046; VOGEL F, 1997, HUM GENET, P267; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Zinn AR, 1998, CURR OPIN GENET DEV, V8, P322, DOI 10.1016/S0959-437X(98)80089-0	24	418	450	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					278	283		10.1038/6791	http://dx.doi.org/10.1038/6791			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080179				2022-12-27	WOS:000078977900020
J	Wilson, CA; Ramos, L; Villasenor, MR; Anders, KH; Press, MF; Clarke, K; Karlan, B; Chen, JJ; Scully, R; Livingston, D; Zuch, RH; Kanter, MH; Cohen, S; Calzone, FJ; Slamon, DJ				Wilson, CA; Ramos, L; Villasenor, MR; Anders, KH; Press, MF; Clarke, K; Karlan, B; Chen, JJ; Scully, R; Livingston, D; Zuch, RH; Kanter, MH; Cohen, S; Calzone, FJ; Slamon, DJ			Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas	NATURE GENETICS			English	Article							CANCER SUSCEPTIBILITY GENE; EARLY-ONSET BREAST; OVARIAN-CANCER; SUBCELLULAR-LOCALIZATION; NUCLEAR PHOSPHOPROTEIN; MUTATIONS; EXPRESSION; POLYMORPHISMS; FAMILIES; LOCATION	Although the link between the BRCA1 tumour-suppressor gene and hereditary breast and ovarian cancer is established(1-5), the role, if any, of BRCA1 in non-familial cancers is unclear. BRCA1 mutations are rare in sporadic cancers(6-8), but loss of BRCA1 resulting from reduced expression or incorrect subcellular localization(9,10) is postulated to be important in non-familial breast and ovarian cancers. Epigenetic loss, however, has not received general acceptance due to controversy regarding the subcellular localization of BRCA1 proteins, reports of which have ranged from exclusively nuclear(11-15), to conditionally nuclear(10), to the ER/golgi(16), to cytoplasmic invaginations into the nucleus(17). In an attempt to resolve this issue, we have comprehensively characterized 19 anti-BRCA1. antibodies. These reagents detect a 220-kD protein localized in discrete nuclear foci in all epithelial cell lines, including those derived from breast malignancies. Immunohistochemical staining of human breast specimens also revealed BRCA1 nuclear foci in benign breast, invasive lobular cancers and low-grade ductal carcinomas. Conversely, BRCA1 expression was reduced or undetectable in the majority of high-grade, ductal carcinomas, suggesting that absence of BRCA1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA 91365 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of Southern California; Harvard University; Dana-Farber Cancer Institute; Amgen	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.	dslamon@med1.medsch.ucla.edu	Scully, Ralph/F-5008-2013		NCI NIH HHS [R01 CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Coene E, 1997, NAT GENET, V16, P122, DOI 10.1038/ng0697-122; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Dobrovic A, 1997, CANCER RES, V57, P3347; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Schmutzler RK, 1997, INT J CANCER, V74, P322, DOI 10.1002/(SICI)1097-0215(19970620)74:3<322::AID-IJC15>3.3.CO;2-J; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924	27	353	364	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					236	240		10.1038/6029	http://dx.doi.org/10.1038/6029			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988281				2022-12-27	WOS:000078399500031
J	Karet, FE; Finberg, KE; Nelson, RD; Nayir, A; Mocan, H; Sanjad, SA; Rodriguez-Soriano, J; Santos, F; Cremers, CWRJ; Di Pietro, A; Hoffbrand, BI; Winiarski, J; Bakkaloglu, A; Ozen, S; Dusunsel, R; Goodyer, P; Hulton, SA; Wu, DK; Skvorak, AB; Morton, CC; Cunningham, MJ; Jha, V; Lifton, RP				Karet, FE; Finberg, KE; Nelson, RD; Nayir, A; Mocan, H; Sanjad, SA; Rodriguez-Soriano, J; Santos, F; Cremers, CWRJ; Di Pietro, A; Hoffbrand, BI; Winiarski, J; Bakkaloglu, A; Ozen, S; Dusunsel, R; Goodyer, P; Hulton, SA; Wu, DK; Skvorak, AB; Morton, CC; Cunningham, MJ; Jha, V; Lifton, RP			Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness	NATURE GENETICS			English	Article							DIFFERENTIAL EXPRESSION; INNER-EAR; HETEROGENEITY; ASSOCIATION; EXCHANGER; CHILDREN; ISOFORM; CELLS; DNA	H+-ATPases are ubiquitous in nature; V-ATPases pump protons against an electrochemical gradient, whereas F-ATPases reverse the process, synthesizing ATP. We demonstrate here that mutations in ATP6B1, encoding the B-subunit of the apical proton pump mediating distal nephron acid secretion, cause distal renal tubular acidosis, a condition characterized by impaired renal acid secretion resulting in metabolic acidosis. Patients with ATP6B1 mutations also have sensorineural hearing loss; consistent with this finding, we demonstrate expression of ATP6B1 in cochlea and endolymphatic sac. Our data, together with the known requirement for active proton secretion to maintain proper endolymph pH, implicate ATP6B1 in endolymph pH homeostasis and in normal auditory function. ATP6B1 is the first member of the H+-ATPase gene family in which mutations are shown to cause human disease.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Med, New Haven, CT 06510 USA; Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA; Univ Istanbul, Dept Pediat Nephrol, Istanbul, Turkey; Karadeniz Tekn Univ, Dept Pediat Nephrol, Trabzon, Turkey; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Hosp Cruces, Dept Pediat, Bilbao, Spain; Univ Oviedo, Div Pediat Nephrol, Oviedo, Spain; Acad Ziekenhuis, Dept Otorhinolaryngol, Nijmegen, Netherlands; Serv Osped Rilievo Nazl, Serv Nefrol Pediat, Naples, Italy; Whittington Hosp, Dept Nephrol, London N19 5NF, England; Karolinska Inst, Dept Pediat, Huddinge, Sweden; Hacettepe Univ, Dept Pediat Nephrol, Ankara, Turkey; Erciyes Univ, Dept Pediat Nephrol, Kayseri, Turkey; Montreal Childrens Hosp, Div Pediat Nephrol, Montreal, PQ H3H 1P3, Canada; Childrens Hosp, Dept Nephrol, Birmingham B16 8ET, W Midlands, England; Natl Inst Deafness & Other Commun Disorders, Rockville, MD USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA; Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh 160012, India	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Utah System of Higher Education; University of Utah; Istanbul University; Karadeniz Technical University; King Faisal Specialist Hospital & Research Center; Hospital Universitario Cruces; University of Oviedo; University of London; University College London; Karolinska Institutet; Hacettepe University; Erciyes University; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Lifton, RP (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06510 USA.	richard.lifton@yale.edu	NAYIR, AHMET NEVZAT/A-9276-2019; OZEN, SEZA/I-9096-2013; Cremers, C.W.R.J./L-4254-2015	Karet, Fiona/0000-0002-2457-2869; Jha, Vivekanand/0000-0002-8015-9470	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003402] Funding Source: NIH RePORTER; NIDCD NIH HHS [DCO3402] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bastani B, 1996, MINER ELECTROL METAB, V22, P396; BATLLE DC, 1981, KIDNEY INT, V20, P389, DOI 10.1038/ki.1981.151; BATTLE D, 1996, AM J KIDNEY DIS, V6, P896; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BROWN MT, 1993, ARCH OTOLARYNGOL, V119, P458; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Butler AM, 1936, J PEDIATR-US, V8, P489, DOI 10.1016/S0022-3476(36)80111-5; CANLON B, 1991, HEARING RES, V53, P7, DOI 10.1016/0378-5955(91)90209-R; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Craig HD, 1998, HUM MOL GENET, V7, P1851, DOI 10.1093/hmg/7.12.1851; CREMERS CWRJ, 1980, ARCH OTOLARYNGOL, V106, P287; DONCKERWOLCKE RA, 1976, ACTA PAEDIATR SCAND, V65, P100, DOI 10.1111/j.1651-2227.1976.tb04414.x; GYORY AZ, 1968, AM J MED, V45, P43, DOI 10.1016/0002-9343(68)90006-5; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Lightwood R., 1935, ARCH DIS CHILD, V10, P205, DOI [10.1136/adc.10.57.205, DOI 10.1136/ADC.10.57.205]; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; MISRAHY GA, 1958, AM J PHYSIOL, V194, P393, DOI 10.1152/ajplegacy.1958.194.2.393; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NANCE W E, 1971, Birth Defects Original Article Series, V7, P70; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROYER P, 1967, P ACTUALITES NEPHROL; SELLICK P M, 1975, Progress in Neurobiology (Oxford), V5, P337, DOI 10.1016/0301-0082(75)90015-5; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Stankovic KM, 1997, HEARING RES, V114, P21, DOI 10.1016/S0378-5955(97)00072-5; STERKERS O, 1984, AM J PHYSIOL, V246, pF47, DOI 10.1152/ajprenal.1984.246.1.F47; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TASAKI I, 1959, J NEUROPHYSIOL, V22, P149, DOI 10.1152/jn.1959.22.2.149; VANHILLE B, 1994, BIOCHEM J, V303, P191, DOI 10.1042/bj3030191; Walker W G, 1971, Birth Defects Orig Artic Ser, V07, P126; ZAKZOUK SM, 1995, J LARYNGOL OTOL, V109, P930, DOI 10.1017/S0022215100131706	41	532	558	0	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					84	90		10.1038/5022	http://dx.doi.org/10.1038/5022			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916796				2022-12-27	WOS:000077960700014
J	Lipshutz, RJ; Fodor, SPA; Gingeras, TR; Lockhart, DJ				Lipshutz, RJ; Fodor, SPA; Gingeras, TR; Lockhart, DJ			High density synthetic oligonucleotide arrays	NATURE GENETICS			English	Review							LIGHT-DIRECTED SYNTHESIS; DNA ARRAYS; HYBRIDIZATION	Experimental genomics involves taking advantage of sequence information to investigate and understand the workings of genes, cells and organisms. We have developed an approach in which sequence information is used directly to design high-density, two-dimensional arrays of synthetic oligonucleotides. The GeneChip(R) probe arrays are made using spatially patterned, light-directed combinatorial chemical synthesis, and contain up to hundreds of thousands of different oligonucleotides on a small glass surface. The arrays have been designed and used for quantitative and highly parallel measurements of gene expression, to discover polymorphic loci and to detect the presence of thousands of alternative alleles. Here, we describe the fabrication of the arrays, their design and some specific: applications to high-throughput genetic and cellular analysis.	Affymetrix Inc, Santa Clara, CA 95051 USA	Affymetrix	Lipshutz, RJ (corresponding author), Affymetrix Inc, 3380 Cent Expressway, Santa Clara, CA 95051 USA.			Gingeras, Thomas/0000-0001-9106-3573				BEECHER JE, 1997, POLYM MAT SCI ENG, V76, P597; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 1998, P NATL ACAD SCI USA, V95, P3752, DOI 10.1073/pnas.95.7.3752; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; Fodor SPA, 1997, SCIENCE, V277, P393, DOI 10.1126/science.277.5324.393; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gingeras TR, 1998, GENOME RES, V8, P435, DOI 10.1101/gr.8.5.435; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GUNDERSON KL, IN PRESS GENOME RES; Gunthard HF, 1998, AIDS RES HUM RETROV, V14, P869, DOI 10.1089/aid.1998.14.869; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; KOZAL M, 1996, NAT MED, V7, P753; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mack DH, 1998, BIOLOGY OF TUMORS, P85; McGall G, 1996, P NATL ACAD SCI USA, V93, P13555, DOI 10.1073/pnas.93.24.13555; McGall GH, 1997, J AM CHEM SOC, V119, P5081, DOI 10.1021/ja964427a; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Pirrung MC, 1998, J ORG CHEM, V63, P241, DOI 10.1021/jo970872s; Sapolsky RJ, 1996, GENOMICS, V33, P445, DOI 10.1006/geno.1996.0219; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; TROESCH A, IN PRESS J CLIN MICR; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; ZHU H, IN PRESS P NATL ACAD	32	1558	1777	3	97	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			20	24		10.1038/4447	http://dx.doi.org/10.1038/4447			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915496				2022-12-27	WOS:000078008200007
J	Boehnke, M				Boehnke, M			A look at linkage disequilibrium	NATURE GENETICS			English	Editorial Material							GENOME	The extent of linkage disequilibrium critically determines the efficiency of strategies to identify genetic variants that predispose to human disease. New data indicate that the extent of disequilibrium is highly variable across the genome, and that differences in disequilibrium levels between isolated and mixed populations are modest.	Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Boehnke, M (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Biostat, 1420 Washington Hts, Ann Arbor, MI 48109 USA.							Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Eaves IA, 2000, NAT GENET, V25, P320; Kruglyak L, 1999, P NATL ACAD SCI USA, V96, P1170, DOI 10.1073/pnas.96.4.1170; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Martin ER, 2000, GENOMICS, V63, P7, DOI 10.1006/geno.1999.6057; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Taillon-Miller P, 2000, NAT GENET, V25, P324, DOI 10.1038/77100	8	49	49	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					246	247		10.1038/76980	http://dx.doi.org/10.1038/76980			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888861				2022-12-27	WOS:000087920900003
J	Bergen, AAB; Plomp, AS; Schuurman, EJ; Terry, S; Breuning, M; Dauwerse, H; Swart, J; Kool, M; van Soest, S; Baas, F; ten Brink, JB; de Jong, PTVM				Bergen, AAB; Plomp, AS; Schuurman, EJ; Terry, S; Breuning, M; Dauwerse, H; Swart, J; Kool, M; van Soest, S; Baas, F; ten Brink, JB; de Jong, PTVM			Mutations in ABCC6 cause pseudoxanthoma elasticum	NATURE GENETICS			English	Article							CHROMOSOME 16P13.1; REGION; GENE; EXPRESSION; CLONING; CANCER; TISSUE; MAPS	Pseudoxanthoma elasticum (PXE) is a heritable disorder of the connective tissue. PXE patients frequently experience visual field loss and skin lesions, and occasionally cardiovascular complication(1-4). Histopathological findings reveal calcification of the elastic fibres and abnormalities of the collagen fibrils(5). Most PXE patients are sporadic, but autosomal recessive and dominant inheritance are also observed(6,7). We previously localized the PXE gene to chromosome 16p13.1 (refs 8,9) and constructed a physical map(10). Here we describe homozygosity mapping in five PXE families and the detection of deletions or mutations in ABCC6 (formerly MRP6) associated with all genetic forms of PXE in seven patients or families.	Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands; AMC, Dept Clin Genet, Amsterdam, Netherlands; AMC, Dept Neurol, Amsterdam, Netherlands; AMC, Dept Ophthalmol, Amsterdam, Netherlands; PXE Int Inc, Sharon, MA USA; Leiden Univ, Ctr Med Genet, Dept Human Genet, Leiden, Netherlands; EUR, Dept Epidemiol & Stat, Rotterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	Bergen, AAB (corresponding author), Netherlands Ophthalm Res Inst, POB 12141, NL-1100 AC Amsterdam, Netherlands.		Breuning, Martijn H/E-3429-2010; Bergen, Arthur/J-3637-2013; Kool, Marcel/H-2541-2013; Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428; Bergen, Arthur/0000-0002-6333-9576; /0000-0002-4903-8232				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; BERGEN AAB, 1993, CYTOGENET CELL GENET, V62, P231, DOI 10.1159/000133484; Christiano AM, 1996, AM J HUM GENET, V58, P671; CHRISTIANO AM, 1992, J INVEST DERMATOL, V99, P660, DOI 10.1111/1523-1747.ep12668156; CHRISTIANO AM, 1994, J INVEST DERMATOL, V103, P535; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; HAUSSER I, 1991, HUM GENET, V87, P693; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 1999, GENOMICS, V62, P1, DOI 10.1006/geno.1999.5925; LEBWOHL M, 1993, ARCH DERMATOL RES, V285, P121, DOI 10.1007/BF01112912; LEBWOHL M, 1994, J AM ACAD DERMATOL, V30, P103, DOI 10.1016/S0190-9622(08)81894-4; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; MENDELSOHN G, 1978, ARCH PATHOL LAB MED, V102, P298; Struk B, 1997, HUM MOL GENET, V6, P1823, DOI 10.1093/hmg/6.11.1823; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VANOMMEN GB, 1987, AM J HUM GENET, V41, P689; vanSoest S, 1997, GENOME RES, V7, P830, DOI 10.1101/gr.7.8.830; YAP EY, 1992, RETINA-J RET VIT DIS, V12, P315, DOI 10.1097/00006982-199212040-00004	23	401	417	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					228	231		10.1038/76109	http://dx.doi.org/10.1038/76109			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835643				2022-12-27	WOS:000087459200027
J	Karkkainen, MJ; Ferrell, RE; Lawrence, EC; Kimak, MA; Levinson, KL; McTigue, MA; Alitalo, K; Finegold, DN				Karkkainen, MJ; Ferrell, RE; Lawrence, EC; Kimak, MA; Levinson, KL; McTigue, MA; Alitalo, K; Finegold, DN			Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema	NATURE GENETICS			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CRYSTAL-STRUCTURE; LYMPHATIC ENDOTHELIUM; FLT4; LYMPHEDEMA; ANGIOGENESIS; PROTEIN; LIGAND; DOMAIN	Primary lymphoedema is a rare, autosomal dominant disorder that leads to a disabling and disfiguring swelling of the extremities and, when untreated, tends to worsen with time. Here we link primary human lymphoedema to the FLT4 locus, encoding vascular endothelial growth factor receptor-3 (VEGFR-3). in several families. All disease-associated alleles analysed had missense mutations and encoded proteins with an inactive tyrosine kinase, preventing downstream gene activation, Our study establishes that VEGFR-3 is important for normal lymphatic vascular function and that mutations interfering with VEGFR-3 signal transduction are a cause of primary lymphoedema.	Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA; Univ Helsinki, Haartman Inst, Ludwig Inst Canc Res, Mol Canc Biol Lab, Helsinki, Finland; Agouron Pharmaceut Inc, San Diego, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ludwig Institute for Cancer Research; University of Helsinki; Pfizer	Ferrell, RE (corresponding author), Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA.	rferrell@helex.hgen.pitt.edu	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Finegold, David/0000-0001-9901-2578	NICHD NIH HHS [HD35174] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035174] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Barber JCK, 1996, AM J MED GENET, V62, P84, DOI 10.1002/(SICI)1096-8628(19960301)62:1<84::AID-AJMG17>3.3.CO;2-C; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; BESMER P, 1993, DEVELOPMENT, P125; Brunger A.T., 1992, X PLOR VERSION 3 1 M; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Evans AL, 1999, AM J HUM GENET, V64, P547, DOI 10.1086/302248; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrell RE, 1998, HUM MOL GENET, V7, P2073, DOI 10.1093/hmg/7.13.2073; GALLAND F, 1993, ONCOGENE, V8, P1233; Groen SE, 1998, AM J MED GENET, V80, P448, DOI 10.1002/(SICI)1096-8628(19981228)80:5<448::AID-AJMG3>3.0.CO;2-Q; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hardie G., 1995, PROTEIN KINASE FACTS; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEU JJ, 1995, VASCULAR PATHOLOGY, P489; Mangion J, 1999, AM J HUM GENET, V65, P427, DOI 10.1086/302500; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meige H., 1898, PRESSE MED, V6, P341; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Milroy WF., 1892, N Y MED J, V56, P505; Mowat D, 1999, AM J MED GENET, V83, P361, DOI 10.1002/(SICI)1096-8628(19990423)83:5<361::AID-AJMG3>3.0.CO;2-W; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robertson K, 1997, GUT, V41, P436, DOI 10.1136/gut.41.4.436; SCHINZEL A, 1983, CATALOG UNBALANCED C; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SPRITZ RA, 1994, J INVEST DERMATOL, V103, P1375; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veikkola T, 2000, CANCER RES, V60, P203; Witte MH, 1998, LYMPHOLOGY, V31, P145; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	46	455	485	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					153	159		10.1038/75997	http://dx.doi.org/10.1038/75997			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835628				2022-12-27	WOS:000087459200012
J	Lindblad-Toh, K; Winchester, E; Daly, MJ; Wang, DG; Hirschhorn, JN; Laviolette, JP; Ardlie, K; Reich, DE; Robinson, E; Sklar, P; Shah, N; Thomas, D; Fan, JB; Gingeras, T; Warrington, J; Patil, N; Hudson, TJ; Lander, ES				Lindblad-Toh, K; Winchester, E; Daly, MJ; Wang, DG; Hirschhorn, JN; Laviolette, JP; Ardlie, K; Reich, DE; Robinson, E; Sklar, P; Shah, N; Thomas, D; Fan, JB; Gingeras, T; Warrington, J; Patil, N; Hudson, TJ; Lander, ES			Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse	NATURE GENETICS			English	Article							GENOME	Single-nucleotide polymorphisms (SNPs) have been the focus of much attention in human genetics because they are extremely abundant and well-suited for automated large-scale genotyping, Human SNPs, however, are less informative than other types of genetic markers (such as simple-sequence length polymorphisms or microsatellites) and thus more loci are required for mapping traits. SNPs offer similar advantages for experimental genetic organisms such as the mouse, but they entail no loss of informativeness because bi-allelic markers are fully informative in analysing crosses between inbred strains. Here we report a large-scale analysis of SNPs in the mouse genome. We characterized the rate of nucleotide polymorphism in eight mouse strains and identified a collection of 2,848 SNPs located in 1,755 sequence-tagged sites (STSs) using high-density oligonucleotide arrays. Three-quarters of these SNPs have been mapped on the mouse genome, providing a first-generation SNP map of the mouse. We have also developed a multiplex genotyping procedure by which a genome scan can be performed with only six genotyping reactions per animal.	MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Bristol Myers Squibb, Princeton, NJ USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Affymetrix Inc, Santa Clara, CA USA; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3A 2T5, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Bristol-Myers Squibb; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Affymetrix; McGill University; Massachusetts Institute of Technology (MIT)	Lindblad-Toh, K (corresponding author), MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA.		Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752; Gingeras, Thomas/0000-0001-9106-3573	NHGRI NIH HHS [HG01806] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001806] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ATCHLEY WR, 1993, MOL BIOL EVOL, V10, P1150; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FERRIS SD, 1983, GENETICS, V105, P681; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; SAGE RD, 1981, MOUSE BIOMEDICAL RES, P40; Syvanen AC, 1999, HUM MUTAT, V13, P1; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	11	323	360	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					381	386		10.1038/74215	http://dx.doi.org/10.1038/74215			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742102				2022-12-27	WOS:000086192800017
J	Hughes, AE; Ralston, SH; Marken, J; Bell, C; MacPherson, H; Wallace, RGH; van Hul, W; Whyte, MP; Nakatsuka, K; Hovy, L; Anderson, DM				Hughes, AE; Ralston, SH; Marken, J; Bell, C; MacPherson, H; Wallace, RGH; van Hul, W; Whyte, MP; Nakatsuka, K; Hovy, L; Anderson, DM			Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis	NATURE GENETICS			English	Article							CHROMOSOME 18Q	Familial expansile osteolysis(1,2) (FEO, MIM 174810) is a rare, autosomal dominant bone disorder characterized by focal areas of increased bone remodelling. The osteolytic lesions, which develop usually in the long bones during early adulthood, show increased osteoblast and osteoclast activity. Our previous linkage studies mapped the gene responsible for FEO to an interval of less than 5 cM between D18564 and D18551 on chromosome 18q21.2-21.3 in a large Northern Irish family(3,4). The gene encoding receptor activator of nuclear factor-kappa B (RANK; ref. 5), TNFRSF11A, maps to this region. RANK is essential in osteoclast formation(6,7). We identified two heterozygous insertion mutations in exon 1 of TNFRSF11A in affected members of four families with FEO or familial Paget disease of bone (PDB). One was a duplication of 18 bases and the other a duplication of 27 bases, both of which affected the signal peptide region of the RANK molecule. Expression of recombinant forms of the mutant RANK proteins revealed perturbations in expression levels and lack of normal cleavage of the signal peptide. Both mutations caused an increase in RANK-mediated nuclear factor-kappa B (NF-kappa B) signalling in vitro, consistent with the presence of an activating mutation.	Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland; Immunex Res & Dev Corp, Dept Mol Biol, Seattle, WA 98101 USA; Musgrave Pk Hosp, Dept Orthopaed Surg, Belfast, Antrim, North Ireland; Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO USA; Osaka City Hosp, Dept Internal Med 2, Osaka, Japan; Univ Frankfurt, Orthopad Klin, Frankfurt, Germany	Queens University Belfast; University of Aberdeen; University of Antwerp; Washington University (WUSTL); Osaka City General Hospital; Goethe University Frankfurt	Hughes, AE (corresponding author), Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland.		Hughes, Anne/A-1307-2012	Van Hul, Wim/0000-0002-5065-7858				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ENDERLE A, 1979, ARCH ORTHOP TRAUM SU, V94, P127, DOI 10.1007/BF00433578; Haslam SI, 1998, J BONE MINER RES, V13, P911, DOI 10.1359/jbmr.1998.13.6.911; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; HUGHES AE, 1994, HUM MOL GENET, V3, P359, DOI 10.1093/hmg/3.2.359; HUGHES AE, 1996, MOL BIOL PAGETS DIS, P179; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Ogilvie D J, 1996, Methods Mol Biol, V54, P131; OSTERBERG PH, 1988, J BONE JOINT SURG BR, V70, P255, DOI 10.1302/0301-620X.70B2.3346299; OSTERBERG PH, 1976, BONE DIS CALCITONIN, P185; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	14	368	383	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					45	48		10.1038/71667	http://dx.doi.org/10.1038/71667			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615125	Green Published			2022-12-27	WOS:000084609200013
J	Stockton, DW; Das, P; Goldenberg, M; D'Souza, RN; Patel, PI				Stockton, DW; Das, P; Goldenberg, M; D'Souza, RN; Patel, PI			Mutation of PAX9 is associated with oligodontia	NATURE GENETICS			English	Article							GENES; MSX1		Univ Texas, Hlth Sci Ctr, Dent Branch, Houston, TX 77225 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Patel, PI (corresponding author), Univ Texas, Hlth Sci Ctr, Dent Branch, Houston, TX 77225 USA.		Patel, Pragna/H-9129-2017	Patel, Pragna/0000-0003-3584-1072; D'Souza, Rena/0000-0002-1505-5173	NEI NIH HHS [EY00375] Funding Source: Medline; NIDCR NIH HHS [DE13368, DE11663] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011663, R01DE013368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Gorlin RJ, 1990, PLAST RECONSTR SURG; GRABER LW, 1978, J AM DENT ASSOC, V96, P266, DOI 10.14219/jada.archive.1978.0054; JORGENSON RJ, 1980, J AM DENT ASSOC, V101, P283, DOI 10.14219/jada.archive.1980.0186; NIEMINEN P, 1995, HUM GENET, V96, P305; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; SEMENZA GL, 1998, PAX PROTEINS, P169; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; VASTARDIS H, 1996, THESIS HARVARD U	9	371	393	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					18	19		10.1038/71634	http://dx.doi.org/10.1038/71634			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615120				2022-12-27	WOS:000084609200009
J	Li, YP; Chen, W; Liang, YQ; Li, E; Stashenko, P				Li, YP; Chen, W; Liang, YQ; Li, E; Stashenko, P			Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification	NATURE GENETICS			English	Article							PROTON PUMP; RESORPTION; CELLS; PH	Solubilization of bone mineral by osteoclasts depends on the formation of an acidic extracellular compartment through the action of a V-proton pump that has not yet been characterized at the molecular level(1-3). We previously cloned a gene (Atp6i, for V-proton pump, H+ transporting (vacuolar proton pump) member I) encoding a putative osteoclast-specific proton pump subunit, termed OC-116kD (ref, 4), Here we show that targeted disruption of Atp6i in mice results in severe osteopetrosis. Atp6i(-/-) osteoclast-like cells (OCLs) lose the function of extracellular acidification, but retain intracellular lysosomal proton pump activity. The pH in Atp6i(-/-) liver lysosomes and proton transport in microsomes of Atp6i(-/-) kidney are identical to that in wild-type mice. Atp6i(-/-) mice exhibit a normal acid-base balance in blood and urine. Our results demonstrate that Atp6i is unique and necessary for osteoclast-mediated extracellular acidification.	Forsyth Inst, Dept Cytokine Biol, Boston, MA USA; Harvard Univ, Forsyth Inst, Forsyth Dept Oral Biol, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr,Dept Med, Charlestown, MA USA	Harvard University; Forsyth Institute; Harvard University; Forsyth Institute; Harvard School of Dental Medicine; Harvard University; Harvard School of Dental Medicine; Harvard University; Massachusetts General Hospital	Li, YP (corresponding author), Forsyth Inst, Dept Cytokine Biol, Boston, MA USA.	ypli@forsyth.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007378] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44741] Funding Source: Medline; NIDCR NIH HHS [DE-07378] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Blair Harry C., 1992, P259; Chen W, 1998, J BONE MINER RES, V13, P1112, DOI 10.1359/jbmr.1998.13.7.1112; DAVID P, 1994, J BIOL CHEM, V269, P30158; GERRITSEN EJA, 1994, PEDIATRICS, V93, P247; Horton W. A., 1990, GROWTH GENET HORM, V6, P1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; SHIBUTANI T, 1993, J BONE MINER RES, V8, P331; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAMURA T, 1993, J BONE MINER RES, V8, P953; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VAES G, 1968, J CELL BIOL, V39, P676, DOI 10.1083/jcb.39.3.676; WANG SJ, 1992, J OPT SOC AM B, V9, P360, DOI 10.1364/JOSAB.9.000360; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	20	386	402	2	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					447	451		10.1038/70563	http://dx.doi.org/10.1038/70563			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581033				2022-12-27	WOS:000084023900022
J	Laberge-le Couteulx, S; Jung, HH; Labauge, P; Houtteville, JP; Lescoat, C; Cecillon, M; Marechal, E; Joutel, A; Bach, JF; Tournier-Lasserve, E				Laberge-le Couteulx, S; Jung, HH; Labauge, P; Houtteville, JP; Lescoat, C; Cecillon, M; Marechal, E; Joutel, A; Bach, JF; Tournier-Lasserve, E			Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas	NATURE GENETICS			English	Article							CHROMOSOME 7Q; GENE; MALFORMATION; PROTEINS; RAS; LOCALIZATION; APOPTOSIS; MICE; RAP1	Cavernous angiomas are vascular malformations mostly located in the central nervous system and characterized by enlarged capillary cavities without intervening brain parenchyma(1). Clinical symptoms include seizures, haemorrhage and focal neurological deficits. Cavernous angiomas prevalence is close to 0.5% in the general population(2). They may be inherited as an autosomal dominant condition in as much as 50% of cases(3). Cerebral cavernous malformations (CCM) loci were previously identified on 7q, 7p and 3q (refs 4,5). A strong founder effect was observed in the Hispano-American population, all families being linked to CCM1 on 7q (refs 4,6,7). CCM1 locus assignment was refined to a 4-cM interval bracketed by D7S2410 and D7S689 (ref. 8). Here we report a physical and transcriptional map of this interval and that CCM1, a gene whose protein product, KRIT1, interacts with RAP1A (also known as KREV1; ref. 9), a member of the RAS family of GTPases, is mutated in CCM1 families. Our data suggest the involvement of the RAP1A signal transduction pathway in vasculogenesis or angiogenesis(10).	Fac Med Necker, INSERM, U25, F-75730 Paris 15, France; CHR Cote Nacre, Serv Neurochirurg, Caen, France; Hop Lariboisiere, Lab Cytogenet, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Tournier-Lasserve, E (corresponding author), Fac Med Necker, INSERM, U25, 156 Rue Vaugirard, F-75730 Paris 15, France.		Tournier-Lasserve, Elisabeth/N-7134-2017; Laberge, Sophie/ABD-7353-2020; Joutel, Anne/K-5601-2017	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Laberge, Sophie/0000-0003-4722-0361; Joutel, Anne/0000-0003-3963-3860				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASHA H, EMBO J, V18, P60599; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Craig HD, 1998, HUM MOL GENET, V7, P1851, DOI 10.1093/hmg/7.12.1851; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; Gunel M, 1996, NEW ENGL J MED, V334, P946, DOI 10.1056/NEJM199604113341503; Gunel M, 1996, NEUROSURGERY, V38, P1265; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; JOHNSON EW, 1995, GENOME RES, V5, P368, DOI 10.1101/gr.5.4.368; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Labauge P, 1998, LANCET, V352, P1892, DOI 10.1016/S0140-6736(98)03011-6; Laberge S, 1999, EUR J HUM GENET, V7, P499, DOI 10.1038/sj.ejhg.5200324; OTTEN P, 1989, NEUROCHIRURGIE, V35, P82; PIZON V, 1988, ONCOGENE, V3, P201; Pizon V, 1996, EUR J CELL BIOL, V69, P224; Quarck R, 1996, EUR J CELL BIOL, V70, P269; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293	22	349	354	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					189	193		10.1038/13815	http://dx.doi.org/10.1038/13815			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508515				2022-12-27	WOS:000082827500018
J	Drenth, JPH; Cuisset, L; Grateau, G; Vasseur, C; van de Velde-Visser, SD; de Jong, JGN; Beckmann, JS; van der Meer, JWM; Delpech, M				Drenth, JPH; Cuisset, L; Grateau, G; Vasseur, C; van de Velde-Visser, SD; de Jong, JGN; Beckmann, JS; van der Meer, JWM; Delpech, M		Int Hyper-IgD Study Grp	Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome	NATURE GENETICS			English	Article							FAMILIAL HIBERNIAN FEVER; HYPERIMMUNOGLOBULINEMIA-D; CLINICAL SPECTRUM; IDENTIFICATION; ACIDURIA; LINKAGE; ATTACKS; 12P13	Hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM 260920) is a rare, apparently monogenic, autosomal recessive disorder characterized by recurrent episodes of fever accompanied with lymphadenopathy, abdominal distress,joint involvement and skin lesions'.;All patients have high serum IgD values (>100 U/ml) and HIDS 'attacks' are associated with an intense acute phase reaction whose exact pathophysiology remains obscure(2-4). Two other hereditary febrile disorders have been described. Familial Mediterranean fever (MIM 249100) is an autosomal recessive disorder affecting mostly populations from the Mediterranean basin and is caused by mutations in the gene MEFV(refs 5,6). Familial Hibernian fever (MIM 142680), also known as autosomal: dominant familial recurrent-fever, is caused by missense mutations in the gene encoding type 1 tumour necrosis factor receptor(7-10). Here we perform a genome-wide search to map the HIDS; gene. Haplotype analysis:placed the gene at 12q24 between D12S330 and D12S79. We identified the gene MVK,: encoding mevalonate kinase (MK, ATP:mevalonate 5-phosphotransferase; EC 2.7.1.36), as a candidate gene. We characterized 3 missense mutations, a 92-bp loss stemming from a deletion or from exon skipping, and the absence of expression of one allele Functional analysis demonstrated diminished MK activity in: fibroblasts from HIDS-patients. Our data establish MVK as the: gene responsible for HIDS.	Inst Cochin Genet Mol, Lab Genet Mol Humaine, Paris, France; Hop Cochin, Assistance Publ Hopitaux Paris, F-75674 Paris, France; Univ Nijmegen St Radboud Hosp, Dept Med, Div Gen Internal Med, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Hotel Dieu, Serv Med Interne, AP HP, Paris, France; Univ Nijmegen St Radboud Hosp, Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands; URA CNRS 1922, Evry, France; Ctr Natl Genotypage, Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Radboud University Nijmegen; Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Delpech, M (corresponding author), Inst Cochin Genet Mol, Lab Genet Mol Humaine, Paris, France.		van der Meer, Jos W.M./C-8521-2013; Drenth, Joost/V-7436-2019; Drenth, J.P.H./H-8025-2014; Beckmann, Jacques S/A-9772-2008	van der Meer, Jos W.M./0000-0001-5120-3690; Beckmann, Jacques S/0000-0002-9741-1900				Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; DRENTH JPH, 1995, BLOOD, V85, P3586, DOI 10.1182/blood.V85.12.3586.bloodjournal85123586; Drenth JPH, 1996, J IMMUNOL, V157, P400; DRENTH JPH, 1995, EUR J CLIN INVEST, V25, P683, DOI 10.1111/j.1365-2362.1995.tb01986.x; DRENTH JPH, 1994, HUM GENET, V94, P616, DOI 10.1007/BF00206953; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; McDermott MF, 1998, AM J HUM GENET, V62, P1446, DOI 10.1086/301886; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Mulley J, 1998, AM J HUM GENET, V62, P884, DOI 10.1086/301793; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Ott J., 1991, ANAL HUMAN GENETIC L; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Potter D, 1997, J BIOL CHEM, V272, P25449, DOI 10.1074/jbc.272.41.25449; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; Yamagishi A, 1996, HUM MUTAT, V7, P23, DOI 10.1002/(SICI)1098-1004(1996)7:1<23::AID-HUMU3>3.3.CO;2-K	21	412	425	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					178	181		10.1038/9696	http://dx.doi.org/10.1038/9696			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369262				2022-12-27	WOS:000080680900025
J	Hayashi, T; Motulsky, AG; Deeb, SS				Hayashi, T; Motulsky, AG; Deeb, SS			Position of a 'green-red' hybrid gene in the visual pigment array determines colour-vision phenotype	NATURE GENETICS			English	Article							MOLECULAR-GENETICS; TANDEM ARRAY; EXPRESSION; DEFECTS; SEVERITY; LOCUS; XQ28; BLUE	The X-linked red- and green-pigment genes are arranged in a head-to-tail tandem array(1-3). The colour-vision defect of deuteranomaly (in 5% of males of European descent) is associated with a 5'-green-red-3' visual-pigment hybrid gene(4,5), which may also exist in males with normal colour vision(5-7). To explain why males with a normal red, a normal green and a green-red hybrid gene may have either normal or deutan colour vision, we hypothesized that only the first two genes are expressed(8,9) and deuteranomaly results only if the green-red hybrid gene occupies the second position and is expressed preferentially over normal green-pigment genes occupying more distal positions. We used long-range PCR amplification and studied 10 deutan males (8 deuteranomalous and 2 deuteranopic) with 3 visual pigment genes (red, green and green-red hybrid) to investigate whether position of the hybrid gene in the array determined gene expression. The green-red hybrid gene was always at the second position land the first position was always occupied by the red gene). Conversely, in two men with red, green and green-red hybrid genes and normal colour vision, the hybrid gene occupied the third position. When pigment gene mRNA expression was assessed in post-mortem retinae of three men with the red, green and green-red genotype, the green-red hybrid gene was expressed only when located in the second position. We conclude that the green-red hybrid gene will only cause deutan defects when it occupies the second position of the pigment gene array.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Deeb, SS (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.				NEI NIH HHS [EY08395] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008395] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Crognale MA, 1998, VISION RES, V38, P3377, DOI 10.1016/S0042-6989(97)00425-2; DEEB SS, 1992, AM J HUM GENET, V51, P687; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DRUMMONDBORG M, 1989, P NATL ACAD SCI USA, V86, P983, DOI 10.1073/pnas.86.3.983; FARRELL DF, 1993, NEUROLOGY, V43, P1518, DOI 10.1212/WNL.43.8.1518; FEIL R, 1990, GENOMICS, V6, P367, DOI 10.1016/0888-7543(90)90578-I; Hanna MC, 1997, GENOMICS, V43, P384, DOI 10.1006/geno.1997.4830; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; Kitahara Kenji, 1998, Nippon Ganka Gakkai Zasshi, V102, P837; Macke JP, 1997, INVEST OPHTH VIS SCI, V38, P1040; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; MILER SA, 1988, NUCLEIC ACIDS RES, V16, P1215; NATHANS J, 1993, AM J HUM GENET, V53, P987; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Neitz J, 1996, SCIENCE, V274, P801, DOI 10.1126/science.274.5288.801; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; Sanocki E, 1997, VISION RES, V37, P1897, DOI 10.1016/S0042-6989(97)00005-9; Sharpe LT, 1998, J NEUROSCI, V18, P10053; Shevell SK, 1997, VISION RES, V37, P1115, DOI 10.1016/S0042-6989(96)00270-2; Sjoberg SA, 1998, VISION RES, V38, P3213, DOI 10.1016/S0042-6989(97)00367-2; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WINDERICKX J, 1992, P NATL ACAD SCI USA, V89, P9710, DOI 10.1073/pnas.89.20.9710; Yamaguchi T, 1997, HUM MOL GENET, V6, P981, DOI 10.1093/hmg/6.7.981	26	71	72	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					90	93		10.1038/8798	http://dx.doi.org/10.1038/8798			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319869				2022-12-27	WOS:000080096300030
J	Koob, MD; Moseley, ML; Schut, LJ; Benzow, KA; Bird, TD; Day, JW; Ranum, LPW				Koob, MD; Moseley, ML; Schut, LJ; Benzow, KA; Bird, TD; Day, JW; Ranum, LPW			An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8)	NATURE GENETICS			English	Article							MACHADO-JOSEPH DISEASE; RNA-BINDING-PROTEIN; MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEAT; CLINICAL-FEATURES; MICE; TRANSCRIPTS; FAMILIES; MYOPATHY; LENGTH	Myotonic dystrophy (DM) is the only disease reported to be caused by a CTG expansion. We now report that a non-coding CTC expansion causes a novel form of spinocerebellar ataxia (SCA8). This expansion, located on chromosome 13q21, was isolated directly from the genomic DNA of an ataxia patient by RAPID cloning. SCA8 patients have expansions similar in size (107-127 CTG repeats) to those found among adult-onset DM patients. SCA8 is the first example of a dominant SCA not caused by a CAG expansion translated as a polyglutamine tract.	Univ Minnesota, Dept Neurol & Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Cell Biol & Dev, Minneapolis, MN 55455 USA; Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Koob, MD (corresponding author), Univ Minnesota, Dept Neurol & Genet, Box 295 UMHC,420 Delaware St SE, Minneapolis, MN 55455 USA.				NINDS NIH HHS [P01 NS33718, R01 NS36282] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033718, R01NS036282] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brice A, 1998, J NEUROL, V245, P505, DOI 10.1007/s004150050234; Cancel G, 1997, HUM MOL GENET, V6, P709, DOI 10.1093/hmg/6.5.709; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Groenen P, 1998, BIOESSAYS, V20, P901, DOI 10.1002/(SICI)1521-1878(199811)20:11<901::AID-BIES5>3.0.CO;2-0; HARDING AE, 1982, BRAIN, V105, P1, DOI 10.1093/brain/105.1.1; HOFFMANRADVANYI H, 1993, HUM MOL GENET, V2, P1263; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Jodice C, 1997, HUM MOL GENET, V6, P1973, DOI 10.1093/hmg/6.11.1973; Klockgether T, 1998, TRENDS NEUROSCI, V21, P413, DOI 10.1016/S0166-2236(98)01315-0; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MACIEL P, 1995, AM J HUM GENET, V57, P54; MARUYAMA H, 1995, HUM MOL GENET, V4, P807, DOI 10.1093/hmg/4.5.807; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SCHANK SC, 1993, BIOMASS BIOENERG, V4, P1, DOI 10.1016/0961-9534(93)90021-U; SUBRAMONY SH, 1991, HDB CLIN NEUROLOGY, P271; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; Zoghbi HY, 1991, CURR NEUROL, V11, P121	29	458	483	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					379	384		10.1038/7710	http://dx.doi.org/10.1038/7710			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192387				2022-12-27	WOS:000079439700018
J	Munroe, PB; Olgunturk, RO; Fryns, JP; Van Maldergem, L; Ziereisen, F; Yuksel, B; Gardiner, RM; Chung, E				Munroe, PB; Olgunturk, RO; Fryns, JP; Van Maldergem, L; Ziereisen, F; Yuksel, B; Gardiner, RM; Chung, E			Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome	NATURE GENETICS			English	Article							VITAMIN-K; ASSIGNMENT; MOUSE; MAP	Keutel syndrome (KS, MIM 245150) is an autosomal recessive disorder characterized by abnormal cartilage calcification, peripheral pulmonary stenosis and midfacial hypoplasia(1). A genome search using homozygosity mapping provided evidence of linkage to chromosome 12p12.3-13.1 (maximum multipoint lod score, 4.06). MGP was a candidate on the basis of its localization to this chromosomal region and the known function of its protein(2-4). MGP maps to chromosome 12p near D12S363 (refs 2,3). Human MCP is a 10-kD skeletal extracellular matrix (ECM) protein that consists of an 84-aa mature protein and a 19-aa transmembrane signal peptide(5). It is a member of the Gla protein family, which includes osteocalcin(6), another skeletal ECM protein, and a number of coagulation factors(7) (factors II, VII, IX, X and proteins S and C). All members of this family have glutamic acid residues modified to gamma-carboxyglutamic acids (Gla) by a specific gamma-carboxylase using Vitamin K as a cofactors(8,9). The modified glutamic acid residues of Gla proteins confer a high affinity for mineral ions such as calcium, phosphate and hydroxyapatite crystals, the mineral components of the skeletal ECM. The pattern and tissue distribution of Mgp expression in mice suggest a role for Mgp in regulating ECM calcification(10). Mglap-deficient mice (Mglap(-/-)) have been reported to have inappropriate calcification of cartilage(4). Mutational analysis of MGP in three unrelated probands identified three different mutations: c.69delG, IVS1-2A-->G and c.113T-->A. All three mutations predict a non-functional MGP. Our data indicate that mutations in MGP are responsible for KS and confirm its role in the regulation of extracellular matrix calcification.	UCL Royal Free & Univ Coll Med Sch, Dept Paediat, Rayne Inst, London, England; Gazi Univ Hosp, Dept Paediat Cardiol, Ankara, Turkey; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Inst Pathol & Genet, Ctr Human Genet, Loverval, Belgium; Hop Univ Enfants Reine Fabiola, Dept Radiol, Brussels, Belgium; Chase Farm Hosp NHS Trust, Dept Paediat, London, England	University of London; King's College London; University College London; UCL Medical School; Gazi University; KU Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Munroe, PB (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Paediat, Rayne Inst, Univ St, London, England.	p.munroe@ucl.ac.uk	Van Maldergem, Lionel/G-9849-2017; Van Maldergem, Lionel/O-3242-2019	Van Maldergem, Lionel/0000-0001-8880-5214; Van Maldergem, Lionel/0000-0001-8880-5214; Munroe, Patricia/0000-0002-4176-2947				CANCELA L, 1990, J BIOL CHEM, V265, P15040; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; CORMODE EJ, 1986, AM J MED GENET, V24, P289, DOI 10.1002/ajmg.1320240209; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FRANKE TF, 1995, CELL, V81, P1; FRASER JD, 1988, J BIOL CHEM, V263, P11033; FRYNS JP, 1984, EUR J PEDIATR, V142, P201, DOI 10.1007/BF00442449; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALLOP PM, 1980, NEW ENGL J MED, V302, P1460, DOI 10.1056/NEJM198006263022608; HALE JE, 1988, J BIOL CHEM, V263, P5820; HOWE AM, 1995, AM J MED GENET, V58, P238, DOI 10.1002/ajmg.1320580309; JOHNSON TL, 1991, GENOMICS, V11, P770, DOI 10.1016/0888-7543(91)90089-W; KEUTEL J, 1972, Birth Defects Original Article Series, V8, P60; KHOSROSHAHI HE, 1989, EUR J PEDIATR, V149, P188, DOI 10.1007/BF01958278; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LUO GB, 1995, J BONE MINER RES, V10, P325; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Munroe PB, 1997, AM J HUM GENET, V61, P310, DOI 10.1086/514846; PAULI RM, 1987, AM J HUM GENET, V41, P566; PETTIFOR JM, 1975, J PEDIATR-US, V86, P459; Say B, 1973, Pediatr Radiol, V1, P127, DOI 10.1007/BF00973228; SHEFFIELD LJ, 1976, J PEDIATR-US, V89, P916, DOI 10.1016/S0022-3476(76)80596-3; SPRANGER JW, 1970, HUM GENET, V11, P190; Watanabe I, 1998, J HUM GENET, V43, P75, DOI 10.1007/s100380050044	27	315	324	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					142	144		10.1038/5102	http://dx.doi.org/10.1038/5102			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916809				2022-12-27	WOS:000077960700027
J	Hughes, TR; Roberts, CJ; Dai, HY; Jones, AR; Meyer, MR; Slade, D; Burchard, J; Dow, S; Ward, TR; Kidd, MJ; Friend, SH; Marton, MJ				Hughes, TR; Roberts, CJ; Dai, HY; Jones, AR; Meyer, MR; Slade, D; Burchard, J; Dow, S; Ward, TR; Kidd, MJ; Friend, SH; Marton, MJ			Widespread aneuploidy revealed by DNA microarray expression profiling	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST; GENOME; IDENTIFICATION; BIOSYNTHESIS; EVOLUTION; SCALE	Expression profiling using DNA microarrays holds great promise for a variety of research applications, including the systematic characterization of genes discovered by sequencing projects(1,2) To demonstrate the general usefulness of this approach, we recently obtained expression profiles for nearly 300 Saccharomyces cerevisiae deletion mutants(3). Approximately 8% of the mutants profiled exhibited chromosome-wide expression biases, leading to spurious correlations among profiles. Competitive hybridization of genomic DNA from the mutant strains and their isogenic parental wild-type strains showed they were aneuploid for whole chromosomes or chromosomal segments. Expression profile data published by several other laboratories also suggest the use of aneuploid strains. In five separate cases. the extra chromosome harboured a close homologue of the deleted gene; in two cases, a clear growth advantage for cells acquiring the extra chromosome was demonstrated. Our results have implications for interpreting whole-genome expression data, particularly from cells known to suffer genomic instability, such as malignant or immortalized cells.	Rosetta Inpharmat Inc, Kirkland, WA USA		Marton, MJ (corresponding author), Rosetta Inpharmat Inc, Kirkland, WA USA.							Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; HARTWELL LH, 1985, GENETICS, V110, P381; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUGHES TR, IN PRESS CELL; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; LAI MH, 1994, GENE, V140, P41; Lussier M, 1997, GENETICS, V147, P435; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Pennisi E, 1998, SCIENCE, V282, P1972, DOI 10.1126/science.282.5396.1972; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Smith NGC, 1999, BIOESSAYS, V21, P697, DOI 10.1002/(SICI)1521-1878(199908)21:8<697::AID-BIES9>3.0.CO;2-X; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	24	375	385	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					333	337		10.1038/77116	http://dx.doi.org/10.1038/77116			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888885				2022-12-27	WOS:000087920900025
J	Rountree, MR; Bachman, KE; Baylin, SB				Rountree, MR; Bachman, KE; Baylin, SB			DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci	NATURE GENETICS			English	Article							HISTONE DEACETYLASE COMPLEX; DNA METHYLTRANSFERASE; METHYLATION; CHROMATIN; CELLS; TRANSCRIPTION; ORGANIZATION; DOMAIN; MECP2; (CYTOSINE-5)-METHYLTRANSFERASE	DNA methylation can contribute to transcriptional silencing through several transcriptionally repressive complexes, which include methyl-CpG binding domain proteins (MBDs) and histone deacetylases (HDACs). We show here that the chief enzyme that maintains mammalian DNA methylation, DNMT1, can also establish a repressive transcription complex. The non-catalytic amino terminus of DNMT1 binds to HDAC2 and a new protein, DMAP1 (for DNMT1 associated protein), and can mediate transcriptional repression. DMAP1 has intrinsic transcription repressive activity, and binds to the transcriptional co-repressor TSG101. DMAP1 is targeted to replication foci through interaction with the far N terminus of DNMT1 throughout S phase, whereas HDAC2 joins DNMT1 and DMAP1 only during late S phase, providing a platform for how histones may become deacetylated in heterochromatin following replication. Thus, DNMT1 not only maintains DNA methylation, but also may directly target, in a heritable manner, transcriptionally repressive chromatin to the genome during DNA replication.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Tumor Biol Lab, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Grad Program Cellular & Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Rountree, MR (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Tumor Biol Lab, Baltimore, MD 21205 USA.	rountree@jhmi.edu	Rountree, Michael R/C-6332-2018	Rountree, Michael R/0000-0003-2371-6389	NATIONAL CANCER INSTITUTE [R01CA043318, R01CA054396] Funding Source: NIH RePORTER; NCI NIH HHS [CA43318, CA54396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; KASS SU, 1996, EPIGENETIC MECH GENE, P529; Krude T, 1999, CURR BIOL, V9, pR394, DOI 10.1016/S0960-9822(99)80251-6; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Leonhardt H., 1993, Experientia Supplementum (Basel), V64, P109; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; Li E, 1999, NAT GENET, V23, P5, DOI 10.1038/12595; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Mertineit C, 1998, DEVELOPMENT, V125, P889; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Zhong Q, 1998, CANCER RES, V58, P2699	48	820	846	2	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					269	277		10.1038/77023	http://dx.doi.org/10.1038/77023			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888872				2022-12-27	WOS:000087920900012
J	Follenzi, A; Ailles, LE; Bakovic, S; Geuna, M; Naldini, L				Follenzi, A; Ailles, LE; Bakovic, S; Geuna, M; Naldini, L			Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences	NATURE GENETICS			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEMATOPOIETIC STEM-CELLS; MURINE LEUKEMIA-VIRUS; IN-VIVO; NONDIVIDING CELLS; POLYPURINE TRACT; REVERSE TRANSCRIPTION; STABLE TRANSDUCTION; MATRIX PROTEIN; CD34(+) CELLS	Gene-transfer vectors based on lentiviruses are distinguished by their ability to transduce non-dividing cells(1,2). The HIV-1 proteins Matrix, Vpr and Integrase have been implicated in the nuclear import of the viral genome in non-dividing cells(3-5). Here we show that a sequence within polis also required in cis. It contains structural elements previously associated with the progress of reverse transcription in target cells(6-9). We restored these elements in cis within late-generation lentiviral vectors(10,11). The new vector transduced to a much higher efficiency several types of human primary cells, when both growing and growth-arrested, including haematopoietic stem cells assayed by longterm repopulation of NOD/SCID mice. On in vivo administration into SCID mice, the vector induced higher plasma levels of human clotting factor IX (F.IX) than non-modified vector. Our results indicate that nuclear translocation of the genome is a rate-limiting step in lentiviral infection of both dividing and non-dividing cells, and that it depends on protein and nucleic acid sequence determinants. Full rescue of this step in lentivirus-based vectors improves performance for gene-therapy applications.	Univ Turin, Sch Med, Labs Gene Transfer & Therapy, Turin, Italy; Univ Turin, IRCCS, Labs Tumor Immunol, Inst Canc Res & Treatment, Turin, Italy	University of Turin; University of Turin	Naldini, L (corresponding author), Univ Turin, Sch Med, Labs Gene Transfer & Therapy, Turin, Italy.		Naldini, Luigi/E-9083-2012; Geuna, Massimo/AAY-1441-2021	Follenzi, Antonia/0000-0001-9780-300X; NALDINI, Luigi/0000-0002-7835-527X; Geuna, Massimo/0000-0002-6475-5547	Telethon [A.143] Funding Source: Medline	Telethon(Fondazione Telethon)		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Andreadis ST, 1997, J VIROL, V71, P7541, DOI 10.1128/JVI.71.10.7541-7548.1997; Bukrinskaya A, 1998, J EXP MED, V188, P2113, DOI 10.1084/jem.188.11.2113; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Case SS, 1999, P NATL ACAD SCI USA, V96, P2988, DOI 10.1073/pnas.96.6.2988; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Hansen MST, 1999, NAT BIOTECHNOL, V17, P578, DOI 10.1038/9886; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; Kay MA, 1999, P NATL ACAD SCI USA, V96, P9973, DOI 10.1073/pnas.96.18.9973; Kiernan RE, 1998, J VIROL, V72, P4116, DOI 10.1128/JVI.72.5.4116-4126.1998; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; Marandin A, 1998, HUM GENE THER, V9, P1497, DOI 10.1089/hum.1998.9.10-1497; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Schmidtmayerova H, 1998, J VIROL, V72, P4633, DOI 10.1128/JVI.72.6.4633-4642.1998; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	30	755	832	0	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					217	+		10.1038/76095	http://dx.doi.org/10.1038/76095			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835641				2022-12-27	WOS:000087459200025
J	Roest Crollius, H; Jaillon, O; Bernot, A; Dasilva, C; Bouneau, L; Fischer, C; Fizames, C; Wincker, P; Brottier, P; Quetier, F; Saurin, W; Weissenbach, J				Roest Crollius, H; Jaillon, O; Bernot, A; Dasilva, C; Bouneau, L; Fischer, C; Fizames, C; Wincker, P; Brottier, P; Quetier, F; Saurin, W; Weissenbach, J			Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence	NATURE GENETICS			English	Article							MODEL; MAP	The number of genes in the human genome is unknown, with estimates ranging from 50,000 to 90,000 (refs 1,2), and to more than 140,000 according to unpublished sources. We have developed 'Exofish', a procedure based on homology searches, to identify human genes quickly and reliably. This method relies on the sequence of another vertebrate, the pufferfish Tetraodon nigroviridis, to detect conserved sequences with a very low background. Similar to Fugu rubripes a marine pufferfish proposed by Brenner et al.(3) as a model for genomic studies, T. nigroviridis is a more practical alternative(4) with a genome also eight times more compact than that of human. Many comparisons have been made between F. rubripes and human DNA that demonstrate the potential of comparative genomics using the pufferfish genome(5). Application of Exofish to the December version of the working draft sequence of the human genome and to Unigene showed that the human genome contains 28,000-34,000 genes, and that Unigene contains less than 40% of the protein-coding fraction of the human genome.	Genoscope, Evry, France; CNRS FRE2231, Evry, France	Centre National de la Recherche Scientifique (CNRS)	Weissenbach, J (corresponding author), Genoscope, Evry, France.	jsbach@genosocope.cns.fr	Jaillon, Olivier/GRY-6287-2022; Quetier, Francis/J-7923-2017	ROEST CROLLIUS, Hugues/0000-0002-8209-173X; Fizames, Cecile/0000-0002-0551-8250; Quetier, Francis/0000-0003-4388-9287; Jaillon, Olivier/0000-0002-7237-9596				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; CrnogoracJurcevic T, 1997, GENOMICS, V41, P177, DOI 10.1006/geno.1997.4646; CROLLIUS HR, IN PRESS GENOME RES; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Elgar G, 1999, GENOME RES, V9, P960, DOI 10.1101/gr.9.10.960; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Glemet E, 1997, COMPUT APPL BIOSCI, V13, P137; JIN L, 1994, AM J HUM GENET, V55, P582; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5	14	244	259	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					235	238		10.1038/76118	http://dx.doi.org/10.1038/76118			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835645				2022-12-27	WOS:000087459200029
J	Holland, EC; Celestino, J; Dai, CK; Schaefer, L; Sawaya, RE; Fuller, GN				Holland, EC; Celestino, J; Dai, CK; Schaefer, L; Sawaya, RE; Fuller, GN			Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice	NATURE GENETICS			English	Article							GROWTH-FACTOR-I; HUMAN ASTROCYTOMAS; RECEPTOR; PATHWAYS; PROLIFERATION; EXPRESSION; PROTEIN	Gliomas are the most common primary malignant brain tumours and are classified into four clinical grades', with the most aggressive tumours being grade 4 astrocytomas (also known as glioblastoma multiforme; GBM). Frequent genetic alterations in GBMs (refs 2-5) result in stimulation of common signal transduction pathways involving Ras, Akt and other proteins(6-10). It is not known which of these pathways, if any, are sufficient to induce GBM formation, Here we transfer, in a tissue-specific manner, genes encoding activated forms of Ras and Akt to astrocytes and neural progenitors in mice. We found that although neither activated Ras nor Akt alone is sufficient to induce GBM formation, the combination of activated Ras and Akt induces high-grade gliomas with the histological features of human GBMs. These tumours appear to arise after gene transfer to neural progenitors, but not after transfer to differentiated astrocytes. Increased activity of RAS is found in many human GBMs (ref. 11), and we show here that Akt activity is increased in most of these tumours, implying that combined activation of these two pathways accurately models the biology of this disease.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Holland, EC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Feldkamp MM, 1997, J NEURO-ONCOL, V35, P223, DOI 10.1023/A:1005800114912; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Hermanson M, 1996, CANCER RES, V56, P164; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KLEHUES P, 1993, HISTOLOGICAL TYPING; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Li J, 1998, CANCER RES, V58, P5667; SCHLEGEL J, 1994, INT J CANCER, V56, P72	15	689	714	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					55	57		10.1038/75596	http://dx.doi.org/10.1038/75596			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802656				2022-12-27	WOS:000086884000016
J	Kahn, CR				Kahn, CR			Triglycerides and toggling the tummy	NATURE GENETICS			English	Editorial Material							TRANSGENIC MICE; ADIPOSE-TISSUE; OBESITY; LEPTIN; GENE; PEPTIDES; RECEPTOR	Multiple-mechanisms regulate adipose mass and body weight. In addition to factors controlling appetite and energy expenditure, mechanisms controlling adipocyte number, triglyceride synthesis and triglyceride breakdown have important functions. But recent studies challenge our concepts concerning each of these.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Beamer BA, 1998, DIABETES, V47, P1806, DOI 10.2337/diabetes.47.11.1806; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gavrilova O, 2000, NATURE, V403, P850, DOI 10.1038/35002663; Hagan MM, 1999, J NEUROSCI, V19, P2362; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Smith S M, 1987, Neonatal Netw, V5, P25; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	19	21	26	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					6	7		10.1038/75610	http://dx.doi.org/10.1038/75610			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802641				2022-12-27	WOS:000086884000004
J	Anand, A; Chada, K				Anand, A; Chada, K			In vivo modulation of Hmgic reduces obesity	NATURE GENETICS			English	Article							MESENCHYMAL TUMORS; ADIPOSE-TISSUE; DNA-BINDING; EXPRESSION; MOUSE; GENE; PROTEIN; ENHANCEOSOME; DISRUPTION; PATHWAYS	The HMGI family of proteins consists of three members(1,2), HMGIC, HMGI and HMGI(Y), that function as architectural factors(3-5) and are essential components of the enhancesome(6,7) HMGIC is predominantly expressed in proliferating, undifferentiated mesenchymal cells and is not detected in adult tissues(8,9). It is disrupted and misexpressed in a number of mesenchymal tumour cell types(10-12), including fat-cell tumours(12) (lipomas), In addition Hmgic(-/-) mice have a deficiency in fat tissue(13), To study its role in adipogenesis and obesity, we examined Hmgic expression in the adipose tissue of adult, obese mice. Mice with a partial or complete deficiency of Hmgic resisted diet-induced obesity. Disruption of Hmgic caused a reduction in the obesity induced by leptin deficiency (Lep(Ob)/Lep(Ob)) in a gene-dose-dependent manner, Our studies implicate a role for HMGIC in fat-cell proliferation, indicating that it may be an adipose-specific target for the treatment of obesity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Chada, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA077929] Funding Source: NIH RePORTER; NCI NIH HHS [CA77929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ASHAR HR, 1995, CELL, V82, P57; BATES MARGARET W., 1955, AMER JOUR PHYSIOL, V180, P301; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Frankel WN, 1996, NAT GENET, V14, P371, DOI 10.1038/ng1296-371; GREEN MC, 1989, GENETIC VARIANTS STR; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; JOHNSON PR, 1972, J LIPID RES, V13, P2; KLYDE BJ, 1979, J LIPID RES, V20, P705; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Rogalla P, 1996, AM J PATHOL, V149, P775; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tkachenko A, 1997, CANCER RES, V57, P2276; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou X, 1998, Keio J Med, V47, P73; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	29	168	175	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					377	380		10.1038/74207	http://dx.doi.org/10.1038/74207			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742101				2022-12-27	WOS:000086192800016
J	Boute, N; Gribouval, O; Roselli, S; Benessy, F; Lee, H; Fuchshuber, A; Dahan, K; Gubler, MC; Niaudet, P; Antignac, C				Boute, N; Gribouval, O; Roselli, S; Benessy, F; Lee, H; Fuchshuber, A; Dahan, K; Gubler, MC; Niaudet, P; Antignac, C			NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome	NATURE GENETICS			English	Article							INTEGRAL MEMBRANE-PROTEIN; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IN-SITU HYBRIDIZATION; MESSENGER-RNA; GENE; ALIGNMENT; SEQUENCES; MATRIX	Familial idiopathic nephrotic syndromes represent a heterogeneous group of kidney disorders, and include autosomal recessive steroid-resistant nephrotic syndrome, which is characterized by early childhood onset of proteinuria, rapid progression to end-stage renal disease and focal segmental glomerulosclerosis. A causative gene for this disease, NPHS2, was mapped to 1q25-31 and we report here its identification by positional cloning. NPHS2 is almost exclusively expressed in the podocytes of fetal and mature kidney glomeruli, and encodes a new integral membrane protein, podocin, belonging to the stomatin protein family. We found ten different NPHS2 mutations, comprising nonsense, frameshift and missense mutations, to segregate with the disease, demonstrating a crucial role for podocin in the function of the glomerular filtration barrier.	INSERM, U423, Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Serv Nephrol Pediat, Paris, France; Univ Louvain, Sch Med, Ctr Human Genet, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Antignac, C (corresponding author), INSERM, U423, Tour Lavoisier, Paris, France.		ANTIGNAC, Corinne/H-8945-2017; Gribouval, Olivier/A-7689-2015	ANTIGNAC, Corinne/0000-0002-9934-4940; Gribouval, Olivier/0000-0003-0238-8224; Gubler, Marie-Claire/0000-0002-3526-5661; roselli, severine/0000-0001-7896-9127				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Brandenberger AW, 1997, J CLIN ENDOCR METAB, V82, P3509, DOI 10.1210/jc.82.10.3509; Broyer M., 1998, OXFORD TXB CLIN NEPH, P493; CONNOLLY JO, 1995, QJM-MON J ASSOC PHYS, V88, P627; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fuchshuber A, 1996, LANCET, V347, P1050, DOI 10.1016/S0140-6736(96)90193-2; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; Heidet L, 1997, LAB INVEST, V76, P233; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kalatzis V, 1998, DEV DYNAM, V213, P486, DOI 10.1002/(SICI)1097-0177(199812)213:4<486::AID-AJA13>3.0.CO;2-L; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Mannsfeldt AG, 1999, MOL CELL NEUROSCI, V13, P391, DOI 10.1006/mcne.1999.0761; Mathis BJ, 1998, KIDNEY INT, V53, P282, DOI 10.1046/j.1523-1755.1998.00828.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; OLSON JL, 1998, HEPTINSTALLS PATHOLO, P187; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; SIBONY M, 1995, LAB INVEST, V73, P586; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; TRASK BJ, 1991, SOMAT CELL MOLEC GEN, V17, P117, DOI 10.1007/BF01232970; VERANI RR, 1992, AM J KIDNEY DIS, V20, P629, DOI 10.1016/S0272-6386(12)70230-5; Winn MP, 1999, GENOMICS, V58, P113, DOI 10.1006/geno.1999.5828	40	1082	1173	2	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					349	354		10.1038/74166	http://dx.doi.org/10.1038/74166			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742096				2022-12-27	WOS:000086192800011
J	Shirasawa, S; Arata, A; Onimaru, H; Roth, KA; Brown, GA; Horning, S; Arata, S; Okumura, K; Sasazuki, T; Korsmeyer, SJ				Shirasawa, S; Arata, A; Onimaru, H; Roth, KA; Brown, GA; Horning, S; Arata, S; Okumura, K; Sasazuki, T; Korsmeyer, SJ			Rnx deficiency results in congenital central hypoventilation	NATURE GENETICS			English	Article							HOMEOBOX GENE-EXPRESSION; SPINAL CORD PREPARATIONS; ONDINES-CURSE; DEVELOPMENTAL EXPRESSION; NEWBORN RATS; CHICK-EMBRYO; HOX11 GENE; BRAIN; MEDULLA; HINDBRAIN	The genes Tlx1 (Hox11), Enx (Hox11L1, Tlx-2) and Rnx (Hox11L2, Tlx-3) constitute a family of orphan homeobox genes(1-10). In situ hybridization has revealed considerable overlap in their expression within the nervous system, but Rnx is singularly expressed in the developing dorsal and ventral region of the medulla oblongata. Tlx1-deficient and Enx-deficient mice display phenotypes in tissues where the mutated gene is singularly expressed, resulting in asplenogenesis(3,4) and hyperganglionic megacolon(8), respectively. To determine the developmental role of Rnx. we disrupted the locus in mouse embryonic stem (ES) cells. Rnx-deficient mice developed to term, but all died within 24 hours after birth from a central respiratory failure. The electromyographic activity of intercostal muscles coupled with the C4 ventral root activity assessed in a medulla-spinal cord preparation revealed a high respiratory rate with short inspiratory duration and frequent apnea. Furthermore, a coordinate pattern existed between the abnormal activity of inspiratory neurons in the ventrolateral medulla and C4 motorneuron output, indicating a central respiratory defect in Rnx(-/-) mice. Thus, Rnx is critical for the development of the ventral medullary respiratory centre and its deficiency results in a syndrome resembling congenital central hypoventilation.	Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Kyushu Univ, Med Inst Bioregulat, Dept Genet, Fukuoka 812, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Tokyo 138, Japan; Showa Univ, Sch Med, Dept Physiol, Tokyo 142, Japan; Showa Univ, Ctr Biotechnol, Tokyo 142, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Kyushu University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Showa University; Showa University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Korsmeyer, SJ (corresponding author), Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.			Arata, Akiko/0000-0001-7418-8294; Roth, Kevin/0000-0002-0643-995X				Amiel J, 1998, AM J HUM GENET, V62, P715, DOI 10.1086/301759; ARATA A, 1990, BRAIN RES BULL, V24, P599, DOI 10.1016/0361-9230(90)90165-V; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Bolk S, 1996, NAT GENET, V13, P395, DOI 10.1038/ng0896-395; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Jacquin TD, 1996, NEURON, V17, P747, DOI 10.1016/S0896-6273(00)80206-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Logan C, 1998, J NEUROSCI, V18, P5389, DOI 10.1523/JNEUROSCI.18-14-05389.1998; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; Masson N, 1998, MOL CELL BIOL, V18, P3502, DOI 10.1128/MCB.18.6.3502; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLINS RB, 1970, MEDICINE, V49, P487, DOI 10.1097/00005792-197011000-00003; NAKAHARA S, 1995, J PEDIATR SURG, V30, P1481, DOI 10.1016/0022-3468(95)90413-1; ONIMARU H, 1992, PFLUG ARCH EUR J PHY, V420, P399, DOI 10.1007/BF00374476; ONIMARU H, 1995, NEUROSCI RES, V21, P183, DOI 10.1016/0168-0102(94)00863-B; ONIMARU H, 1988, BRAIN RES, V445, P314, DOI 10.1016/0006-8993(88)91194-8; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RICKLING JC, 1996, J NEUROPHYSIOL, V75, P795; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; ROBERTS CWM, 1995, AM J PATHOL, V146, P1089; RUBENSTEIN JLR, 1994, CURR TOP DEV BIOL, V29, P1, DOI 10.1016/S0070-2153(08)60546-3; Shirasawa S, 1997, NAT MED, V3, P646, DOI 10.1038/nm0697-646; SUZUE T, 1984, J PHYSIOL-LONDON, V354, P173, DOI 10.1113/jphysiol.1984.sp015370; VERLOES A, 1993, EUR J PEDIATR, V152, P75, DOI 10.1007/BF02072522; WEESEMAYER DE, 1993, AM J MED GENET, V47, P360, DOI 10.1002/ajmg.1320470313	27	131	138	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					287	290		10.1038/73516	http://dx.doi.org/10.1038/73516			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700185				2022-12-27	WOS:000085590600022
J	Zuber, J; Tchernitsa, OI; Hinzmann, B; Schmitz, AC; Grips, M; Hellriegel, M; Sers, C; Rosenthal, A; Schafer, R				Zuber, J; Tchernitsa, OI; Hinzmann, B; Schmitz, AC; Grips, M; Hellriegel, M; Sers, C; Rosenthal, A; Schafer, R			A genome-wide survey of RAS transformation targets	NATURE GENETICS			English	Article							HA-RAS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; DOWN-REGULATION; CANCER-CELLS; INSTABILITY; FIBROBLASTS; SUPPRESSION; ACTIVATION; H-REV107	An important aspect of multi-step tumorigenesis is the mutational activation of genes of the RAS family, particularly in sporadic cancers of the pancreas, colon, lung and myeloid system(1). RAS genes encode small GTP-binding proteins that affect gene expression in a global way by acting as major switches in signal transduction processes, coupling extracellular signals with transcription factors(2-4). Oncogenic farms of RAS are locked in their active state and transduce signals essential for transformation, angiogenesis, invasion and metastasis via downstream pathways involving the RAF/MEK/ERK cascade of cytoplasmic kinases, the small GTP-binding proteins RAC and RHO, phosphatidylinositol 3-kinase and others(5,6). We have used subtractive suppression hybridization (SSH), a PCR-based cDNA subtraction technique(7), to contrast differential gene expression profiles in immortalized, non-tumorigenic rat embryo fibroblasts and in HRAS-transformed cells. Sequence and expression analysis of more than 1,200 subtracted cDNA fragments revealed transcriptional stimulation or repression of 104 ESTs, 45 navel sequences and 244 known genes in HRAS-transformed cells compared with normal cells. Furthermore, we identified common and distinct targets in cells transformed by mutant HRAS, KRAS and NRAS, as well as 61 putative target genes controlled by the RAF/MEK/ERK pathway in reverted cells treated with the MEK-specific inhibitor PD 98059.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany; Gesell Genomforsch mbH, MetaGen, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010; Zuber, Johannes/E-7517-2011	Zuber, Johannes/0000-0001-8810-6835; Sers, christine/0000-0002-6219-1514; Schafer, Reinhold/0000-0001-7952-2124				ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOWNWARD J, 1998, MOL B INT U, V3, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; LIU HS, 1992, CANCER RES, V52, P983; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Patton SE, 1998, CANCER RES, V58, P2253; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	228	242	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					144	152		10.1038/72799	http://dx.doi.org/10.1038/72799			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655059				2022-12-27	WOS:000085104600014
J	Huettner, CS; Zhang, P; Van Etten, RA; Tenen, DG				Huettner, CS; Zhang, P; Van Etten, RA; Tenen, DG			Reversibility of acute B-cell leukaemia induced by BCR-ABL1	NATURE GENETICS			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TRANSGENIC MICE; BCR-ABL; TYROSINE KINASE; GENE-EXPRESSION; BONE-MARROW; P210(BCR/ABL); PROMOTER; ANTIGEN	Cancer is thought to arise from multiple genetic events that establish irreversible malignancy. A different mechanism might be present in certain leukaemias initiated by a chromosomal translocation. We have taken a new approach to determine if ablation of the genetic abnormality is sufficient for reversion by generating a conditional transgenic model of BCR-ABL1 (also known as BCR-ABL)-induced leukaemia. This oncogene(1) is the of a reciprocal translocation and is associated with differ-ent forms of leukaemia(2). The most common form, p210 BCR-ABL1, is found in more than 90% of patients with chronic myelogenous leukaemia(3,4) (CML) and in up to 15% of adult patients with de novo acute lymphoblastic leukaemia(5) (ALL). Efforts to establish a useful transgenic model have been hampered by embryonic lethality when the oncogene is expressed during embryogenesis(6,7), by reduced penetrance or by extremely long latency periods(8,9). One model uses the 'knock-in' approach to induce leukaemia by p190 BCR-ABL1 (ref. 10). Given the limitations of models with p210, we used a different experimental approach(11) Lethal leukaemia developed within an acceptable time frame in all animals, and complete remission was achieved by suppression of BCR-ABL1 expression, even after multiple rounds of induction and reversion. Our results demonstrate that BCR-ABL1 is required for both induction and maintenance of leukaemia.	Harvard Univ, Inst Med, Div Hematol Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA USA	Harvard University; Harvard University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Tenen, DG (corresponding author), Harvard Univ, Inst Med, Div Hematol Oncol, Cambridge, MA 02138 USA.	dtenen@caregroup.harvard.edu		Tenen, Daniel/0000-0002-6423-3888				BEDI A, 1994, BLOOD, V83, P2038; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CROSS NCP, 1993, BRIT J HAEMATOL, V84, P67, DOI 10.1111/j.1365-2141.1993.tb03026.x; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KRAIG E, 1983, J EXP MED, V158, P192, DOI 10.1084/jem.158.1.192; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melo JV, 1996, LEUKEMIA, V10, P751; NOWELL PC, 1960, SCIENCE, V132, P1497; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANETTEN RA, 1993, LEUKEMIA ADV TREATME, P294; VANETTEN RA, 1998, MED MANAGEMENT CHRON, P77	27	320	347	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					57	60		10.1038/71691	http://dx.doi.org/10.1038/71691			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615128				2022-12-27	WOS:000084609200016
J	Festenstein, R; Sharghi-Namini, S; Fox, M; Roderick, K; Tolaini, M; Norton, T; Saveliev, A; Kioussis, D; Singh, P				Festenstein, R; Sharghi-Namini, S; Fox, M; Roderick, K; Tolaini, M; Norton, T; Saveliev, A; Kioussis, D; Singh, P			Heterochromatin protein 1 modifies mammalian PEV in a dose- and chromosomal-context-dependent manner	NATURE GENETICS			English	Article							POSITION-EFFECT VARIEGATION; GENE-EXPRESSION; TRANSGENIC MICE; HIGH-LEVEL; DROSOPHILA; TRANSCRIPTION; COMPLEXES; PROBABILITY; INCREASE; DISEASE	Locus control regions (LCRs) are gene regulatory elements in mammals that can overcome the highly repressive effects normally associated with heterochromatic transgene locations (for example the centromere) in mice(1-3). Deletion of essential LCR sequences renders the cognate gene susceptible to this form of repression, so a proportion of the cells from transgenic mice that would normally express the transgene are silenced-a phenomenon known as position effect variegation(4-6) (PEV). We show here that PEV can also occur when the transgene is non-centromeric and that the extent of variegation can be developmentally regulated. Furthermore, by overexpressing a mammalian homologue (M31) of Drosophila melanogaster heterochromatin protein 1 (HP1; refs 7.8) in transgenic mouse lines that exhibit PEV, it is possible to modify the proportion of cells that silence the transgene in a dose-dependent manner. Thus, we show M31 overexpression to have two contrasting effects which are dependent on chromosomal context: (i) it enhanced PEV in those lines with centromeric or pericentromeric transgene locations; and (ii) it suppressed PEV when the transgene was non-centromeric. Our results indicate that components or modifiers of heterochromatin may have a chromosomal-context-dependent role in gene silencing and activation decisions in mammals.	Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England; Hammersmith Hosp, MRC, Ctr Clin Sci, Imperial Coll Sci Technol & Med,Dept Med, London, England; UCL, Galton Lab, MRC, Human Biochem Genet Unit, London, England; Babraham Inst, Chromatin Funct Lab, Cambridge, England; Roslin Inst, Nucl Reprogramming Lab, Edinburgh, Midlothian, Scotland	MRC National Institute for Medical Research; Imperial College London; University of London; University College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Festenstein, R (corresponding author), Natl Inst Med Res, Div Mol Immunol, Mill Hill, London NW7 1AA, England.	r-festen@nimr.mrc.ac.uk	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Saveliev, Alexander/0000-0003-0840-4774				APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; EISSENBERG JC, 1992, GENETICS, V131, P345; ELGIN SC, 1996, CURR OPIN GENE DEV, V6, P163; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LOCKE J, 1988, GENETICS, V120, P181; Lu BY, 1998, DEVELOPMENT, V125, P2223; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Singh PB, 1998, DEV GENET, V22, P85, DOI 10.1002/(SICI)1520-6408(1998)22:1<85::AID-DVG9>3.0.CO;2-3; SINGH PB, 1994, J CELL SCI, V107, P2653; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	29	106	107	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					457	461		10.1038/70579	http://dx.doi.org/10.1038/70579			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581035				2022-12-27	WOS:000084023900024
J	Toomes, C; James, J; Wood, AJ; Wu, CL; McCormick, D; Lench, N; Hewitt, C; Moynihan, L; Roberts, E; Woods, CG; Markham, A; Wong, M; Widmer, R; Ghaffar, KA; Pemberton, M; Hussein, IR; Temtamy, SA; Davies, R; Read, AP; Sloan, P; Dixon, MJ; Thakker, NS				Toomes, C; James, J; Wood, AJ; Wu, CL; McCormick, D; Lench, N; Hewitt, C; Moynihan, L; Roberts, E; Woods, CG; Markham, A; Wong, M; Widmer, R; Ghaffar, KA; Pemberton, M; Hussein, IR; Temtamy, SA; Davies, R; Read, AP; Sloan, P; Dixon, MJ; Thakker, NS			Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis	NATURE GENETICS			English	Article							PAPILLON-LEFEVRE-SYNDROME; DIPEPTIDYL-PEPTIDASE-I; MOLECULAR-CLONING; LINKAGE ANALYSIS; EXPRESSION; LOCALIZATION; 11Q14-Q21	Papillon-Lefevre syndrome, or keratosis palmoplantaris with periodontopathia (PLS, MIM 245000), is an autosomal recessive disorder that is mainly ascertained by dentists because of the severe periodontitis that afflicts patients(1,2). Both the deciduous and permanent dentitions are affected, resulting in premature tooth loss. Palmoplantar keratosis, varying from mild psoriasiform scaly skin to overt hyperkeratosis, typically develops within the first three years of life. Keratosis also affects other sites such as elbows and knees. Most PLS patients display both periodontitis and hyperkeratosis. some patients have only palmoplantar keratosis or periodontitis, and in rare individuals the periodontitis is mild and of late onset(3-6). The PLS locus has been mapped to chromosome 11q14-q21 (refs 7-9). Using homozygosity mapping in eight small consanguineous families, we have narrowed the candidate region to a 1.2-cM interval between D11S4082 and D11S931. The gene (CTSC) encoding the lysosomal protease cathepsin C (or dipeptidyl aminopeptidase I) lies within this interval. We defined the genomic structure of CTSC and found mutations in all eight families. In two of these families we used a functional assay to demonstrate an almost total loss of cathepsin C activity in PLS patients and reduced activity in obligate carriers.	Univ Manchester, St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Manchester, Turner Dent Sch, Dept Dent Med & Surg, Manchester, Lancs, England; Queens Univ Belfast, Dept Oncol, Belfast City Hosp Tower, Belfast, Antrim, North Ireland; St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; New Childrens Hosp, Dept Immunol & Infect Dis, Westmead, NSW, Australia; Westmead Hosp, Dept Paediat Dent, Dent Clin Sch, Westmead, NSW 2145, Australia; Eins Shams Univ, Dept Oral Diagnosis & Periodontol, Cairo, Egypt; Natl Res Ctr, Dept Human Genet, Cairo, Egypt; Dent Hlth Unit, Manchester, Lancs, England	University of Manchester; University of Manchester; University of Manchester; Belfast City Hospital; Queens University Belfast; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Sydney; University of Sydney; Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); University of Manchester	Thakker, NS (corresponding author), Univ Manchester, St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England.		hussein, ibtessam M.R/H-9489-2012; Lench, Nicholas/AAB-1791-2021; Hussein, ibtessam R/L-4020-2014; woods, christopher g/A-1361-2010	Thakker, Nalin/0000-0002-8664-1508; Toomes, Carmel/0000-0001-8373-9545; Lench, Nicholas/0000-0002-6108-0759; Hussein, ibtessam/0000-0001-9909-9888; temtamy, samia/0000-0002-6452-823X; Ghaffar, khaled/0000-0001-5340-789X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROWN J, 1993, SIGHT SOUND, V3, P64; BULLON P, 1993, J CLIN PERIODONTOL, V20, P662, DOI 10.1111/j.1600-051X.1993.tb00712.x; Cigic B, 1999, BIOCHEM BIOPH RES CO, V258, P6, DOI 10.1006/bbrc.1999.0570; Fardal O, 1998, J CLIN PERIODONTOL, V25, P181, DOI 10.1111/j.1600-051X.1998.tb02425.x; FISHER J, 1997, EUR J HUM GENET, V51, P56; GORLIN RJ, 1964, J PEDIATR-US, V65, P895, DOI 10.1016/S0022-3476(64)80014-7; HAMILTON RE, 1974, ORAL SURG ORAL MED O, V37, P754, DOI 10.1016/0030-4220(74)90141-8; Hart T C, 1994, Periodontol 2000, V6, P88, DOI 10.1111/j.1600-0757.1994.tb00029.x; Hart TC, 1998, AM J MED GENET, V79, P134, DOI 10.1002/(SICI)1096-8628(19980901)79:2<134::AID-AJMG9>3.0.CO;2-Q; Kruglyak L, 1998, J COMPUT BIOL, V5, P1, DOI 10.1089/cmb.1998.5.1; KURIBAYASHI M, 1993, J BIOCHEM-TOKYO, V113, P441, DOI 10.1093/oxfordjournals.jbchem.a124064; Laass MW, 1997, HUM GENET, V101, P376, DOI 10.1007/s004390050645; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; Oguzkurt P, 1996, J PEDIATR SURG, V31, P955; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; Pham CTN, 1997, J BIOL CHEM, V272, P10695, DOI 10.1074/jbc.272.16.10695; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Rao NV, 1997, J BIOL CHEM, V272, P10260; SMYTH M, 1994, J NEUROCHEM, V63, P1439; Soskolne WA, 1996, J CLIN PERIODONTOL, V23, P764, DOI 10.1111/j.1600-051X.1996.tb00607.x; TEMPEL TR, 1972, J PERIODONTAL RE S10, V7, P26; WALLACE IJC, 1990, IRISH J MED SCI, V159, P203, DOI 10.1007/BF02937266	25	341	363	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					421	424		10.1038/70525	http://dx.doi.org/10.1038/70525			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581027	Green Published			2022-12-27	WOS:000084023900016
J	Matin, A; Collin, GB; Asada, Y; Varnum, D; Nadeau, JH				Matin, A; Collin, GB; Asada, Y; Varnum, D; Nadeau, JH			Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain	NATURE GENETICS			English	Article							MOUSE CHROMOSOME-18; GENETIC DISSECTION; COMPLEX TRAITS; MICE; TERATOMAS; MUTATION; DEFICIENCY; MAPS	The identification of genes that control susceptibility to testicular germ-cell tumours (TGCTs), the most common cancer affecting young men(1), has been difficult. In laboratory mice, TGCTs arise from primordial germ cells(2,3) in only the 129 inbred strains(4), and susceptibility is under multigenic control. The spontaneously arising mutation Ter (ref. 5) on mouse chromosome 18 (refs 6,7) increases TGCT frequency(5,8) on a 129/Sv background. We originally used Ter in genetic crosses to identify loci that control tumorigenesis. A genome scan of tumour-bearing progeny from backcrosses between the 129/Sv-Ter/+ and MOLF/Ei strains provided modest evidence that MOLF-derived alleles on chromosome 19 enhance development of bilateral TGCTs (ref. 9). To obtain independent evidence for linkage to the MOLF chromosome, we made an autosomal chromosome substitution strain (CSS; or 'consomic strain') in which chromosome 19 of 129/SV+/+ was replaced by its MOLF-derived homologue. The unusually high frequency of TGCTs in this CSS (even in the absence of the Ter mutation) provides evidence confirming the genome survey results, identifies linkage for a naturally occurring strain variant allele that confers susceptibility to TGCTs and illustrates the power of CSSs in complex trait analysis.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Nihon Univ, Sch Dent, Dept Pedodont, Chiba, Japan	Case Western Reserve University; University Hospitals of Cleveland; University Hospitals of Cleveland; Jackson Laboratory; Nihon University	Nadeau, JH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.				NCI NIH HHS [CA75056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2012, BIOMETRY PRINCIPLES; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; Bonhomme F., 1996, GENETIC VARIANTS STR, P1577; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Collin GB, 1996, MAMM GENOME, V7, P68, DOI 10.1007/s003359900017; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; Moriwaki Kazuo, 1994, pXIII; NOGUCHI T, 1985, JNCI-J NATL CANCER I, V75, P385; Poirier C, 1998, MAMM GENOME, V8, pS353, DOI 10.1007/s003359900664; SAKURAI T, 1994, MAMM GENOME, V5, P333, DOI 10.1007/BF00356550; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SILVER LM, 1995, MOUSE GENETICS CONCE, P15; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; STEVENS LC, 1962, J NATL CANCER I, V28, P247; STEVENS LC, 1957, J NATL CANCER I, V18, P719; Stevens LC, 1983, COLD SPRING HARB C C, P23; Threadgill DW, 1997, MAMM GENOME, V8, P441, DOI 10.1007/s003359900464	23	84	89	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					237	240		10.1038/13874	http://dx.doi.org/10.1038/13874			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508525				2022-12-27	WOS:000082827500028
J	Sullivan, LS; Heckenlively, JR; Bowne, SJ; Zuo, J; Hide, WA; Gal, A; Denton, M; Inglehearn, CF; Blanton, SH; Daiger, SP				Sullivan, LS; Heckenlively, JR; Bowne, SJ; Zuo, J; Hide, WA; Gal, A; Denton, M; Inglehearn, CF; Blanton, SH; Daiger, SP			Mutations in a novel retina-specific gene cause autosomal dominant retinitis pigmentosa	NATURE GENETICS			English	Article							RECESSIVE MUTATIONS; ALPHA-SUBUNIT; PROTEIN; PHOSPHODIESTERASE; DOUBLECORTIN; LINKAGE; REGION; TULP1; MOUSE; ABCR	Inherited retinal diseases are a common cause of visual impairment in children and young adults, often resulting in severe loss of vision in later life. The most frequent form of inherited retinopathy is retinitis pigmentosa (RP), with an approximate incidence of 1 in 3,500 individuals worldwide(1,2). RP is characterized by night blindness and progressive degeneration of the midperipheral retina, accompanied by bone spicule-like pigmentary deposits and a reduced or absent electroretinogram (ERG). The disease process culminates in severe reduction of visual fields or blindness. RP is genetically heterogeneous, with autosomal dominant, autosomal recessive and X-linked forms. Here we have identified two mutations in a novel retina-specific gene from chromosome 8q that cause the RP1 form of autosomal dominant RP in three unrelated families. The protein encoded by this gene is 2,156 amino acids and its function is currently unknown, although the amino terminus has similarity to that of the doublecortin protein, whose gene (DCX) has been implicated in lissencephaly in humans(17). Two families have a nonsense mutation in codon 677 of this gene (Arg677stop), whereas the third family has a nonsense mutation in codon 679 (Gln679stop). In one family, two individuals homozygous for the mutant gene have more severe retinal disease compared with heterozygotes.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Western Cape, S African Natl Bioinformat Inst, ZA-7535 Bellville, South Africa; Univ Hosp Eppendorf, Inst Human Genet, Hamburg, Germany; Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Leeds, Mol Med Unit, Leeds LS2 9JT, W Yorkshire, England; Univ Virginia, Dept Pediat, Charlottesville, VA 22903 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles; St Jude Children's Research Hospital; South African National Biodiversity Institute; University of the Western Cape; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Otago; University of Leeds; University of Virginia	Sullivan, LS (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, 6901 Bertner St, Houston, TX 77030 USA.		Inglehearn, Chris/GYD-9783-2022; Blanton, Susan Halloran/ABF-1323-2021; Hide, Winston/R-3815-2019; Hide, Winston Hide/C-7217-2009; Hide, Winston A/V-2727-2017	Hide, Winston/0000-0002-8621-3271; Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston A/0000-0002-8621-3271	NATIONAL EYE INSTITUTE [R01EY007142] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007142-12A2, EY07142, R01 EY007142] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Daiger SP, 1997, DEGENERATIVE RETINAL DISEASES, P277; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; Hannan AJ, 1999, J NEUROSCI RES, V55, P650, DOI 10.1002/(SICI)1097-4547(19990301)55:5<650::AID-JNR12>3.3.CO;2-J; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HECKENLIVELY JR, 1997, PRINCIPALS PRACTICES, P2555; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; INGLEHEARN CF, IN PRESS J MED GENET; JIMENEZ JB, 1991, HUM GENET, V86, P265; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Matsumoto N, 1999, GENOMICS, V56, P179, DOI 10.1006/geno.1998.5673; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; Roderick TH, 1997, GENOMICS, V42, P393, DOI 10.1006/geno.1997.4717; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Sossey-Alaoui K, 1998, HUM MOL GENET, V7, P1327, DOI 10.1093/hmg/7.8.1327; Xu SY, 1996, HUM GENET, V98, P741, DOI 10.1007/s004390050296	28	130	137	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					255	259		10.1038/10314	http://dx.doi.org/10.1038/10314			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391212	Green Accepted			2022-12-27	WOS:000081125900017
J	Kitao, S; Shimamoto, A; Goto, M; Miller, RW; Smithson, WA; Lindor, NM; Furuichi, Y				Kitao, S; Shimamoto, A; Goto, M; Miller, RW; Smithson, WA; Lindor, NM; Furuichi, Y			Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome	NATURE GENETICS			English	Article							WERNERS-SYNDROME GENES; MOLECULAR-CLONING; BLOOMS-SYNDROME; IN-VIVO; INSTABILITY; HELICASE; HOMOLOG; SGS1; INTERACTS; MOSAICISM	Rothmund-Thomson syndrome (RTS; also known as poikiloderma congenitale) is a rare, autosomal recessive genetic disorder characterized by abnormalities in skin and skeleton, juvenile cataracts, premature ageing and a predisposition to neoplasia(1-4). Cytogenetic studies indicate that cells from affected patients show genomic instability often associated with chromosomal rearrangements causing an acquired somatic mosaicism(5-9). The gene(s) responsible for RTS remains unknown. The genes responsible for Werner(10) and Bloom(11) syndromes (WRN and BLM, respectively) have been identified as homologues of Escherichia coli RecQ, which encodes a DNA helicase(12) that unwinds double-stranded DNA into single-stranded DNAs. Other eukaryotic homologues thus far identified are human RECQL (refs 13,14), Saccharomyces cerevisiae SGS1 (refs 15,16) and Schizosaccharomyces pombe rqh1(+) (ref, 17). We recently cloned two new human helicase genes, RECQL4 at 8q24.3 and RECQL5 at 17q25, which encode members of the RecQ helicase family(18), Here, we report that three RTS patients carried two types of compound heterozygous mutations in RECQL4, The fact that the mutated alleles were inherited from the parents in one affected family and were not found in ethnically matched controls suggests that mutation of RECQL4 at human chromosome 8q24.3 is responsible for at least some cases of RTS.	AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan; Tokyo Metropolitan Otsuka Hosp, Toshima Ku, Tokyo 1700005, Japan; NCI, Bethesda, MD 20892 USA; Mayo Clin, Rochester, MN USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Furuichi, Y (corresponding author), AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan.							DERKALOUSTIAN VM, 1990, AM J MED GENET, V37, P336, DOI 10.1002/ajmg.1320370308; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Lindor NM, 1996, CLIN GENET, V49, P124; Miozzo M, 1998, INT J CANCER, V77, P504; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; ORSTAVIK KH, 1994, J MED GENET, V31, P570, DOI 10.1136/jmg.31.7.570; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROTHMUND A, 1868, ARCH KLIN EXP OPHTHA, V4, P159; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Thomson MS, 1936, BRIT J DERMATOL, V48, P221; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; VENNOS EM, 1992, J AM ACAD DERMATOL, V27, P750, DOI 10.1016/0190-9622(92)70249-F; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YING KL, 1990, J MED GENET, V27, P258, DOI 10.1136/jmg.27.4.258; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	19	519	534	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					82	84		10.1038/8788	http://dx.doi.org/10.1038/8788			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319867				2022-12-27	WOS:000080096300028
J	Shayesteh, L; Lu, YL; Kuo, WL; Baldocchi, R; Godfrey, T; Collins, C; Pinkel, D; Powell, B; Mills, GB; Gray, JW				Shayesteh, L; Lu, YL; Kuo, WL; Baldocchi, R; Godfrey, T; Collins, C; Pinkel, D; Powell, B; Mills, GB; Gray, JW			PIK3CA is implicated as an oncogene in ovarian cancer	NATURE GENETICS			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CELLS; OVERREPRESENTATION; TRANSFORMATION; HYBRIDIZATION; CARCINOMAS; APOPTOSIS; ADHESION; SURVIVAL; PATHWAY	Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women(1), yet little is known about its molecular aetiology. Studies using comparative genomic: hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number(2-4) that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian(2) and other(5) cancers contains PIK3CA, which encodes the p110 alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). The association between PIK3CA copy number and PI3-kinase activity makes PIK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with PI3-kinase mediated signalling(6). These include proliferation(7), glucose transport and catabotism(8), cell adhesion(9), apoptosis(10), RAS signalling6 and oncogenic transformation(11-14). In addition, downstream effecters of Pl3-kinase, AKT1 and AKR, have been found to be amplified(15,16) or activated(17) in human tumours, including ovarian cancer. We show here that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PIK3CA transcription, p110 alpha protein expression and PO-kinase activity and that treatment with the PI3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer.	Univ Calif San Francisco, Ctr Canc, San Francisco, CA USA; Univ Texas, Md Anderson Canc Ctr, Houston, TX 77030 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94702 USA	University of California System; University of California San Francisco; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Gray, JW (corresponding author), Univ Calif San Francisco, Ctr Canc, San Francisco, CA USA.	gray@cc.ucsf.edu	Godfrey, Tony/A-5572-2013	Godfrey, Tony/0000-0002-3283-6983	NCI NIH HHS [P01-CA64602, CA09215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064602, T32CA009215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gibson S, 1998, BIOCHEM J, V330, P1123, DOI 10.1042/bj3301123; Gorczyca W, 1998, METH MOL B, V91, P217; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HINSON D, 1998, BIOTECHNIQUES, V6, P14; HURTEAU J, 1994, CANCER, V74, P93, DOI 10.1002/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu AX, 1998, CANCER RES, V58, P2973; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nigro JM, 1997, CANCER RES, V57, P3635; PHYLLIS A, 1995, CA-CANCER J CLIN, V45, P8; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Schildkraut JM, 1997, JNCI-J NATL CANCER I, V89, P932, DOI 10.1093/jnci/89.13.932; SHI YF, 1995, CANCER RES, V55, P1982; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; STERNBERG N, 1990, New Biologist, V2, P151; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071	34	953	1041	3	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					99	102		10.1038/5042	http://dx.doi.org/10.1038/5042			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916799				2022-12-27	WOS:000077960700017
J	Eaves, IA; Merriman, TR; Barber, RA; Nutland, S; Tuomilehto-Wolf, E; Tuomilehto, J; Cucca, F; Todd, JA				Eaves, IA; Merriman, TR; Barber, RA; Nutland, S; Tuomilehto-Wolf, E; Tuomilehto, J; Cucca, F; Todd, JA			The genetically isolated populations of Finland and Sardinia may not be a panacea for linkage disequilibrium mapping of common disease genes	NATURE GENETICS			English	Article							ALLELIC ASSOCIATION; GENOMEWIDE SCAN; LOCI; FAMILIES; IDDM6	The choice of which population to study in the mapping of common disease genes may be critical(1,2). Isolated founder populations, such as that found in Finland, have already proved extremely useful for mapping the genes for specific rare monogenic disorders(3,4) and are being used in attempts to map the genes underlying common, complex diseases(5-8). But simulation results suggest that, under the common disease-common variant hypothesis(9-13), most isolated populations will prove no more useful for linkage disequilibrium (LD) mapping of common disease genes than large outbred populations(12). There is very little empirical data to either support or refute this conclusion at present(14-16) Therefore, we evaluated LD between 21 common microsatellite polymorphisms on chromosome 18q21 in 2 genetic isolates (Finland and Sardinia) and compared the results with those observed in two mixed populations (United Kingdom and United States of America). Mean levels of LD were similar across all four populations. Our results provide empirical support for the expectation that genetic isolates like Finland and Sardinia will not prove significantly more valuable than general populations for LD mapping of common variants underlying complex disease.	Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland; Univ Cagliari, Ist Clin & Biol Eta Evolut, I-09100 Cagliari, Italy	University of Cambridge; University of Oxford; Wellcome Centre for Human Genetics; Finland National Institute for Health & Welfare; University of Cagliari	Todd, JA (corresponding author), Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust Ctr Mol Mechanisms Dis, Wellcome Trust MRC Bldg, Cambridge, England.		Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148	NIDDK NIH HHS [DK73957] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Escamilla MA, 1999, AM J HUM GENET, V64, P1670, DOI 10.1086/302400; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P2198, DOI 10.1073/pnas.96.5.2198; HEDRICK PW, 1987, GENETICS, V117, P331; Huttley GA, 1999, GENETICS, V152, P1711; Jorde LB, 2000, HUM HERED, V50, P57, DOI 10.1159/000022891; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; Laan M, 1997, NAT GENET, V17, P435, DOI 10.1038/ng1297-435; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LEWONTIN RC, 1964, GENETICS, V49, P49; Lonjou C, 1999, P NATL ACAD SCI USA, V96, P1621, DOI 10.1073/pnas.96.4.1621; Merriman T, 1997, HUM MOL GENET, V6, P1003, DOI 10.1093/hmg/6.7.1003; Merriman TR, 1998, HUM MOL GENET, V7, P517, DOI 10.1093/hmg/7.3.517; Pajukanta P, 1999, AM J HUM GENET, V64, P1453, DOI 10.1086/302365; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3; THOMSON G, 1995, AM J HUM GENET, V57, P487; TODD JA, IN PRESS METABOLIC M; Weir B. S., 1996, GENETIC DATA ANAL; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501	25	135	136	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					320	323						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888882				2022-12-27	WOS:000087920900022
J	Witt, H; Luck, W; Hennies, HC; Classen, M; Kage, A; Lass, U; Landt, O; Becker, M				Witt, H; Luck, W; Hennies, HC; Classen, M; Kage, A; Lass, U; Landt, O; Becker, M			Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis	NATURE GENETICS			English	Article							CATIONIC TRYPSINOGEN GENE; CYSTIC-FIBROSIS GENE; HEREDITARY PANCREATITIS; LINKAGE DISEQUILIBRIUM	Chronic pancreatitis (CP) is a continuing or relapsing inflammatory disease of the pancreas. In approximately one-third of all cases, no aetiological factor can be found, and these patients are classified as having idiopathic disease. Pathophysiologically, autodigestion and inflammation may be caused by either increased proteolytic activity or decreased protease inhibition. Several studies have demonstrated mutations in the cationic trypsinogen gene (PRSS1) in patients with hereditary(1-3) or idiopathic(4) CP. It is thought that these mutations result in increased trypsin activity within the pancreatic parenchyma. Most patients with idiopathic or hereditary CP. however, do not have mutations in PRSS1 (ref. 4). Here we analysed 96 unrelated children and adolescents with CP for mutations in the gene encoding the serine protease inhibitor. Kazal type 1 (SPINK1). a pancreatic trypsin inhibitor. We found mutations in 23% of the patients. In 18 patients. 6 of whom were homozygous. we detected a missense mutation of codon 34 (N34S). We also found four other sequence variants. Our results indicate that mutations in SPINK1 are associated with chronic pancreatitis.	Humboldt Univ, Dept Pediat, Charite, Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Mol Genet, Berlin, Germany; Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Berlin, Germany; Zent Krankenhaus Links der Weser, Dept Pediat, Bremen, Germany; Humboldt Univ, Inst Lab Med & Pathobiochem, Berlin, Germany; TIB MOLBIOL, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Witt, H (corresponding author), Humboldt Univ, Dept Pediat, Charite, Campus Virchow Klinikum, Berlin, Germany.		Hennies, Hans C/G-9424-2014	Hennies, Hans C/0000-0001-7210-2389				BARTELT DC, 1977, ARCH BIOCHEM BIOPHYS, V179, P189, DOI 10.1016/0003-9861(77)90103-5; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Ferec C, 1999, J MED GENET, V36, P228; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; HORII A, 1987, BIOCHEM BIOPH RES CO, V149, P635, DOI 10.1016/0006-291X(87)90415-3; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Marchbank T, 1998, DIGESTION, V59, P167, DOI 10.1159/000007485; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Rinderknecht Heinrich, 1993, P219; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3	16	725	746	0	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					213	216		10.1038/76088	http://dx.doi.org/10.1038/76088			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835640				2022-12-27	WOS:000087459200024
J	Ashburner, M; Ball, CA; Blake, JA; Botstein, D; Butler, H; Cherry, JM; Davis, AP; Dolinski, K; Dwight, SS; Eppig, JT; Harris, MA; Hill, DP; Issel-Tarver, L; Kasarskis, A; Lewis, S; Matese, JC; Richardson, JE; Ringwald, M; Rubin, GM; Sherlock, G				Ashburner, M; Ball, CA; Blake, JA; Botstein, D; Butler, H; Cherry, JM; Davis, AP; Dolinski, K; Dwight, SS; Eppig, JT; Harris, MA; Hill, DP; Issel-Tarver, L; Kasarskis, A; Lewis, S; Matese, JC; Richardson, JE; Ringwald, M; Rubin, GM; Sherlock, G		Gene Ontology Consortium	Gene Ontology: tool for the unification of biology	NATURE GENETICS			English	Editorial Material							YEAST; IDENTIFICATION; ANNOTATION; PROTEINS	Genomic sequencing has made it clear that a large fraction of the genes specifying the core biological functions are shared by all eukaryotes. Knowledge of the biological role of such shared proteins in one organism can often be transferred to other organisms. The goal of the Gene Ontology Consortium is to produce a dynamic, controlled vocabulary that can be applied to all eukaryotes even as knowledge of gene and protein roles in cells is accumulating and changing. To this end, three independent ontologies accessible on the World-Wide Web (http://www.geneontology.org) are being constructed: biological process, molecular function and cellular component.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University	Botstein, D (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.		Kessenbrock, Kai/B-6936-2011; Sherlock, Gavin J/E-9110-2012; yang, xiao-jun/B-1927-2009; Sherlock, Gavin J/B-1831-2009; Dolinski, Kara/GPP-4026-2022	Blake, Judith/0000-0001-8522-334X; Lewis, Suzanna/0000-0002-8343-612X; Dolinski, Kara/0000-0002-7010-0264; Matese, John/0000-0002-9432-8909; Sherlock, Gavin/0000-0002-1692-4983; Harris, Midori/0000-0003-4148-4606; Cherry, J. Michael/0000-0001-9163-5180; Rubin, Gerald/0000-0001-8762-8703	NHGRI NIH HHS [P41 HG001315, P41 HG001315-16, P41 HG000739-19, U41 HG000739, P41 HG01315, P41 HG00330, P41 HG000739, P41 HG000330-22, U41 HG001315, P41 HG000330] Funding Source: Medline; NICHD NIH HHS [R01 HD033745-11, HD33745, R01 HD033745] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033745] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG001315, P41HG000739, P41HG000330] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P304, DOI 10.1093/nar/28.1.304; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Baker W, 2000, NUCLEIC ACIDS RES, V28, P19, DOI 10.1093/nar/28.1.19; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Barker WC, 2000, NUCLEIC ACIDS RES, V28, P41, DOI 10.1093/nar/28.1.41; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; BOTSTEIN D, 1988, SCIENCE, V240, P1439, DOI 10.1126/science.3287619; Chervitz SA, 1999, NUCLEIC ACIDS RES, V27, P74, DOI 10.1093/nar/27.1.74; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fleischmann W, 1999, BIOINFORMATICS, V15, P228, DOI 10.1093/bioinformatics/15.3.228; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; NC-IUBMB, 1992, ENZ NOM REC NOM COMM; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; Ringwald M, 2000, NUCLEIC ACIDS RES, V28, P115, DOI 10.1093/nar/28.1.115; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tang ZH, 2000, MOL CELL BIOL, V20, P816, DOI 10.1128/MCB.20.3.816-824.2000; Tateno Y, 2000, NUCLEIC ACIDS RES, V28, P24, DOI 10.1093/nar/28.1.24; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; *WORM SEQ CONS, 1998, SCIENCE, V282, P2012	33	25302	26060	100	1887	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					25	29		10.1038/75556	http://dx.doi.org/10.1038/75556			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802651	Green Accepted			2022-12-27	WOS:000086884000011
J	Grimm, C; Wenzel, A; Hafezi, F; Yu, S; Redmond, TM; Reme, CE				Grimm, C; Wenzel, A; Hafezi, F; Yu, S; Redmond, TM; Reme, CE			Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration	NATURE GENETICS			English	Article							APOPTOTIC CELL-DEATH; PHOTORECEPTOR DEGENERATION; MACULAR DEGENERATION; PIGMENT EPITHELIUM; DIFFUSIBLE FACTOR; MUTANT RHODOPSIN; TRANSGENIC MICE; BLUE-LIGHT; C-FOS; SURVIVAL	Light-induced apoptosis of photoreceptors represents an animal model for retinal degeneration(1). Major human diseases that affect vision, such as age-related macular degeneration (AMD) and some forms of retinitis pigmentosa (RP), may be promoted by light(2-7). The receptor mediating light damage, however, has not yet been conclusively identified; candidate molecules include prostaglandin synthase(8), cytochrome oxidase(9), rhodopsin(10), and opsins of the cones and the retinal pigment epithelium(11) (PE). We exposed to bright light two groups of genetically altered mice that lack the visual pigment rhodopsin (Rpe65(-/-) and Rho(-/-)). The gene Rpe65 is specifically expressed in the PE and essential for the re-isomerization of all-trans retinol in the visual cycle and thus for the regeneration of rhodopsin after bleaching(12). Rho(-/-) mice do not express the apoprotein opsin in photoreceptors, which, consequently, do not contain rhodopsin(13). We show that photoreceptors lacking rhodopsin in these mice are completely protected against light-induced apoptosis. The transcription factor AP-1, a central element in the apoptotic response to light(14,15), is not activated in the absence of rhodopsin, indicating that rhodopsin is essential for the generation or transduction of the intracellular death signal induced by light.	Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland; NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Zurich; University Zurich Hospital; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Grimm, C (corresponding author), Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland.		Hafezi, Farhad/A-1446-2010	Hafezi, Farhad/0000-0001-8935-4558; Redmond, T. Michael/0000-0002-1813-5291; Grimm, Christian/0000-0001-9318-4352	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Campochiaro PA, 1996, J NEUROSCI, V16, P1679; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHEN EP, 1993, GRAEF ARCH CLIN EXP, V231, P416, DOI 10.1007/BF00919652; Chen J, 1999, INVEST OPHTH VIS SCI, V40, P2978; Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P7103, DOI 10.1073/pnas.95.12.7103; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; GAUR VP, 1992, EXP EYE RES, V54, P645, DOI 10.1016/0014-4835(92)90020-S; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Hafezi F, 1999, VISION RES, V39, P2511, DOI 10.1016/S0042-6989(98)00313-7; Hanna N, 1997, FREE RADICAL BIO MED, V23, P885, DOI 10.1016/S0891-5849(97)00083-X; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; LaVail MM, 1999, INVEST OPHTH VIS SCI, V40, P1020; LAVAIL MM, 1987, CURR EYE RES, V6, P825, DOI 10.3109/02713688709034850; LI AR, 1995, J NEUROSCI, V15, P385; Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357; Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775; NIR I, 1993, MOL BRAIN RES, V19, P47, DOI 10.1016/0169-328X(93)90147-H; Organisciak DT, 1999, CURR EYE RES, V19, P188, DOI 10.1076/ceyr.19.2.188.5333; Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; SANYAL S, 1986, VISION RES, V26, P1177, DOI 10.1016/0042-6989(86)90099-4; SIMONS K, 1993, ARCH OPHTHALMOL-CHIC, V111, P297, DOI 10.1001/archopht.1993.01090030015002; Streichert LC, 1999, J NEUROBIOL, V39, P475, DOI 10.1002/(SICI)1097-4695(19990615)39:4<475::AID-NEU2>3.0.CO;2-#; Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000; WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285	29	212	220	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					63	66		10.1038/75614	http://dx.doi.org/10.1038/75614			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802658				2022-12-27	WOS:000086884000018
J	Haider, NB; Jacobson, SG; Cideciyan, AV; Swiderski, R; Streb, LM; Searby, C; Beck, G; Hockey, R; Hanna, DB; Gorman, S; Duhl, D; Carmi, R; Bennett, J; Weleber, RG; Fishman, GA; Wright, AF; Stone, EM; Sheffield, VC				Haider, NB; Jacobson, SG; Cideciyan, AV; Swiderski, R; Streb, LM; Searby, C; Beck, G; Hockey, R; Hanna, DB; Gorman, S; Duhl, D; Carmi, R; Bennett, J; Weleber, RG; Fishman, GA; Wright, AF; Stone, EM; Sheffield, VC			Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate	NATURE GENETICS			English	Article							SENSITIVITY	Hereditary human retinal degenerative diseases usually affect the mature photoreceptor topography by reducing the number of cells through apoptosis, resulting in loss of visual function(1). Only one inherited retinal disease, the enhanced S-cone syndrome (ESCS), manifests a gain in function of photoreceptors. ESCS is an autosomal recessive retinopathy in which patients have an increased sensitivity to blue light; perception of blue light is mediated by what is normally the least populous cone photoreceptor subtype, the S (short wavelength, blue) cones(2-8). People with ESCS also suffer visual loss, with night blindness occurring from early in life, varying degrees of L (long, red)- and M (middle, green)-cone vision, and retinal degeneration. The altered ratio of S- to L/M-cone photoreceptor sensitivity in ESCS may be due to abnormal cone cell fate determination during retinal development(7). In 94% of a cohort of ESCS probands we found mutations in NR2E3 (also known as PNR), which encodes a retinal nuclear receptor recently discovered to be a ligand-dependent transcription factor(9). Expression of NR2E3 was limited to the outer nuclear layer of the human retina. Our results suggest that NR2E3 has a role in determining photoreceptor phenotype during human retinogenesis.	Univ Iowa, Howard Hughes Med Inst, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Dept Ophthalmol, Iowa City, IA 52242 USA; Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA; Chiron Corp, Emeryville, CA 94608 USA; Ben Gurion Univ Negev, Inst Genet, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA; Univ Illinois, Coll Med, Dept Ophthalmol, Chicago, IL USA; Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Pennsylvania; Pennsylvania Medicine; Novartis; Ben Gurion University; Soroka Medical Center; Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Edinburgh	Sheffield, VC (corresponding author), Univ Iowa, Howard Hughes Med Inst, Dept Pediat, Iowa City, IA 52242 USA.	val-sheffield@uiowa.edu	Cideciyan, Artur V/A-1075-2007	Cideciyan, Artur V/0000-0002-2018-0905; Searby, Charles/0000-0002-8108-8782; Jacobson, Samuel/0000-0003-2122-169X; Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835	NEI NIH HHS [EY05627, EY11298, EY10539] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010539, R01EY011298] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1993, INVEST OPHTH VIS SCI, V34, P1677; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Bumsted K, 1999, J COMP NEUROL, V403, P502; CARMI R, 1995, AM J MED GENET, V59, P199, DOI 10.1002/ajmg.1320590216; CEPKO CL, 1993, PROG RETIN RES, V12, P1, DOI 10.1016/0278-4327(93)90002-B; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen F, 1999, P NATL ACAD SCI USA, V96, P15149, DOI 10.1073/pnas.96.26.15149; Daniel A, 1999, DEVELOPMENT, V126, P2945; FAVRE M, 1958, Ophthalmologica, V135, P604; FISHMAN GA, 1976, BRIT J OPHTHALMOL, V60, P345, DOI 10.1136/bjo.60.5.345; FISHMAN GA, 1989, OPHTHALMOLOGY, V96, P913; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Greenstein VC, 1996, VISION RES, V36, P3711, DOI 10.1016/0042-6989(96)00073-9; HENDRICKSON A, 1996, GREAT BAS VIS SCI S, P42; HOOD DC, 1995, VISION RES, V35, P1473, DOI 10.1016/0042-6989(95)98727-Q; JACOB JB, 1991, 6TH P WORLD TEL FOR, V1, P111; JACOBSON SG, 1990, INVEST OPHTH VIS SCI, V31, P827; Jacobson SG, 1998, INVEST OPHTH VIS SCI, V39, P2417; KELLNER U, 1993, CLIN VISION SCI, V8, P425; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; MARMOR MF, 1990, AM J OPHTHALMOL, V110, P124, DOI 10.1016/S0002-9394(14)76980-6; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; ROMAN AJ, 1991, EXP EYE RES, V53, P685, DOI 10.1016/0014-4835(91)90230-C; Swiderski RE, 1999, MOL BRAIN RES, V68, P64, DOI 10.1016/S0169-328X(99)00085-6; SZEL A, 1994, DEV BRAIN RES, V81, P1, DOI 10.1016/0165-3806(94)90062-0; SZEL A, 1994, NATURE, V370, P336, DOI 10.1038/370336a0; WIKLER KC, 1994, P NATL ACAD SCI USA, V91, P6534, DOI 10.1073/pnas.91.14.6534; Wikler KC, 1996, PERSPECT DEV NEUROBI, V3, P161; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307	30	352	367	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					127	131		10.1038/72777	http://dx.doi.org/10.1038/72777			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655056				2022-12-27	WOS:000085104600011
J	Cappellen, D; De Oliveira, C; Ricol, D; de Medina, SGD; Bourdin, J; Sastre-Garau, X; Chopin, D; Thiery, JP; Radvanyi, F				Cappellen, D; De Oliveira, C; Ricol, D; de Medina, SGD; Bourdin, J; Sastre-Garau, X; Chopin, D; Thiery, JP; Radvanyi, F			Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas	NATURE GENETICS			English	Letter							GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; THANATOPHORIC DYSPLASIA; SKELETAL DISORDERS; GENE; TRANSLOCATION; EXPRESSION		CNRS, Lab Morphogenese Cellulaire & Progress Tumorale, UMR 144, Inst Curie,Sect Rech, Paris 05, France; Inst Curie, Med Sect, Dept Pathol, F-75248 Paris 05, France; CHU Henri Mondor, Ctr Rech Chirurg, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Radvanyi, F (corresponding author), CNRS, Lab Morphogenese Cellulaire & Progress Tumorale, UMR 144, Inst Curie,Sect Rech, 26 Rue Ulm, Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Sastre-Garau, Xavier/0000-0001-5992-2083; Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424				Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Delezoide AL, 1997, HUM MOL GENET, V6, P1899, DOI 10.1093/hmg/6.11.1899; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; MURGUE B, 1994, CANCER RES, V54, P5206; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1	16	569	658	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					18	20		10.1038/12615	http://dx.doi.org/10.1038/12615			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471491				2022-12-27	WOS:000082337300009
J	Drazen, JM; Yandava, CN; Dube, L; Szczerback, N; Hippensteel, R; Pillari, A; Israel, E; Schork, N; Silverman, ES; Katz, DA; Drajesk, J				Drazen, JM; Yandava, CN; Dube, L; Szczerback, N; Hippensteel, R; Pillari, A; Israel, E; Schork, N; Silverman, ES; Katz, DA; Drajesk, J			Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment	NATURE GENETICS			English	Article							GENE-TRANSCRIPTION; 5-LIPOXYGENASE; ZILEUTON; THERAPY	Clinically similar asthma patients may develop airway obstruction by different mechanisms(1,2). Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway(3-5) provide a method to identify those patients in whom the products of the ALOX5 pathway (that is, the leukotrienes) contribute to the expression of the asthma phenotype. Failure of an asthma,patient to respond to treatment with ALOX5-pathway modifiers indicates that leukotrienes are not critical to the expression of the asthmatic phenotype in that patient. We previously defined a family of DNA sequence variants in the core promoter of the gene ALOX5 (on chromosome 10q11.2) associated with diminished promoter-reporter activity in tissue culture(6,7) 7. Because expression of ALOX5 is in part transcriptionally regulated(8), we reasoned that patients with these sequence variants may have diminished gene transcription, and therefore decreased ALOX5 product production and a diminished clinical response to treatment with a drug targeting this pathway. Such an effect indicates an interaction between gene promoter sequence variants and. drug-treatment responses, that is, a pharmacogenetic effect of a promoter sequence on treatment responses.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Abbott Labs, Abbott Pk, IL 60064 USA; Genset Corp, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Abbott Laboratories	Drazen, JM (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	jdrazen@rics.bwh.harvard.edu	Drazen, Jeffrey M/E-5841-2012	Schork, Nicholas/0000-0003-0920-5013; Katz, David/0000-0002-4400-5669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056383] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL-56383] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0; BARNES PJ, 1987, AM REV RESPIR DIS, V136, pS77, DOI 10.1164/ajrccm/136.6_Pt_2.S77; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Busse WW, 1998, AM J RESP CRIT CARE, V157, pS210, DOI 10.1164/ajrccm.157.6.mar-1; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Hancox RJ, 1998, EUR RESPIR J, V11, P589; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; McGill KA, 1996, LANCET, V348, P519, DOI 10.1016/S0140-6736(95)12297-4; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; NADEL JA, 1989, CHEST, V95, P1328, DOI 10.1378/chest.95.6.1328; NEBERT DW, 1990, PRINCIPLES DRUG ACTI; OByrne PM, 1997, ANN INTERN MED, V127, P472, DOI 10.7326/0003-4819-127-6-199709150-00009; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Schwartz HJ, 1998, ARCH INTERN MED, V158, P141, DOI 10.1001/archinte.158.2.141; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; SMITH LJ, 1991, AM REV RESPIR DIS, V143, pS100, DOI 10.1164/ajrccm/143.5_Pt_2.S100; STANKOVA J, 1995, BLOOD, V85, P3719, DOI 10.1182/blood.V85.12.3719.bloodjournal85123719; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; Wong SL, 1998, CLIN PHARMACOL THER, V63, P324, DOI 10.1016/S0009-9236(98)90164-3; Wong SL, 1998, EUR J CLIN PHARMACOL, V54, P715, DOI 10.1007/s002280050540	25	412	442	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					168	170		10.1038/9680	http://dx.doi.org/10.1038/9680			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369259				2022-12-27	WOS:000080680900022
J	Knight, JC; Udalova, I; Hill, AVS; Greenwood, BM; Peshu, N; Marsh, K; Kwiatkowski, D				Knight, JC; Udalova, I; Hill, AVS; Greenwood, BM; Peshu, N; Marsh, K; Kwiatkowski, D			A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria	NATURE GENETICS			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; DISEASE; SUSCEPTIBILITY; MACROPHAGES; PROTECTION	Genetic Variation in cytokine promoter regions is postulated to influence susceptibility to infection, but the molecular mechanisms by which such polymorphisms might affect gene, regulation are unknown. Through systematic DNA footprinting of the TNF (encoding tumour necrosis factor, TNF) promoter region, we have identified a single nucleotide polymorphism (SNP) that causes the helix-turn-helix transcription factor OCT-1 to bind to a novel region of complex protein-DNA interactions and alters gene expression in human monocytes. The OCT-1-binding genotype, found in approximately 5% of Africans, is associated with fourfold increased susceptibility to cerebral malaria in large case-control studies of West African and East African populations, after correction for other known TNF polymorphisms and linked HLA alleles.	Inst Mol Med, Mol Infect Dis Grp, Oxford OX3 9DS, England; Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DS, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Med Res Council Labs, Fajara, Senegal; Wellcome Clin Res Unit, Kilifi, Kenya	University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Knight, JC (corresponding author), Inst Mol Med, Mol Infect Dis Grp, Oxford OX3 9DS, England.		Knight, Julian Charles/W-2399-2019; HILL, Adrian V>S>/C-1306-2008; Knight, Julian/C-7242-2009	Knight, Julian Charles/0000-0002-0377-5536; Knight, Julian/0000-0002-0377-5536; Udalova, Irina/0000-0002-6716-2528; Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; Brinkman BMN, 1996, J INFLAMM, V46, P32; Brinkman BMN, 1997, BRIT J RHEUMATOL, V36, P516; Brinkman BMN, 1997, J INFECT DIS, V175, P188, DOI 10.1093/infdis/175.1.188; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; Conway DJ, 1997, INFECT IMMUN, V65, P1003, DOI 10.1128/IAI.65.3.1003-1006.1997; DALFONSO S, 1994, IMMUNOGENETICS, V39, P150; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; HAMANN A, 1995, BIOCHEM BIOPH RES CO, V211, P833, DOI 10.1006/bbrc.1995.1887; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Hohler T, 1997, J INVEST DERMATOL, V109, P562, DOI 10.1111/1523-1747.ep12337469; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; LEWONTIN RC, 1964, GENETICS, V49, P49; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; MOLYNEUX ME, 1989, Q J MED, V71, P441; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; Stuber F, 1996, J INFLAMM, V46, P42; UDALOVA IA, 1995, DOKL AKAD NAUK+, V342, P413; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; Wu GD, 1997, J BIOL CHEM, V272, P2396; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; Zuckerkandl E, 1997, J MOL EVOL, V44, pS2, DOI 10.1007/PL00000048	39	372	402	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					145	150		10.1038/9649	http://dx.doi.org/10.1038/9649			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369255				2022-12-27	WOS:000080680900018
J	Kruglyak, L				Kruglyak, L			Prospects for whole-genome linkage disequilibrium mapping of common disease genes	NATURE GENETICS			English	Article							SEQUENCE VARIATION; ALLELE MODEL; POPULATIONS; EXPANSION; BIOLOGY	Recently attention has focused on the use of whole-genome linkage disequilibrium (LD) studies to map common disease genes. Such studies would employ a dense map of single nucleotide polymorphisms (SNPs) to detect association between a marker and disease. Construction of SNP maps is currently underway. An essential issue yet to be settled is the required marker density of such maps. Here, I use population simulations to estimate the extent of LD surrounding common gene variants in the general human population as well as in isolated populations. Two main conclusions emerge from these investigations. First, a useful level of LD is unlikely to extend beyond an average distance of roughly 3 kb in the general population, which implies that approximately 500,000 SNPs will be required for whole-genome studies. Second, the extent of LD is similar in isolated populations unless the founding bottleneck is very narrow or the frequency of the variant is low (<5%).	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Kruglyak, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Peng, Bo/A-6920-2009; Holloway, John/B-5424-2009	Peng, Bo/0000-0001-8225-2284; Holloway, John/0000-0001-9998-0464				AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; Camp NJ, 1997, AM J HUM GENET, V61, P1424, DOI 10.1086/301648; CARLSON CS, 1998, AM J HUM GENET, V63, pA284; Chapman NH, 1998, AM J HUM GENET, V63, P1872, DOI 10.1086/302139; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; DONNELLY P, 1995, ANNU REV GENET, V29, P40; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Hudson R, 1991, OXFORD SURVEYS EVOLU, V7, P1; HUDSON RR, 1985, GENETICS, V109, P611; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; HUDSON RR, 1992, MECH MOL EVOLUTION, P23; JORDE LB, 1995, AM J HUM GENET, V56, P11; KAPLAN N, 1992, AM J HUM GENET, V51, P333; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; Landegren U, 1998, GENOME RES, V8, P769, DOI 10.1101/gr.8.8.769; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Li W. H, 1997, MOL EVOLUTION; MullerMyhsok B, 1997, SCIENCE, V275, P1328; Reich DE, 1998, P NATL ACAD SCI USA, V95, P8119, DOI 10.1073/pnas.95.14.8119; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROBERTSON A, 1983, PROC R SOC SER B-BIO, V219, P253, DOI 10.1098/rspb.1983.0073; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; Terwilliger JD, 1998, HUM HERED, V48, P138, DOI 10.1159/000022794; Thompson EA, 1997, AM J HUM GENET, V60, P197; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	31	1032	1087	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					139	144		10.1038/9642	http://dx.doi.org/10.1038/9642			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369254				2022-12-27	WOS:000080680900017
J	Kalman, S; Mitchell, W; Marathe, R; Lammel, C; Fan, L; Hyman, RW; Olinger, L; Grimwood, L; Davis, RW; Stephens, RS				Kalman, S; Mitchell, W; Marathe, R; Lammel, C; Fan, L; Hyman, RW; Olinger, L; Grimwood, L; Davis, RW; Stephens, RS			Comparative genomes of Chlamydia pneumoniae and C-trachomatis	NATURE GENETICS			English	Article							CORONARY-ARTERIES; INFECTED-CELLS; TWAR; DISEASE; ATHEROSCLEROSIS; ASSOCIATION; LESIONS	Chlamydia are obligate intracellular eubacteria that are phylogenetically separated from other bacterial divisions. C. trachomatis and C. pneumoniae are both pathogens of humans but differ in their tissue tropism and spectrum of diseases. C. pneumoniae is a newly recognized species of Chlamydia that is a natural pathogen of humans(1), and causes pneumonia and bronchitis. In the United States, approximately 10% of pneumonia cases and 5% of bronchitis cases are attributed to C. pneumoniae infection(2). Chronic disease may result following respiratory-acquired infection, such as reactive airway disease(3), adult-onset asthma(4) and potentially lung cancer(5). In addition, C, pneumoniae infection has been associated with atherosclerosis(6-11). C trachomatis infection causes trachoma, an ocular infection that leads to blindness, and sexually transmitted diseases such as pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy and epididymitis(12), Although relatively little is known about C. trachomatis biology(13), even less is known concerning C. pneomoniae. Comparison of the C. pneumoniae genome with the C. trachomatis genome(14) will provide an understanding of the common biological processes required for infection and survival in mammalian cells. Genomic differences are implicated in the unique properties that differentiate the two species in disease spectrum, Analysis of the 1,230,230-nt C. pneumoniae genome revealed 214 protein-coding sequences not found in C. trachomatis, most without homologues to other known sequences. Prominent comparative findings include expansion of a novel family of 21 sequence-variant outer-membrane proteins, conservation of a type-ill secretion virulence system, three serine/threonine protein kinases and a pair of parologous phospholipase-D-like proteins, additional purine and biotin biosynthetic capability, a homologue for aromatic amino acid (tryptophan) hydroxylase and the loss of tryptophan biosynthesis genes.	Univ Calif Berkeley, Program Infect Dis, Berkeley, CA 94720 USA; Stanford Univ, Stanford DNA Sequencing & Technol Ctr, Stanford, CA 94305 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; Stanford University; University of California System; University of California San Francisco	Stephens, RS (corresponding author), Univ Calif Berkeley, Program Infect Dis, Berkeley, CA 94720 USA.	ctgenome@socrates.berkeley.edu	Mitchell, Wayne P/C-5219-2008					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CAMPBELL LA, 1987, J CLIN MICROBIOL, V25, P1911, DOI 10.1128/JCM.25.10.1911-1916.1987; EMRE U, 1995, J INFECT DIS, V172, P265, DOI 10.1093/infdis/172.1.265; Fong IW, 1997, J CLIN MICROBIOL, V35, P48, DOI 10.1128/JCM.35.1.48-52.1997; GRAYSTON JT, 1989, INT J SYST BACTERIOL, V39, P88, DOI 10.1099/00207713-39-1-88; Hahn DL, 1996, EPIDEMIOL INFECT, V117, P513, DOI 10.1017/S0950268800059197; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; Laurila AL, 1997, INT J CANCER, V74, P31, DOI 10.1002/(SICI)1097-0215(19970220)74:1&lt;31::AID-IJC6&gt;3.0.CO;2-1; Longbottom D, 1998, FEMS MICROBIOL LETT, V164, P111, DOI 10.1111/j.1574-6968.1998.tb13075.x; MITCHELL WP, 1998, CHLAMYDIAL INFECT, P543; Mlot C, 1996, SCIENCE, V272, P1422, DOI 10.1126/science.272.5267.1422; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; ROCKEY DD, 1994, INFECT IMMUN, V62, P106, DOI 10.1128/IAI.62.1.106-112.1994; ROCKEY DD, 1995, MOL MICROBIOL, V15, P617, DOI 10.1111/j.1365-2958.1995.tb02371.x; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SCHACHTER J, 1990, WESTERN J MED, V153, P523; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; STEPHENS RS, 1992, INFECT AGENT DIS, V1, P279; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	23	545	1067	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1999	21	4					385	389		10.1038/7716	http://dx.doi.org/10.1038/7716			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192388				2022-12-27	WOS:000079439700019
J	Wu, KJ; Grandori, C; Amacker, M; Simon-Vermot, N; Polack, A; Lingner, J; Dalla-Favera, R				Wu, KJ; Grandori, C; Amacker, M; Simon-Vermot, N; Polack, A; Lingner, J; Dalla-Favera, R			Direct activation of TERT transcription by c-MYC	NATURE GENETICS			English	Article							TELOMERASE ACTIVITY; CATALYTIC SUBUNIT; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; GENE; PROTEINS; DIFFERENTIATION; SENESCENCE; MAX	The MYC proto-oncogene encodes a ubiquitous transcription factor (c-MYC) involved in the control of cell proliferation and differentiation(1). Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis(2). The function of c-MYC and its role in tumorigenesis are poorly understood because few c-MYC targets have been identified(3). Here we show that c-MYC has a direct role in induction of the activity of telomerase, the ribonucleoprotein complex expressed in proliferating and transformed cells, in which it preserves chromosome integrity by maintaining telomere length(4-6). c-MYC activates telomerase by inducing expression of its catalytic subunit, telomerase reverse transcriptase(7-9) (TERT). Telomerase complex activity is dependent on TERT, a specialized type of reverse transcriptase(10,11). TERT and c-MYC are expressed in normal and transformed proliferating cells, downregulated in quiescent and terminally differentiated cells(1,9,12,13), and can both induce immortalization when constitutively expressed in transfected cells(2,10,11). Consistent with the recently reported association between MYC overexpression and induction of telomerase activity(14), we find here that the TERT promoter contains numerous c-MYC-binding sites that mediate TERT transcriptional activation. c-MYC-induced TERT expression is rapid and independent of cell proliferation and additional protein synthesis, consistent with direct transcriptional activation of TERT. Our results indicate that TERT is a target of c-MYC activity and identify a pathway linking cell proliferation and chromosome integrity in normal and neoplastic cells.	Columbia Univ, Dept Pathol, New York, NY 10027 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10027 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; GSF Munich, Natl Res Inst Environm & Hlth, Inst Clin Mol Biol & Tumor Gent, D-81377 Munich, Germany	Columbia University; Columbia University; Fred Hutchinson Cancer Center; Swiss Institute Experimental Cancer Research; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dalla-Favera, R (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10027 USA.	rd10@columbia.edu	Wu, Kou-Juey/P-4654-2015	Lingner, Joachim/0000-0002-2853-5803	NCI NIH HHS [CA37165, CA20525, CA75125-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037165, R29CA075125, R01CA020525, R37CA020525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; Ramakrishnan S, 1998, CANCER RES, V58, P622; SASSON S, 1991, PATHOL BIOL, V39, P59; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; WU KJ, IN PRESS SCIENCE	30	729	787	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					220	224		10.1038/6010	http://dx.doi.org/10.1038/6010			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988278				2022-12-27	WOS:000078399500028
J	Puel, A; Ziegler, SF; Buckley, RH; Leonard, WJ				Puel, A; Ziegler, SF; Buckley, RH; Leonard, WJ			Defective IL7R expression in T-B+NK+ severe combined immunodeficiency	NATURE GENETICS			English	Article							RECEPTOR-GAMMA-CHAIN; NATURAL-KILLER-CELLS; IL-2 RECEPTOR; INTERLEUKIN-7 RECEPTOR; FUNCTIONAL COMPONENT; PROGENITOR CELLS; LIGAND-BINDING; DIFFERENTIATION; MUTATION; JAK3	Severe combined immunodeficiency (SCID) is caused by multiple genetic defects(1-3). The most common form of SCID, X-linked SCID (XSCID), results from mutations in IL2RG (ref. 4), which encodes the common cytokine receptor gamma chain (gamma(c)) that is shared by the IL-2, IL-4, IL-7, IL-9 and IL-15 receptors(1,5-10). In XSCID and SCID resulting from mutations in JAK3, which encodes a Janus family tyrosine kinase that couples to gamma(c) (refs 9,11,12) and is required for gamma(c)-dependent signalling, T- and natural killer (NK)-cells are decreased but B-cell numbers are normal(1-3,13,14) (T-B+NK- SCID). Some SCID patients lack T cells but retain NK cells. Given diminished T-cell development in IL7- or IL7r-deficient mice(15,16) and that Il7r-deficient mice have NK cells(17), we hypothesized that T-B+NK+ SCID might result from defective IL-7 signalling, although apparent differences in the role of the IL-7/IL-7R pathway in humans and mice in T-cell and B-cell development have been suggested(1,18). We now demonstrate medium control that defective IL7R expression causes T-B+NK+ SCID, indicating that the T-cell, but not the NK-cell, defect in XSCID results from inactivation of IL-7 alpha signalling.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Virginia Mason Med Ctr, Seattle, WA 98101 USA; Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Sch Med, Dept Pediat, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Virginia Mason Medical Center; Duke University; Duke University	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022; Puel, Anne/H-7305-2017; Buckley, Rebecca/AAB-1578-2019	Puel, Anne/0000-0003-2603-0323; 				BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; CavazzanaCalvo M, 1996, BLOOD, V88, P3901, DOI 10.1182/blood.V88.10.3901.bloodjournal88103901; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; He YW, 1996, J EXP MED, V184, P289, DOI 10.1084/jem.184.1.289; ISHII N, 1994, J IMMUNOL, V153, P1310; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Leclercq G, 1996, J EXP MED, V184, P325, DOI 10.1084/jem.184.2.325; Leonard WJ, 1996, ANNU REV MED, V47, P229; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; Puck JM, 1997, BLOOD, V89, P1968; Puzanov IJ, 1996, J IMMUNOL, V157, P4282; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	29	607	621	1	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					394	397		10.1038/3877	http://dx.doi.org/10.1038/3877			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843216				2022-12-27	WOS:000077199600031
J	Grady, WM; Willis, J; Guilford, PJ; Dunbier, AK; Toro, TT; Lynch, H; Wiesner, G; Ferguson, K; Eng, C; Park, JG; Kim, SJ; Markowitz, S				Grady, WM; Willis, J; Guilford, PJ; Dunbier, AK; Toro, TT; Lynch, H; Wiesner, G; Ferguson, K; Eng, C; Park, JG; Kim, SJ; Markowitz, S			Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer	NATURE GENETICS			English	Article							CADHERIN GERMLINE MUTATIONS; CPG ISLAND METHYLATION; DNA METHYLATION; COLORECTAL-CANCER; HYPERMETHYLATION; TUMORS; CELLS		Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Human Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand; Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA; Ohio State Univ, Sch Med, Clin Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Med, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Med, Div Human Genet, Dept Internal Med, Columbus, OH 43210 USA; Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Howard Hughes Med Inst, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Otago; Creighton University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Seoul National University (SNU); Seoul National University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute	Markowitz, S (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA.		Park, Jae-Gahb/J-5494-2012	Guilford, Parry/0000-0002-7256-9576; Dunbier, Anita/0000-0003-4621-7419; Eng, Charis/0000-0002-3693-5145	NCI NIH HHS [KO8 CA77676, R01 CA67409, R01 CA72160] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA077676, R01CA072160, R01CA067409] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 1998, CANCER RES, V58, P5489; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Myohanen SK, 1998, CANCER RES, V58, P591; Prowse AH, 1997, AM J HUM GENET, V60, P765; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Stirzaker C, 1997, CANCER RES, V57, P2229; Toyota M, 1999, CANCER RES, V59, P5438	15	330	348	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					16	17		10.1038/79120	http://dx.doi.org/10.1038/79120			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973239				2022-12-27	WOS:000089078000009
J	Wager-Smith, K; Kay, SA				Wager-Smith, K; Kay, SA			Circadian rhythm genetics: from flies to mice to humans	NATURE GENETICS			English	Article							DROSOPHILA CLOCK GENE; SLEEP-PHASE SYNDROME; SUPRACHIASMATIC NUCLEUS; DARK CYCLES; PERIOD GENE; TIMELESS; LIGHT; MELANOGASTER; BEHAVIOR; MUTANTS	A successful genetic dissection of the circadian regulation of behaviour has been achieved through phenotype-driven mutagenesis screens in flies and mice. Cloning and biochemical analysis of these evolutionarily conserved proteins has led to detailed molecular insight into the clock mechanism. Few behaviours enjoy the degree of understanding that exists for circadian rhythms at the genetic, cellular and anatomical levels. The circadian clock has so eagerly spilled her secrets that we may soon know the unbroken chain of events from gene to behaviour. It will likely be fruitful to wield this uncommon degree of knowledge to attack one of the most challenging problems in genetics: the basis of complex human behavioural disorders. We review here the genetic screens that provided the entree into the heart of the circadian clock, the model of the clock mechanism that has resulted, and the prospects for using the homologues as candidate genes in studies of human circadian dysrhythmias.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; NSF, Ctr Biol Timing, Arlington, VA 22230 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing	Wager-Smith, K (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.		Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878				Akashi M, 2000, GENE DEV, V14, P645; Akiyama M, 1999, J NEUROSCI, V19, P1115; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Sleep Disorders Association International Classification of Sleep Disorders, 1997, INT CLASS SLEEP DIS; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Bunney WE, 2000, NEUROPSYCHOPHARMACOL, V22, P335, DOI 10.1016/S0893-133X(99)00145-1; Czeisler CA, 1999, SCIENCE, V284, P2177, DOI 10.1126/science.284.5423.2177; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Franken P, 2000, J NEUROSCI, V20, P617, DOI 10.1523/JNEUROSCI.20-02-00617.2000; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hall JC, 1998, ADV GENET, V38, P135, DOI 10.1016/S0065-2660(08)60143-1; Hamblen MJ, 1998, GENETICS, V149, P165; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Hardin PE, 1999, SCIENCE, V286, P2460, DOI 10.1126/science.286.5449.2460; Hastings M, 2000, BIOESSAYS, V22, P23, DOI 10.1002/(SICI)1521-1878(200001)22:1<23::AID-BIES6>3.0.CO;2-Z; Hochgeschwender U, 1999, BIOESSAYS, V21, P157; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lakin-Thomas PL, 2000, TRENDS GENET, V16, P135, DOI 10.1016/S0168-9525(99)01945-9; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; MOLDOFSKY H, 1986, SLEEP, V9, P61, DOI 10.1093/sleep/9.1.61; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NEWBY LM, 1993, GENETICS, V135, P1077; Osiel S, 1998, PHYSIOL BEHAV, V65, P123, DOI 10.1016/S0031-9384(98)00140-1; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Ripperger JA, 2000, GENE DEV, V14, P679; Rothenfluh A, 2000, NEURON, V26, P505, DOI 10.1016/S0896-6273(00)81182-4; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Scully AL, 2000, CELL, V100, P297, DOI 10.1016/S0092-8674(00)80665-0; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri V, 1999, EMBO J, V18, P675, DOI 10.1093/emboj/18.3.675; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; YU Q, 1987, P NATL ACAD SCI USA, V84, P784, DOI 10.1073/pnas.84.3.784; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	59	150	157	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					23	27		10.1038/79134	http://dx.doi.org/10.1038/79134			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973243				2022-12-27	WOS:000089078000012
J	Alexander, CM; Reichsman, F; Hinkes, MT; Lincecum, J; Becker, KA; Cumberledge, S; Bernfield, M				Alexander, CM; Reichsman, F; Hinkes, MT; Lincecum, J; Becker, KA; Cumberledge, S; Bernfield, M			Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice	NATURE GENETICS			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; TRANSGENIC MICE; EPITHELIAL-CELLS; DROSOPHILA; FAMILY; GENE; TRANSFORMATION; RECEPTOR; WNT-1	Syndecan-1 is a cell-surface, heparan-sulphate proteoglycan (HSPG) predominantly expressed by epithelial cells. It binds specifically to many proteins, including oncoproteins. For example, it induces the assembly of a signalling complex between FCF ligands and their cognate receptors(1). But so far there has been no direct evidence that this proteoglycan contributes to tumorigenesis. Here we have examined the role of syndecan-1 (encoded by Sdc1) during mammary tumour formation in response to the ectopic expression of the proto-oncogene Wnt1. We crossed syndecan-1-deficient mice with transgenic mice that express Wnt1 in mammary gland (TgN(Wnt-1)1Hev; ref. 2). Ectopic Wnt-1 expression induces generalized mammary hyperplasia, followed by the development of solitary tumours (median time 22 weeks(3)). We show that in Sdc1(-/-) mice, Wnt-1-induced hyperplasia in virgin mammary gland was reduced by 70%, indicating that the Wnt-1 signalling pathway was inhibited. Of the 39 tumours that developed in a test cohort of mice, only 1 evolved in the Sdc1(-/-) background. In addition, we show that soluble syndecan-1 ectodomain purified from mouse mammary epithelial cells stimulates the activity of a Wnt-1 homologue in a tissue culture assay. Our results provide both genetic and biochemical evidence that syndecan-1 can modulate Wnt signalling, and is critical for Wnt-1-induced tumorigenesis of the mouse mammary gland.	Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	Harvard University; Boston Children's Hospital; University of Massachusetts System; University of Massachusetts Amherst	Alexander, CM (corresponding author), Childrens Hosp, Div Newborn Med, Enders 950, Boston, MA 02115 USA.							Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Conrad H. E., 1998, HEPARIN BINDING PROT; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Jackson D, 1997, J MAMMARY GLAND BIOL, V2, P385, DOI 10.1023/A:1026351414004; Jackson SM, 1997, DEVELOPMENT, V124, P4113; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374	32	278	285	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					329	332		10.1038/77108	http://dx.doi.org/10.1038/77108			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888884				2022-12-27	WOS:000087920900024
J	Ellegren, H				Ellegren, H			Heterogeneous mutation processes in human microsatellite DNA sequences	NATURE GENETICS			English	Article							MALE-DRIVEN EVOLUTION; MOLECULAR EVOLUTION; DIRECTIONALITY; INSTABILITY; LENGTH; BIAS; LOCI	Although microsatellite polymorphisms are one of the most commonly used tools in genetic analyses(1-3), it remains to be understood how microsatellite DNA has evolved as a ubiquitous and highly abundant class of repetitive sequences in eukaryotic genomes(4). On the basis of analyses of spontaneous human microsatellite mutations of germline origin, I show here that different mutation biases underlie the evolution of microsatellite repeats. The within-locus mutation rate increases with allele length, but is not affected by the size difference between an individual's two alleles (allele span). Within loci, long alleles tend to mutate to shorter lengths, thereby acting to prevent infinite growth. Expansions are more common than contractions among dinucleotide repeats, whereas no such trend is evident among tetranucleotide repeats. This observation is consistent with the longer repeat lengths and higher frequency of di- compared with tetranucleotide repeats. An excess of paternally transmitted mutations (male-to-female ratio of 4.9) supports a male-biased mutation rate in the human genome.	Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Biol, SE-75236 Uppsala, Sweden	Uppsala University	Ellegren, H (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Biol, Norbyvagen 18D, SE-75236 Uppsala, Sweden.	Hans.Ellegren@evolution.uu.se						Amos W, 1996, NAT GENET, V13, P390, DOI 10.1038/ng0896-390; BANCHS I, 1994, HUM MUTAT, V3, P365, DOI 10.1002/humu.1380030407; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Brinkmann B, 1998, AM J HUM GENET, V62, P1408, DOI 10.1086/301869; Chakraborty R, 1997, P NATL ACAD SCI USA, V94, P1041, DOI 10.1073/pnas.94.3.1041; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; Crow JF, 1997, NAT GENET, V17, P129, DOI 10.1038/ng1097-129; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; El-Maarri O, 1998, AM J HUM GENET, V63, P1001, DOI 10.1086/302065; Ellegren H, 1997, NATURE, V389, P593, DOI 10.1038/39303; Ellegren H, 1997, NAT GENET, V17, P182, DOI 10.1038/ng1097-182; ELLEGREN H, 1995, NAT GENET, V11, P360, DOI 10.1038/ng1295-360; Farbman Albert I., 1994, Seminars in Cell Biology, V5, P3; Farrall M, 1998, AM J HUM GENET, V62, P1260, DOI 10.1086/301829; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; Hurst LD, 1998, TRENDS GENET, V14, P446, DOI 10.1016/S0168-9525(98)01577-7; Jones AG, 1999, GENETICS, V152, P1057; Kimura M., 1983, NEUTRAL THEORY MOL E; McVean GT, 1997, NATURE, V386, P388, DOI 10.1038/386388a0; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; Primmer CR, 1998, MOL BIOL EVOL, V15, P1047, DOI 10.1093/oxfordjournals.molbev.a026003; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; RUBINSZTEIN DC, 1995, NAT GENET, V10, P337, DOI 10.1038/ng0795-337; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; Smith NGC, 1999, GENETICS, V152, P661; Vogel F., 1997, HUMAN GENETICS; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; Wierdl M, 1997, GENETICS, V146, P769	30	251	260	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					400	402		10.1038/74249	http://dx.doi.org/10.1038/74249			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742106				2022-12-27	WOS:000086192800021
J	Jordan, KC; Clegg, NJ; Blasi, JA; Morimoto, AM; Sen, J; Stein, D; McNeill, H; Deng, WM; Tworoger, M; Ruohola-Baker, H				Jordan, KC; Clegg, NJ; Blasi, JA; Morimoto, AM; Sen, J; Stein, D; McNeill, H; Deng, WM; Tworoger, M; Ruohola-Baker, H			The homeobox gene mirror links EGF signalling to embryonic dorso-ventral axis formation through Notch activation	NATURE GENETICS			English	Article							ANTERIOR-POSTERIOR AXIS; DROSOPHILA OOGENESIS; STEM-CELLS; BODY AXES; RECEPTOR; EXPRESSION; POLARITY; ESTABLISHMENT; POLARIZATION; PATHWAY	Recent studies in vertebrates and Drosophila melanogaster have revealed that Fringe-mediated activation of the Notch pathway has a role in patterning cell layers during organogenesis(1,2). In these processes, a homeobox-containing transcription factor is responsible for spatially regulating fringe (fng) expression and thus directing activation of the Notch pathway along the fng expression border. Here we show that this may be a general mechanism for patterning epithelial cell layers. At three stages in Drosophila oogenesis, mirror (mirr) and fng have complementary expression patterns in the follicle-cell epithelial layer, and at all three stages loss of mirr enlarges, and ectopic expression of mirr restricts, fng expression, with consequences for follicle-cell patterning. These morphological changes are similar to those caused by Notch mutations. Ectopic expression of mirr in the posterior follicle cells induces a stripe of rhomboid (rho) expression and represses pipe (pip), a gene with a role in the establishment of the dorsal-ventral axis, at a distance. Ectopic Notch activation has a similar long-range effect on pip. Our results suggest that Mirror and Notch induce secretion of diffusible morphogens and we have identified TGF-beta (encoded by dpp) as such a molecule in germarium. We also found that mirr expression in dorsal follicle cells is induced by the EGF-receptor (EGFR) pathway and that mirr then represses pip expression in all but the ventral follicle cells, connecting EGFR activation in the dorsal follicle cells to repression of pip in the dorsal and lateral follicle cells. Our results suggest that the differentiation of ventral follicle cells is not a direct consequence of germline signalling, but depends on long-range signals from dorsal follicle cells, and provide a link between early and late events in Drosophila embryonic dorsal-ventral axis formation.	Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Ctr Dev Biol, Seattle, WA 98195 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Imperial Canc Res Fund, Dev Patterning Lab, London WC2A 3PX, England	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yeshiva University; Albert Einstein College of Medicine; Cancer Research UK	Ruohola-Baker, H (corresponding author), Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA.	hannele@u.washington.edu	McNeill, Helen/E-4579-2013	McNeill, Helen/0000-0003-1126-5154				Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; Bryant Z, 1999, P NATL ACAD SCI USA, V96, P5559, DOI 10.1073/pnas.96.10.5559; Duffy JB, 1998, DEVELOPMENT, V125, P2263; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P2837; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Kehl BT, 1998, DEVELOPMENT, V125, P1217; Larkin MK, 1999, DEV GENES EVOL, V209, P301, DOI 10.1007/s004270050256; Larkin MK, 1996, DEVELOPMENT, V122, P3639; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Morimoto AM, 1996, DEVELOPMENT, V122, P3745; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; O'Donohue MF, 1998, BIOTECHNIQUES, V24, P910, DOI 10.2144/98246bm01; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tworoger M, 1999, GENETICS, V151, P739; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Wu JY, 1999, CURR OPIN NEUROBIOL, V9, P537, DOI 10.1016/S0959-4388(99)00020-3; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; XU T, 1992, DEVELOPMENT, V115, P913	30	69	69	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					429	433		10.1038/74294	http://dx.doi.org/10.1038/74294			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742112				2022-12-27	WOS:000086192800027
J	Tavernarakis, N; Wang, SL; Dorovkov, M; Ryazanov, A; Driscoll, M				Tavernarakis, N; Wang, SL; Dorovkov, M; Ryazanov, A; Driscoll, M			Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; EXPRESSION; SEQUENCE; IDENTIFICATION; DEGRADATION; MORPHOLOGY; PLANTS	Double-stranded RNA interference (RNAi) is an effective method for disrupting expression of specific genes in Caenorhabditis elegans and other organisms(1-5). Applications of this reverse-genetics tool, however, am somewhat restricted in nematodes because introduced dsRNA is not stably inherited(5). Another difficulty is that RNAi disruption of late-acting genes has been generally less consistent than that of embryonically expressed genes, perhaps because the concentration of dsRNA becomes lower as cellular division proceeds or as developmental time advances(1). In particular, some neuronally expressed genes appear refractory to dsRNA-mediated interference. We sought to extend the applicability of RNAi by in vivo expression of heritable inverted-repeat (IR) genes. We assayed the efficacy of in vivo-driven RNAi in three situations for which heritable, inducible RNAi would be advantageous: (i) production of large numbers of animals deficient for gene activities required for viability or reproduction; (ii) generation of large populations of phenocopy mutants for biochemical analysis; and (iii) effective gene inactivation in the nervous system. We report that heritable IR genes confer potent and specific gene inactivation for each of these applications. We suggest that a similar strategy might be used to test for dsRNA interference effects in higher organisms in which it is feasible to construct transgenic animals, but impossible to directly or transiently introduce high concentrations of dsRNA.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Driscoll, M (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA.		Tavernarakis, Nektarios/B-9684-2013; ryazanov, alexey/J-8081-2017	Tavernarakis, Nektarios/0000-0002-5253-1466; 	NIGMS NIH HHS [GM57300] Funding Source: Medline; NINDS NIH HHS [NS344435, NS37955] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037955] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; BRENNER S, 1974, GENETICS, V77, P71; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; JONES D, 1986, J BIOL CHEM, V261, P2006; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; MADURO M, 1995, GENETICS, V141, P977; MELLO CC, 1994, METHODS CELL BIOL CA, P451; MITANI S, 1993, DEVELOPMENT, V119, P773; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PARK EC, 1986, GENETICS, V113, P821; Ren XC, 1999, J NEUROBIOL, V39, P107, DOI 10.1002/(SICI)1097-4695(199904)39:1&lt;107::AID-NEU9&gt;3.0.CO;2-7; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	25	329	446	1	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					180	183		10.1038/72850	http://dx.doi.org/10.1038/72850			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655066				2022-12-27	WOS:000085104600021
J	Wakayama, T; Tateno, H; Mombaerts, P; Yanagimachi, R				Wakayama, T; Tateno, H; Mombaerts, P; Yanagimachi, R			Nuclear transfer into mouse zygotes	NATURE GENETICS			English	Article							EMBRYOS; TRANSPLANTATION		Rockefeller Univ, New York, NY 10021 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	Rockefeller University; University of Hawaii System	Wakayama, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	wakayat@rockvax.rockefeller.edu						Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; HOWLETT SK, 1987, DEVELOPMENT, V101, P915; Illmensee K, 1999, NATURE, V398, P19, DOI 10.1038/17905; ILLMENSEE K, 1981, CELL, V23, P9, DOI 10.1016/0092-8674(81)90265-8; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Sasaki, 1983, RAD INDUCED CHROMOSO, P411; Solter D, 1999, NATURE, V399, P13, DOI 10.1038/19841; STICE SL, 1994, MOL REPROD DEV, V38, P61, DOI 10.1002/mrd.1080380111; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632	11	113	118	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					108	109		10.1038/72749	http://dx.doi.org/10.1038/72749			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655051				2022-12-27	WOS:000085104600007
J	de Winter, JP; Rooimans, MA; van der Weel, L; van Berkel, CGM; Alon, N; Bosnoyan-Collins, L; de Groot, J; Zhi, Y; Waisfisz, Q; Pronk, JC; Arwert, F; Mathew, CG; Scheper, RJ; Hoatlin, ME; Buchwald, M; Joenje, H				de Winter, JP; Rooimans, MA; van der Weel, L; van Berkel, CGM; Alon, N; Bosnoyan-Collins, L; de Groot, J; Zhi, Y; Waisfisz, Q; Pronk, JC; Arwert, F; Mathew, CG; Scheper, RJ; Hoatlin, ME; Buchwald, M; Joenje, H			The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM	NATURE GENETICS			English	Article							ANEMIA		Free Univ Amsterdam, Dept Clin Genet & Human Genet, Amsterdam, Netherlands; Univ Toronto, Dept Med & Mol Genet, Toronto, ON, Canada; Free Univ Amsterdam Hosp, Dept Pathol, Amsterdam, Netherlands; Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; Guys Hosp, Div Med & Mol Genet, GKT Sch Med, London SE1 9RT, England	Vrije Universiteit Amsterdam; University of Toronto; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Oregon Health & Science University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Joenje, H (corresponding author), Free Univ Amsterdam, Dept Clin Genet & Human Genet, Amsterdam, Netherlands.		Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Waisfisz, Quinten/0000-0002-7384-9182	NHLBI NIH HHS [HL50301, HL56045] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056045, R29HL056045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; Waisfisz Q, 1999, AM J HUM GENET, V64, P1400, DOI 10.1086/302385; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341	11	217	222	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					15	16		10.1038/71626	http://dx.doi.org/10.1038/71626			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615118				2022-12-27	WOS:000084609200007
J	Wright, AF; Carothers, AD; Pirastu, M				Wright, AF; Carothers, AD; Pirastu, M			Population choice in mapping genes for complex diseases	NATURE GENETICS			English	Editorial Material							DEPENDENT DIABETES-MELLITUS; HUMAN LIPOPROTEIN-LIPASE; LINKAGE DISEQUILIBRIUM; DEMOGRAPHIC HISTORY; APOLIPOPROTEIN-E; GENOME; SUSCEPTIBILITY; TRAITS; LOCI; IDENTIFICATION	The difficulty of identifying susceptibility genes for common diseases has polarized geneticists' views on what disease models are appropriate and how best to proceed once high-density genome maps become available. Different disease models have different implications for using linkage or linkage-disequilibrium-based approaches for mapping complex disease genes. We argue that the choice of study population is a critical factor when designing a study, and that genetically simplified isolates are more useful than diverse continental populations under most assumptions.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; CNR, Inst Genet Mol, Alghero, Sardinia, Italy	University of Edinburgh; Consiglio Nazionale delle Ricerche (CNR)	Wright, AF (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.							BAIRD PA, 1988, AM J HUM GENET, V42, P677; Balciuniene J, 1998, AM J HUM GENET, V63, P786, DOI 10.1086/302012; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; BEAR JC, 1988, AM J MED GENET, V29, P649, DOI 10.1002/ajmg.1320290324; BELL JI, 1992, GENETIC BASIS COMMON; BERTRANPETIT J, 1995, ANN HUM GENET, V59, P63, DOI 10.1111/j.1469-1809.1995.tb01606.x; Bickeboller H, 1997, AM J HUM GENET, V60, P439; Camp NJ, 1997, AM J HUM GENET, V61, P1424, DOI 10.1086/301648; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Cox NJ, 1999, NAT GENET, V21, P213, DOI 10.1038/6002; ELLIS WS, 1978, AM J HUM GENET, V30, P366; Falconer D.S., 1986, INTRO QUANTITATIVE G; Genin E, 1996, AM J HUM GENET, V58, P861; Graham J, 1998, AM J HUM GENET, V63, P1517, DOI 10.1086/302102; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Harding RM, 1997, AM J HUM GENET, V60, P772; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Jarvik GP, 1997, ANN EPIDEMIOL, V7, P357, DOI 10.1016/S1047-2797(97)00028-8; JORDE LB, 1994, AM J HUM GENET, V54, P884; JORDE LB, 1995, AM J HUM GENET, V56, P11; Kainulainen K, 1999, HYPERTENSION, V33, P844, DOI 10.1161/01.HYP.33.3.844; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAPLAN NL, 1995, AM J HUM GENET, V56, P18; KIMURA M, 1969, GENETICS, V61, P893; Kruglyak L, 1997, AM J HUM GENET, V61, P810, DOI 10.1086/514893; KRUGLYAK L, 1995, AM J HUM GENET, V56, P1212; KRUGLYAK L, 1999, PROSPECTS WHOLEGENOM, V22, P139; Kruglyak S, 1998, P NATL ACAD SCI USA, V95, P10774, DOI 10.1073/pnas.95.18.10774; Laan M, 1997, NAT GENET, V17, P435, DOI 10.1038/ng1297-435; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Mackay TFC, 1996, BIOESSAYS, V18, P113, DOI 10.1002/bies.950180207; Martin ER, 1997, AM J HUM GENET, V61, P439, DOI 10.1086/514860; McKeigue PM, 1998, AM J HUM GENET, V63, P241, DOI 10.1086/301908; MCKUSICK VA, 1974, GENETIC POLYMORPHISM; MOUTULSKY AG, 1992, GENETIC BASIS COMMON; NEEL JV, 1962, AM J HUM GENET, V14, P353; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; PETERSON AC, 1995, HUM MOL GENET, V4, P887, DOI 10.1093/hmg/4.5.887; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Rieder MJ, 1999, NAT GENET, V22, P59, DOI 10.1038/8760; Risch N, 1997, SCIENCE, V275, P1329; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1993, AM J HUM GENET, V53, P702; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROGERS AR, 1995, EVOLUTION, V49, P608, DOI 10.1111/j.1558-5646.1995.tb02297.x; Schaid DJ, 1998, AM J HUM GENET, V63, P935, DOI 10.1086/302077; Scott WK, 1997, SCIENCE, V275, P1327, DOI 10.1126/science.275.5304.1327; Service SK, 1999, AM J HUM GENET, V64, P1728, DOI 10.1086/302398; SING CF, 1996, GENETIC ARCHITECTURE, P211; Soubrier F, 1995, Curr Opin Nephrol Hypertens, V4, P177, DOI 10.1097/00041552-199503000-00011; SUAREZ BK, 1994, PROBLEMS REPLICATING; Sullivan LS, 1996, MOL MED TODAY, V2, P380, DOI 10.1016/S1357-4310(96)10037-X; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; Teng J, 1997, AM J HUM GENET, V60, P979; Terwilliger JD, 1997, AM J HUM GENET, V61, P430, DOI 10.1086/514855; Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3; Terwilliger JD, 1998, HUM HERED, V48, P138, DOI 10.1159/000022794; Thompson EA, 1997, AM J HUM GENET, V60, P197; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813; Tu IP, 1999, AM J HUM GENET, V64, P641, DOI 10.1086/302253; VanCamp G, 1997, AM J HUM GENET, V60, P758; VOGELSTEIN B, 1998, HUMAN CANC; vonHaeseler A, 1996, NAT GENET, V14, P135, DOI 10.1038/ng1096-135; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WEISS KM, 1993, PRINCIPLES EVOLUTION; WORKMAN PL, 1975, AM J PHYS ANTHROPOL, V43, P165, DOI 10.1002/ajpa.1330430204; Zerba KE, 1998, HUM GENET, V103, P346, DOI 10.1007/s004390050828	74	266	271	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					397	404		10.1038/70501	http://dx.doi.org/10.1038/70501			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581024				2022-12-27	WOS:000084023900013
J	Li, JY; Shen, H; Himmel, KL; Dupuy, AJ; Largaespada, DA; Nakamura, T; Shaughnessy, JD; Jenkins, NA; Copeland, NG				Li, JY; Shen, H; Himmel, KL; Dupuy, AJ; Largaespada, DA; Nakamura, T; Shaughnessy, JD; Jenkins, NA; Copeland, NG			Leukaemia disease genes: large-scale cloning and pathway predictions	NATURE GENETICS			English	Article							POLYMERASE CHAIN-REACTION; DNA; LEUKEMIAS; PROTEIN; MICE; TRISTETRAPROLIN; ACTIVATION; NEOPLASMS; FRAGMENTS; LYMPHOMAS		NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA; Univ Minnesota, Ctr Canc, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; JST, PRESTO, Tokyo, Japan; Japanese Fdn Canc Res, Tokyo, Japan; Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System; University of Minnesota Twin Cities; Japan Science & Technology Agency (JST); Japanese Foundation for Cancer Research; University of Arkansas System; University of Arkansas Medical Sciences	Copeland, NG (corresponding author), NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA.		Largaespada, David/C-9832-2014	Dupuy, Adam/0000-0002-8561-4911				Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; CABLE S, 1992, VIRCHOWS ARCH B, V62, P221, DOI 10.1007/BF02899685; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1999, ANIMAL MODELS CANC P, P53; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ericsson J, 1999, J BIOL CHEM, V274, P14508, DOI 10.1074/jbc.274.20.14508; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ogawa S, 1996, ONCOGENE, V13, P183; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Shannon K, 1995, Curr Opin Hematol, V2, P305; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SORENSEN AB, 1993, J VIROL, V67, P7118; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Valk PJM, 1997, NUCLEIC ACIDS RES, V25, P4419, DOI 10.1093/nar/25.21.4419; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VITOLS S, 1985, LANCET, V2, P1150; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	30	194	221	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					348	353		10.1038/15531	http://dx.doi.org/10.1038/15531			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610183				2022-12-27	WOS:000083792200027
J	Rust, S; Rosier, M; Funke, H; Real, J; Amoura, Z; Piette, JC; Deleuze, JF; Brewer, HB; Duverger, N; Denefle, P; Assmann, G				Rust, S; Rosier, M; Funke, H; Real, J; Amoura, Z; Piette, JC; Deleuze, JF; Brewer, HB; Duverger, N; Denefle, P; Assmann, G			Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1	NATURE GENETICS			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; ABC TRANSPORTERS; A-I; RECEPTOR; CHOLESTEROL; CLONING; 9Q31	Tangier disease (TD) was first discovered nearly 40 years ago in two siblings living on Tangier Island(1). This autosomal co-dominant condition is characterized in the homozygous state by the absence of HDL-cholesterol (HDL-C) from plasma, hepatosplenomegaly, peripheral neuropathy and frequently premature coronary artery disease(1) (CAD). In heterozygotes, HDL-C levels are about one-half those of normal individuals(1). Impaired cholesterol efflux from macrophages leads to the presence of foam cells throughout the body, which may explain the increased risk of coronary heart disease in some TD families(2). We report here refining of our previous linkage of the TD gene(3) to a 1-cM region between markers D9S271 and D9S1866 on chromosome 9q31, in which we found the gene encoding human ATP cassette-binding transporter 1 (ABC1). We also found a change in ABC1 expression level on cholesterol loading of phorbol ester-treated THP1 macrophages, substantiating the role of ABC1 in cholesterol efflux. We cloned the full-length cDNA and sequenced the gene in two unrelated families with four TD homozygotes. In the first pedigree, a 1-bp deletion in exon 13, resulting in truncation of the predicted protein to approximately one-fourth of its normal size, co-segregated with the disease phenotype. An in-frame insertion-deletion in exon 12 was found in the second family. Our findings indicate that defects in ABC1, encoding a member of the ABC transporter superfamily, are the cause of TD.	Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Rhone Poulenc Rorer, Core Genom Biotechno Dept, F-91006 Evry, France; Rhone Poulenc Rorer, Dept Cardiovasc, F-91006 Evry, France; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Valencia, Dept Med, Hosp Clin, Valencia 46010, Spain; Hop La Pitie Salpetriere, Serv Med Interne, Paris, France; NHLBI, NIH, Bethesda, MD 20892 USA	University of Munster; University of Munster; University of Valencia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rust, S (corresponding author), Univ Munster, Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.	Rusts@uni-muenster.de	Amoura, Zahir/P-5325-2017; AMOURA, Zahir/P-5324-2017	AMOURA, Zahir/0000-0003-0292-9043				Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; FERRANS VJ, 1975, AM J PATHOL, V78, P101; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742	22	1208	1269	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					352	355		10.1038/11921	http://dx.doi.org/10.1038/11921			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431238				2022-12-27	WOS:000081772500016
J	Cheung, VG; Morley, M; Aguilar, F; Massimi, A; Kucherlapati, R; Childs, G				Cheung, VG; Morley, M; Aguilar, F; Massimi, A; Kucherlapati, R; Childs, G			Making and reading microarrays	NATURE GENETICS			English	Review							GENE-EXPRESSION; DNA; MAP	There are a variety of options for making microarrays and obtaining microarray data. Here, we describe the building and the use of two microarray facilities in academic settings. In addition to specifying technical detail, we comment on the advantages and disadvantages of components and approaches, and provide a protocol for hybridization. The fact that we are now making and using microarrays to answer biological questions demonstrates that the technology can be implemented in university environment.	Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine	Cheung, VG (corresponding author), Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA.	vcheung@mail.med.upenn.edu; childs@aecom.yu.edu	Cheung, Vivian G./AAT-3115-2020; Kucherlapati, Raju/ABC-8807-2021	Morley, Michael/0000-0002-0958-7376	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13330] Funding Source: Medline; NIDCD NIH HHS [DC00154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; Cheung VG, 1998, NAT GENET, V18, P225, DOI 10.1038/ng0398-225; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Ermolaeva O, 1998, NAT GENET, V20, P19, DOI 10.1038/1670; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865	14	502	613	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21			S			15	19		10.1038/4439	http://dx.doi.org/10.1038/4439			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915495				2022-12-27	WOS:000078008200006
J	Edelmann, W; Cohen, PE; Kneitz, B; Winand, N; Lia, M; Heyer, J; Kolodner, R; Pollard, JW; Kucherlapati, R				Edelmann, W; Cohen, PE; Kneitz, B; Winand, N; Lia, M; Heyer, J; Kolodner, R; Pollard, JW; Kucherlapati, R			Mammalian MutS homologue 5 is required for chromosome pairing in meiosis	NATURE GENETICS			English	Article							DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; CROSSING-OVER; GENE; MUTATION; MICE; MSH2; RECOMBINATION; ASSOCIATION	MSH5 (MutS homologue 5) is a member of a family of proteins known to be involved in DNA mismatch repair(1,2). Germline mutations in MSH2, MLH1 and GTBP (also known as MSH6) cause hereditary non-polyposis colon cancer (HNPCC) or Lynch syndrome(3-8). Inactivation of Msh2, Mlh1, Gtmbp (also known as Msh6) or Pms2 in mice leads to hereditary predisposition to intestinal and other cancers(9-14). Early studies in yeast revealed a role for some of these proteins, including Msh5, in meiosis(15-17). Gene targeting studies in mice confirmed roles for Mlh1 and Pms2 in mammalian meiosis(12-14,18). To assess the role of Msh5 in mammals, we generated and characterized mice with a null mutation in Msh5 Msh5(-/-) mice are viable but sterile. Meiosis in these mice is affected due to the disruption of chromosome pairing in prophase I. We found that this meiotic failure leads to a diminution in testicular size and a complete loss of ovarian structures, Our results show that normal Msh5 function is essential for meiotic progression and, in females, gonadal maintenance.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Dana-Farber Cancer Institute	Edelmann, W (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kucherlapati, Raju/ABC-8807-2021		NCI NIH HHS [CA 76329, N01-CN-65031, CA 67944] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN065031] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA076329, R01CA067944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COUNCE SJ, 1973, CHROMOSOMA, V44, P231, DOI 10.1007/BF00329119; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MCDONOUGH PG, 1972, PEDIATR CLIN N AM, V19, P631; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moens PB, 1998, CURR TOP DEV BIOL, V37, P241; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Plug AW, 1998, J CELL SCI, V111, P413; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SINGH RP, 1966, ANAT REC, V155, P369, DOI 10.1002/ar.1091550309; Spyropoulos B, 1994, Methods Mol Biol, V33, P131; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	30	294	301	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					123	127		10.1038/5075	http://dx.doi.org/10.1038/5075			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916805				2022-12-27	WOS:000077960700023
J	Jin, LQ; Zeng, H; Chien, S; Otto, KG; Richard, RE; Emery, DW; Blau, CA				Jin, LQ; Zeng, H; Chien, S; Otto, KG; Richard, RE; Emery, DW; Blau, CA			In vivo selection using a cell-growth switch	NATURE GENETICS			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; IN-VIVO; PROLIFERATION; TRANSDUCTION; EXPRESSION	A major obstacle to stem-cell gene therapy rests in the inability to deliver a gene into a therapeutically relevant fraction of stem cells'. One way to circumvent this obstacle is to use selection. Vectors containing two linked genes serve as the basis for selection. with one gene encoding a selectable product and the other, a therapeutic protein. Applying selection in vivo has the potential to bring a minor population of genetically corrected cells into the therapeutic range. But strategies for achieving in vivo selection have traditionally relied on genes that confer resistance to cytotoxic drugs(2,3) and are encumbered by toxicity. Here we describe a new system for in vivo selection that uses a 'cell-growth switch'. allowing a minor population of genetically modified cells to be inducibly amplified, thereby averting the risks associated with cytotoxic drugs. This system provides a general platform for conditionally expanding genetically modified cell populations in vivo. and may have widespread applications in gene and cell therapy.	Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Blau, CA (corresponding author), Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA.				NHLBI NIH HHS [2P01HL53750] Funding Source: Medline; NIDDK NIH HHS [5R01DK52997, 1R01DK57525] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052997, R01DK057525] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allay JA, 1998, NAT MED, V4, P1136, DOI 10.1038/2632; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; HAWLEY RG, 1994, GENE THER, V1, P136; HODGSON GS, 1973, CELL TISSUE KINET, V6, P199, DOI 10.1111/j.1365-2184.1973.tb01608.x; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SORRENTION BP, IN PRESS MOL BASIS B; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0	17	91	101	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					64	66		10.1038/79194	http://dx.doi.org/10.1038/79194			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973250				2022-12-27	WOS:000089078000019
J	Watnick, T; He, N; Wang, KR; Liang, Y; Parfrey, P; Hefferton, D; St George-Hyslop, P; Germino, G; Pei, Y				Watnick, T; He, N; Wang, KR; Liang, Y; Parfrey, P; Hefferton, D; St George-Hyslop, P; Germino, G; Pei, Y			Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; MOLECULAR-BASIS; 2-HIT MODEL; GENE; CYSTOGENESIS		Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA; Univ Hlth Network, Dept Med, Toronto, ON, Canada; Tanz Res Inst, Toronto, ON, Canada; Hlth Sci Ctr, Dept Med, Div Nephrol, St John, NF, Canada	Johns Hopkins University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba	Germino, G (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.	ggermino@welch.jhu.edu; York.Pei@uhn.on.can		Germino, Gregory/0000-0002-3609-5588; St George-Hyslop, Peter/0000-0003-0796-7209	NIDDK NIH HHS [DK02562, DK48006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048006, R37DK048006, K08DK002562] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Koptides M, 2000, HUM MOL GENET, V9, P447, DOI 10.1093/hmg/9.3.447; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Ong ACM, 1997, LANCET, V349, P1039, DOI 10.1016/S0140-6736(05)62286-6; Pei Y, 1999, J AM SOC NEPHROL, V10, P1524; Pei Y, 1998, J AM SOC NEPHROL, V9, P1853; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Torra P, 1999, KIDNEY INT, V56, P28, DOI 10.1046/j.1523-1755.1999.00534.x; Watnick T, 1999, AM J HUM GENET, V65, P1561, DOI 10.1086/302657; Watnick TJ, 1997, HUM MOL GENET, V6, P1473, DOI 10.1093/hmg/6.9.1473; Watnick TJ, 1998, MOL CELL, V2, P247, DOI 10.1016/S1097-2765(00)80135-5; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	15	97	100	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					143	144		10.1038/75981	http://dx.doi.org/10.1038/75981			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835625				2022-12-27	WOS:000087459200009
J	Lyle, R; Watanabe, D; Vruchte, DT; Lerchner, W; Smrzka, OW; Wutz, A; Schageman, J; Hahner, L; Davies, C; Barlow, DP				Lyle, R; Watanabe, D; Vruchte, DT; Lerchner, W; Smrzka, OW; Wutz, A; Schageman, J; Hahner, L; Davies, C; Barlow, DP			The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1	NATURE GENETICS			English	Article							CPG ISLAND; EXPRESSION; MOUSE; PROTOONCOGENE; TRANSCRIPT; GENE		Netherlands Canc Inst H5, Amsterdam, Netherlands; NIMR, London, England; Whitehead Inst, Cambridge, MA 02142 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Bayer Corp, Div Biotechnol, Berkeley, CA USA	Netherlands Cancer Institute; MRC National Institute for Medical Research; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Bayer AG	Barlow, DP (corresponding author), Netherlands Canc Inst H5, Amsterdam, Netherlands.			Lerchner, Walter/0000-0003-0842-4409				Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; Greger IH, 1998, NUCLEIC ACIDS RES, V26, P1294, DOI 10.1093/nar/26.5.1294; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; METZGER R, 1995, FEBS LETT, V357, P27, DOI 10.1016/0014-5793(94)01292-9; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Schweifer N, 1997, GENOMICS, V43, P285, DOI 10.1006/geno.1997.4816; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	13	218	228	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					19	21		10.1038/75546	http://dx.doi.org/10.1038/75546			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802648				2022-12-27	WOS:000086884000010
J	Grachtchouk, M; Rong, M; Yu, S; Zhang, XY; Sasaki, H; Hui, CC; Dlugosz, AA				Grachtchouk, M; Rong, M; Yu, S; Zhang, XY; Sasaki, H; Hui, CC; Dlugosz, AA			Basal cell carcinomas in mice overexpressing Gli2 in skin	NATURE GENETICS			English	Article							SONIC HEDGEHOG; TRANSCRIPTION FACTOR; HUMAN HOMOLOG; NEURAL-TUBE; EXPRESSION; MUTATIONS; GENE		Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Osaka Univ, Inst Mol & Cellular Biol, Dev Biol Lab, Osaka, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Osaka University	Dlugosz, AA (corresponding author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NCI NIH HHS [CA46592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Booth DR, 1999, CANCER METAST REV, V18, P261, DOI 10.1023/A:1006377425099; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Ding Q, 1998, DEVELOPMENT, V125, P2533; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Lee J, 1997, DEVELOPMENT, V124, P2537; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; SMOLLER BR, 1994, BRIT J DERMATOL, V131, P28, DOI 10.1111/j.1365-2133.1994.tb08453.x; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	16	314	328	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					216	217		10.1038/73417	http://dx.doi.org/10.1038/73417			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700170				2022-12-27	WOS:000085590600009
J	Marcelino, J; Carpten, JD; Suwairi, WM; Gutierrez, OM; Schwartz, S; Robbins, C; Sood, R; Makalowska, I; Baxevanis, A; Johnstone, B; Laxer, RM; Zemel, L; Kim, CA; Herd, JK; Ihle, J; Williams, C; Johnson, M; Raman, V; Alonso, LG; Brunoni, D; Gerstein, A; Papadopoulos, N; Bahabri, SA; Trent, JM; Warman, ML				Marcelino, J; Carpten, JD; Suwairi, WM; Gutierrez, OM; Schwartz, S; Robbins, C; Sood, R; Makalowska, I; Baxevanis, A; Johnstone, B; Laxer, RM; Zemel, L; Kim, CA; Herd, JK; Ihle, J; Williams, C; Johnson, M; Raman, V; Alonso, LG; Brunoni, D; Gerstein, A; Papadopoulos, N; Bahabri, SA; Trent, JM; Warman, ML			CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome	NATURE GENETICS			English	Article							ADENOMATOUS POLYPOSIS; FAMILIAL ARTHROPATHY; RHEUMATOID-ARTHRITIS; CONTRACTURES; SYNOVIOCYTES; PATHOLOGY; SYNOVITIS; FEATURES; FINGERS		Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Natl Human Genome Res Inst, Canc Genet Branch, NIH, Bethesda, MD USA; Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD USA; King Faisal Specialist Hosp & Res Ctr, Riyadh Armed Forces Hosp, Dept Pediat, Riyadh, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh, Saudi Arabia; Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Newington Childrens Hosp, Div Rheumatol, Hartford, CT USA; Univ Sao Paulo, Dept Genet, Sao Paulo, Brazil; E Tennessee State Univ, James H Quillen Coll Med, Dept Pediat, Johnson City, TN 37614 USA; Univ Tubingen, Childrens Hosp, Div Rheumatol, Tubingen, Germany; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Univ Fed Sao Paulo, Paulista Sch Med, Inst Med Genet, Sao Paulo, Brazil; Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); King Faisal Specialist Hospital & Research Center; Prince Sultan Military Medical City; King Faisal Specialist Hospital & Research Center; Case Western Reserve University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Universidade de Sao Paulo; East Tennessee State University; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Universidade Federal de Sao Paulo (UNIFESP); Columbia University	Warman, ML (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.	mlw14@po.cwru.edu	Brunoni, Decio/K-3155-2012; Papadopoulos, Nickolas/K-7272-2012; Makalowska, Izabela/AAU-2682-2021; Makalowska, Izabela/AAF-4967-2021; Sivaraman, Vidya/AAI-5010-2021; Alonso, Luis/I-2841-2013	Makalowska, Izabela/0000-0002-8144-5671; Alonso, Luis/0000-0002-1704-6676; Sivaraman, Vidya/0000-0003-3077-6726; Kim, Chong/0000-0002-1754-1300; Baxevanis, Andy/0000-0002-5370-0014	NIAMS NIH HHS [AR43827] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043827] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATHREYA BH, 1978, ARTHRITIS RHEUM-US, V21, P429, DOI 10.1002/art.1780210405; Bahabri SA, 1998, ARTHRITIS RHEUM, V41, P730, DOI 10.1002/1529-0131(199804)41:4<730::AID-ART22>3.0.CO;2-Y; BULUTLAR G, 1986, ARTHRITIS RHEUM, V29, P436, DOI 10.1002/art.1780290321; CASE JP, 1989, AM J PATHOL, V135, P1055; DAVID G, 1991, BIOCHEM SOC T, V19, P816, DOI 10.1042/bst0190816; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Ferlanti ES, 1999, BIOINFORMATICS, V15, P422, DOI 10.1093/bioinformatics/15.5.422; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; Flannery CR, 1999, BIOCHEM BIOPH RES CO, V254, P535, DOI 10.1006/bbrc.1998.0104; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GRAHAM WR, 1990, SOUTHERN MED J, V83, P973, DOI 10.1097/00007611-199008000-00030; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; LEVICK JR, 1984, HDB PHYSL 2, V4, P917; MARTINEZLAVIN M, 1983, NEW ENGL J MED, V309, P224, DOI 10.1056/NEJM198307283090407; McRorie ER, 1997, BRIT J RHEUMATOL, V36, P100; MERBERG DM, 1993, INT CONGR SER, V1042, P45; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; OCHI T, 1983, ARTHRITIS RHEUM, V26, P896, DOI 10.1002/art.1780260711; Ponta H, 1998, INT J BIOCHEM CELL B, V30, P299, DOI 10.1016/S1357-2725(97)00152-0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Sambrook J., 2002, MOL CLONING LAB MANU; Schumacher BL, 1999, J ORTHOP RES, V17, P110, DOI 10.1002/jor.1100170117; SCHUMACHER BL, 1994, ARCH BIOCHEM BIOPHYS, V311, P144, DOI 10.1006/abbi.1994.1219; SOREN A, 1978, HISTODIAGNOSIS CLIN; TURNER KJ, 1991, BLOOD S, V78, P279; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VERMA UN, 1995, J RHEUMATOL, V22, P2349; WALLIS WJ, 1985, ARTHRITIS RHEUM, V28, P1096, DOI 10.1002/art.1780281004; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6	31	219	229	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					319	322		10.1038/15496	http://dx.doi.org/10.1038/15496			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545950				2022-12-27	WOS:000083792200021
J	Cho, RJ; Mindrinos, M; Richards, DR; Sapolsky, RJ; Anderson, M; Drenkard, E; Dewdney, L; Reuber, TL; Stammers, M; Federspiel, N; Theologis, A; Yang, WH; Hubbell, E; Au, M; Chung, EY; Lashkari, D; Lemieux, B; Dean, C; Lipshutz, RJ; Ausubel, FM; Davis, RW; Oefner, PJ				Cho, RJ; Mindrinos, M; Richards, DR; Sapolsky, RJ; Anderson, M; Drenkard, E; Dewdney, L; Reuber, TL; Stammers, M; Federspiel, N; Theologis, A; Yang, WH; Hubbell, E; Au, M; Chung, EY; Lashkari, D; Lemieux, B; Dean, C; Lipshutz, RJ; Ausubel, FM; Davis, RW; Oefner, PJ			Genome-wide mapping with biallelic markers in Arabidopsis thaliana	NATURE GENETICS			English	Article							DENSITY OLIGONUCLEOTIDE ARRAYS; MUTATION DETECTION; YEAST GENOME; PLANT; DNA; HYBRIDIZATION; POLYMORPHISMS; INFORMATION; LINKAGE; RPS2	Single-nucleotide polymorphisms, as well as small insertions and deletions (here referred to collectively as simple nucleotide polymorphisms, or SNPs), comprise the largest set of sequence variants in most organisms(1,2). Positional cloning based on SNPs may accelerate the identification of human disease traits and a range of biologically informative mutations(3-6). The recent application of high-density oligonucleotide arrays to allele identification has made it feasible to genotype thousands of biallelic SNPs in a single experiment(3,7). It has yet to be established, however, whether SNP detection using oligonucleotide arrays can be used to accelerate the mapping of traits in diploid genomes. The cruciferous weed Arabidopsis thaliana is an attractive model system for the construction and use of biallelic SNP maps. Although important biological processes ranging from fertilization and cell fate determination(8-11) to disease resistance(12,13) have been modelled in A. thaliana, identifying mutations in this organism has been impeded by the lack of a high-density genetic: map consisting of easily genotyped DNA markers(14). We report here the construction of a biallelic genetic map in A. thaliana with a resolution of 3.5 cM and its use in mapping Eds16, a gene involved in the defence response to the fungal pathogen Erysiphe orontii. Mapping of this trait involved the high-throughput generation of meiotic maps of F-2 individuals using high-density oligonucleotide probe array-based genotyping. We developed a software package called InterMap and used it to automatically delimit Eds16 to a 7-cM interval on chromosome 1. These results are the first demonstration of biallelic mapping in diploid genomes and establish means for generalizing SNP-based maps to virtually any genetic organism.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Genencor, Palo Alto, CA 94304 USA; Univ Nottingham, Div Plant Sci Univ Pk, Nottingham Arabidopsis Stock Ctr, Nottingham NG7 2RD, England; John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UH, Norfolk, England; Stanford DNA Sequencing & Technol Ctr, Palo Alto, CA 94304 USA; Plant Gene Express Ctr Genome Sequencing Lab, Albany, CA 94710 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; Incyte Pharmaceut, Fremont, CA 94555 USA; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	Stanford University; Stanford University; Harvard University; Massachusetts General Hospital; University of Nottingham; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Stanford University; Affymetrix; Incyte; York University - Canada	Oefner, PJ (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.	oefner@genome.stanford.edu	Cho, Raymond/AAO-8125-2020	Cho, Raymond/0000-0001-6090-6603; Hubbell, Earl/0000-0001-7301-3759; Stammers, Melanie/0000-0003-0369-8611; Reuber, Lynne/0000-0001-7806-2437	NHGRI NIH HHS [3R37 HG00198-23] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R37HG000198] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adam L, 1996, PLANT J, V9, P341, DOI 10.1046/j.1365-313X.1996.09030341.x; Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Hoogendoorn B, 1999, HUM GENET, V104, P89, DOI 10.1007/s004390050915; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Kwok PY, 1996, GENOMICS, V31, P123, DOI 10.1006/geno.1996.0019; LANDVIK JY, 1987, POLAR RES, V5, P1; Li JM, 1998, METH MOL B, V82, P55; Liu YG, 1996, PLANT J, V10, P733, DOI 10.1046/j.1365-313X.1996.10040733.x; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; MEYEROWITZ EM, 1994, CURR OPIN GENET DEV, V4, P602, DOI 10.1016/0959-437X(94)90079-I; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; O'Donovan MC, 1998, GENOMICS, V52, P44, DOI 10.1006/geno.1998.5411; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; Sawa S, 1999, PLANT CELL, V11, P69, DOI 10.1105/tpc.11.1.69; Volko SM, 1998, GENETICS, V149, P537; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Winzeler EA, 1997, CURR OPIN GENET DEV, V7, P771, DOI 10.1016/S0959-437X(97)80039-1; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194	26	206	235	1	35	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					203	207		10.1038/13833	http://dx.doi.org/10.1038/13833			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508518				2022-12-27	WOS:000082827500021
J	Piedrahita, JA; Oetama, B; Bennett, GD; van Waes, J; Kamen, BA; Richardson, J; Lacey, SW; Anderson, RGW; Finnell, RH				Piedrahita, JA; Oetama, B; Bennett, GD; van Waes, J; Kamen, BA; Richardson, J; Lacey, SW; Anderson, RGW; Finnell, RH			Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development	NATURE GENETICS			English	Article							NEURAL-TUBE DEFECTS; FOLATE-DEFICIENCY; IN-VIVO; HOMOCYSTEINE; EXPRESSION; RECEPTOR; RATS	Periconceptional folic acid supplementation reduces the occurrence of several human congenital malformations, including craniofacial, heart and neural tube defects(1-4). Although the underlying mechanism is unknown, there may be a maternal-to-fetal folate-transport defect or an inherent fetal biochemical disorder that is neutralized by supplementation. Previous experiments have identified a folate-binding protein(5-7) (Folbp1) that functions as a membrane receptor to mediate the high-affinity internalization and delivery of folate to the cytoplasm of the cell(8-10). In vitro, this receptor facilitates the accumulation of cellular folate a thousand-fold relative to the media, suggesting that it may be essential in cytoplasmic folate delivery in vivo. The importance of an adequate intracellular folate pool for normal embryogenesis has long been recognized in humans(11-16) and experimental animals(17-19). To determine whether Folbp1 is involved in maternal-to-fetal folate transport, we inactivated Folbp1 in mice. We also produced mice lacking Folbp2, another member of the folate receptor family that is GPI anchored but binds folate poorly(20). Folbp2(-/-) embryos developed normally, but Folbp 1(-/-) embryos had severe morphogenetic abnormalities and died in utero by embryonic day (E) 10. Supplementing pregnant Folbp1(+/-) dams with folinic acid reversed this phenotype in nullizygous pups. Our results suggest that Folbp1 has a critical role in folate homeostasis during development, and that functional defects in the human homologue (FOLR1) of Folbp1 may contribute to similar defects in humans.	Texas A&M Univ, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Div Gastroenterol, Dallas, TX 75235 USA; Univ Nebraska, Med Ctr, Ctr Human Mol Genet, Omaha, NE 68198 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System; University of Nebraska Medical Center	Finnell, RH (corresponding author), Texas A&M Univ, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA.	rfinnell@unmc.edu	Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35396] Funding Source: Medline; NIEHS NIH HHS [P30-ES09106, ES07165] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BIRN H, 1993, AM J PHYSIOL, V264, pC302, DOI 10.1152/ajpcell.1993.264.2.C302; BOWER C, 1993, BRIT J NUTR, V69, P827, DOI 10.1079/BJN19930083; BRANDNER M, 1969, ANN RADIOL-RADIOL CL, V12, pR703; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; EMERSON DJ, 1962, AM J OBSTET GYNECOL, V84, P356, DOI 10.1016/0002-9378(62)90132-1; FORD JE, 1969, P NUTR SOC, V28, pA39; GOETSCH C, 1962, AM J OBSTET GYNECOL, V83, P1474, DOI 10.1016/S0002-9378(16)35992-0; GOLDEN JA, 1995, PEDIATRICS, V95, P506; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HJELLE JT, 1991, AM J PHYSIOL, V260, pC338, DOI 10.1152/ajpcell.1991.260.2.C338; Ma GT, 1997, DEVELOPMENT, V124, P907; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; NELSON M M, 1949, J Nutr, V38, P11; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; REFSUM H, 1989, CLIN CHEM, V35, P1921; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SHAW EB, 1968, AM J DIS CHILD, V115, P477, DOI 10.1001/archpedi.1968.02100010479013; SHAW GM, 1994, TERATOLOGY, V49, P143, DOI 10.1002/tera.1420490210; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1298; WELTMAN S, 1994, VITAMIN RECEPTORS VI, P105; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P2847	30	288	294	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					228	232		10.1038/13861	http://dx.doi.org/10.1038/13861			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508523				2022-12-27	WOS:000082827500026
J	Saigoh, K; Wang, YL; Suh, TG; Yamanishi, T; Sakai, Y; Kiyosawa, H; Harada, T; Ichihara, N; Wakana, S; Kikuchi, T; Wada, K				Saigoh, K; Wang, YL; Suh, TG; Yamanishi, T; Sakai, Y; Kiyosawa, H; Harada, T; Ichihara, N; Wakana, S; Kikuchi, T; Wada, K			Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice	NATURE GENETICS			English	Article							AXONAL DYSTROPHY GAD; PGP 9.5; MUTANT MOUSE; NEURODEGENERATIVE DISEASES; DEUBIQUITINATING ENZYMES; SENSORY NEURONS; NERVE-TERMINALS; DEGENERATION; PROTEIN; AXONOPATHY	The gracile axonal dystrophy (gad) mouse is an autosomal recessive mutant that shows sensory ataxia at an early stage, followed by motor ataxia at a later stage(1). Pathologically, the mutant is characterized by 'dying-back' type axonal degeneration and formation of spheroid bodies in nerve terminals(2-5) Recent pathological observations have associated brain ageing and neurodegenerative diseases with progressive accumulation of ubiquitinated protein conjugates(6,7). In gad mice, accumulation of amyloid beta-protein and ubiquitin-positive deposits occur retrogradely along the sensory and motor nervous systems(8,9). We previously reported that the gad mutation was transmitted by a gene on chromosome 5 (refs 10,11). Here we find that the gad mutation is caused by an in-frame deletion including exons 7 and 8 of Uchl1, encoding the ubiquitin carboxy-terminal hydrolase (UCH) isozyme (Uch-ll) selectively expressed in the nervous system and testis(12-15). The gad allele encodes a truncated Uch-ll lacking a segment of 42 amino acids containing a catalytic residue(16). As Uch-ll is thought to stimulate protein degradation by generating free monomeric ubiquitin(16-18), the gad mutation appears to affect protein turnover. Our data suggest that altered function of the ubiquitin system directly causes neurodegeneration, The gad mouse provides a useful model for investigating human neurodegenerative disorders.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Anim Models Human Dis, Tokyo 1878502, Japan; Kinki Univ, Sch Med, Dept Neurol, Osaka 5898511, Japan; Cent Inst Expt Anim, Dept Genet, Kawasaki, Kanagawa 216, Japan	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Kindai University (Kinki University)	Wada, K (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo 1878502, Japan.		Saigoh, Kazumasa/AAG-2956-2020; saigoh, Kazumasa/AFK-6417-2022; saigoh, Kazumasa/AAG-4678-2022	Saigoh, Kazumasa/0000-0002-0905-5935; 				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Arnold J, 1998, PROG BRAIN RES, V117, P23; BIZZI A, 1991, BRAIN RES, V548, P292, DOI 10.1016/0006-8993(91)91135-N; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; DAY INM, 1987, FEBS LETT, V210, P157, DOI 10.1016/0014-5793(87)81327-3; DAY INM, 1990, BIOCHEM J, V268, P521, DOI 10.1042/bj2680521; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Harada T, 1998, J NEUROSCI, V18, P3336; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; KAJIMOTO Y, 1992, J BIOCHEM-TOKYO, V112, P28, DOI 10.1093/oxfordjournals.jbchem.a123860; KIKUCHI T, 1990, ACTA NEUROPATHOL, V80, P145, DOI 10.1007/BF00308917; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MIURA H, 1993, NEUROPATH APPL NEURO, V19, P41, DOI 10.1111/j.1365-2990.1993.tb00403.x; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; ODA K, 1992, NEUROPATH APPL NEURO, V18, P265, DOI 10.1111/j.1365-2990.1992.tb00789.x; Ophoff RA, 1998, TRENDS PHARMACOL SCI, V19, P121, DOI 10.1016/S0165-6147(98)01182-1; SUH JG, 1995, GENOMICS, V27, P549, DOI 10.1006/geno.1995.1091; Wakana S, 1997, MAMM GENOME, V8, P698, DOI 10.1007/s003359900542; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WU J, 1996, ALZHEIMERS RES, V2, P163; YAMAZAKI K, 1988, P SOC EXP BIOL MED, V187, P209; YAMAZAKI K, 1987, JPN J GENET, V62, P479, DOI 10.1266/jjg.62.479	30	431	441	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					47	51		10.1038/12647	http://dx.doi.org/10.1038/12647			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471497				2022-12-27	WOS:000082337300014
J	Calogero, S; Grassi, F; Aguzzi, A; Voigtlander, T; Ferrier, P; Ferrari, S; Bianchi, ME				Calogero, S; Grassi, F; Aguzzi, A; Voigtlander, T; Ferrier, P; Ferrari, S; Bianchi, ME			The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice	NATURE GENETICS			English	Article							MOBILITY GROUP-1 PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID RECEPTOR; ACTIVATION; INTERACTS; COMPLEX	High mobility group 1 (HMG1) protein is an abundant component of all mammalian nuclei, and related proteins exist in all eukaryotes(1,2). HMG1 binds linear DNA with moderate affinity and no sequence specificity(3), but bends the double helix significantly on binding through the minor groove(4). It binds with high affinity to DNA that is already sharply bent, such as linker DNA at the entry and exit of nucleosomes(5-7); thus, it is considered a structural protein of chromatin, HMG1 is also recruited to DNA by interactions with proteins required,for basal and regulated transcriptions(8-13) and V(D)J recombination(14,15). Here we generate mice harbouring deleted Hmg1. Hmg1(-/-) pups are born alive, hut die within 24 hours due to hypoglycaemia, Hmg1-deficient mice survive for several days if given glucose parenterally, then waste away with pleiotropic defects (but no alteration in the immune repertoire). Cell lines lacking Hmg1 grow normally, but the activation of gene expression by the glucocorticoid receptor (GR, encoded by the gene Grl1) is impaired. Thus, Hmg1 is not essential for the overall organization of chromatin in the cell nucleus, but is critical for proper transcriptional control by specific transcription factors.	San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy; Univ Milan, Dipartimento Biol & Genet Sci Med, I-20132 Milan, Italy; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; CNRS Marseille Luminy, Ctr Immunol, INSERM, F-13288 Marseille, France; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy	University of Milan; University of Zurich; University Zurich Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Milan	Bianchi, ME (corresponding author), San Raffaele Sci Inst, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Aguzzi, Adriano/A-3351-2008; Bianchi, Marco Emilio/K-3417-2018	Bianchi, Marco Emilio/0000-0002-5329-6445; Aguzzi, Adriano/0000-0002-0344-6708; GRASSI, FABIO/0000-0003-3348-1712				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; FERRARI S, 1994, J BIOL CHEM, V269, P28803; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; NODA C, 1985, BIOCHEM BIOPH RES CO, V132, P232, DOI 10.1016/0006-291X(85)91012-5; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; REUE K, 1988, J BIOL CHEM, V263, P6857; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; Vaccari T, 1998, GENOMICS, V49, P247, DOI 10.1006/geno.1998.5214; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; YOOWARREN H, 1981, J BIOL CHEM, V256, P224; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	26	428	454	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					276	280		10.1038/10338	http://dx.doi.org/10.1038/10338			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391216				2022-12-27	WOS:000081125900021
J	Barrett, MT; Sanchez, CA; Prevo, LJ; Wong, DJ; Galipeau, PC; Paulson, TG; Rabinovitch, PS; Reid, BJ				Barrett, MT; Sanchez, CA; Prevo, LJ; Wong, DJ; Galipeau, PC; Paulson, TG; Rabinovitch, PS; Reid, BJ			Evolution of neoplastic cell lineages in Barrett oesophagus	NATURE GENETICS			English	Article							HIGH-GRADE DYSPLASIA; ALLELIC LOSSES; ENDOSCOPIC SURVEILLANCE; ESOPHAGEAL ADENOCARCINOMA; GENETIC ALTERATIONS; ULCERATIVE-COLITIS; CLONAL EVOLUTION; CANCER; PROGRESSION; POPULATIONS		Fred Hutchinson Canc Res Ctr, Program Canc Biol, GI Oncol, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98104 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Reid, BJ (corresponding author), Fred Hutchinson Canc Res Ctr, Program Canc Biol, GI Oncol, 1124 Columbia St, Seattle, WA 98104 USA.		Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NATIONAL CANCER INSTITUTE [R01CA061202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007742] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA61202, R01 CA061202] Funding Source: Medline; NIDDK NIH HHS [DK07742-03, T32 DK007742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett MT, 1996, ONCOGENE, V12, P1873; Barrett MT, 1996, CANCER RES, V56, P4351; Barrett MT, 1996, ONCOGENE, V13, P1867; Bedi GC, 1996, CANCER RES, V56, P2484; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; Califano J, 1996, CANCER RES, V56, P2488; CORREA P, 1990, CANCER RES, V50, P4737; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; LEVINE DS, 1991, GASTROENTEROLOGY, V101, P1198, DOI 10.1016/0016-5085(91)90068-V; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PETERSEN SE, 1980, FLOW CYTOMETRY, V4, P412; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; ROZEN P, 1995, GASTROENTEROLOGY, V108, P1361, DOI 10.1016/0016-5085(95)90683-5; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SPECHLER SJ, 1987, ANN INTERN MED, V106, P902, DOI 10.7326/0003-4819-106-6-902; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Wong DJ, 1997, CANCER RES, V57, P2619; Wu TT, 1998, AM J PATHOL, V153, P287, DOI 10.1016/S0002-9440(10)65570-8	29	359	366	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					106	109		10.1038/8816	http://dx.doi.org/10.1038/8816			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319873	Green Accepted			2022-12-27	WOS:000080096300034
J	Knoppers, BM				Knoppers, BM			Status, sale and patenting of human genetic material: an international survey	NATURE GENETICS			English	Editorial Material							DNA; INNOVATION	Following a decade of debate, the European Directive on the Legal Protection of Biotechnological Inventions(1) was adopted by the European Parliament and the Council of the European Union on July 6, 1998. The Directive constitutes a legal and social policy landmark in biotechnology, taking an explicit position on the contentious issue of the patentability of higher life forms. It fails, however, to provide definitive statements on the legal status of human genetic material or the possibility of personal financial gain in relation to such material. An overview of the international, regional and national positions las found in laws and official policy statements) on the status, commodification and patentability of human genetic material indicates that, although the Directive represents a consolidation of opinions, many issues remain unresolved.	Univ Montreal, Fac Droit, Ctr Droit Rech Droit Publ, Genet & Soc Project, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Knoppers, BM (corresponding author), Univ Montreal, Fac Droit, Ctr Droit Rech Droit Publ, Genet & Soc Project, Montreal, PQ H3C 3J7, Canada.	knoppers@droit.umontreal.ca						*ADV COMM GEN TEST, 1997, CODE PRACT GUID HUM; Baslar K., 1998, CONCEPT COMMON HERIT; Black J, 1998, Mod Law Rev, V61, P621; *COMM HLTH COUNC N, 1989, HER SCI SOC; *COMM OFF SCI TECH, 1995, HUM GEN SCI ITS CONS; *COUNC EUR, 1990, INT DIG HLTH LEGISLA, V41, P461; *COUNC EUR, 1997, INT DIG HLTH LEG, V48, P99; COUNCIL OF EUROPE, 1992, INT DIGEST HLTH LEGI, V43, P284; *DAN COUNC ETH, 1994, PAT HUM GEN REP; Eisenberg RS, 1998, TRENDS GENET, V14, P379, DOI 10.1016/S0168-9525(98)01589-3; *ETH LEG SOC ISS C, 1996, GENOME DIG, V3, P2; *EUR COMM EUR GROU, 1998, ETH ASP HUM TISS BAN; *EUR COMM WORK GRO, 1993, B MED ETHICS, P19; *FIGO COMM STUD ET, 1997, INT DIG HLTH LEG, V48, P447; *GROUP ADV ETH ASP, 1997, INT DIG HLTH LEG, V48, P423; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; *HUGO, 1995, GENOME DIG, V2, P6; *HUGO, 1997, GENOME DIG, V4, P3; *HUM RIGHTS EQ OPP, 1996, 5 HUM RIGHTS EQ OPP; *JAP SOC HUM GEN, 1996, EUBIOS J ASIAN INT B, V6, P137; Juengst ET, 1998, AM J HUM GENET, V63, P673, DOI 10.1086/302032; Knoppers B., 1991, HUMAN DIGNITY GENETI; Knoppers BM, 1998, AM J HUM GENET, V62, P474; Knoppers BM, 1998, GENOMICS, V50, P385, DOI 10.1006/geno.1998.5287; KNOPPERS BM, IN PRESS COMMERCIALI; *LAT AM HUM GEN PR, 1997, INT DIG HLTH LEG, V48, P424; *LAW REF COMM CAN, 1992, 66 LAW REF COMM CAN; Marshall E, 1998, SCIENCE, V282, P654, DOI 10.1126/science.282.5389.654; Merz JF, 1997, MOL DIAGN, V2, P299, DOI 10.1016/S1084-8592(97)80041-0; *MIN SOC AFF, 1993, 25 MIN SOC AFF; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; PHILLIPS JA, 1995, AM J HUM GENET, V57, P1499; Pottage A, 1998, Mod Law Rev, V61, P740, DOI 10.1111/1468-2230.00177; Service RF, 1998, SCIENCE, V282, P397, DOI 10.1126/science.282.5388.397; STERCKX S, 1997, BIOTECHNOLOGY PATENT; *UNESCO INT BIOETH, 1997, UN DECL HUM GEN HUM; *WHO, 1996, CONTR HER DIS; World Health Organization, 1998, PROP INT GUID ETH IS; *WORLD MED ASS DEC, 1993, INT DIG HLTH LEG, V44, P150; 1993, INT DIG HLTH LEG, V44, P362; 1994, INT DIG HLTH LEG, V45, P473	41	32	32	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					23	26		10.1038/8735	http://dx.doi.org/10.1038/8735			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319857				2022-12-27	WOS:000080096300018
J	Behrens, A; Sibilia, M; Wagner, EF				Behrens, A; Sibilia, M; Wagner, EF			Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation	NATURE GENETICS			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MICE LACKING; KAINIC ACID; FOS; RECOMBINATION; EXPRESSION; LETHALITY; INDUCTION; ABSENCE	c-Jun is a major component of the heterodimeric transcription factor AP-1 and is essential for embryonic development, as fetuses lacking Jun die at mid-gestation(1,2) with impaired hepatogenesis(1) and primary Jun(-/-) fibroblasts have a severe proliferation defect and undergo premature senescence in vitro(2). c-Jun and AP-1 activities are regulated by E-Jun N-terminal phosphorylation (JNP) at serines 63 and 73 through Jun N-terminal kinases(3,4) (JNKs). INP is thought to be required for the anti-apoptotic function of c-Jun during hepatogenesis, as mice lacking the JNK kinase SEK1 exhibit river defects similar to those seen in Jun(-/-) fetuses(5). To investigate the physiological relevance of JNP, we replaced endogenous Jun by a mutant Jun allele with serines 63 and 73 mutated to alanines (Jun(tm1Wag-); hereafter referred to as JunAA). Here we show that primary JunAA fibroblasts have proliferation- and stress-induced apoptotic defects, accompanied by reduced AP-1 activity. JunAA mice are viable and fertile, smaller than controls and resistant to epileptic seizures and neuronal apoptosis induced by the excitatory amino acid kainate. Primary mutant neurons are also protected from apoptosis and exhibit unaltered JNK activity. Our results provide evidence that JNP is dispensable for mouse development, and identify c-Jun as the essential substrate of INK signalling during kainate-induced neuronal apoptosis.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196; Sibilia, Maria/0000-0001-6129-5613; Behrens, Axel/0000-0002-1557-1143				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Morrison RS, 1996, J NEUROSCI, V16, P1337; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xiang H, 1998, J NEUROSCI, V18, P1363; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	22	576	591	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					326	329		10.1038/6854	http://dx.doi.org/10.1038/6854			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080190				2022-12-27	WOS:000078977900031
J	Talbot, CJ; Nicod, A; Cherny, SS; Fulker, DW; Collins, AC; Flint, J				Talbot, CJ; Nicod, A; Cherny, SS; Fulker, DW; Collins, AC; Flint, J			High-resolution mapping of quantitative trait loci in outbred mice	NATURE GENETICS			English	Article							INBRED MOUSE STRAINS; CONFIDENCE-INTERVALS; LABORATORY MICE; QTL LOCATION; PREFERENCE; POPULATION; MAP	Screening the whole genome of a cross between two inbred animal strains has proved to be a powerful method for detecting genetic loci underlying quantitative behavioural traits(1-7), but the level of resolution offered by quantitative trait loci (QTL) mapping is still too coarse to permit molecular cloning of the genetic determinants(8). To achieve high-resolution mapping, we used an outbred stock of mice for which the entire genealogy is known. The heterogeneous stock (HS) was established 30 years ago from an eight-way cross of C57BL/6, BALB/c, RIII, AKR, DBA/2, I, All and C3H inbred mouse strains(9). At the time of the experiment reported here, the HS mice were at generation 58, theoretically offering at least a 30-fold increase in resolution for QTL mapping compared with a backcross or an F2 intercross(10,11). Using the HS mice we have mapped a QTL influencing a psychological trait in mice to a 0.8-cM interval on chromosome 1. This method allows simultaneous fine mapping of multiple QTLs, as shown by our report of a second QTL on chromosome 12. The high resolution possible with this approach makes QTLs accessible to positional cloning.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Inst Psychiat, Social Genet & Dev & Psychiat Res Ctr, London SE5 8AF, England; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	University of Oxford; University of London; King's College London; University of Colorado System; University of Colorado Boulder	Flint, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.	jf@worf.molbiol.ox.ac.uk	Cherny, Stacey S/B-3315-2008	Cherny, Stacey S/0000-0002-0269-3352; Flint, Jonathan/0000-0002-9427-4429; Talbot, Christopher/0000-0001-7406-8962	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; Buck KJ, 1997, J NEUROSCI, V17, P3946; Caldarone B, 1997, NAT GENET, V17, P335, DOI 10.1038/ng1197-335; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Darvasi A, 1997, BEHAV GENET, V27, P125, DOI 10.1023/A:1025685324830; DARVASI A, 1995, GENETICS, V141, P1199; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; DEFRIES JC, 1978, BEHAV GENET, V8, P3, DOI 10.1007/BF01067700; DeFries JC, 1970, CONTRIBUTIONS BEHAVI, P23; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Efron B., 1982, JACKNIFE BOOTSTRAP O; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Falconer DS, 1996, QUANTITATIVE GENETIC; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; Gershenfeld HK, 1997, BEHAV GENET, V27, P201, DOI 10.1023/A:1025653812535; JIANG CJ, 1995, GENETICS, V140, P1111; JORDE LB, 1994, AM J HUM GENET, V54, P884; KOROL AB, 1995, GENETICS, V140, P1137; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LINCOLN S, 1992, MAPPING GENES CONTRO; Mangin B, 1997, HEREDITY, V78, P345, DOI 10.1038/hdy.1997.57; MANGIN B, 1994, GENETICS, V138, P1301; Mangin B, 1998, BIOMETRICS, V54, P88, DOI 10.2307/2533998; MCCLEARN G. E., 1970, Contributions to behavior-genetic analysis., P3; Melo JA, 1996, NAT GENET, V13, P147, DOI 10.1038/ng0696-147; Rosenberg M, 1997, GENOME RES, V7, P917, DOI 10.1101/gr.7.9.917; Wehner JM, 1997, NAT GENET, V17, P331, DOI 10.1038/ng1197-331	31	193	198	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	1999	21	3					305	308		10.1038/6825	http://dx.doi.org/10.1038/6825			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080185				2022-12-27	WOS:000078977900026
J	Nezu, JI; Tamai, I; Oku, A; Ohashi, R; Yabuuchi, H; Hashimoto, N; Nikaido, H; Sai, A; Koizumi, K; Shoji, Y; Takada, G; Matsuishi, T; Yoshino, M; Kato, H; Ohura, T; Tsujimoto, G; Hayakawa, J; Shimane, M; Tsuji, A				Nezu, JI; Tamai, I; Oku, A; Ohashi, R; Yabuuchi, H; Hashimoto, N; Nikaido, H; Sai, A; Koizumi, K; Shoji, Y; Takada, G; Matsuishi, T; Yoshino, M; Kato, H; Ohura, T; Tsujimoto, G; Hayakawa, J; Shimane, M; Tsuji, A			Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter	NATURE GENETICS			English	Article							CARDIOMYOPATHY; CHROMOSOME-11	Primary systemic carnitine deficiency (SCD; OMIM 212140) is an autosomal recessive disorder characterized by progressive cardiomyopathy, skeletal myopathy, hypoglycaemia and hyperammonaemia(1-3), SCD has also been linked to sudden infant death syndrome(4). Membrane-physiological studies have suggested a defect of the carnitine transport system in the plasma membrane in SCD patients(5) and in the mouse model, juvenile visceral steatosis (jvs; ref, 6), Although the responsible loci have been mapped in both human(7) and mouse(8), the underlying gene has not yet been identified. Recently, we cloned and analysed the function of a novel transporter protein termed OCTN2 (ref, 9). Our observation that OCTN2 has the ability to transport carnitine in a sodium-dependent manner prompted us to search for mutations in the gene encoding OCTN2. SLC22A5. initially we analysed the mouse gene and found a missense mutation in Slc22a5 in jvs mice. Biochemical analysis revealed that this mutation abrogates carnitine transport, Subsequent analysis of the human gene identified four mutations in three SCD pedigrees. Affected individuals in one family were homozygous for the deletion of a 113-bp region containing the start codon. In the second pedigree, the affected individual was shown to be a compound heterozygote for two mutations that cause a frameshift and a premature stop codon, respectively. In an affected individual belonging to a third family, we found a homozygous splice-site mutation also resulting in a premature stop codon, These mutations provide the first evidence that loss of OCTN2 function causes SCD.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Fac Med, Inst Expt Anim, Kanazawa, Ishikawa 9208640, Japan; Akita Univ, Sch Med, Dept Hyg, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Pediat, Akita 0108543, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Tohoku Univ, Sch Med, Dept Pediat, Sendai, Miyagi 9808575, Japan; Natl Childrens Med Res Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548509, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Chugai Res Inst Mol Med, Ibaraki, Osaka 3004101, Japan	Kanazawa University; Kanazawa University; Akita University; Akita University; Kurume University; Tohoku University; National Center for Child Health & Development - Japan; Japan Science & Technology Agency (JST)	Tsuji, A (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	tsuji@kenroku.ipc.kanazawa-u.ac.jp	TAMAI, Ikumi/D-8412-2015	Yoshino, Makoto/0000-0001-9048-1490				BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; CHAPOY PR, 1980, NEW ENGL J MED, V303, P1389, DOI 10.1056/NEJM198012113032403; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Hashimoto N, 1998, BIOCHEM PHARMACOL, V55, P1729, DOI 10.1016/S0006-2952(97)00670-9; HORIUCHI M, 1994, BBA-MOL BASIS DIS, V1226, P25, DOI 10.1016/0925-4439(94)90054-X; KARPATI G, 1975, NEUROLOGY, V25, P16, DOI 10.1212/WNL.25.1.16; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MATSUISHI T, 1985, NEUROPEDIATRICS, V16, P6, DOI 10.1055/s-2008-1052536; NIKAIDO H, 1995, MAMM GENOME, V6, P369, DOI 10.1007/BF00364804; Okita K, 1996, GENOMICS, V33, P289, DOI 10.1006/geno.1996.0194; Rinaldo P, 1997, J PEDIATR-US, V131, P304, DOI 10.1016/S0022-3476(97)70171-9; Roe CR, 1995, METABOLIC MOL BASES, P1508; Shoji Y, 1998, AM J HUM GENET, V63, P101, DOI 10.1086/301911; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TRIPP ME, 1981, NEW ENGL J MED, V305, P385, DOI 10.1056/NEJM198108133050707; WABER LJ, 1982, J PEDIATR-US, V101, P700, DOI 10.1016/S0022-3476(82)80294-1; Walter JH, 1996, ARCH DIS CHILD, V74, P475, DOI 10.1136/adc.74.6.475	21	411	432	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					91	94		10.1038/5030	http://dx.doi.org/10.1038/5030			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916797				2022-12-27	WOS:000077960700015
J	Sekine, K; Ohuchi, H; Fujiwara, M; Yamasaki, M; Yoshizawa, T; Sato, T; Yagishita, N; Matsui, D; Koga, Y; Itoh, N; Kato, S				Sekine, K; Ohuchi, H; Fujiwara, M; Yamasaki, M; Yoshizawa, T; Sato, T; Yagishita, N; Matsui, D; Koga, Y; Itoh, N; Kato, S			Fgf10 is essential for limb and lung formation	NATURE GENETICS			English	Article							CHICK LIMB; VERTEBRATE LIMB; GROWTH; MORPHOGENESIS; INVOLVEMENT; EXPRESSION; GENE; INITIATION; INDUCTION; OUTGROWTH	The interactions between fibroblast growth factors (FGF) and their receptors have important roles in mediating mesenchymal-epithelial cell interactions during embryogenesis(1,2). In particular, Fgf10 is predicted to function as a regulator of brain, lung and limb development an the basis of its spatiotemporal expression pattern in the developing embryo. To define the role of Fgf10, we generated Fgf10-deficient mice. Fgf10(-/-) mice died at birth due to the lack of lung development Trachea was formed, but subsequent pulmonary branching morphogenesis was disrupted. In addition, mutant mice had complete truncation of the fore- and hindlimbs. In Fgf10(-/-) embryos, limb bud formation was initiated but outgrowth of the limb buds did not occur; however, formation of the clavicles was not affected. Analysis of the expression of marker genes in the mutant limb buds indicated that the apical ectodermal ridge (AER) and the tone of polarizing activity (ZPA) did not form. Thus, we show here that Fgf10 serves as an essential regulator of lung and limb formation.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genet Biochem, Kyoto 6068501, Japan; Sumitomo Pharmaceut Res Ctr, Osaka 554, Japan; CREST, Japan Sci & Technol Corp, Saitama 332, Japan	University of Tokyo; Kyoto University; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	uskato@hongo.ecc.u-tokyo.ac.jp		Yoshizawa, Tatsuya/0000-0002-5728-1996; Yamasaki, Masahiro/0000-0002-5296-4974; Sekine, Keisuke/0000-0001-5133-0876				Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grieshammer U, 1996, DEVELOPMENT, V122, P3851; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Ohuchi H, 1998, DEVELOPMENT, V125, P51; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUBIN L, 1972, DEV BIOL, V28, P94, DOI 10.1016/0012-1606(72)90129-7; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Vogel A, 1996, DEVELOPMENT, V122, P1737; Xu XL, 1998, DEVELOPMENT, V125, P753; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	30	906	932	0	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					138	141		10.1038/5096	http://dx.doi.org/10.1038/5096			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916808				2022-12-27	WOS:000077960700026
J	Wang, JM; Wilhelmsson, H; Graff, C; Li, H; Oldfors, A; Rustin, P; Bruning, JC; Kahn, CR; Clayton, DA; Barsh, GS; Thoren, P; Larsson, NG				Wang, JM; Wilhelmsson, H; Graff, C; Li, H; Oldfors, A; Rustin, P; Bruning, JC; Kahn, CR; Clayton, DA; Barsh, GS; Thoren, P; Larsson, NG			Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression	NATURE GENETICS			English	Article							KEARNS-SAYRE SYNDROME; SKELETAL-MUSCLE; DEVELOPMENTAL REGULATION; MESSENGER-RNAS; IN-VIVO; DEFICIENCY; DELETIONS; DISEASE; MICE; TRANSCRIPTION	Mutations of mitochondrial DNA (mtDNA) cause several well-recognized human genetic syndromes with deficient oxidative phosphorytation(1-4) and may also have a role in ageing and acquired diseases of old age(5). We report here that hallmarks of mtDNA mutation disorders can be reproduced in the mouse using a conditional mutation strategy tl manipulate the expression of the gene encoding mitochondrial transcription factor A (Tfam, previously named mtTFA), which regulates transcription and replication of mtDNA (refs 6,7). Using a loxP-flanked Tfam allele (Tfam(loxP); ref. 8) in combination with a cre-recombinase transgene under control of the muscle creatinine kinase promoter(9,10), we have disrupted Tfam in heart and muscle. Mutant animals develop a mosaic cardiac-specific progressive respiratory chain deficiency, dilated cardiomyopathy, atrioventricular heart conduction blocks and die at 2-4 weeks of age. This animal model reproduces biochemical, morphological and physiological features of the dilated cardiomyopathy of Kearns-Sayre syndrome(1-4). Furthermore, our findings provide genetic evidence that the respiratory chain is critical for normal heart function.	Karolinska Hosp, Dept Mol Med, Ctr Mol Med L8 02, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden; Sahlgrenska Hosp, Dept Pathol, S-41345 Gothenburg, Sweden; Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, INSERM U393, F-75015 Paris, France; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat & Genet, Stanford, CA 94305 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Stanford University; Karolinska Institutet	Larsson, NG (corresponding author), Karolinska Hosp, Dept Mol Med, Ctr Mol Med L8 02, S-17176 Stockholm, Sweden.	nils-goran.larsson@cmm.ki.se	graff, caroline/A-2545-2009; Larsson, Nils-Göran/GVS-5578-2022; Kahn, Ronald/AAY-2435-2021	Larsson, Nils-Göran/0000-0001-5100-996X; Kahn, Ronald/0000-0002-7583-9228; Graff, Caroline/0000-0002-9949-2951; Oldfors, Anders/0000-0002-5758-7397	NIGMS NIH HHS [R37-GM33088-28] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXENBORG JE, 1993, COMPUT METH PROG BIO, V41, P55, DOI 10.1016/0169-2607(93)90065-S; BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Connor MK, 1996, ARCH BIOCHEM BIOPHYS, V333, P103, DOI 10.1006/abbi.1996.0369; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; GROVE D, 1969, CIRC RES, V25, P473, DOI 10.1161/01.RES.25.4.473; HAKULINEN T, 1987, APPL STAT-J ROY ST C, V36, P309; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Johansson C, 1997, ACTA PHYSIOL SCAND, V160, P133, DOI 10.1046/j.1365-201X.1997.00134.x; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LARSSON NG, 1992, AM J HUM GENET, V51, P1201; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MOORE GW, 1980, AM HEART J, V100, P610, DOI 10.1016/0002-8703(80)90224-0; MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359; MULLERHOCKER J, 1992, HUM PATHOL, V23, P1431, DOI 10.1016/0046-8177(92)90065-B; Munnich A, 1996, EUR J PEDIATR, V155, P262; OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Weber K, 1997, AM J HUM GENET, V60, P373; ZAK R, 1974, CIRC RES, V35, P17	30	300	312	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					133	137		10.1038/5089	http://dx.doi.org/10.1038/5089			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916807				2022-12-27	WOS:000077960700025
J	Lane, KB; Machado, RD; Pauciulo, MW; Thomson, JR; Phillips, JA; Loyd, JE; Nichols, WC; Trembath, RC				Lane, KB; Machado, RD; Pauciulo, MW; Thomson, JR; Phillips, JA; Loyd, JE; Nichols, WC; Trembath, RC		Int PPH Consortium	Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension	NATURE GENETICS			English	Article							GROWTH-FACTOR-BETA; II RECEPTOR; CLONING; PROTEINS; COMPLEX; GENE	Primary pulmonary hypertension (PPH). characterized by obstruction of pre-capillary pulmonary arteries, leads to sustained elevation of pulmonary arterial pressure (mean >25 mm Hg at rest or >30 mm Hg during exercise(1)). The aetiology is unknown, but the histological features reveal proliferation of endothelial and smooth muscle cells with vascular remodelling(2) (Fig. 1). More than one affected relative has been identified in at least 6% of cases(3) (familial PPH, MIM 178600). Familial PPH (FPPH) segregates as an autosomal dominant disorder with reduced penetrance and has been mapped to a locus designated PPH1 on 2q33. with no evidence of heterogeneity(4-6). We now show that FPPH is caused by mutations in BMPR2. encoding a TGF-beta type II receptor (BMPR-II). Members of the TGF-beta superfamily transduce signals by binding to heteromeric complexes of type I and II receptors, which activates serine/threonine kinases. leading to transcriptional regulation by phosphorylated Smads(7). By comparison with in vitro studies, identified defects of BMPR-II in FPPH are predicted to disrupt ligand binding, kinase activity and heteromeric dimer formation(8-10). Our data demonstrate the molecular basis of FPPH and underscore the importance in vivo of the TGF-beta signalling pathway in the maintenance of blood vessel integrity.	Vanderbilt Univ, Med Ctr, Nashville, TN 37240 USA; Univ Leicester, Dept Genet, Div Med Genet, Leicester, Leics, England; Univ Leicester, Dept Med, Div Med Genet, Leicester, Leics, England; Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; Indiana Univ, Sch Med, Indianapolis, IN USA	Vanderbilt University; University of Leicester; University of Leicester; Cincinnati Children's Hospital Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis	Loyd, JE (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37240 USA.	Jim.Loyd@mcmail.vanderbilt.edu; bill.nichols@chmcc.org; rtrembat@hgmp.mrc.ac.uk	Vilarino-Guell, Carles/D-8628-2011; Machado, Rajiv D./AAD-7813-2019; Morgan, Neil V/A-5475-2009	Vilarino-Guell, Carles/0000-0002-5612-5940; Machado, Rajiv D./0000-0001-9247-0744; Morgan, Neil V/0000-0001-6433-5692; Loyd, James/0000-0002-5042-7390; Trembath, Richard/0000-0003-0550-3400	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061997, R01HL048164] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61997, HL48164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beppu H, 1997, BIOCHEM BIOPH RES CO, V235, P499, DOI 10.1006/bbrc.1997.6816; BOTNEY MD, 1994, AM J PATHOL, V144, P286; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Gaine SP, 1998, LANCET, V352, P719, DOI 10.1016/S0140-6736(98)02111-4; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Hadano S, 1999, GENOMICS, V55, P106, DOI 10.1006/geno.1998.5637; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOYD JE, 1984, AM REV RESPIR DIS, V129, P194; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MACHADO RD, IN PRESS GENOMICS; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Massague J, 2000, GENE DEV, V14, P627; Morse JH, 1997, CIRCULATION, V95, P2603, DOI 10.1161/01.CIR.95.12.2603; Nichols WC, 1997, NAT GENET, V15, P277, DOI 10.1038/ng0397-277; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; THOMSON JR, IN PRESS J CLIN PATH; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944	23	1051	1107	1	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2000	26	1					81	84		10.1038/79226	http://dx.doi.org/10.1038/79226			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973254				2022-12-27	WOS:000089078000023
J	Shimohata, T; Nakajima, T; Yamada, M; Uchida, C; Onodera, O; Naruse, S; Kimura, T; Koide, R; Nozaki, K; Sano, Y; Ishiguro, H; Sakoe, K; Ooshima, T; Sato, A; Ikeuchi, T; Oyake, M; Sato, T; Aoyagi, Y; Hozumi, I; Nagatsu, T; Takiyama, Y; Nishizawa, M; Goto, J; Kanazawa, I; Davidson, I; Tanese, N; Takahashi, H; Tsuji, S				Shimohata, T; Nakajima, T; Yamada, M; Uchida, C; Onodera, O; Naruse, S; Kimura, T; Koide, R; Nozaki, K; Sano, Y; Ishiguro, H; Sakoe, K; Ooshima, T; Sato, A; Ikeuchi, T; Oyake, M; Sato, T; Aoyagi, Y; Hozumi, I; Nagatsu, T; Takiyama, Y; Nishizawa, M; Goto, J; Kanazawa, I; Davidson, I; Tanese, N; Takahashi, H; Tsuji, S			Expanded polyglutamine stretches interact with TAF(II)130, interfering with CREB-dependent transcription	NATURE GENETICS			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; NUCLEAR-LOCALIZATION; AGGREGATE FORMATION; MAMMALIAN-CELLS; ANDROGEN RECEPTOR; TRANSGENIC MICE; BINDING PROTEIN; DRPLA PROTEIN; PC12 CELLS; HUNTINGTIN	At least eight inherited neurodegenerative diseases are caused by expanded CAG repeats encoding polyglutamine (polyQ) stretches. Although cytotoxicities of expanded polyQ stretches are implicated, the molecular mechanisms of neurodegeneration remain unclear. We found that expanded! polyQ stretches preferentially bind to TAF(II)130, a coactivator involved in cAMP-responsive element binding protein (CREB)-dependent transcriptional activation, and strongly suppress CREB-dependent transcriptional activation. The suppression of CREB-dependent transcription and the cell death induced by polyQ stretches were restored by the co-expression of TAF(II)130. Our results indicate that interference of transcription by the binding of TAF(II)130 with expanded polyQ stretches is involved in the pathogenetic mechanisms underlying neurodegeneration.	Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan; Niigata Univ, Brain Res Inst, Dept Pathol, Niigata 951, Japan; Univ Tsukuba, TARA Ctr, Inst Appl Biochem, Tsukuba, Ibaraki, Japan; St Marianna Univ, Inst Med Sci, PRESTO JST, Kawasaki, Kanagawa, Japan; Hamamatsu Univ Sch Med, Dept Biochem, Shizuoka, Japan; Fujita Hlth Univ, Inst Comprehens Med Sci, Aichi, Japan; Jichi Med Sch, Dept Neurol, Jichi, Tochigi, Japan; Univ Tokyo, Fac Med, Inst Brain Res, Dept Neurol, Tokyo 113, Japan; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Strasbourg, France; NYU Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	Niigata University; Niigata University; University of Tsukuba; Japan Science & Technology Agency (JST); Saint Marianna University; Hamamatsu University School of Medicine; Fujita Health University; Jichi Medical University; University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; New York University; New York University	Tsuji, S (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan.	tsuji@cc.niigaa-u.ac.jp	Onodera, Osamu/K-7327-2013	Onodera, Osamu/0000-0003-3354-5472; Sato, Toshiya/0000-0001-7844-9930; Tanese, Naoko/0000-0002-1946-3211; Hozumi, Isao/0000-0003-0984-6291; Davidson, Irwin/0000-0001-5533-1171; OHSHIMA, Takayuki/0000-0002-1501-6430				Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DESOUZA EB, 1987, BRAIN RES, V437, P355, DOI 10.1016/0006-8993(87)91651-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koyano S, 1999, NEUROSCI LETT, V273, P117, DOI 10.1016/S0304-3940(99)00656-4; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Li SH, 1999, J NEUROSCI, V19, P5159; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Miyashita T, 1998, BIOCHEM BIOPH RES CO, V249, P96, DOI 10.1006/bbrc.1998.9096; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moulder KL, 1999, J NEUROSCI, V19, P705; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; Parker D, 1996, MOL CELL BIOL, V16, P694; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Sato A, 1999, HUM MOL GENET, V8, P997, DOI 10.1093/hmg/8.6.997; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Timmers HJLM, 1996, BRAIN RES, V728, P141, DOI 10.1016/0006-8993(96)00080-7; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	48	326	334	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					29	36		10.1038/79139	http://dx.doi.org/10.1038/79139			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973244				2022-12-27	WOS:000089078000013
J	Clarke, G; Goldberg, AFX; Vidgen, D; Collins, L; Ploder, L; Schwarz, L; Molday, LL; Rossant, J; Szel, A; Molday, RS; Birch, DG; McInnes, RR				Clarke, G; Goldberg, AFX; Vidgen, D; Collins, L; Ploder, L; Schwarz, L; Molday, LL; Rossant, J; Szel, A; Molday, RS; Birch, DG; McInnes, RR			Rom-1 is required for rod photoreceptor viability and the regulation of disk morphogenesis	NATURE GENETICS			English	Article							RDS MUTANT MICE; MEMBRANE MORPHOGENESIS; RETINAL DEGENERATION; RETINITIS-PIGMENTOSA; RIM PROTEIN; PERIPHERIN/RDS; CLONING; CELLS; CONE; LOCALIZATION	The homologous membrane proteins Rom-1 and peripherin-2 are localized to the disk rims of photoreceptor outer segments (OSs), where they associate as tetramers and larger oligomers(1-3). Disk rims are thought to be critical for disk morphogenesis, OS renewal(4) and the maintenance of OS structure(5), but the molecules which regulate these processes are unknown. Although peripherin-2 is known to be required for OS formation (because Prph2(-/-) mice do not form OSs; ref. 6), and mutations in RDS (the human homologue of Prph2) cause retinal degeneration(7), the relationship of Rom-1 to these processes is uncertain. Here we show that Rom1(-/-) mice form OSs in which peripherin-2 homotetramers are localized to the disk rims, indicating that peripherin-2 alone is sufficient for both disk and OS morphogenesis, The disks produced in Rom1(-/-) mice were large, rod OSs were highly disorganized (a phenotype which largely normalized with age) and rod photoreceptors died slowly by apoptosis. Furthermore, the maximal photoresponse of Rom1(-/-) rod photoreceptors was lower than that of controls. We conclude that Rom-1 is required for the regulation of disk morphogenesis and the viability of mammalian rod photoreceptors, and that mutations in human ROM1 may cause recessive photoreceptor degeneration.	Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Genet Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Semmelweis Univ, Sch Med, Electron Microscopy Lab, Dept Anat Histol & Embryol 2, Budapest, Hungary	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of British Columbia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Semmelweis University	McInnes, RR (corresponding author), Hosp Sick Children, Res Inst, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Birch, David/0000-0002-6594-2897	NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BASCOM RA, 1993, HUM MOL GENET, V2, P385, DOI 10.1093/hmg/2.4.385; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Kohl S, 1998, ACTA ANAT, V162, P75; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MICHON JJ, 1991, INVEST OPHTH VIS SCI, V32, P280; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; ROHLICH P, 1993, CURR EYE RES, V12, P935, DOI 10.3109/02713689309020400; Sambrook J., 2002, MOL CLONING LAB MANU; SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILLIAMS DS, 1991, BIOESSAYS, V13, P171, DOI 10.1002/bies.950130405; WILLIAMS DS, 1988, J COMP NEUROL, V272, P161, DOI 10.1002/cne.902720202; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	30	129	130	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					67	73		10.1038/75621	http://dx.doi.org/10.1038/75621			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802659				2022-12-27	WOS:000086884000019
J	DeChiara, TM; Kimble, RB; Poueymirou, WT; Rojas, J; Masiakowski, P; Valenzuela, DM; Yancopoulos, GD				DeChiara, TM; Kimble, RB; Poueymirou, WT; Rojas, J; Masiakowski, P; Valenzuela, DM; Yancopoulos, GD			Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development	NATURE GENETICS			English	Article							HORMONE-RELATED PEPTIDE; ENDOCHONDRAL BONE-FORMATION; MICE LACKING; PARATHYROID-HORMONE; NEUROMUSCULAR-JUNCTION; INDIAN HEDGEHOG; TIE2 RECEPTOR; IN-VIVO; EXPRESSION; ANGIOPOIETIN-1	Receptor tyrosine kinases often have critical roles in particular cell lineages by initiating signalling cascades in those lineages. Examples include the neural-specific TRK receptors(1), the VEGF and angiopoietin endothelial-specific receptors(2-8), and the muscle-specific MUSK receptor(9-11). Many lineage-restricted receptor tyrosine kinases were initially identified as 'orphans' homologous to known receptors, and only subsequently used to identify their unknown growth factors. Some receptor-tyrosine-kinase-like orphans still lack identified ligands as well as biological roles. Here we characterize one such orphan, encoded by Ror2 (ref, 12). We report that disruption of mouse Ror2 leads to profound skeletal abnormalities, with essentially all endochondrally derived bones foreshortened or misshapen, albeit to differing degrees. Further, we find that Ror2 is selectively expressed in the chondrocytes of all developing cartilage anlagen, where it essential during initial growth and patterning, as well as subsequently in the proliferating chondrocytes of mature growth plates, where it is required for normal expansion. Thus, Ror2 encodes a receptor-like tyrosine kinase that is selectively expressed in, and particularly important for, the chondrocyte lineage.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Regeneron	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.							BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1998, DEVELOPMENT, V125, P4977; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; ten Berge D, 1998, DEVELOPMENT, V125, P3831; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Vanky P, 1998, BONE, V22, P331, DOI 10.1016/S8756-3282(97)00286-X; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WILKIE AOM, 1995, CURR BIOL, V5, P500	30	181	195	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					271	274		10.1038/73488	http://dx.doi.org/10.1038/73488			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700181				2022-12-27	WOS:000085590600018
J	Rankin, CT; Bunton, T; Lawler, AM; Lee, SJ				Rankin, CT; Bunton, T; Lawler, AM; Lee, SJ			Regulation of left-right patterning in mice by growth/differentiation factor-1	NATURE GENETICS			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; NODAL EXPRESSION; BETA SUPERFAMILY; MOUSE; MEMBER; DIFFERENTIATION; EMBRYOS; PITX2; GENE	The transforming growth factor-beta (TGF-beta) superfamily encompasses a large group of structurally related polypeptides that are capable of regulating cell growth and differentiation in a wide range of embryonic and adult tissues(1). Growth/differentiation factor-1 (Gdf-1. encoded by Gdf1) is a TGF-beta family member of unknown function that was originally isolated from an early mouse embryo cDNA library(2) and is expressed specifically in the nervous system in late-stage embryos and adult mice(3). Here we show that at early stages of mouse development, Gdf1 is expressed initially throughout the embryo proper and then most prominently in the primitive node, ventral neural tube, and intermediate and lateral plate mesoderm. To examine its biological function, we generated a mouse line carrying a targeted mutation in Gdf1. Gdf1(-/-) mice exhibited a spectrum of defects related to left-right axis formation, including visceral situs inversus, right pulmonary isomerism and a range of cardiac anomalies. In most Gdf1(-/-) embryos, the expression of Ebaf (formerly lefty-1) in the left side of the floor plate and Leftb (formerly lefty-2), nodal and Pitx2 in the left lateral plate mesoderm was absent, suggesting that Gdf1 acts upstream of these genes either directly or indirectly to activate their expression. Our findings suggest that Gdf1 acts early in the pathway of gene activation that leads to the establishment of left-right asymmetry.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Comparat Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Lee, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035887, R01HD030740] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Hummel K. P., 1959, Journal of Heredity, V50, P9; Ivemark B., 1955, ACTA PAEDIATR, V44, P590; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; Kosaki K, 1998, SEMIN CELL DEV BIOL, V9, P89, DOI 10.1006/scdb.1997.0187; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	21	168	174	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					262	265		10.1038/73472	http://dx.doi.org/10.1038/73472			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700179				2022-12-27	WOS:000085590600016
J	Wu, GQ; Markowitz, GS; Li, L; D'Agati, VD; Factor, SM; Geng, L; Tibara, S; Tuchman, J; Cai, YQ; Park, JH; van Adelsberg, J; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S				Wu, GQ; Markowitz, GS; Li, L; D'Agati, VD; Factor, SM; Geng, L; Tibara, S; Tuchman, J; Cai, YQ; Park, JH; van Adelsberg, J; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S			Cardiac defects and renal failure in mice with targeted mutations in Pkd2	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; HEART; GENE; ENCODES; PROTEIN; MOUSE	PKD2, mutations in which cause autosomal dominant polycystic kidney disease(1) (ADPKD), encodes an integral membrane glycoprotein(2) with similarity to calcium channel subunits(1,3). We induced two mutations in the mouse homologue Pkd2 (ref. 4): an unstable allele (WS25; hereafter denoted pkd2(WS25)) that can undergo homologous-recombination-based somatic rearrangement to form a null allele; and a true null mutation (WS183; hereafter denoted Pkd2(-)). We examined these mutations to understand the function of polycystin-2, the protein product of Pkd2, and to provide evidence that kidney and liver cyst formation associated with Pkd2 deficiency occurs by a two-hit mechanism(4-9). Pkd2(-/-) mice die in utero between embryonic day (E) 13.5 and parturition. They have structural defects in cardiac septation and cyst formation in maturing nephrons and pancreatic ducts. Pancreatic ductal cysts also occur in adult pkd2(WS25/-) mice, suggesting that this clinical manifestation of ADPKD also occurs by a two-hit mechanism. As in human ADPKD, formation of kidney cysts in adult pkd2(WS25/-) mice is associated with renal failure and early death (median survival, 65 weeks versus 94 weeks for controls). Adult Pkd2(+/-) mice have intermediate survival in the absence of cystic disease or renal failure, providing the first indication of a deleterious effect of haploinsufficiency at Pkd2 on long-term survival. Our studies advance our understanding of the function of polycystin-2 in development and our mouse models recapitulate the complex human ADPKD phenotype.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University; Columbia University; Yale University	Somlo, S (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06510 USA.	stefan.somlo@yale.edu	Kucherlapati, Raju/ABC-8807-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051041, R01DK054053] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1 DK54053, R01 DK051041] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardaji A, 1998, AM J KIDNEY DIS, V32, P970, DOI 10.1016/S0272-6386(98)70071-X; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Clark TG, 1999, DEVELOPMENT, V126, P2631; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gittes GK, 1996, DEVELOPMENT, V122, P439; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Hateboer N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Pei Y, 1999, J AM SOC NEPHROL, V10, P1524; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; Stockelman MG, 1998, AM J PHYSIOL-RENAL, V275, pF154, DOI 10.1152/ajprenal.1998.275.1.F154; Torra R, 1999, AM J HUM GENET, V65, P345, DOI 10.1086/302501; Torra R, 1997, CLIN NEPHROL, V47, P19; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	28	271	280	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					75	78		10.1038/71724	http://dx.doi.org/10.1038/71724			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615132				2022-12-27	WOS:000084609200020
J	Guarente, L				Guarente, L			Diverse and dynamic functions of the Sir silencing complex	NATURE GENETICS			English	Article							CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; RIBOSOMAL DNA; YEAST KU; PROTEIN; TELOMERES; GENE; REGULATOR; END	The yeast Sir protein complex has been implicated in transcriptional silencing and suppression of recombination. The Sir complex creates structured chromosomal domains at telomeres, silent mating-type loci and ribosomal DNA to invoke these functional states. Mechanistic insights into the function of Sir proteins implicate a range of activities in yeast, including repair of DNA double-strand breaks, regulation of the mitotic cell cycle, meiosis and ageing. I speculate that the Sir proteins may be capable of enzymatic modification of chromatin and other substrates, which enables them to carry out a broad range of cellular functions.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu						Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; Bi X, 1997, MOL CELL BIOL, V17, P7077, DOI 10.1128/MCB.17.12.7077; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CRAIG IW, 1994, J INHERIT METAB DIS, V17, P391, DOI 10.1007/BF00711355; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Park PU, 1999, MOL CELL BIOL, V19, P3848; Perez-Martin J, 1999, EMBO J, V18, P2580, DOI 10.1093/emboj/18.9.2580; RINE J, 1987, GENETICS, V116, P9; Rothstein R, 1999, NAT GENET, V22, P4, DOI 10.1038/8705; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sherman JM, 1999, MOL BIOL CELL, V10, P3045, DOI 10.1091/mbc.10.9.3045; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Tsang AW, 1996, J BACTERIOL, V178, P7016, DOI 10.1128/jb.178.23.7016-7019.1996; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	52	127	137	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					281	285		10.1038/15458	http://dx.doi.org/10.1038/15458			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545947				2022-12-27	WOS:000083792200015
J	Tao, WF; Zhang, S; Turenchalk, GS; Stewart, RA; St John, MAR; Chen, WL; Xu, T				Tao, WF; Zhang, S; Turenchalk, GS; Stewart, RA; St John, MAR; Chen, WL; Xu, T			Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity	NATURE GENETICS			English	Article							PROTEIN-KINASE; GENETIC MOSAICS; CYCLIN-A; ENCODES; CANCER; CELLS; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; TRANSITION	We have previously used mosaic flies to screen for tumour suppressors or negative regulators of cell proliferation(1). The cellular composition of these flies resembles that of cancer patients who are chimaeric individuals carrying a small number of mutated somatic cells. One of the genes we identified is the large tumour suppressor gene, lats (also known as wts), which encodes a putative serine/threonine kinase(1,2). Somatic cells mutant for lats undergo extensive proliferation and form large tumours in many tissues in mosaic adults. Homozygous mutants for various lats alleles display a range of developmental defects including embryonic lethality(1). Although many tumour suppressors have been identified in Drosophila melanogaster(3-7) it is not clear whether these fly genes are directly relevant to tumorigenesis in mammals. Here, we have isolated mammalian homologues of Drosophila lats. Human LATS1 suppresses tumour growth and rescues all developmental defects, including embryonic lethality in flies. In mammalian cells, LATS1 is phosphorylated in a cell-cycle-dependent manner and complexes with CDC2 in early mitosis. LATS1-associated CDC2 has no mitotic cyclin partner and no kinase activity for histone H1. Furthermore, lats mutant cells in Drosophila abnormally accumulate cyclin A. These biochemical observations indicate that LATS is a novel negative regulator of CDC2/cyclin A, a finding supported by genetic data in Drosophila demonstrating that lats specifically interacts with cdc2 and cyclin A.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Biol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Cell Biol, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, 295 Congress Ave, New Haven, CT 06536 USA.	Tian.Xu@yale.edu	Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NCI NIH HHS [R01CA69408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY I, 1994, SURG ONCOL, V3, P153, DOI 10.1016/0960-7404(94)90044-2; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Bryant P.J, 1978, GENETICS BIOL DROSOP; CLEGG NJ, 1993, GENOME, V36, P676, DOI 10.1139/g93-091; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, DNA CLONING PRACTICA, P170; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; MAHONEY PA, 1991, CELL, V67, P583; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; StJohn MAR, 1997, AM J HUM GENET, V61, P1006, DOI 10.1086/301619; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053; ZINZAR SN, 1971, TRANSPLANTATION, V11, P499, DOI 10.1097/00007890-197105000-00015	30	226	245	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					177	181		10.1038/5960	http://dx.doi.org/10.1038/5960			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988268				2022-12-27	WOS:000078399500018
J	Marsh, DJ; Hollopeter, G; Huszar, D; Laufer, R; Yagaloff, KA; Fisher, SL; Burn, P; Palmiter, RD				Marsh, DJ; Hollopeter, G; Huszar, D; Laufer, R; Yagaloff, KA; Fisher, SL; Burn, P; Palmiter, RD			Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides	NATURE GENETICS			English	Article							MOLECULAR-CLONING; LEPTIN DEFICIENCY; OBESITY; GENE; IDENTIFICATION; NEUROPEPTIDE; ANTAGONIST; PROTEIN	Mutations reducing the functional activity of leptin(1,2), the leptin receptor(3,4), alpha-melanocyte stimulating hormone(5) (alpha-MSH) and the melanocortin-4 receptor(6) (Mc4r) all lead to obesity in mammals. Moreover, mutant mice that ectopically express either agouti(7) (Aula mice) or agouti-related protein(8) (Agrp), antagonists of melanocortin signalling(8,9), become obese. These data suggest that alpha-MSH signalling transduced by Mc4r tonically inhibits feeding; however, it is not known to what extent this pathway mediates leptin signalling. We show here that Mc4r-deficient (Mc4r(-/-)) mice do not respond to the anorectic actions of MTII, an MSH-like agonist, suggesting that alpha-MSH inhibits feeding primarily by activating Mc4r. Obese Mc4(-/-) mice do not respond significantly to the inhibitory effects of leptin on feeding, whereas non-obese Mc4r(-/-) mice do. These data demonstrate that melanocortin signalling transduced by Mc4r is not an exclusive target of leptin action and that factors resulting from obesity contribute to leptin resistance. Leptin resistance of obese Mc4r(-/-) mice does not prevent their response to the anorectic actions of ciliary neurotrophic factor (CNTF), corticotropin releasing factor (CRF), or urocortin; or the orexigenic actions of neuropeptide Y (NPY) or peptide YY (PYY), indicating that these neuromodulators act independently or downstream of Mdr signalling.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Millennium Pharmaceut, Cambridge, MA 02139 USA; Ist Ric Biol Mol P Angeletti, IRBM, I-00040 Rome, Italy; Hoffmann La Roche, Dept Metab Dis, Nutley, NJ 07110 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Merck & Company; Roche Holding	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	palmiter@u.washington.edu	Laufer, Ralph/H-9336-2013					Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Costa A, 1997, NEUROREPORT, V8, P1131, DOI 10.1097/00001756-199703240-00014; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HOLLOPETER G, IN PRESS REGUL PEPT; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	437	458	1	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					119	122		10.1038/5070	http://dx.doi.org/10.1038/5070			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916804				2022-12-27	WOS:000077960700022
J	Bitner-Glindzicz, M; Lindley, KJ; Rutland, P; Blaydon, D; Smith, VV; Milla, PJ; Hussain, K; Furth-Lavi, J; Cosgrove, KE; Shepherd, RM; Barnes, PD; O'Brien, RE; Farndon, PA; Sowden, J; Liu, XZ; Scanlan, MJ; Malcolm, S; Dunne, MJ; Aynsley-Green, A; Glaser, B				Bitner-Glindzicz, M; Lindley, KJ; Rutland, P; Blaydon, D; Smith, VV; Milla, PJ; Hussain, K; Furth-Lavi, J; Cosgrove, KE; Shepherd, RM; Barnes, PD; O'Brien, RE; Farndon, PA; Sowden, J; Liu, XZ; Scanlan, MJ; Malcolm, S; Dunne, MJ; Aynsley-Green, A; Glaser, B			A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene	NATURE GENETICS			English	Article							RECTIFYING POTASSIUM CHANNEL; SYNDROME TYPE-I; BETA-CELLS; HYPOGLYCEMIA; INFANCY; MAPS; LOCALIZATION; EXPRESSION; PROTEIN; MEMBRANE	Usher syndrome type 1 describes the association of profound, congenital sensorineural deafness, vestibular hypofunction and childhood onset retinitis pigmentosa(1). It is an autosomal recessive condition and is subdivided on the basis of linkage analysis into types 1A through 1E (refs 2-6), Usher type 1C maps to the region containing the genes ABCC8 and KCNJ11 (encoding components of ATP-sensitive K+ (KATP) channels), which may be mutated in patients with hyperinsulinism(7-10). We identified three individuals from two consanguineous families with severe hyperinsulinism, profound congenital sensorineural deafness, enteropathy and renal tubular dysfunction. The molecular basis of the disorder is a homozygous 122-kb deletion of 11p14-15. which includes part of ABCC8 and overlaps with the locus for Usher syndrome type 1C and DFNB18 (ref. 11). The centromeric boundary of this deletion includes part of a gene shown to be mutated in families with type 1C Usher syndrome, and is hence assigned the name USH1C. The pattern of expression of the USH1C protein is consistent with the clinical features exhibited by individuals with the contiguous gene deletion and with isolated Usher type 1C.	Inst Child Hlth, Dept Clin & Mol Genet, London, England; Great Ormond St Hosp Children NHS Trust, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Dept Gastroenterol, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Dept Histopathol, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, London Ctr Paediat Endocrinol & Metab, London WC1N 3JH, England; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Endocrinol & Metab, IL-91010 Jerusalem, Israel; Univ Sheffield, Inst Mol Physiol, Western Bank, Sheffield, S Yorkshire, England; Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield, S Yorkshire, England; Birmingham Womens Hosp, Clin Genet Unit, Birmingham, W Midlands, England; Inst Child Hlth, Dev Biol Unit, London, England; Med Coll Virginia, Dept Human Genet, Richmond, VA USA; Mem Sloan Kettering Canc Ctr, New York Branch, Ludwig Inst Canc Res, New York, NY 10021 USA	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Hebrew University of Jerusalem; University of Sheffield; University of Sheffield; Birmingham Women's Hospital; University of London; University College London; Virginia Commonwealth University; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Bitner-Glindzicz, M (corresponding author), Inst Child Hlth, Dept Clin & Mol Genet, 30 Guilford St, London, England.		hussain, khalid/C-5730-2008; Glaser, Benjamin/F-8411-2017; Bitner-Glindzicz, Maria/A-4231-2009; Smith, Virpi/C-2159-2008	Glaser, Benjamin/0000-0003-4711-5000; Blaydon, Diana/0000-0002-9998-2563; Cosgrove, Karen/0000-0002-5162-0985; Sowden, Jane/0000-0003-0937-2479	NIDCD NIH HHS [DC04530] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC004530] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Glaser B, 1999, TRENDS ENDOCRIN MET, V10, P55, DOI 10.1016/S1043-2760(98)00102-7; Hibino H, 1997, J NEUROSCI, V17, P4711; Higgins MJ, 1998, GENOME RES, V8, P57, DOI 10.1101/gr.8.1.57; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Ishii M, 1997, J NEUROSCI, V17, P7725; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; Kane C, 1997, J CLIN INVEST, V100, P1888, DOI 10.1172/JCI119718; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KLOEPFER HW, 1966, LARYNGOSCOPE, V76, P850; Kobayashi I, 1999, GASTROENTEROLOGY, V117, P823, DOI 10.1016/S0016-5085(99)70340-9; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; PELIAS MZ, 1998, CELL GENET, V47, P111; Scanlan MJ, 1999, BBA-GENE STRUCT EXPR, V1445, P39, DOI 10.1016/S0167-4781(99)00033-0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	25	236	238	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					56	60		10.1038/79178	http://dx.doi.org/10.1038/79178			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973248				2022-12-27	WOS:000089078000017
J	Smith, AN; Skaug, J; Choate, KA; Nayir, A; Bakkaloglu, A; Ozen, S; Hulton, SA; Sanjad, SA; Al-Sabban, EA; Lifton, RP; Scherer, SW; Karet, FE				Smith, AN; Skaug, J; Choate, KA; Nayir, A; Bakkaloglu, A; Ozen, S; Hulton, SA; Sanjad, SA; Al-Sabban, EA; Lifton, RP; Scherer, SW; Karet, FE			Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing	NATURE GENETICS			English	Article							H+-ATPASE; GENE; HYPERTENSION; LINKAGE; VPH1P	The multi-subunit H+-ATPase pump is present at particularly high density on the apical (luminal) surface of alpha-intercalated cells of the cortical collecting duct of the distal nephron, where vectorial proton transport is required for urinary acidification(1). The complete subunit composition of the apical ATPase, however, has not been fully agreed upon. Functional failure of alpha-intercalated cells results in a group of disorders, the distal renal tubular acidoses (dRTA), whose features include metabolic acidosis accompanied by disturbances of potassium balance, urinary calcium solubility, bone physiology and growth(2). Mutations in the gene encoding the B-subunit of the apical pump (ATP6B1) cause dRTA accompanied by deafness(3). We previously localized a gene for dRTA with preserved hearing to 7q33-34 (ref. 4). We report here the identification of this gene, ATP6N1B, which encodes an 840 amino acid novel kidney-specific isoform of ATP6N1A, the 116-kD non-catalytic accessory subunit of the proton pump. Northern-blot analysis demonstrated ATP6N1B expression in kidney but not other main organs. Immunofluorescence studies in human kidney cortex revealed that ATP6N1B localizes almost exclusively to the apical surface of alpha-intercalated cells. We screened nine dRTA kindreds with normal audiometry that linked to the ATP6N1B locus, and identified different homozygous mutations in ATP6N1B in eight. These include nonsense, deletion and splice-site changes, all of which will truncate the protein. Our findings identify a new kidney-specific proton pump 116-kD accessory subunit that is highly expressed in proton-secreting cells in the distal nephron, and illustrate its essential role in normal vectorial acid transport into the urine by the kidney.	Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Yale Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Istanbul Univ, Dept Pediat Nephrol, Istanbul, Turkey; Univ Hacettepe, Dept Pediat Nephrol, TR-06100 Ankara, Turkey; Birmingham Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England; Amer Univ Beirut, Dept Pediat, Med Ctr, Beirut, Lebanon; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia	University of Cambridge; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Istanbul University; Hacettepe University; University of Birmingham; American University of Beirut; King Faisal Specialist Hospital & Research Center	Karet, FE (corresponding author), Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England.		OZEN, SEZA/I-9096-2013; Scherer, Stephen W./B-3785-2013; NAYIR, AHMET NEVZAT/A-9276-2019	Scherer, Stephen W./0000-0002-8326-1999; Karet, Fiona/0000-0002-2457-2869				Bastani B, 1996, MINER ELECTROL METAB, V22, P396; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BRODY LC, 1995, GENOMICS, V25, P238, DOI 10.1016/0888-7543(95)80131-5; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751; Karet FE, 1999, AM J HUM GENET, V65, P1656, DOI 10.1086/302679; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Mansfield TA, 1997, NAT GENET, V16, P202, DOI 10.1038/ng0697-202; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; PENG SB, 1994, J BIOL CHEM, V269, P17262; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X	21	320	340	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					71	75		10.1038/79208	http://dx.doi.org/10.1038/79208			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973252				2022-12-27	WOS:000089078000021
J	Delepine, M; Nicolino, M; Barrett, T; Golamaully, M; Lathrop, GM; Julier, C				Delepine, M; Nicolino, M; Barrett, T; Golamaully, M; Lathrop, GM; Julier, C			EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome	NATURE GENETICS			English	Article							DIABETES SUSCEPTIBILITY GENES; PANCREATIC EIF-2-ALPHA KINASE; GENOME-WIDE SEARCH; PAX4 GENE; MELLITUS; GLUCOSE; PROTEIN; LOCUS; CELLS; PEK	Wolcott-Rallison syndrome (WRS) is a rare, autosomal recessive disorder characterized by permanent neonatal or early infancy insulin-dependent diabetes. Epiphyseal dysplasia, osteoporosis and growth retardation occur at a later age. Other frequent multisystemic manifestations include hepatic and renal dysfunction, mental retardation and cardiovascular abnormalities(1-5). On the basis of two consanguineous families, we mapped WRS to a region of less than 3 cM on chromosome 2p12, with maximal evidence of linkage and homozygosity at 4 microsatellite markers within an interval of approximately 1 cM. The gene encoding the eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) resides in this interval; thus we explored it as a candidate. We identified distinct mutations of EIF2AK3 that segregated with the disorder in each of the families, The first mutation produces a truncated protein in which the entire catalytic domain is missing. The other changes an amino acid, located in the catalytic domain of the protein, that is highly conserved among kinases from the same subfamily. Our results provide evidence for the role of EIF2AK3 in WRS, The identification of this gene may provide insight into the understanding of the more common forms of diabetes and other pathologic manifestations of WRS.	Inst Pasteur, Lab Genet Predisposit Malad Infect, Paris, France; Wellcome Trust Ctr Human Genet, Oxford, England; Birmingham Childrens Hosp, Dept Endocrinol, Birmingham, W Midlands, England; Hop Debrousse, Lyon, France; Ctr Natl Genotypage, Evry, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham; CHU Lyon; CEA; UDICE-French Research Universities; Universite Paris Saclay	Julier, C (corresponding author), Inst Pasteur, Lab Genet Predisposit Malad Infect, Paris, France.	cjulier@pasteur.fr	JULIER, Cécile/M-9824-2017; Barrett, Timothy/F-1682-2010	JULIER, Cécile/0000-0002-1538-0240; Barrett, Timothy/0000-0002-6873-0750				ALGAZALI LI, 1995, CLIN DYSMORPHOL, V4, P227; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bonthron DT, 1998, J MED GENET, V35, P288, DOI 10.1136/jmg.35.4.288; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DETTMAN C, 1972, J PEDIATR-US, V80, P292, DOI 10.1016/S0022-3476(72)80596-1; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Froguel P, 1999, TRENDS ENDOCRIN MET, V10, P142, DOI 10.1016/S1043-2760(98)00134-9; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GOUMY P, 1980, ARCH FR PEDIATR, V37, P323; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; Hayes SE, 1999, CYTOGENET CELL GENET, V86, P327, DOI 10.1159/000015328; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Mein CA, 1998, NAT GENET, V19, P297, DOI 10.1038/991; NICOLINO PM, 1998, HORM RES, V50, pA215; Pratley RE, 1998, J CLIN INVEST, V101, P1757, DOI 10.1172/JCI1850; Rosenblum BB, 1997, NUCLEIC ACIDS RES, V25, P4500, DOI 10.1093/nar/25.22.4500; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stewart FJ, 1996, CLIN GENET, V49, P152; STOSS H, 1982, EUR J PEDIATR, V138, P120, DOI 10.1007/BF00441137; Thornton CM, 1997, PEDIATR PATHOL LAB M, V17, P487, DOI 10.1080/107710497174778; Winter WE, 1999, ENDOCRIN METAB CLIN, V28, P765, DOI 10.1016/S0889-8529(05)70101-8	30	593	620	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					406	409		10.1038/78085	http://dx.doi.org/10.1038/78085			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932183				2022-12-27	WOS:000088615000014
J	Rogner, UC; Spyropoulos, DD; Le Novere, N; Changeux, JP; Avner, P				Rogner, UC; Spyropoulos, DD; Le Novere, N; Changeux, JP; Avner, P			Control of neurulation by the nucleosome assembly protein-1-like 2	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; NEURAL-TUBE DEFECTS; HISTONE CHAPERONE; MUTANT MOUSE; IN-VITRO; PROLIFERATION; NEURONS; GENE; DIFFERENTIATION; INHERITANCE	Neurulation is a complex process of histogenesis involving the precise temporal and spatial organization of gene expression(1,2) Genes influencing neurulation include proneural genes determining primary cell fate, neurogenic genes involved in lateral inhibition pathways and genes controlling the frequency of mitotic events. This is reflected in the aetiology and genetics of human and mouse neural tube defects, which are of both multifactorial and multigenic origin(3). The X-linked gene Nap1l2, specifically expressed in neurons, encodes a protein that is highly similar to the nucleosome assembly (NAP) and SET proteins. We inactivated Nap1l2 in mice by gene targeting, leading to embryonic lethality from mid-gestation onwards. Surviving mutant chimaeric embryos showed extensive surface ectoderm defects as well as the presence of open neural tubes and exposed brains similar to those observed in human spina bifida and anencephaly. These defects correlated with an overproduction of neuronal precursor cells. Protein expression studies showed that the Nap1l2 protein binds to condensing chromatin during S phase and in apoptotic cells, but remained cytoplasmic during G1 phase. Nap1l2 therefore likely represents a class of tissue-specific factors interacting with chromatin to regulate neuronal cell proliferation.	Inst Pasteur, CNRS, URA 1947, Paris 15, France; Inst Pasteur, CNRS, URA 1284, Paris 15, France; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Medical University of South Carolina	Rogner, UC (corresponding author), Inst Pasteur, CNRS, URA 1947, Paris 15, France.	urogner@pasteur.fr	Le Novère, Nicolas/F-9973-2010	Le Novère, Nicolas/0000-0002-6309-7327; Rogner, Ute Christine/0000-0001-9993-269X				Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; COPP AJ, 1994, DEV BIOL, V165, P20, DOI 10.1006/dbio.1994.1230; EMERY AEH, 1986, METHODOLOGY MED GENE, V58; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GARDNER RL, 1968, NATURE, V220, P596, DOI 10.1038/220596a0; HOGAN B, 1994, MANIPULATING MOUSE E, P373; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Ito T, 1996, MOL CELL BIOL, V16, P3112; JENSSON O, 1988, J MED GENET, V25, P227, DOI 10.1136/jmg.25.4.227; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kerszberg M, 1998, BIOESSAYS, V20, P758, DOI 10.1002/(SICI)1521-1878(199809)20:9<758::AID-BIES9>3.0.CO;2-C; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NARUSE I, 1995, PROG NEUROBIOL, V47, P135, DOI 10.1016/0301-0082(95)00024-P; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; Papenbrock T, 1998, DEV DYNAM, V212, P540, DOI 10.1002/(SICI)1097-0177(199808)212:4<540::AID-AJA7>3.0.CO;2-H; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; ROUGEULLE C, 1994, MAMM GENOME, V5, P416, DOI 10.1007/BF00357001; Rougeulle C, 1996, HUM MOL GENET, V5, P41, DOI 10.1093/hmg/5.1.41; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; WILSON DB, 1974, J COMP NEUROL, V154, P249, DOI 10.1002/cne.901540303; Wilson PA, 1997, NEURON, V18, P699, DOI 10.1016/S0896-6273(00)80311-6; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827	30	72	74	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					431	435		10.1038/78124	http://dx.doi.org/10.1038/78124			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932189				2022-12-27	WOS:000088615000020
J	Takahashi, Y; Koizumi, K; Takagi, A; Kitajima, S; Inoue, T; Koseki, H; Saga, Y				Takahashi, Y; Koizumi, K; Takagi, A; Kitajima, S; Inoue, T; Koseki, H; Saga, Y			Mesp2 initiates somite segmentation through the Notch signalling pathway	NATURE GENETICS			English	Article							PARAXIAL MESODERM; DELTA-HOMOLOG; XENOPUS EMBRYOS; LUNATIC FRINGE; MOUSE GENE; EXPRESSION; DROSOPHILA; DII1; MICE; PRESENILIN	The Notch-signalling pathway is important in establishing metameric pattern during somitogenesis. In mice, the lack of either of two molecules involved in the Notch-signalling pathway. Mesp2 or presenilin-1 (Ps1), results in contrasting phenotypes: caudalized versus rostralized vertebra. Here we adopt a genetic approach to analyse the molecular mechanism underlying the establishment of rostro-caudal polarity in somites. By focusing on the fact that expression of a Notch ligand, DII1, is important for prefiguring somite identity, we found that Mesp2 initiates establishment of rostro-caudal polarity by controlling two Notch-signalling pathways. Initially, Mesp2 activates a Ps1-independent Notch-signalling cascade to suppress DII1 expression and specify the rostral half of the somite. Ps1-mediated Notch-signalling is required to induce DII1 expression in the caudal half of the somite. Therefore, Mesp2- and Ps1-dependent activation of Notch-signalling pathways might differentially regulate DII1 expression, resulting in the establishment of the rostro-caudal polarity of somites.	Natl Inst Hlth Sci, Cellular & Mol Toxicol Div, Setagaya Ku, Tokyo, Japan; Chiba Univ, Sch Med, Dept Dev Biol, Chuo Ku, Chiba, Japan	National Institute of Health Sciences - Japan; Chiba University	Koseki, H (corresponding author), Natl Inst Hlth Sci, Cellular & Mol Toxicol Div, Setagaya Ku, Tokyo, Japan.		Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854				Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DELAMO FF, 1992, DEVELOPMENT, V115, P737; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; GOLDSTEIN RS, 1992, DEVELOPMENT, V116, P441; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Neidhardt LM, 1997, DEV GENES EVOL, V207, P330, DOI 10.1007/s004270050120; OKA C, 1995, DEVELOPMENT, V121, P3291; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Sparrow DB, 1998, DEVELOPMENT, V125, P2041; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; Tam PPL, 2000, CURR TOP DEV BIOL, V47, P1; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	29	162	170	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					390	396		10.1038/78062	http://dx.doi.org/10.1038/78062			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932180				2022-12-27	WOS:000088615000011
J	Barna, M; Hawe, N; Niswander, L; Pandolfi, PP				Barna, M; Hawe, N; Niswander, L; Pandolfi, PP			Plzf regulates limb and axial skeletal patterning	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; ALPHA RAR-ALPHA; HOMEOTIC TRANSFORMATIONS; RETINOIC ACID; TRANSCRIPTIONAL REPRESSOR; SONIC-HEDGEHOG; HOX GENES; MISEXPRESSION; MICE	The promyelocytic leukaemia zinc finger (Plzf) protein (encoded by the gene Zfp 145) belongs to the POZ/zinc-finger family of transcription factors. Here we generate Zfp 145(-/-) mice and show that Plzf is essential for patterning of the limb and axial skeleton. Plzf inactivation results in patterning defects affecting all skeletal structures of the limb, including homeotic transformations of anterior skeletal elements into posterior structures. We demonstrate that Plzf acts as a growth-inhibitory and pro-apoptotic factor in the limb bud. The expression of members of the abdominal b (Abdb) Hox gene complex, as well as genes encoding bone morphogenetic proteins (Bmps). is altered in the developing limb of Zfp 145(-/-) mice. Plzf regulates the expression of these genes in the absence of aberrant polarizing activity and independently of known patterning genes. Zfp145(-/-) mice also exhibit anterior-directed homeotic transformation throughout the axial skeleton with associated alterations in Hox gene expression. Plzf is therefore a mediator of anterior-to-posterior (AP) patterning in both the axial and appendicular skeleton and acts as a regulator of Hox gene expression.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Howard Hughes Med Inst, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594; O'Connor, Nicola/0000-0003-1981-3055	NATIONAL CANCER INSTITUTE [R01CA071692, P30CA008748, R37CA071692] Funding Source: NIH RePORTER; NCI NIH HHS [CA71692, CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Goff DJ, 1997, DEVELOPMENT, V124, P627; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Knezevic V, 1997, DEVELOPMENT, V124, P4523; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Pearse RV, 1998, J EXP ZOOL, V282, P677, DOI 10.1002/(SICI)1097-010X(19981215)282:6<677::AID-JEZ4>3.0.CO;2-F; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	32	231	240	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					166	172		10.1038/76014	http://dx.doi.org/10.1038/76014			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835630				2022-12-27	WOS:000087459200014
J	Bielinska, B; Blaydes, SM; Buiting, K; Yang, T; Krajewska-Walasek, M; Horsthemke, B; Brannan, CI				Bielinska, B; Blaydes, SM; Buiting, K; Yang, T; Krajewska-Walasek, M; Horsthemke, B; Brannan, CI			De novo deletions of SNRPN exon 1 in early human and mouse embryos result in a paternal to maternal imprint switch	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; SYNDROME CRITICAL REGION; ANGELMAN-SYNDROMES; TARGETED MUTATION; DNA METHYLATION; EXPRESSED GENE; NECDIN GENE; TRANSCRIPT; LETHALITY; 15Q11-13	Prader-Willi syndrome (PWS) is a neurogenetic disease characterized by infantile hypotonia, gonadal hypoplasia, obsessive behaviour and neonatal feeding difficulties followed by hyperphagia, leading to profound obesity(1). PWS is due to a lack of paternal genetic information at 15q11-q13 (ref. 2). Five imprinted, paternally expressed genes map to the PWS region, MKRN3 (ref. 3), NDN (ref. 4), NDNL1 (ref. 5), SNRPN (refs 6-8) and IPW (ref. 9), as well as two poorly characterized framents designated PAR-1 and PAR-5 (ref. 10). Imprinting of this region involves a bipartite 'imprinting centre' (IC), which overlaps SNRPN (refs 10,11). Deletion of the SNRPN promoter/exon 1 region (the PWS IC element) appears to impair the establishment of the paternal imprint in the male germ line and leads to PWS. Here we report a PWS family in which the father is mosaic for an IC deletion on his paternal chromosome. The deletion chromosome has acquired a maternal methylation imprint in his somatic cells. We have made identical findings in chimaeric mice generated from two independent embryonic stem (ES) cell lines harbouring a similar deletion. Our studies demonstrate that the PWS IC element is not only required for the establishment of the paternal imprint, but also for its postzygotic maintenance.	Univ Essen Gesamthsch, Inst Human Genet, Essen, Germany; Childrens Mem Hlth Inst, Dept Genet, Warsaw, Poland; Univ Florida, Coll Med, Inst Brain, Gainesville, FL USA; Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Mol Genet & Microbiol, Gainesville, FL USA	University of Duisburg Essen; Children's Memorial Health Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Horsthemke, B (corresponding author), Univ Essen Gesamthsch, Inst Human Genet, Essen, Germany.			Krajewska-Walasek, Malgorzata/0000-0001-8721-210X	NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09126] Funding Source: Medline; NIGMS NIH HHS [GM55272] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blaydes SM, 1999, MAMM GENOME, V10, P549, DOI 10.1007/s003359901042; Boccaccio I, 1999, HUM MOL GENET, V8, P2497, DOI 10.1093/hmg/8.13.2497; Buiting K, 1998, AM J HUM GENET, V63, P170, DOI 10.1086/301935; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; BUITING K, 1994, HUM MOL GENET, V3, P893, DOI 10.1093/hmg/3.6.893; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; DITTRICH B, 1992, HUM GENET, V90, P313; DITTRICH B, 1994, HUM GENET, V94, P583; Farber C, 1999, HUM MOL GENET, V8, P337, DOI 10.1093/hmg/8.2.337; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; Hogan B, 1994, MANIPULATING MOUSE E; HOLM VA, 1993, PEDIATRICS, V91, P398; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jong MTC, 1999, HUM MOL GENET, V8, P795, DOI 10.1093/hmg/8.5.795; Jong MTC, 1999, HUM MOL GENET, V8, P783, DOI 10.1093/hmg/8.5.783; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schumacher A, 1998, NAT GENET, V19, P324, DOI 10.1038/1211; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; ZECHNIGK M, 1997, EUR J HUM GENET, V5, P94	29	124	124	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					74	78		10.1038/75629	http://dx.doi.org/10.1038/75629			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802660				2022-12-27	WOS:000086884000020
J	Saxton, TM; Ciruna, BG; Holmyard, D; Kulkarni, S; Harpal, K; Rossant, J; Pawson, T				Saxton, TM; Ciruna, BG; Holmyard, D; Kulkarni, S; Harpal, K; Rossant, J; Pawson, T			The SH2 tyrosine phosphatase Shp2 is required for mammalian limb development	NATURE GENETICS			English	Article							VERTEBRATE LIMB; CELL-ADHESION; MOUSE EMBRYOS; INDUCTION; BUD; EXPRESSION; CHIMERAS; MUTANT; BINDS; FGF8	The tyrosine phosphatase Shp2 is recruited into tyrosine-kinase signalling pathways through binding of its two amino-terminal SH2 domains to specific phosphotyrosine motifs, concurrent with its re-localization and stimulation of phosphatase activity(1) Shp2 can potentiate signalling through the MAP-kinase pathway(2-6) and is required during early mouse development for gastrulation(4,7). Chimaeric analysis can identify, by study of phenotypically normal embryos, tissues that tolerate mutant cells land therefore do not require the mutated gene) or lack mutant cells land presumably require the mutated gene during their developmental history(8)). We therefore generated chimaeric mouse embryos to explore the cellular requirements for Shp2. This analysis revealed an obligatory role for Shp2 during outgrowth of the limb. Shp2 is specifically required in mesenchyme cells of the progress zone (PZ), directly beneath the distal ectoderm of the limb bud. Comparison of Ptpn11 (encoding Shp2)-mutant and Fgfr1 (encoding fibroblast growth factor receptor-1)-mutant chimaeric limbs indicated that in both cases mutant cells fail to contribute to the PZ of phenotypically normal chimaeras, leading to the hypothesis that a signal transduction pathway, initiated by Fgfr1 and acting through Shp2, is essential within PZ cells. Rather than integrating proliferative signals, Shp2 probably exerts it effects on limb development by influencing cell shape, movement or adhesion. Furthermore, the branchial arches, which also use Fgfs during bud outgrowth, similarly require Shp2. Thus, Shp2 regulates phosphotyrosine-signalling events during the complex ectodermal-mesenchymal interactions that regulate mammalian budding morphogenesis.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013					Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; CONLON RA, 1992, DEVELOPMENT, V116, P357; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; EDE DA, 1969, NATURE, V221, P244, DOI 10.1038/221244a0; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gardner RL, 1998, DEVELOPMENT, V125, P2397; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Li SG, 1999, DEV BIOL, V211, P335, DOI 10.1006/dbio.1999.9317; Manes S, 1999, MOL CELL BIOL, V19, P3125; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Oh ES, 1999, MOL CELL BIOL, V19, P3205; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Rossant J, 1998, TRENDS GENET, V14, P358, DOI 10.1016/S0168-9525(98)01552-2; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL A, 1995, DEV BIOL, V171, P507, DOI 10.1006/dbio.1995.1300; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; Xu XL, 1998, DEVELOPMENT, V125, P753; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	30	96	99	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					420	423		10.1038/74279	http://dx.doi.org/10.1038/74279			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742110				2022-12-27	WOS:000086192800025
J	Scherf, U; Ross, DT; Waltham, M; Smith, LH; Lee, JK; Tanabe, L; Kohn, KW; Reinhold, WC; Myers, TG; Andrews, DT; Scudiero, DA; Eisen, MB; Sausville, EA; Pommier, Y; Botstein, D; Brown, PO; Weinstein, JN				Scherf, U; Ross, DT; Waltham, M; Smith, LH; Lee, JK; Tanabe, L; Kohn, KW; Reinhold, WC; Myers, TG; Andrews, DT; Scudiero, DA; Eisen, MB; Sausville, EA; Pommier, Y; Botstein, D; Brown, PO; Weinstein, JN			A gene expression database for the molecular pharmacology of cancer	NATURE GENETICS			English	Article							TUMOR-CELL-LINES; ANTICANCER DRUG SCREEN; DIHYDROPYRIMIDINE DEHYDROGENASE; ELLIPTICINE ANALOGS; CLUSTER-ANALYSIS; DNA MICROARRAY; L-ASPARAGINASE; INSTITUTE; PATTERNS; DISCOVERY	We used cDNA microarrays to assess gene expression profiles in 60 human cancer cell lines used in a drug discovery screen by the National Cancer Institute. Using these data, we linked bioinformatics and chemoinformatics by correlating gene expression and drug activity patterns in the NCI60 lines. Clustering the cell lines on the basis of gene expression yielded relationships very different from those obtained by clustering the cell lines on the basis of their response to drugs. Gene-drug relationships for the clinical agents 5-fluorouracil and L-asparaginase exemplify how variations in the transcript levels of particular genes relate to mechanisms of drug sensitivity and resistance. This is the first study to integrate large databases on gene expression and molecular pharmacology.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; NCI, Informat Technol Branch,Dev Therapeut Program, Div Canc Treatment & Diagnosis, NIH, Bethesda, MD 20892 USA; NCI, SAIC, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA; NCI, Off Associate Director, DTP,DCTD, NIH, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Stanford University	Weinstein, JN (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37-5D-02, Bethesda, MD 20892 USA.	pbrown@cmgm.stanford.edu; weinstein@dtpax2.ncifcrf.gov	Waltham, Mark/A-1728-2009; Reinhold, William/J-6704-2017	Weinstein, John/0000-0001-9401-6908; Myers, Timothy Gene/0000-0002-7059-5906; Reinhold, William/0000-0001-5513-9323; Eisen, Michael/0000-0002-7528-738X	NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NCI NIH HHS [CA77097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; ALVAREZ M, 1995, J CLIN INVEST, V95, P2205, DOI 10.1172/JCI117910; Bates S E, 1994, Prog Clin Biol Res, V389, P33; BATES SE, 1995, J CANCER RES CLIN, V121, P495, DOI 10.1007/BF01197759; Boyd M.R., 1997, ANTICANCER DRUG DEV, P23, DOI [DOI 10.1007/978-1-4615-8152-9_2, 10.1007/978-1-4615-8152-9_2]; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CAPIZZI RL, 1970, ANNU REV MED, V21, P433, DOI 10.1146/annurev.me.21.020170.002245; Capranico G, 1998, J BIOL CHEM, V273, P12732, DOI 10.1074/jbc.273.21.12732; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; COONEY DA, 1970, ANNU REV PHARMACOLOG, V10, P421, DOI 10.1146/annurev.pa.10.040170.002225; DeRisi J, 1996, NAT GENET, V14, P457; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fischel JL, 1995, CLIN CANCER RES, V1, P991; Freije JMP, 1997, NAT MED, V3, P395, DOI 10.1038/nm0497-395; GREVER MR, 1992, SEMIN ONCOL, V19, P622; Izquierdo MA, 1996, INT J CANCER, V65, P230; Kitada S, 1998, AM J PATHOL, V152, P51; Koo HM, 1996, CANCER RES, V56, P5211; LEE JS, 1994, MOL PHARMACOL, V46, P627; McLeod HL, 1998, BRIT J CANCER, V77, P461, DOI 10.1038/bjc.1998.73; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Myers TG, 1997, ELECTROPHORESIS, V18, P647, DOI 10.1002/elps.1150180351; OConnor PM, 1997, CANCER RES, V57, P4285; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PAULL KD, 1993, CANC CHEMOTHERAPEUTI, P1574; Pommier Yves, 1997, P153; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Scudiero DA, 1998, J NATL CANCER I, V90, P862, DOI 10.1093/jnci/90.11.862; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shi LM, 1998, MOL PHARMACOL, V53, P241, DOI 10.1124/mol.53.2.241; Shi LM, 1998, J CHEM INF COMP SCI, V38, P189, DOI 10.1021/ci970085w; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Tanabe L, 1999, BIOTECHNIQUES, V27, P1210, DOI 10.2144/99276bc03; VANOSDOL WW, 1994, J NATL CANCER I, V86, P1853, DOI 10.1093/jnci/86.24.1853; WADA H, 1990, ANN NY ACAD SCI, V613, P95, DOI 10.1111/j.1749-6632.1990.tb18151.x; WEINSTEIN JN, 1994, STEM CELLS, V12, P13, DOI 10.1002/stem.5530120106; Weinstein JN, 1998, SCIENCE, V282, P628; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wosikowski K, 1997, JNCI-J NATL CANCER I, V89, P1505, DOI 10.1093/jnci/89.20.1505; WU L, 1992, CANCER RES, V52, P3029	46	1139	1236	2	69	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					236	244		10.1038/73439	http://dx.doi.org/10.1038/73439			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700175				2022-12-27	WOS:000085590600012
J	Symula, DJ; Frazer, KA; Ueda, Y; Denefle, P; Stevens, ME; Wang, ZE; Locksley, R; Rubin, EM				Symula, DJ; Frazer, KA; Ueda, Y; Denefle, P; Stevens, ME; Wang, ZE; Locksley, R; Rubin, EM			Functional screening of an asthma QTL in YAC transgenic mice	NATURE GENETICS			English	Article							T-CELL DEVELOPMENT; GENE; LINKAGE	Many quantitative trait loci (QTLs) contributing to genetically complex conditions have been discovered, but few causative genes have been identified. This is mainly due to the large size of QTLs and the subtle connection between genotype and quantitative phenotype associated with these conditions(1,2) Transgenic mice have been successfully used to analyse well-characterized genes suspected of contributing to quantitative traits(3-5). Although this approach is powerful for examining one gene at a time, it can be impractical for surveying the large genomic intervals containing many genes that are typically associated with QTLs. To screen for genes contributing to an asthma QTL mapped to human chromosome 5q3 (refs 6,7), we characterized a panel of large-insert 5q31 transgenics based on studies demonstrating that altering gene dosage frequently affects quantitative phenotypes normally influenced by that gene. This panel of human YAC transgenics, propagating a 1Mb interval of chromosome 5q31 containing 6 cytokine genes and 17 partially characterized genes(8), was screened for quantitative changes in several asthma-associated phenotypes. Multiple independent transgenic lines with altered IgE response to antigen treatment shared a 180-kb region containing 5 genes, including those encoding human interleukin 4 (IL4) and interleukin 13(IL 13), which induce IgE class switching in B cells(9). Further analysis of these mice and mice transgenic for mouse Il14 and Il13 demonstrated that moderate changes in Il4 and Il13 expression affect asthma-associated phenotypes in vivo. This functional screen of large-insert transgenics enabled us to identify genes that influence the QTL phenotype in vivo.	Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Rhone Poulenc Rorer Res Dev, Vitry Sur Seine, France	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Sanofi-Aventis	Rubin, EM (corresponding author), Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA.	emrubin@lbl.gov		Frazer, Kelly/0000-0002-6060-8902	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, P01HL056385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56385, HL-07279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289; Chomarat Pascale, 1998, P133; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Dausset J, 1992, Behring Inst Mitt, P13; de Vries J E, 1996, Eur Respir J Suppl, V22, p58s; deVries JE, 1996, CHEM IMMUNOL, V63, P204; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; FAVRE N, 1993, J IMMUNOL METHODS, V164, P213, DOI 10.1016/0022-1759(93)90314-W; Fowell DJ, 1997, IMMUNITY, V6, P559, DOI 10.1016/S1074-7613(00)80344-1; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; Georges M, 1997, GENOME RES, V7, P663, DOI 10.1101/gr.7.7.663; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Jacinto SM, 1999, AM J PHYSIOL-RENAL, V276, pF315, DOI 10.1152/ajprenal.1999.276.2.F315; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LABITLEBOUTEILLER C, 1995, J IMMUNOL METHODS, V181, P29, DOI 10.1016/0022-1759(94)00323-O; LEHMANN EL, 1975, NONPARAMETRICS STATI, P123; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ollmann MM, 1998, SCIENCE, V281, P1615; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PENNOCK BE, 1979, J APPL PHYSIOL, V46, P399, DOI 10.1152/jappl.1979.46.2.399; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0; RUBIN EM, 1994, TRENDS GENET, V10, P199, DOI 10.1016/0168-9525(94)90256-9; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4783, DOI 10.1093/nar/21.20.4783; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3	29	43	46	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					241	244		10.1038/13880	http://dx.doi.org/10.1038/13880			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508526				2022-12-27	WOS:000082827500029
J	Headon, DJ; Overbeek, PA				Headon, DJ; Overbeek, PA			Involvement of a novel Tnf receptor homologue in hair follicle induction	NATURE GENETICS			English	Article							FACTOR LIGAND SUPERFAMILY; ECTODERMAL DYSPLASIA; EDA GENE; MOUSE; TABBY; PROTEIN; DOMAIN; MICE; MUTATIONS; CLONING	Although inductive interactions are known to be essential for specification of cell fate in many vertebrate tissues, the signals and receptors responsible for transmitting this information remain largely unidentified. Mice with mutations in the downless (dl) gene have defects in hair follicle induction, lack sweat glands and have malformed teeth(1). These structures originate as ectodermal placodes, which invaginate into the underlying mesenchyme and differentiate to form specific organs(2-4). Positional cloning of the dl gene began with identification of the transgenic family OVE1. One branch of the family, dl(OVE1B), Carries an approximately 600-kb deletion at the dl locus caused by transgene integration. The mutated locus has been physically mapped in this family(5), and a 200-kb mouse YAC clone, YAC D9, has been identified and shown to rescue the dl phenotype in the spontaneous dl(Jackson) (dl(J), recessive) and Dl(sleek) (Dl(slk), dominant negative) mutants(6), Here we report the positional cloning of the dl gene, which encodes a novel member of the tumour necrosis factor (Tnf) receptor (Tnfr) family. The mutant phenotype and dl expression pattern suggests that this gene encodes a receptor that specifies hair follicle fate. Its ligand is likely to be the product of the tabby (Ta) gene, as Ta mutants have a phenotype identical to that of dl (ref. 1) mutants and Ta encodes a Tnf-like protein.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Overbeek, PA (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Overbeek, Paul/0000-0001-9784-2084	NHLBI NIH HHS [HL49953] Funding Source: Medline; NIAMS NIH HHS [AR45316] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045316] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BYRNE C, 1994, DEVELOPMENT, V120, P2369; FALCONER DS, 1953, Z INDUKT ABSTAMM VER, V85, P210, DOI 10.1007/BF00309836; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; GRUNEBERG H, 1971, J EMBRYOL EXP MORPH, V25, P1; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Gruss HJ, 1996, INT J CLIN LAB RES, V26, P143, DOI 10.1007/BF02592977; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HARDY MH, 1969, ADV BIOL SKIN, V9, P35; KAGHAD M, 1985, EMBO J, V4, P2911, DOI 10.1002/j.1460-2075.1985.tb04022.x; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LYON MF, 1996, GENETIC VARIANTS STR; Majumder K, 1998, MAMM GENOME, V9, P863, DOI 10.1007/s003359900884; MANN SJ, 1962, ANAT RECORD, V144, P135, DOI 10.1002/ar.1091440208; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Montonen O, 1998, J HISTOCHEM CYTOCHEM, V46, P281, DOI 10.1177/002215549804600301; NAUNSMITH JH, 1998, TRENDS BIOL SCI, V23, P74; PENNYCUIK PR, 1984, GENET RES, V43, P51, DOI 10.1017/S0016672300025714; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; Sengel P., 1976, MORPHOGENESIS SKIN; SHAWLOT W, 1989, MOL BIOL MED, V6, P299; SOAFER JA, 1974, GENET RES, V23, P219; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Vielkind U, 1996, ACTA ANAT, V157, P183	29	292	308	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					370	374		10.1038/11943	http://dx.doi.org/10.1038/11943			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431242				2022-12-27	WOS:000081772500020
J	Mara, M; Kucaba, T; Sekhon, M; Hillier, L; Martienssen, R; Chinwalla, A; Crockett, J; Fedele, J; Grover, H; Gund, C; McCombie, WR; McDonald, K; McPherson, J; Mudd, N; Parnell, L; Schein, J; Seim, R; Shelby, P; Waterston, R; Wilson, R				Mara, M; Kucaba, T; Sekhon, M; Hillier, L; Martienssen, R; Chinwalla, A; Crockett, J; Fedele, J; Grover, H; Gund, C; McCombie, WR; McDonald, K; McPherson, J; Mudd, N; Parnell, L; Schein, J; Seim, R; Shelby, P; Waterston, R; Wilson, R			zA map for sequence analysis of the Arabidopsis thaliana genome	NATURE GENETICS			English	Article							BAC LIBRARY; CLONES; YEAST; DNA	Arabidopsis thaliana has emerged as a model system for studies of plant genetics and development, and its genome has been targeted for sequencing(1) by an international consortium (the Arabidopsis Genome Initiative; http://genome-www. stanford.edu/Arabidopsis/agi.html). To support the genome-sequencing effort, we fingerprinted more than 20,000 BACs (ref. 2) from two high-quality publicly available libraries(3-5), generating an estimated 17-fold redundant coverage of the genome, and used the fingerprints to nucleate assembly of the data by computer. Subsequent manual revision of the assemblies resulted in the incorporation of 19,661 fingerprinted BACs into 169 ordered sets of overlapping clones ('contigs'), each containing at least 3 clones. These contigs are ideal for parallel selection of BACs for large-scale sequencing and have supported the generation of more than 5.8 Mb of finished genome sequence submitted to GenBank; analysis of the sequence has confirmed the integrity of contigs constructed using this fingerprint data. Placement of contigs onto chromosomes can now be performed, and is being pursued by groups involved in both sequencing and positional cloning studies. To our knowledge, these data provide the first example of whole-genome random PAC fingerprint analysis of a eucaryote, and have provided a model essential to efforts aimed at generating similar databases of fingerprint contigs to support sequencing of other complex genomes, including that of human.	Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Washington University (WUSTL); Cold Spring Harbor Laboratory	Mara, M (corresponding author), Washington Univ, Genome Sequencing Ctr, 4444 Forest Pk Blvd, St Louis, MO 63108 USA.	mmarra@alu.wustl.edu	Marra, Marco A/B-5987-2008; Wilson, Richard K./AAF-4139-2019; Schein, Jacquie E/G-3674-2015; McPherson, John D/D-2633-2017	Marra, Marco A/0000-0001-7146-7175; Wilson, Richard K./0000-0002-1992-1358; McPherson, John D/0000-0001-8049-9347; Chinwalla, Asif/0000-0001-7831-3996; McCombie, W. Richard/0000-0003-1899-0682				Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHOI S, 1995, WEEDS WORLD, V2, P17; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; Parsons JD, 1995, COMPUT APPL BIOSCI, V11, P615; RILES L, 1993, GENETICS, V134, P81; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; SULSTON J, 1989, COMPUT APPL BIOSCI, V5, P101; SULSTON J, 1988, COMPUT APPL BIOSCI, V4, P125; Wilson RK, 1997, GENOME ANAL, V1, P397; WONG GK, 1997, P NATL ACAD SCI USA, V13, P5225	20	93	105	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1999	22	3					265	270		10.1038/10327	http://dx.doi.org/10.1038/10327			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391214				2022-12-27	WOS:000081125900019
J	Chakravarti, A				Chakravarti, A			Population genetics - making sense out of sequence	NATURE GENETICS			English	Review							LINKAGE DISEQUILIBRIUM; HUMAN GENOME; DNA; EVOLUTION; IDENTIFICATION; DIVERSITY; VARIANTS; CLUSTER; GLOBIN	The complete human genome nucleotide sequence and technologies for assessing sequence Variation on a genome-scale will prompt comprehensive studies of comparative genomic diversity inhuman populations across the globe. These studies, besides rejuvenating population genetics and our interest in how genetic Variation is created and maintained, will provide the intellectual basis for understanding the genetic basis for complex diseases-and traits.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Chakravarti, A (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.	axc39@po.cwru.edu						Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Chakravarti A, 1998, NAT GENET, V19, P216, DOI 10.1038/885; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; *COMM HUM GEN DIV, 1997, EV HUM GEN DIV; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eichler EE, 1996, HUM MOL GENET, V5, P899, DOI 10.1093/hmg/5.7.899; Fisher RA, 1930, GENETICAL THEORY NAT; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Haldane JB., 1990, CAUSES EVOLUTION; HALUSHKA M, 1998, GENOME MAPPING SEQUE; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; HARRIS H, 1966, PROC R SOC SER B-BIO, V164, P298, DOI 10.1098/rspb.1966.0032; HUDSON RR, 1993, P NATL ACAD SCI USA, V90, P7425, DOI 10.1073/pnas.90.16.7425; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JORDE LB, 1995, AM J HUM GENET, V56, P11; Juengst ET, 1998, KENNEDY INST ETHIC J, V8, P183, DOI 10.1353/ken.1998.0010; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; KIMURA M, 1983, NEURTRAL THEORY MOL; KIMURA M, 1995, COLD SPRING HARB SYM, V20, P33; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lewontin R.C., 1972, EVOL BIOL, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; LI WH, 1991, GENETICS, V129, P513; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; McKusick V.A., 1998, MENDELIAN INHERITANC; NEI M, 1972, SCIENCE, V177, P434, DOI 10.1126/science.177.4047.434; Nei M., 1987, MOL EVOLUTIONARY GEN; Nei M., 1975, MOL POPULATION GENET; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Provine, 1971, ORIGINS THEORETICAL; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Seielstad MT, 1998, NAT GENET, V20, P278, DOI 10.1038/3088; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WRIGHT S, 1997, EVOLUTION GENETICS P, V2; Wright S., 1977, EVOLUTION GENETICS P, V3	51	427	446	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21			S			56	60		10.1038/4482	http://dx.doi.org/10.1038/4482			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915503				2022-12-27	WOS:000078008200014
J	Jiang, XR; Jimenez, G; Chang, E; Frolkis, M; Kusler, B; Sage, M; Beeche, M; Bodnar, AG; Wahl, GM; Tlsty, TD; Chiu, CP				Jiang, XR; Jimenez, G; Chang, E; Frolkis, M; Kusler, B; Sage, M; Beeche, M; Bodnar, AG; Wahl, GM; Tlsty, TD; Chiu, CP			Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype	NATURE GENETICS			English	Article							WILD-TYPE P53; NORMAL HUMAN FIBROBLASTS; NUDE-MICE; GENE AMPLIFICATION; CYCLE CONTROL; HUMAN BREAST; TUMORIGENICITY; MATRIGEL; INVITRO; PROTEIN	Expression of the human telomerase catalytic component, hTERT, in normal human somatic cells can reconstitute telomerase activity and extend their replicative lifespan(1,2). We report here that at twice the normal number of population doublings, telomerase-expressing human skin fibroblasts (BJ-hTERT) and retinal pigment epithelial cells (RPE-hTERT) retain normal growth control in response to serum deprivation, high cell density, G1 or GZ phase blockers and spindle inhibitors. In addition, we observed no cell growth in soft agar and detected no tumour formation in vivo. Thus, we find that telomerase expression in normal cells does not appear to induce changes associated with a malignant phenotype.	Geron Corp, Menlo Park, CA 94025 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Geron Corporation; Salk Institute; University of California System; University of California San Francisco	Chiu, CP (corresponding author), Geron Corp, Menlo Park, CA 94025 USA.	cchiu@geron.com			NCI NIH HHS [CA 61449, CA 42765, CA 51912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042765, R01CA061449, R01CA051912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BENN PA, 1976, AM J HUM GENET, V28, P465; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; JOHNSON TE, 1992, J CELL PHYSIOL, V150, P17, DOI 10.1002/jcp.1041500104; Khan SH, 1998, CANCER RES, V58, P396; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; SAKSELA E, 1963, P NATL ACAD SCI USA, V50, P390, DOI 10.1073/pnas.50.2.390; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wright WE, 1996, DEV GENET, V18, P173; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	23	531	565	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					111	114		10.1038/5056	http://dx.doi.org/10.1038/5056			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916802	Green Published			2022-12-27	WOS:000077960700020
J	Matsumura, Y; Uchida, S; Kondo, Y; Miyazaki, H; Ko, SBH; Hayama, A; Morimoto, T; Liu, W; Arisawa, M; Sasaki, S; Marumo, F				Matsumura, Y; Uchida, S; Kondo, Y; Miyazaki, H; Ko, SBH; Hayama, A; Morimoto, T; Liu, W; Arisawa, M; Sasaki, S; Marumo, F			Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel	NATURE GENETICS			English	Article							THIN ASCENDING LIMB; HUMAN KIDNEY; TRANSPORT; CLONING; HENLE; LOCALIZATION; MEDULLA; LOOP; GENE; RAT	CLC-K1 is a kidney-specific chloride channel that mediates transepithelial chloride transport in the thin ascending limb of Henle's loop (tAL) in the inner medulla(1,2). Transport of NaCl in the tAL is thought to be a component of urinary concentration in a passive model of the countercurrent multiplication system(3-5), but there has been no direct evidence that CLC-K1 is involved in urine concentration. To analyse the physiological function of CLC-K1 in vivo, we generated mice lacking CLC-K1 by targeted gene disruption. Clcnk1(-/-) mice were physically normal appearance, but produced approximately five times more urine than Clcnk1(-/-) and Clcnk(+/+) mice. After 24 hours of water deprivation, Clcnk1(-/-) mice were severely dehydrated and lethargic, with a decrease of approximately 27% in body weight. Intraperitoneal injection of the V2 agonist 1-deamino-8-D-arginine vasopressin (dDAVP) induced a threefold increase in urine osmolarity in Clcnk1(+/-) and Clcnk1(+/+) mice, whereas only a minimal increase was seen in Clcnk1(-/-) mice, indicating nephrogenic diabetes insipidus, After in vitro perfusion of the tAL, the lumen-to-bath chloride gradient did not produce a diffusion potential in Clcnk1(-/-) mice in contrast to Clcnk1(+/+) and Clcnk1(+/-) mice. These results establish that CLC-K1 has a role in urine concentration, and that the countercurrent system in the inner medulla is involved in the generation and maintenance of hypertonic medullary interstitium.	Tokyo Med & Dent Univ, Dept Internal Med 2, Tokyo, Japan; Tohoku Univ, Dept Pediat, Sch Med, Sendai, Miyagi 980, Japan	Tokyo Medical & Dental University (TMDU); Tohoku University	Uchida, S (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 2, Tokyo, Japan.		Uchida, Shinichi/D-1111-2013; Ko, Shigeru/H-3450-2012	Ko, Shigeru/0000-0003-1913-6357				DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; IMAI M, 1987, KIDNEY INT, V31, P565, DOI 10.1038/ki.1987.37; IMAI M, 1976, J CLIN INVEST, V58, P1054, DOI 10.1172/JCI108556; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOKKO JP, 1972, KIDNEY INT, V2, P214, DOI 10.1038/ki.1972.97; KONDO Y, 1987, AM J PHYSIOL, V253, pF1206; KONDO Y, 1987, AM J PHYSIOL, V253, pF1216; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; TAKEUCHI Y, 1995, KIDNEY INT, V48, P1497, DOI 10.1038/ki.1995.439; UCHIDA S, 1995, J CLIN INVEST, V95, P104, DOI 10.1172/JCI117626; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; YOSHITOMI K, 1988, J CLIN INVEST, V82, P866, DOI 10.1172/JCI113691	14	196	199	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21	1					95	98		10.1038/5036	http://dx.doi.org/10.1038/5036			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916798				2022-12-27	WOS:000077960700016
J	Snel, B; Bork, P; Huynen, MA				Snel, B; Bork, P; Huynen, MA			Genome phylogeny based on gene content	NATURE GENETICS			English	Article							SEQUENCE; ARCHAEON	Species phylogenies derived from comparisons of single genes are rarely consistent with each other, due to horizontal gene transfer(1), unrecognized paralogy and highly variable rates of evolution(2). The advent of completely sequenced genomes allows the construction of a phylogeny that is less sensitive to such inconsistencies and more representative of whole-genomes than are single-gene trees. Here, we present a distance-based phytogeny(3) constructed on the basis of gene content, rather than on sequence identity, of 13 completely sequenced genomes of unicellular species. The similarity between two species is defined as the number of genes that they have in common divided by their total number of genes, Tn this type of phylogenetic analysis, evolutionary distance can be interpreted in terms of evolutionary events such as the acquisition and loss of genes, whereas the underlying properties (the gene content) can be interpreted in terms of function. As such, it takes a position intermediate to phylogenies based on single genes and phylogenies based on phenotypic characteristics. Although our comprehensive genome phylogeny is independent of phylogenies based on the level of sequence identity of individual genes, it correlates with the standard reference of prokarytic phylogeny based on sequence similarity of 16s rRNA (ref, 4). Thus, shared gene content between genomes is quantitatively determined by phylogeny, rather than by phenotype, and horizontal gene transfer has only a limited role in determining the gene content of genomes.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Utrecht, Bioinformat Grp, NL-3584 CH Utrecht, Netherlands	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Utrecht University	Bork, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bork@embl-heidelberg.de	Huynen, Martijn A/A-1530-2014; Snel, Berend/B-8886-2011; Bork, Peer/F-1813-2013; Huijnen, M.A./H-8051-2014	Huynen, Martijn A/0000-0001-6189-5491; Snel, Berend/0000-0002-5804-8547; Bork, Peer/0000-0002-2627-833X; 				Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Doolittle WF, 1998, CURR BIOL, V8, pR209, DOI 10.1016/S0960-9822(98)70127-7; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Huynen M, 1998, FEBS LETT, V426, P1, DOI 10.1016/S0014-5793(98)00276-2; Huynen MA, 1998, P NATL ACAD SCI USA, V95, P5849, DOI 10.1073/pnas.95.11.5849; Kaneko T, 1996, DNA Res, V3, P109; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KLENK HP, 1994, J MOL EVOL, V38, P420, DOI 10.1007/BF00163158; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WU CFJ, 1986, ANN STAT, V14, P1261, DOI 10.1214/aos/1176350142	30	494	517	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					108	110		10.1038/5052	http://dx.doi.org/10.1038/5052			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916801				2022-12-27	WOS:000077960700019
J	Katsanis, N; Beales, PL; Woods, MO; Lewis, RA; Green, JS; Parfrey, PS; Ansley, SJ; Davidson, WS; Lupski, JR				Katsanis, N; Beales, PL; Woods, MO; Lewis, RA; Green, JS; Parfrey, PS; Ansley, SJ; Davidson, WS; Lupski, JR			Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome	NATURE GENETICS			English	Article							GENETIC-HETEROGENEITY; SYNDROME LOCUS; 5TH LOCUS; IDENTIFICATION; POPULATION	Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder predominantly characterized by obesity, retinal dystrophy, polydactyly, learning difficulties, hypogenitalism and renal malformations, with secondary features that include diabetes mellitus, endocrinological dysfunction and behavioural abnormalities(1,2) Despite an initial expectation of genetic homogeneity due to relative clinical uniformity, five BBS loci have been reported, with evidence for additional loci in the human genome(3-7); however, no genes for BBS have yet been identified. We performed a genome screen with BBS families from Newfoundland that were excluded from BBS1-5 and identified linkage with D205189. Fine-mapping reduced the critical interval to 1.9 cM between D20S851 and D20S189, encompassing a chaperonin-like gene. Mutations in this gene were recently reported to be associated with McKusick-Kaufman syndrome (MKKS; ref. 8). Given both the mapping position and clinical similarities of these two syndromes, we screened MKKS and identified mutations in five Newfoundland and two European-American BBS pedigrees. Most are frameshift alleles that are likely to result in a non-functional protein. Our data suggest that a complete loss of function of the MKKS product, and thus an inability to fold a range of target proteins, is responsible for the clinical manifestations of BBS.	Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX USA; Baylor Coll Med, Dept Med, Houston, TX USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX USA; Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; Mem Univ Newfoundland, Fac Med, St John, NF, Canada; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; UCL, Inst Child Hlth, Mol Med Unit, London, England	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Memorial University Newfoundland; Simon Fraser University; University of London; University College London	Lupski, JR (corresponding author), Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA.	jlupski@bcm.tmc.edu	Beales, Philip L/C-7367-2009; Katsanis, Nicholas/E-1837-2012	Katsanis, Nicholas/0000-0002-2480-0171	NATIONAL EYE INSTITUTE [R01EY012666] Funding Source: NIH RePORTER; NEI NIH HHS [EY12666] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Beales PL, 1999, J MED GENET, V36, P437; BEAR JC, 1988, AM J MED GENET, V29, P649, DOI 10.1002/ajmg.1320290324; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; David A, 1999, J MED GENET, V36, P599; DAVIDSON WS, 2000, BIOTECH FOCUS, V2, P13; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; Scharf B., 1970, FDN MODERN AUDITORY, V1, P157; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Woods MO, 1999, GENOMICS, V55, P2, DOI 10.1006/geno.1998.5626; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301	17	238	246	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					67	70		10.1038/79201	http://dx.doi.org/10.1038/79201			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973251				2022-12-27	WOS:000089078000020
J	Soong, NW; Nomura, L; Pekrun, K; Reed, M; Sheppard, L; Dawes, G; Stemmer, WPC				Soong, NW; Nomura, L; Pekrun, K; Reed, M; Sheppard, L; Dawes, G; Stemmer, WPC			Molecular breeding of viruses	NATURE GENETICS			English	Article							EVOLUTION; RETROVIRUSES; GLYCOSYLATION; DIVERSITY; RECEPTOR; PROTEIN; FAMILY	Genetic recombination is a major force driving the evolution of many viruses. Recombination between two copackaged retroviral genomes may occur at rates as high as 40% per replication cycle(1). This enables genetic information to be shuffled rapidly leading to recombinants with new patterns of mutations and phenotypes. The in vitro process of DNA shuffling(2,3) (molecular breeding) mimics this mechanism on a vastly parallel and accelerated scale. Multiple homologous parental sequences are recombined in parallel, leading to a diverse library of complex recombinants from which desired improvements can be selected. Different proteins and enzymes have been improved using DNA shuffling(4-6). We report here the first application of molecular breeding to viruses. A single round of shuffling envelope sequences from six murine leukaemia viruses (MLV) followed by selection yielded a chimaeric clone with a completely new tropism for Chinese Hamster Ovary (CHOK1) cells. The composition and properties of the selected clone indicated that this particular permutation of parental sequences cannot be readily attained by natural retroviral recombination. This example demonstrates that molecular breeding can enhance the inherently high evolutionary potential of retroviruses to obtain desired phenotypes. It can be an effective tool, when information is limited, to optimize viruses for gene therapy and vaccine applications when multiple complex functions must be simultaneously balanced.	Maxygen Inc, Redwood City, CA USA		Soong, NW (corresponding author), Maxygen Inc, Redwood City, CA USA.							Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; DEUTSCHERT SL, 1996, J BIOL CHEM, V261, P96; EIDEN MV, 1994, J VIROL, V68, P626, DOI 10.1128/JVI.68.2.626-631.1994; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; Masuda M, 1996, J VIROL, V70, P8534, DOI 10.1128/JVI.70.12.8534-8539.1996; MILLER DG, 1992, J VIROL, V66, P78, DOI 10.1128/JVI.66.1.78-84.1992; Ness JE, 1999, NAT BIOTECHNOL, V17, P893, DOI 10.1038/12884; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Wang H, 1996, J VIROL, V70, P6884, DOI 10.1128/JVI.70.10.6884-6891.1996	16	83	96	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					436	439		10.1038/78132	http://dx.doi.org/10.1038/78132			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932190				2022-12-27	WOS:000088615000021
J	Dequeker, E; Cassiman, JJ				Dequeker, E; Cassiman, JJ			Genetic testing and quality control in diagnostic laboratories	NATURE GENETICS			English	Article							CYSTIC-FIBROSIS		Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium	KU Leuven	Dequeker, E (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium.							Dequeker E, 1998, EUR J HUM GENET, V6, P165, DOI 10.1038/sj.ejhg.5200195; DEQUEKER E, IN PRESS EUR J HUM G; ELLES R, 1996, METHODS MOL MED MOL; Estivill X, 1997, HUM MUTAT, V10, P135, DOI 10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.3.CO;2-P; Grody WW, 1998, AM J HUM GENET, V62, P1252, DOI 10.1086/301842; Holtzman NA, 1999, CLIN CHEM, V45, P732; Holtzman NA, 1998, BMJ-BRIT MED J, V316, P852, DOI 10.1136/bmj.316.7134.852; Losekoot M, 1999, EUR J HUM GENET, V7, P217, DOI 10.1038/sj.ejhg.5200252; McGovern MM, 1999, JAMA-J AM MED ASSOC, V281, P835, DOI 10.1001/jama.281.9.835; Prence EM, 1999, GENET TEST, V3, P201, DOI 10.1089/gte.1999.3.201; Robinson RA, 1999, AM J CLIN PATHOL, V112, P11; Schwartz MK, 1999, CLIN CHEM, V45, P739	12	62	67	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					259	260		10.1038/77008	http://dx.doi.org/10.1038/77008			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888869				2022-12-27	WOS:000087920900010
J	Filliol, D; Ghozland, S; Chluba, J; Martin, M; Matthes, HWD; Simonin, F; Befort, K; Gaveriaux-Ruff, C; Dierich, A; LeMeur, M; Valverde, O; Maldonado, R; Kieffer, BL				Filliol, D; Ghozland, S; Chluba, J; Martin, M; Matthes, HWD; Simonin, F; Befort, K; Gaveriaux-Ruff, C; Dierich, A; LeMeur, M; Valverde, O; Maldonado, R; Kieffer, BL			Mice deficient for delta- and gamma-opioid receptors exhibit opposing alterations of emotional responses	NATURE GENETICS			English	Article							ENDOGENOUS ENKEPHALINS; ANXIETY; LACKING; PAIN; RAT; ANTIDEPRESSANTS; INVOLVEMENT; EXPRESSION; WITHDRAWAL; ANALGESIA	The role of the opioid system in controlling pain(1), reward and addidion(2,3) is well established, but its role in regulating other emotional responses is poorly documented in pharmacology(4). The mu-. delta- and kappa- opioid receptors (encoded by Oprm, Oprd1 and Oprk1, respectively) mediate the biological activity of opioids(5) We have generated Oprd1-deficient mice and compared the behavioural responses of mice lacking Oprd1, Oprm (ref. 6) and Oprk1 (ref. 7) in several models of anxiety and depression. Our data show no detectable phenotype in Oprk1(-/-) mutants. suggesting that ic-receptors do not have a role in this aspect of opioid function; opposing phenotypes in Oprm(-/-) and Oprd1(-/-) mutants which contrasts with the classical notion of similar activities of mu-and delta-receptors; and consistent anxiogenic- and depressive-like responses in Oprd1(-/-) mice, indicating that delta-receptor activity contributes to improvement of mood states. We conclude that the Oprdl-encoded receptor, which has been proposed to be a promising target for the clinical management of pain(8,9), should also be considered in the treatment of drug addiction and other mood-related disorders.	Univ Strasbourg 1, ESBS, UPR 9050 CNRS, Strasbourg, France; Univ Pompeu Fabra, Fac Ciencies Salut & Vida, Lab Neurofarmacol, Barcelona, Spain; Inst Genet & Biol Mol & Cellulaire, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Pompeu Fabra University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Kieffer, BL (corresponding author), Univ Strasbourg 1, ESBS, UPR 9050 CNRS, Strasbourg, France.		Maldonado, Rafael/F-5657-2014; GAVERIAUX-RUFF, Claire/A-9671-2017; Valverde, Olga/D-8654-2012; Chluba, Johanna/D-1224-2012	Maldonado, Rafael/0000-0002-4359-8773; GAVERIAUX-RUFF, Claire/0000-0002-3523-8102; Valverde, Olga/0000-0003-2264-7852; Chluba, Johanna/0000-0001-8779-8016				Asakawa A, 1998, NEUROREPORT, V9, P2265, DOI 10.1097/00001756-199807130-00022; BAAMONDE A, 1992, EUR J PHARMACOL, V216, P157, DOI 10.1016/0014-2999(92)90356-9; CALENCOCHOUKROUN G, 1991, PSYCHOPHARMACOLOGY, V103, P493, DOI 10.1007/BF02244249; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; Dondio G, 1997, EXPERT OPIN THER PAT, V7, P1075, DOI 10.1517/13543776.7.10.1075; KAMEYAMA T, 1985, NEUROPHARMACOLOGY, V24, P59; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; NABER D, 1993, HDB EXP PHARM OPIOID, V2, P781; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RAPAKA RS, 1991, PHARM RES-DORDR, V8, P1, DOI 10.1023/A:1015809702296; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; SMADJA C, 1995, PSYCHOPHARMACOLOGY, V120, P400, DOI 10.1007/BF02245811; Tejedor-Real P, 1998, EUR J PHARMACOL, V354, P1, DOI 10.1016/S0014-2999(98)00423-3; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Valverde O, 1996, EUR J PHARMACOL, V312, P15, DOI 10.1016/0014-2999(96)00437-2; WALSH TD, 1983, CLIN NEUROPHARMACOL, V6, P271; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; [No title captured]	30	528	546	1	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					195	200		10.1038/76061	http://dx.doi.org/10.1038/76061			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835636				2022-12-27	WOS:000087459200020
J	Menasche, G; Pastural, E; Feldmann, J; Certain, S; Ersoy, F; Dupuis, S; Wulffraat, N; Bianchi, D; Fischer, A; Le Deist, F; de Saint Basile, G				Menasche, G; Pastural, E; Feldmann, J; Certain, S; Ersoy, F; Dupuis, S; Wulffraat, N; Bianchi, D; Fischer, A; Le Deist, F; de Saint Basile, G			Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome	NATURE GENETICS			English	Article							BRAIN MYOSIN-V; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; UNCONVENTIONAL MYOSIN; PARTIAL ALBINISM; PROTEINS; GENE; IMMUNODEFICIENCY; TRANSPORT; GTPASES; CLONING	Griscelli syndrome (GS, MIM 214450), a rare, autosomal recessive disorder, results in pigmentary dilution of the skin and the hair, the presence of large clumps of pigment in hair shafts and an accumulation of melanosomes in melanocytes. Most patients also develop an uncontrolled T-lymphocyte and macrophage activation syndrome (known as haemophagocytic syndrome, HS), leading to death in the absence of bone-marrow transplantation(1,2). In contrast, early in life some GS patients show a severe neurological impairment without apparent immune abnormalities(3-5). We previously mapped the GS locus to chromosome 15q21 and found a mutation in a gene (MY05A) encoding a molecular motor in two patients(5). Further linkage analysis suggested a second gene associated with CS was in the same chromosomal region(6). Homozygosity mapping in additional families narrowed the candidate region to a 3.1-cM interval between D1551003 and D155962. We detected mutations in RAB27A, which lies within this interval, in 16 patients with CS. Unlike MYO5A, the GTP-binding protein RAB27A appears to be involved in the control of the immune system, as all patients with RAB27A mutations, but none with the MY05A mutation, developed HS. In addition, RAB27A-deficient T cells exhibited reduced cytotoxicity and cytolytic granule exocytosis, whereas MYO5A-defective T cells did not. RAB27A appears to be a key effector of cytotoxic granule exocytosis, a pathway essential for immune homeostasis.	INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, Paris, France; Hacettepe Univ, Hacettepe Childrens Hosp, Pediat Immunol Unit, Ankara, Turkey; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; Wilhelmina Childrens Hosp, Utrecht, Netherlands; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Hacettepe University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Wilhelmina Kinderziekenhuis; Tufts Medical Center	de Saint Basile, G (corresponding author), INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, Paris, France.	sbasile@necker.fr	menasche, gael/D-8280-2017; de Saint Basile, Genevieve/G-9731-2017	DOGNIAUX, Stephanie/0000-0003-3309-1204; Menasche, Gael/0000-0001-6671-3642; de Saint Basile, Genevieve/0000-0002-1913-5269				Barrat FJ, 1999, P NATL ACAD SCI USA, V96, P8645, DOI 10.1073/pnas.96.15.8645; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Dufourcq-Lagelouse R, 1999, INT J MOL MED, V4, P127; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; ELEJALDE BR, 1979, AM J MED GENET, V3, P65, DOI 10.1002/ajmg.1320030112; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; HURVITZ H, 1993, EUR J PEDIATR, V152, P402, DOI 10.1007/BF01955897; Kim S, 1998, CELL IMMUNOL, V183, P106, DOI 10.1006/cimm.1998.1252; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KLEIN C, 1994, J PEDIATR-US, V125, P886, DOI 10.1016/S0022-3476(05)82003-7; Mazerolles F, 1998, INT IMMUNOL, V10, P1897, DOI 10.1093/intimm/10.12.1897; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Pastural E, 2000, GENOMICS, V63, P299, DOI 10.1006/geno.1999.6081; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Tolmachova T, 1999, GENE, V239, P109, DOI 10.1016/S0378-1119(99)00371-6	23	670	693	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					173	176		10.1038/76024	http://dx.doi.org/10.1038/76024			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835631				2022-12-27	WOS:000087459200015
J	Sarkar, PS; Appukuttan, B; Han, J; Ito, Y; Ai, CW; Tsai, WL; Chai, Y; Stout, JT; Reddy, S				Sarkar, PS; Appukuttan, B; Han, J; Ito, Y; Ai, CW; Tsai, WL; Chai, Y; Stout, JT; Reddy, S			Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts	NATURE GENETICS			English	Article							DYSTROPHY PROTEIN-KINASE; UNSTABLE CTG REPEAT; MYOTONIC-DYSTROPHY; REDUCES EXPRESSION; TRIPLET REPEAT; MESSENGER-RNAS; GENE; EXPANSION; MUTATION; DISRUPTION	Myotonic dystrophy (DM) is an autosomal dominant disorder characterized by skeletal muscle wasting, myotonia, cardiac arrhythmia, hyperinsulinaemia, mental retardation and ocular cataracts(1). The genetic defect in DM is a CTG repeat expansion located in the 3' untranslated region of DMPK and 5' of a homeodomain-encoding gene, SIX5 (formerly DMAHP; refs 2-5). There are three mechanisms by which CTG expansion can result in DM. First, repeat expansion may alter the processing or transport of the mutant DMPK mRNA and consequently reduce DMPK levels(6). Second, CTG expansion may establish a region of heterochromatin 3' of the repeat sequence and decrease SIX5 transcription(7-9). Third, toxic effects of the repeat expansion may be intrinsic to the repeated elements at the level of DNA or RNA (refs 10,11). Previous studies have demonstrated that a dose-dependent loss of Dm15 (the mouse DMPK homologue) in mice produces a partial DM phenotype characterized by decreased development of skeletal muscle force and cardiac conduction disorders(12-15). To test the role of Six5 loss in DM, we have analysed a strain of mice in which Six5 was deleted. Our results demonstrate that the rate and severity of cataract formation is inversely related to Six5 dosage and is temporally progressive. Six5(+/-) and Six(5-/-) mice show increased steady-state levels of the Na+/K+-ATPase alpha-1 subunit and decreased Dm15 mRNA levels. Thus, altered ion homeostasis within the lens may contribute to cataract formation. As ocular cataracts are a characteristic feature of DM, these results demonstrate that decreased SIX5 transcription is important in the aetiology of DM. Our data support the hypothesis that DM is a contiguous gene syndrome associated with the partial loss of both DMPK and SIX5.	Univ So Calif, Keck Sch med, Inst Med Genet, Los Angeles, CA 90089 USA; Univ So Calif, Childrens Hosp Los Angeles, Div Ophthalmol, Los Angeles, CA USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA USA	University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California	Reddy, S (corresponding author), Univ So Calif, Keck Sch med, Inst Med Genet, Los Angeles, CA 90089 USA.	sitaredd@hsc.usc.edu			NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI NIH HHS [EYO3040] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Benders AAGM, 1997, J CLIN INVEST, V100, P1440, DOI 10.1172/JCI119664; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GRAW J, 1989, EXP EYE RES, V49, P469, DOI 10.1016/0014-4835(89)90055-9; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; JOHNS KJ, 1995, BASIC CLIN SCI COURS; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Murakami Y, 1998, HUM MOL GENET, V7, P2103, DOI 10.1093/hmg/7.13.2103; Ohto H, 1999, MOL CELL BIOL, V19, P6815; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Steinbach P, 1998, AM J HUM GENET, V62, P278, DOI 10.1086/301711; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILKINSON DG, 1998, PRACTICAL APPROACH S; Winchester CL, 1999, HUM MOL GENET, V8, P481, DOI 10.1093/hmg/8.3.481; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298	30	130	134	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					110	114		10.1038/75500	http://dx.doi.org/10.1038/75500			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802668				2022-12-27	WOS:000086884000028
J	Niwa, H; Miyazaki, J; Smith, AG				Niwa, H; Miyazaki, J; Smith, AG			Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; BINDING TRANSCRIPTION FACTOR; MOUSE EMBRYO; EXTRAEMBRYONIC MEMBRANES; MAMMALIAN EMBRYO; GENE-EXPRESSION; POU-DOMAIN; ACTIVATION; ENHANCER; DEPENDS	Cell fate during development is defined by transcription factors that act as molecular switches to activate or repress specific less than twofold increase in expression causes differentiation gene expression programmes. The POU transcription factor into primitive endoderm and mesoderm, In contrast, repression Oct-3/4 (encoded by Pou5f1) is a candidate regulator in pluripotent and germline cells(1-4) and is essential for the initial formation of a pluripotent founder cell population in the mammalian embryo(5). Here we use conditional expression and repression in embryonic stem (ES) cells to determine requirements for Oct-3/4 in the maintenance of developmental potency. Although transcriptional determination has usually been considered as a binary on-off control system, we found that the precise level of Oct-3/4 governs three distinct fates of ES cells, A less than twofold increase in expression causes differentiation of Oct-3/4 induces loss of pluripotency and dedifferentiation to trophectoderm. Thus a critical amount of Oct-3/4 is required to sustain stem-cell self-renewal, and up- or downregulation induce divergent developmental programmes. Our findings establish a pole for Oct-3/4 as a master regulator of pluripotency that controls lineage commitment and illustrate the sophistication of critical transcriptional regulators and the consequent importance of quantitative analyses.	Univ Edinburgh, Ctr Genome Res, Edinburgh, Midlothian, Scotland; Osaka Univ, Dept Nutr & Physiol Chem, Osaka, Japan	University of Edinburgh; Osaka University	Niwa, H (corresponding author), Univ Edinburgh, Ctr Genome Res, Kings Bldg, Edinburgh, Midlothian, Scotland.	hniwa@nutri.med.osaka-u.ac.jp; austin.smith@ed.ac.uk	Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X; Smith, Austin/0000-0002-3029-4682				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Burdon T, 1999, CELLS TISSUES ORGANS, V165, P131, DOI 10.1159/000016693; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; GASSMANN M, 1995, P NATL ACAD SCI USA, V92, P1292, DOI 10.1073/pnas.92.5.1292; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEBERT JM, 1991, DEVELOPMENT, V112, P407; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0	30	2708	2896	9	258	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					372	376		10.1038/74199	http://dx.doi.org/10.1038/74199			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742100				2022-12-27	WOS:000086192800015
J	Rapley, EA; Crockford, GP; Teare, D; Biggs, P; Seal, S; Barfoot, R; Edwards, S; Hamoudi, R; Heimdal, K; Fossa, SD; Tucker, K; Donald, J; Collins, F; Friedlander, M; Hogg, D; Goss, P; Heidenreich, A; Ormiston, W; Daly, PA; Forman, D; Oliver, RTD; Leahy, M; Huddart, R; Cooper, CS; Bodmer, JG; Easton, DF; Stratton, MR; Bishop, DT				Rapley, EA; Crockford, GP; Teare, D; Biggs, P; Seal, S; Barfoot, R; Edwards, S; Hamoudi, R; Heimdal, K; Fossa, SD; Tucker, K; Donald, J; Collins, F; Friedlander, M; Hogg, D; Goss, P; Heidenreich, A; Ormiston, W; Daly, PA; Forman, D; Oliver, RTD; Leahy, M; Huddart, R; Cooper, CS; Bodmer, JG; Easton, DF; Stratton, MR; Bishop, DT			Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours	NATURE GENETICS			English	Article							KLINEFELTER SYNDROME; EUROPEAN COUNTRIES; CANCER INCIDENCE; CHROMOSOME; INCREASE; PATIENT; TESTIS	Testicular germ-cell tumours (TGCT) affect 1 in 500 men and are the most common cancer in males aged 15-40 in Western European populations(1). The incidence of TGCT has risen dramatically over the last century(2-5) Known risk factors for TGCT include a history of undescended testis (UDT), testicular dysgenesis, infertility(6), previously diagnosed TGCT (ref. 7) and a family history of the disease(8-10). Brothers of men with TGCT have an 8-10-fold risk of developing TGCT (refs 8,9), whereas the relative risk to fathers and sons is fourfold (ref. 9). This familial relative risk is much higher than that for most other types of cancer. We have collected samples from 134 families with two or mom cases of TGCT, 87 of which are affected sibpairs. A genome-wide linkage search yielded a heterogeneity Iod (hIod) score of 2.01 on chromosome Xq27 using all families compatible with X inheritance. We obtained a hIod score of 4.7 from families with at least one bilateral case, corresponding to a genome-wide significance level of P=0.034. The proportion of families with UDT linked to this locus was 73% compared with 26% of families without UDT (P=0.03). Our results provide evidence for a TGCT susceptibility gene on chromosome Xq27 that may also predispose to UDT.	Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton, Surrey, England; Inst Canc Res, Haddow Labs, Sect Mol Carcinogenesis, Sutton, Surrey, England; Imperial Canc Res Fund, Genet Epidemiol Lab, Leeds, W Yorkshire, England; CRC, Genet Epidemiol Unit, Strangeways Res Labs, Cambridge, England; Norwegian Radium Hosp, Dept Oncol, Unit Med Genet, Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, Oslo, Norway; Prince Wales Hosp, Dept Oncol, Randwick, NSW 2031, Australia; Macquarie Univ, Dept Biol Sci, N Ryde, NSW, Australia; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Marburg, Dept Urol, Marburg, Germany; St James Hosp, Hope Directorate, Dept Med Oncol, Dublin, Ireland; John Radcliffe Hosp, Imperial Canc Res Fund, Canc Genet & Immunol Lab, Oxford OX3 9DU, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of Oslo; University of Oslo; Macquarie University; University of Toronto; Philipps University Marburg; Trinity College Dublin; University of Oxford	Stratton, MR (corresponding author), Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton, Surrey, England.	mikes@icr.ac.uk	Heimdal, Ketil Riddervold/H-3038-2019; Leahy, Michael G/K-8697-2015; Biggs, Patrick Jon/H-3355-2014	Heimdal, Ketil Riddervold/0000-0002-8911-3508; Leahy, Michael G/0000-0002-9936-0537; Biggs, Patrick Jon/0000-0002-0285-4101; huddart, robert/0000-0003-3604-1990; Bishop, Tim/0000-0002-8752-8785; Teare, Marion Dawn/0000-0003-3994-0051; Donald, Jennifer/0000-0002-2732-1379; Hamoudi, Rifat/0000-0002-1402-0868				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; BOKEMEYER C, 1993, EUR J CANCER, V29A, P874, DOI 10.1016/S0959-8049(05)80429-0; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CARROLL PR, 1988, UROLOGY, V31, P72, DOI 10.1016/0090-4295(88)90579-1; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; FORMAN D, 1992, BRIT J CANCER, V65, P255, DOI 10.1038/bjc.1992.51; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HASLE H, 1992, EUR J PEDIATR, V151, P735, DOI 10.1007/BF01959079; Heimdal K, 1997, BRIT J CANCER, V75, P1084, DOI 10.1038/bjc.1997.185; Heimdal K, 1996, BRIT J CANCER, V73, P964, DOI 10.1038/bjc.1996.173; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; MORTON NE, 1992, ANN HUM GENET, V56, P223, DOI 10.1111/j.1469-1809.1992.tb01147.x; MULLER J, 1995, INT J ANDROL, V18, P57, DOI 10.1111/j.1365-2605.1995.tb00386.x; NICHOLS BS, 1995, NURS CONNECT, V8, P5; Okada H, 1999, HUM REPROD, V14, P946, DOI 10.1093/humrep/14.4.946; OLIVER RTD, 1990, CANCER SURV, V9, P263; PHELAN MC, 1988, AM J MED GENET, V30, P77, DOI 10.1002/ajmg.1320300106; Rapley E, 1998, APMIS, V106, P64; REDDY SR, 1991, SOUTHERN MED J, V84, P773, DOI 10.1097/00007611-199106000-00026; TOLLERUD DJ, 1985, CANCER, V55, P1849, DOI 10.1002/1097-0142(19850415)55:8<1849::AID-CNCR2820550834>3.0.CO;2-1; Wanderas EH, 1995, EUR J CANCER, V31A, P2044, DOI 10.1016/0959-8049(95)00321-5; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Zheng TZ, 1996, INT J CANCER, V65, P723, DOI 10.1002/(SICI)1097-0215(19960315)65:6<723::AID-IJC2>3.0.CO;2-0	28	190	195	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					197	200		10.1038/72877	http://dx.doi.org/10.1038/72877			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655070				2022-12-27	WOS:000085104600025
J	Liu, XY; Dangel, AW; Kelley, RI; Zhao, W; Denny, P; Botcherby, M; Cattanach, B; Peters, J; Hunsicker, PR; Mallon, AM; Strivens, MA; Bate, R; Miller, W; Rhodes, M; Brown, SDM; Herman, GE				Liu, XY; Dangel, AW; Kelley, RI; Zhao, W; Denny, P; Botcherby, M; Cattanach, B; Peters, J; Hunsicker, PR; Mallon, AM; Strivens, MA; Bate, R; Miller, W; Rhodes, M; Brown, SDM; Herman, GE			The gene mutated in bare patches and striated mice encodes a novel 3 beta-hydroxysteroid dehydrogenase	NATURE GENETICS			English	Article							LEMLI-OPITZ-SYNDROME; STR CRITICAL REGIONS; CHOLESTEROL-BIOSYNTHESIS; STEROL BIOSYNTHESIS; REDUCTASE GENE; HUMAN XQ28; MUTATIONS; MOUSE; 7-DEHYDROCHOLESTEROL; TRANSCRIPTS	X-linked dominant disorders that are exclusively lethal prenatally in hemizygous males have been described in human and (1). None of the genes responsible has been isolated in mouse either species; The bare patches (Bpa):and striated (Str) mouse mutations were originally identified in female offspring of X-irradiated males(2) (3). Subsequently, additional independent alleles were described. We have previously mapped these X-linked dominant, male-lethal mutations to an overlapping region:of 600 kb that is homologous to human Xq28 (ref. 4) and identified several candidate genes in this: interval(5). Here we report mutations in one of these genes, Nsdhl, encoding an NAD(P)H steroid dehydrogenase-like protein, in two independent Bpa and three independent Str alleles. Quantitative analysis of sterols from tissues of affected Bpa mice support a role for Nsdhl in cholesterol biosynthesis. Our results demonstrate that Bpa and Sfr are allelic mutations and identify the first mammalian locus associated with an X-linked dominant, male-lethal phenotype. They also expand the spectrum of phenotypes associated with abnormalities of cholesterol metabolism.	Ohio State Univ, Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; Johns Hopkins Univ, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21205 USA; MRC, Mouse Genome Ctr, Didcot OX11 ORD, Oxon, England; MRC, Mammalian Genet Lab, Didcot OX11 ORD, Oxon, England; MRC, Human Genome Mapping Project Resource Ctr, Cambridge, England; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Penn State Univ, Dept Comp Sci, University Pk, PA 16802 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; United States Department of Energy (DOE); Oak Ridge National Laboratory; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Herman, GE (corresponding author), Ohio State Univ, Childrens Hosp Res Fdn, Columbus, OH 43205 USA.			Denny, Paul/0000-0003-4659-6893	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034953] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM005110] Funding Source: NIH RePORTER; MRC [MC_U142684171] Funding Source: UKRI; Medical Research Council [MC_U142684171] Funding Source: Medline; NINDS NIH HHS [R01 NS34953] Funding Source: Medline; NLM NIH HHS [R01 LM05110] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANGEL T, 1993, GENOME, V4, P171; AnsariLari MA, 1996, BIOTECHNIQUES, V21, P34; Antoine JP, 1996, REV MATH PHYS, V8, P1, DOI 10.1142/S0129055X96000020; BJORCK S, 1987, QUATERNARY RES, V28, P1, DOI 10.1016/0033-5894(87)90030-5; CHATTERJEE A, 1995, MAMM GENOME, V6, P802, DOI 10.1007/BF00539008; Clayton PT, 1998, ARCH DIS CHILD, V78, P185, DOI 10.1136/adc.78.2.185; Cunniff C, 1997, AM J MED GENET, V68, P263, DOI 10.1002/(SICI)1096-8628(19970131)68:3<263::AID-AJMG4>3.3.CO;2-5; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; GIBSON KM, 1990, J LIPID RES, V31, P515; HAPPLE R, 1983, HUM GENET, V63, P24, DOI 10.1007/BF00285392; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Heiss NS, 1996, GENOME RES, V6, P478, DOI 10.1101/gr.6.6.478; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kelley RI, 1998, AM J HUM GENET, V63, P322, DOI 10.1086/301987; Kelley RI, 1999, AM J MED GENET, V83, P213, DOI 10.1002/(SICI)1096-8628(19990319)83:3<213::AID-AJMG15>3.0.CO;2-C; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; Levin ML, 1996, GENOME RES, V6, P465, DOI 10.1101/gr.6.6.465; Payne AH, 1997, STEROIDS, V62, P169, DOI 10.1016/S0039-128X(96)00177-8; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; PHILLIPS RJ, 1963, GENET RES, V4, P151, DOI 10.1017/S0016672300003499; PHILLIPS RJ, 1973, GENET RES, V22, P91, DOI 10.1017/S0016672300012866; PUCK JM, 1989, AM J HUM GENET, V44, P724; REED V, 1994, NAT GENET, V8, P11, DOI 10.1038/ng0994-11; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Wassif CA, 1998, AM J HUM GENET, V63, P55, DOI 10.1086/301936; Waterham HR, 1998, AM J HUM GENET, V63, P329, DOI 10.1086/301982	30	123	126	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					182	187		10.1038/9700	http://dx.doi.org/10.1038/9700			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369263				2022-12-27	WOS:000080680900026
J	Jouanguy, E; Lamhamedi-Cherradi, S; Lammas, D; Dorman, SE; Fondaneche, MC; Dupuis, S; Doffinger, R; Altare, F; Girdlestone, J; Emile, JF; Ducoulombier, H; Edgar, D; Clarke, J; Oxelius, VA; Brai, M; Novelli, V; Heyne, K; Fischer, A; Holland, SM; Kumararatne, DS; Schreiber, RD; Casanova, JL				Jouanguy, E; Lamhamedi-Cherradi, S; Lammas, D; Dorman, SE; Fondaneche, MC; Dupuis, S; Doffinger, R; Altare, F; Girdlestone, J; Emile, JF; Ducoulombier, H; Edgar, D; Clarke, J; Oxelius, VA; Brai, M; Novelli, V; Heyne, K; Fischer, A; Holland, SM; Kumararatne, DS; Schreiber, RD; Casanova, JL			A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection	NATURE GENETICS			English	Article							INTERFERON-GAMMA-RECEPTOR; CALMETTE-GUERIN INFECTION; GENE; IDENTIFICATION; RESISTANCE; SEQUENCE; BCG; DEFICIENCY; CHILDREN; BINDING	The immunogenetic basis of severe infections caused by bacille Calmette-Guerin vaccine and environmental mycobacteria in humans remains largely unknown. We describe 18 patients from several generations of 12 unrelated families who were heterozygous for 1 to 5 overlapping IFNCR1 frameshift small deletions and a wild-type IFNGR1 allele. There were 12 independent mutation events at a single mutation site, defining a small deletion hotspot. Neighbouring sequence analysis favours a small deletion model of slipped mispairing events during replication. The mutant alleles encode cell-surface IFN gamma receptors that lack the intra-cytoplasmic domain, which, through a combination of impaired recycling, abrogated signalling and normal binding to IFN gamma exert a dominant-negative effect. We thus report a hotspot for human IFNGR1 small deletions that confer dominant susceptibility to infections caused by poorly virulent mycobacteria.	Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England; NIH, Host Def Lab, Bethesda, MD 20892 USA; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Hop Paul Brousse, Serv Anat Pathol, F-94804 Villejuif, France; Hop St Antoine, Serv Pediat, F-59019 Lille, France; Royal Victoria Hosp, Reg Immunol Serv, Belfast BT12 6BN, Antrim, North Ireland; Childrens Hosp, Resp & Cyst Fibrosis Unit, Birmingham B4 6NH, W Midlands, England; Univ Lund, Dept Pediat, S-22185 Lund, Sweden; Ist Patol Gen, I-90134 Palermo, Italy; Great Ormond St Hosp Children, Infect Dis Unit, London WC1N 3JH, England; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Birmingham Heartlands Hosp, Reg Dept Immunol, Birmingham, W Midlands, England; Washington Univ, Dept Pathol, St Louis, MO 63110 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Birmingham; National Institutes of Health (NIH) - USA; University of Birmingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Sorbonne Universite; Lund University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Heart of England NHS Foundation Trust; University of Birmingham; Washington University (WUSTL)	Casanova, JL (corresponding author), Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France.	casanova@ceylan.necker.fr	Schreiber, Robert/Q-7550-2019; Boisson-Dupuis, Stéphanie/I-2040-2017; Schreiber, Robert D/A-1276-2013; altare, frederic/K-8664-2015; Casanova, Jean-Laurent/I-3418-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Jouanguy, Emmanuelle/H-7901-2017	Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Schreiber, Robert D/0000-0001-6311-0432; altare, frederic/0000-0002-5077-4616; Jouanguy, Emmanuelle/0000-0002-7358-9157; Girdlestone, John/0000-0001-7422-9674; Edgar, John David Moore/0000-0003-2969-4475; Casanova, Jean-Laurent/0000-0002-7782-4169; Schreiber, Robert/0000-0003-1590-2341	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, Z01AI000647] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL L, 1988, AM J HUM GENET, V42, P256; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Altare F, 1998, CURR OPIN IMMUNOL, V10, P413, DOI 10.1016/S0952-7915(98)80114-3; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BENNETT RL, 1995, AM J HUM GENET, V56, P745, DOI 10.1007/BF01408073; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 1996, PEDIATRICS, V98, P774; CELADA A, 1985, J CLIN INVEST, V76, P2196, DOI 10.1172/JCI112228; Cooper DN, 1998, GENETIC BASIS HUMAN, P65; Coughlin CM, 1998, IMMUNITY, V9, P25, DOI 10.1016/S1074-7613(00)80585-3; de Jong R, 1998, SCIENCE, V280, P1435; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; Emile JF, 1997, J PATHOL, V181, P25, DOI 10.1002/(SICI)1096-9896(199701)181:1<25::AID-PATH747>3.0.CO;2-Z; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; Frucht DM, 1996, J IMMUNOL, V157, P411; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRUNDY CB, 1991, BLOOD, V78, P1027; HEYNE K, 1976, EUR J PEDIATR, V121, P179, DOI 10.1007/BF00445481; Holland SM, 1998, J INFECT DIS, V178, P1095, DOI 10.1086/515670; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1997, J INTERF CYTOK RES, V17, P583, DOI 10.1089/jir.1997.17.583; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; KRAWCZAK M, 1991, HUM GENET, V86, P425; KRAWCZAK M, 1993, HUMAN GENE MUTATIONS, P163; LAMBAMEDI S, 1998, INT J MOL MED, V1, P415; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Mckusick V.A., 1994, MENDELIAN INHERITANC; Merlin G, 1997, IMMUNOGENETICS, V45, P413, DOI 10.1007/s002510050223; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; RASZKA WV, 1994, CLIN PEDIATR, V33, P611, DOI 10.1177/000992289403301007; ROESLER J, IN PRESS EXP HAEMATO; Schonell M E, 1968, Tubercle, V49, P12, DOI 10.1016/S0041-3879(68)80003-0; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; Winfield JB, 1997, CLIN EXP IMMUNOL, V109, P1, DOI 10.1046/j.1365-2249.1997.00439.x	50	368	383	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					370	378		10.1038/7701	http://dx.doi.org/10.1038/7701			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192386				2022-12-27	WOS:000079439700017
J	Borsani, G; Bassi, MT; Sperandeo, MP; De Grandi, A; Buoninconti, A; Riboni, M; Manzoni, M; Incerti, B; Pepe, A; Andria, G; Ballabio, A; Sebastio, G				Borsani, G; Bassi, MT; Sperandeo, MP; De Grandi, A; Buoninconti, A; Riboni, M; Manzoni, M; Incerti, B; Pepe, A; Andria, G; Ballabio, A; Sebastio, G			SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance	NATURE GENETICS			English	Article							GENE; DATABASE	Lysinuric protein intolerance (LPI, MIM 222700) is an autosomal recessive multisystem disorder found mainly in Finland and Italy. On a normal diet, LPI patients present poor feeding, vomiting, diarrhoea, episodes of hyperammoniaemic coma and failure to thrive. Hepatosplenomegaly, osteoporosis and a life-threatening pulmonary involvement (alveolar proteinosis) are also seen(1). LIP is caused by defective cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in kidney and intestine(1). Metabolic derangement is characterized by increased renal excretion of CAA, reduced CAA absorption from intestine and orotic aciduria. The gene causing LPI was assigned using linkage analysis to chromosome 14q11.2 near the T-cell receptor alpha/delta chains locus, and a critical region has been defined(2). We have identified two new transcripts (SLC7A8 and SLC7A7) homologous to amino acid transporters, highly expressed in kidney and mapping in the LPI critical region. Mutational analysis of both transcripts revealed that SLC7A7 (for solute carrier family 7, member 7) is mutated in LPI. In five Italian patients, we found either an insertion or deletion in the coding sequence, which provides evidence of a causative role of SLC7A7 in LPI. Furthermore, we detected a splice acceptor change resulting in a frameshift and premature translation termination in four unrelated Finnish patients. The mutation may represent the founder LPI allele in Finland(2).	TIGEM, I-20132 Milan, Italy; Univ Naples, Dept Pediat, I-80131 Naples, Italy; Univ Vita & Salute, I-20132 Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Naples Federico II; Vita-Salute San Raffaele University	Borsani, G (corresponding author), TIGEM, San Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		andria, generoso/V-7172-2019; Borsani, Giuseppe/B-1709-2010; BALLABIO, Andrea/AAL-2672-2020; Melis, Daniela/AAD-3623-2019; Bassi, Maria Teresa T/A-3517-2014	Borsani, Giuseppe/0000-0003-0110-1148; BALLABIO, Andrea/0000-0003-1381-4604; Melis, Daniela/0000-0002-9458-3926; Bassi, Maria Teresa T/0000-0002-8236-1197	Telethon [TGM06S01, E.0652, TGM97000] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banfi S, 1998, TRENDS GENET, V14, P80, DOI 10.1016/S0168-9525(97)01354-1; Beckmann JS, 1996, AM J HUM GENET, V59, P1400; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Lauteala T, 1998, EUR J HUM GENET, V6, P612, DOI 10.1038/sj.ejhg.5200236; Lauteala T, 1997, AM J HUM GENET, V60, P1479, DOI 10.1086/515457; Lauteala T, 1997, HUM GENET, V100, P80, DOI 10.1007/s004390050469; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PARENTI G, 1995, J PEDIATR-US, V126, P246, DOI 10.1016/S0022-3476(95)70552-X; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Sambrook J., 2002, MOL CLONING LAB MANU; Simell O, 1995, METAB MOL BASES INHE, V1, P3603; Sperandeo MP, 1998, GENOMICS, V49, P230, DOI 10.1006/geno.1998.5252; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Wolf DA, 1996, CANCER RES, V56, P5012	21	176	183	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					297	301		10.1038/6815	http://dx.doi.org/10.1038/6815			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080183				2022-12-27	WOS:000078977900024
J	Sosa-Pineda, B; Wigle, JT; Oliver, G				Sosa-Pineda, B; Wigle, JT; Oliver, G			Hepatocyte migration during liver development requires Prox1	NATURE GENETICS			English	Article							MOUSE DEVELOPMENT; ENDODERM; GENE; GUT		St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684	NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; LEDOUARIN NM, 1975, MED BIOL, V53, P427; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; ZARET KS, 1988, CURR OPIN GENE DEV, V8, P526	12	270	278	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					254	255		10.1038/76996	http://dx.doi.org/10.1038/76996			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888866				2022-12-27	WOS:000087920900007
J	Lim, KC; Lakshmanan, G; Crawford, SE; Gu, Y; Grosveld, F; Engel, JD				Lim, KC; Lakshmanan, G; Crawford, SE; Gu, Y; Grosveld, F; Engel, JD			Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system	NATURE GENETICS			English	Article							TYROSINE-HYDROXYLASE GENE; MOUSE FETAL DEVELOPMENT; REGULATORY ELEMENTS; TARGETED DISRUPTION; EXPRESSION; TRANSCRIPTION; MICE; DIFFERENTIATION; LOCUS; PROMOTER	Mouse embryos deficient in Gata3 die by 11 days post coitum (d.p.c) from pathology of undetermined origin(1). We recently showed that Gata3-directed lacZ expression of a 625-kb Gata3 YAC transgene in mice mimics endogenous Gata3 expression, except in thymus and the sympathoadrenal system(2). As this transgene failed to overcome embryonic lethality (unpublished data and ref. 3) in Gata3(-/-) mice, we hypothesized that a neuroendocrine deficiency in the sympathetic nervous system (SNS) might cause embryonic lethality in these mutants. We find here that null mutation of Gata3 leads to reduced accumulation of Th (encoding tyrosine hydroxylase, Th) and Dbh (dopamine beta-hydroxylase. Dbh) mRNA. whereas several other SNS genes are unaffected. We show that Th and Dbh deficiencies lead to reduced noradrenaline in the SNS, and that noradrenaline deficiency is a proximal cause of death in mutants by feeding catechol intermediates to pregnant dams, thereby partially averting Gata3 mutation-induced lethality. These older, pharmacologically rescued mutants revealed abnormalities that previously could not be detected in untreated mutants. These late embryonic defects include renal hypoplasia and developmental defects in structures derived from cephalic neural crest cells. Thus we have shown that Gata3 has a role in the differentiation of multiple cell lineages during embryogenesis.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pathol, Evanston, IL 60208 USA; Erasmus Univ, Dept Cell Biol & Genet, Rotterdam, Netherlands	Northwestern University; Northwestern University; Erasmus University Rotterdam	Engel, JD (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.				NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028896] Funding Source: NIH RePORTER; NCI NIH HHS [CA60553] Funding Source: Medline; NIGMS NIH HHS [GM28896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; Esler M, 1997, AM J CARDIOL, V80, pL7, DOI 10.1016/S0002-9149(97)00844-8; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GROVES AK, 1995, DEVELOPMENT, V121, P887; Hirsch MR, 1998, DEVELOPMENT, V125, P599; HOYLE GW, 1994, J NEUROSCI, V14, P2455; Joh T H, 1998, Adv Pharmacol, V42, P33; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; Lakshmanan G, 1998, DEV BIOL, V204, P451, DOI 10.1006/dbio.1998.8991; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; LEONARD MW, 1993, DEVELOPMENT, V119, P519; Lieuw KH, 1997, DEV BIOL, V188, P1, DOI 10.1006/dbio.1997.8575; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; RAHMAN MK, 1981, BIOCHEM PHARMACOL, V30, P645, DOI 10.1016/0006-2952(81)90139-8; ten Berge D, 1998, DEVELOPMENT, V125, P3831; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Tiveron MC, 1996, J NEUROSCI, V16, P7649; Vainio S, 1997, CELL, V90, P975, DOI 10.1016/S0092-8674(00)80363-3; Yang CY, 1998, J NEUROCHEM, V71, P1358; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	27	264	267	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					209	212		10.1038/76080	http://dx.doi.org/10.1038/76080			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835639				2022-12-27	WOS:000087459200023
J	Streicher, J; Donat, MA; Strauss, B; Sporle, R; Schughart, K; Muller, GB				Streicher, J; Donat, MA; Strauss, B; Sporle, R; Schughart, K; Muller, GB			Computer-based three-dimensional visualization of developmental gene expression	NATURE GENETICS			English	Article							SERIAL SECTIONS; 3D RECONSTRUCTION; 3-DIMENSIONAL RECONSTRUCTION; MOUSE EMBRYOS; SYSTEM; SEGMENTATION; DERIVATIVES; DATABASE; DESIGN; MUTANT	A broad understanding of the relationship between gene activation, pattern formation and morphogenesis will require adequate tools for three-dimensional and, perhaps four-dimensional, representation and analysis of molecular developmental processes. We present a novel, computer-based method for the 3D visualization of embryonic gene expression and morphological structures from serial sections. The information from these automatically aligned 3D reconstructions exceeds that from single-section and whole-mount visualizations of in situ hybridizations. In addition, these 3D models of gene-expression patterns can become a central component of a future developmental database designed for the collection and presentation of digitized, morphological and gene-expression data. This work is accompanied by a web site (http://www. univie.ac.at/GeneEMAC).	Univ Vienna, Dept Anat, Integrat Morphol Grp, Vienna, Austria; GSF, Natl Res Ctr Environm & Hlth Neuherberg, Inst Mammalian Genet, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1947, Dept Mol Biol, F-75724 Paris 15, France; Transgene SA, Dept Mol & Cellular Biol, Strasbourg, France	University of Vienna; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Transgene SA	Streicher, J (corresponding author), Univ Vienna, Dept Anat, Integrat Morphol Grp, Vienna, Austria.	johannes.streicher@univie.ac.at		Schughart, Klaus/0000-0002-6824-7523; Streicher, Johannes/0000-0002-4114-2246				ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; ARNOLDS WJA, 1978, STAIN TECHNOL, V53, P287; ARRAEZAYBAR LA, 1994, SURG RADIOL ANAT, V16, P419, DOI 10.1007/BF01627664; Born G, 1883, ARCH MIKROSK ANAT, V22, P584, DOI 10.1007/bf02952679; BRANDLE K, 1989, COMPUT BIOMED RES, V22, P52, DOI 10.1016/0010-4809(89)90015-3; BRAVERMAN MS, 1986, J INVEST DERMATOL, V86, P290, DOI 10.1111/1523-1747.ep12285445; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; HIBBARD LS, 1988, J NEUROSCI METH, V26, P55, DOI 10.1016/0165-0270(88)90129-X; His W., 1887, ANAT ANZEIGER, V2, P382; Holland Linda Z., 1996, P267; HOSONO M, 1995, J DIGIT IMAGING, V8, P105, DOI 10.1007/BF03168084; HUIJSMANS DP, 1986, ANAT RECORD, V216, P449, DOI 10.1002/ar.1092160402; IWAMOTO Y, 1995, ACTA ORTHOP SCAND, V66, P80, DOI 10.3109/17453679508994646; KERI C, 1991, J NEUROSCI METH, V37, P241, DOI 10.1016/0165-0270(91)90030-4; KNOX CK, 1990, P E MULT SOC COMP SI, P12; Krams R, 1997, ARTERIOSCL THROM VAS, V17, P2061, DOI 10.1161/01.ATV.17.10.2061; MITCHIE A, 1983, COMPUTER GRAPHICS IM, V22, P296; MOSS VA, 1990, J MICROSC-OXFORD, V158, P187, DOI 10.1111/j.1365-2818.1990.tb02992.x; Muller GB, 1996, AM ZOOL, V36, P4; OTT MO, 1991, DEVELOPMENT, V111, P1097; PROTHERO JS, 1986, COMPUT BIOMED RES, V19, P361, DOI 10.1016/0010-4809(86)90048-0; RINGWALD M, 1994, SCIENCE, V265, P2033, DOI 10.1126/science.8091224; Roush W, 1997, SCIENCE, V278, P1397, DOI 10.1126/science.278.5342.1397; RYDMARK M, 1992, J MICROSC-OXFORD, V165, P29, DOI 10.1111/j.1365-2818.1992.tb04303.x; Scarborough J, 1997, J ANAT, V191, P117, DOI 10.1046/j.1469-7580.1997.19110117.x; Seidler H, 1997, J HUM EVOL, V33, P691, DOI 10.1006/jhev.1997.0163; SJOSTRAND FS, 1958, J ULTRA MOL STRUCT R, V2, P122, DOI 10.1016/S0022-5320(58)90050-9; SKOGLUND TS, 1995, J NEUROSCI METH, V61, P105, DOI 10.1016/0165-0270(94)00031-B; Smith BR, 1999, SCI AM, V280, P76, DOI 10.1038/scientificamerican0399-76; Sporle R, 1996, DEVELOPMENT, V122, P79; Sporle R, 1998, DEV GENET, V22, P359, DOI 10.1002/(SICI)1520-6408(1998)22:4<359::AID-DVG6>3.0.CO;2-5; Sporle R, 1997, DEV DYNAM, V210, P216; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Stevens J. K., 1994, 3 DIMENSIONAL CONFOC; Streicher J, 1997, ANAT REC, V248, P583; Tajbakhsh S, 1998, CELL, V92, P9, DOI 10.1016/S0092-8674(00)80894-6; Theiler K., 1972, P1; Vazquez MD, 1998, ANAT HISTOL EMBRYOL, V27, P283, DOI 10.1111/j.1439-0264.1998.tb00194.x; VERBEEK FJ, 1995, MICROSC RES TECHNIQ, V30, P496, DOI 10.1002/jemt.1070300607; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209	40	73	76	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					147	152		10.1038/75989	http://dx.doi.org/10.1038/75989			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835627				2022-12-27	WOS:000087459200011
J	Kay, MA; Manno, CS; Ragni, MV; Larson, PJ; Couto, LB; McClelland, A; Glader, B; Chew, AJ; Tai, SJ; Herzog, RW; Arruda, V; Johnson, F; Scallan, C; Skarsgard, E; Flake, AW; High, KA				Kay, MA; Manno, CS; Ragni, MV; Larson, PJ; Couto, LB; McClelland, A; Glader, B; Chew, AJ; Tai, SJ; Herzog, RW; Arruda, V; Johnson, F; Scallan, C; Skarsgard, E; Flake, AW; High, KA			Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector	NATURE GENETICS			English	Article							ADENOASSOCIATED VIRUS	Pre-clinical studies in mice and haemophilic dogs have shown that introduction of an adeno-associated viral (AAV) vector encoding blood coagulation factor IX (F.IX) into skeletal muscle results in sustained expression of F.IX at levels sufficient to correct the haemophilic phenotype(1,2). On the basis of these data and additional pre-clinical studies demonstrating an absence of vector-related toxicity, we initiated a clinical study of intramuscular injection of an AAV vector expressing human F.IX in adults with severe haemophilia B. The study has a dose-escalation design, and all patients have now been enrolled in the initial dose cohort (2x10(11) vg/kg), Assessment in the first three patients of safety and gene transfer and expression show no evidence of germline transmission of vector sequences or formation of inhibitory antibodies against F.IX. We found that the vector sequences are present in muscle by PCR and Southern-blot analyses of muscle biopsies and we demonstrated expression of F.IX by immunohistochemistry. We observed modest changes in clinical endpoints including circulating levels of F.IX and frequency of F.IX protein infusion. The evidence of gene expression at low doses of vector suggests that dose calculations based on animal data may have overestimated the amount of vector required to achieve therapeutic levels in humans, and that the approach offers the possibility of converting severe haemophilia B to a milder form of the disease.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Genet, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Surg, Palo Alto, CA 94304 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA; Avigen Inc, Alameda, CA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Stanford University; Stanford University; Stanford University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	High, KA (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.		High, Katherine A./AAB-9322-2020	McClelland, Alan/0000-0003-2949-3542; Skarsgard, Erik/0000-0003-3713-8196; Manno, Catherine/0000-0001-8029-0391; Kay, Mark/0000-0002-2799-2615	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682, R01HL053668, R01HL061921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53668, R01 HL53682, R01 HL61921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burton M, 1999, P NATL ACAD SCI USA, V96, P12725, DOI 10.1073/pnas.96.22.12725; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; Ljung RCR, 1998, BRIT J HAEMATOL, V101, P215, DOI 10.1046/j.1365-2141.1998.00707.x; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; MANNO CS, 1999, GUIDELINES RES INVOL; Mannucci PM, 1999, SEMIN HEMATOL, V36, P104; Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680; Miller JH., 1972, EXPT MOL GENETICS; PARKS W P, 1970, Infection and Immunity, V2, P716; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	16	792	855	0	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					257	261		10.1038/73464	http://dx.doi.org/10.1038/73464			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700178				2022-12-27	WOS:000085590600015
J	Waeber, G; Delplanque, J; Bonny, C; Mooser, V; Steinmann, M; Widmann, C; Maillard, A; Miklossy, J; Dina, C; Hani, EH; Vionnet, N; Nicod, P; Boutin, P; Froguel, P				Waeber, G; Delplanque, J; Bonny, C; Mooser, V; Steinmann, M; Widmann, C; Maillard, A; Miklossy, J; Dina, C; Hani, EH; Vionnet, N; Nicod, P; Boutin, P; Froguel, P			The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes	NATURE GENETICS			English	Article							INSULIN CONTROL ELEMENT; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; LINKAGE ANALYSIS; MEK KINASE-1; BETA-CELLS; GLUT2 GENE; GLUCOSE; EXPRESSION; GLUCOKINASE	Type 2 diabetes is a polygenic and genetically heterogenous disease(1). The age of onset of the disease is usually late and environmental factors may be required to induce the complete diabetic phenotype. Susceptibility genes for diabetes have not yet been identified. Islet-brain-1 (IB1, encoded by MAPK8IP1), a novel DNA-binding transactivator of the glucose transporter GLUT2 (encoded by SLC2A2), is the homologue of the c-Jun amino-terminal kinase-interacting protein-1 (JIP-1; refs 2-5). We evaluated the role of IB1 in beta-cells by expression of a MAPK8IP1 antisense RNA in a stable insulinoma beta-cell line, A 38% decrease in IB1 protein content resulted in a 49% and a 41% reduction in SLC2A2 and INS (encoding insulin) mRNA expression, respectively. In addition, we detected MAPK8IP1 transcripts and IB1 protein in human pancreatic islets. These data establish MAPK8IP1 as a candidate gene for human diabetes. Sibpair analyses performed on 149 multiplex French families with type 2 diabetes excluded MAPK8IP1 as a major diabetogenic locus. We did, however, identify in one family a missense mutation located in the coding region of MAPK8IP1 (S59N) that segregated with diabetes. In vitro, this mutation was associated with an inability of IB1 to prevent apoptosis induced by MAPK/ERK kinase kinase 1 (MEKK1) and a reduced ability to counteract the inhibitory action of the activated c-JUN amino-terminal kinase (JNK) pathway on INS transcriptional activity. Identification of this novel non-maturity onset diabetes of the young (MODY) form of diabetes demonstrates that IB1 is a key regulator of beta-cell function.	CHUV Univ Hosp, Dept Internal Med, Lausanne, Switzerland; CHUV Univ Hosp, Dept Pathol, Lausanne, Switzerland; Inst Pasteur, Inst Biol, CNRS, F-59019 Lille, France; Univ Lausanne, Inst Morphol & Cellular Biol, CH-1015 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Lausanne	Waeber, G (corresponding author), CHUV Univ Hosp, Dept Internal Med, Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch	Bonny, Christophe/AAV-7214-2021; Widmann, Christian/N-9851-2013; Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017; Vionnet, Nathalie/N-6302-2017	Widmann, Christian/0000-0002-6881-0363; Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; Waeber, Gerard/0000-0003-4193-788X; Miklossy, Judith/0000-0003-4948-8708				Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kahn BB, 1998, NAT GENET, V20, P223, DOI 10.1038/3018; Mooser V, 1999, GENOMICS, V55, P202, DOI 10.1006/geno.1998.5641; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; Vionnet N, 1997, DIABETES, V46, P1062, DOI 10.2337/diabetes.46.6.1062; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WAEBER G, 1994, J BIOL CHEM, V269, P26912; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; ZOUALI H, 1993, DIABETES, V42, P1238, DOI 10.2337/diabetes.42.9.1238	29	151	153	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					291	295		10.1038/73523	http://dx.doi.org/10.1038/73523			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700186				2022-12-27	WOS:000085590600023
J	Li, H; Arber, S; Jessell, TM; Edlund, H				Li, H; Arber, S; Jessell, TM; Edlund, H			Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9	NATURE GENETICS			English	Article							HEDGEHOG; DIFFERENTIATION; MESENCHYME; NOTOCHORD	The initial stages of pancreatic development occur early during mammalian embryogenesis(1), but the genes governing this process remain largely unknown. The homeodomain protein Pdx1 is expressed in the developing pancreatic anlagen from the approximately 10-somite stage(2,3), and mutations in the gene Pdx1 prevent the development of the pancreas(3-5). The initial stages of pancreatic development, however, still occur in Pdx1-deficient mice(3). Hlxb9 (encoding Hb9; ref. 6) is a homeobox gene that in humans has been linked to dominant inherited sacral agenesis(7) and we show here that Hb9 is expressed at early stages of mouse pancreatic development and later in differentiated beta-cells. H1xb9 has an essential function in the initial stages of pancreatic development. In absence of Hlxb9 expression, the dorsal region of the gut epithelium fails to initiate a pancreatic differentiation program. In contrast, the ventral pancreatic endoderm develops but exhibits a later and more subtle perturbation in beta-cell differentiation and in islet cell organization, Thus, dorsally Hlxb9 is required for specifying the gut epithelium to a pancreatic fate and ventrally for ensuring proper endocrine cell differentiation.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; Columbia Univ, Ctr Neurobiol & Behav, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Umea University; Columbia University; Howard Hughes Medical Institute	Edlund, H (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.	helena.edlund@micro.umu.se		Edlund, Helena/0000-0002-3553-7348; Arber, Silvia/0000-0002-6261-250X				Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; ARBER S, IN PRESS NEURON; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kim SK, 1997, DEVELOPMENT, V124, P4243; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ross AJ, 1998, NAT GENET, V20, P358, DOI 10.1038/3828; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5	16	292	306	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					67	70						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471501				2022-12-27	WOS:000082337300018
J	Pollack, JR; Perou, CM; Alizadeh, AA; Eisen, MB; Pergamenschikov, A; Williams, CF; Jeffrey, SS; Botstein, D; Brown, PO				Pollack, JR; Perou, CM; Alizadeh, AA; Eisen, MB; Pergamenschikov, A; Williams, CF; Jeffrey, SS; Botstein, D; Brown, PO			Genome-wide analysis of DNA copy-number changes using cDNA microarrays	NATURE GENETICS			English	Article							GENE-EXPRESSION PATTERNS; BREAST-CANCER; SOLID TUMORS; HYBRIDIZATION; MAP; AMPLIFICATION; REGION; CARCINOMA; SEQUENCES; COMPLEX	Gene amplifications and deletions frequently contribute to tumorigenesis. Characterization of these DNA copy-number changes is important for both the basic understanding of cancer and its diagnosis. Comparative genomic hybridization (CGH) was developed to survey DNA copy-number variations across a whole genome(1). With CCH, differentially labelled test and reference genomic DNAs are co-hybridized to normal metaphase chromosomes, and fluorescence ratios along the length of chromosomes provide a cytogenetic representation of DNA copy-number variation. CCH, however, has a limited (similar to 20 Mb) mapping resolution, and higher-resolution techniques, such as fluorescence in situ hybridization (FISH), are prohibitively labour-intensive on a genomic scale. Array-based CCH, in which fluorescence ratios at arrayed DNA elements provide a locus-by-locus measure of DNA copy-number variation, represents another means of achieving increased mapping resolution(2-4) Published array CGH methods have relied on large genomic clone (for example BAC) array targets and have covered only a small fraction of the human genome. cDNAs representing over 30,000 radiation-hybrid (RH)-mapped human genes(5,6) provide an alternative and readily available genomic resource for mapping DNA copy-number changes. Although cDNA microarrays have been used extensively to characterize variation in human gene expression(7-9), human genomic DNA is a far more complex mixture than the mRNA representation of human cells. Therefore, analysis of DNA copy-number variation using cDNA microarrays would require a sensitivity of detection an order of magnitude greater than has been routinely reported(7). We describe here a cDNA microarray-based CGH method, and its application to DNA copy-number variation analysis in breast cancer cell lines and tumours, Using this assay, we were able to identify gene amplifications and deletions genome-wide and with high resolution, and compare alterations in DNA copy number and gene expression.	Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University	Brown, PO (corresponding author), Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Alizadeh, Ash A/C-5594-2009; Perou, Charles M/H-9934-2014	Alizadeh, Ash A/0000-0002-5153-5625; Perou, Charles M/0000-0001-9827-2247; Jeffrey, Stefanie/0000-0003-4478-2764; Lonning, Per Eystein/0000-0002-8890-6303; Eisen, Michael/0000-0002-7528-738X				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Gelmini S, 1997, CLIN CHEM, V43, P752; Geschwind DH, 1998, DEV GENET, V23, P215, DOI 10.1002/(SICI)1520-6408(1998)23:3<215::AID-DVG7>3.0.CO;2-X; Guan XY, 1996, CANCER RES, V56, P3446; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lucito R, 1998, P NATL ACAD SCI USA, V95, P4487, DOI 10.1073/pnas.95.8.4487; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351	30	1044	1231	2	71	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					41	46		10.1038/12640	http://dx.doi.org/10.1038/12640			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471496	Green Submitted			2022-12-27	WOS:000082337300013
J	Nusbaum, C; Slonim, DK; Harris, KL; Birren, BW; Steen, RG; Stein, LD; Miller, J; Dietrich, WF; Nahf, R; Wang, V; Merport, O; Castle, AB; Husain, Z; Farino, G; Gray, D; Anderson, MO; Devine, R; Horton, LT; Ye, WJ; Wu, XY; Kouyoumjian, V; Zemsteva, IS; Wu, Y; Collymore, AJ; Courtney, DF; Tam, J; Cadman, M; Haynes, AR; Heuston, C; Marsland, T; Southwell, A; Trickett, P; Strivens, MA; Ross, MT; Makalowski, W; Xu, YX; Boguski, MS; Carter, NP; Denny, P; Brown, SDM; Hudson, TJ; Lander, ES				Nusbaum, C; Slonim, DK; Harris, KL; Birren, BW; Steen, RG; Stein, LD; Miller, J; Dietrich, WF; Nahf, R; Wang, V; Merport, O; Castle, AB; Husain, Z; Farino, G; Gray, D; Anderson, MO; Devine, R; Horton, LT; Ye, WJ; Wu, XY; Kouyoumjian, V; Zemsteva, IS; Wu, Y; Collymore, AJ; Courtney, DF; Tam, J; Cadman, M; Haynes, AR; Heuston, C; Marsland, T; Southwell, A; Trickett, P; Strivens, MA; Ross, MT; Makalowski, W; Xu, YX; Boguski, MS; Carter, NP; Denny, P; Brown, SDM; Hudson, TJ; Lander, ES			A YAC-based physical map of the mouse genome	NATURE GENETICS			English	Article							RESOLUTION; SYSTEM	A physical map of the mouse genome is an essential tool for both positional cloning and genomic sequencing in this key model system for biomedical research, Indeed, the construction of a mouse physical map with markers spaced at an average interval of 300 kb is one of the stated goals of the Human Genome Project(1). Here we report the results of a project at the Whitehead Institute/MIT Center for Genome Research to construct such a physical map of the mouse. We built the map by screening sequenced-tagged sites (STSs) against a large-insert yeast artificial chromosome (YAC) library and then integrating the STS-content information with a dense genetic map. The integrated map shows the location of 9,787 loci, providing landmarks with an average spacing of approximately 300 kb and affording YAC coverage of approximately 92% of the mouse genome. We also report the results of a project at the MRC UK Mouse Genome Centre targeted at chromosome X. The project produced a YAC-based map containing 619 loci (with 121 loci in common with the Whitehead map and 498 additional loci), providing especially dense coverage of this sex chromosome. The YAC-based physical map directly facilitates positional cloning of mouse mutations by providing ready access to most of the genome. More generally, use of this map in addition to a newly constructed radiation hybrid (RH) map(2) provides a comprehensive framework for mouse genomic studies.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MRC, UK Mouse Genome Ctr, Harwell OX11 0RD, Berks, England; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; Sanger Ctr Wellcome Trust Genome Campus, Cambridge CB10 1SA, England; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Johns Hopkins Univ, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Wellcome Trust Sanger Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Johns Hopkins University; McGill University; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		wang, vicky/AAO-6474-2020	Denny, Paul/0000-0003-4659-6893; Hudson, Thomas/0000-0002-1376-4849; Makalowski, Wojciech/0000-0003-2303-9541; Slonim, Donna/0000-0003-3357-437X; Xu, Ethan/0000-0002-7496-0835	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANAND R, 1991, GENOMICS, V9, P124, DOI 10.1016/0888-7543(91)90229-8; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DENNY P, 1999, MOUSE GENETICS TRANS; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; EVANS EP, 1996, GENETIC VARIANTS STR, P1446; Haldi ML, 1996, MAMM GENOME, V7, P767, DOI 10.1007/s003359900228; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; RABBITTS P, 1995, NAT GENET, V9, P369, DOI 10.1038/ng0495-369; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Soderlund C, 1995, COMPUT APPL BIOSCI, V11, P645; Strivens MA, 1997, MAMM GENOME, V8, P467, DOI 10.1007/s003359900478; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962	15	58	66	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					388	393		10.1038/11967	http://dx.doi.org/10.1038/11967			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431246				2022-12-27	WOS:000081772500024
J	Fleming, JC; Tartaglini, E; Steinkamp, MP; Schorderet, DF; Cohen, N; Neufeld, EJ				Fleming, JC; Tartaglini, E; Steinkamp, MP; Schorderet, DF; Cohen, N; Neufeld, EJ			The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter	NATURE GENETICS			English	Article							MEGALOBLASTIC-ANEMIA SYNDROME; SACCHAROMYCES-CEREVISIAE; DATABASE; CELLS	Thiamine-responsive megaloblastic anaemia with diabetes and deafness(1) (TRMA; MIM 249270) is an autosomal recessive disease thought to be due to a defect in thiamine (vitamin B1) transport(2,3). Pharmacological doses of thiamine correct the anaemia, and in some cases improve the diabetes, although progressive sensorineural deafness is irreversible(4). Previous studies localized the TRMA gene to a 4-cM region on chromosome 1q23.3 (ref. 5), and fine-mapping has recently narrowed that region further(6,7). We have previously demonstrated that fibroblasts from people with TRMA lack high-affinity thiamine transports. Expression of a gene encoding a known yeast thiamine transporter, THI10 (refs 8-10), in TRMA mutant cells prevents apoptotic cell death in thiamine-depleted medium. On the basis of these studies, we hypothesized that a defective thiamine transporter causes TRMA. We undertook a candidate gene approach to identify putative thiamine transporters in the 1q23.3 critical region. Here we present evidence that the gene SLC19A2 (for solute carrier family 19 (thiamine transporter), member 2) encodes the first known mammalian thiamine transporter, which we designate thiamine transporter-1 (THTR-1).	Childrens Hosp, Dana Farber Canc Inst, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Ancona, Inst Biochem, I-60100 Ancona, Italy; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Tamkin Human Mol Genet Res Facil, Dept Genet, IL-31096 Haifa, Israel	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Marche Polytechnic University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Neufeld, EJ (corresponding author), Childrens Hosp, Dana Farber Canc Inst, Div Hematol, Boston, MA 02115 USA.		Neufeld, Ellis J./F-9331-2011	Neufeld, Ellis J./0000-0001-8092-6281; Steinkamp, Mara/0000-0003-1226-9325	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007574] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Banikazemi M, 1999, MOL GENET METAB, V66, P193, DOI 10.1006/mgme.1998.2799; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; Enjo F, 1997, J BIOL CHEM, V272, P19165, DOI 10.1074/jbc.272.31.19165; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; Neufeld EJ, 1997, AM J HUM GENET, V61, P1335, DOI 10.1086/301642; POGGI V, 1984, J INHERIT METAB DIS, V7, P153; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Raz T, 1998, HUM GENET, V103, P455, DOI 10.1007/s004390050850; RINDI G, 1992, J INHERIT METAB DIS, V15, P231, DOI 10.1007/BF01799637; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; ROST B, 1995, PROTEIN SCI, V4, P521; Sambrook J., 2002, MOL CLONING LAB MANU; Singleton CK, 1997, GENE, V199, P111, DOI 10.1016/S0378-1119(97)00354-5; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468	18	182	185	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					305	308		10.1038/10379	http://dx.doi.org/10.1038/10379			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391222				2022-12-27	WOS:000081125900027
J	Rieder, MJ; Taylor, SL; Clark, AG; Nickerson, DA				Rieder, MJ; Taylor, SL; Clark, AG; Nickerson, DA			Sequence variation in the human angiotensin converting enzyme	NATURE GENETICS			English	Article							HUMAN LIPOPROTEIN-LIPASE; CARDIOVASCULAR-DISEASE; DNA-SEQUENCES; GENE; POLYMORPHISM; POPULATIONS; INFERENCE; GENOTYPE; AFRICAN; NUMBER	Angiotensin converting enzyme (encoded by the gene DCP1, also known as ACE) catalyses the conversion of angiotensin I to the physiologically active peptide angiotensin II, which controls fluid-electrolyte balance and systemic blood pressure. Because of its key function in the renin-angiotensin system, many association studies have been performed with DCP1. Nearly all studies have associated the presence (insertion, I) or absence (deletion, D) of a 287-bp Alu repeat element in intron 16 with the levels of circulating enzyme or cardiovascular pathophysiologies(1-3). Many epidemiological studies suggest that the DCP1*D allele confers increased susceptibility to cardiovascular disease; however, other reports have found no such association or even a beneficial effect (refs 4-7), We present here the complete genomic sequence of DCP1 from 11 individuals, representing the longest contiguous scan (24 kb) for sequence variation in human DNA, We identified 78 varying sites in 22 chromosomes that resolved into 13 distinct haplotypes. Of the variant sites, 17 were in absolute linkage disequilibrium with the commonly typed Alu insertion/deletion polymorphism, producing two distinct and distantly related clades. We also identified a major subdivision in the Alu deletion clade that enables further analysis of the traits associated with this gene. The diversity uncovered in DCP1 is comparable to that described for other regions in the human genomes-(8-11), The highly correlated structure in DCP1 raises important issues for the determination of functional DNA variants within genes and genetic studies in humans based on marker association.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Penn State Univ, Dept Biol, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Rieder, MJ (corresponding author), Univ Washington, Dept Mol Biotechnol, Box 357730, Seattle, WA 98195 USA.		Rieder, Michael J/L-2397-2013	Clark, Andrew/0000-0001-7159-8511	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058240, R01HL058238] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001436] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01436] Funding Source: Medline; NHLBI NIH HHS [HL58238, HL58240] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; EVANS AE, 1994, Q J MED, V87, P211; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; GRIFFITHS RC, 1994, STAT SCI, V9, P307, DOI 10.1214/ss/1177010378; Harding RM, 1997, AM J HUM GENET, V60, P772; Hey J, 1997, MOL BIOL EVOL, V14, P166, DOI 10.1093/oxfordjournals.molbev.a025749; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUDSON RR, 1985, GENETICS, V111, P147; Keavney B, 1998, HUM MOL GENET, V7, P1745, DOI 10.1093/hmg/7.11.1745; Long AD, 1998, GENETICS, V149, P999; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Nachman MW, 1998, GENETICS, V150, P1133; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; O'Donnell CJ, 1998, CIRCULATION, V97, P1766, DOI 10.1161/01.CIR.97.18.1766; O'Malley JP, 1998, CIRCULATION, V97, P1780, DOI 10.1161/01.CIR.97.18.1780; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Schunkert H, 1997, J MOL MED-JMM, V75, P867, DOI 10.1007/s001090050178; SCRIVER CR, 1996, VARIATION HUMAN GENO, P73; SING CF, 1992, EUR J EPIDEMIOL, V8, P3, DOI 10.1007/BF00145343; SOUBRIER F, 1994, EUR HEART J, V15, P24, DOI 10.1093/eurheartj/15.suppl_D.24; TAJIMA F, 1989, GENETICS, V123, P585; TAJIMA F, 1983, GENETICS, V105, P437; Tavare S, 1997, GENETICS, V145, P505; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	30	377	391	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					59	62		10.1038/8760	http://dx.doi.org/10.1038/8760			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319862				2022-12-27	WOS:000080096300023
J	Levy, JE; Jin, O; Fujiwara, Y; Kuo, F; Andrews, NC				Levy, JE; Jin, O; Fujiwara, Y; Kuo, F; Andrews, NC			Transferrin receptor is necessary for development of erythrocytes and the nervous system	NATURE GENETICS			English	Article							IRON UPTAKE; MOUSE; CELLS; MICE; ATRANSFERRINEMIA; HEMOCHROMATOSIS; PRECURSORS; LACKING; DEFECT; GENE	Plasma iron circulates bound to transferrin (Trf), which solubilizes the ferric ion and attenuates its reactivity. Diferric Trf interacts with cell-surface Trf receptor (Trfr) to undergo receptor-mediated endocytosis into specialized endosomes. Endosomal acidification leads to iron release, and iron is transported out of the endosome through the activity of divalent metal transporter 1 (DMT1, formerly Nramp2), a transmembrane iron transporter that functions only at low pH (ref. 1). Trf and Trfr then return to the cell surface for reuse, completing a highly efficient cycle. Although the Trf cycle is assumed to be the general mechanism for cellular iron uptake, this has not been validated experimentally. Mice with hypotransferrinaemia (hpx) have little or no plasma Trf (refs 2,3). They have severe anaemia, indicating that the Trf cycle is essential for iron uptake by erythroid cells'. Other hpx tissues, however, are generally normal, and there is a paradoxical increase in intestinal iron absorption and iron storage(3,4). To test the hypothesis that the Trf cycle has unique importance for erythropoiesis, we disrupted the Trfr gene in mice. This results in elimination of the Trf cycle, but leaves other Trf functions intact. Mice lacking Trfr have a more severe phenotype than hpx mice, affecting both erythropoiesis and neurologic development. Furthermore, haploinsufficiency for Trfr results in impaired erythroid development and abnormal iron homeostasis.	Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Andrews, NC (corresponding author), Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.			Andrews, Nancy/0000-0003-0243-4462	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051057, R29HL051057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03503, HL51057] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GJ, 1990, GASTROENTEROLOGY, V98, P576, DOI 10.1016/0016-5085(90)90276-7; ANDREWS NC, 1997, HEMATOLOGY INFANCY C, P423; BERNSTEIN SE, 1987, J LAB CLIN MED, V110, P690; CRAVEN CM, 1987, P NATL ACAD SCI USA, V84, P3457, DOI 10.1073/pnas.84.10.3457; DICKINSON TK, 1994, BRAIN RES, V635, P169, DOI 10.1016/0006-8993(94)91436-2; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gelvan D, 1996, BLOOD, V88, P3200, DOI 10.1182/blood.V88.8.3200.bloodjournal8883200; HUGGENVIK JI, 1989, BLOOD, V74, P482; INMAN RS, 1993, J BIOL CHEM, V268, P8521; JOINER CH, 1995, BLOOD, V86, P4307, DOI 10.1182/blood.V86.11.4307.bloodjournal86114307; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TORRENCE JD, 1980, METHODS HAEMATOLOGY, P104; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	21	432	444	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					396	399		10.1038/7727	http://dx.doi.org/10.1038/7727			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192390				2022-12-27	WOS:000079439700021
J	Perez, GI; Robles, R; Knudson, CM; Flaws, JA; Korsmeyer, SJ; Tilly, JL				Perez, GI; Robles, R; Knudson, CM; Flaws, JA; Korsmeyer, SJ; Tilly, JL			Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency	NATURE GENETICS			English	Article							EXPRESSION; APOPTOSIS; BCL-2; MICE	Female mammals are endowed with a finite number of oocytes at birth, each enclosed by a single layer of somatic (granulosa) cells in a primordial follicle(1,2). The fate of most follicles is atretic degeneration(1,3), a process that culminates in near exhaustion of the oocyte reserve at approximately the fifth decade of life in women, leading to menopause(4,5). Apoptosis has a fundamental role in follicular atresia(6,7), and recent studies have shown that Bax, which is expressed in both granulosa cells(8,9) and oocytes(10), may be central to ovarian cell death(6-12). Here we show that young adult female Bax(-/-) mice possess threefold more primordial follicles in their ovarian reserve than their wild-type sisters, and this surfeit of follicles is maintained in advanced chronological age, such that 20-22-month-old female Bax(-/-) mice possess hundreds of follicles at ail developmental stages and exhibit ovarian steroid-driven uterine hypertrophy. These observations contrast with the ovarian and uterine atrophy seen in aged wild-type female mice. Aged female Bax(-/-) mice fail to become pregnant when housed with young adult males; however, metaphase II oocytes can be retrieved from, and corpora lutea form in, ovaries of aged Bax(-/-) females following superovulation with exogenous gonadotropins, and some oocytes are competent for in vitro fertilization and early embryogenesis. Therefore, ovarian lifespan can be extended by selectively disrupting Bax function, but other aspects of normal reproductive performance remain defective in aged Bax(-/-) female mice.	Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore	Tilly, JL (corresponding author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.		Perez, Gloria I/GMX-1286-2022	Knudson, Charles Michael/0000-0003-3964-5466	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49712] Funding Source: Medline; NIA NIH HHS [R01-AG12279] Funding Source: Medline; NICHD NIH HHS [R01-HD34226] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; GOSDEN RG, 1983, BIOL REPROD, V28, P255, DOI 10.1095/biolreprod28.2.255; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; HAMMOND CB, 1996, OBSTET GYNECOL, V87, P25; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kugu K, 1998, CELL DEATH DIFFER, V5, P67, DOI 10.1038/sj.cdd.4400316; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly J. L., 1996, CONTEMP OBSTET GYNEC, V41, P59; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TILLY JL, 1998, CELLS DIE COMPREHENS, P431; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	15	295	320	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					200	203		10.1038/5985	http://dx.doi.org/10.1038/5985			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988273				2022-12-27	WOS:000078399500023
J	Bassett, DE; Eisen, MB; Boguski, MS				Bassett, DE; Eisen, MB; Boguski, MS			Gene expression informatics - it's all in your mine	NATURE GENETICS			English	Review							DATABASE; HYBRIDIZATION; ARRAYS	Technologies for whole-genome RNA expression studies are becoming increasingly reliable and accessible. However, universal standards to make the data more suitable for comparative analysis and for inter-operability with other information resources have yet to emerge. Improved access to large electronic data sets, reliable and consistent annotation and effective tools for 'data mining' are critical. Analysis methods that exploit large data warehouses of gene expression experiments will be necessary to realize the full potential of this technology.	Rosetta Inpharmat, Kirkland, WA 98034, Australia; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Bassett, DE (corresponding author), Rosetta Inpharmat, Kirkland, WA 98034, Australia.	boguski@ncbi.nlm.nih.gov		Eisen, Michael/0000-0002-7528-738X; Bassett, Douglas/0000-0002-1619-4618				Baxevanis A, 1998, BIOINFORMATICS PRACT; Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; Berry M, 1997, DATA MINING TECHNIQU; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Brownstein MJ, 1998, TRENDS BIOTECHNOL, P27, DOI 10.1016/S0167-7799(98)00134-6; Carr D.B., 1997, STAT COMPUTING GRAPH, V8, P20; Chen Y., 1997, BIOMED OPTICS, V2, P364; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; EISEN MB, IN PRESS P NATL ACAD; Ermolaeva O, 1998, NAT GENET, V20, P19, DOI 10.1038/1670; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; IYER VR, IN PRESS SCIENCE; Kanehisa M, 1998, TRENDS BIOTECHNOL, P24, DOI 10.1016/S0167-7799(98)00133-4; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; McEntyre J, 1998, TRENDS GENET, V14, P39, DOI 10.1016/S0168-9525(97)01325-5; Michaels G S, 1998, Pac Symp Biocomput, P42; Ouellette BFF, 1997, GENOME RES, V7, P952, DOI 10.1101/gr.7.10.952; RINGWALD M, 1994, SCIENCE, V265, P2033, DOI 10.1126/science.8091224; Ringwald M, 1997, SEMIN CELL DEV BIOL, V8, P489, DOI 10.1006/scdb.1997.0177; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuler GD, 1996, METHOD ENZYMOL, V266, P141; SPELLMAN PT, IN PRESS MOL BIOL CE; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334	37	280	313	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21			S			51	55		10.1038/4478	http://dx.doi.org/10.1038/4478			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915502				2022-12-27	WOS:000078008200013
J	Brown, PO; Botstein, D				Brown, PO; Botstein, D			Exploring the new world of the genome with DNA microarrays	NATURE GENETICS			English	Review							GENE-EXPRESSION; OLIGONUCLEOTIDE ARRAYS; HYBRIDIZATION	Thousands of genes are being discovered for the first time by sequencing the genomes of model organisms, an exhilarating reminder that much of the natural world remains to be explored at the molecular level. DNA microarrays provide a natural vehicle for this exploration. The model organisms are the first for which comprehensive genome-wide surveys of gene expression patterns or function are possible. The results can be viewed as maps that reflect the order and logic of the genetic program, rather than the physical order of genes on chromosomes. Exploration of the genome using DNA microarrays and other genome-scale technologies should narrow the gap in our knowledge of gene function and molecular biology between the currently-favoured model organisms and other species.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu						Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CHERVITZ SA, IN PRESS SCIENCE; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 1998, P NATL ACAD SCI USA, V95, P3752, DOI 10.1073/pnas.95.7.3752; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; EISEN M, IN PRESS P NATL ACAD; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Hauser NC, 1998, YEAST, V14, P1209, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1209::AID-YEA311>3.0.CO;2-N; IYER VR, IN PRESS SCIENCE; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTON MJ, IN PRESS NATURE MED; NELSON SF, 1993, NAT GENET, V4, P11, DOI 10.1038/ng0593-11; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SPELLMAN PT, 1998, MOL BIOL CELL, V95, P14863; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	27	1706	1839	3	223	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			33	37		10.1038/4462	http://dx.doi.org/10.1038/4462			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915498				2022-12-27	WOS:000078008200009
J	Nadeau, JH; Frankel, WN				Nadeau, JH; Frankel, WN			The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs	NATURE GENETICS			English	Editorial Material							QUANTITATIVE TRAIT LOCI; COMPLEX TRAITS; MOUSE GENOME; MICE; SUSCEPTIBILITY; DISSECTION	In model organisms, chemical mutagenesis provides a powerful alternative to natural, polygenic Variation (for example, quantitative trait loci (QTLs)) for identifying functional pathways and complex disease genes. Despite recent progress in QTLs, we expect that mutagenesis will ultimately prove more effective because the prospects of gene identification are high and every gene affecting a trait is potentially a target.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Case Western Reserve University; University Hospitals of Cleveland; Jackson Laboratory	Nadeau, JH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.	jhn4@po.cwru.edu; wnf@jax.org			NCI NIH HHS [CA75056] Funding Source: Medline; NCRR NIH HHS [RR12305] Funding Source: Medline; NHLBI NIH HHS [HL58982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075056] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012305] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012; Chen YJ, 2000, MAMM GENOME, V11, P598, DOI 10.1007/s003350010114; CHURCHILL GA, 1994, GENETICS, V138, P963; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DARVASI A, 1995, GENETICS, V141, P1199; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Davis AP, 1998, TRENDS GENET, V14, P438, DOI 10.1016/S0168-9525(98)01579-0; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Fridman E, 2000, P NATL ACAD SCI USA, V97, P4718, DOI 10.1073/pnas.97.9.4718; Glenister PH, 2000, MAMM GENOME, V11, P565, DOI 10.1007/s003350010108; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; Legare ME, 2000, GENOME RES, V10, P42; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Manenti G, 1999, GENOME RES, V9, P639; Marker PC, 1997, GENETICS, V145, P435; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; MUNROE RJ, 2000, MAMM GENOME, V11, P507; Nadeau JH, 2000, NAT GENET, V24, P221, DOI 10.1038/73427; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Paterson A. H., 1998, MOL DISSECTION COMPL; RINCHIK EM, 1991, TRENDS GENET, V7, P15, DOI 10.1016/0168-9525(91)90016-J; Schimenti J, 1998, GENOME RES, V8, P698, DOI 10.1101/gr.8.7.698; Symula DJ, 1999, NAT GENET, V23, P241, DOI 10.1038/13880; Sztein J, 1998, BIOL REPROD, V58, P1071, DOI 10.1095/biolreprod58.4.1071; Sztein JM, 1997, CRYOBIOLOGY, V35, P46, DOI 10.1006/cryo.1997.2024; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; You Y, 1997, NAT GENET, V15, P285, DOI 10.1038/ng0397-285; ZENG ZB, 1994, GENETICS, V136, P1457	34	150	164	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					381	384		10.1038/78051	http://dx.doi.org/10.1038/78051			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932178				2022-12-27	WOS:000088615000009
J	Shimura, H; Hattori, N; Kubo, S; Mizuno, Y; Asakawa, S; Minoshima, S; Shimizu, N; Iwai, K; Chiba, T; Tanaka, K; Suzuki, T				Shimura, H; Hattori, N; Kubo, S; Mizuno, Y; Asakawa, S; Minoshima, S; Shimizu, N; Iwai, K; Chiba, T; Tanaka, K; Suzuki, T			Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase	NATURE GENETICS			English	Article							ALPHA-SYNUCLEIN; LEWY BODIES; DEGRADATION; INCLUSIONS; PATHWAY; SPECIFICITY; PROTEASOME; MUTATIONS; ENZYMES; SYSTEM	Autosomal recessive juvenile parkinsonism (AR-JP). one of the most common familial forms of Parkinson disease, is characterized by selective dopaminergic neural cell death and the absence of the Lewy body, a cytoplasmic inclusion body consisting of aggregates of abnormally accumulated proteins(1). We previously cloned PARK2, mutations of which cause AR-JP (ref. 2). but the function of the gene product, parkin. remains unknown. We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conjugating enzyme UbcH7. and that mutant parkins from AR-JP patients show loss of the ubiquitin-protein ligase activity. Our findings indicate that accumulation of proteins that have yet to be identified causes a selective neural cell death without formation of Lewy bodies. Our findings should enhance the exploration of the molecular mechanisms of neurodegeneration in Parkinson disease as well as in other neurodegenerative diseases that are characterized by involvement of abnormal protein ubiquitination. including Alzheimer disease, other tauopathies. CAG triplet repeat disorders and amyotrophic lateral sclerosis(3-10).	Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Japan Sci & Technol Corp, JST, CREST, Bunkyo Ku, Tokyo, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 113, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Juntendo University; Keio University; Kyoto University	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan.		shimura, hideki/AAA-2864-2020; Longo, Kenneth A/A-5631-2010; Hattori, Nobutaka/ACR-0069-2022; IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951; Suzuki, Toshiaki/0000-0002-0650-6251; Minoshima, Satoshi/0000-0002-0043-3047				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Floyd JA, 1999, NEURON, V24, P765, DOI 10.1016/S0896-6273(00)81022-3; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; MAYER RJ, 1998, UBIQUITIN BIOL CELL, P429; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Pallares-Trujillo J, 1998, INT J MOL MED, V2, P3; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	30	1558	1647	1	135	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					302	305		10.1038/77060	http://dx.doi.org/10.1038/77060			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888878				2022-12-27	WOS:000087920900018
J	Albertson, DG; Ylstra, B; Segraves, R; Collins, C; Dairkee, SH; Kowbel, D; Kuo, WL; Gray, JW; Pinkel, D				Albertson, DG; Ylstra, B; Segraves, R; Collins, C; Dairkee, SH; Kowbel, D; Kuo, WL; Gray, JW; Pinkel, D			Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene	NATURE GENETICS			English	Article							BREAST-CANCER; VITAMIN-D; HYBRIDIZATION; CLONING; SYSTEM; MAP		Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, Canc Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, Breast Oncol Program, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.		Ylstra, Bauke/D-2906-2012; Dairkee, Shanaz Hashmi/D-6743-2012	Ylstra, Bauke/0000-0001-9479-3010; Dairkee, Shanaz/0000-0002-2073-9684	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017665] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045919, R01CA080314] Funding Source: NIH RePORTER; NCI NIH HHS [CA80314, CA45919] Funding Source: Medline; NICHD NIH HHS [HD17665] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSON DG, 1993, GENETICS, V134, P211; ALBERTSON DG, 1995, CAENORHABDITIS ELEGA, P339; Alini M, 1996, DEV BIOL, V176, P124, DOI 10.1006/dbio.1996.9989; BRODEUR GM, 1998, GENETIC BASIS HUMAN, P161; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Courjal F, 1997, CANCER RES, V57, P4360; Geschwind DH, 1998, DEV GENET, V23, P215, DOI 10.1002/(SICI)1520-6408(1998)23:3<215::AID-DVG7>3.0.CO;2-X; John EM, 1999, CANCER EPIDEM BIOMAR, V8, P399; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719	15	464	480	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					144	146		10.1038/75985	http://dx.doi.org/10.1038/75985			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835626				2022-12-27	WOS:000087459200010
J	Arbour, NC; Lorenz, E; Schutte, BC; Zabner, J; Kline, JN; Jones, M; Frees, K; Watt, JL; Schwartz, DA				Arbour, NC; Lorenz, E; Schutte, BC; Zabner, J; Kline, JN; Jones, M; Frees, K; Watt, JL; Schwartz, DA			TLR4 mutations are associated with endotoxin hyporesponsiveness in humans	NATURE GENETICS			English	Article							TOLL-LIKE RECEPTOR-4; DROSOPHILA TOLL; GENE-TRANSFER; GRAIN DUST; LIPOPOLYSACCHARIDE; MICE; RESPONSIVENESS; INDUCTION	There is much variability between individuals in the response to inhaled toxins, but it is not known why certain people develop disease when challenged with environmental agents and others remain healthy. To address this, we investigated whether TLR4 (encoding the toll-like receptor-4), which has been shown to affect lipopolysaccharide (LPS) responsiveness in mice(1,2) underlies the variability in airway responsiveness to inhaled LPS in humans(3). Here we show that common, co-segregating missense mutations (Asp299Gly and Thr399Ile) affecting the extracellular domain of the TLR4 receptor are associated with a blunted response to inhaled LPS in humans. Transfection of THP-1 cells demonstrates that the Asp299Gly mutation (but not the Thr399Ile mutation) interrupts TLR4-mediated LPS signalling. Moreover. the wild-type allele of TLR4 rescues the LPS hyporesponsive phenotype in either primary airway epithelial cells or alveolar macrophages obtained from individuals with the TLR4 mutations. Our findings provide the first genetic evidence that common mutations in TLR4 are associated with differences in LPS responsiveness in humans, and demonstrate that gene-sequence changes can alter the ability of the host to respond to environmental stress.	Univ Iowa, Dept Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Vet Affairs Med Ctr, Dept Pediat, Iowa City, IA USA; Univ Iowa, Dept Vet Affairs Med Ctr, Dept Biostat, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Schwartz, DA (corresponding author), Univ Iowa, Dept Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA.			Zabner, Joseph/0000-0002-9606-1339; kline, joel/0000-0002-5523-8855	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607, R01ES007498, R01ES006537] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07498, ES06537, ES09607] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Becker S, 1999, AM J RESP CRIT CARE, V160, P1309, DOI 10.1164/ajrccm.160.4.9901062; Bonner JC, 1998, AM J RESP CELL MOL, V19, P672, DOI 10.1165/ajrcmb.19.4.3176; BRIGGS D, 1986, SURF INTERFACE ANAL, V8, P133, DOI 10.1002/sia.740080306; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Fisher L, 1993, BIOSTATISTICS METHOD; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GUYER M, 1992, SCIENCE, V258, P67; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; OBRIEN AD, 1980, NATURE, V287, P440, DOI 10.1038/287440a0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RASKANDERSEN A, 1989, BRIT J IND MED, V46, P412; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SANTAMARIA P, 1989, J IMMUNOL, V143, P913; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603, DOI 10.1164/ajrccm.152.2.7633714; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; WARREN W, 1997, CURRENT PROTOCOLS HU; ZABNER J, 1996, J VIROL, V70, P6694	25	1609	1706	2	65	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					187	+		10.1038/76048	http://dx.doi.org/10.1038/76048			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835634				2022-12-27	WOS:000087459200018
J	Schultz, J; Doerks, T; Ponting, CP; Copley, RR; Bork, P				Schultz, J; Doerks, T; Ponting, CP; Copley, RR; Bork, P			More than 1,000 putative new human signalling proteins revealed by EST data mining	NATURE GENETICS			English	Article							GENES	Cloning procedures aided by homology searches of EST databases have accelerated the pace of discovery of new genes' but EST database searching remains an involved and onerous task. More than 1.6 million human EST sequences have been deposited in public databases, making it difficult to identify ESTs that represent new genes. Compounding the problems of scale are difficulties in detection associated with a high sequencing error rate and low sequence similarity between distant homologues. We have developed a new method, coupling BLAST-based(2) searches with a domain identification protocol(3,4) that filters candidate homologues. Application of this method in a large-scale analysis of 100 signalling domain families has led to the identification of ESTs representing more than 1,000 novel human signalling genes. The 4,206 publicly available ESTs representing these genes are a valuable resource for rapid cloning of novel human signalling proteins. For example, we were able to identify ESTs of at least 106 new small GTPases, of which 6 are likely to belong to new subfamilies. In some cases, further analyses of genomic DNA led to the discovery of previously unidentified full-length protein sequences. This is exemplified by the in silico cloning (prediction of a gene product sequence using only genomic and EST sequence data) of a new type of GTPase with two catalytic domains.	EMBL, Heidelberg, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, Oxford, England	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oxford	Bork, P (corresponding author), EMBL, Heidelberg, Germany.		Bork, Peer/F-1813-2013; Ponting, Chris/AAV-2621-2021; Schultz, Joerg/B-9346-2008	Bork, Peer/0000-0002-2627-833X; Ponting, Chris/0000-0003-0202-7816				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRNEY E, 1997, ISMB, V5, P56; Bork P, 1996, METHOD ENZYMOL, V266, P162; Pandey A, 1999, TRENDS BIOCHEM SCI, V24, P276, DOI 10.1016/S0968-0004(99)01400-0; PRIGENT C, 1998, IN SILICO BIOL, V1, P11; Retief JD, 1999, GENOME RES, V9, P373; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SUNYAEV S, IN PRESS ADV PROTEIN; Wadman M, 1999, NATURE, V398, P177, DOI 10.1038/18250; Wolff AM, 1999, YEAST, V15, P427, DOI 10.1002/(SICI)1097-0061(19990330)15:5<427::AID-YEA362>3.3.CO;2-X	12	35	46	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					201	204		10.1038/76069	http://dx.doi.org/10.1038/76069			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835637				2022-12-27	WOS:000087459200021
J	Gatei, M; Young, D; Cerosaletti, KM; Desai-Mehta, A; Spring, K; Kozlov, S; Lavin, MF; Gatti, RA; Concannon, P; Khanna, K				Gatei, M; Young, D; Cerosaletti, KM; Desai-Mehta, A; Spring, K; Kozlov, S; Lavin, MF; Gatti, RA; Concannon, P; Khanna, K			ATM-dependent phosphorylation of nibrin in response to radiation exposure	NATURE GENETICS			English	Article							STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; IONIZING-RADIATION; C-ABL; PROTEIN; KINASE; GENE; P53; PHENOTYPE; PRODUCT	Mutations in the gene ATM are responsible for the genetic disorder ataxia-telangiectasia (A-T), which is characterized by cerebellar dysfunction, radiosensitivity, chromosomal instability and cancer predisposition. Both the A-T phenotype and the similarity of the ATM protein to other DNA-damage sensors suggests a role for ATM in biochemical pathways involved in the recognition, signalling and repair of DNA double-strand breaks (DSBs). Them are strong parallels between the pattern of radiosensitivity, chromosomal instability and cancer predisposition in A-T patients and that in patients with Nijmegen breakage syndrome (NBS). The protein defective in NBS, nibrin (encoded by NBS1), forms a complex with MRE11 and RAD50 (refs 1,2). This complex localizes to DSBs within 30 minutes after cellular exposure to ionizing radiation (1R) and is observed in brightly staining nuclear foci after a longer period of time(3). The overlap between clinical and cellular phenotypes in A-T and NBS suggests that ATM and nibrin may function in the same biochemical pathway. Here we demonstrate that nibrin is phosphorylated within one hour of treatment of cells with IR. This response is abrogated in A-T cells that either do not express ATM protein or express near full-length mutant protein. We also show that ATM physically interacts with and phosphorylates nibrin on serine 343 both in vivo and in vitro. Phosphorylation of this site appears to be functionally important because mutated nibrin (S343A) does not completely complement radiosensitivity in NBS cells. ATM phosphorylation of nibrin does not affect nibrin-MRE11-RAD50 association as revealed by radiation-induced foci formation. Our data provide a biochemical explanation for the similarity in phenotype between A-T and NBS.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; Univ Washington, Virginia Mason Res Ctr, Mol Genet Program, Seattle, WA USA; Univ Queensland, Dept Pathol, Joint Oncol Programme, Brisbane, Qld, Australia; Univ Queensland, Dept Surg, Brisbane, Qld, Australia; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Queensland; University of Queensland; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Khanna, K (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld, Australia.		Khanna, Kum Kum/I-1747-2013; Kozlov, Sergei/M-2067-2014; Lavin, Martin F/F-5961-2014; Kozlov, Sergei/T-9779-2019	Kozlov, Sergei/0000-0001-6183-7339; Lavin, Martin F/0000-0002-5940-4769; Concannon, Patrick/0000-0002-5801-1859; Khanna, Kum Kum/0000-0001-8650-5381; Spring, Kevin/0000-0003-0601-924X	NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057569, CA57569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FRANK JR, 1993, BIOMASS BIOENERG, V5, P1, DOI 10.1016/0961-9534(93)90002-L; GATEI M, IN PRESS CANCER; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; PEAR WS, 1996, GENE THERAPY PROTOCO, P41; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	19	388	398	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					115	119		10.1038/75508	http://dx.doi.org/10.1038/75508			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802669				2022-12-27	WOS:000086884000029
J	Chen, BB; Bronson, RT; Klaman, LD; Hampton, TG; Wang, JF; Green, PJ; Magnuson, T; Douglas, PS; Morgan, JP; Neel, BG				Chen, BB; Bronson, RT; Klaman, LD; Hampton, TG; Wang, JF; Green, PJ; Magnuson, T; Douglas, PS; Morgan, JP; Neel, BG			Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis	NATURE GENETICS			English	Article							HUMAN EPIDERMOID CARCINOMA; TRANSCRIPTION FACTOR; NF-ATC; RECEPTOR; GROWTH; MUTATION; TRANSFORMATION; PHENOTYPE; LACKING; ERBB3	Atrioventricular and semilunar valve abnormalities are common birth defects, but how cardiac valvulogenesis is directed remains largely unknown. During studies of genetic interaction between Egfr, encoding the epidermal growth factor receptor, and Ptpn11, encoding the protein-tyrosine-phosphatase Shp2, we discovered that Egfr is required for semilunar, but not atrioventricular, valve development. Although unnoticed in earlier studies(1,2), 2, mice homozygous for the hypomorphic Egfr allele waved-2 (Egfr(wa2/wa2)) exhibit semilunar valve enlargement resulting from over-abundant mesenchymal cells. Egfr(-/-) mice (CD1 background) have similar defects. The penetrance and severity of the defects in Egfr(wa2/wa2) mice are enhanced by heterozygosity for a targeted mutation of exon 2 of Ptpn11 (ref. 3). Compound (Egfr(wa2/wa2):Ptpn11(+/-)) mutant mice also show premature lethality. Electrocardiography, echocardiography and haemodynamic analyses showed that affected mice develop aortic stenosis and regurgitation. Our results identify the Egfr and Shp2 as components of a growth-factor signalling pathway required specifically for semilunar valvulogenesis, support the hypothesis that Shp2 is required for Egfr signalling in vivo, and provide an animal model for aortic valve disease.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiol, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Tufts Univ, Sch Vet Med, Dept Pathol, Boston, MA 02111 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University; Case Western Reserve University	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026722] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49152] Funding Source: Medline; NHLBI NIH HHS [P50 HL56993-01] Funding Source: Medline; NICHD NIH HHS [HD26722] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Clarke Edward H., 1995, DEV MECH HEART DIS, P157; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GILLIN FD, 1981, J ANTIMICROB CHEMOTH, V8, P305, DOI 10.1093/jac/8.4.305; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MACLEOD CL, 1986, J CELL PHYSIOL, V127, P175, DOI 10.1002/jcp.1041270121; MCLAREN A, 1971, GENET RES, V17, P257, DOI 10.1017/S0016672300012271; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; POTTS JD, 1989, DEV BIOL, V134, P392, DOI 10.1016/0012-1606(89)90111-5; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309	30	215	225	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					296	299		10.1038/73528	http://dx.doi.org/10.1038/73528			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700187				2022-12-27	WOS:000085590600024
J	Orso, E; Broccardo, C; Kaminski, WE; Bottcher, A; Liebisch, G; Drobnik, W; Gotz, A; Chambenoit, O; Diederich, W; Langmann, T; Spruss, T; Luciani, MF; Rothe, G; Lackner, KJ; Chimini, G; Schmitz, G				Orso, E; Broccardo, C; Kaminski, WE; Bottcher, A; Liebisch, G; Drobnik, W; Gotz, A; Chambenoit, O; Diederich, W; Langmann, T; Spruss, T; Luciani, MF; Rothe, G; Lackner, KJ; Chimini, G; Schmitz, G			Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice	NATURE GENETICS			English	Article							FREE-CHOLESTEROL; A-I; LIPOPROTEINS; MACROPHAGES; METABOLISM; CAVEOLAE; EFFLUX; CELLS	Mutations in the gene encoding ATP-binding cassette transporter 1 (ABC1) have been reported in Tangier disease(1-3) (TD), an autosomal recessive disorder that is characterized by almost complete absence of plasma high-density lipoprotein (HDL), deposition of cholesteryl esters in the reticulo-endothelial system(4) (RES) and aberrant cellular lipid trafficking(5-12). We demonstrate here that mice with a targeted inactivation of Abc1 display morphologic abnormalities and perturbations in their lipoprotein metabolism concordant with TD. ABC1 is expressed on the plasma membrane and the Golgi complex, mediates apo-Al associated export of cholesterol and phospholipids from the cell, and is regulated by cholesterol flux. Structural and functional abnormalities in caveolar processing and the trans-Golgi secretory pathway of cells lacking functional ABC1 indicate that lipid export processes involving vesicular budding between the Golgi and the plasma membrane are severely disturbed.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany; CNRS Marseille Luminy, INSERM, Ctr Immunol, Marseille 9, France; Univ Regensburg, Lab Anim Facil, D-8400 Regensburg, Germany	University of Regensburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Regensburg	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.		Liebisch, Gerhard/G-6130-2010; Broccardo, Cyril/G-2796-2017; Langmann, Thomas/HHZ-9814-2022	Liebisch, Gerhard/0000-0003-4886-0811; Broccardo, Cyril/0000-0003-3016-6549; Langmann, Thomas/0000-0001-6826-529X; Schmitz, Gerd/0000-0002-1325-1007				ASSMANN G, 1989, METABOLIC BASIS INHE, P1267; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GINGRAS D, 1993, AM J PHYSIOL, V265, pF316, DOI 10.1152/ajprenal.1993.265.2.F316; Glauert AM., 1975, PRACTICAL METHODS EL; Huber AM, 1999, BBA-GEN SUBJECTS, V1426, P43, DOI 10.1016/S0304-4165(98)00121-4; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Li N, 1997, BRIT J HAEMATOL, V99, P808, DOI 10.1046/j.1365-2141.1997.4993305.x; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Schmitz G, 1997, ELECTROPHORESIS, V18, P1807, DOI 10.1002/elps.1150181015; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SCHMITZ G, 1990, ARTERIOSCLEROSIS, V10, P1010, DOI 10.1161/01.ATV.10.6.1010; SCHMITZ G, 1984, J CHROMATOGR, V307, P65, DOI 10.1016/S0378-4347(00)84073-6; Schmitz G, 1998, P SOC PHOTO-OPT INS, V3260, P127, DOI 10.1117/12.307088; Stohr J, 1998, ARTERIOSCL THROM VAS, V18, P1424, DOI 10.1161/01.ATV.18.9.1424; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; WILLIAMS MA, 1977, PRACTICLA METHODS EL	30	412	434	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					192	196		10.1038/72869	http://dx.doi.org/10.1038/72869			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655069				2022-12-27	WOS:000085104600024
J	Rideout, WM; Wakayama, T; Wutz, A; Eggan, K; Jackson-Grusby, L; Dausman, J; Yanagimachi, R; Jaenisch, R				Rideout, WM; Wakayama, T; Wutz, A; Eggan, K; Jackson-Grusby, L; Dausman, J; Yanagimachi, R; Jaenisch, R			Generation of mice from wild-type and targeted ES cells by nuclear cloning	NATURE GENETICS			English	Article							ADULT		MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Hawaii System	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA.		Eggan, Kevin/P-7119-2018					Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Dean W, 1998, DEVELOPMENT, V125, P2273; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	11	248	277	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					109	110		10.1038/72753	http://dx.doi.org/10.1038/72753			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655052				2022-12-27	WOS:000085104600008
J	Beck, JA; Lloyd, S; Hafezparast, M; Lennon-Pierce, M; Eppig, JT; Festing, MFW; Fisher, EMC				Beck, JA; Lloyd, S; Hafezparast, M; Lennon-Pierce, M; Eppig, JT; Festing, MFW; Fisher, EMC			Genealogies of mouse inbred strains	NATURE GENETICS			English	Editorial Material							PCR-ANALYZED MICROSATELLITES; GENETIC-VARIATION; MICE; POLYMORPHISMS; EVOLUTION; C57BL/10; COMPLEX; ORIGIN; 129/SV; FVB/N	The mouse is a prime organism of choice for modelling human disease. Over 450 inbred strains of mice have been described, providing a wealth of different genotypes and phenotypes for genetic and other studies. As new strains are generated and others become extinct, it is useful to review periodically what strains are available and how they are related to each other, particularly in the light of available DNA polymorphism data from microsatellite and other markers. We describe the origins and relationships of inbred mouse strains, 90 years after the generation of the first inbred strain. Given the large collection of inbred strains available, and that published information on these strains is incomplete, we propose that all genealogical and genetic data on inbred strains be submitted to a common electronic database to ensure this valuable information resource is preserved and used efficiently.	Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Neurogenet, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, MRC Prion Unit, London, England; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England	Imperial College London; Imperial College London; University of London; University College London; Jackson Laboratory; University of Leicester	Fisher, EMC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Neurogenet, London, England.		Fisher, Elizabeth MC/C-2168-2008; Hafezparast, Majid/N-8292-2019; Hafezparast, Majid/H-6728-2018	Fisher, Elizabeth MC/0000-0003-2850-9936; Hafezparast, Majid/0000-0002-5262-7150; 	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000330, P41HG000330] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00330] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; ATCHLEY WR, 1993, MOL BIOL EVOL, V10, P1150; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; BONHOMME F, 1987, BIOL J LINN SOC, V30, P51, DOI 10.1111/j.1095-8312.1987.tb00288.x; Bonhomme F., 1996, GENETIC VARIANTS STR, P1577; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; CUI SL, 1993, LAB ANIM, V27, P116, DOI 10.1258/002367793780810397; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; DAVISSON MT, 1996, GENETIC VARIANTS STR, P1532; Festing M., 1997, Mouse Genome, V95, P845; FESTING MFW, 1989, GENET RES, V53, P45, DOI 10.1017/S0016672300027853; FESTING MFW, 1975, FOOD COSMET TOXICOL, V13, P369, DOI 10.1016/S0015-6264(75)80302-6; FESTING MFW, 1996, GENETIC VARIANTS STR, P1537; Festing MFW, 1979, INBRED STRAINS BIOME; FITCH WM, 1985, SCIENCE, V228, P1169, DOI 10.1126/science.4001935; FOWLIS GA, 1992, MAMM GENOME, V3, P192, DOI 10.1007/BF00355718; Ginsburg Benson E., 1992, V8, P3; HILGERS J, 1988, GENET RES, V51, P29, DOI 10.1017/S0016672300023910; KEELER CE, 1931, LAB MOUSE ISTS ORIGI; KLEIN J, 1975, PRINCIPLES IMMUNOGEN; Le Voyer TE, 1999, MAMM GENOME, V10, P542, DOI 10.1007/s003359901040; MARONPOT RR, 1983, ENV SCI RES, V27, P341; Martin JE, 1997, TRENDS GENET, V13, P254, DOI 10.1016/S0168-9525(97)01193-1; Matin A, 1998, MAMM GENOME, V9, P668, DOI 10.1007/s003359900842; Matouk C, 1996, MAMM GENOME, V7, P603, DOI 10.1007/s003359900178; MCCLIVE PJ, 1994, IMMUNOGENETICS, V39, P286, DOI 10.1007/BF00188793; Morse H., 1978, ORIGINS INBRED MICE; Neuhaus IM, 1997, MAMM GENOME, V8, P506, DOI 10.1007/s003359900485; Panoutsakopoulou V, 1997, MAMM GENOME, V8, P357, DOI 10.1007/s003359900441; Peirce JL, 1998, MAMM GENOME, V9, P942, DOI 10.1007/s003359900904; POTTER M, 1979, INBRED GENETICALLY D, V1, P16; ROUTMAN EJ, 1995, MAMM GENOME, V6, P401, DOI 10.1007/BF00355640; Russell E S, 1985, Annu Rev Genet, V19, P1, DOI 10.1146/annurev.ge.19.120185.000245; Silver L. M., 1995, MOUSE GENETICS; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Slingsby JH, 1996, IMMUNOGENETICS, V43, P72; STAATS JOAN, 1966, P45; STAATS JOAN, 1966, P1; Takeda T, 1997, EXP GERONTOL, V32, P105, DOI 10.1016/S0531-5565(96)00036-8; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; TAYLOR BA, 1972, J HERED, V63, P83, DOI 10.1093/oxfordjournals.jhered.a108235; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W	44	625	645	1	45	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					23	+		10.1038/71641	http://dx.doi.org/10.1038/71641			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615122				2022-12-27	WOS:000084609200010
J	Sohocki, MM; Bowne, SJ; Sullivan, LS; Blackshaw, S; Cepko, CL; Payne, AM; Bhattacharya, SS; Khaliq, S; Mehdi, SQ; Birch, DG; Harrison, WR; Elder, FFB; Heckenlively, JR; Daiger, SP				Sohocki, MM; Bowne, SJ; Sullivan, LS; Blackshaw, S; Cepko, CL; Payne, AM; Bhattacharya, SS; Khaliq, S; Mehdi, SQ; Birch, DG; Harrison, WR; Elder, FFB; Heckenlively, JR; Daiger, SP			Mutations in a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis	NATURE GENETICS			English	Article							RETINITIS-PIGMENTOSA; HOMEOBOX GENE; PROTEIN; CRX	Leber congenital amaurosis (LCA, MIM 204000) accounts for at least 5% of all inherited retinal disease(1) and is the most severe inherited retinopathy with the earliest age of onset(2). Individuals affected with LCA are diagnosed at birth or in the first few months of life with severely impaired vision or blindness, nystagmus and an abnormal or flat electroretinogram (ERG). Mutations in GUCY2D (ref. 3), RPE65 (ref. 4) and CRX (ref. 5) are known to cause LCA, but one study identified disease-causing GUCY2D mutations in only 8 of 15 families whose LCA locus maps to 17p13.1 (ref. 3), suggesting another LCA locus might be located on 17p13.1. Confirming this prediction, the LCA in one Pakistani family mapped to 17p13.1, between D17S849 and D17S960-a region that excludes GUCY2D. The LCA in this family has been designated LCA4 (ref. 6). We describe here a new photoreceptor/pineal-expressed gene, AIPL1 (encoding aryl-hydrocarbon interacting protein-like 1), that maps within the LCA4 candidate region and whose protein contains three tetratricopeptide (TPR) motifs, consistent with nuclear transport or chaperone activity. A homozygous nonsense mutation at codon 278 is present in all affected members of the original LCA4 family. AIPL1 mutations may cause approximately 20% of recessive LCA, as disease-causing mutations were identified in 3 of 14 LCA families not tested previously for linkage.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA USA; UCL, Dept Mol Genet, Inst Ophthalmol, London, England; Dr AQ Khan Res Labs, Biomed & Genet Engn Div, Islamabad, Pakistan; Retina Fdn SW, Dallas, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of London; University College London; Retina Foundation of the Southwest; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles	Daiger, SP (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77225 USA.	sdaiger@utsph.sph.uth.tmc.edu	Khaliq, Shagufta/G-2337-2015; Bhattacharya, Shom/N-2926-2016; Payne, annette/F-8877-2013; Mehdi, Syed Qasim/L-2385-2015	Bhattacharya, Shom/0000-0002-1601-6344; Payne, annette/0000-0002-2009-0141; Birch, David/0000-0002-6594-2897	NATIONAL EYE INSTITUTE [R01EY007142] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007142, R01 EY007142-12A2, EY07142] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		FOXMAN SG, 1985, ARCH OPHTHALMOL-CHIC, V103, P1502; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GREENBERG J, 1994, HUM MOL GENET, V3, P915, DOI 10.1093/hmg/3.6.915; HADLEY ME, 1996, ENDOCRINOLOGY, P458; HAMEED A, IN PRESS INVEST OPHT; KAPLAN J, 1990, HUM GENET, V85, P635; Ma Q, 1997, J BIOL CHEM, V272, P8878; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; Sohocki MM, 1999, GENOMICS, V58, P29, DOI 10.1006/geno.1999.5810	12	216	222	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					79	83		10.1038/71732	http://dx.doi.org/10.1038/71732			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615133	Green Accepted			2022-12-27	WOS:000084609200021
J	Cote, PD; Moukhles, H; Lindenbaum, M; Carbonetto, S				Cote, PD; Moukhles, H; Lindenbaum, M; Carbonetto, S			Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses	NATURE GENETICS			English	Article							BETA-DYSTROGLYCAN; BASEMENT-MEMBRANE; AGRIN RECEPTOR; LAMININ; MUSCLE; UTROPHIN; COMPLEX; IDENTIFICATION; GLYCOPROTEINS; ASSOCIATION		McGill Univ, Montreal Gen Hosp, Res Inst, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	McGill University	Carbonetto, S (corresponding author), McGill Univ, Montreal Gen Hosp, Res Inst, Neurosci Res Ctr, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Cote, Patrice/0000-0002-4189-7526				BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DICKSON G, 1992, J CELL SCI, V103, P1223; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; FRITZ JD, 1995, PEDIATR RES, V37, P693, DOI 10.1203/00006450-199506000-00004; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; Montanaro F, 1998, J NEUROSCI, V18, P1250; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PETERSON AC, 1978, BIOCHEM GENET, V16, P681, DOI 10.1007/BF00484725; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	31	197	198	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					338	342		10.1038/15519	http://dx.doi.org/10.1038/15519			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610181				2022-12-27	WOS:000083792200025
J	Lai, ZW; Jing, JP; Aston, C; Clarke, V; Apodaca, J; Dimalanta, ET; Carucci, DJ; Gardner, MJ; Mishra, B; Anantharaman, TS; Paxia, S; Hoffman, SL; Venter, JC; Huff, EJ; Schwartz, DC				Lai, ZW; Jing, JP; Aston, C; Clarke, V; Apodaca, J; Dimalanta, ET; Carucci, DJ; Gardner, MJ; Mishra, B; Anantharaman, TS; Paxia, S; Hoffman, SL; Venter, JC; Huff, EJ; Schwartz, DC			A shotgun optical map of the entire Plasmodium falciparum genome	NATURE GENETICS			English	Article							DNA-MOLECULES; GEL-ELECTROPHORESIS; MALARIA; SEPARATION		WM Keck Lab Biomol Imaging, Dept Chem, New York, NY USA; NYU, Dept Chem, Dept Comp Sci, Courant Inst Math Sci, New York, NY 10003 USA; USN, Med Res Ctr, Malaria Program, Rockville, MD USA; Inst Genom Res, Rockville, MD USA	New York University; United States Department of Defense; United States Navy; J. Craig Venter Institute	Schwartz, DC (corresponding author), Univ Wisconsin, Ctr Biotechnol, Dept Chem, Madison, WI 53705 USA.	schwad01@mcrcr.med.nyu.edu			NCI NIH HHS [R01CA 79063-1] Funding Source: Medline; NHGRI NIH HHS [2 RO1 HG00225-01-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079063] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anantharaman T, 1999, Proc Int Conf Intell Syst Mol Biol, P18; ANANTHARAMAN TS, 1998, 760 NEW YORK U COUR; Aston C, 1999, METHOD ENZYMOL, V303, P55; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAI WW, 1995, P NATL ACAD SCI USA, V92, P5164, DOI 10.1073/pnas.92.11.5164; Cai WW, 1998, P NATL ACAD SCI USA, V95, P3390, DOI 10.1073/pnas.95.7.3390; CORCORAN LM, 1986, CELL, V44, P87, DOI 10.1016/0092-8674(86)90487-3; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Jing JP, 1998, P NATL ACAD SCI USA, V95, P8046, DOI 10.1073/pnas.95.14.8046; Jing JP, 1999, GENOME RES, V9, P175; Lin JY, 1999, SCIENCE, V285, P1558, DOI 10.1126/science.285.5433.1558; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; MORITZ KB, 1976, NATURE, V259, P55, DOI 10.1038/259055a0; Mullikin JC, 1999, SCIENCE, V283, P1867, DOI 10.1126/science.283.5409.1867; Netzel TL, 1995, J PHYS CHEM-US, V99, P17936, DOI 10.1021/j100051a019; PACE T, 1995, MOL BIOCHEM PARASIT, V69, P257, DOI 10.1016/0166-6851(94)00206-3; SAID A, 1994, PARASITE, V1, P31, DOI 10.1051/parasite/1994011031; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; Schwartz DC, 1997, CURR OPIN BIOTECH, V8, P70, DOI 10.1016/S0958-1669(97)80160-7; SPITHILL TW, 1985, NUCLEIC ACIDS RES, V13, P4155, DOI 10.1093/nar/13.11.4155; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERPLOEG LHT, 1984, CELL, V37, P77, DOI 10.1016/0092-8674(84)90302-7; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wirth D, 1998, NAT MED, V4, P1360, DOI 10.1038/3943; [No title captured]	30	64	96	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					309	313		10.1038/15484	http://dx.doi.org/10.1038/15484			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610179				2022-12-27	WOS:000083792200019
J	Rabinowicz, PD; Schutz, K; Dedhia, N; Yordan, C; Parnell, LD; Stein, L; McCombie, WR; Martienssen, RA				Rabinowicz, PD; Schutz, K; Dedhia, N; Yordan, C; Parnell, LD; Stein, L; McCombie, WR; Martienssen, RA			Differential methylation of genes and retrotransposons facilitates shotgun sequencing of the maize genome	NATURE GENETICS			English	Article							ESCHERICHIA-COLI; DNA METHYLATION; CYTOSINE METHYLATION; RESTRICTION; CLONING; ELEMENTS; ORGANIZATION; TRANSPOSONS; EXPRESSION; EVOLUTION		Cold Spring Harbor Lab, New York, NY 11724 USA; Lita Annen Hazenburg Genome Sequencing Ctr, New York, NY USA	Cold Spring Harbor Laboratory	Martienssen, RA (corresponding author), Cold Spring Harbor Lab, New York, NY 11724 USA.			McCombie, W. Richard/0000-0003-1899-0682				ADAMS MD, 1995, NATURE, V377, P3; Arumuganathan K, 1991, PLANT MOL BIOL REP, V9, P208, DOI DOI 10.1007/BF02672069; BENNETZEN JL, 1994, GENOME, V37, P565, DOI 10.1139/g94-081; BENNETZEN JL, 1985, UCLA SYMP MOL CELL B, V35, P343; Bird A, 1997, TRENDS GENET, V13, P469, DOI 10.1016/S0168-9525(97)01310-3; BLUMENTHAL RM, 1985, J BACTERIOL, V164, P501, DOI 10.1128/JB.164.2.501-509.1985; Bureau TE, 1996, P NATL ACAD SCI USA, V93, P8524, DOI 10.1073/pnas.93.16.8524; BURR B, 1988, GENETICS, V118, P519; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; DOHERTY JP, 1991, GENE, V98, P77, DOI 10.1016/0378-1119(91)90106-L; Gaut BS, 1997, P NATL ACAD SCI USA, V94, P6809, DOI 10.1073/pnas.94.13.6809; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; HAKE S, 1980, CHROMOSOMA, V79, P251, DOI 10.1007/BF00327318; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Martienssen R, 1998, TRENDS GENET, V14, P263, DOI 10.1016/S0168-9525(98)01518-2; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MOORE G, 1993, GENOMICS, V15, P472, DOI 10.1006/geno.1993.1097; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; White S, 1998, TRENDS GENET, V14, P327, DOI 10.1016/S0168-9525(98)01524-8; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; WILLIAMSON MR, 1993, GENE, V124, P37, DOI 10.1016/0378-1119(93)90759-V; WOODCOCK DM, 1988, NUCLEIC ACIDS RES, V25, P4465; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	30	172	190	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					305	308		10.1038/15479	http://dx.doi.org/10.1038/15479			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545948				2022-12-27	WOS:000083792200018
J	Chen, C; Kolodner, RD				Chen, C; Kolodner, RD			Gross chromosomal rearrangements in Saccharomyces cerevisiae replication and recombination defective mutants	NATURE GENETICS			English	Article							NIJMEGEN BREAKAGE SYNDROME; INDUCED DNA-REPLICATION; PROTEIN-A; REPAIR; YEAST; TRANSLOCATIONS; GENE; METABOLISM; DELETIONS; LEUKEMIA	Cancer progression is often associated with the accumulation of gross chromosomal rearrangements (GCRs), such as translocations, deletion of a chromosome arm, interstitial deletions or inversions(1-3). In many instances, GCRs inactivate tumour-suppressor genes or generate novel fusion proteins that initiate carcinogenesis(3,4). The mechanism underlying GCR formation appears to involve interactions between DNA sequences of little or no homology(5-8). We previously demonstrated that mutations in the gene encoding the largest subunit of the Saccharomyces cerevisiae single-stranded DNA binding protein (RFA1) increase microhomology-medialed GCR formations. To further our understanding of GCR formation, we have developed a novel mutator assay in 5. cerevisiae that allows specific detection of such events. In this assay, the rate of GCR formation was increased 600-5,000-fold by mutations in RFA1, RAD27, MRE11, XRS2 and RAD50, but was minimally affected by mutations in RAD51, RAD54, RAD57, YKU70, YKU80, LIG4 and POL30. Genetic analysis of these mutants suggested that at least three distinct pathways can suppress GCRs: two that suppress microhomology-mediated GCRs (RFA1 and RAD27) and one that suppresses non-homology-mediated GCRs (RAD50/MRE11/XRS2).	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA.		Chen, Clark C/C-8714-2013	Chen, Clark C/0000-0001-6258-9277	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026017, R01GM050006, R01GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50006, GM26017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amin NS, 1996, GENETICS, V144, P479; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Bosco G, 1998, GENETICS, V150, P1037; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen SH, 1998, J POLYM RES-TAIWAN, V5, P9, DOI 10.1007/s10965-006-0034-y; CHRZANOWSKA KH, 1995, AM J MED GENET, V57, P462, DOI 10.1002/ajmg.1320570321; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GILMAN JG, 1987, BRIT J HAEMATOL, V67, P369, DOI 10.1111/j.1365-2141.1987.tb02360.x; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LUZI P, 1995, HUM MOL GENET, V4, P2335, DOI 10.1093/hmg/4.12.2335; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Maniar HS, 1997, GENETICS, V145, P891; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Merrill BJ, 1998, GENETICS, V148, P611; MITELMAN F, 1991, CATALOG CHROMOSOME A; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; NINIO J, 1991, GENETICS, V129, P957; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHIKANO T, 1993, CANCER GENET CYTOGEN, V71, P22, DOI 10.1016/0165-4608(93)90198-U; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsukamoto Y, 1997, MOL GEN GENET, V255, P543, DOI 10.1007/s004380050527; Tsukamoto Y, 1996, GENETICS, V142, P383; Umezu K, 1998, GENETICS, V148, P989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2	29	330	331	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					81	85		10.1038/12687	http://dx.doi.org/10.1038/12687			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471504				2022-12-27	WOS:000082337300021
J	Schott, JJ; Alshinawi, C; Kyndt, F; Probst, V; Hoorntje, TM; Hulsbeek, M; Wilde, AAM; Escande, D; Mannens, MMAM; Le Marec, H				Schott, JJ; Alshinawi, C; Kyndt, F; Probst, V; Hoorntje, TM; Hulsbeek, M; Wilde, AAM; Escande, D; Mannens, MMAM; Le Marec, H			Cardiac conduction defects associate with mutations in SCN5A	NATURE GENETICS			English	Letter							DILATED CARDIOMYOPATHY; DISEASE; GENE; MAPS; EXCITABILITY; TISSUE; SODIUM; BLOCK		Hop Hotel Dieu, Lab Physiolpathol & Pharmacol Cellulaires & Mol, INSERM, Nantes, France; Hop G&R Laennec, Nantes, France; Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Utrecht Hosp, Dept Pediat Cardiol, Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center	Le Marec, H (corresponding author), Hop Hotel Dieu, Lab Physiolpathol & Pharmacol Cellulaires & Mol, INSERM, CJF96-01, Nantes, France.		Schott, jean-Jacques/F-8842-2013; KYNDT, Florence/D-6370-2015; probst, vincent/D-4996-2015; Le Marec, Hervé/D-2718-2015	Schott, jean-Jacques/0000-0002-9578-9475; KYNDT, Florence/0000-0001-6651-1696; probst, vincent/0000-0002-5492-8619; Le Marec, Hervé/0000-0002-8288-8693; Bezzina, Connie/0000-0002-0633-3514				Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; BRINK PA, 1995, CIRCULATION, V91, P1633, DOI 10.1161/01.CIR.91.6.1633; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; DEMEEUS A, 1995, CIRC RES, V77, P735, DOI 10.1161/01.RES.77.4.735; KASS S, 1994, NAT GENET, V7, P546, DOI 10.1038/ng0894-546; KRAWCZAK M, 1992, HUM GENET, V90, P41; KULBERTUS HE, 1975, CARDIAC ARRHYTHMIAS, P16; LENEGRE J, 1964, PROG CARDIOVASC DIS, V6, P317; LEV M, 1970, CIRCULATION, V42, P409, DOI 10.1161/01.CIR.42.3.409; Messina DN, 1997, AM J HUM GENET, V61, P909, DOI 10.1086/514896; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Rohr S, 1998, CIRC RES, V83, P781, DOI 10.1161/01.RES.83.8.781; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Shaw RM, 1997, CIRC RES, V81, P727; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236	16	440	468	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					20	21		10.1038/12618	http://dx.doi.org/10.1038/12618			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471492				2022-12-27	WOS:000082337300010
J	Wade, PA; Gegonne, A; Jones, PL; Ballestar, E; Aubry, F; Wolffe, AP				Wade, PA; Gegonne, A; Jones, PL; Ballestar, E; Aubry, F; Wolffe, AP			Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation	NATURE GENETICS			English	Article							PROTEIN; GENE; IDENTIFICATION; METASTASIS; FAMILY; MTA1	Methylation of DNA at the dinucleotide CpG is essential for mammalian development and is correlated with stable transcriptional silencing(1-3). This transcriptional silencing has recently been linked at a molecular level to histone deacetylation MeCP2 (refs 4,5). We previously purified a histone deacetylase through the demonstration of a physical association between histone deacetylases and the methyl CpG-binding protein complex from Xenopus laevis egg extracts that consists of six subunits, including an Rpd3-like deacetylase, the RbA p48/p46 histone-binding protein and the nucleosome-stimulated ATPase Mi-2 (ref. 6). Similar species were subsequently isolated from human cell lines(7-9), implying functional conservation across evolution. This complex represents the most abundant form of deacetylase in amphibian eggs and cultured mammalian cells(6-9). Here we identify the remaining three subunits of this across enzyme complex, One of them binds specifically to methylated DNA in vitro and molecular cloning reveals a similarity to a known methyl CpG-binding protein. Our data substantiate the mechanistic link between DNA methylation, histone deacetylation and transcriptional silencing.	NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; INSERM, U435, F-35042 Rennes, France	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Institut National de la Sante et de la Recherche Medicale (Inserm)	Wade, PA (corresponding author), NICHHD, Mol Embryol Lab, NIH, Bldg 18T Room 106, Bethesda, MD 20892 USA.	awlme@helix.nih.gov	Aubry, Florence/I-2746-2015; Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X; Ballestar, Esteban/0000-0002-1400-2440				Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 1995, J CELL SCI, P37; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Martienssen R, 1999, NAT GENET, V22, P6, DOI 10.1038/8708; Moore DD, 1995, GLOB MOB SURV; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; Solari F, 1999, DEVELOPMENT, V126, P2483; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; VAUTIER D, 1994, MOL REPROD DEV, V38, P119, DOI 10.1002/mrd.1080380202; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	669	688	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					62	66		10.1038/12664	http://dx.doi.org/10.1038/12664			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471500				2022-12-27	WOS:000082337300017
J	Hacia, JG; Fan, JB; Ryder, O; Jin, L; Edgemon, K; Ghandour, G; Mayer, RA; Sun, B; Hsie, L; Robbins, CM; Brody, LC; Wang, D; Lander, ES; Lipshutz, R; Fodor, SPA; Collins, FS				Hacia, JG; Fan, JB; Ryder, O; Jin, L; Edgemon, K; Ghandour, G; Mayer, RA; Sun, B; Hsie, L; Robbins, CM; Brody, LC; Wang, D; Lander, ES; Lipshutz, R; Fodor, SPA; Collins, FS			Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays	NATURE GENETICS			English	Article							HUMAN-EVOLUTION; GENE; CHIMPANZEE; DIVERSITY; PRIMATES; SEQUENCES; LINKAGE; NUCLEAR; REGION; GENOME	Here we report the application of high-density oligonucleotide array (DNA chip)-based analysis to determine the distant history of single nucleotide polymorphisms (SNPs) in current human populations. We analysed orthologues for 397 human SNP sites (identified in CEPH:pedigrees from Amish, Venezuelan and Utah populations(1)) from 23 common chimpanzee, 19 pygmy chimpanzee and 11 gorilla genomic DNA samples. From this data we determined 214 proposed ancestral alleles (the sequence found in the last common ancestor of humans and chimpanzees). In a diverse human population set, we found that SNP alleles with higher frequencies were more likely to be ancestral than less frequently occurring alleles, There were, however, exceptions. We also found three shared human/pygmy chimpanzee polymorphisms, all involving CpG dinucleotides, and two shared human/gorilla polymorphisms, one involving a CpG dinucleotide. We demonstrate that mi;microarray-based assays allow rapid comparative sequence analysis of intra- and interspecies genetic variation.	Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Affymetrix, Santa Clara, CA 95051 USA; Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China; Univ Texas, Inst Human Genet, Houston, TX 77225 USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Affymetrix; Zoological Society of San Diego; Fudan University; University of Texas System; Massachusetts Institute of Technology (MIT); Whitehead Institute	Collins, FS (corresponding author), Natl Human Genome Res Inst, Bldg 49-3A14, Bethesda, MD 20892 USA.		Jin, Li/C-1468-2009; Jin, Li/M-5063-2019	Jin, Li/0000-0002-4546-2415; Sun, Bryan/0000-0002-0740-0125	NHGRI NIH HHS [5POLHGO1323-03] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000120, P01HG001323, Z01HG000120] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bergstrom TF, 1998, NAT GENET, V18, P237, DOI 10.1038/ng0398-237; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Clark AG, 1997, P NATL ACAD SCI USA, V94, P7730, DOI 10.1073/pnas.94.15.7730; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Cooper G, 1998, HUM MOL GENET, V7, P1425, DOI 10.1093/hmg/7.9.1425; CrouauRoy B, 1996, HUM MOL GENET, V5, P1131, DOI 10.1093/hmg/5.8.1131; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; Garner KJ, 1996, MOL PHYLOGENET EVOL, V6, P39, DOI 10.1006/mpev.1996.0056; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Jaeger EEM, 1998, IMMUNOGENETICS, V47, P115; Kimura M., 1983, NEUTRAL THEORY MOL E; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; MARTINKO JM, 1993, IMMUNOGENETICS, V37, P274; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; MOUNTAIN JL, 1994, P NATL ACAD SCI USA, V91, P6515, DOI 10.1073/pnas.91.14.6515; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Ruvolo M, 1996, MOL PHYLOGENET EVOL, V5, P202, DOI 10.1006/mpev.1996.0014; SAVATIER P, 1985, J MOL BIOL, V182, P21, DOI 10.1016/0022-2836(85)90024-5; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WATKINS DI, 1995, CRIT REV IMMUNOL, V15, P1; WATTERSON GA, 1977, THEOR POPUL BIOL, V11, P141, DOI 10.1016/0040-5809(77)90023-5; Wise CA, 1997, MOL BIOL EVOL, V14, P707, DOI 10.1093/oxfordjournals.molbev.a025810; Yang AS, 1996, J MOL BIOL, V258, P240, DOI 10.1006/jmbi.1996.0246	28	297	371	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					164	167		10.1038/9674	http://dx.doi.org/10.1038/9674			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369258				2022-12-27	WOS:000080680900021
J	Xu, XL; Wagner, KU; Larson, D; Weaver, Z; Li, CL; Ried, T; Hennighausen, L; Wynshaw-Boris, A; Deng, CX				Xu, XL; Wagner, KU; Larson, D; Weaver, Z; Li, CL; Ried, T; Hennighausen, L; Wynshaw-Boris, A; Deng, CX			Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation	NATURE GENETICS			English	Article							SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; MOUSE; P53; EXPRESSION; MICE; RAD51; DIFFERENTIATION; LOCALIZATION; HOMOLOG	Cre-mediated excision of exon 11 of the breast-tumour suppressor gene Brca1 in mouse mammary epithelial cells causes increased apoptosis and abnormal ductal development Mammary tumour formation occurs after long latency and is associated with genetic instability characterized by aneuploidy, chromosomal rearrangements or alteration of Trp53 (encoding p53) transcription. To directly test the role of p53 in Brca1-associated tumorigenesis, we introduced a Trp53-null allele into mice with mammary epithelium-specific inactivation of Brca1. The loss of p53 accelerated the formation of mammary tumours in these females. Our results demonstrate that disruption of Brca1 causes genetic instability and triggers further alterations, including the inactivation of p53, that lead to tumour formation.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, Div Clin Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Wagner, Kay-Uwe/B-6044-2009	Hennighausen, Lothar/0000-0001-8319-9841; Wagner, Kay-Uwe/0000-0002-5081-0226; Weaver Ohler, Zoe/0000-0002-6287-2504	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000, ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cui JQ, 1998, ONCOL REP, V5, P585; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hill ADK, 1997, BRIT J SURG, V84, P1334; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Robinson GW, 1997, DEVELOPMENT, V124, P2701; ROTTER V, 1984, MOL CELL BIOL, V4, P383, DOI 10.1128/MCB.4.2.383; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	579	597	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					37	43		10.1038/8743	http://dx.doi.org/10.1038/8743			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319859				2022-12-27	WOS:000080096300020
J	Cameron, EE; Bachman, KE; Myohanen, S; Herman, JG; Baylin, SB				Cameron, EE; Bachman, KE; Myohanen, S; Herman, JG; Baylin, SB			Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; DNA METHYLATION; CHROMATIN STRUCTURE; TOPOLOGY INVIVO; CPG ISLANDS; CELL-LINES; TRANSCRIPTION; ACETYLATION; PROMOTER	Densely methylated DNA associates with transcriptionally repressive chromatin characterized by the presence of underacetylated histones(1,2). Recently, these two epigenetic processes have been dynamically linked. The methyl-CpG-binding protein MeCP2 appears to reside in a complex with histone deacetylase activity(3,4). MeCP2 can mediate formation of transcriptionally repressive chromatin on methylated promoter templates in vitro, and this process can be reversed by trichostatin A (TSA), a specific inhibitor of histone deacetylase(3-5). Little is known, however, about the relative roles of methylation and histone deacetylase activity in the stable inhibition of transcription on densely methylated endogenous promoters, such as those for silenced alleles of imprinted genes(6), genes on the female inactive X chromosome(7) and tumour-suppressor genes inactivated in cancer cells(8,9). We show here that the hypermethylated genes MLH1, TIMP3 (TIMP3), CDKN2B (INK4B, p15) and CDKN2A (INK4, p16) cannot be transcriptionally reactivated with TSA alone in tumour cells in which we have shown that TSA alone can upregulate the expression of non-methylated genes. Following minimal demethylation and slight gene reactivation in the presence of low dose 5-aza-2'deoxycytidine (5Aza-dC), however, TSA treatment results in robust re-expression of each gene. TSA does not contribute to demethylation of the genes, and none of the treatments alter the chromatin structure associated with the hypermethylated promoters. Thus, although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Grad Program Cellular & Mol Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 424 N Bond St, Baltimore, MD 21231 USA.	sbaylin@welchlink.welch.jhu.edu						ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Drabik CE, 1997, J MOL BIOL, V267, P794, DOI 10.1006/jmbi.1997.0917; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kane MF, 1997, CANCER RES, V57, P808; KASLOW DC, 1987, P NATL ACAD SCI USA, V84, P6210, DOI 10.1073/pnas.84.17.6210; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; Riggs AD, 1998, CIBA F SYMP, V214, P214; RIGGS AD, 1998, NOVART FDN SYMP, V214, P225; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WICK M, 1995, BIOCHEM J, V311, P549, DOI 10.1042/bj3110549; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	30	1580	1640	1	95	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21	1					103	107		10.1038/5047	http://dx.doi.org/10.1038/5047			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	155RT	9916800				2022-12-27	WOS:000077960700018
J	Sakmar, TP				Sakmar, TP			Restoration of compact discs	NATURE GENETICS			English	Editorial Material							DEGENERATION SLOW RDS; RETINAL DEGENERATION; RETINITIS-PIGMENTOSA; RESCUE; MOUSE; MICE; PERIPHERIN	More than 100 genes have been mapped that cause inherited blinding diseases. The majority affect the outer layer of the retina. which is composed of photoreceptor cells and retinal pigment epithelium. Gene therapy is a potential means of correcting defects in specialized cellular structures that mediate phototransduction or visual pigment regeneration, as illustrated by a paper in this issue.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biol & Biochem, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Sakmar, TP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biol & Biochem, New York, NY 10021 USA.		Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953				Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; GOURAS P, 1994, INVEST OPHTH VIS SCI, V35, P3145; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; JANSEN HG, 1984, J COMP NEUROL, V224, P71, DOI 10.1002/cne.902240107; Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; Wright AF, 1997, NAT GENET, V17, P132, DOI 10.1038/ng1097-132	14	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					245	246		10.1038/76976	http://dx.doi.org/10.1038/76976			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888860				2022-12-27	WOS:000087920900002
J	Chavanas, S; Bodemer, C; Rochat, A; Hamel-Teillac, D; Ali, M; Irvine, AD; Bonafe, JL; Wilkinson, J; Taieb, A; Barrandon, Y; Harper, JI; de Prost, Y; Hovnanian, A				Chavanas, S; Bodemer, C; Rochat, A; Hamel-Teillac, D; Ali, M; Irvine, AD; Bonafe, JL; Wilkinson, J; Taieb, A; Barrandon, Y; Harper, JI; de Prost, Y; Hovnanian, A			Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome	NATURE GENETICS			English	Article							ACTIVATION; CONSEQUENCES; RECEPTOR; ATOPY		Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Necker Hosp, Dept Dermatol, Paris, France; Ecole Normale Super, Epithelial Differentiat Lab, F-75231 Paris, France; Amersham Hosp, Dept Dermatol, Amersham, England; Great Ormond St Hosp Children, Dept Paediat Dermatol, London WC1N 3JH, England; Rangueil Hosp, Dept Dermatol, Toulouse, France; St Andre Hosp, Dept Dermatol, Bordeaux, France	University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; CHU de Toulouse; CHU Bordeaux	Hovnanian, A (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.		Hovnanian, Alain/I-4711-2017; TAIEB, ALAIN/AAB-1085-2021; Chavanas, stephane/K-1183-2014; Irvine, Alan D/A-3982-2008	Hovnanian, Alain/0000-0003-3412-7512; Irvine, Alan D/0000-0002-9048-2044; chavanas, stephane/0000-0003-4323-2656				Chavanas S, 2000, AM J HUM GENET, V66, P914, DOI 10.1086/302824; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Fartasch M, 1999, ARCH DERMATOL, V135, P823, DOI 10.1001/archderm.135.7.823; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; TRAUPE H, 1989, ICHTHYOSIS GUIDE CLI; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	15	603	626	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					141	142		10.1038/75977	http://dx.doi.org/10.1038/75977			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835624				2022-12-27	WOS:000087459200008
J	Simmler, MC; Cohen-Salmon, M; El-Amraoui, A; Guillaud, L; Benichou, JC; Petit, C; Panthier, JJ				Simmler, MC; Cohen-Salmon, M; El-Amraoui, A; Guillaud, L; Benichou, JC; Petit, C; Panthier, JJ			Targeted disruption of Otog results in deafness and severe imbalance	NATURE GENETICS			English	Article							TECTORIAL MEMBRANE; INNER-EAR; ULTRASTRUCTURAL ORGANIZATION; SENSORINEURAL DEAFNESS; MATRIX; GENE; PROTEOGLYCANS; LOCALIZATION; MUTATIONS; COLLAGEN	Genes specifically expressed in the inner ear are candidates to underlie hereditary nonsyndromic deafness(1). The gene Otog has been isolated from a mouse subtractive cDNA cochlear library(2). It encodes otogelin, an N-glycosylated protein that is present in the acellular membranes covering the six sensory epithelial patches of the inner ear: in the cochlea (the auditory sensory organ), the tectorial membrane (TM) over the organ of Corti; and in the vestibule (the balance sensory organ), the otoconial membranes over the utricular and saccular maculae as well as the cupulae over the cristae ampullares of the three semi-circular canals. These membranes are involved in the mechanotransduction process. Their movement, which is induced by sound in the cochlea or acceleration in the vestibule, results in the deflection of the stereocilia bundle at the apex of the sensory hair cells, which in turn opens the mechanotransduction channels located at the tip of the stereo-cilia(3). We sought to elucidate the role of otogelin in the auditory and vestibular functions by generating mice with a targeted disruption of Otog. In Otog(-/-) mice, both the vestibular and the auditory functions were impaired. Histological analysis of these mutants demonstrated that in the vestibule, otogelin is required for the anchoring of the otoconial membranes and cupulae to the neuroepithelia. In the cochlea, ultrastructural analysis of the TM indicated that otogelin is involved in the organization of its fibrillar network. Otogelin is likely to have a role in the resistance of this membrane to sound stimulation. These results support OTOG as a possible candidate gene for a human nonsyndromic form of deafness.	Ecole Natl Vet, INRA Genet Mol & Cellulaire, UMR 955, Maisons Alfort, France; Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Dev, CNRS, URA 1960, F-75724 Paris, France	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Simmler, MC (corresponding author), Ecole Natl Vet, INRA Genet Mol & Cellulaire, UMR 955, Maisons Alfort, France.		PANTHIER, Jean-Jacques/I-4366-2014	PANTHIER, Jean-Jacques/0000-0002-7966-0663; Cohen-Salmon, Martine/0000-0002-5312-8476; EL-AMRAOUI, Aziz/0000-0003-2692-4984; Petit, Christine/0000-0002-9069-002X				Bernex F, 1996, DEVELOPMENT, V122, P3023; Cohen-Salmon M, 1999, MAMM GENOME, V10, P520, DOI 10.1007/s003359901033; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; COHENTANNOUDJI M, 1995, MAMM GENOME, V6, P844, DOI 10.1007/BF00292433; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; Grifa A, 1999, NAT GENET, V23, P16, DOI 10.1038/12612; HASKO JA, 1988, HEARING RES, V35, P21, DOI 10.1016/0378-5955(88)90037-8; HENRY KR, 1979, AUDIOLOGY, V18, P93; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; KEATS BJB, 1994, AM J HUM GENET, V54, P681; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KRONESTERFREI A, 1978, CELL TISSUE RES, V193, P11; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LIM DJ, 1972, ARCHIV OTOLARYNGOL, V96, P199; LLORENS J, 1993, TOXICOL APPL PHARM, V123, P199, DOI 10.1006/taap.1993.1238; MUNYER PD, 1994, HEARING RES, V79, P83, DOI 10.1016/0378-5955(94)90129-5; OSSENKOPP KP, 1990, PHARMACOL BIOCHEM BE, V36, P875, DOI 10.1016/0091-3057(90)90093-W; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PORTER JD, 1990, PHYSIOL BEHAV, V48, P27, DOI 10.1016/0031-9384(90)90255-3; Rau A, 1999, J COMP NEUROL, V405, P271; SLEPECKY NB, 1992, CELL TISSUE RES, V267, P413, DOI 10.1007/BF00319363; SLEPECKY NB, 1992, MATRIX, V12, P80, DOI 10.1016/S0934-8832(11)80108-3; STEEL KP, 1996, WHATS WRONG MY MOUSE, P26; Tsuprun V, 1997, HEARING RES, V110, P107, DOI 10.1016/S0378-5955(97)00068-3; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9; ZWISLOCKI JJ, 1988, HEARING RES, V33, P207, DOI 10.1016/0378-5955(88)90151-7	30	111	112	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					139	143		10.1038/72793	http://dx.doi.org/10.1038/72793			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655058				2022-12-27	WOS:000085104600013
J	Bodzioch, M; Orso, E; Klucken, T; Langmann, T; Bottcher, L; Diederich, W; Drobnik, W; Barlage, S; Buchler, C; Porsch-Ozcurumez, M; Kaminski, WE; Hahmann, HW; Oette, K; Rothe, G; Aslanidis, C; Lackner, KJ; Schmitz, G				Bodzioch, M; Orso, E; Klucken, T; Langmann, T; Bottcher, L; Diederich, W; Drobnik, W; Barlage, S; Buchler, C; Porsch-Ozcurumez, M; Kaminski, WE; Hahmann, HW; Oette, K; Rothe, G; Aslanidis, C; Lackner, KJ; Schmitz, G			The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease	NATURE GENETICS			English	Article							APOLIPOPROTEIN-A-I; CELLULAR CHOLESTEROL; ABC TRANSPORTERS; PHOSPHOLIPIDS; FIBROBLASTS; RECEPTOR; EFFLUX	Tangier disease (TD) is an autosomal recessive disorder of lipid metabolism(1). It is characterized by absence of plasma high-density lipoprotein (HDL) and deposition of cholesteryl esters in the reticulo-endothelial system with splenomegaly and enlargement of tonsils and lymph nodes(.)(2) Although low HDL cholesterol is associated with an increased risk for coronary artery disease, this condition is not consistently found in TD pedigrees. Metabolic studies in TD patients have revealed a rapid catabolism of HDL and its precursors(2). In contrast to normal mononuclear phagocytes (MNP), MNP from TD individuals degrade internalized HDL in unusual lysosomes, indicating a defect in cellular lipid metabolism(3,4). HDL-mediated cholesterol efflux and intracellular lipid trafficking and turnover are abnormal in TD fibroblasts(5-7), which have a reduced in vitro growth rates. The TD locus has been mapped to chromosome 9q31 (ref. 9). Here we present evidence that TD is caused by mutations in ABC1, encoding a member of the ATP-binding cassette (ABC) transporter family, located on chromosome 9q22-31 (ref. 10), We have analysed five kindreds with TD and identified seven different mutations, including three that are expected to impair the function of the gene product. The identification of ABC1 as the TD locus has implications for the understanding of cellular HDL metabolism and reverse cholesterol transport, and its association with premature cardiovascular disease.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany; Klin Schwabenland, D-88315 Isny Neutrauchbturg, Germany; Univ Cologne, Fac Med, D-50924 Cologne, Germany	University of Regensburg; University of Cologne	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.		Özcürümez, Mustafa/AAQ-3250-2021; Langmann, Thomas/HHZ-9814-2022; Özcürümez, Mustafa K./GRS-4840-2022; Buechler, Christa/AAH-3004-2020	Özcürümez, Mustafa/0000-0002-4360-5005; Langmann, Thomas/0000-0001-6826-529X; Özcürümez, Mustafa K./0000-0002-4360-5005; Schmitz, Gerd/0000-0002-1325-1007				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ASSMANN G, 1977, J CLIN INVEST, V59, P565, DOI 10.1172/JCI108672; ASSMANN G, 1989, METABOLIC BASIS INHE, P1267; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FREDRICKSON D, 1961, ANN INTERN MED, V55, P1016, DOI 10.7326/0003-4819-55-6-1016; GIBBELS E, 1985, J NEUROL, V232, P283, DOI 10.1007/BF00313867; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; SCHMITZ G, 1990, ARTERIOSCLEROSIS, V10, P1010, DOI 10.1161/01.ATV.10.6.1010; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; von Eckardstein A, 1998, J LIPID RES, V39, P987	29	1289	1353	0	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					347	351		10.1038/11914	http://dx.doi.org/10.1038/11914			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431237				2022-12-27	WOS:000081772500015
J	Biesecker, BB; Marteau, TM				Biesecker, BB; Marteau, TM			The future of genetic counselling: an international perspective	NATURE GENETICS			English	Article							UNITED-KINGDOM; PRENATAL-DIAGNOSIS; FETAL-ABNORMALITY; CLINICAL-PRACTICE; CYSTIC-FIBROSIS; SERVICES; ATTITUDES; WOMEN; ECONOMICS; PROVIDERS	The focus of clinical genetics, and thus genetic counselling, is forecast to expand from the diagnosis and prediction of rare, often untreatable conditions, to the prediction of common, often treatable or preventable conditions'. Whether this evolution is likely to proceed rapidly or at a pace that permits sensible integration of molecular genetic tools is unknown and a source of debate(2,3) . It is clear, however, that genetic discoveries will modify the way in which disease and risk are conceptualized. Here, we predict how genetic counselling, specifically for more common diseases, might be provided in the decades to come. We envisage an expansion of professional roles and expertise for many health care providers and highlight the need for counselling practices to become more evidence based. Although we support an evidentiary-based approach to the integration of genetic testing into practice, genetic advance is unlikely to occur in an orderly and standardized manner within countries, much less among different countries and health care systems(4). Geneticists will become increasingly involved in professional education and policy-making regarding genetic testing and screening programs.	Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD USA; United Med & Dent Sch Guys & St Thomass Hosp, Psychol & Genet Res Grp, London SE1 7EH, England	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of London; King's College London	Biesecker, BB (corresponding author), Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD USA.	barbarab@nhgri.nih.gov		Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS LB, 1994, ASSESSING GENETIC RI, P202; ANNAS G, 1994, NEW ENGL J MED, V331, P1024; [Anonymous], 1975, Am J Hum Genet, V27, P240; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Bernhardt BA, 1997, AM J HUM GENET, V60, P17; BERNHARDT BA, 1989, AM J HUM GENET, V44, P288; Bernhardt BA, 1998, OBSTET GYNECOL, V91, P648, DOI 10.1016/S0029-7844(98)00011-8; BERNHARDT BA, 1992, AM J HUM GENET, V50, P84; Calzone K A, 1997, Oncol Nurs Forum, V24, P712; CAPLAN AL, 1993, PRESCRIBING OUR FUTU, P149; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; CLARKE A, 1991, LANCET, V338, P998, DOI 10.1016/0140-6736(91)91849-P; Clarke Angus., 1997, GENETICS SOC CLIN PR, P179; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; Djurdjinovic L, 1998, GUIDE TO GENETIC COUNSELING, P127; FARNISH S, 1988, J MED GENET, V25, P392, DOI 10.1136/jmg.25.6.392; Fine B A, 1996, J Genet Couns, V5, P113, DOI 10.1007/BF01408656; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; HARPER PS, 1993, PRACTICAL GENETIC CO, P3; Harris R, 1998, J ROY COLL PHYS LOND, V32, P335; HOFMAN KJ, 1993, ACAD MED, V68, P625, DOI 10.1097/00001888-199308000-00013; Holtzman NA, 1997, SCIENCE, V278, P602, DOI 10.1126/science.278.5338.602; Holtzman NA, 1997, PROMOTING SAFE EFFEC; HOLTZMAN NA, 1989, P CAUTION PREDICTING, P232; Hughes HE, 1998, J MED GENET, V35, P309, DOI 10.1136/jmg.35.4.309; Hunter A, 1998, CLIN GENET, V53, P447; Karanjawala ZE, 1998, JAMA-J AM MED ASSOC, V280, P1533, DOI 10.1001/jama.280.17.1533; Kenen R H, 1995, J Genet Couns, V4, P115, DOI 10.1007/BF01408634; Kenen RH, 1997, SOC SCI MED, V45, P1377, DOI 10.1016/S0277-9536(97)00062-2; Kessler S, 1997, J Genet Couns, V6, P379, DOI 10.1023/A:1025644825912; Kessler S, 1997, J Genet Couns, V6, P287, DOI 10.1023/A:1025676205440; Kessler S., 1990, J PSYCHOSOM OBST GYN, V11, P5; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Loeben GL, 1998, AM J HUM GENET, V63, P1181, DOI 10.1086/302036; Lowther GW, 1997, EUR J HUM GENET, V5, P84, DOI 10.1159/000484823; Mao X, 1997, CLIN GENET, V52, P100; MARTEAU T, 1994, J MED GENET, V31, P864, DOI 10.1136/jmg.31.11.864; Marteau Theresa, 1994, European Journal of Human Genetics, V2, P96; Marteau TM, 1993, J REPROD INFANT PSYC, V11, P3; MARTEAU TM, IN PRESS BR MED B; Marymee K, 1998, J Genet Couns, V7, P133, DOI 10.1023/A:1022849922560; Matloff E T, 1994, J Genet Couns, V3, P215, DOI 10.1007/BF01412228; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; Michie S, 1997, AM J HUM GENET, V60, P40; Michie S, 1996, TROUBLED HELIX SOCIA, P104; Morrison PJ, 1998, CLIN GENET, V54, P375; Murray Thomas H., 1996, WORTH CHILD; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Penchaszadeh V B, 1998, Rev Panam Salud Publica, V3, P409; Press N, 1997, SOC SCI MED, V45, P979, DOI 10.1016/S0277-9536(97)00011-7; PRESS NA, 1993, FETAL DIAGN THER, V8, P97, DOI 10.1159/000263878; Rothenberg K H, 1997, J Am Med Womens Assoc (1972), V52, P43; SCANLON C, 1996, CRIT CARE NURSE, V16, P9; Skirton H, 1998, J MED GENET, V35, P410, DOI 10.1136/jmg.35.5.410; Skirton H, 1997, J MED GENET, V34, P141, DOI 10.1136/jmg.34.2.141; SMURL JF, 1987, AM J MED GENET, V26, P247, DOI 10.1002/ajmg.1320260203; SORENSON JR, 1992, GENE MAPPING USING L, P203; SORENSON JR, 1981, REPRODUCTIVE PASTS R, V17, P131; Wertz D C, 1997, J Contemp Health Law Policy, V13, P299; Wertz D C, 1989, Theor Med, V10, P123, DOI 10.1007/BF00539878; WERTZ DC, 1990, AM J HUM GENET, V46, P1200; WERTZ DC, 1988, AM J HUM GENET, V42, P592; WERTZ DC, 1986, AM J HUM GENET, V39, P253; Wertz DC, 1998, SOC SCI MED, V46, P255, DOI 10.1016/S0277-9536(97)00159-7; Wertz DC, 1997, AM J HUM GENET, V61, P1163, DOI 10.1086/301593; WILFOND BS, 1995, AM J HUM GENET, V57, P1233; WILFOND BS, 1993, JAMA-J AM MED ASSOC, V270, P2948, DOI 10.1001/jama.270.24.2948	68	65	65	2	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					133	137		10.1038/9641	http://dx.doi.org/10.1038/9641			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369253				2022-12-27	WOS:000080680900016
J	Stone, EM; Lotery, AJ; Munier, FL; Heon, E; Piguet, B; Guymer, RH; Vandenburgh, K; Cousin, P; Nishimura, D; Swiderski, RE; Silvestri, G; Mackey, DA; Hageman, GS; Bird, AC; Sheffield, VC; Schorderet, DF				Stone, EM; Lotery, AJ; Munier, FL; Heon, E; Piguet, B; Guymer, RH; Vandenburgh, K; Cousin, P; Nishimura, D; Swiderski, RE; Silvestri, G; Mackey, DA; Hageman, GS; Bird, AC; Sheffield, VC; Schorderet, DF			A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy	NATURE GENETICS			English	Article							AGE-RELATED MACULOPATHY; BEAVER DAM EYE; MACULAR DEGENERATION; GENE; FIBRILLIN; PROTEIN; DRUSEN; PREVALENCE; FAMILY; DNA	Malattia Leventinese (ML) and Doyne honeycomb retinal dystrophy (DHRD) refer to two autosomal dominant diseases characterized by yellow-white deposits known as drusen that accumulate beneath the retinal pigment epithelium(1-4) (RPE). Both loci were mapped to chromosome 2p16-21 (refs 5,6) and this genetic interval has been subsequently narrowed(6) (7). The importance of these diseases is due in large part to their close phenotypic similarity to age-related macular degeneration (AMD), a disorder with a strong genetic: components(8-10) that accounts for approximately 50% of registered blindness in the Western world(11-14). Just as in ML and DHRD, the early hallmark of AMD is the presence of drusen(15) (16). Here we use a combination of positional and candidate gene methods to identify a single non-conservative mutation (Arg345Trp) in the gene EFEMP1 (for EGF-containing fibrillin-like extracellular matrix protein 1) in all families studied. This change was not present in 477 control individuals or in 494 patients with age-related macular degeneration. Identification of this mutation may aid in the development of an animal model for drusen, as well as in the identification of other genes involved in human macular degeneration.	Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; Hop Jules Gonin, Lausanne, Switzerland; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Eye Res Inst Canada, Toronto, ON, Canada; Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Parkville, Vic 3052, Australia; Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland; Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia; Moorfields Eye Hosp, Inst Ophthalmol, London, England; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA USA	University of Iowa; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Toronto; Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne; University of Iowa; University of Tasmania; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Howard Hughes Medical Institute; University of Iowa	Stone, EM (corresponding author), Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.		Mackey, David A/H-5340-2014	Mackey, David A/0000-0001-7914-4709; Stone, Edwin M./0000-0003-3343-4414; Lotery, Andrew/0000-0001-5541-4305; Guymer, Robyn/0000-0002-9441-4356; Sheffield, Val/0000-0002-6282-0835; Silvestri, Giuliana/0000-0001-5662-5374	NEI NIH HHS [EY10539, EY11515] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010539, R01EY011515] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; BUFFONE GJ, 1985, CLIN CHEM, V31, P164; Collins T., 1913, OPHTHALMOSCOPE, V11, P537; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Doyne R., 1899, T OPHTHAL SOC UK, V19, P71; Edwards AO, 1998, AM J OPHTHALMOL, V126, P417, DOI 10.1016/S0002-9394(98)00097-X; Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9; Fingert JH, 1998, GENOME RES, V8, P377, DOI 10.1101/gr.8.4.377; FORNI S, 1962, Ophthalmologica, V143, P313; Gregory CY, 1996, HUM MOL GENET, V5, P1055, DOI 10.1093/hmg/5.7.1055; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014; Ikegawa S, 1996, GENOMICS, V35, P590, DOI 10.1006/geno.1996.0402; Jay M, 1996, EYE, V10, P469, DOI 10.1038/eye.1996.103; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Saemisch T, 1925, HDB GESAMMTEN AUGENH, P1; SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57; SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WELLISZ T, 1993, J LONG-TERM EFF MED, V3, P223	30	339	352	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					199	202		10.1038/9722	http://dx.doi.org/10.1038/9722			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369267				2022-12-27	WOS:000080680900030
J	Chan, EF; Gat, U; McNiff, JM; Fuchs, E				Chan, EF; Gat, U; McNiff, JM; Fuchs, E			A common human skin tumour is caused by activating mutations in beta-catenin	NATURE GENETICS			English	Article							ADENOMATOUS POLYPOSIS; GARDNER SYNDROME; PROTEIN; PHOSPHORYLATION; APC; UBIQUITINATION; CANCER; SIGNAL	WNT signalling orchestrates a number of developmental programs(1-3), In response to this stimulus, cytoplasmic beta-catenin (encoded by CTNNB1) is stabilized, enabling downstream transcriptional activation by members of the LEF/TCF family(4,5). One of the target genes for beta-catenin/TCF encodes c-MYC, explaining why constitutive activation of the WNT pathway can lead to cancer, particularly in the colon(6). Most colon cancers arise from mutations in the gene encoding adenomatous polyposis coli (APC), a protein required for ubiquitin-mediated degradation of beta-catenin(7), but a small percentage of colon and some other cancers harbour beta-catenin-stabilizing mutations (refs 8-17). Recently, we discovered that transgenic mice expressing an activated beta-catenin are predisposed to developing skin tumours resembling pilomatricoma(18). Given that the skin of these adult mice also exhibits signs of de novo hair-follicle morphogenesis, we wondered whether human pilomatricomas might originate from hair matrix cells and whether they might possess beta-catenin-stabilizing mutations. Here, we explore the cell origin and aetiology of this common human skin tumour. We found nuclear LEF-1 in the dividing tumour cells, providing biochemical evidence that pilomatricomas are derived from hair matrix cells. At least 75% of these tumours possess mutations affecting the amino-terminal segment, normally involved in phosphorylation-dependent, ubiquitin-mediated degradation of the protein. This percentage of CTNNB1 mutations is greater than in all other human tumours examined thus far, and directly implicates beta-catenin/LEF misregulation as the major cause of hair matrix cell tumorigenesis in humans.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Howard Hughes Medical Institute; University of Chicago; Yale University	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.		高, 雨莉/HGU-8187-2022; Fuchs, Elaine/G-1565-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER; NIAMS NIH HHS [NIH-RO1-AR31737] Funding Source: Medline; NIDCR NIH HHS [NCI-P50DE/CA-11921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Foulkes WD, 1995, QJM-MON J ASSOC PHYS, V88, P853; Fukuchi T, 1998, CANCER RES, V58, P3526; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller O, 1998, GENE CHROMOSOME CANC, V22, P37; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Palacios J, 1998, CANCER RES, V58, P1344; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Pujol RM, 1995, PEDIATR DERMATOL, V12, P331, DOI 10.1111/j.1525-1470.1995.tb00195.x; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Voeller HJ, 1998, CANCER RES, V58, P2520; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHOU P, 1995, GENE DEV, V9, P570; Zurawel RH, 1998, CANCER RES, V58, P896	30	486	515	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					410	413		10.1038/7747	http://dx.doi.org/10.1038/7747			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192393				2022-12-27	WOS:000079439700024
J	Wigle, JT; Chowdhury, K; Gruss, P; Oliver, G				Wigle, JT; Chowdhury, K; Gruss, P; Oliver, G			Prox1 function is crucial for mouse lens-fibre elongation	NATURE GENETICS			English	Article							MORPHOGENESIS; GENE	Although insights have emerged regarding genes controlling the early stages of eye formation, little is known about lens-fibre differentiation and elongation, The expression pattern of the Prox1 homeobox gene suggests it has a role in a variety of embryonic tissues, including lens'. To analyse the requirement far Prox1 during mammalian development, we inactivated the locus in mice, Homozygous Prox1-null mice die at mid-gestation from multiple developmental defects; here we describe the specific effect an lens development Prox1 inactivation causes abnormal cellular proliferation, downregulated expression of the cell-cycle inhibitors Cdkn Ib (also known as p27(KIP1)) and Cdkn1b (also known as p57(KIP2)), misexpression of E-cadherin and inappropriate apoptosis. Consequently, mutant lens cells fail to polarize and elongate properly, resulting in a hollow lens, Our data provide evidence that the progression of terminal fibre differentiation and elongation is dependent on Prox1 activity during lens development.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	St Jude Children's Research Hospital; Max Planck Society	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOBER E, 1994, DEVELOPMENT, V120, P603; CARTIER M, 1992, NAT GENET, V2, P42, DOI 10.1038/ng0992-42; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Lang RA, 1997, CELL DEATH DIFFER, V4, P12, DOI 10.1038/sj.cdd.4400211; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; SANDILANDS A, 1995, J CELL SCI, V108, P1397; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	12	336	343	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					318	322		10.1038/6844	http://dx.doi.org/10.1038/6844			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080188				2022-12-27	WOS:000078977900029
J	Watanabe, H; Yamada, Y				Watanabe, H; Yamada, Y			Mice lacking link protein develop dwarfism and craniofacial abnormalities	NATURE GENETICS			English	Article							HORMONE-RELATED PEPTIDE; PARATHYROID-HORMONE; CHONDROCYTE DIFFERENTIATION; SKELETAL DEVELOPMENT; ENDOCHONDRAL BONE; INDIAN HEDGEHOG; CORE PROTEIN; GENE; CARTILAGE; AGGRECAN	Link protein (LP), an extracellular matrix protein in cartilage, stabilizes aggregates of aggrecan and hyaluronan, giving cartilage its tensile strength and elasticity(1-3). Cartilage provides the template for endochondral ossification and is crucial for determining the length and width of the skeleton. During endochondral bone formation, hypertrophic chondrocytes die and the cartilage is replaced with bone matrix. Here, we have generated targeted mutations in mice in the gene encoding LP (Crtl1). Homozygotes showed defects in cartilage development and delayed bone formation with short limbs and craniofacial anomalies. Most Crtl1(tm1Nid/tm1Nid) mice died shortly after birth due to respiratory failure, but some survived and developed progressive dwarfism and lordosis of the cervical spine. They showed small epiphysis, slightly flared metaphysis of long bones and flattened vertebrae, characteristic of spondyloepiphyseal dysplasias. The cartilage contained significantly reduced aggrecan depositions in the hypertrophic zone, and decreased numbers of prehypertrophic and hypertrophic chondrocytes. Reduced Indian hedgehog (Ihh) expression was observed in prehypertrophic chondrocytes, and apoptosis was inhibited in hypertrophic chondrocytes. These results indicate that LP is important for the formation of proteoglycan aggregates and normal organization of hypertrophic chondrocytes, and suggest that cartilage matrix has a role in chondrocyte differentiation and maturation.	Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, Y (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.	yamada@yoda.nidr.nih.gov						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; DOEGE K, 1987, J BIOL CHEM, V262, P17757; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; Hascall V.C., 1991, CELL BIOL EXTRACELLU, P149; HECHT JT, 1991, NUCLEIC ACIDS RES, V19, P6666, DOI 10.1093/nar/19.23.6666; KONG RYC, 1993, EUR J BIOCHEM, V213, P99, DOI 10.1111/j.1432-1033.1993.tb17739.x; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Li YF, 1997, MATRIX BIOL, V16, P49, DOI 10.1016/S0945-053X(97)90071-8; McAlister W.H., 1995, DIAGNOSIS BONE JOINT, VThird ed., P4163; MUNDLOS S, 1991, MATRIX, V11, P339, DOI 10.1016/S0934-8832(11)80205-2; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; Peters PWJ, 1977, METHODS PRENATAL TOX, P153; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wallis GA, 1996, CURR BIOL, V6, P1577, DOI 10.1016/S0960-9822(02)70776-8; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154	29	145	148	2	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					225	229		10.1038/6016	http://dx.doi.org/10.1038/6016			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988279				2022-12-27	WOS:000078399500029
J	Hacia, JG				Hacia, JG			Resequencing and mutational analysis using oligonucleotide microarrays	NATURE GENETICS			English	Review							DNA ANALYSIS; ARRAYS; HYBRIDIZATION; SEQUENCE; POLYMORPHISMS; DIAGNOSTICS; MICROCHIPS	Oligonucleotide microarray (DNA chip)-based hybridization analysis is a promising new technology which potentially allows rapid and cost-effective screens for all possible mutations and sequence variations in genomic DNA. Here, I review current strategies and uses for DNA chip-based resequencing and mutational analysis, the underlying principles of experimental designs, and future efforts to improve the sensitivity and specificity of chip-based assays.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Hacia, JG (corresponding author), NHGRI, Genet & Mol Biol Branch, NIH, Bldg 49-3A14, Bethesda, MD 20892 USA.	jhacia@nhgri.nih.gov						Arlinghaus HF, 1997, ANAL CHEM, V69, P3747, DOI 10.1021/ac970267p; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; Blanchard AP, 1996, BIOSENS BIOELECTRON, V11, P687, DOI 10.1016/0956-5663(96)83302-1; BROUDE NE, 1994, P NATL ACAD SCI USA, V91, P3072, DOI 10.1073/pnas.91.8.3072; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; DRMANAC R, 1989, GENOMICS, V4, P114; Drmanac S, 1998, NAT BIOTECHNOL, V16, P54, DOI 10.1038/nbt0198-54; Dubiley S, 1997, NUCLEIC ACIDS RES, V25, P2259, DOI 10.1093/nar/25.12.2259; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Edman CF, 1997, NUCLEIC ACIDS RES, V25, P4907, DOI 10.1093/nar/25.24.4907; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HACIA J, IN PRESS GENOME RES; Hacia JG, 1998, NUCLEIC ACIDS RES, V26, P3865, DOI 10.1093/nar/26.16.3865; Hacia JG, 1998, NUCLEIC ACIDS RES, V26, P4975, DOI 10.1093/nar/26.21.4975; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Head SR, 1997, NUCLEIC ACIDS RES, V25, P5065, DOI 10.1093/nar/25.24.5065; HOFKER MH, 1986, AM J HUM GENET, V39, P438; Hoheisel JD, 1996, NUCLEIC ACIDS RES, V24, P430, DOI 10.1093/nar/24.3.430; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; McGall G, 1996, P NATL ACAD SCI USA, V93, P13555, DOI 10.1073/pnas.93.24.13555; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; Moldin SO, 1997, SCHIZOPHRENIA BULL, V23, P547, DOI 10.1093/schbul/23.4.547; Nguyen HK, 1998, NUCLEIC ACIDS RES, V26, P4249, DOI 10.1093/nar/26.18.4249; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; NIKIFOROV TT, 1994, NUCLEIC ACIDS RES, V22, P4167, DOI 10.1093/nar/22.20.4167; Parinov S, 1996, NUCLEIC ACIDS RES, V24, P2998, DOI 10.1093/nar/24.15.2998; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; Proudnikov D, 1998, ANAL BIOCHEM, V259, P34, DOI 10.1006/abio.1998.2620; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shumaker JM, 1996, HUM MUTAT, V7, P346, DOI 10.1002/(SICI)1098-1004(1996)7:4<346::AID-HUMU9>3.3.CO;2-9; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; Southern EM, 1996, TRENDS GENET, V12, P110, DOI 10.1016/0168-9525(96)81422-3; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Weiler J, 1997, NUCLEIC ACIDS RES, V25, P2792, DOI 10.1093/nar/25.14.2792; WILSON RK, 1990, GENOMICS, V6, P626, DOI 10.1016/0888-7543(90)90497-I; Yershov G, 1996, P NATL ACAD SCI USA, V93, P4913, DOI 10.1073/pnas.93.10.4913; Zhang HP, 1997, ANN MED, V29, P493, DOI 10.3109/07853899709007473	55	384	491	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	1999	21			S			42	47		10.1038/4469	http://dx.doi.org/10.1038/4469			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915500				2022-12-27	WOS:000078008200011
J	Molday, LL; Rabin, AR; Molday, RS				Molday, LL; Rabin, AR; Molday, RS			ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy	NATURE GENETICS			English	Article							DISEASE GENE ABCR; ROD OUTER SEGMENTS; RETINITIS-PIGMENTOSA; RIM PROTEIN; DEGENERATION; MUTATIONS; MEMBRANE		Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada.							Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Klevering BJ, 1999, BRIT J OPHTHALMOL, V83, P914, DOI 10.1136/bjo.83.8.914; Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Osterberg G., 1935, ACTA OPHTHALMOL    S, V13, P1; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	15	188	194	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					257	258		10.1038/77004	http://dx.doi.org/10.1038/77004			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888868				2022-12-27	WOS:000087920900009
J	Rinkenberger, J; Werb, Z				Rinkenberger, J; Werb, Z			The labyrinthine placenta	NATURE GENETICS			English	Editorial Material							ANGIOGENESIS; REGULATOR; GROWTH	Fetal nutrition depends on the placenta, and specifically, the branching of a layer of placental trophoblast cells that sits between the maternal blood and fetal blood vessels. The discovery that expression of the transcription factor Gcm1 in trophoblast stem cells regulates branching of this specialized epithelium offers new insights into a process whose pivotal features have been generally obscure.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rinkenberger, J (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	zena@itsa.ucsf.edu						Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Janatpour MJ, 2000, DEVELOPMENT, V127, P549; Kingdom JCP, 1999, ADV EXP MED BIOL, V474, P259; Li YH, 1998, NAT GENET, V20, P309, DOI 10.1038/3129; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; Rinkenberger JL, 1997, DEV GENET, V21, P6, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;6::AID-DVG2&gt;3.0.CO;2-B; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Voss AK, 2000, DEVELOPMENT, V127, P1; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1	14	50	52	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					248	250		10.1038/76985	http://dx.doi.org/10.1038/76985			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888863				2022-12-27	WOS:000087920900005
J	Diehn, M; Eisen, MB; Botstein, D; Brown, PO				Diehn, M; Eisen, MB; Botstein, D; Brown, PO			Large-scale identification of secreted and membrane-associated gene products using DNA microarrays	NATURE GENETICS			English	Article							MESSENGER-RNA; BOUND POLYSOMES; SIGNAL PEPTIDES; PROTEINS; EXPRESSION; YEAST; CLONING; CELLS; LOCALIZATION; COMPLEXITY	Membrane-associated and secreted proteins are an important class of proteins and include receptors, transporters, adhesion molecules, hormones and cytokines. Although algorithms have been developed to recognize potential amino-terminal membrane-targeting signals or transmembrane domains in protein sequences, their accuracy is limited and they require knowledge of the entire coding sequence, including the N terminus(1), which is not currently available for most of the genes in most organisms, including human. Several experimental approaches for identifying secreted and membrane proteins have been described, but none have taken a comprehensive genomic approach(2-6). Furthermore, none of these methods allow easy classification of clones from arrayed cDNA libraries, for which large-scale gene-expression data are now becoming available through the use of DNA microarrays. We describe here a rapid and efficient method for identifying genes that encode secreted or membrane proteins. mRNA species bound to membrane-associated polysomes were separated from other mRNAs by sedimentation equilibrium or sedimentation velocity. The distribution of individual transcripts in the 'membrane-bound' and 'cytosolic' fractions was quantitated for thousands of genes by hybridization to DNA microarrays. Transcripts known to encode secreted or membrane proteins were enriched in the membrane-bound fractions, whereas those known to encode cytoplasmic proteins were enriched in the fractions containing mRNAs associated with free and cytoplasmic ribosomes. On this basis, we identified over 275 human genes and 285 yeast genes that are likely to encode previously unrecognized secreted or membrane proteins.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu		Eisen, Michael/0000-0002-7528-738X	NCI NIH HHS [CA77097] Funding Source: Medline; NHGRI NIH HHS [HG00983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Egea G, 1997, BIOCHEM J, V322, P557, DOI 10.1042/bj3220557; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kacharmina JE, 1999, METHOD ENZYMOL, V303, P3; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lightowlers RN, 1996, BIOCHEM SOC T, V24, P527, DOI 10.1042/bst0240527; Lukyanetz EA, 1997, NEUROSCIENCE, V78, P625, DOI 10.1016/S0306-4522(97)00020-1; MECHLER B, 1981, J CELL BIOL, V88, P29, DOI 10.1083/jcb.88.1.29; MECHLER BM, 1987, METHOD ENZYMOL, V152, P241; MUECKLER MM, 1981, J CELL BIOL, V90, P495, DOI 10.1083/jcb.90.2.495; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STOLTENBURG R, 1995, BIOTECHNIQUES, V18, P564; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Zannettino ACW, 1996, J IMMUNOL, V156, P611	26	173	183	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					58	62		10.1038/75603	http://dx.doi.org/10.1038/75603			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802657				2022-12-27	WOS:000086884000017
J	Manley, K; Shirley, TL; Flaherty, L; Messer, A				Manley, K; Shirley, TL; Flaherty, L; Messer, A			Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice	NATURE GENETICS			English	Article							TRINUCLEOTIDE-REPEAT; SACCHAROMYCES-CEREVISIAE; (CAG)(N) REPEAT; GENE; DNA; PHENOTYPE; EXPANSION; SPERM; RECOMBINATION; INACTIVATION	Huntington disease (HD), an autosomal dominant, progressive neurodegenerative disorder, is caused by an expanded CAG repeat sequence leading to an increase in the number of glutamine residues in the encoded protein(1). The normal CAG repeat range is 5-36, whereas 38 or more repeats are found in the diseased state; the severity of disease is roughly proportional to the number of CAG repeats(1-5). HD shows anticipation, in which subsequent generations display earlier disease onsets due to intergenerational repeat expansion(1-6). For longer repeat lengths, somatic instability of the repeat size has been observed both in human cases at autopsy(7,8) and in transgenic mouse models containing either a genomic fragment of human HD exon 1 (ref. 9) or an expanded repeat inserted into the endogenous mouse gene Hdh (ref. 10). With increasing repeat number, the protein changes conformation and becomes increasingly prone to aggregation(11), suggesting important functional correlations between repeat length and pathology. Because dinucleotide repeat instability is known to increase when the mismatch repair enzyme MSH2 is missing(12-15), we examined instability of the HD CAC repeat by crossing transgenic mice carrying exon 1 of human HD (ref, 16) with Msh2(-/-) mice(15), Our results show that Msh2 is required for somatic instability of the CAC repeat.	New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Messer, A (corresponding author), New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY USA.	messer@wadsworth.org			NIDDK NIH HHS [DK 52822] Funding Source: Medline; NINDS NIH HHS [NS37299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052822] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; DEROOIJ KE, 1995, HUM GENET, V95, P270, DOI 10.1007/BF00225192; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Giovannone B, 1997, HUM MUTAT, V10, P458, DOI 10.1002/(SICI)1098-1004(1997)10:6<458::AID-HUMU7>3.0.CO;2-9; Goellner GM, 1997, AM J HUM GENET, V60, P879; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V240, P239, DOI 10.1006/bbrc.1997.7643; LEEFLANG EP, 1995, HUM MOL GENET, V4, P1519; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Manley K, 1999, BRAIN RES, V835, P74, DOI 10.1016/S0006-8993(99)01451-1; Morgan LJ, 1996, MAMM GENOME, V7, P553, DOI 10.1007/s003359900164; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Reitmair AH, 1997, CANCER RES, V57, P3765; Saparbaev M, 1996, GENETICS, V142, P727; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; ZUHLKE C, 1993, HUM MOL GENET, V2, P2063, DOI 10.1093/hmg/2.12.2063	27	285	290	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					471	473		10.1038/70598	http://dx.doi.org/10.1038/70598			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581038				2022-12-27	WOS:000084023900027
J	di Fagagna, FD; Hande, MP; Tong, WM; Lansdorp, PM; Wang, ZQ; Jackson, SP				di Fagagna, FD; Hande, MP; Tong, WM; Lansdorp, PM; Wang, ZQ; Jackson, SP			Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability	NATURE GENETICS			English	Article							LACKING TELOMERASE; DNA; CELLS; MICE; RECOMBINATION; CYTOMETRY; DYNAMICS; ABSENCE; FUSIONS; CANCER	In most eukaryotes, poly(ADP-ribose) polymerase (PARP) recognizes DNA strand interruptions generated in vivo. DNA binding by PARP triggers primarily its own modification by the sequential addition of ADP-ribose units to form polymers; this modification, in turn, causes the release of PARP from DNA ends(1). Studies on the effects of the disruption of the gene encoding PARP (Adprt1, formerly Adprp) in mice have demonstrated roles for PARP in recovery from DNA damage and in suppressing recombination processes involving DNA ends(1-5). Telomeres are the natural termini of chromosomes and are, therefore, potential targets of PARP. Here, by the use of two different techniques, we show that mice lacking PARP display telomere shortening compared with wild-type mice. Telomere shortening is seen in different genetic backgrounds and in different tissues, both from embryos and adult mice. In vitro telomerase activity, however, is not altered in Adprt1(-/-) mouse fibroblasts. Furthermore, cytogenetic analysis of mouse embryonic fibroblasts reveals that lack of PARP is associated with severe chromosomal instability, characterized by increased frequencies of chromosome fusions and aneuploidy. The absence of PARP does not affect the presence of single-strand overhangs, naturally present at the ends of telomeres. This study therefore reveals an unanticipated role for PARP in telomere length regulation and provides insights into its functions in maintaining genomic integrity.	Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Int Agcy Res Canc, F-69372 Lyon, France; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	University of Cambridge; British Columbia Cancer Agency; World Health Organization; International Agency for Research on Cancer (IARC); University of British Columbia	Jackson, SP (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	spj13@mole.bio.cam.ac.uk	d'Adda di Fagagna, Fabrizio/AAC-4683-2022; Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019; Hande, M. Prakash/B-1645-2008	d'Adda di Fagagna, Fabrizio/0000-0002-9603-5966; Jackson, Stephen Philip/0000-0001-9317-7937; Hande, M. Prakash/0000-0002-4511-6256; DADDADIFAGAGNA, FABRIZIO/0000-0002-1976-3185; Lansdorp, Peter/0000-0001-7435-1071	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cristovao L, 1998, BRIT J CANCER, V77, P1628, DOI 10.1038/bjc.1998.266; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1992, J BIOL CHEM, V267, P12804; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Henderson LO, 1998, CYTOMETRY, V33, P97, DOI 10.1002/(SICI)1097-0320(19981001)33:2<97::AID-CYTO3>3.0.CO;2-H; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lindahl T, 1997, Ciba Found Symp, V211, P198; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Riboni R, 1997, CANCER GENET CYTOGEN, V95, P130, DOI 10.1016/S0165-4608(96)00248-8; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WANG ZQ, 1997, GENES DEV, V11; WRIGHT JJ, 1995, PROF ENG, V8, P23; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	28	210	229	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					76	80						5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471503				2022-12-27	WOS:000082337300020
J	Geisler, R; Rauch, GJ; Baier, H; van Bebber, F; Bross, L; Dekens, MPS; Finger, K; Fricke, C; Gates, MA; Geiger, H; Geiger-Rudolph, S; Gilmour, D; Glaser, S; Gnugge, L; Habeck, H; Hingst, K; Holley, S; Keenan, J; Kirn, A; Knaut, H; Lashkari, D; Maderspacher, F; Martyn, U; Neuhauss, S; Neumann, C; Nicolson, T; Pelegri, F; Ray, R; Rick, JM; Roehl, H; Roeser, T; Schauerte, HE; Schier, AF; Schonberger, U; Schonthaler, HB; Schulte-Merker, S; Seydler, C; Talbot, WS; Weiler, C; Nusslein-Volhard, C; Haffter, P				Geisler, R; Rauch, GJ; Baier, H; van Bebber, F; Bross, L; Dekens, MPS; Finger, K; Fricke, C; Gates, MA; Geiger, H; Geiger-Rudolph, S; Gilmour, D; Glaser, S; Gnugge, L; Habeck, H; Hingst, K; Holley, S; Keenan, J; Kirn, A; Knaut, H; Lashkari, D; Maderspacher, F; Martyn, U; Neuhauss, S; Neumann, C; Nicolson, T; Pelegri, F; Ray, R; Rick, JM; Roehl, H; Roeser, T; Schauerte, HE; Schier, AF; Schonberger, U; Schonthaler, HB; Schulte-Merker, S; Seydler, C; Talbot, WS; Weiler, C; Nusslein-Volhard, C; Haffter, P			A radiation hybrid map of the zebrafish genome	NATURE GENETICS			English	Article							DANIO-RERIO; CHROMOSOMES; VERTEBRATE; GENES	Recent large-scale mutagenesis screens have made the zebrafish the first vertebrate organism to allow a forward genetic approach to the discovery of developmental control genes(1-3). Mutations can be cloned positionally, or placed on a simple sequence length polymorphism (SSLP) map(4-6) to match them with mapped candidate genes and expressed sequence tags(7,8) (ESTs). To facilitate the mapping of candidate genes and to increase the density of markers available for positional cloning, we have created a radiation hybrid (RH) map of the zebrafish genome. This technique is based on somatic cell hybrid lines produced by fusion of lethally irradiated cells of the species of interest with a rodent cell line. Random fragments of the donor chromosomes are integrated into recipient chromosomes or retained as separate minichromosomesg (9,10) The radiation-induced breakpoints can be used for mapping in a manner analogous to genetic mapping, but at higher resolution and without a need for polymorphism. Genome-wide maps exist for the human, based on three RH panels of different resolutions(11-13), as well as for the dog(14) rat(15) and mouse(16, 17). For our map of the zebrafish genome, we used an existing RH panel (18, 19) and 1,451 sequence tagged site (STS) markers, including SSLPs, cloned candidate genes and ESTs. Of these, 1,275 (87.9%) have significant linkage to at least one other marker. The fraction of ESTs with significant linkage, which can be used as an estimate of map coverage, is 87.9%. We found the average marker retention frequency to be 18.4%. One cR(3000) is equivalent to 61 kb, resulting in a potential resolution of approximately 350 kb.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; NYU, Med Ctr, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA; Stanford Univ, Sch Med, Beckman Ctr B407, Stanford, CA 94305 USA	Max Planck Society; New York University; Stanford University	Geisler, R (corresponding author), Max Planck Inst Entwicklungsbiol, Spemannstr 35, D-72076 Tubingen, Germany.		Geisler, Robert/K-6201-2013; Neuhauss, Stephan/AAX-9915-2020; Schönthaler, Helia/AAG-4767-2021	Geisler, Robert/0000-0002-3909-8311; Neuhauss, Stephan/0000-0002-9615-480X; Gilmour, Darren/0000-0001-7613-090X; Knaut, Holger/0000-0002-8399-8720; Dekens, Marcus P.S./0000-0003-1689-3491; Maderspacher, Florian/0000-0003-4324-8455; Schier, Alexander Franz/0000-0001-7645-5325	NCRR NIH HHS [R01RR12349] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012349] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Driever W, 1996, DEVELOPMENT, V123, P37; Gates MA, 1999, GENOME RES, V9, P334; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Haffter P, 1996, INT J DEV BIOL, V40, P221; Haffter P, 1996, DEVELOPMENT, V123, P1; HINEGARDNER R, 1972, AM NAT, V106, P621, DOI 10.1086/282801; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUKRIEDE N, IN PRESS P NATL ACAD; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Knapik EW, 1996, DEVELOPMENT, V123, P451; Kwok C, 1999, METHOD CELL BIOL, V60, P287; Kwok C, 1998, NUCLEIC ACIDS RES, V26, P3562, DOI 10.1093/nar/26.15.3562; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737	24	225	228	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					86	89		10.1038/12692	http://dx.doi.org/10.1038/12692			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471505				2022-12-27	WOS:000082337300022
J	Rane, SG; Dubus, P; Mettus, RV; Galbreath, EJ; Boden, G; Reddy, EP; Barbacid, M				Rane, SG; Dubus, P; Mettus, RV; Galbreath, EJ; Boden, G; Reddy, EP; Barbacid, M			Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia	NATURE GENETICS			English	Article							DEPENDENT KINASE INHIBITORS; PANCREATIC B-CELL; MICE LACKING; LEYDIG-CELLS; CYCLIN D1; GROWTH; GENE; PROLIFERATION; DISRUPTION; RAT	To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, we have targeted the mouse Cdk4 locus by homologous recombination to generate two strains of mice, one that lacks Cdk4 expression and one that expresses a Cdk4 molecule with an activating mutation. Embryonic fibroblasts proliferate normally in the absence of Cdk4 but have a delayed S phase on re-entry into the cell cycle. Moreover, mice devoid of Cdk4 are viable, but small in size and infertile. These mice also develop insulin-deficient diabetes due to a reduction in beta-islet pancreatic cells. In contrast, mice expressing a mutant Cdk4 that cannot bind the cell-cycle inhibitor p16(INK4a) display pancreatic hyperplasia due to abnormal proliferation of beta-islet cells. These results establish Cdk4 as an essential regulator of specific cell types.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Bordeaux 2, Lab Histol Embryol, F-33076 Bordeaux, France; Eli Lilly & Co, Indianapolis, IN 46285 USA; Temple Univ, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Gen Clin Res Ctr, Philadelphia, PA 19140 USA; Ctr Nacl Invest Oncol Carlos III, Madrid 28220, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; UDICE-French Research Universities; Universite de Bordeaux; Eli Lilly; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011	Dubus, Pierre/0000-0003-1803-4711; Galbreath, Elizabeth/0000-0003-0162-8329	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010221] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIAAA NIH HHS [R01-AA-10221] Funding Source: Medline; NIA NIH HHS [R01-AG-07988] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Ashcroft FM, 1992, INSULIN MOL BIOL PAT; Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Balvers M, 1998, ENDOCRINOLOGY, V139, P2960, DOI 10.1210/en.139.6.2960; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CAMERON DF, 1985, ANAT REC, V213, P53, DOI 10.1002/ar.1092130108; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DELLA NG, 1995, CELL TISSUE RES, V279, P411, DOI 10.1007/s004410050298; Dunlop M, 1996, BIOCHEM BIOPH RES CO, V218, P132, DOI 10.1006/bbrc.1996.0023; Duvillie B, 1997, P NATL ACAD SCI USA, V94, P5137, DOI 10.1073/pnas.94.10.5137; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GRANA X, 1995, ONCOGENE, V11, P211; HELLERSTROM C, 1984, DIABETOLOGIA, V26, P393; HELLERSTROM C, 1991, DIABETES, V40, P89, DOI 10.2337/diab.40.2.S89; HIRAMA T, 1995, BLOOD, V86, P841; HOPPENER JWM, 1994, J CELL BIOCHEM, V55, P39, DOI 10.1002/jcb.240550006; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lejeune H, 1998, J MOL ENDOCRINOL, V20, P1, DOI 10.1677/jme.0.0200001; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MARTINEZ AR, 1995, INT J FERTIL MENOP S, V40, P139; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MURRAY FT, 1983, METABOLISM, V32, P141, DOI 10.1016/S0026-0495(83)80028-6; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAYNE AH, 1995, BIOL REPROD, V52, P217, DOI 10.1095/biolreprod52.2.217; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SWENNE I, 1983, DIABETES, V32, P14, DOI 10.2337/diabetes.32.1.14; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UNGER R H, 1985, P1018; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	42	586	602	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					44	52		10.1038/8751	http://dx.doi.org/10.1038/8751			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319860				2022-12-27	WOS:000080096300021
J	Lee, JT; Davidow, LS; Warshawsky, D				Lee, JT; Davidow, LS; Warshawsky, D			Tsix, a gene antisense to Xist at the X-inactivation centre	NATURE GENETICS			English	Article							CHROMOSOME INACTIVATION; RNA; DNA; DIFFERENTIATION; STABILIZATION; INTERPHASE; EXPRESSION; NUCLEUS; INVITRO; REGION	In mammals, dosage compensation is achieved by X inactivation(1) and is regulated in cis by the X-inactivation centre(2) (Xic) and Xist (refs 3-5). The Xic controls X-chromosome counting, choice of X to inactivate and initiation of silencing. Xic action culminates in a change in Xist RNA property from a scarce, unstable RNA (refs 6,7) to highly expressed Xist RNA that coats the future inactive X (ref. 8). Deleting a 65-kb region downstream of Xist results in constitutive Xist expression and X inactivation, implying the presence of a cis-regulatory element(9). In this region, we now report the discovery of a gene antisense to Xist. Tsix is a 40-kb RNA originating 15 kb downstream of Xist and transcribed across the Xist locus. Tsix sequence is conserved at the human XIC. Tsix RNA has no conserved ORFs, is seen exclusively in the nucleus and is localized at Xic. Before the onset of X inactivation, Tsix is expressed from both X chromosomes. At the onset of X inactivation, Tsix expression becomes monoallelic, is associated with the future active X and persists until Xist is turned off. Tsix is not found on the inactive X once cells enter the X-inactivation pathway. Tsix has features suggesting a role in regulating the early steps of X inactivation, but not the silencing step.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02115 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE JA, IN PRESS P NATL ACAD; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	26	627	664	1	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					400	404		10.1038/7734	http://dx.doi.org/10.1038/7734			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192391				2022-12-27	WOS:000079439700022
J	Jensen, S; Gassama, MP; Heidmann, T				Jensen, S; Gassama, MP; Heidmann, T			Taming of transposable elements by homology-dependent gene silencing	NATURE GENETICS			English	Article							R-HYBRID DYSGENESIS; DROSOPHILA-MELANOGASTER; TRANSGENIC PLANTS; I-FACTOR; RNA; COSUPPRESSION; SUPPRESSION; REPEATS	Transposable elements can invade virgin genomes within a few generations, after which the elements are 'tamed' and retain only limited transpositional activity. Introduction of the I element, a transposon similar to mammalian LINE elements, into Drosophila melanogaster genomes devoid of such elements initially results in high-frequency transposition of the incoming transposon, high mutation rate, chromosomal nondisjunction and female sterility, a syndrome referred to as hybrid dysgenesis' (for review, see refs 2-4); a related syndrome has also been described in mammals(5). High-frequency transposition is transient, as the number of I elements reaches a finite value and transposition ceases after approximately ten generations(6,7). It has been proposed that the I elements encode a factor that negatively regulates their own transcription, but evidence for such a mechanism is lacking(8). Using the hybrid dysgenesis syndrome in Drosophila(1-4) as a model, we show here that transpositional activity of the I element can be repressed by prior introduction of transgenes expressing a small internal region of the I element. This autoregulation presents features characteristic of homology-dependent gene silencing, a process known as cosuppression(9-15) Repression does not require any translatable sequence, its severity correlates with transgene copy number and it develops in a generation-dependent manner via germline transmission of a silencing effector in females only. These results demonstrate that transposable elements are prone to and can be tamed by homology-dependent gene silencing, a process that may have emerged during the course of evolution as a specific defense mechanism against these elements.	Inst Gustave Roussy, CNRS, UMR 1537, Unite Retrovir Endogen & Elem Retroid Eucaryot, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 1537, Unite Retrovir Endogen & Elem Retroid Eucaryot, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	heidemann@igr.fr		Jensen, Silke/0000-0002-1858-8792				ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bingham PM, 1997, CELL, V90, P385, DOI 10.1016/S0092-8674(00)80496-1; BREGLIANO JC, 1980, SCIENCE, V207, P606, DOI 10.1126/science.6766221; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; Dawson A, 1997, EMBO J, V16, P4448, DOI 10.1093/emboj/16.14.4448; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FINNEGAN DJ, 1989, DROSOPHILA MELANOGAS, P503; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; JENSEN S, 1995, MOL GEN GENET, V248, P381, DOI 10.1007/BF02191637; JENSEN S, 1994, NUCLEIC ACIDS RES, V22, P1484, DOI 10.1093/nar/22.8.1484; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Meyer P, 1996, ANNU REV PLANT PHYS, V47, P23, DOI 10.1146/annurev.arplant.47.1.23; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PELISSON A, 1987, MOL GEN GENET, V207, P306, DOI 10.1007/BF00331594; Picard G, 1971, DIS, V46, P54; PRITCHARD MA, 1988, MOL GEN GENET, V214, P533, DOI 10.1007/BF00330491; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; VAUCHERET H, 1995, MOL GEN GENET, V248, P311, DOI 10.1007/BF02191598; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8	30	173	188	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					209	212		10.1038/5997	http://dx.doi.org/10.1038/5997			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988275				2022-12-27	WOS:000078399500025
J	Wong, KK; Chang, S; Weiler, SR; Ganesan, S; Chaudhuri, J; Zhu, CM; Artandi, SE; Rudolph, KL; Gottlieb, GJ; Chin, L; Alt, FW; DePinho, RA				Wong, KK; Chang, S; Weiler, SR; Ganesan, S; Chaudhuri, J; Zhu, CM; Artandi, SE; Rudolph, KL; Gottlieb, GJ; Chin, L; Alt, FW; DePinho, RA			Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation	NATURE GENETICS			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MAMMALIAN-CELLS; LIGASE-IV; CHROMOSOME BREAKAGE; STEM-CELLS; MICE; KU; IDENTIFICATION; PROTEINS	Telomeres are specialized nucleoprotein complexes that serve as protective caps of linear eukaryotic chromosomes. Loss of telomere function is associated with rampant genetic instability and loss of cellular viability and renewal potential. The telomere also participates in processes of chromosomal repair, as evidenced by the 'capture' or de novo synthesis of telomere repeats at double-stranded breaks(1-4) and by the capacity of yeast telomeres to serve as repositories of essential components of the DNA repair machinery, particularly those involved in non-homologous end-joining(5-7) (NHEJ). Here we used the telomerase-deficient mouse. null for the essential telomerase RNA gene (Terc). to assess the role of telomerase and telomere function on the cellular and organismal response to ionizing radiation. Although the loss of telomerase activity per se had no discernable impact on the response to ionizing radiation, the emergence of telomere dysfunction in late-generation Terc(-/-) mice imparted a radiosensitivity syndrome associated with accelerated mortality. On the cellular level, the gastrointestinal crypt stem cells and primary thymocytes showed increased rates of apoptosis, and mouse embryonic fibroblasts (MEFs) showed diminished dose-dependent clonogenic survival. The radiosensitivity of telomere dysfunctional cells correlated with delayed DNA break repair kinetics, persistent chromosomal breaks and cytogenetic profiles characterized by complex chromosomal aberrations and massive fragmentation. Our findings establish a intimate relationship between functionally intact telomeres and the genomic. cellular and organismal response to ionizing radiation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA 02115 USA; Quest Diagnost Inc, Anat Pathol, Teterboro, NJ USA; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.			Rudolph, Karl Lenhard/0000-0002-4839-2862; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317, R01HD034880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG001019] Funding Source: NIH RePORTER; NIAMS NIH HHS [K08AR02104-01] Funding Source: Medline; NIA NIH HHS [K08 AG001019] Funding Source: Medline; NICHD NIH HHS [R01HD28317, R01HD 34880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; Hall E.J., 2019, RADIOBIOLOGY RADIOLO, Veighth; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Kiltie AE, 1997, NUCLEIC ACIDS RES, V25, P2945, DOI 10.1093/nar/25.14.2945; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SAVAGE JRK, 1975, J MED GENET, V12, P103; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Slijepcevic P, 1998, MUTAGENESIS, V13, P45; Sprung CN, 1999, P NATL ACAD SCI USA, V96, P6781, DOI 10.1073/pnas.96.12.6781; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20	30	263	282	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					85	88		10.1038/79232	http://dx.doi.org/10.1038/79232			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973255				2022-12-27	WOS:000089078000024
J	Wu, JY; Ribar, TJ; Cummings, DE; Burton, KA; McKnight, GS; Means, AR				Wu, JY; Ribar, TJ; Cummings, DE; Burton, KA; McKnight, GS; Means, AR			Spermiogenesis and exchange of basic nuclear proteins are impaired in male germ cells lacking Camk4	NATURE GENETICS			English	Article							KINASE-IV; MICE; PHOSPHORYLATION; ACTIVATION; PROTAMINE-1; EXPRESSION; PRECURSOR; COMPLEX; SPERM; MOUSE	Ca2+/calmodulin-dependent protein kinase IV (Camk4; also known as CaMKIV), a multifunctional serine/threonine protein kinase with limited tissue distribution, has been implicated in transcriptional regulation in lymphocytes, neurons and male germ cells(1-6). In the mouse testis, however, Camk4 is expressed in spermatids and associated with chromatin and nuclear matrix.(7) Elongating spermatids are not transcriptionally active(8), raising the possibility that Camk4 has a novel function in male germ cells. To investigate the role of Camk4 in spermatogenesis, we have generated mice with a targeted deletion of the gene Camk4. Male Camk4(-/-) mice are infertile with impairment of spermiogenesis in late elongating spermatids. The sequential deposition of sperm basic nuclear proteins on chromatin is disrupted, with a specific loss of protamine-2 and prolonged retention of transition protein-2 (Tnp2) in step-15 spermatids. Protamine-2 is phosphorylated by Camk4 in vitro, implicating a connection between Camk4 signalling and the exchange of basic nuclear proteins in mammalian male germ cells. Defects in protamine-2 have been identified in sperm of infertile men, suggesting that our results may have clinical implications for the understanding of human male infertility.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; VA Med Ctr, Dept Med, Seattle, WA USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Duke University; University of Washington; University of Washington Seattle	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.				NICHD NIH HHS [HD07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Bench G, 1998, MOL REPROD DEV, V50, P345, DOI 10.1002/(SICI)1098-2795(199807)50:3<345::AID-MRD11>3.0.CO;2-3; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; de Yebra L, 1998, FERTIL STERIL, V69, P755, DOI 10.1016/S0015-0282(98)00012-0; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ELSEVIER SM, 1991, EUR J BIOCHEM, V196, P167, DOI 10.1111/j.1432-1033.1991.tb15800.x; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GREEN D, 1994, APPL COGNITIVE PSYCH, V8, P37, DOI 10.1002/acp.2350080105; KENNEDY BP, 1981, J BIOL CHEM, V256, P9254; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; LOUIE AJ, 1972, J BIOL CHEM, V247, P7962; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PIRHONEN A, 1994, EUR J BIOCHEM, V223, P165, DOI 10.1111/j.1432-1033.1994.tb18979.x; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P119; SODERSTROM KO, 1976, MOL CELL ENDOCRINOL, V5, P181, DOI 10.1016/0303-7207(76)90082-4; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wu JY, 2000, J BIOL CHEM, V275, P7994, DOI 10.1074/jbc.275.11.7994; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	27	183	186	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					448	452		10.1038/78153	http://dx.doi.org/10.1038/78153			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932193				2022-12-27	WOS:000088615000024
J	Lee, CK; Weindruch, R; Prolla, TA				Lee, CK; Weindruch, R; Prolla, TA			Gene-expression profile of the ageing brain in mice	NATURE GENETICS			English	Article							DIETARY RESTRICTION; ALZHEIMERS-DISEASE; CALORIC RESTRICTION; NEURONS; INFLAMMATION; RESPONSES; LESIONS; ROLES; BETA; RAT	Ageing of the brain leads to impairments in cognitive and motor skills, and is the major risk factor for several common neurological disorders such as Alzheimer disease (AD) and Parkinson disease (PD). Recent studies suggest that normal brain ageing is associated with subtle morphological and functional alterations in specific neuronal circuits, as opposed to large-scale neuronal loss'. In fact, ageing of the central nervous system in diverse mammalian species shares many features, such as atrophy of pyramidal neurons, synaptic atrophy, decrease of striatal dopamine receptors. accumulation of fluorescent pigments, cytoskeletal abnormalities, and reactive astrocytes and microglia(2). To provide the first global analysis of brain ageing at the molecular level, we used oligonucleotide arrays representing 6,347 genes to determine the gene-expression profile of the ageing neocortex and cerebellum in mice. Ageing resulted in a gene-expression profile indicative of an inflammatory response, oxidative stress and reduced neurotrophic support in both brain regions. At the transcriptional level, brain ageing in mice displays parallels with human neurodegenerative disorders. Caloric restriction, which retards the ageing process in mammals, selectively attenuated the age-associated induction of genes encoding inflammatory and stress responses.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53706 USA; Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center	Weindruch, R (corresponding author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA.		Lee, Cheol-Koo/F-2103-2013	Lee, Cheol-Koo/0000-0003-3927-9195	NCI NIH HHS [R01CA78723] Funding Source: Medline; NIA NIH HHS [P01AG11915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blumenthal HT, 1997, J GERONTOL A-BIOL, V52, pB1, DOI 10.1093/gerona/52A.1.B1; DISTERHOFT JF, 1994, CALCIUM HYPOTHESIS A; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Finch Caleb E., 1999, P613; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gaubatz JW, 1995, MOL BASIS AGING, P71; HALLGREN R, 1982, INFLAMMATION, V6, P291, DOI 10.1007/BF00916410; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hermann DM, 1999, NEUROSCIENCE, V88, P599, DOI 10.1016/S0306-4522(98)00249-8; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEMERE CA, 1995, AM J PATHOL, V146, P848; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; McEwen BS, 1999, FRONT NEUROENDOCRIN, V20, P49, DOI 10.1006/frne.1998.0173; MOROIFETTERS SE, 1989, NEUROBIOL AGING, V10, P317, DOI 10.1016/0197-4580(89)90042-0; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; NICHOLS NR, 1993, NEUROBIOL AGING, V14, P421, DOI 10.1016/0197-4580(93)90100-P; Pasinetti GM, 1999, SYNAPSE, V31, P278, DOI 10.1002/(SICI)1098-2396(19990315)31:4<278::AID-SYN5>3.0.CO;2-0; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Ryseck RP, 1996, BRAZ J MED BIOL RES, V29, P895; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Suo ZM, 1998, BRAIN RES, V807, P110, DOI 10.1016/S0006-8993(98)00780-X; WEINDRUCH R, 1988, RETARDATION AGING DI	26	835	871	0	60	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					294	297		10.1038/77046	http://dx.doi.org/10.1038/77046			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888876				2022-12-27	WOS:000087920900016
J	Paloneva, J; Kestila, M; Wu, J; Salminen, A; Bohling, T; Ruotsalainen, V; Hakola, P; Bakker, ABH; Phillips, JH; Pekkarinen, P; Lanier, LL; Timonen, T; Peltonen, L				Paloneva, J; Kestila, M; Wu, J; Salminen, A; Bohling, T; Ruotsalainen, V; Hakola, P; Bakker, ABH; Phillips, JH; Pekkarinen, P; Lanier, LL; Timonen, T; Peltonen, L			Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts	NATURE GENETICS			English	Article							POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA; NATURAL-KILLER-CELLS; SCLEROSING LEUKOENCEPHALOPATHY; MEMBRANOUS LIPODYSTROPHY; CUTTING EDGE; PLO-SL; PROTEIN; GENE; RECEPTORS; ACTIVATION	Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL; MIM 221770), also known as Nasu-Hakola disease, is a recessively inherited disease characterized by a combination of psychotic symptoms rapidly progressing to presenile dementia and bone cysts restricted to wrists and ankles(1-3). PLOSL has a global distribution, although most of the patients have been diagnosed in Finland(4) and Japan. with an estimated population prevalence of 2x10(-6) (ref. 2) in the Finns. We have previously identified a shared 153-kb ancestor haplotype in all Finnish disease alleles between markers D1951175 and D195608 on chromosome 19q13.1 (refs 5,6). Here we characterize the molecular defect in PLOSL by identifying one large deletion in all Finnish PLOSL alleles and another mutation in a Japanese patient, both representing loss-of-function mutations, in the gene encoding TYRO protein tyrosine kinase binding protein(7) (TYROBP; formerly DAP12). TYROBP is a transmembrane protein that has been recognized as a key activating signal transduction element in natural killer (NK) cells(8). On the plasma membrane of NK cells, TYROBP associates with activating receptors recognizing major histocompatibility complex (MHC) class I molecules(7,9). No abnormalities in NK cell function were detected in PLOSL patients homozygous for a null allele of TYROBP.	Natl Publ Hlth Inst, Dept Human Mol Genet, Helsinki, Finland; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Gonda Ctr, Los Angeles, CA USA; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki, Finland; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Ctr, San Francisco, CA 94143 USA; Dept Biochem, Oulu, Finland; Bioctr Oulu, Oulu, Finland; Univ Kuopio, Dept Forens Psychiat, FIN-70211 Kuopio, Finland; DNAX Res Inst Molec & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA USA	Finland National Institute for Health & Welfare; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Helsinki; University of Helsinki; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Finland National Institute for Health & Welfare; University of Oulu; University of Eastern Finland; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Peltonen, L (corresponding author), Natl Publ Hlth Inst, Dept Human Mol Genet, Mannerheimintie 166, Helsinki, Finland.	lpeltonen@mednet.ucla.edu	Paloneva, Juha/K-2419-2019; Ijäs, Petra/F-8280-2015; Lanier, Lewis L/E-2139-2014; Bakker, Arnold B./F-8494-2010	Ijäs, Petra/0000-0002-7292-1971; Lanier, Lewis L/0000-0003-1308-3952; Bakker, Arnold B./0000-0003-1489-1847; Paloneva, Juha/0000-0003-3340-9390				ABRAMSKY O, 1989, DISSECTION TISSUE CU, P1; Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Campbell KS, 1999, INT J BIOCHEM CELL B, V31, P631, DOI 10.1016/S1357-2725(99)00022-9; Chang CW, 1999, J IMMUNOL, V163, P4651; Colonna M, 1998, NATURE, V391, P642, DOI 10.1038/35515; Cuadros MA, 1998, PROG NEUROBIOL, V56, P173, DOI 10.1016/S0301-0082(98)00035-5; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; EDVARDSEN P, 1983, INT ORTHOP, V7, P99; Hakola H P, 1972, Acta Psychiatr Scand Suppl, V232, P1; Hakola P., 1990, MONOGRAPHS PSYCHIAT, V17, P1; Harris NL, 1997, GENOME RES, V7, P754, DOI 10.1101/gr.7.7.754; Heymann D, 1998, CYTOKINE, V10, P155, DOI 10.1006/cyto.1997.0277; KALIMO H, 1994, ACTA NEUROL SCAND, V89, P353; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Lenkkeri U, 1998, HUM GENET, V102, P192, DOI 10.1007/s004390050676; MAKELA P, 1982, SKELETAL RADIOL, V8, P51; McVicar DW, 1998, J BIOL CHEM, V273, P32934, DOI 10.1074/jbc.273.49.32934; NASU T, 1973, ACTA PATHOL JAPON, V23, P539; Nylander PO, 1996, CLIN GENET, V50, P353; Pekkarinen P, 1998, AM J HUM GENET, V62, P362, DOI 10.1086/301722; Pekkarinen P, 1998, GENOMICS, V54, P307, DOI 10.1006/geno.1998.5591; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; Rolstad B, 1998, SCAND J IMMUNOL, V47, P412; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Smith KM, 1998, J IMMUNOL, V161, P7; Verloes A, 1997, J MED GENET, V34, P753, DOI 10.1136/jmg.34.9.753; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730	30	337	349	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					357	361		10.1038/77153	http://dx.doi.org/10.1038/77153			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888890				2022-12-27	WOS:000087920900030
J	Rogge, L; Bianchi, E; Biffi, M; Bono, E; Chang, SYP; Alexander, H; Santini, C; Ferrari, G; Sinigaglia, L; Seiler, M; Neeb, M; Mous, J; Sinigaglia, F; Certa, U				Rogge, L; Bianchi, E; Biffi, M; Bono, E; Chang, SYP; Alexander, H; Santini, C; Ferrari, G; Sinigaglia, L; Seiler, M; Neeb, M; Mous, J; Sinigaglia, F; Certa, U			Transcript imaging of the development of human T helper cells using oligonucleotide arrays	NATURE GENETICS			English	Article							REGULATORY FACTOR-I; SELECTIVE EXPRESSION; IMMUNE-RESPONSES; P-SELECTIN; INTERLEUKIN-12; T-HELPER-1; CYTOKINE; RECEPTOR; TYPE-1; LYMPHOCYTES	Many pathological processes, including those causing allergies and autoimmune diseases, are associated with the presence of specialized subsets of T helper cells at the site of inflammation(1) Understanding the genetic program that controls the functional properties of T helper type 1 (Th1) versus T helper type 2 (Th2) cells may provide insight into the pathophysiology of inflammatory diseases. We compared the gene-expression profiles of human Th1 and Th2 cells using high-density oligonucleotide arrays with the capacity to display transcript levels of 6,000 human genes'. Here we analyse the data sets derived from five independent experiments using statistical algorithms. This approach resulted in the identification of 215 differentially expressed genes, encoding proteins involved in transcriptional regulation, apoptosis, proteolysis, and cell adhesion and migration. A-subset of these genes was further upregulated by exposure of differentiated Th1 cells to interleukin-12 (IL-12), as confirmed by kinetic PCR analysis, indicating that IL-12 modulates the effector functions of Th1 cells in the absence of antigenic stimulation. Functional assays and in vivo expression of selected genes have validated the biological relevance of our study. Our results provide new insight into the transcriptional program controlling the functional diversity of subsets of T helper cells.	Roche Milano Ric, Milan, Italy; Ist Sci San Raffaele, DIBIT, Milan, Italy; Roche Mol Syst, Alameda, CA USA; TIGET HS Raffaele, Milan, Italy; Ist Ortoped Gaetano Pini, Chair Rheumatol, Milan, Italy; F Hoffmann La Roche & Co Ltd, PRPZB, CH-4002 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4002 Basel, Switzerland	Roche Holding; Vita-Salute San Raffaele University; Roche Holding; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); ASST Gaetano Pini CTO; Roche Holding; Roche Holding	Rogge, L (corresponding author), Roche Milano Ric, Milan, Italy.		Rogge, Lars/GYJ-6142-2022; Ferrari, Giuliana/AAB-5546-2019	Ferrari, Giuliana/0000-0003-0790-3133; Biffi, Mauro/0000-0002-6914-2854; Rogge, Lars/0000-0003-1262-9204	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Coccia EM, 1999, J BIOL CHEM, V274, P6698, DOI 10.1074/jbc.274.10.6698; Colantonio L, 1999, BLOOD, V94, P2981, DOI 10.1182/blood.V94.9.2981.421k27_2981_2989; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Dolhain RJEM, 1996, ARTHRITIS RHEUM-US, V39, P1961, DOI 10.1002/art.1780391204; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HIGUCHI R, 1999, PCR APPL PROTOCOLS F, P263; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rogge L, 1998, J IMMUNOL, V161, P6567; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Verzeletti S, 1998, HUM GENE THER, V9, P2243, DOI 10.1089/hum.1998.9.15-2243; Xu DM, 1998, J EXP MED, V188, P1485, DOI 10.1084/jem.188.8.1485; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	29	188	200	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					96	101		10.1038/75671	http://dx.doi.org/10.1038/75671			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802665				2022-12-27	WOS:000086884000025
J	Szczypka, MS; Rainey, MA; Palmiter, RD				Szczypka, MS; Rainey, MA; Palmiter, RD			Dopamine is required for hyperphagia in Lep(ob/ob) mice	NATURE GENETICS			English	Article							DEFICIENT MICE; NUCLEUS-ACCUMBENS; FEEDING-BEHAVIOR; BASAL GANGLIA; BODY-WEIGHT; FOOD REWARD; OBESE GENE; MECHANISMS; LEPTIN; MICRODIALYSIS	Feeding is a complex process responsive to sensory information related to sight and smell of food, previous feeding experiences, satiety signals elicited by ingestion and hormonal signals related to energy balance. Dopamine released in specific brain regions is associated with pleasurable and rewarding events(1,2) and may reinforce positive aspects of feeding. Dopamine also influences initiation and coordination of motor activity and is required for sensorimotor functions(3-5). Thus, dopamine may facilitate integration of sensory cues related to hunger, initiating the search for food and its consumption. Dopaminergic neurons in the substantia nigra and ventral tegmental area project to the caudate putamen and nucleus accumbens, where they modulate movement and reward(2,6-8). There are projections from the nucleus accumbens to the lateral hypothalamus that regulate feeding(9). Dopamine-deficient mice (Dbh(Th/s+), Th-/-; hereafter DD mice) cannot synthesize dopamine in dopaminergic neurons. They gradually become aphagic and die of starvation. Daily treatment of DD mice with L-3,4-dihydroxyphenylalanine (L-DOPA) transiently restores brain dopamine, locomotion and feeding. Leptin-null (Lep(ob/ob)) mice exhibit obesity, decreased energy expenditure and hyperphagia. As the hypothalamic leptin-melanocortin pathway appears to regulate appetite and metabolism(10), we generated mice lacking both dopamine and leptin (DDxLep(ob/ob)) to determine if leptin deficiency overcomes the aphagia of DD mice. DDxLep(ob/ob) mice became obese when treated daily with L-DOPA, but when L-DOPA treatment was terminated the double mutants were capable of movement, but did not feed. Our data show that dopamine is required for feeding in leptin-null mice.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.				NICHD NIH HHS [HD-09172, HD-08121] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALBIN RL, 1995, TRENDS NEUROSCI, V18, P63; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chase TN, 1996, ADV NEUROL, V69, P497; Cousins MS, 1996, BRAIN RES, V732, P186, DOI 10.1016/0006-8993(96)00519-7; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GRAYBIEL AM, 1990, ADV NEUROL, V53, P17; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, LIFE SCI, V42, P1705, DOI 10.1016/0024-3205(88)90036-7; Koob GF, 1999, ANN NY ACAD SCI, V877, P445, DOI 10.1111/j.1749-6632.1999.tb09282.x; MALDONADOIRIZARRY CS, 1995, J NEUROSCI, V15, P6779; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Martel P, 1996, PHARMACOL BIOCHEM BE, V53, P221, DOI 10.1016/0091-3057(95)00187-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; ROWLAND N, 1979, PHYSIOL BEHAV, V22, P635, DOI 10.1016/0031-9384(79)90222-1; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Szczypka MS, 1999, P NATL ACAD SCI USA, V96, P12138, DOI 10.1073/pnas.96.21.12138; Szczypka MS, 1999, NEURON, V22, P167, DOI 10.1016/S0896-6273(00)80688-1; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0	25	114	116	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					102	104		10.1038/75484	http://dx.doi.org/10.1038/75484			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802666				2022-12-27	WOS:000086884000026
J	Bale, TL; Contarino, AB; Smith, GW; Chan, R; Gold, LH; Sawchenko, PE; Koob, GF; Vale, WW; Lee, KF				Bale, TL; Contarino, AB; Smith, GW; Chan, R; Gold, LH; Sawchenko, PE; Koob, GF; Vale, WW; Lee, KF			Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress	NATURE GENETICS			English	Article							ACOUSTIC STARTLE REFLEX; CENTRAL NUCLEUS; ACTH-SECRETION; RAT-BRAIN; NEUROPEPTIDE; UROCORTIN; AMYGDALA; PARTICIPATION; HYPOTHALAMUS; EXPRESSION	Corticotropin-releasing hormone (Crh) is a critical coordinator of the hypothalamic-pituitary-adrenal (HPA) axis. In response to stress, Crh released from the paraventricular nucleus (PVN) of the hypothalamus activates Crh receptors on anterior pituitary corticotropes, resulting in release of adrenocorticotropic hormone (Acth) into the bloodstream. Acth in turn activates Acth receptors in the adrenal cortex to increase synthesis and release of glucocorticoids(1). The receptors for Crh, Crhr1 and Crhr2, are found throughout the central nervous system and periphery. Crh has a higher affinity for Crhr1 than for Crhr2, and urocortin (Ucn); a Crh-related peptide, is thought to be the endogenous ligand for Crhr2 because it binds with almost 40-fold higher affinity than does Crh (ref. 2). Crhr1 and Crhr2 share approximately 71% amino acid sequence similarity and are distinct in their localization within the brain and peripheral tissues(3-6). We generated mice deficient for Crhr2 to determine the physiological role of this receptor. Crhr2-mutant mice are hypersensitive to stress and display increased anxiety-like behaviour. Mutant mice have normal basal feeding and weight gain, but decreased food intake following food deprivation. intravenous Ucn produces no effect on mean arterial pressure in the mutant mice.	Salk Inst, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Salk Inst, Neuronal Struct & Funct Lab, La Jolla, CA USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA USA	Salk Institute; Salk Institute; Scripps Research Institute	Lee, KF (corresponding author), Salk Inst, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA.		Contarino, Angelo/C-9429-2014	Contarino, Angelo/0000-0002-7286-6941	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009841, P01DK026741, F32DK009551] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09551, DK-26741, DK09841] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN JP, 1975, NEUROENDOCRINOLOGY, V19, P115, DOI 10.1159/000122432; BALE TL, 1995, ENDOCRINOLOGY, V136, P27, DOI 10.1210/en.136.1.27; BEAULIEU S, 1987, NEUROENDOCRINOLOGY, V45, P37, DOI 10.1159/000124701; BEAULIEU S, 1986, NEUROENDOCRINOLOGY, V44, P247, DOI 10.1159/000124652; BELZUNG C, 1994, PHYSIOL BEHAV, V56, P623, DOI 10.1016/0031-9384(94)90311-5; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; KING FA, 1958, SCIENCE, V128, P655, DOI 10.1126/science.128.3325.655; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Lee YL, 1997, J NEUROSCI, V17, P6424; LIANG KC, 1992, J NEUROSCI, V12, P2313; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Marcilhac A, 1996, EXP PHYSIOL, V81, P1035, DOI 10.1113/expphysiol.1996.sp003987; MELIA KR, 1991, PHYSIOL BEHAV, V49, P603, DOI 10.1016/0031-9384(91)90286-W; Moreau JL, 1997, NEUROREPORT, V8, P1697, DOI 10.1097/00001756-199705060-00027; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Rodgers RJ, 1997, BEHAV PHARMACOL, V8, P477, DOI 10.1097/00008877-199711000-00003; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; STENZEL P, 1995, MOL ENDOCRINOL, V9, P537; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0	24	676	692	1	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					410	414		10.1038/74263	http://dx.doi.org/10.1038/74263			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742108				2022-12-27	WOS:000086192800023
J	Kishimoto, T; Radulovic, J; Radulovic, M; Lin, CR; Schrick, C; Hooshmand, F; Hermanson, O; Rosenfeld, MG; Spiess, J				Kishimoto, T; Radulovic, J; Radulovic, M; Lin, CR; Schrick, C; Hooshmand, F; Hermanson, O; Rosenfeld, MG; Spiess, J			Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2	NATURE GENETICS			English	Article							IMPAIRED STRESS-RESPONSE; RAT-BRAIN; MICE; IDENTIFICATION; ANXIETY; MOUSE; HEART; NEUROENDOCRINE; EXPRESSION; SAUVAGINE	Corticotropin-releasing hormone(1,2) (Crh), a 41-residue polypeptide, activates two G-protein-coupled receptors, Crhr1 (refs 3-5) and Crhr2 (refs 6-9), causing (among other transductional events) phosphorylation of the transcription factor Creb (ref. 10). The physiologic;role of these receptors is only partially understood. Here we report that male, but not female, Crhr2-deficient mice exhibit enhanced anxious behaviour in several tests of anxiety in contrast to mice lacking Crhr1 (refs 11,12). The enhanced anxiety of Crhr2-deficient mice is not due to changes in hypothalamic-pituitary-adrenal (HPA) axis activity, but rather reflects impaired responses in specific brain regions involved in emotional and autonomic function, as monitored by a reduction of Creb phosphorylation in male, but not female, Crhr2(-/-) mice. We propose that Crhr2 predominantly mediates a central anxiolytic response, opposing the general anxiogenic effect of Crh mediated by Crhr1. Neither male nor female Crhr2-deficient mice show alterations of baseline feeding behaviour. Both respond with increased edema formation in response to thermal exposure, however, indicating that in contrast to its central role in anxiety, the peripheral role of Crhr2 in vascular permeability is independent of gender.	Max Planck Inst Expt Med, Dept Mol Neuroendocrinol, D-37075 Gottingen, Germany; Univ Calif San Diego, Howard Hughes Med Inst, Dept & Sch Med, La Jolla, CA 92093 USA	Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Diego	Radulovic, J (corresponding author), Max Planck Inst Expt Med, Dept Mol Neuroendocrinol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	radulovic@mail.mpiem.gwdg.de; mrosenfeld@ucsd.edu; spiess@mail.mpiem.gwdg.de	, Ola/AAF-5126-2021	Radulovic, Jelena/0000-0002-0268-2426; Hermanson, Ola/0000-0001-9320-7921; Radulovic, Marko/0000-0002-2314-7457				Allen E, 1922, AM J ANAT, V30, P297, DOI 10.1002/aja.1000300303; BALDWIN HA, 1991, PSYCHOPHARMACOLOGY, V103, P227, DOI 10.1007/BF02244208; CAREY MP, 1992, PHARMACOL BIOCHEM BE, V41, P719, DOI 10.1016/0091-3057(92)90218-5; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN Y, 1993, MOL PHARMACOL, V44, P8; FISHER LA, 1989, TRENDS PHARMACOL SCI, V10, P189, DOI 10.1016/0165-6147(89)90236-8; FOX MW, 1965, ANIM BEHAV, V13, P232, DOI 10.1016/0003-3472(65)90040-0; Hinks GL, 1996, EUR J PHARMACOL, V312, P153, DOI 10.1016/0014-2999(96)00471-2; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; LEE EHY, 1989, BEHAV NEURAL BIOL, V51, P412, DOI 10.1016/S0163-1047(89)91052-2; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Radulovic J, 1998, J NEUROSCI, V18, P7452; Radulovic J, 1999, J NEUROSCI, V19, P5016; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rossant CJ, 1999, ENDOCRINOLOGY, V140, P1525, DOI 10.1210/en.140.4.1525; Ruhmann A, 1998, P NATL ACAD SCI USA, V95, P15264, DOI 10.1073/pnas.95.26.15264; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; SPIESS J, 1981, P NATL ACAD SCI-BIOL, V78, P6517, DOI 10.1073/pnas.78.10.6517; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; STENZELPOORE MP, 1994, J NEUROSCI, V14, P2579; TAKAHASHI LK, BEHAV NEUROSCI, V103, P645; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Turnbull AV, 1996, EUR J PHARMACOL, V303, P213, DOI 10.1016/0014-2999(96)00141-0; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; WEI ET, 1994, EUR J PHARMACOL, V263, P319, DOI 10.1016/0014-2999(94)90729-3	29	400	412	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					415	419		10.1038/74271	http://dx.doi.org/10.1038/74271			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742109				2022-12-27	WOS:000086192800024
J	Costello, JF; Fruhwald, MC; Smiraglia, DJ; Rush, LJ; Robertson, GP; Gao, X; Wright, FA; Feramisco, JD; Peltomaki, P; Lang, JC; Schuller, DE; Yu, L; Bloomfield, CD; Caligiuri, MA; Yates, A; Nishikawa, R; Huang, HJS; Petrelli, NJ; Zhang, XL; O'Dorisio, MS; Held, WA; Cavenee, WK; Plass, C				Costello, JF; Fruhwald, MC; Smiraglia, DJ; Rush, LJ; Robertson, GP; Gao, X; Wright, FA; Feramisco, JD; Peltomaki, P; Lang, JC; Schuller, DE; Yu, L; Bloomfield, CD; Caligiuri, MA; Yates, A; Nishikawa, R; Huang, HJS; Petrelli, NJ; Zhang, XL; O'Dorisio, MS; Held, WA; Cavenee, WK; Plass, C			Aberrant CpG-island methylation has non-random and tumour-type-specific patterns	NATURE GENETICS			English	Article							DNA METHYLATION; MOUSE; GENES; GENOME; CELLS	CpG islands frequently contain gene promoters or exons(1) and are usually unmethylated in normal cells(1-3). Methylation of CPG islands is associated with delayed replication, condensed chromatin and inhibition of transcription initiation(4-7). The investigation of aberrant CpG-island methylation in human cancer has primarily taken a candidate gene approach, and has focused on less than 15 of the estimated 45,000 CpG islands(8) in the genome. Here we report a global analysis of the methylation status of 1,184 unselected CpG islands in each of 98 primary human rumours using restriction landmark genomic scanning(9) (RLGS). We estimate that an average of 600 CpG islands (range of 0 to 4,500) of the 45,000 in the genome were aberrantly methylated in the rumours, including early stage tumours. We identified patterns of CpG;island methylation that were shared within each tumour type, together with patterns and targets that displayed distinct tumour-type specificity. The expression of many of these genes was reactivated by experimental demethylation in cultured tumour cells. Thus, the methylation of particular subsets of CpG islands may have consequences for specific tumour types.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA; Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Otolaryngol, Columbus, OH 43210 USA; Ohio State Univ, Div Hematol & Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Saitama Med Sch, Dept Neurosurg, Iruma, Saitama, Japan; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Saitama Medical University; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Costello, JF (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.		Plass, Christoph/H-7192-2014; Smiraglia, Dominic/R-2069-2019; Robertson, Gavin P./A-6106-2017	Smiraglia, Dominic/0000-0001-8852-1510; Robertson, Gavin P./0000-0003-0152-2997; Peltomaki, Paivi/0000-0001-8819-2980; O'Dorisio, M Sue/0000-0003-0690-1160	NCI NIH HHS [CA80912, 3U10CA31946-17S3, P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA031946, P30CA016058, R21CA080912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama TO, 1997, CANCER RES, V57, P3294; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Bachman KE, 1999, CANCER RES, V59, P798; Barbour A.D., 1992, POISSON APPROXIMATIO; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Costello JF, 1997, CANCER RES, V57, P1250; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FREUND RJ, 1997, STAT METHODS; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lehman EL, 1975, NONPARAMETRICS; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1999, ONCOGENE, V18, P3159, DOI 10.1038/sj.onc.1202651; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Stirzaker C, 1997, CANCER RES, V57, P2229; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005	25	1072	1175	1	72	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					132	138		10.1038/72785	http://dx.doi.org/10.1038/72785			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655057				2022-12-27	WOS:000085104600012
J	McGuirt, WT; Prasad, SD; Griffith, AJ; Kunst, HPM; Green, GE; Shpargel, KB; Runge, C; Huybrechts, C; Mueller, RF; Lynch, E; King, MC; Brunner, HG; Cremers, CWRJ; Takanosu, M; Li, SW; Arita, M; Mayne, R; Prockop, DJ; Van Camp, G; Smith, RJH				McGuirt, WT; Prasad, SD; Griffith, AJ; Kunst, HPM; Green, GE; Shpargel, KB; Runge, C; Huybrechts, C; Mueller, RF; Lynch, E; King, MC; Brunner, HG; Cremers, CWRJ; Takanosu, M; Li, SW; Arita, M; Mayne, R; Prockop, DJ; Van Camp, G; Smith, RJH			Mutations in COL11A2 cause non-syndromic hearing loss (DFNA13)	NATURE GENETICS			English	Article							AUTOSOMAL-DOMINANT; STICKLER-SYNDROME; XI COLLAGEN; MOLECULAR HETEROGENEITY; TECTORIAL MEMBRANE; FIBRILLAR COLLAGEN; COCHLEAR PATHOLOGY; II COLLAGEN; GENE; IMPAIRMENT	We report that mutation of COL11A2 causes deafness previously mapped to the DFNA13 locus on chromosome 6p. We found two families (one American and one Dutch) with autosomal dominant, non-syndromic hearing loss to have mutations in COL11A2 that are predicted to affect the triple-helix domain of the collagen protein. In both families, deafness is non-progressive and predominantly affects middle frequencies. Mice with a targeted disruption of Col11a2 also were shown to have hearing loss. Electron microscopy of the tectorial membrane of these mice revealed loss of organization of the collagen fibrils. Our findings revealed a unique ultrastructural malformation of inner-ear architecture associated with non-syndromic hearing loss, and suggest that tectorial membrane abnormalities may be one aetiology of sensorineural hearing loss primarily affecting the mid-frequencies.	Univ Iowa, Dept Otolaryngol Head & Neck Surg, Mol Otolayngol Res Labs, Iowa City, IA 52242 USA; Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA; Univ Nijmegen Hosp, Dept Otorhinolaryngol, NL-6500 HB Nijmegen, Netherlands; Univ Antwerp, Dept Genet, Antwerp, Belgium; St James Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Med Coll Penn & Hahnemann Univ, Ctr Gene Therapy, Philadelphia, PA USA	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Radboud University Nijmegen; University of Antwerp; Saint James's University Hospital; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; Drexel University	Smith, RJH (corresponding author), Univ Iowa, Dept Otolaryngol Head & Neck Surg, Mol Otolayngol Res Labs, Iowa City, IA 52242 USA.	richard-smith@uiowa.edu	Kunst, Henricus P.M./J-6456-2012; Cremers, C.W.R.J./L-4254-2015; Van Camp, Guy/F-3386-2013; Brunner, Han/C-9928-2013	Kunst, Henricus P.M./0000-0003-1162-6394; Van Camp, Guy/0000-0001-5105-9000; Shpargel, Karl/0000-0002-9658-456X; Smith, Richard/0000-0003-1201-6731; Runge, Christina/0000-0003-0330-5857; King, Mary-Claire/0000-0001-9426-1743	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000054, R29DC000054, R01DC003544, T32DC000040] Funding Source: NIH RePORTER; NIDCD NIH HHS [Z01-DC00054-01, R01-DC03544, 5-T32-DC00040] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALAKOKKO L, IN PRESS KELLYS TXB; Bleasel JF, 1998, HUM MUTAT, V12, P172, DOI 10.1002/(SICI)1098-1004(1998)12:3<172::AID-HUMU4>3.0.CO;2-J; BONAVENTURE J, 1995, BIOCHEM J, V307, P823, DOI 10.1042/bj3070823; Brown MR, 1997, AM J HUM GENET, V61, P924, DOI 10.1086/514892; Busler DE, 1996, BIOTECHNIQUES, V21, P1002; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; Gates GA, 1999, ARCH OTOLARYNGOL, V125, P654, DOI 10.1001/archotol.125.6.654; Jacobson J, 1990, J Am Acad Audiol, V1, P37; Khetarpal U, 1998, ACTA OTO-LARYNGOL, V118, P177; Kikuti YY, 1997, GENOMICS, V42, P422, DOI 10.1006/geno.1997.4745; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KORKKO J, 1993, AM J HUM GENET, V53, P55; KUNST D, IN PRESS LARYNGOSCOP; LEAKE PA, 1988, HEARING RES, V33, P11, DOI 10.1016/0378-5955(88)90018-4; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER CA, 1994, HEARING RES, V78, P11, DOI 10.1016/0378-5955(94)90039-6; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Pihlajamaa T, 1998, AM J MED GENET, V80, P115, DOI 10.1002/(SICI)1096-8628(19981102)80:2<115::AID-AJMG5>3.0.CO;2-O; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Sirko-Osadsa D, 1998, J PEDIATR-US, V132, P368, DOI 10.1016/S0022-3476(98)70466-4; SLEPECKY NB, 1992, ACTA OTO-LARYNGOL, V112, P611, DOI 10.3109/00016489209137449; SPOENDLIN H, 1974, ARCH OTO-RHINO-LARYN, V208, P137, DOI 10.1007/BF00453927; Spranger J, 1998, PEDIATR RADIOL, V28, P745, DOI 10.1007/s002470050459; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STEINMANN B, 1986, J BIOL CHEM, V261, P8958; THALMANN I, 1993, CONNECT TISSUE RES, V29, P191, DOI 10.3109/03008209309016826; Tsuprun V, 1997, HEARING RES, V110, P107, DOI 10.1016/S0378-5955(97)00068-3; VanCamp G, 1997, AM J HUM GENET, V60, P758; vanSteensel MAM, 1997, AM J MED GENET, V70, P315; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Vuoristo MM, 1996, ANN NY ACAD SCI, V785, P343, DOI 10.1111/j.1749-6632.1996.tb56304.x; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	38	181	195	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					413	419		10.1038/70516	http://dx.doi.org/10.1038/70516			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581026				2022-12-27	WOS:000084023900015
J	Garkavtsev, I				Garkavtsev, I			Suppression of the novel growth inhibitor p33(ING1) promotes neoplastic transformation (vol 14, pg 415, 1996)	NATURE GENETICS			English	Correction																		Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415	1	29	33	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					373	373		10.1038/15566	http://dx.doi.org/10.1038/15566			1	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545957	Bronze			2022-12-27	WOS:000083792200034
J	Carrie, A; Jun, L; Bienvenu, T; Vinet, MC; McDonell, N; Couvert, P; Zemni, R; Cardona, A; Van Buggenhout, G; Frints, S; Hamel, B; Moraine, C; Ropers, HH; Strom, T; Howell, GR; Whittaker, A; Ross, MT; Kahn, A; Fryns, JP; Beldjord, C; Marynen, P; Chelly, J				Carrie, A; Jun, L; Bienvenu, T; Vinet, MC; McDonell, N; Couvert, P; Zemni, R; Cardona, A; Van Buggenhout, G; Frints, S; Hamel, B; Moraine, C; Ropers, HH; Strom, T; Howell, GR; Whittaker, A; Ross, MT; Kahn, A; Fryns, JP; Beldjord, C; Marynen, P; Chelly, J			A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation	NATURE GENETICS			English	Article							LONG-TERM POTENTIATION; MICRODELETION; MUTATIONS; MEMORY; IDENTIFICATION; INTERLEUKIN-1; CLONING; REGION; GENE	We demonstrate here the importance of interleukin signalling pathways in cognitive function and the normal physiology of the CNS. Thorough investigation of an MRX critical region in Xp22.1-21.3 enabled us to identify a new gene expressed in brain that is responsible for a non-specific form of X-linked mental retardation. This gene encodes a 696 amino acid protein that has homology to IL-l receptor accessory proteins. Non-overlapping deletions and a nonsense mutation in this gene were identified in patients with cognitive impairment only. Its high level of expression in post-natal brain structures involved in the hippocampal memory system suggests a specialized role for this new gene in the physiological processes underlying memory and learning abilities.	CHU Cochin, INSERM, U129, IGGM, F-75014 Paris, France; Univ Hosp Gasthuisberg VIB, B-3000 Louvain, Belgium; Inst Pasteur, Lab Technol Cellulaires, F-75724 Paris 15, France; Clin Genet Univ, Ctr Human Genet, UZ Gasthuisberg, B-3000 Louvain, Belgium; Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Ctr Hosp Tours, Serv Genet, Hop Bretonneau, F-37044 Tours, France; Max Planck Inst Mol Genet, Berlin, Germany; Abt Med Genet, D-80336 Munich, Germany; Sanger Ctr, Cambridge, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Flanders Institute for Biotechnology (VIB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven; University Hospital Leuven; Radboud University Nijmegen; CHU Tours; Max Planck Society; Wellcome Trust Sanger Institute	Chelly, J (corresponding author), CHU Cochin, INSERM, U129, IGGM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	chelly@infobiogen.fr	Chelly, Jamel/J-7528-2015; Glover, Vivette/M-2711-2016	Chelly, Jamel/0000-0002-0939-8719; Glover, Vivette/0000-0001-6543-1651; Couvert, Philippe/0000-0002-7607-2057; Frints, Suzanna G.M./0000-0002-5027-8364	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Bianchi M, 1998, BIOL SIGNAL RECEPT, V7, P45; Bienvenu T, 1998, HUM MOL GENET, V7, P1311, DOI 10.1093/hmg/7.8.1311; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Billuart P, 1996, HUM MOL GENET, V5, P977, DOI 10.1093/hmg/5.7.977; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CASSEL JC, 1995, NEUROSCIENCE, V69, P1, DOI 10.1016/0306-4522(95)00241-A; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CrumeyrolleArias M, 1996, HISTOCHEM J, V28, P801, DOI 10.1007/BF02272153; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; des Portes V, 1999, AM J MED GENET, V85, P263, DOI 10.1002/(SICI)1096-8628(19990730)85:3<263::AID-AJMG15>3.0.CO;2-0; des Portes V, 1998, CLIN GENET, V53, P136; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FERRERO GB, 1995, HUM MOL GENET, V4, P1821, DOI 10.1093/hmg/4.10.1821; FRIES MH, 1993, AM J MED GENET, V46, P363, DOI 10.1002/ajmg.1320460404; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Gedeon AK, 1996, AM J MED GENET, V64, P158, DOI 10.1002/(SICI)1096-8628(19960712)64:1<158::AID-AJMG26>3.3.CO;2-V; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HAGBERG B, 1983, BRAIN DEV-JPN, V5, P441, DOI 10.1016/S0387-7604(83)80072-2; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; KOCSIS B, 1994, J NEUROSCI, V14, P7040; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHRACH H., 1990, GENOME ANAL, P39; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MOSER HW, 1983, PRINCIPLES PRACTICE; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; Raeymaekers P, 1996, AM J MED GENET, V64, P7; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9	40	234	247	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					25	31		10.1038/12623	http://dx.doi.org/10.1038/12623			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471494				2022-12-27	WOS:000082337300011
J	Monreal, AW; Ferguson, BM; Headon, DJ; Street, SL; Overbeek, PA; Zonana, J				Monreal, AW; Ferguson, BM; Headon, DJ; Street, SL; Overbeek, PA; Zonana, J			Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia	NATURE GENETICS			English	Article							AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ECTODYSPLASIN-A; EDA GENE; RECEPTOR; PROTEIN; IDENTIFICATION; ACTIVATION; APOPTOSIS; ENCODES; TABBY	X-linked hypohidrotic ectodermal dysplasia results in abnormal morphogenesis of teeth, hair and eccrine sweat glands(1). The gene (ED1) responsible for the disorder has been identified(2-4), as well as the analogous X-linked gene (Ta) in the mouse(5,6). Autosomal recessive disorders, phenotypically indistinguishable from the X-linked forms, exist in humans(7) and at two separate loci (crinkled, cr, and downless, dl) in mice(8). Dominant disorders, possibly allelic to the recessive loci, are seen in both species(9,10) (ED3, Dl(slk)). A candidate gene has recently been identified at the dl locus(11) that is mutated in both dl and Dl(slk) mutant alleles. We isolated and characterized its human DL homologue, and identified mutations in three families displaying recessive inheritance and two with dominant inheritance. The disorder does not map to the candidate gene locus in all autosomal recessive families, implying the existence of at least one additional human locus. The putative protein is predicted to have a single transmembrane domain, and shows similarity to two separate domains of the tumour necrosis factor receptor (TNFR) family(12,13).	Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Oregon Health & Science University; Baylor College of Medicine; Baylor College of Medicine	Ferguson, BM (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, 3181 SW San Jackson Pk Rd, Portland, OR 97201 USA.			Overbeek, Paul/0000-0001-9784-2084	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011311] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45316] Funding Source: Medline; NIDCR NIH HHS [DE11311] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arnold C, 1991, PCR Methods Appl, V1, P39; Baala L, 1999, AM J HUM GENET, V64, P651, DOI 10.1086/302239; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; BELDJORD C, 1988, NUCLEIC ACIDS RES, V16, P4927, DOI 10.1093/nar/16.11.4927; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; CLARKE A, 1987, J MED GENET, V24, P659, DOI 10.1136/jmg.24.11.659; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Ferguson BM, 1998, J MED GENET, V35, P112, DOI 10.1136/jmg.35.2.112; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Ho LL, 1998, AM J HUM GENET, V62, P1102, DOI 10.1086/301839; Infante AJ, 1998, J PEDIATR-US, V133, P629, DOI 10.1016/S0022-3476(98)70102-7; JORGENSON RJ, 1987, J CRAN GENET DEV BIO, V7, P403; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Konrad M, 1995, GENOMICS, V30, P514, DOI 10.1006/geno.1995.1272; Majumder K, 1998, MAMM GENOME, V9, P863, DOI 10.1007/s003359900884; Malek NP, 1998, RECENT RES CANCER, V147, P97; Monreal AW, 1998, AM J HUM GENET, V63, P380, DOI 10.1086/301984; Munoz F, 1997, AM J HUM GENET, V61, P94; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Padanilam B. J., 1992, Human Molecular Genetics, V1, P407, DOI 10.1093/hmg/1.6.407; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Sundberg, 1994, HDB MOUSE MUTATIONS; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; ZONANA J, 1992, AM J HUM GENET, V51, P1036	31	290	300	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					366	369		10.1038/11937	http://dx.doi.org/10.1038/11937			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431241				2022-12-27	WOS:000081772500019
J	Diaz, GA; Banikazemi, M; Oishi, K; Desnick, RJ; Gelb, BD				Diaz, GA; Banikazemi, M; Oishi, K; Desnick, RJ; Gelb, BD			Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; ANEMIA SYNDROME	Thiamine-responsive megaloblastic anaemia syndrome (TRMA; MIM 249270) is an autosomal recessive disorder with features that include megaloblastic anaemia, mild thrombocytopenia and leucopenia, sensorineural deafness and diabetes mellitus(1-3). Treatment with pharmacologic doses of thiamine ameliorates the megaloblastic anaemia and diabetes mellitus. A defect in the plasma membrane transport of thiamine has been demonstrated in erythrocytes and cultured skin fibroblasts from TRMA patients(4-6). The gene causing TRMA was assigned to 1q23.2-q23.3 by linkage analysis(7). Here we report the cloning of a new gene, SLC19A2, identified from high-throughput genomic sequences due to homology with SLC19A1, encoding reduced folate carrier 1 (refs 8-10). We cloned the entire coding region by screening a human fetal brain cDNA library. SLC19A2 encodes a protein (of 497 aa) predicted to have 12 transmembrane domains. We identified 2 frameshift mutations in exon 2, a 1-bp insertion and a 2-bp deletion, among four Iranian families with TRMA. The sequence homology and predicted structure of SLC19A2, as well as its role in TRMA, suggest that its gene product is a thiamine carrier, the first to be identified in complex eukaryotes.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Gelb, BD (corresponding author), Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.		Diaz, George/AAF-6199-2021	Oishi, Kimihiko/0000-0001-9446-8912	NICHD NIH HHS [5 P30 HD 28822, P01-HD28822] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Banikazemi M, 1999, MOL GENET METAB, V66, P193, DOI 10.1006/mgme.1998.2799; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Enjo F, 1997, J BIOL CHEM, V272, P19165, DOI 10.1074/jbc.272.31.19165; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laforenza U, 1998, J MEMBRANE BIOL, V161, P151, DOI 10.1007/s002329900322; MANDEL H, 1984, NEW ENGL J MED, V311, P836, DOI 10.1056/NEJM198409273111307; Neufeld EJ, 1997, AM J HUM GENET, V61, P1335, DOI 10.1086/301642; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; RINDI G, 1992, J INHERIT METAB DIS, V15, P231, DOI 10.1007/BF01799637; RINDI G, 1994, J INHERIT METAB DIS, V17, P667, DOI 10.1007/BF00712009; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; Singleton CK, 1997, GENE, V199, P111, DOI 10.1016/S0378-1119(97)00354-5; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VIANA MB, 1978, J PEDIATR-US, V93, P235, DOI 10.1016/S0022-3476(78)80503-4; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WILSON JD, 1998, HARRISONS PRINCIPLES, P480; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468	19	169	176	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					309	312		10.1038/10385	http://dx.doi.org/10.1038/10385			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391223				2022-12-27	WOS:000081125900028
J	Cox, NJ; Frigge, M; Nicolae, DL; Concannon, P; Hanis, CL; Bell, GI; Kong, A				Cox, NJ; Frigge, M; Nicolae, DL; Concannon, P; Hanis, CL; Bell, GI; Kong, A			Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; COMPLEX TRAITS; EARLY-ONSET; GENE; MUTATIONS; MELLITUS; GLUCOKINASE; MODELS; MICE	Complex disorders such as diabetes, cardiovascular disease, asthma, hypertension and psychiatric illnesses account for a large and disproportionate share of health care costs, but remain poorly characterized with respect to aetiology. The transmission of such disorders is complex, reflecting the actions and interactions of multiple genetic and environmental factors. Genetic analyses that allow for the simultaneous consideration of susceptibility from multiple regions may improve the ability to map genes for complex disorders(1,2), but such analyses are currently computationally intensive and narrowly focused. We describe here an approach to assessing the evidence for statistical interactions between unlinked regions that allows multipoint allele-sharing analysis to take the evidence for linkage at one region into account in assessing the evidence for linkage over the rest of the genome. Using this method, we show that the interaction of genes on chromosomes 2 (NIDDM1) and 15 (near CYP19) makes a contribution to susceptibility to type 2 diabetes in Mexican Americans from Starr County, Texas.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; DeCODE Genet, IS-110 Reykjavik, Iceland; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77030 USA	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health Science Center Houston	Cox, NJ (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.			Concannon, Patrick/0000-0002-5801-1859; Nicolae, Dan/0000-0002-0918-4630	NIDDK NIH HHS [DK-47481, DK-20595] Funding Source: Medline; NIGMS NIH HHS [GM-46800] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047481, P60DK020595, P30DK020595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046800] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell GI, 1997, DIABETES REV, V5, P277; BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Buhler J, 1997, HUM HERED, V47, P211, DOI 10.1159/000154415; CORDELL HJ, 1995, AM J HUM GENET, V57, P920; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Iwasaki N, 1997, DIABETES, V46, P1504, DOI 10.2337/diabetes.46.9.1504; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MACLEAN CJ, 1993, AM J HUM GENET, V53, P353; Mahtani MM, 1996, NAT GENET, V14, P90, DOI 10.1038/ng0996-90; RISCH N, 1990, AM J HUM GENET, V46, P229; SCHORK NJ, 1993, AM J HUM GENET, V53, P1127; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	21	322	336	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	1999	21	2					213	215		10.1038/6002	http://dx.doi.org/10.1038/6002			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988276				2022-12-27	WOS:000078399500026
J	Duggan, DJ; Bittner, M; Chen, YD; Meltzer, P; Trent, JM				Duggan, DJ; Bittner, M; Chen, YD; Meltzer, P; Trent, JM			Expression profiling using cDNA microarrays	NATURE GENETICS			English	Review							GENE-EXPRESSION; HUMAN GENOME; SEQUENCE TAGS; HYBRIDIZATION; PATTERNS; SCALE; RNAS	cDNA microarrays are capable of profiling gene expression patterns of tens of thousands of genes in a single experiment. DNA targets, in the form of 3' expressed sequence tags (ESTs), are arrayed onto glass slides (or membranes) and probed with fluorescent- or radioactively-labelled cDNAs. Here,we review technical aspects of cDNA microarrays, including the general principles, fabrication of the arrays, target labelling, image analysis and data extraction, management and mining.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Duggan, DJ (corresponding author), NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.		Simpson, Peter/F-1225-2010; Jones, Chris/ABE-6059-2021	Simpson, Peter/0000-0002-4816-8289; Jones, Chris/0000-0001-8118-2296				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ermolaeva O, 1998, NAT GENET, V20, P19, DOI 10.1038/1670; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Khan J, 1998, CANCER RES, V58, P5009; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; Thorp HH, 1998, TRENDS BIOTECHNOL, V16, P117, DOI 10.1016/S0167-7799(97)01162-1; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	33	1234	1467	1	139	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	1999	21			S			10	14		10.1038/4434	http://dx.doi.org/10.1038/4434			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	156NU	9915494				2022-12-27	WOS:000078008200005
J	Haracska, L; Yu, SL; Johnson, RE; Prakash, L; Prakash, S				Haracska, L; Yu, SL; Johnson, RE; Prakash, L; Prakash, S			Efficient and accurate replication in the presence of 7,8-dihydro-8-oxoguanine by DNA polymerase eta	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; 8-OXO-GUANINE; TRANSVERSIONS; MUTAGENESIS; REQUIREMENT; FIDELITY; BYPASS; ASSAY; CELLS	Oxidative damage to DNA has been proposed to have a role in cancer and ageing(1). Oxygen-free radicals formed during normal aerobic cellular metabolism attack bases in DNA, and 7,8-dihydro-8-oxoguanine (8-oxoG) is one of the adducts formed(2,3). Eukaryotic replicative DNA polymerases replicate DNA containing 8-oxoG by inserting an adenine opposite the lesion(4); consequently. 8-oxoG is highly mutagenic and causes G:C to T:A transversions(5). Genetic studies in yeast have indicated a role for mismatch repair in minimizing the incidence of these mutations. In Saccharomyces cerevisiae, deletion of OGG1, encoding a DNA glycosylase that functions in the removal of 8-oxoG when paired with C, causes an increase in the rate of G:C to TA transversions(6). The ogg1 Delta msh2 Delta double mutant displays a higher rate of CAN1(S) to can1(r) forward mutations than the ogg1 Delta or msh2 Delta single mutants, and this enhanced mutagenesis is primarily due to C:C to T:A transversions(7). The gene RAD30 of S. cerevisiae encodes a DNA polymerase, Pol eta, that efficiently replicates DNA containing a cis-syn thymine-thymine (T-T) dimer by inserting two adenines across from the dimers. In humans, mutations in the yeast RAD30 counterpart, POLH, cause the variant form of xeroderma pigmentosum(9,10) (XP-V), and XP-V individuals suffer from a high incidence of sunlight-induced skin cancers. Here we show that yeast and human POL eta replicate DNA containing 8-oxoG efficiently and accurately by inserting a cytosine across from the lesion and by proficiently extending from this base pair. Consistent with these biochemical studies, a synergistic increase in the rate of spontaneous mutations occurs in the absence of POL eta in the yeast ogg1 Delta mutant. Our results suggest an additional role for Pol eta in the prevention of internal cancers in humans that would otherwise result from the mutagenic replication of 8-oxoG in DNA.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77550 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL CANCER INSTITUTE [R01CA080882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA80882] Funding Source: Medline; NIEHS NIH HHS [P30-ES06676] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; HOFMANN H, 1978, B CANCER, V65, P347; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Saparbaev M, 1996, GENETICS, V142, P727; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835	20	300	306	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					458	461		10.1038/78169	http://dx.doi.org/10.1038/78169			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932195				2022-12-27	WOS:000088615000026
J	Netchine, I; Sobrier, ML; Krude, H; Schnabel, D; Maghnie, M; Marcos, E; Duriez, B; Cacheux, V; von Moers, A; Goossens, M; Gruters, A; Amselem, S				Netchine, I; Sobrier, ML; Krude, H; Schnabel, D; Maghnie, M; Marcos, E; Duriez, B; Cacheux, V; von Moers, A; Goossens, M; Gruters, A; Amselem, S			Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency	NATURE GENETICS			English	Article							GENOMIC STRUCTURE; GENE-EXPRESSION; MOTOR-NEURONS; LIM; SPECIFICATION; HYBRIDIZATION; SENSITIVITY; GLAND	Combined pituitary hormone deficiency (CPHD) has been linked with rare abnormalities in genes encoding transcription factors necessary for pituitary development(1). We have isolated LHX3, a gene involved in a new syndrome, using a candidate-gene approach developed on the basis of documented pituitary abnormalities of a recessive lethal mutation in mice generated by targeted disruption of Lhx3 (ref. 2). LHX3, encoding a member of the LIM class of homeodomain proteins(3), consists of at least six exons located at 9q34. We identified a homozygous LHX3 defect in patients of two unrelated consanguineous families displaying a complete deficit in all but one (adrenocorticotropin) anterior pituitary hormone and a rigid cervical spine leading to limited head rotation. Two of these patients also displayed a severe pituitary hypoplasia, whereas one patient presented secondarily with an enlarged anterior pituitary. These LHX3 mutations consist of a missense mutation (Y116C) in the LIM2 domain at a phylogenetically conserved residue and an intragenic deletion predicting a severely truncated protein lacking the entire homeodomain. These data are consistent with function of LHX3 in the proper development of all anterior pituitary cell types, except corticotropes, and extrapituitary structures.	Hop Henri Mondor, INSERM, U468, Lab Genet & Physiopathol, F-94010 Creteil, France; Humboldt Univ, Dept Pediat, Charite, Berlin, Germany; Humboldt Univ, Dept Pediat Neurol, Charite, Berlin, Germany; Univ Pavia, Policlin San Matteo, IRCCS, Dept Pediat, I-27100 Pavia, Italy	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; IRCCS Fondazione San Matteo; University of Pavia	Amselem, S (corresponding author), Hop Henri Mondor, INSERM, U468, Lab Genet & Physiopathol, F-94010 Creteil, France.		Sobrier, Marie-Laure/L-4820-2017; Duriez, Benedicte/Z-4690-2019	Sobrier, Marie-Laure/0000-0001-6396-100X				Appel B, 1995, DEVELOPMENT, V121, P4117; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Burrows HL, 1999, TRENDS ENDOCRIN MET, V10, P343, DOI 10.1016/S1043-2760(99)00189-7; COULY G, 1988, DEVELOPMENT, V103, P101; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Duquesnoy P, 1998, FEBS LETT, V437, P216, DOI 10.1016/S0014-5793(98)01234-4; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; IKEDA H, 1988, ANAT EMBRYOL, V178, P327, DOI 10.1007/BF00698663; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Mendonca BB, 1999, J CLIN ENDOCR METAB, V84, P942, DOI 10.1210/jc.84.3.942; Parks JS, 1999, J CLIN ENDOCR METAB, V84, P4362, DOI 10.1210/jc.84.12.4362; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147; ZHADANOV AB, 1995, GENOMICS, V27, P27, DOI 10.1006/geno.1995.1004	20	235	242	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					182	186		10.1038/76041	http://dx.doi.org/10.1038/76041			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835633				2022-12-27	WOS:000087459200017
J	Pennisi, D; Gardner, J; Chambers, D; Hosking, B; Peters, J; Muscat, G; Abbott, C; Koopman, P				Pennisi, D; Gardner, J; Chambers, D; Hosking, B; Peters, J; Muscat, G; Abbott, C; Koopman, P			Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice	NATURE GENETICS			English	Article							DISTAL MOUSE CHROMOSOME-2; RECEPTOR TYROSINE KINASE; SONIC HEDGEHOG; MAPS	Analysis of classical mouse mutations has been useful in the identification and study of many genes. We previously mapped Sox18, encoding an SRY-related transcription factor(1), to distal mouse chromosome 2 (ref, 2), This region contains a known mouse mutation, ragged (Ra), that affects the coat and vasculature(3-5). Here we have directly evaluated Sox18 as a candidate for Ra, We found that Sox18 is expressed in the developing vascular endothelium and hair follicles in mouse embryos. Furthermore, we found no recombination between Sox18 and Ra in an interspecific backcross segregating for the Ra phenotype, We found point mutations in Sox18 in two different Ra alleles that result in missense translation and premature truncation of the encoded protein. Fusion proteins containing these mutations lack the ability to activate transcription relative to wild-type controls in an in vitro assay. Our observations implicate mutations in Sox18 as the underlying cause of the Ra phenotype, and identify Sox18 as a critical gene for cardiovascular and hair follicle formation.	Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld, Australia; Western Gen Hosp, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; MRC, Mammalian Genet Unit, Didcot, Oxon, England	University of Queensland; University of Edinburgh; MRC Harwell	Koopman, P (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld, Australia.	p.koopman@cmcb.uq.edu.au	Abbott, Catherine M/C-7306-2013; Koopman, Peter A/C-9416-2009; Muscat, George/A-6401-2017	Koopman, Peter A/0000-0001-6939-0914; Muscat, George/0000-0002-5829-5695; Abbott, Catherine/0000-0001-8794-7173; Gardner, Jennifer/0000-0002-4215-955X; Pennisi, David/0000-0001-8247-2965				ABBOTT C, 1994, GENOMICS, V20, P94, DOI 10.1006/geno.1994.1131; CARTER TC, 1954, J HERED, V45, P150; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GREEN EL, 1961, J HERED, V52, P223, DOI 10.1093/oxfordjournals.jhered.a107077; Greenfield A, 1996, GENOMICS, V36, P558, DOI 10.1006/geno.1996.0510; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HERBERTSON B M, 1964, J Med Genet, V1, P10, DOI 10.1136/jmg.1.1.10; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; MANN SJ, 1963, GENET RES, V4, P1, DOI 10.1017/S0016672300003372; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SLEE JOHN, 1957, JOUR GENETICS, V55, P570, DOI 10.1007/BF02984073; SLEE JOHN, 1957, JOUR GENETICS, V55, P100, DOI 10.1007/BF02981618; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Theiler K., 1972, HOUSE MOUSE; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WALLACE ME, 1979, HEREDITY, V43, P9, DOI 10.1038/hdy.1979.54; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	21	172	177	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					434	437		10.1038/74301	http://dx.doi.org/10.1038/74301			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742113				2022-12-27	WOS:000086192800028
J	Kaplan, JM; Kim, SH; North, KN; Rennke, H; Correia, LA; Tong, HQ; Mathis, BJ; Rodriguez-Perez, JC; Allen, PG; Beggs, AH; Pollak, MR				Kaplan, JM; Kim, SH; North, KN; Rennke, H; Correia, LA; Tong, HQ; Mathis, BJ; Rodriguez-Perez, JC; Allen, PG; Beggs, AH; Pollak, MR			Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis	NATURE GENETICS			English	Article							ALPHA-ACTININ; ULTRASTRUCTURAL ORGANIZATION; NEPHROTIC SYNDROME; PROTEINS; CONTRACTILE; PODOCYTES; GENE; RAT	Focal and segmental glomerulosclerosis(1) (FSGS) is a common, non-specific renal lesion. Although it is often secondary to other disorders, including HIV infection, obesity, hypertension and diabetes, FSGS also appears as an isolated, idiopathic condition. FSGS is characterized by increased urinary protein excretion and decreasing kidney function. Often, renal insufficiency in affected patients progresses to end-stage renal failure, a highly morbid state requiring either dialysis therapy or kidney transplantation. Here we present evidence implicating mutations in the gene encoding alpha-actinin-4 (ACTN4; ref. 2), an actin-filament crosslinking protein, as the cause of disease in three families with an autosomal dominant form of FSCS. In vitro, mutant alpha-actinin-4 binds filamentous actin (F-actin) more strongly than does wild-type alpha-actinin-4. Regulation of the actin cytoskeleton of glomerular podocytes may be altered in this group of patients. Our results have implications for understanding the role of the cytoskeleton in the pathophysiology of kidney disease and may lead to a better understanding of the genetic basis of susceptibility to kidney damage.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal,Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA; Oklahoma State Univ, Coll Osteopath Med, Dept Med, Tulsa, OK USA; Hosp Ntra Sra Pino, Serv Nephrol, Las Palmas Gran Canaria, Spain	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Oklahoma State University System; Oklahoma State University Center for Health Sciences	Pollak, MR (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal,Dept Med, Boston, MA 02115 USA.	mpollak@rics.bwh.harvard.edu	North, Kathryn N/K-6476-2012; Rodriguez-Perez, J.C./C-1247-2010	North, Kathryn N/0000-0003-0841-8009; Beggs, Alan/0000-0001-8818-0568	NIAMS NIH HHS [AR02026, AR44345] Funding Source: Medline; NIDDK NIH HHS [DK54931] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002026, R01AR044345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054931, R56DK054931] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGGS AH, 1992, J BIOL CHEM, V267, P9281; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; DRENCKHAHN D, 1990, AM J PATHOL, V137, P1343; DRENCKHAHN D, 1988, LAB INVEST, V59, P673; Eilertsen KJ, 1997, EUR J CELL BIOL, V74, P361; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 1998, J CELL BIOL, V143, P277; Ichikawa I, 1996, PEDIATR NEPHROL, V10, P374; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; MATHIS B J, 1992, Journal of the American Osteopathic Association, V92, P875; Mathis BJ, 1998, KIDNEY INT, V53, P282, DOI 10.1046/j.1523-1755.1998.00828.x; North KN, 1996, NEUROMUSCULAR DISORD, V6, P229, DOI 10.1016/0960-8966(96)00361-6; North KN, 1999, NAT GENET, V21, P353, DOI 10.1038/7675; Papa I, 1999, J MUSCLE RES CELL M, V20, P187, DOI 10.1023/A:1005489319058; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Shirato I, 1996, AM J PATHOL, V148, P1283; Smoyer WE, 1997, AM J PHYSIOL-RENAL, V273, pF150, DOI 10.1152/ajprenal.1997.273.1.F150; TOMERO JAS, 1985, INT J PED NEPHROL, V6, P199; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Wilson K, 1995, CURRENT PROTOCOLS MO; Winn MP, 1999, GENOMICS, V58, P113, DOI 10.1006/geno.1999.5828	29	941	1025	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					251	256		10.1038/73456	http://dx.doi.org/10.1038/73456			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700177				2022-12-27	WOS:000085590600014
J	Amir, RE; Van den Veyver, IB; Wan, M; Tran, CQ; Francke, U; Zoghbi, HY				Amir, RE; Van den Veyver, IB; Wan, M; Tran, CQ; Francke, U; Zoghbi, HY			Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2	NATURE GENETICS			English	Article							CHROMOSOME INACTIVATION; HISTONE DEACETYLASE; EXCLUSION MAP; INHERITANCE; GENE; DNA; LOCALIZATION; LINKAGE; FAMILY; SITES	Rett syndrome(1) (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females, with an incidence of 1 in 10,000-15,000 (ref. 2). Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use, and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements(3). After initial regression, the condition stabilizes and patients usually survive into adulthood. As RTT occurs almost exclusively in females, it has been proposed that RTT is caused by an X-linked dominant mutation with lethality in hemizygous males(3-8). Previous exclusion mapping studies using RTT families mapped the locus to Xq28 (refs 6,7,9-11). Using a systematic gene screening approach, we have identified mutations in the gene (MECP2) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some Eases of RTT. MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A (refs 12,13). In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation, both of which disrupt the transcription repression domain (TRD). In two affected half-sisters of a RTT family, we found segregation of an additional missense mutation not detected in their obligate carrier mother. This suggests that the mother is a germline mosaic for this mutation. Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.		Van den Veyver, Ignatia B/AAF-4510-2021	Van den Veyver, Ignatia B/0000-0002-0651-5924; Zoghbi, Huda/0000-0002-0700-3349	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NICHD NIH HHS [HD242346, HD 24064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; AMIR RE, IN PRESS AM J MED GE; ARCHIDIACONO N, 1991, HUM GENET, V86, P604; Coy JF, 1999, HUM MOL GENET, V8, P1253, DOI 10.1093/hmg/8.7.1253; CURTIS ARJ, 1993, HUM GENET, V90, P551; DEsposito M, 1996, MAMM GENOME, V7, P533, DOI 10.1007/s003359900157; ELLISON KA, 1992, AM J HUM GENET, V50, P278; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; GANGULY A, 1994, P NATL ACAD SCI USA, V91, P5217; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1985, ACTA PAEDIATR SCAND, V74, P405, DOI 10.1111/j.1651-2227.1985.tb10993.x; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Rett A., 1966, WIENER MED WOCHENSCH, V116, P723; Schanen C, 1998, AM J HUM GENET, V63, P267, DOI 10.1086/301932; Schanen NC, 1997, AM J HUM GENET, V61, P634, DOI 10.1086/515525; Sirianni N, 1998, AM J HUM GENET, V63, P1552, DOI 10.1086/302105; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; Wan MH, 1998, AM J MED GENET, V78, P169, DOI 10.1002/(SICI)1096-8628(19980630)78:2<169::AID-AJMG14>3.3.CO;2-D; ZOGHBI H, 1988, J CHILD NEUROL, V3, P576; ZOGHBI HY, 1990, BRAIN DEV-JPN, V12, P131, DOI 10.1016/S0387-7604(12)80194-X	26	3466	3562	8	330	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					185	188		10.1038/13810	http://dx.doi.org/10.1038/13810			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508514				2022-12-27	WOS:000082827500017
J	den Hollander, AI; ten Brink, JB; de Kok, YJM; van Soest, S; van den Born, LI; van Driel, MA; van de Pol, DJR; Payne, AM; Bhattacharya, SS; Kellner, U; Hoyng, CB; Westerveld, A; Brunner, HG; Bleeker-Wagemakers, EM; Deutman, AF; Heckenlively, JR; Cremers, FPM; Bergen, AAB				den Hollander, AI; ten Brink, JB; de Kok, YJM; van Soest, S; van den Born, LI; van Driel, MA; van de Pol, DJR; Payne, AM; Bhattacharya, SS; Kellner, U; Hoyng, CB; Westerveld, A; Brunner, HG; Bleeker-Wagemakers, EM; Deutman, AF; Heckenlively, JR; Cremers, FPM; Bergen, AAB			Mutations in a human homologue of Drosophila crumbs cause retinitis pigmentosa (RP12)	NATURE GENETICS			English	Article							EPIDERMAL GROWTH-FACTOR; EPITHELIAL-CELL LINE; PROTEIN; LAMININ; SEQUENCE; DOMAINS; GENE; PROTEOGLYCAN; EXPRESSION; RECEPTOR	Retinitis pigmentosa (RP) comprises a clinically and genetically heterogeneous group of diseases that afflicts approximately 1.5 million people worldwide. Affected individuals suffer from a progressive degeneration of the photoreceptors, eventually resulting in severe visual impairment. To isolate candidate genes for chorioretinal diseases, we cloned cDNAs specifically or preferentially expressed in the human retina and the retinal pigment epithelium (RPE) through a novel suppression subtractive hybridization (SSH) method(1,2). One of these cDNAs (RET3C11) mapped to chromosome 1q31-q32.1, a region harbouring a gene involved in a severe form of autosomal recessive RP characterized by a typical preservation of the para-arteriolar RPE (RP12; ref. 3). The full-length cDNA encodes an extracellular protein with 19 EGF-like domains, 3 laminin A G-like domains and a C-type lectin domain. This protein is homologous to the Drosophila melanogaster protein crumbs (CRB), and denoted CRB1 (crumbs homologue 1). In ten unrelated RP patients with preserved para-arteriolar RPE, we identified a homozygous AluY insertion disrupting the ORF, five homozygous missense mutations and four compound heterozygous mutations in CRB1. The similarity to CRB suggests a role for CRB1 in cell-cell interaction and possibly in the maintenance of cell polarity in the retina. The distinct RPE abnormalities observed in RP12 patients suggest that CRB1 mutations trigger a novel mechanism of photoreceptor degeneration.	Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands; Hosp Eye, Rotterdam, Netherlands; UCL, Inst Ophthalmol, London, England; Free Univ Berlin, Univ Clin Benjamin Franklin, Dept Ophthalmol, D-1000 Berlin, Germany; Univ Nijmegen Hosp, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands; Univ Amsterdam, Inst Human Genet, Amsterdam, Netherlands; Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA	Radboud University Nijmegen; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Rotterdam Eye Hospital; University of London; University College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Radboud University Nijmegen; University of Amsterdam; University of California System; University of California Los Angeles	Cremers, FPM (corresponding author), Univ Nijmegen Hosp, Dept Human Genet, Geert Grooteplein 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.	F.Cremers@antrg.azn.nl	Hoyng, C.B./H-8050-2014; Payne, annette/F-8877-2013; Hollander, Anneke den/N-4911-2014; Brunner, Han/C-9928-2013; Cremers, Frans/A-5625-2014; Bhattacharya, Shom/N-2926-2016; van Driel, Marc/D-5844-2013; Bergen, Arthur/J-3637-2013	Payne, annette/0000-0002-2009-0141; Cremers, Frans/0000-0002-4954-5592; Bhattacharya, Shom/0000-0002-1601-6344; Bergen, Arthur/0000-0002-6333-9576				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; den Hollander AI, 1999, GENOMICS, V58, P240, DOI 10.1006/geno.1999.5823; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; HECKENLIVELY JR, 1982, BRIT J OPHTHALMOL, V66, P26, DOI 10.1136/bjo.66.1.26; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; KNUST E, 1987, EMBO J, V6, P761, DOI 10.1002/j.1460-2075.1987.tb04818.x; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; PATTHY L, 1992, FEBS LETT, V298, P182, DOI 10.1016/0014-5793(92)80051-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; van Soest S, 1999, CYTOGENET CELL GENET, V84, P22, DOI 10.1159/000015204; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VANDENBORN LI, 1994, AM J OPHTHALMOL, V118, P430, DOI 10.1016/S0002-9394(14)75792-7; VANSOEST S, 1994, GENOMICS, V22, P499, DOI 10.1006/geno.1994.1422; Vidaud Dominique, 1993, European Journal of Human Genetics, V1, P30; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5	30	367	376	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					217	221		10.1038/13848	http://dx.doi.org/10.1038/13848			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508521				2022-12-27	WOS:000082827500024
J	Gerard, M; Hernandez, L; Wevrick, R; Stewart, CL				Gerard, M; Hernandez, L; Wevrick, R; Stewart, CL			Disruption of the mouse necdin gene results in early post-natal lethality	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; SYNDROME REGION; GROWTH SUPPRESSOR; IMPRINTING-CENTER; NUCLEAR-PROTEIN; EXPRESSED GENE; DELETION; IDENTIFICATION; SNRPN	Prader-Willi syndrome (PWS) is a neurobehavioural disorder characterized by neonatal respiratory depression, hypotonia and failure to thrive in infancy, followed by hyperphagia and obesity among other symptoms(1,2). PWS is caused by the loss of one or more paternally expressed genes on chromosome 15q11-q13, which can be due to gene deletions, maternal uniparental disomy or mutations disrupting the imprinting mechanism. Imprinted genes mapped to this region include SNRPN (refs 3,4), ZNF127 (ref. 5), IPW (ref. 6) and NDN (which encodes the DNA-binding protein necdin; refs 7-10). The mouse homologues of these genes map to mouse chromosome 7 in a region syntenic with human chromosome 15q11-q13 (refs 7,11). Imprinting of the human genes is under the control of an imprinting center (IC), a long-range, cis-acting element located in the 5 ' region of SNRPN (ref. 12). A related control element was isolated in the mouse Snrpn genomic region which, when deleted on the paternally inherited chromosome, resulted in the loss of expression of all four genes and early post-natal lethality(13). To determine the possible contribution of Ndn to the PWS phenotype, we generated Ndn mutant mice. Heterozygous mice inheriting the mutated maternal allele were indistinguishable from their wild-type littermates. Mice carrying a paternally inherited Ndn deletion allele demonstrated early post-natal lethality. This is the first example of a single gene being responsible for phenotypes associated with PWS.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Canc & Dev Biol Lab, Frederick, MD 21702 USA; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Alberta	Stewart, CL (corresponding author), CEA Saclay, SBGM, F-91191 Gif Sur Yvette, France.		GERARD, Matthieu/D-2235-2014	GERARD, Matthieu/0000-0001-8956-0597; Wevrick, Rachel/0000-0002-3343-5794				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; GLENN CC, 1993, HUM MOL GENET, V2, P1377, DOI 10.1093/hmg/2.9.1377; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HOLM VA, 1993, PEDIATRICS, V91, P398; Horsthemke B, 1997, J CELL PHYSIOL, V173, P237, DOI 10.1002/(SICI)1097-4652(199711)173:2<237::AID-JCP28>3.0.CO;2-B; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jong MTC, 1999, HUM MOL GENET, V8, P795, DOI 10.1093/hmg/8.5.795; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; Sutcliffe JS, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63943-8; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tsai TF, 1999, NAT GENET, V22, P15, DOI 10.1038/8722; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Watrin F, 1997, EUR J HUM GENET, V5, P324, DOI 10.1159/000484784; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; WHARTON RH, 1989, DEV MED CHILD NEUROL, V31, P231; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393	22	169	174	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					199	202		10.1038/13828	http://dx.doi.org/10.1038/13828			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508517				2022-12-27	WOS:000082827500020
J	McPherron, AC; Lawler, AM; Lee, SJ				McPherron, AC; Lawler, AM; Lee, SJ			Regulation of anterior posterior patterning of the axial skeleton by growth differentiation factor 11	NATURE GENETICS			English	Article							BETA SUPERFAMILY; NEURAL TISSUE; MOUSE EMBRYO; HOX GENES; CELLS; EMBRYOGENESIS; EXPRESSION; MEMBER	The bones that comprise the axial skeleton have distinct morphological features characteristic of their positions along the anterior/posterior axis. We previously described a novel TGF-beta family member, myostatin (encoded by the gene Mstn, formerly Gdf8), that has an essential role in regulating skeletal muscle mass(1). We also identified a gene related to Mstn by low-stringency screening(1). While the work described here was being completed, the cloning of this gene, designated Gdf11 (also called Bmp11), was also reported by other groups(2,3). Here we show that Gdf11, a new transforming growth factor beta (TGF beta) superfamily member, has an important role in establishing this skeletal pattern. During early mouse embryogenesis, Gdf11 is expressed in the primitive streak and tail bud regions, which are sites where new mesodermal cells are generated. Homozygous mutant mice carrying a targeted deletion of Cdf11 exhibit anteriorly directed homeotic transformations throughout the axial skeleton and posterior displacement of the hindlimbs. The effect of the mutation is dose dependent, as Cdf11(+/-) mice have a milder phenotype than Gdf11(-/-) mice. Mutant embryos show alterations in patterns of Hox gene expression, suggesting that Gdf11 acts upstream of the Hox genes. Our findings suggest that Gdf11 is a secreted signal that acts globally to specify positional identity along the anterior/posterior axis.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Lee, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.							Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Durston AJ, 1997, CELL MOL LIFE SCI, V53, P339, DOI 10.1007/PL00000610; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; Nakashima M, 1999, MECH DEVELOP, V80, P185, DOI 10.1016/S0925-4773(98)00205-6; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; PETERSON RL, 1992, MECH DEVELOP, V37, P151, DOI 10.1016/0925-4773(92)90077-W; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; TAM PPL, 1992, DEVELOPMENT, V115, P703; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	16	338	390	0	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					260	264		10.1038/10320	http://dx.doi.org/10.1038/10320			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391213				2022-12-27	WOS:000081125900018
J	Cheng, SWG; Davies, KP; Yung, E; Beltran, RJ; Yu, J; Kalpana, GV				Cheng, SWG; Davies, KP; Yung, E; Beltran, RJ; Yu, J; Kalpana, GV			c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function	NATURE GENETICS			English	Article							TRANSCRIPTIONAL REPRESSION; PROTEIN; GROWTH; TRANSFORMATION; INTEGRASE; MACHINES; NETWORK; DOMAIN; SNF5	Chromatin organization plays a key role in the regulation of gene expression(1,2). The evolutionarily conserved SWI/SNF complex is one of several multiprotein complexes that activate transcription by remodelling chromatin in an ATP-dependent manner(3-5). SWI2/SNF2 is an ATPase whose homologues, BRG1 and hBRM, mediate cell-cycle arrest(6,7); the SNF5 homologue, INI1/hSNF5, appears to be a tumour suppressor(8,9). A search for INI1-interacting proteins using the two-hybrid system(10,11) led to the isolation of c-MYC, a transactivator(12,13). The c-MYC-INI1 interaction was observed both in vitro and in vivo. The c-MYC basic helix-loop-helix (bHLH) and leucine zipper (Zip) domains and the INI1 repeat 1 (Rpt1) region were required for this interaction. c-MYC-mediated transactivation was inhibited by a deletion fragment of INI1 and the ATPase mutant of BRG1/hSNF2 in a dominant-negative manner contingent upon the presence of the c-MYC bHLH-Zip domain. Our results suggest that the SWI/SNF complex is necessary for c-MYC-mediated transactivation and that the c-MYC-INI1 interaction helps recruit the complex.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Columbia University	Kalpana, GV (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,U821, Bronx, NY 10461 USA.	kalpana@aecom.yu.edu		Yung, Eric/0000-0002-7328-7204; Davies, Kelvin/0000-0002-0201-9210; Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI039951, R21AI039951, R01AI039951] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39951] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Biegel JA, 1999, CANCER RES, V59, P74; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Young KH, 1998, BIOL REPROD, V58, P302, DOI 10.1095/biolreprod58.2.302	23	298	312	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					102	105		10.1038/8811	http://dx.doi.org/10.1038/8811			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319872				2022-12-27	WOS:000080096300033
J	Jeddeloh, JA; Stokes, TL; Richards, EJ				Jeddeloh, JA; Stokes, TL; Richards, EJ			Maintenance of genomic methylation requires a SW12/SNF2-like protein	NATURE GENETICS			English	Article							DNA METHYLATION; HISTONE DEACETYLASE; PLANT DEVELOPMENT; ARABIDOPSIS; MUTATIONS; TRANSCRIPTION; SUPERFAMILY; NEUROSPORA; MUTANTS	Altering cytosine methylation by genetic means leads to a variety of developmental defects in mice(1), plants(2-5) and fungi(6,7) Deregulation of cytosine methylation also has a role in human carcinogenesis(8). In some cases, these defects have been tied to the inheritance of epigenetic alterations (such as chromatin imprints and DNA methylation patterns) that do not involve changes in DNA sequence(3,8-10). Using a forward genetic screen, we identified a gene (DDM1, decrease in DNA methylation) from the flowering plant Arabidopsis thaliana required to maintain normal cytosine methylation patterns(11). Additional ddm1 alleles (som4, 5, 6, 7, 8) were isolated in a selection for mutations that relieved transgene silencing(12) (E.J.R., unpublished data). Loss of DDM1 function causes a 70% reduction of genomic cytosine methylation, with most of the immediate hypomethylation occurring in repeated sequences(11). In contrast, many low-copy sequences initially retain their methylation in ddm1 homozygotes, but lose methylation over time as the mutants are propagated through multiple generations by self-pollination(3,13). The progressive effect of ddm1 mutations on low-copy sequence methylation suggests that ddm1 mutations compromise the efficiency of methylation of newly incorporated cytosines after DNA replication. In parallel with the slow decay of methylation during inbreeding, ddm1 mutants accumulate heritable alterations (mutations or stable epialleles) at dispersed sites in the genome that lead to morphological abnormalities(3,5,14). Here we report that DDM1 encodes a SWI2/SNF2-like protein, implicating chromatin remodelling as an important process for maintenance of DNA methylation and genome integrity.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Richards, EJ (corresponding author), Washington Univ, Dept Biol, 1 Brookings Dr, St Louis, MO 63130 USA.	richards@biology.wustl.edu	Richards, Eric/E-6866-2012	Richards, Eric/0000-0002-8665-7470				Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; CHOI S, 1995, WEEDS WORLD, V2, P17; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; ELSEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jarvis CD, 1996, GENE, V169, P203, DOI 10.1016/0378-1119(95)00843-8; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; Kakutani T, 1997, PLANT J, V12, P1447, DOI 10.1046/j.1365-313x.1997.12061447.x; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Malagnac F, 1997, CELL, V91, P281, DOI 10.1016/S0092-8674(00)80410-9; Martienssen R, 1998, CURR OPIN GENET DEV, V8, P240, DOI 10.1016/S0959-437X(98)80147-0; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Richards EJ, 1997, TRENDS GENET, V13, P319, DOI 10.1016/S0168-9525(97)01199-2; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Scheid OM, 1998, P NATL ACAD SCI USA, V95, P632, DOI 10.1073/pnas.95.2.632; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	31	537	562	0	22	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					94	97		10.1038/8803	http://dx.doi.org/10.1038/8803			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319870				2022-12-27	WOS:000080096300031
J	Kaessmann, H; Heissig, F; von Haeseler, A; Paabo, S				Kaessmann, H; Heissig, F; von Haeseler, A; Paabo, S			DNA sequence variation in a non-coding region of low recombination on the human X chromosome	NATURE GENETICS			English	Article							EVOLUTION; DISTRIBUTIONS; POLYMORPHISMS; SITES	DNA sequence variation has become a major source of insight regarding the origin and history of our species(1-5) as well as an important tool for the identification of allelic variants associated with disease. Comparative sequencing of DNA has to date focused mainly on mitochondrial (mt) DNA, which due to its apparent lack of recombination and high evolutionary rate lends itself well to the study of human evolution(1). These advantages also entail limitations. For example, the high mutation rate of mtDNA results in multiple substitutions that make phylogenetic analysis difficult and, because mtDNA is maternally inherited, it reflects only the history of females. For the history of males, the non-recombining part of the paternally inherited Y chromosome can be studied(2). The extent of variation on the Y chromosome is so low that variation at particular sites known to be polymorphic rather than entire sequences are typically determined(6). It is currently unclear how some forms of analysis (such as the coalescent) should be applied to such data, Furthermore, the lack of recombination means that selection at any locus affects all 59 Mb of DNA. To gauge the extent and pattern of point substitutional variation in non-coding parts of the human genome, we have sequenced 10 kb of non-coding DNA in a region of low recombination at Xq13.3. Analysis of this sequence in 69 individuals representing all major linguistic groups reveals the highest overall diversity in Africa, whereas deep divergences also exist in Asia. The time elapsed since the most recent common ancestor (MRCA) is 535.000+/-119.000 years, We expect this type of nuclear locus to provide more answers about the genetic origin and history of humans.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany	Max Planck Society	Kaessmann, H (corresponding author), Max Planck Inst Evolutionary Anthropol, Inselstr 22, D-04103 Leipzig, Germany.		von Haeseler, Arndt/HCI-9958-2022; Kaessmann, Henrik/B-4989-2013	von Haeseler, Arndt/0000-0002-3366-4458; Kaessmann, Henrik/0000-0001-7563-839X				ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; CHARLESWORTH B, 1993, GENETICS, V134, P1289; Foley R, 1998, GENOME RES, V8, P339, DOI 10.1101/gr.8.4.339; GRIFFITHS RC, 1995, MATH BIOSCI, V127, P77, DOI 10.1016/0025-5564(94)00044-Z; GRIFFITHS RC, 1994, THEOR POPUL BIOL, V46, P131, DOI 10.1006/tpbi.1994.1023; Hammer MF, 1997, GENETICS, V145, P787; Harding RM, 1997, AM J HUM GENET, V60, P772; Harris EE, 1999, P NATL ACAD SCI USA, V96, P3320, DOI 10.1073/pnas.96.6.3320; Kimmel M, 1998, GENETICS, V148, P1921; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Nachman MW, 1998, GENETICS, V150, P1133; Nagaraja R, 1997, GENOME RES, V7, P210, DOI 10.1101/gr.7.3.210; NELSON DL, 1995, CYTOGENET CELL GENET, V71, P308; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Robinson BH, 1996, J INHERIT METAB DIS, V19, P452, DOI 10.1007/BF01799106; Ruhlen M, 1991, GUIDE WORLDS LANGUAG; SATTA Y, 1998, FRONT BIOSCI, V3, P459; SHERRY ST, 1994, HUM BIOL, V66, P761; Stoneking M, 1997, GENOME RES, V7, P1061, DOI 10.1101/gr.7.11.1061; STONEKING M, 1997, PROGR POPULATION GEN, P1; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAJIMA F, 1989, GENETICS, V123, P585; TAKAHATA N, 1995, ANNU REV ECOL SYST, V26, P342; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; WARD RH, 1993, P NATL ACAD SCI USA, V90, P10663, DOI 10.1073/pnas.90.22.10663; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WEISS G, 1996, SCIENCE, V272, P1358; Wilson JF, 1998, BIOL CHEM, V379, P1287; Wolpoff M. H., 1997, RACE HUMAN EVOLUTION	31	184	188	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					78	81		10.1038/8785	http://dx.doi.org/10.1038/8785			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319866				2022-12-27	WOS:000080096300027
J	Jansen, G; Thijssen, KL; Werner, P; van der Horst, M; Hazendonk, E; Plasterk, RHA				Jansen, G; Thijssen, KL; Werner, P; van der Horst, M; Hazendonk, E; Plasterk, RHA			The complete family of genes encoding G proteins of Caenorhabditis elegans	NATURE GENETICS			English	Article							C-ELEGANS; CHEMOSENSORY RECEPTORS; SENSORY NEURONS; CHEMOTAXIS; EXPRESSION; MUTATIONS; MUTANTS; SYSTEM; G(O)	Caenorhabditis elegans is the first animal whose genomic sequence has been determined(1). One of the new possibilities in post-sequence genetics is the analysis of complete gene families at once. We studied the family of heterotrimeric G proteins(2). C, elegans has 20 G alpha, 2 G beta and 2 G gamma genes. There is 1 homologue of each of the 4 mammalian classes of G alpha genes, G(i)/G(o)alpha, G(s)alpha, G(q)alpha and G(12)alpha, and there are 16 new alpha genes. Although the conserved G alpha subunits are expressed in many neurons and muscle cells(3-7), GFP fusions indicate that 14 new G alpha genes are expressed almost exclusively in a small subset of the chemosensory neurons of C, elegans(8,9). We generated loss-of-function alleles using target-selected gene inactivation(10,11). None of the amphid-expressed genes are essential for viability, and only four show any detectable phenotype (chemotaxis defects), suggesting extensive functional redundancy. On the basis of functional analysis, the 20 genes encoding G alpha proteins can be divided into two groups: those that encode subunits affecting muscle activity (homologues of G(i)/G(o)alpha G(s)alpha and G(q); refs 3-6), and those (14 new genes) that encode proteins most likely involved in perception.	Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Plasterk, RHA (corresponding author), Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	rplas@nki.nl	Jansen, Gert/HCI-8852-2022	Jansen, Gert/0000-0002-7524-171X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; CULOTTI JG, 1978, GENETICS, V90, P243; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Korswagen HC, 1997, GENE DEV, V11, P1493, DOI 10.1101/gad.11.12.1493; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Park JH, 1997, GENE, V194, P183, DOI 10.1016/S0378-1119(97)00122-4; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zwaal RR, 1997, GENETICS, V145, P715; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	30	230	277	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	1999	21	4					414	419		10.1038/7753	http://dx.doi.org/10.1038/7753			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192394				2022-12-27	WOS:000079439700025
J	Jaye, M; Lynch, KJ; Krawiec, T; Marchadier, D; Maugeais, C; Doan, K; South, V; Amin, D; Perrone, M; Rader, DJ				Jaye, M; Lynch, KJ; Krawiec, T; Marchadier, D; Maugeais, C; Doan, K; South, V; Amin, D; Perrone, M; Rader, DJ			A novel endothelial-derived lipase that modulates HDL metabolism	NATURE GENETICS			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEPATIC TRIGLYCERIDE LIPASE; CHOLESTEROL LEVELS; PANCREATIC LIPASE; TRANSGENIC MICE; DEFICIENT MICE; GENE-TRANSFER; PLASMA HDL; ATHEROSCLEROSIS; OVEREXPRESSION	High-density lipoprotein (HDL) cholesterol levels are inversely associated with risk of atherosclerotic cardiovascular disease(1). At least 50% of the variation in HDL cholesterol levels is genetically determined(2,3), but the genes responsible for variation in HDL levels have not been fully elucidated. Lipoprotein lipase (LPL) and hepatic lipase (HL), two members of the triacylglyerol (TC) lipase family, both influence HDL metabolism(2,4-6) and the HL (LIPC) locus has been associated with variation in HDL cholesterol levels in humans(7,8). We describe here the cloning and in vivo functional analysis of a new member of the TG lipase family. In contrast to other family members, this new lipase is synthesized by endothelial cells in vitro and thus has been termed endothelial lipase (encoded by the LIPG gene). EL is expressed in vivo in organs including liver, lung, kidney and placenta, but not in skeletal muscle. In contrast to LPL and HL, EL has a lid of only 19 residues. EL has substantial phospholipase activity, but less triglyceride lipase activity. Overexpression of EL in mice reduced plasma concentrations of HDL cholesterol and its major protein apolipoprotein A-I. The endothelial expression, enzymatic profile and in vivo effects of EL suggest that it may have a role in lipoprotein metabolism and vascular biology.	Univ Penn, Hlth Syst, Dept Med, Philadelphia, PA 19104 USA; Rhone Poulenc Rorer, Res & Dev, Dept Cardiovasc Biol, Collegeville, PA 19426 USA	University of Pennsylvania	Rader, DJ (corresponding author), Univ Penn, Hlth Syst, Dept Med, Philadelphia, PA 19104 USA.							Bensadoun A, 1996, CURR OPIN LIPIDOL, V7, P77, DOI 10.1097/00041433-199604000-00005; BLADES B, 1993, ARTERIOSCLER THROMB, V13, P1227, DOI 10.1161/01.ATV.13.8.1227; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; COHEN JC, 1994, J CLIN INVEST, V94, P2377, DOI 10.1172/JCI117603; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Goldberg IJ, 1996, J LIPID RES, V37, P693; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Guerra R, 1997, P NATL ACAD SCI USA, V94, P4532, DOI 10.1073/pnas.94.9.4532; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HELLER DA, 1993, NEW ENGL J MED, V328, P1150, DOI 10.1056/NEJM199304223281603; Hokanson JE, 1997, INT J CLIN LAB RES, V27, P24, DOI 10.1007/BF02827239; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; MAHANEY MC, 1995, ARTERIOSCL THROM VAS, V15, P1730, DOI 10.1161/01.ATV.15.10.1730; Mahley RW, 1999, J LIPID RES, V40, P1; Mezdour H, 1997, J BIOL CHEM, V272, P13570, DOI 10.1074/jbc.272.21.13570; Murthy V, 1996, PHARMACOL THERAPEUT, V70, P101, DOI 10.1016/0163-7258(96)00005-8; PIMSTONE SN, 1995, ARTERIOSCL THROM VAS, V15, P1704, DOI 10.1161/01.ATV.15.10.1704; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; Tsukamoto K, 1997, J LIPID RES, V38, P1869; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	27	398	439	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					424	428		10.1038/7766	http://dx.doi.org/10.1038/7766			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192396				2022-12-27	WOS:000079439700027
J	Scott, DA; Wang, R; Kreman, TM; Sheffield, VC; Karniski, LP				Scott, DA; Wang, R; Kreman, TM; Sheffield, VC; Karniski, LP			The Pendred syndrome gene encodes a chloride-iodide transport protein	NATURE GENETICS			English	Article							SULFATE TRANSPORTER; EXCHANGE; CLONING; MUTATIONS; VESICLES; GOITER; MAPS	Pendred syndrome is the most common form of syndromic deafness and characterized by congenital sensorineural hearing loss and goitre(1-3). This disorder was mapped to chromosome 7 and the gene causing Pendred syndrome (PDS) was subsequently identified by positional cloning(4-6). PDS encodes a putative transmembrane protein designated pendrin. Pendrin is closely related to a family of sulfate transport proteins that includes the rat sulfate-anion transporter(7) (encoded by Sat-1; 29% amino acid sequence identity), the human diastrophic dysplasia sulfate transporter(8) (encoded by DTD; 32%) and the human sulfate transporter 'downregulated in adenoma'(9,10) (encoded by DRA; 45%), On the basis of this homology and the presence of a slightly modified sulfate-transporter signature sequence comprising its putative second transmembrane domain(6-9), pendrin has been proposed to function as a sulfate transporter. We were unable to detect evidence of sulfate transport following the expression of pendrin in Xenopus laevis oocytes by microinjection of PDS cRNA or in Sf9 cells following infection with PDS-recombinant baculovirus. The rates of transport for iodide and chloride were significantly increased following the expression of pendrin in both cell systems. Our results demonstrate that pendrin functions as a transporter of chloride and iodide, but not sulfate, and may provide insight into thyroid physiology and the pathophysiology of Pendred syndrome.	Dept Vet Affairs Med Ctr, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa	Karniski, LP (corresponding author), Dept Vet Affairs Med Ctr, Howard Hughes Med Inst, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Sheffield, Val/0000-0002-6282-0835	NHGRI NIH HHS [HG00457] Funding Source: Medline; NIDDK NIH HHS [DK-47881] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047881, R55DK047881] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOWICZ MJ, 1992, J CLIN INVEST, V90, P1200, DOI 10.1172/JCI115981; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BROWN CDA, 1989, AM J PHYSIOL, V257, pG661, DOI 10.1152/ajpgi.1989.257.4.G661; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Coyle B, 1996, NAT GENET, V12, P421, DOI 10.1038/ng0496-421; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; GORLIN JR, 1995, HEREDITARY HEARING L, P337; HAGEN GA, 1971, NEW ENGL J MED, V285, P1394, DOI 10.1056/NEJM197112162852502; HALLIGAN RD, 1991, AM J PHYSIOL, V260, pC347, DOI 10.1152/ajpcell.1991.260.2.C347; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; JOHNSEN T, 1986, ACTA OTO-LARYNGOL, V102, P239, DOI 10.3109/00016488609108673; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; Karniski LP, 1998, AM J PHYSIOL-RENAL, V275, pF79, DOI 10.1152/ajprenal.1998.275.1.F79; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Reardon W, 1997, QJM-MON J ASSOC PHYS, V90, P443, DOI 10.1093/qjmed/90.7.443; Reardon W, 1996, J MED GENET, V33, P1037, DOI 10.1136/jmg.33.12.1037; Sheffield VC, 1996, NAT GENET, V12, P424, DOI 10.1038/ng0496-424; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; TROTTER WR, 1960, BRIT MED BULL, V16, P92, DOI 10.1093/oxfordjournals.bmb.a069828	24	450	548	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					440	443		10.1038/7783	http://dx.doi.org/10.1038/7783			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192399				2022-12-27	WOS:000079439700030
J	Draptchinskaia, N; Gustavsson, P; Andersson, B; Pettersson, M; Willig, TN; Dianzani, I; Ball, S; Tchernia, G; Klar, J; Matsson, H; Tentler, D; Mohandas, N; Carlsson, B; Dahl, N				Draptchinskaia, N; Gustavsson, P; Andersson, B; Pettersson, M; Willig, TN; Dianzani, I; Ball, S; Tchernia, G; Klar, J; Matsson, H; Tentler, D; Mohandas, N; Carlsson, B; Dahl, N			The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia	NATURE GENETICS			English	Article							MESSENGER-RNAS; SEQUENCE-ANALYSIS; TURNER SYNDROME; DNA-SEQUENCE; ANEMIA; CHROMOSOME; EXPRESSION; GROWTH	Diamond-Blackfan anaemia (DBA) is a constitutional erythroblastopenia characterized by absent or decreased erythroid precursors. The disease, previously mapped to human chromosome 19q13, is frequently associated with a variety of malformation. To identify the gene involved in DBA, we cloned the chromosome 19q13 breakpoint in a patient with a reciprocal X; 19 chromosome translocation. The breakpoint occurred in the gene encoding ribosomal protein S19. Furthermore, we identified mutations in RPS19 in 10 of 40 unrelated DMA patients, including nonsense, frameshift, splice site and missense mutations, as well as two intragenic deletions. These mutations are associated with clinical features that suggest a function for RPS19 in erythropoiesis and embryogenesis.	Uppsala Univ, Dept Genet & Pathol, Clin Genet Unit, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Unit Med Genet, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Unit Pathol, S-75185 Uppsala, Sweden; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Hop Bicetre, AP HP, Dept Hematol, Le Kremlin Bicetre, France; Fac Med Paris Sud, Le Kremlin Bicetre, France; Univ Turin, Dept Pediat, I-10126 Turin, Italy; Univ London St Georges Hosp, Sch Med, Dept Haematol, London SW17 0RE, England	Uppsala University; Uppsala University; Uppsala University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Turin; St Georges University London	Dahl, N (corresponding author), Uppsala Univ, Dept Genet & Pathol, Clin Genet Unit, S-75185 Uppsala, Sweden.	niklas.dahl@klingen.uu.se	Klar, Joakim/H-2900-2019; Tentler, Dmitri/AAE-4519-2019; Matsson, Hans/A-5787-2019; Andersson, Bjorn/G-9832-2013	Klar, Joakim/0000-0003-4185-7409; Tentler, Dmitri/0000-0003-3976-1205; Matsson, Hans/0000-0001-6161-1559; Andersson, Bjorn/0000-0002-4624-0259	NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline; Telethon [E.0619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK026263, R37DK026263] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersson B, 1996, BIOTECHNIQUES, V20, P1022; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; BAGNARA GP, 1991, BLOOD, V78, P2203; Ball SE, 1996, BRIT J HAEMATOL, V94, P645, DOI 10.1046/j.1365-2141.1996.d01-1839.x; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRAMTON SE, 1994, GENETICS, V137, P1039; Diamond L K, 1976, Adv Pediatr, V22, P349; Dianzani I, 1996, BLOOD, V87, P2568, DOI 10.1182/blood.V87.6.2568.bloodjournal8762568; ETTER A, SCIENCE, V265, P954; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Gelbart WM, 1997, NUCLEIC ACIDS RES, V25, P63, DOI 10.1093/nar/25.1.63; Gustavsson P, 1997, NAT GENET, V16, P368, DOI 10.1038/ng0897-368; Gustavsson P, 1998, AM J HUM GENET, V63, P1388, DOI 10.1086/302100; Gustavsson P, 1997, J MED GENET, V34, P779, DOI 10.1136/jmg.34.9.779; HALPERIN DS, 1989, AM J PEDIAT HEMATOL, V11, P380; HART K, 1993, MECH DEVELOP, V43, P101, DOI 10.1016/0925-4773(93)90028-V; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HASHIMOTO S, 1994, IMMUNOGENETICS, V40, P287; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Janov AJ, 1996, MEDICINE, V75, P77, DOI 10.1097/00005792-199603000-00004; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; KONDOH N, 1992, CANCER RES, V52, P791; MCGUCKIN CP, 1995, BRIT J HAEMATOL, V89, P457, DOI 10.1111/j.1365-2141.1995.tb08349.x; Meyuhas Oded, 1996, V30, P363; MUGISHIMA H, 1995, BONE MARROW TRANSPL, V15, P55; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; PETTERSSON M, 1995, BLOOD, V86, P2747; Richards S., 1994, AUTOMATED DNA SEQUEN, P191; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; TSAI PH, 1989, BRIT J HAEMATOL, V73, P112, DOI 10.1111/j.1365-2141.1989.tb00229.x; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; Willig T N, 1998, Curr Opin Hematol, V5, P109; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; WOOL IG, 1996, RIBOSOMAL RNA GROUP, P153; Young N. S., 1994, APLASTIC ANEMIA ACQU	43	616	635	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					169	175		10.1038/5951	http://dx.doi.org/10.1038/5951			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988267				2022-12-27	WOS:000078399500017
J	Jimenez, GS; Nister, M; Stommel, JM; Beeche, M; Barcarse, EA; Zhang, XQ; O'Gorman, S; Wahl, GM				Jimenez, GS; Nister, M; Stommel, JM; Beeche, M; Barcarse, EA; Zhang, XQ; O'Gorman, S; Wahl, GM			A transactivation-deficient mouse model provides insights into Trp53 regulation and function	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; NUCLEAR EXPORT; P53 PROTEIN; APOPTOSIS; MDM2; PATHWAY; MICE	The gene Trp53 is among the most frequently mutated and studied genes in human cancer, but the mechanisms by which it suppresses tumour formation remain unclear. We generated mice with an allele encoding changes at Leu25 and Trp26, known to be essential for transcriptional transactivation and Mdm2 binding, to enable analyses of Trp53 structure and function in vivo. The mutant Trp53 was abundant, its level was not affected by DNA damage and it bound DNA constitutively; however, it showed defects in cell-cycle regulation and apoptosis. Both mutant and Trp53-null mouse embryonic fibroblasts (MEFs) were readily transformed by oncogenes, and the corresponding mice were prone to tumours. We conclude that the determining pathway for Trp53 tumour-suppressor function in mice requires the transactivation domain.	Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Uppsala, Rudbeck Lab, Dept Genet & Pathol, Tumor Biol Lab, Uppsala, Sweden; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Salk Institute; Uppsala University; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA.		Stommel, Jayne M/M-3439-2017					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wahl GM, 1997, CANCER SURV, V29, P183; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	181	187	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					37	43		10.1038/79152	http://dx.doi.org/10.1038/79152			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973245				2022-12-27	WOS:000089078000014
J	Huttley, GA; Easteal, S; Southey, MC; Tesoriero, A; Giles, GG; McCredie, MRE; Hopper, JL; Venter, DJ				Huttley, GA; Easteal, S; Southey, MC; Tesoriero, A; Giles, GG; McCredie, MRE; Hopper, JL; Venter, DJ		Australian Breast Canc Family Stud	Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees	NATURE GENETICS			English	Article							BREAST-CANCER; NUCLEOTIDE SUBSTITUTION; SEQUENCE VARIANTS; AUSTRALIAN WOMEN; OVARIAN-CANCER; MEIOTIC CELLS; GENE BRCA1; POPULATION; SELECTION; SUSCEPTIBILITY	Mutations in BRCA1 (ref. 1) confer an increased risk of female breast cancer(2). In a genome-wide scan of linkage disequilibrium (LD), a high revel of LD was detected among microsatellite markers flanking BRCA1 (ref. 3), raising the prospect that positive natural selection may have acted on this gene. We have used the predictions of evolutionary genetic theory to investigate this further. Using phylogeny-based maximum likelihood analysis of the BRCA1 sequences from primates and other mammals, we found that the ratios of replacement to silent nucleotide substitutions on the human and chimpanzee lineages were not different from one another (P=0.8), were different from those of other primate lineages (P=0.004) and were greater than 1 (P=0.04). This is consistent with the historic occurrence of positive darwinian selection pressure on the BRCA1 protein in the human and chimpanzee lineages. Analysis of genetic variation in a sample of female Australians of Northern European origin showed evidence for Hardy-Weinberg (HW) disequilibrium at polymorphic sites in BRCA1, consistent with the possibility that natural selection is affecting genotype frequencies in modern Europeans. The clustering of between-species variation in the region of the gene encoding the RAD51-interaction domain of BRCA1 suggests the maintenance of genomic integrity as a possible target of selection.	Australian Natl Univ, John Curtin Sch Med Res, Human Genet Grp, Canberra, ACT 2601, Australia; Peter MacCallum Canc Inst, Dept Pathol, E Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Res Dept, E Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia; New S Wales Canc Council, Canc & Epidemiol Res Unit, Woolloomooloo, NSW, Australia; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Melbourne, Ctr Genet Epidemiol, Carlton, Vic, Australia	Australian National University; John Curtin School of Medical Research; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Cancer Council New South Wales; University of Otago; University of Melbourne	Huttley, GA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Human Genet Grp, Canberra, ACT 2601, Australia.		Huttley, Gavin A/G-5169-2015	Huttley, Gavin A/0000-0001-7224-2074; Giles, Graham/0000-0003-4946-9099; Southey, Melissa/0000-0002-6313-9005; Easteal, Simon/0000-0002-0462-502X				Batterham P, 1996, BIOESSAYS, V18, P841, DOI 10.1002/bies.950181011; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Clark AG, 2000, NATURE, V403, P261, DOI 10.1038/35002236; Dunning AM, 1997, HUM MOL GENET, V6, P285, DOI 10.1093/hmg/6.2.285; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hopper JL, 1994, BREAST, V3, P79; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Huttley GA, 1999, GENETICS, V152, P1711; Kimura M., 1983, NEUTRAL THEORY MOL E; KREITMAN M, 1995, ANNU REV ECOL SYST, V26, P403, DOI 10.1146/annurev.es.26.110195.002155; LEWONTIN RC, 1959, EVOLUTION, V13, P561, DOI 10.2307/2406136; Li W. H, 1997, MOL EVOLUTION; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUSE SV, 1994, MOL BIOL EVOL, V11, P715; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Southey MC, 1999, BRIT J CANCER, V79, P34, DOI 10.1038/sj.bjc.6690008; Southey MC, 1998, J NATL CANCER I, V90, P532, DOI 10.1093/jnci/90.7.532; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957	33	90	97	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					410	413		10.1038/78092	http://dx.doi.org/10.1038/78092			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932184				2022-12-27	WOS:000088615000015
J	Dammann, R; Li, C; Yoon, JH; Chin, PL; Bates, S; Pfeifer, GP				Dammann, R; Li, C; Yoon, JH; Chin, PL; Bates, S; Pfeifer, GP			Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3	NATURE GENETICS			English	Article							CANCER; SEARCH; GENERATION; DELETIONS; CARCINOMA; GENES	Allelic loss at the short arm of chromosome 3 is one of the most common and earliest events in the pathogenesis of lung cancer, and is observed in more than 90% of small-cell lung cancers (SCLCs) and in 50-80% of non-small-cell lung cancers(1,2) (NSCLCs). Frequent and early loss of heterozygosity and the presence of homozygous deletions suggested a critical role of the region 3p21.3 in tumorigenesis(2-4) and a region of common homozygous deletion in 3p21.3 was narrowed to 120 kb (ref. 5). Several putative tumour-suppressor genes located at 3p21 have been characterized, but none of these genes appear to be altered in lung cancer. Here we describe the cloning and characterization of a human RAS effector homologue (RASSF1) located in the 120-kb region of minimal homozygous deletion. We identified three transcripts, A, B and C, derived from alternative splicing and promoter usage. The major transcripts A and C were expressed in all normal tissues. Transcript A was missing in all SCLC cell lines analysed and in several other cancer cell lines. loss of expression was correlated with methylation of the CpG-island promoter sequence of RASSF1A. The promoter was highly methylated in 24 of 60 (40%) primary lung tumours, and 4 of 41 tumours analysed carried missense mutations. Re-expression of transcript A in lung carcinoma cells reduced colony formation, suppressed anchorage-independent growth and inhibited tumour formation in nude mice. These characteristics indicate a potential role for RASSF1A asa lung tumour suppresor gene.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.		jia, xu/A-8386-2016					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baylin SB, 1998, ADV CANCER RES, V72, P141; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349	16	913	1048	0	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					315	319		10.1038/77083	http://dx.doi.org/10.1038/77083			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888881				2022-12-27	WOS:000087920900021
J	Bolino, A; Muglia, M; Conforti, FL; LeGuern, E; Salih, MAM; Georgiou, DM; Christodoulou, K; Hausmanowa-Petrusewicz, I; Mandich, P; Schenone, A; Gambardella, A; Bono, F; Quattrone, A; Devoto, M; Monaco, AP				Bolino, A; Muglia, M; Conforti, FL; LeGuern, E; Salih, MAM; Georgiou, DM; Christodoulou, K; Hausmanowa-Petrusewicz, I; Mandich, P; Schenone, A; Gambardella, A; Bono, F; Quattrone, A; Devoto, M; Monaco, AP			Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2	NATURE GENETICS			English	Article							FOLDED MYELIN SHEATHS; DEMYELINATING NEUROPATHY; FAMILY; YEAST		Wellcome Trust Ctr Human Genet, Oxford, England; Natl Res Council, Inst Expt Med & Biotechnol, Cosenza, Italy; Hop La Pitie Salpetriere, Paris, France; King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia; Cyprus Inst Neurol & Genet, Mol Genet Unit D, Nicosia, Cyprus; Polish Acad Sci, MRC, Neuromuscular Unit, Warsaw, Poland; Univ Genoa, Dipartimento Sci Neurol & Riabilitaz, Genoa, Italy; Univ Genoa, Dipartimento Oncol Biol & Genet, Genoa, Italy; Univ Catanzaro, Inst Neurol, Catanzaro, Italy	University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; King Saud University; Polish Academy of Sciences; University of Genoa; University of Genoa; Magna Graecia University of Catanzaro	Monaco, AP (corresponding author), Wellcome Trust Ctr Human Genet, Oxford, England.		Salih, Mustafa/C-1222-2014; Bolino, Alessandra/AAN-5442-2020; Devoto, Marcella/AAP-7595-2021; schenone, angelo/I-3194-2012; Bolino, Alessandra/O-2933-2013; QUATTRONE, Aldo/A-6734-2016; Gambardella, Antonio/F-5295-2012; Conforti, Francesca Luisa/AAT-2428-2020; Monaco, Anthony P/A-4495-2010; Mandich, Paola/CAG-1105-2022; Conforti, Francesca Luisa/K-8877-2016	Salih, Mustafa/0000-0002-4379-2111; Bolino, Alessandra/0000-0002-8980-4878; schenone, angelo/0000-0002-2604-7830; QUATTRONE, Aldo/0000-0003-2001-957X; Gambardella, Antonio/0000-0001-7384-3074; Monaco, Anthony P/0000-0001-7480-3197; Mandich, Paola/0000-0003-3123-3512; Conforti, Francesca Luisa/0000-0001-8364-1783; DEVOTO, MARCELLA/0000-0002-4431-5114; MUGLIA, MARIA/0000-0001-6413-3935; Christodoulou, Kyproula/0000-0002-0622-7594	Telethon [293/B] Funding Source: Medline	Telethon(Fondazione Telethon)		Ben Othmane K, 1999, GENOMICS, V62, P344, DOI 10.1006/geno.1999.6028; Bolino A, 2000, GENOMICS, V63, P271, DOI 10.1006/geno.1999.6088; Bolino A, 1996, HUM MOL GENET, V5, P1051, DOI 10.1093/hmg/5.7.1051; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Gambardella A, 1997, BRAIN, V120, P2113, DOI 10.1093/brain/120.11.2113; Gambardella A, 1998, NEUROLOGY, V50, P799, DOI 10.1212/WNL.50.3.799; Hunter T, 1998, NAT GENET, V18, P303; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Laporte J, 1998, HUM MOL GENET, V7, P1703, DOI 10.1093/hmg/7.11.1703; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Nakagawa M, 1999, NEUROLOGY, V52, P1271, DOI 10.1212/WNL.52.6.1271; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A	12	356	376	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					17	19		10.1038/75542	http://dx.doi.org/10.1038/75542			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802647				2022-12-27	WOS:000086884000009
J	Wagner, A				Wagner, A			Robustness against mutations in genetic networks of yeast	NATURE GENETICS			English	Article							FUNCTIONAL REDUNDANCY; SELECTIVE NEUTRALITY; EVOLUTION; GENOME; TRANSCRIPTION; TRANSPOSITION; DUPLICATION; DATABASE; FITNESS	There are two principal mechanisms that are responsible for the ability of an organism's physiological and developmental processes to compensate for mutations. In the first, genes have overlapping functions, and loss-of-function mutations in one gene will have little phenotypic effect if there are one or more additional genes with similar functions. The second mechanism has its origin in interactions between genes with unrelated functions, and has been documented in metabolic and regulatory gene networks. Here I analyse, on a genome-wide scale, which of these mechanisms of robustness against mutations is more prevalent. I used functional genomics data from the yeast Saccharomyces cerevisiae to test hypotheses related to the following: if gene duplications are mostly responsible for robustness, then a correlation is expected between the similarity of two duplicated genes and the effect of mutations in one of these genes. Wry results demonstrate that interactions among unrelated genes are the major cause of robustness against mutations. This type of robustness is probably an evolved response of genetic networks to stabilizing selection.	Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Santa Fe Inst, Albuquerque, NM USA	University of New Mexico; The Santa Fe Institute	Wagner, A (corresponding author), Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.	wagnera@unm.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRADSHAW VA, 1989, MOL GEN GENET, V218, P465, DOI 10.1007/BF00332411; CADIGAN KM, 1994, P NATL ACAD SCI USA, V91, P6324, DOI 10.1073/pnas.91.14.6324; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Comeron JM, 1995, J MOL EVOL, V41, P1152, DOI 10.1007/BF00173196; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; DUN RB, 1958, NATURE, V181, P1018, DOI 10.1038/1811018a0; DYKHUIZEN D, 1980, GENETICS, V96, P801; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; Fell D., 1997, UNDERSTANDING CONTRO; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; GONZALEZGAITAN M, 1994, P NATL ACAD SCI USA, V91, P8567, DOI 10.1073/pnas.91.18.8567; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HARTL DL, 1985, GENETICS, V111, P655; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Hubbard TJP, 1998, ACTA CRYSTALLOGR D, V54, P1147, DOI 10.1107/S0907444998009172; KACSER H, 1981, GENETICS, V97, P639; Kimura M., 1983, NEUTRAL THEORY MOL E; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; Nadeau JH, 1997, GENETICS, V147, P1259; PAQUIN CE, 1984, SCIENCE, V226, P53, DOI 10.1126/science.226.4670.53; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; RENDEL JM, 1959, EVOLUTION, V13, P425, DOI 10.1111/j.1558-5646.1959.tb03033.x; RENDEL JM, 1979, QUANTITATIVE GENETIC, P139; Rutherford SL, 1998, MOL BIOL CELL, V9, p433A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Seoighe C, 1999, CURR OPIN MICROBIOL, V2, P548, DOI 10.1016/S1369-5274(99)00015-6; Seoighe C, 1998, P NATL ACAD SCI USA, V95, P4447, DOI 10.1073/pnas.95.8.4447; Smith V, 1997, SCIENCE, V275, P464; Sokal R. R, 1981, BIOMETRY; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; Thatcher JW, 1998, P NATL ACAD SCI USA, V95, P253, DOI 10.1073/pnas.95.1.253; Waddington C. H., 1959, STRATEGY GENES; Wagner A, 1999, J EVOLUTION BIOL, V12, P1, DOI 10.1046/j.1420-9101.1999.00008.x; Wagner A, 1996, EVOLUTION, V50, P1008, DOI 10.1111/j.1558-5646.1996.tb02342.x; Wagner A, 2000, GENETICS, V154, P1389; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]; Wang YK, 1996, NATURE, V379, P823, DOI 10.1038/379823a0; WATERMAN MS, 1984, B MATH BIOL, V46, P473, DOI 10.1007/BF02459498; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	48	301	308	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					355	361		10.1038/74174	http://dx.doi.org/10.1038/74174			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742097				2022-12-27	WOS:000086192800012
J	Yang, JH; Boerm, M; McCarty, M; Bucana, C; Fidler, IJ; Zhuang, Y; Su, B				Yang, JH; Boerm, M; McCarty, M; Bucana, C; Fidler, IJ; Zhuang, Y; Su, B			Mekk3 is essential for early embryonic cardiovascular development	NATURE GENETICS			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; TRANSCRIPTION FACTOR MEF2C; BLOOD-VESSEL FORMATION; MOLECULAR-CLONING; IN-VIVO; VASCULOGENESIS; ANGIOGENESIS; PATHWAYS; MORPHOGENESIS	The early development of blood vessels consists of two phases, vasculogenesis and angiogenesis, which involve distinct and also overlapping molecular regulators, but the intracellular signal transduction pathways involved in these processes have not been well defined(1-4). We disrupted Map3k3 (also known as Mekk3), which encodes Mekk3, a member of the Mekk/Ste11 family(5,6). in mice, Map3k3(-/-) embryos died at approximately embryonic day (E) 11, displaying disruption of blood vessel development and the structural integrity of the yolk sac. Angiogenesis was blocked at approximately E9.5 in mutant embryos. Map3k3 disruption did not alter the expression of the genes encoding Vegf-1, angiopoietin or their receptors. The development of embryonic, but not maternal, blood vessels in the placentas of Map3k3(-/-) embryos was impaired, revealing an intrinsic defect in Map3k3(-/-) endothelial cells. Moreover, Mekk3 activated myocyte-specific enhancer factor 2C (Mef2c), a transcription factor crucial for early embryonic cardiovascular development through the p38 mitogen-activated protein kinase (Mapk) cascade. We conclude that Mekk3 is necessary for blood vessel development and may be a possible target for drugs that control angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Duke University	Su, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.			zhuang, yuan/0000-0002-2964-3654				Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9	23	165	176	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					309	313		10.1038/73550	http://dx.doi.org/10.1038/73550			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700190				2022-12-27	WOS:000085590600027
J	Das Gupta, R; Kolodner, RD				Das Gupta, R; Kolodner, RD			Novel dominant mutations in Saccharomyces cerevisiae MSH6	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; HMUTS-ALPHA; GENE; DNA; MUTAGENESIS; ALLELES; HMSH2; PMS2	Inherited mutations in the mismatch repair (MMR) genes MSH2 and MLH1 are found in most hereditary nonpolyposis colon cancer (HNPCC) patients studied(1). Eukaryotic MMR uses two partially redundant mispair-recognition complexes, Msh2p -Msh6p and Msh2p-Msh3p (ref. 2). Inactivation of MSH2 causes high rates of accumulation of both base-substitution and frameshift mutations. Mutations in MSH6 or MSH3 cause partial defects in MMR, with inactivation of MSH6 resulting in high rates of base-substitution mutations and low rates of frameshift mutations; inactivation of MSH3 results in low rates of frameshift mutations. These different mutator phenotypes provide an explanation for the observation that MSH2 mutations are common in HNPCC families, whereas mutations in MSH3 and MSH6 are rare(1,3-5). We have identified novel missense mutations in Saccharomyces cerevisiae MSH6 that appear to inactivate both Msh2p-Msh6p- and Msh2p-Msh3p-dependent MMR. Our work suggests that such mutations may underlie some cases of inherited cancer susceptibility similar to those caused by MSH2 mutations.	Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med & Canc Ctr, Sch Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med & Canc Ctr, Sch Med, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama Y, 1997, CANCER RES, V57, P3920; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 1999, NUCLEIC ACIDS RES, V27, P736, DOI 10.1093/nar/27.3.736; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jeyaprakash A, 1996, MOL CELL BIOL, V16, P3008; JEYAPRAKASH A, 1994, MUTAT RES LETT, V325, P21, DOI 10.1016/0165-7992(94)90023-X; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolodner RD, 1999, CANCER RES, V59, P5068; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rose MD., 1990, METHODS YEAST GENETI; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; Umezu K, 1998, GENETICS, V148, P989; Verma L, 1999, J MED GENET, V36, P678; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; WILLIAMSON MS, 1985, GENETICS, V110, P609; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612	27	51	52	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					53	56		10.1038/71684	http://dx.doi.org/10.1038/71684			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615127				2022-12-27	WOS:000084609200015
J	Momeni, P; Glockner, G; Schmidt, O; von Holtum, D; Albrecht, B; Gillessen-Kaesbach, G; Hennekam, R; Meinecke, P; Zabel, B; Rosenthal, A; Horsthemke, B; Ludecke, HJ				Momeni, P; Glockner, G; Schmidt, O; von Holtum, D; Albrecht, B; Gillessen-Kaesbach, G; Hennekam, R; Meinecke, P; Zabel, B; Rosenthal, A; Horsthemke, B; Ludecke, HJ			Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I	NATURE GENETICS			English	Article							LANGER-GIEDION SYNDROME; LOCALIZATION; SEQUENCE; EXT1	Tricho-rhino-phalangeal syndrome type I (TRPS I, MIM 190350) is a malformation syndrome characterized by craniofacial and skeletal abnormalities and is inherited in an autosomal dominant manner(1). TRPS I patients have sparse scalp hair, a bulbous tip of the nose, a long flat philtrum, a thin upper vermilion border and protruding ears. Skeletal abnormalities include cone-shaped epiphyses at the phalanges, hip malformations and short stature. We assigned TRPS1 to human chromosome 8q24. It maps proximal of EXT1, which is affected in a subgroup of patients with multiple cartilaginous exostoses and deleted in all patients with TRPS type II (TRPS II, or Langer-Giedion syndrome, MIM 150230; refs 2-5). We have positionally cloned a gene that spans the chromosomal breakpoint of two patients with TRPS I and is deleted in five patients with TRPS I and an interstitial deletion(4,6). Northern-blot analyses revealed transcripts of 7 and 10.5 kb. TRPS1 has seven exons and an ORF of 3.843 bp. The predicted protein sequence has two potential nuclear localization signals and an unusual combination of different zinc-finger motifs, including IKAROS-like and GATA-binding sequences. We identified six different nonsense mutations in ten unrelated patients. Our findings suggest that haploinsufficiency for this putative transcription factor causes TRPS I.	Univ Essen Gesamthsch Klinikum, Inst Human Genet, D-4300 Essen, Germany; Inst Mol Biotechnol, Abt Genomanal, Jena, Germany; Univ Amsterdam, Dept Clin Genet & Pediat, Amsterdam, Netherlands; Altonaer Kinderkrankenhaus, Abt Med Genet, Hamburg, Germany; Klinikum Univ Mainz, Kinderklin & Poliklin, Mainz, Germany	University of Duisburg Essen; University of Amsterdam; University of Hamburg; University Medical Center Hamburg-Eppendorf	Ludecke, HJ (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Human Genet, D-4300 Essen, Germany.	hj.luedecke@uni-essen.de	Glöckner, Gernot/A-7800-2010	Glöckner, Gernot/0000-0002-9061-1061				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Antonarakis SE, 1998, HUM MUTAT, V11, P1; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Dai KS, 1998, J MOL CELL CARDIOL, V30, P2365, DOI 10.1006/jmcc.1998.0797; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GIEDION A, 1973, HELV PAEDIATR ACTA, V28, P249; Glockner G, 1998, GENOME RES, V8, P1060; HOU J, 1995, GENOMICS, V29, P87, DOI 10.1006/geno.1995.1218; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; Kalff-Suske M, 1999, HUM MOL GENET, V8, P1769, DOI 10.1093/hmg/8.9.1769; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LUDECKE HJ, 1995, HUM MOL GENET, V4, P31, DOI 10.1093/hmg/4.1.31; LUDECKE HJ, IN PRESS HUM GENET; Nardmann J, 1997, HUM GENET, V99, P638, DOI 10.1007/s004390050420; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; YI Y, 1999, HUM MOL GENET, V8, P533	19	217	234	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					71	74		10.1038/71717	http://dx.doi.org/10.1038/71717			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615131				2022-12-27	WOS:000084609200019
J	Park, F; Ohashi, K; Chiu, W; Naldini, L; Kay, MA				Park, F; Ohashi, K; Chiu, W; Naldini, L; Kay, MA			Efficient lentiviral transduction of liver requires cell cycling in vivo	NATURE GENETICS			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MEDIATED GENE-TRANSFER; IN-VIVO; VECTOR; INTEGRATION; EXPRESSION; DELIVERY; MICE; HEPATOCYTES; PERSISTENT	Human-immunodeficiency-virus (HIV)-based lentiviral vectors are a promising tool for in vivo gene therapy(1). Unlike Moloney-murine-leukaemia-based retroviruses (MLV), lentiviruses are believed to stably transduce quiescent (non-cycling) cells in various organs(2-6). No previous studies, however, have directly established the cell-cycle status of any transduced cell type at the time of vector administration in vivo. In vitro studies using wild-type HIV or HIV-based vectors have shown that, in some cases, cell-cycle activation is required for infection, even though cellular mitosis is not an absolute requirement for integration(7-9). Even if the block in reverse transcription is overcome in quiescent T cells, productive infection by HIV cannot be rescued in the absence of cell-cycle activation(7,10). The potential use of these vectors for gene therapy prompted our study, which establishes a cell-cycle requirement for efficient transduction of hepatocytes in vivo.	Stanford Univ, Dept Pediat & Genet, Stanford, CA 94305 USA; Univ Turin, Sch Med, Canc Res Inst, Turin, Italy	Stanford University; University of Turin	Kay, MA (corresponding author), Stanford Univ, Dept Pediat & Genet, Stanford, CA 94305 USA.		Naldini, Luigi/E-9083-2012; Park, Frank/I-4590-2019	Park, Frank/0000-0003-2324-2937; Kay, Mark/0000-0002-2799-2615; NALDINI, Luigi/0000-0002-7835-527X	NHLBI NIH HHS [R01-HL53682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreadis ST, 1997, J VIROL, V71, P7541, DOI 10.1128/JVI.71.10.7541-7548.1997; Blomer U, 1997, J VIROL, V71, P6641; BRANCHEREAU S, 1994, HUM GENE THER, V5, P803, DOI 10.1089/hum.1994.5.7-803; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Gao CH, 1999, HUM GENE THER, V10, P911, DOI 10.1089/10430349950018319; Higgins GM, 1931, ARCH PATHOL, V12, P186; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Korin YD, 1999, J VIROL, V73, P6526, DOI 10.1128/JVI.73.8.6526-6532.1999; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; Liu ML, 1996, J VIROL, V70, P2497, DOI 10.1128/JVI.70.4.2497-2502.1996; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Patijn GA, 1998, HEPATOLOGY, V28, P707, DOI 10.1002/hep.510280317; Poeschla E, 1996, P NATL ACAD SCI USA, V93, P11395, DOI 10.1073/pnas.93.21.11395; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; Sutton RE, 1999, J VIROL, V73, P3649, DOI 10.1128/JVI.73.5.3649-3660.1999; YOSHIMURA S, 1989, TRANSPL P, V21, P911; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	26	172	181	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					49	52		10.1038/71673	http://dx.doi.org/10.1038/71673			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615126				2022-12-27	WOS:000084609200014
J	Potocki, L; Chen, KS; Park, SS; Osterholm, DE; Withers, MA; Kimonis, V; Summers, AM; Meschino, WS; Anyane-Yeboa, K; Kashork, CD; Shaffer, LG; Lupski, JR				Potocki, L; Chen, KS; Park, SS; Osterholm, DE; Withers, MA; Kimonis, V; Summers, AM; Meschino, WS; Anyane-Yeboa, K; Kashork, CD; Shaffer, LG; Lupski, JR			Molecular mechanism for duplication 17p11.2 - the homologous recombination reciprocal of the Smith-Magenis microdeletion	NATURE GENETICS			English	Article							MARIE-TOOTH-DISEASE; GENE; TYPE-1A; REARRANGEMENTS; BREAKPOINTS; DELETIONS; CMT1A; HNPP	Recombination between repeated sequences at Various loci of the human genome are known to give rise to DNA rearrangements associated with many genetic disorders'. Perhaps the most extensively characterized genomic region prone to rearrangement is 17p12, which is associated with the peripheral neuropathies, hereditary neuropathy with liability to pressure palsies (HNPP) and Charcot-Marie-Tooth disease type 1A (CMT1A; ref. 2). Homologous recombination between 24-kb flanking repeats, termed CMT1A-REPs, results in a 1.5-Mb deletion that is associated with HNPP, and the reciprocal duplication product is associated with CMT1A (ref. 2). Smith-Magenis syndrome (SMS) is a multiple congenital anomalies, mental retardation syndrome associated with a chromosome 17 microdeletion, del(17)(p11.2p11.2) (refs 3,4). Most patients (>90%) carry deletions of the same genetic markers and define a common deletion(5-7). We report seven unrelated patients with de novo duplications of the same region deleted in SMS. A unique junction fragment, of the same apparent size, was identified in each patient by pulsed field gel electrophoresis (PFGE). Further molecular analyses suggest that the de novo 17p11.2 duplication is preferentially paternal in origin, arises from unequal crossing over due to homologous recombination between flanking repeat gene clusters and probably represents the reciprocal recombination product of the SMS deletion. The clinical phenotype resulting from duplication [dup(17)(p11.2p11.2)] is milder than that associated with deficiency of this genomic region. This mechanism of reciprocal deletion and duplication via homologous recombination may not only pertain to the 17p11.2 region, but may also be common to other regions of the genome where interstitial microdeletion syndromes have been defined.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Hosp, Houston, TX 77030 USA; So Illinois Univ, Sch Med, Dept Pediat, Springfield, IL USA; N York Gen Hosp, Dept Genet, Toronto, ON, Canada; Columbia Univ, Dept Pediat, New York, NY 10027 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Southern Illinois University System; Southern Illinois University; University of Toronto; University Toronto Affiliates; North York General Hospital; Columbia University	Lupski, JR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Park, Sung Sup/J-2756-2012; Chen, Ken-Shiung/A-2204-2011	Anyane-Yeboa, Kwame/0000-0002-4977-9719; Park, Sung Sup/0000-0003-3754-4848	NCI NIH HHS [P01CA75719] Funding Source: Medline; NICHD NIH HHS [K08HD01149, HD2406402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA075719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos-Landgraf JM, 1999, AM J HUM GENET, V65, P370, DOI 10.1086/302510; Buiting K, 1998, CYTOGENET CELL GENET, V81, P247, DOI 10.1159/000015039; CHEN HK, 1995, BONE, V17, P175; Chen K-S, 1996, MENTAL RETARD DEV DI, V2, P122; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Christian SL, 1999, HUM MOL GENET, V8, P1025, DOI 10.1093/hmg/8.6.1025; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; Elsea SH, 1997, CYTOGENET CELL GENET, V79, P276, DOI 10.1159/000134742; GREENBERG F, 1991, AM J HUM GENET, V49, P1207; Greenberg F, 1996, AM J MED GENET, V62, P247, DOI 10.1002/(SICI)1096-8628(19960329)62:3<247::AID-AJMG9>3.3.CO;2-9; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Juyal RC, 1996, AM J HUM GENET, V58, P998; KOZMA C, 1991, AM J MED GENET, V41, P446, DOI 10.1002/ajmg.1320410413; Lopes J, 1997, NAT GENET, V17, P136, DOI 10.1038/ng1097-136; Lupski JR, 1998, MOL MED, V4, P3, DOI 10.1007/BF03401724; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Osborne LR, 1997, GENOMICS, V45, P402, DOI 10.1006/geno.1997.4923; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; Pereira MM, 1996, J SOL-GEL SCI TECHN, V7, P59, DOI 10.1007/BF00401884; Potocki L, 1999, AM J HUM GENET, V64, P471, DOI 10.1086/302240; Repetto GR, 1998, AM J MED GENET, V79, P82, DOI 10.1002/(SICI)1096-8628(19980901)79:2<82::AID-AJMG2>3.0.CO;2-P; Roa BB, 1996, HUM GENET, V97, P642; Shaffer LG, 1997, AM J MED GENET, V69, P325, DOI 10.1002/(SICI)1096-8628(19970331)69:3<325::AID-AJMG20>3.0.CO;2-S; Zhao Q, 1998, GENOMICS, V49, P394, DOI 10.1006/geno.1998.5285	27	238	243	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					84	87		10.1038/71743	http://dx.doi.org/10.1038/71743			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615134	Green Published			2022-12-27	WOS:000084609200022
J	Quintana-Murci, L; Semino, O; Bandelt, HJ; Passarino, G; McElreavey, K; Santachiara-Benerecetti, AS				Quintana-Murci, L; Semino, O; Bandelt, HJ; Passarino, G; McElreavey, K; Santachiara-Benerecetti, AS			Genetic evidence of an early exit of Homo sapiens sapiens from Africa through eastern Africa	NATURE GENETICS			English	Article							HUMAN MITOCHONDRIAL-DNA; MTDNA VARIATION; CONTROL REGION; NEW-WORLD; POPULATIONS; ORIGIN; POLYMORPHISMS; DIVERSITY; SEQUENCE; EVOLUTION	The out-of-Africa scenario(1) has hitherto provided little evidence for the precise route by which modern humans left Africa. Two major routes of dispersal have been hypothesized: one through North Africa into the Levant, documented by fossil remains(2), and one through Ethiopia along South Asia, for which little, if any, evidence exists(3). Mitochondrial DNA (mtDNA) can be used to trace maternal ancestry, The geographic distribution and variation of mtDNAs can be highly informative in defining potential range expansions and migration routes in the distant past. The mitochondrial haplogroup M, first regarded as an ancient marker of East-Asian origin(4,5), has been found at high frequency in India(6) and Ethiopia(7), raising the question of its origin. (A haplogroup is a group of haplotypes that share some sequence variations.) Its variation and geographical distribution suggest that Asian haplogroup M separated from eastern-African haplogroup M more than 50.000 years ago. Two other variants (489C and 10873C) also support a single origin of haplogroup M in Africa. These findings, together with the virtual absence of haplogroup M in the Levant and its high frequency in the South-Arabian peninsula, render Rn the first genetic indicator for the hypothesized exit route from Africa through eastern Africa/western India. This was possibly the only successful early dispersal event of modern humans out of Africa.	Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy; Univ Hamburg, Math Seminar, D-2000 Hamburg, Germany; Univ Calabria, Dipartimento Biol Cellulare, Calabria, Italy; Inst Pasteur, Unite Immunogenet Humaine, Paris, France	University of Pavia; University of Hamburg; University of Calabria; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Santachiara-Benerecetti, AS (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol, Via Palestro 3, I-27100 Pavia, Italy.		Quintana-Murci, Lluis/AAB-7468-2022; Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284; Quintana-Murci, Lluis/0000-0003-2429-6320; SEMINO, Ornella/0000-0002-9675-9403				BANDELT HJ, 1995, GENETICS, V141, P743; Brown MD, 1998, AM J HUM GENET, V63, P1852, DOI 10.1086/302155; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHEN YS, 1995, AM J HUM GENET, V57, P133; CorteReal HBSM, 1996, ANN HUM GENET, V60, P331, DOI 10.1111/j.1469-1809.1996.tb01196.x; EXCOFFIER L, 1989, AM J HUM GENET, V44, P73; Forster P, 1996, AM J HUM GENET, V59, P935; GRAVEN L, 1995, MOL BIOL EVOL, V12, P334; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Jin L, 1999, P NATL ACAD SCI USA, V96, P3796, DOI 10.1073/pnas.96.7.3796; Kolman CJ, 1996, GENETICS, V142, P1321; Krings M, 1999, AM J HUM GENET, V64, P1166, DOI 10.1086/302314; Lahr Marta Mirazon, 1994, Evolutionary Anthropology, V3, P48, DOI 10.1002/evan.1360030206; LEWIN R, 1987, SCIENCE, V237, P1292, DOI 10.1126/science.3114877; Lutz S, 1998, INT J LEGAL MED, V111, P67, DOI 10.1007/s004140050117; Lutz S, 1999, INT J LEGAL MED, V112, P145; Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204; MOUNTAIN JL, 1995, AM J HUM GENET, V56, P979; OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z; OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B; Passarino G, 1996, AM J HUM GENET, V59, P927; Passarino G, 1998, AM J HUM GENET, V62, P420, DOI 10.1086/301702; Rando JC, 1998, ANN HUM GENET, V62, P531, DOI 10.1046/j.1469-1809.1998.6260531.x; Schurr TG, 1999, AM J PHYS ANTHROPOL, V108, P1, DOI 10.1002/(SICI)1096-8644(199901)108:1<1::AID-AJPA1>3.0.CO;2-1; Starikovskaya YB, 1998, AM J HUM GENET, V63, P1473, DOI 10.1086/302087; STRINGER CB, 1989, NATURE, V338, P756, DOI 10.1038/338756a0; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Torroni A, 1998, AM J HUM GENET, V62, P1137, DOI 10.1086/301822; TORRONI A, 1993, AM J HUM GENET, V53, P563; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Watson E, 1997, AM J HUM GENET, V61, P691, DOI 10.1086/515503	31	371	383	0	90	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					437	441		10.1038/70550	http://dx.doi.org/10.1038/70550			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581031				2022-12-27	WOS:000084023900020
J	Lyko, F; Ramsahoye, BH; Kashevsky, H; Tudor, M; Mastrangelo, MA; Orr-Weaver, TL; Jaenisch, R				Lyko, F; Ramsahoye, BH; Kashevsky, H; Tudor, M; Mastrangelo, MA; Orr-Weaver, TL; Jaenisch, R			Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila	NATURE GENETICS			English	Article							SEQUENCE SPECIFICITY; EUKARYOTIC DNA; BINDING; EXPRESSION; CELLS; GENE; HYPOMETHYLATION; TRANSCRIPTION; PURIFICATION; ACTIVATION		Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Wales Coll Med, Dept Haematol, Cardiff CF4 4XN, S Glam, Wales; MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Cardiff University; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Tudor, Matthew/0000-0001-8766-195X	NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NIGMS NIH HHS [R01 GM039341, GM39341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039341, R29GM039341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wines DR, 1996, CHROMOSOMA, V104, P332, DOI 10.1007/s004120050123; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	31	158	168	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					363	366		10.1038/15551	http://dx.doi.org/10.1038/15551			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545955				2022-12-27	WOS:000083792200030
J	Malecki, MT; Jhala, US; Antonellis, A; Fields, L; Doria, A; Orban, T; Saad, M; Warram, JH; Montminy, M; Krolewski, AS				Malecki, MT; Jhala, US; Antonellis, A; Fields, L; Doria, A; Orban, T; Saad, M; Warram, JH; Montminy, M; Krolewski, AS			Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus	NATURE GENETICS			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GENE; YOUNG; P300; DIFFERENTIATION; RECOGNITION; BINDING; REGION; DIMER		Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Krolewski, AS (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA.		Doria, Alessandro/H-9157-2018	Doria, Alessandro/0000-0002-3830-4304	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK047475] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36836, DK-47475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHRISTIE MR, 1990, J EXP MED, V172, P789, DOI 10.1084/jem.172.3.789; Doria A, 1999, DIABETES CARE, V22, P253, DOI 10.2337/diacare.22.2.253; Dupont S, 1999, DIABETOLOGIA, V42, P480, DOI 10.1007/s001250051182; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Furuta H, 1998, DIABETES, V47, P1356, DOI 10.2337/diabetes.47.8.1356; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; Ji LN, 1997, DIABETES, V46, P876, DOI 10.2337/diabetes.46.5.876; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Sharma A, 1999, MOL CELL BIOL, V19, P704; Tamimi R, 1996, GENOMICS, V34, P418, DOI 10.1006/geno.1996.0306; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yokoyama M, 1996, MOL BRAIN RES, V42, P135, DOI 10.1016/S0169-328X(96)00154-4; Yoon YS, 1998, NEUROSCI LETT, V251, P17, DOI 10.1016/S0304-3940(98)00490-X	25	424	465	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					323	328		10.1038/15500	http://dx.doi.org/10.1038/15500			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545951				2022-12-27	WOS:000083792200022
J	Zhong, S; Delva, L; Rachez, C; Cenciarelli, C; Gandini, D; Zhang, H; Kalantry, S; Freedman, LP; Pandolfi, PP				Zhong, S; Delva, L; Rachez, C; Cenciarelli, C; Gandini, D; Zhang, H; Kalantry, S; Freedman, LP; Pandolfi, PP			A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RAR alpha and T18 oncoproteins	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; GENE-PRODUCT; HISTONE ACETYLTRANSFERASE; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; THYROID-HORMONE; PROTEIN; EXPRESSION; TRANSACTIVATION	PML and Tif1a are fused to RARA and Braf, respectively, resulting in the production of PML-RAR alpha and Tif1 alpha-B-Raf (T18) oncoproteins. Here we show that PML, Tif1 alpha and RXR alpha/RAR alpha function together in a transcription complex that is dependent on retinoic acid (RA). We found that PML acts as a ligand-dependent coactivator of RXR alpha/RAR alpha. PML interacts with Tif1 alpha and CBP. In Pml(-/-) cells, the RA-dependent induction of genes such as RARB2 and the ability of Tif1 alpha and CBP to act as transcriptional coactivators on RA are impaired. We show that both PML and Tif1 alpha are growth suppressors required for the growth-inhibitory activity of RA. T18, similar to PML-RAR alpha, disrupts the RA-dependent activity of this complex in a dominant-negative manner resulting in a growth advantage. Our data define a new pathway for the control of cell growth and tumorigenesis, and provide a new model for the pathogenesis of acute promyelocytic leukaemia (APL).	Cornell Univ, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Cell Biol Program, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Grad Sch Med Sci, New York, NY USA	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org		DELVA, Laurent/0000-0002-1086-3964; Rachez, Christophe/0000-0001-8502-4738	NCI NIH HHS [CA74031, CA-08748, CA71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692, R01CA074031, R37CA071692, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boddy MN, 1996, ONCOGENE, V13, P971; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VOMBAUR E, 1995, EMBO J, V15, P110; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547	48	112	118	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					287	295		10.1038/15463	http://dx.doi.org/10.1038/15463			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610177				2022-12-27	WOS:000083792200016
J	Evans, MJ; Gurer, C; Loike, JD; Wilmut, I; Schnieke, AE; Schon, EA				Evans, MJ; Gurer, C; Loike, JD; Wilmut, I; Schnieke, AE; Schon, EA			Mitochondrial DNA genotypes in nuclear transfer-derived cloned sheep	NATURE GENETICS			English	Article							MATERNAL INHERITANCE; FETAL FIBROBLASTS; HUMAN OOCYTES; SEGREGATION; MTDNA; TRANSPLANTATION; MUTATION; DISEASE; EMBRYOS; GENOME	Eukaryotic cells contain two distinct genomes. One is located in the nucleus (nDNA) and is transmitted in a mendelian fashion, whereas the other is located in mitochondria (mtDNA) and is transmitted by maternal inheritance. Cloning of mammals(1-6) typically has been achieved via nuclear transfer, in which a donor somatic cell is fused by electoporation with a recipient enucleated oocyte. During this whole-cell electrofusion, nDNA as well as mtDNA ought to be transferred to the oocyte(7, 8). Thus, the cloned progeny should harbour mtDNAs from both the donor and recipient cytoplasms, resulting in heteroplasmy. Although the confirmation of nuclear transfer has been established using somatic cell-specific nDNA markers, no similar analysis of the mtDNA genotype has been reported. We report here the origin of the mtDNA in Dolly, the first animal cloned from an established adult somatic cell line, and in nine other nuclear transfer-derived sheep generated from fetal cells. The mtDNA of each of the ten nuclear-transfer sheep was derived exclusively from recipient enucleated oocytes, with no detectable contribution from the respective somatic donor cells. Thus, although these ten sheep are authentic nuclear clones, they are in fact genetic chimaeras, containing somatic cell-derived nuclear DNA but oocyte-derived mtDNA.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; PPL Therapeut, Roslin EH25 9PP, Midlothian, Scotland; Roslin Inst, Roslin EH25 9PP, Midlothian, Scotland	Columbia University; Columbia University; Columbia University; Columbia University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Schon, EA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.			Schnieke, Angelika/0000-0002-5761-9635; Evans, Matthew/0000-0002-4991-3877	NICHD NIH HHS [P01 HD032062, HD32062] Funding Source: Medline; NINDS NIH HHS [P01 NS011766, NS11766, R01 NS028828-10A1, NS28828] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, R01NS028828, P50NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AnkelSimons F, 1996, P NATL ACAD SCI USA, V93, P13859, DOI 10.1073/pnas.93.24.13859; BUCHANAN FC, 1993, MAMM GENOME, V4, P258, DOI 10.1007/BF00417432; CHEN X, 1995, AM J HUM GENET, V57, P239; CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269; Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889; Ferlin T, 1997, J PEDIATR-US, V131, P447, DOI 10.1016/S0022-3476(97)80074-1; GAERTIG J, 1988, J CELL SCI, V89, P253; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Meirelles FV, 1998, GENETICS, V148, P877; Meirelles FV, 1997, GENETICS, V145, P445; Meng L, 1997, BIOL REPROD, V57, P454, DOI 10.1095/biolreprod57.2.454; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831; RUBENSTEIN DS, 1995, CAMB Q HEALTHC ETHIC, V4, P316, DOI 10.1017/S0963180100006071; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Sekirina GG, 1997, ZYGOTE, V5, P97, DOI 10.1017/S0967199400003762; Shitara H, 1998, GENETICS, V148, P851; SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wood NJ, 1996, ANIM GENET, V27, P25, DOI 10.1111/j.1365-2052.1996.tb01173.x	30	169	199	2	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					90	93		10.1038/12696	http://dx.doi.org/10.1038/12696			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471506	Green Accepted			2022-12-27	WOS:000082337300023
J	Withers, DJ; Burks, DJ; Towery, HH; Altamuro, SL; Flint, CL; White, ME				Withers, DJ; Burks, DJ; Towery, HH; Altamuro, SL; Flint, CL; White, ME			Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling	NATURE GENETICS			English	Article							FACTOR-I RECEPTOR; ENDOCRINE PANCREAS; GROWTH-FACTORS; MICE; GENE; SUBSTRATE-2; EXPRESSION; APOPTOSIS; PHOSPHORYLATION; RAT	Insulin receptor substrates (Irs proteins) mediate the pleiotropic effects of insulin and Igf-l (insulin-like growth factor-1), including regulation of glucose homeostasis and cell growth and survival. We intercrossed mice heterozygous for two null alleles (Irs1(+/-) and Irs2(+/-)) and investigated growth and glucose metabolism in mice with viable genotypes. Our experiments revealed that Irs-1 and Irs-2 are critical for embryonic and post-natal growth, with Irs-l having the predominant role. By contrast, both Irs-l and Irs-2 function in peripheral carbohydrate metabolism, but Irs-2 has the major role in beta-cell development and compensation for peripheral insulin resistance. To establish a role for the Igf-l receptor in beta-cells, we intercrossed mice heterozygous for null alleles of Igf1r and Irs2. Our results reveal that Igf-l receptors promote beta-cell development and survival through the Irs-2 signalling pathway. Thus, Irs-2 integrates the effects of insulin in peripheral target tissues with Igf-l in pancreatic beta-cells to maintain glucose homeostasis.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, ME (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	morris.white@joslin.harvard.edu	Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521	NIDDK NIH HHS [DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bernal D, 1998, DIABETES, V47, P976, DOI 10.2337/diabetes.47.6.976; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GUZ Y, 1995, DEVELOPMENT, V121, P11; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LeRoith D, 1997, ENDOCRINE, V7, P103, DOI 10.1007/BF02778074; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Schuppin GT, 1998, DIABETES, V47, P1074, DOI 10.2337/diabetes.47.7.1074; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Vaisse C, 1997, DIABETES, V46, P1364, DOI 10.2337/diabetes.46.8.1364; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Velloso LA, 1995, FEBS LETT, V377, P353, DOI 10.1016/0014-5793(95)01370-9; WHITEHEAD M, 1994, I C S S, V8, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	36	443	465	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					32	40		10.1038/12631	http://dx.doi.org/10.1038/12631			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471495				2022-12-27	WOS:000082337300012
J	Zheng, BH; Sage, M; Cai, WW; Thompson, DM; Tavsanli, BC; Cheah, YC; Bradley, A				Zheng, BH; Sage, M; Cai, WW; Thompson, DM; Tavsanli, BC; Cheah, YC; Bradley, A			Engineering a mouse balancer chromosome	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; GENE; RECOMBINATION; MUTAGENESIS; GENOME; MAP	Balancer chromosomes are genetic reagents that are used in Drosophila melanogaster for stock maintenance and mutagenesis screens(1). Despite their utility, balancer chromosomes are rarely used in mice because they are difficult to generate using conventional methods. Here we describe the engineering of a mouse balancer chromosome with the Cre-loxP recombination system. The chromosome features a 24-centiMorgan (cM) inversion between Trp53 (also known as p53) and Wnt3 on mouse chromosome 11 that is recessive lethal and dominantly marked with a K14-Agouti transgene(2). When allelic to a wild-type chromosome, the inversion suppresses crossing over in the inversion interval, accompanied by elevated recombination in the flanking regions. The inversion functions as a balancer chromosome because it can be used to maintain a lethal mutation in the inversion interval as a self-sustaining trans-heterozygous stock. This strategy can be used to generate similar genetic reagents throughout the mouse genome. Engineering of visibly marked inversions and deficiencies is an important step toward functional analyses of the mouse genome and will facilitate large-scale mutagenesis programs.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dev Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Bradley, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl, Houston, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839				Araki K, 1997, NUCLEIC ACIDS RES, V25, P868, DOI 10.1093/nar/25.4.868; Ashburner M., 1989, DROSOPHILA LAB HDB; BALDINI A, 1994, IN SITU HYBRIDIZATIO, P75; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; JUSTICE MJ, MOUSE GENETICS TRANS; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu PT, 1998, GENETICS, V150, P1155; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Muller HJ, 1918, GENETICS, V3, P422; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Rinchik E.M., 1990, GENOME ANAL, P121; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; SINGLETON JR, 1964, GENETICS, V49, P541; STRICKBERGER MW, 1985, GENETICS, P435; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354	31	109	116	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					375	378		10.1038/11949	http://dx.doi.org/10.1038/11949			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431243				2022-12-27	WOS:000081772500021
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Retroposition of autosomal mRNA yielded testis-specific gene family on human Y chromosome	NATURE GENETICS			English	Article							DROSOPHILA-MIRANDA; X-CHROMOSOME; HUMAN GENOME; DAZ GENE; MAP; EVOLUTION; CANDIDATE; HOMOLOG; DNA	Most genes in the human NRY (non-recombining portion of the Y chromosome) can be assigned to one of two groups: X-homologous genes or testis-specific gene families with no obvious X-chromosomal homologues(1,2). The CDY genes have been localized to the human Y chromosome(1), and we report here that they are derivatives of a conventional single-copy gene, CDYL (CDY-like), located on human chromosome 13 and mouse chromosome 6. CDY genes retain CDYL exonic sequences but lack its introns. In mice, whose evolutionary linkeage diverged before the appearance of the Y-linked derivatives, the autosomal Cdyl gene produces two transcripts; one is expressed ubiquitously and the other is expressed in testes only. In humans, autosomal CDYL produces only the ubiquitous transcript; the testis-specific transcript is the province of the Y-borne CDY genes. Our data indicate that CDY genes arose during primate evolution by retroposition of a CDYL mRNA and amplification of the retroposed gene. Retroposition contributed to the gene content of the human Y chromosome, together with two other molecular evolutionary processes: persistence of a subset of genes shared wit the X chromosome(3,4) and transposition of genomic DNA harbouring intact transcription units(5).	MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Page, DC (corresponding author), MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.							Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; EICHER EM, 1989, GENETICS, V122, P181; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; GANGULY R, 1992, P NATL ACAD SCI USA, V89, P1340, DOI 10.1073/pnas.89.4.1340; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Ohno S., 1967, SEX CHROMOSOMES SEX; PILBEAM D, 1984, SCI AM, V250, P84, DOI 10.1038/scientificamerican0384-84; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; Shan ZH, 1996, HUM MOL GENET, V5, P2005, DOI 10.1093/hmg/5.12.2005; Steinemann M, 1997, GENETICS, V145, P261; STEINEMANN M, 1992, P NATL ACAD SCI USA, V89, P7591, DOI 10.1073/pnas.89.16.7591; Vogt P. H., 1997, Cytogenetics and Cell Genetics, V79, P1, DOI 10.1159/000134680; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATSON JM, 1991, P NATL ACAD SCI USA, V88, P11256, DOI 10.1073/pnas.88.24.11256; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013	25	167	176	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					429	433		10.1038/7771	http://dx.doi.org/10.1038/7771			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192397				2022-12-27	WOS:000079439700028
J	Tsujikawa, M; Kurahashi, H; Tanaka, T; Nishida, K; Shimomura, Y; Tano, Y; Nakamura, Y				Tsujikawa, M; Kurahashi, H; Tanaka, T; Nishida, K; Shimomura, Y; Tano, Y; Nakamura, Y			Identification of the gene responsible for gelatinous drop-like corneal dystrophy	NATURE GENETICS			English	Article							FAMILIAL AMYLOIDOSIS; MONOCLONAL-ANTIBODY; GELSOLIN GENE; SEQUENCE; SPECIFICITY; RS7-3G11; MUTATION; FINNISH; PIP2; DNA	Gelatinous drop-like corneal dystrophy (GDLD; OMIM 204870) is an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness(1-4), with an incidence of 1 in 300,000 in Japan(5). Our previous genetic linkage study localized the gene responsible to a 2.6-cM interval on chromosome 1p (ref. 6). Clinical manifestations, which appear in the first decade of life, include blurred vision, photophobia and foreign-body sensation. By the third decade, raised, yellowish-grey, gelatinous masses severely impair visual acuity, and lamellar keratoplasty is required for most patients'. Here we report DNA sequencing, cDNA cloning and mutational analyses of four deleterious mutations (Q118X, 632delA, Q207X and S170X) in M1S1 (formerly TROP2 and GA733-1), encoding a gastrointestinal tumour-associated antigen. The Q118X mutation was the most common alteration in the GDLD patients examined, accounting for 33 of 40 (82.5%) disease alleles in our panel of families. Protein expression anaysis revealed aggregation of the mutated, truncated protein in the perinuclear region, whereas the normal protein was distributed diffusely in the cytoplasm with a homogenous or fine granular pattern. Our successful identification of the gene that is defective in GDLD should facilitate genetic diagnosis and potentially treatment of the disease, and enhance general understanding of the mechanisms of amyloidosis.	Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med Genet,Div Clin Genet, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 565, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto 602, Japan	Osaka University; Osaka University; University of Tokyo; Kyoto Prefectural University of Medicine	Nakamura, Y (corresponding author), Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med Genet,Div Clin Genet, Suita, Osaka 565, Japan.		Tanaka, Toshihiro/J-9310-2014	Tanaka, Toshihiro/0000-0001-6201-9784; Nishida, Kohji/0000-0001-9069-3610				BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; DELACHAPELLE A, 1992, GENOMICS, V13, P898, DOI 10.1016/0888-7543(92)90182-R; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; HALTIA M, 1992, AM J MED GENET, V42, P357, DOI 10.1002/ajmg.1320420321; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MIOTTI S, 1987, INT J CANCER, V39, P297, DOI 10.1002/ijc.2910390306; MONDINO BJ, 1981, AM J OPHTHALMOL, V92, P732, DOI 10.1016/S0002-9394(14)74671-9; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; NAKAIZUMI Y, 1914, ACTA SOC OPHTHALMOL, V18, P949; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; SANTO RM, 1995, OPHTHALMOLOGY, V102, P557, DOI 10.1016/S0161-6420(95)30982-7; SMOLIN G, 1994, CORNEA, P499; STEIN R, 1993, INT J CANCER, V55, P938, DOI 10.1002/ijc.2910550611; Tsujikawa M, 1998, AM J HUM GENET, V63, P1073, DOI 10.1086/302071; WEBER FL, 1980, ARCH OPHTHALMOL-CHIC, V98, P144, DOI 10.1001/archopht.1980.01020030146017; YU FX, 1992, J BIOL CHEM, V267, P14616	20	126	137	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					420	423		10.1038/7759	http://dx.doi.org/10.1038/7759			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192395				2022-12-27	WOS:000079439700026
J	St John, MAR; Tao, WF; Fei, XL; Fukumoto, R; Carcangiu, ML; Brownstein, DG; Parlow, AF; McGrath, J; Xu, TA				St John, MAR; Tao, WF; Fei, XL; Fukumoto, R; Carcangiu, ML; Brownstein, DG; Parlow, AF; McGrath, J; Xu, TA			Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction	NATURE GENETICS			English	Article							CYCLINS; PROLIFERATION; HYPERPLASIA; ENCODES; LACKING; CANCER; KINASE; MOUSE; CELLS	The lats gene has been identified as a tumour suppressor in Drosophila melanogaster using mosaic screens(1). Mosaic flies carrying somatic cells that are mutant for lats develop large tumours in many organs(1,2). The human LATS1 homologue res cues embryonic lethality and inhibits tumour growth in lats mutant flies, demonstrating the functional conservation of this gene(3). Biochemical and genetic analyses have revealed that LATS1 functions as a negative regulator of CDC2 (ref. 3). These data suggest that mammalian LATS1 may have a role in tumorigenesis. To elucidate the function of mammalian LATS1, we have generated Lats1(-/-) mice. Lats1(-/-) animals exhibit a lack of mammary grand development, infertility and growth retardation. Accompanying these defects are hyperplastic changes in the pituitary and decreased serum hormone levels. The reproductive hormone defects of Lats1(-/-) mice are reminiscent of isolated LH-hypogonadotropic hypogonadism and corpus luteum insufficiency in humans. Furthermore, Lats1(-/-) mice develop soft-tissue sarcomas and ovarian stromal cell tumours and are highly sensitive to carcinogenic treatments. Our data demonstrate a role for Lats1 in mammalian tumorigenesis and specific endocrine dysfunction.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cell Biol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Comparat Med Sect, New Haven, CT 06536 USA; Univ Calif Los Angeles, Harbor Med Ctr, Natl Hormone & Pituitary Program, Torrance, CA 90509 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; Yale University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Xu, TA (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	Tian.Xu@yale.edu			NCI NIH HHS [R01CA69408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLEMENT PB, 1997, HISTOLOGY PATHOLOGIS, P934; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; WHEATER PR, 1987, FUNCTIONAL HISTOLOGY, P290; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; XU TA, 1995, DEVELOPMENT, V121, P1053	22	350	358	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	1999	21	2					182	186		10.1038/5965	http://dx.doi.org/10.1038/5965			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	163MH	9988269				2022-12-27	WOS:000078399500019
J	Spirio, LN; Samowitz, W; Robertson, J; Robertson, M; Burt, RW; Leppert, M; White, R				Spirio, LN; Samowitz, W; Robertson, J; Robertson, M; Burt, RW; Leppert, M; White, R			Alleles of APC modulate the frequency and classes of mutations that read to colon polyps	NATURE GENETICS			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; GENE; IDENTIFICATION; CHROMOSOME-5Q21; TUMORS; REGION; LOCUS; FAP	Most inherited mutant alleles of the adenomatosis polyposis coli gene (APC) cause the appearance of large numbers of colon polyps(1-4), the familial polyposis syndrome. (These mutant alleles are designated APC(p) alleles.) A subset of APC mutations, the attenuated or APC(AP) alleles, predispose to only a few colon polyps(5). This leads to the hypothesis that if mutation of the inherited normal allele is rate limiting in polyp development, the increased number of polyps associated with the APC(p) allele indicates that the frequency of mutations that can lead to polyp formation is higher among APC(p) carriers than among APC(AP) carriers. We have previously suggested that the APC protein might modulate the frequency of mutations, such as loss of heterozygosity(6) (LOH), necessary for colon polyp formation(5). We thus reasoned that tumours from patients who carry an APC(AP) allele might show a reduced frequency of LOH compared with tumours from patients who carry an APC(p) allele. Loss of AAPC mutant alleles is designated as LOHAP. Screening of tumours from APC(AP) carriers revealed a reduction of LOH compared with that of an unselected group of polyposis patients(7). In fact, no loss of the inherited APC(N) allele was observed, although sequencing showed that the inherited APC(N) allele had frequently undergone point mutations and small deletions in the tumours. A low frequency loss of the inherited APC(AP) allele was seen. These findings support the suggestion that the APC(AP) allele has residual gene activity and that this activity modulates the spectrum and frequency of mutations that lead to adenoma formation.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	White, R (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	ray.white@hci.utah.edu						ADAMSON D, 1995, AM J HUM GENET, V57, P619; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SAMOWITZ WS, 1995, GASTROENTEROLOGY, V109, P1765, DOI 10.1016/0016-5085(95)90742-4; SAMOWITZ WS, 1995, CANCER RES, V55, P3732; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; Spirio LN, 1996, CANCER RES, V56, P955; VANDERLUIJT RB, 1995, HUM GENET, V96, P705, DOI 10.1007/BF00210303; VARESCO L, 1994, HUM GENET, V93, P281, DOI 10.1007/BF00212023; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	19	114	115	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1998	20	4					385	388		10.1038/3865	http://dx.doi.org/10.1038/3865			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	142KM	9843214				2022-12-27	WOS:000077199600029
J	Percin, EF; Ploder, LA; Yu, JJ; Arici, K; Horsford, DJ; Rutherford, A; Bapat, B; Cox, DW; Duncan, AMV; Kalnins, VI; Kocak-Altintas, A; Sowden, JC; Traboulsi, E; Sarfarazi, M; McInnes, RR				Percin, EF; Ploder, LA; Yu, JJ; Arici, K; Horsford, DJ; Rutherford, A; Bapat, B; Cox, DW; Duncan, AMV; Kalnins, VI; Kocak-Altintas, A; Sowden, JC; Traboulsi, E; Sarfarazi, M; McInnes, RR			Human microphthalmia associated with mutations in the retinal homeobox gene CHX10	NATURE GENETICS			English	Article							CONGENITAL MICROPHTHALMIA; DNA; EXPRESSION; LOCALIZATION; ZEBRAFISH; PROTEIN; MOUSE; MAPS	Isolated human microphthalmia/anophthalmia, a cause of congenital blindness, is a clinically and genetically heterogeneous developmental disorder characterized by a small eye and other ocular abnormalities. Three microphthalmia/anophthalmia loci have been identified(1-3), and two others have been inferred by the co-segregation of translocations with the phenotype(4,5). We previously found that mice with ocular retardation (the or-J allele), a microphthalmia phenotype(6), have a null mutation in the retinal homeobox gene Chx10 (refs 7,8). We report here the mapping of a human microphthalmia locus on chromosome 14q24.3, the cloning of CHX10 at this locus and the identification of recessive CHX10 mutations in two families with nonsyndromic microphthalmia (MIM 251600), cataracts and severe abnormalities of the iris. In affected individuals, a highly conserved arginine residue in the DNA-recognition helix of the homeodomain is replaced by glutamine or proline (R200Q and R200P, respectively). Identification of the CHX10 consensus DNA-binding sequence (TAATTAGC) allowed us to demonstrate that both mutations severely disrupt CHX10 function. Human CHX10 is expressed in progenitor cells of the developing neuroretina and in the inner nuclear layer of the mature retina. The strong conservation in vertebrates of the CHX10 sequence, pattern of expression and loss-of-function phenotypes demonstrates the evolutionary importance of the genetic network through which this gene regulates eye development.	Univ Connecticut, Ctr Hlth, Dept Surg, Surg Res Ctr,Mol Ophthalm Genet Lab, Framingham, CT USA; Cumhuriyet Univ, Dept Med Biol, Sivas, Turkey; Cumhuriyet Univ, Dept Genet, Sivas, Turkey; Cumhuriyet Univ, Dept Ophthalmol, Sivas, Turkey; Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON, Canada; Hosp Sick Children, Res Inst, Genet Program, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; UCL, Inst Child Hlth, Dev Biol Unit, London WC1E 6BT, England; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada; McGill Univ, Montreal Childrens Hosp, Ctr Hosp, Dept Pathol, Montreal, PQ, Canada; McGill Univ, Montreal Childrens Hosp, Ctr Hosp, Dept Human Genet, Montreal, PQ, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON, Canada; Ankara Hosp, Ophthalmol Clin, Ankara, Turkey; Cleveland Clin Fdn, Div Ophthalmol, Ctr Genet Eye Dis, Dept Pediat, Cleveland, OH USA	University of Connecticut; Cumhuriyet University; Cumhuriyet University; Cumhuriyet University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of London; University College London; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta; McGill University; McGill University; University of Toronto; Ankara Training & Research Hospital; Cleveland Clinic Foundation	Sarfarazi, M (corresponding author), Univ Connecticut, Ctr Hlth, Dept Surg, Surg Res Ctr,Mol Ophthalm Genet Lab, Framingham, CT USA.	mansoor@neuron.uchc.edu; mcinnes@sickkids.on.ca	Traboulsi, Elias/AAY-7443-2020; Percin, Ferda E/H-6850-2016	Percin, Ferda E/0000-0001-9317-8155; Sowden, Jane/0000-0003-0937-2479; arici, mustafa kemal/0000-0002-6350-9723				ALGAZALI LI, 1990, J MED GENET, V27, P59, DOI 10.1136/jmg.27.1.59; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barabino SML, 1997, MECH DEVELOP, V63, P133, DOI 10.1016/S0925-4773(97)00036-1; BASCOM RA, 1995, HUM MOL GENET, V4, P1895, DOI 10.1093/hmg/4.10.1895; BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293; Bessant DAR, 1998, AM J HUM GENET, V62, P1113, DOI 10.1086/301843; Bone-Larson C, 2000, J NEUROBIOL, V42, P232, DOI 10.1002/(SICI)1097-4695(20000205)42:2<232::AID-NEU7>3.0.CO;2-4; BREITSCHOPF H, 1992, ACTA NEUROPATHOL, V84, P581; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Chen CMA, 2000, MECH DEVELOP, V90, P293; COOPER DN, 1990, HUM GENET, V85, P55; CORMACK B, 1999, CURRENT PROTOCOLS MO; Dattani MT, 1998, NAT GENET, V19, P125, DOI 10.1038/477; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DUNCAN AMV, 1992, CYTOGENET CELL GENET, V60, P212, DOI 10.1159/000133340; GRAHAM CA, 1991, OPHTHALMIC PAED GEN, V12, P43, DOI 10.3109/13816819109023084; Isenberg S., 1994, THE EYE IN INFANCY, P36; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Othman MI, 1998, AM J HUM GENET, V63, P1411, DOI 10.1086/302113; Passini MA, 1997, J COMP NEUROL, V388, P495, DOI 10.1002/(SICI)1096-9861(19971124)388:3<495::AID-CNE11>3.0.CO;2-L; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; POLLOCK RM, 1999, CURRENT PROTOCOLS MO; TRUSLOVE GM, 1962, J EMBRYOL EXP MORPH, V10, P652; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; YOKOYAMA Y, 1992, HUM GENET, V90, P177; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691	28	222	226	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					397	401		10.1038/78071	http://dx.doi.org/10.1038/78071			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932181				2022-12-27	WOS:000088615000012
J	Vervoort, R; Lennon, A; Bird, AC; Tulloch, B; Axton, R; Miano, MG; Meindl, A; Meitinger, T; Ciccodicola, A; Wright, AF				Vervoort, R; Lennon, A; Bird, AC; Tulloch, B; Axton, R; Miano, MG; Meindl, A; Meitinger, T; Ciccodicola, A; Wright, AF			Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa	NATURE GENETICS			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POSITIONAL CLONING; GENE; IDENTIFICATION; SEQUENCES; FAMILIES; DNA; RP3; TRANSCRIPTION; HOMOLOGY	The gene RPGR was previously identified in the RP3 region of Xp21.1 and shown to be mutated in 10-20% of patients with the progressive retinal degeneration X-linked retinitis pigmentosa(1,2) (XLRP). The mutations predominantly affected a domain homologous to RCC1, a guanine nucleotide exchange factor for the small GTPase Ran, although they were present in fewer than the 70-75% of XLRP patients predicted from linkage studies(3-6) Mutations in the RP2 locus at Xp11.3 were found in a further 10-20% of XLRP patients, as predicted from linkage studies(6-8). Because the mutations in the remainder of the XLRP patients may reside in undiscovered exons of RPGR, we sequenced a 172-kb region containing the entire gene. Analysis of the sequence disclosed a new 3' terminal exon that was mutated in 60% of XLRP patients examined. This exon encodes 567 amino acids, with a repetitive domain rich in glutamic acid residues. The sequence is conserved in the mouse, bovine and Fugu rubripes genes. it is preferentially expressed in mouse and bovine retina, further supporting its importance for retinal function. Our results suggest that mutations in RPGR are the only cause of RP3 type XLRP and account for the disease in over 70% of XLRP patients and an estimated 11% of all retinitis pigmentosa patients.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; UCL, Dept Clin Ophthalmol, London WC1E 6BT, England; Moorfields Eye Hosp, London, England; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; Univ Munich, Dept Med Genet, Munich, Germany; GSF, Res Ctr, Clin Ophthalmol Res Cooperat, Neuherberg, Germany	University of Edinburgh; University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Wright, AF (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland.	alan.wright@hgu.mrc.ac.uk	Miano, Maria Giuseppina/AAX-8437-2020; Meitinger, Thomas/O-1318-2015; Giuseppina, Miano Maria/B-9169-2015; Miano, Maria Giuseppina/E-9056-2011	Miano, Maria Giuseppina/0000-0003-1396-9673; Miano, Maria Giuseppina/0000-0003-1396-9673; Meitinger, Thomas/0000-0002-8838-8403; Ciccodicola, Alfredo/0000-0002-9924-1482	Telethon [E.1093] Funding Source: Medline	Telethon(Fondazione Telethon)		Buraczynska M, 1997, AM J HUM GENET, V61, P1287, DOI 10.1086/301646; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cooper D. N., 1993, HUMAN GENE MUTATION; Dry KL, 1999, HUM MUTAT, V13, P141, DOI 10.1002/(SICI)1098-1004(1999)13:2<141::AID-HUMU6>3.3.CO;2-H; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Hardcastle AJ, 1999, AM J HUM GENET, V64, P1210, DOI 10.1086/302325; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; Kirschner R, 1999, HUM MOL GENET, V8, P1571, DOI 10.1093/hmg/8.8.1571; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MEINDL A, 1995, HUM MOL GENET, V4, P2339, DOI 10.1093/hmg/4.12.2339; Miano MG, 1999, EUR J HUM GENET, V7, P687, DOI 10.1038/sj.ejhg.5200352; OTT J, 1990, P NATL ACAD SCI USA, V87, P701, DOI 10.1073/pnas.87.2.701; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 1996, HUM MOL GENET, V5, P827, DOI 10.1093/hmg/5.6.827; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; TEAGUE PW, 1994, AM J HUM GENET, V55, P105; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WOOTTON JC, 1994, CURR OPIN STRUC BIOL, V4, P413, DOI 10.1016/S0959-440X(94)90111-2; Xu Y, 1994, Genet Eng (N Y), V16, P241; Zhang MQ, 1997, P NATL ACAD SCI USA, V94, P565, DOI 10.1073/pnas.94.2.565	23	318	333	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					462	466		10.1038/78182	http://dx.doi.org/10.1038/78182			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932196				2022-12-27	WOS:000088615000027
J	Sun, C; Sklaetsky, H; Birren, B; Devon, K; Tang, ZL; Silber, S; Oates, R; Page, DC				Sun, C; Sklaetsky, H; Birren, B; Devon, K; Tang, ZL; Silber, S; Oates, R; Page, DC			An azoospermic man with a de novo point mutation in the Y-chromosomal gene USP9Y	NATURE GENETICS			English	Article							POLYMERASE CHAIN-REACTION; HUMAN DNA; LONG ARM; CLONES; MICRODELETIONS; POLYMORPHISMS; LOCALIZATION; EXPRESSION; SEQUENCES; DELETIONS	In humans, deletion of any one of three Y-chromosomal regions-AZFa. AZFb or AZFc-disrupts spermatogenesis, causing infertility in otherwise healthy men(1-5). Although candidate genes have been identified in all three regions(3,6-8), no case of spermatogenic failure has been traced to a point mutation in a Y-linked gene, or to a deletion of a single Y-linked gene. We sequenced the AZFa region of the Y chromosome and identified two functional genes previously described: USP9Y(also known as DFFRY) and DBY (refs 7,8). Screening of the two genes in 576 infertile and 96 fertile men revealed several sequence variants, most of which appear to be heritable and of little functional consequence. We found one de novo mutation in USP9Y: a 4-bp deletion in a splice-donor site, causing an exon to be skipped and protein truncation. This mutation was present in a man with nonobstructive azoospermia (that is, no sperm was detected in semen), but absent in his fertile brother, suggesting that the USP9Y mutation caused spermatogenic failure. We also identified a single-gene deletion associated with spermatogenic failure, again involving USP9Y, by re-analysing a published study.	MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA USA; MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; St Lukes Hosp, Infertil Ctr St Louis, St Louis, MO USA; Boston Univ, Sch Med, Dept Urol, Boston, MA 02118 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Saint Luke's Hospital - Missouri; Boston University	Page, DC (corresponding author), MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA.			Oates, Robert/0000-0003-2330-6697				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AndreuttiZaugg C, 1997, CANCER RES, V57, P3288; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Grimaldi P, 1998, MOL HUM REPROD, V4, P1116, DOI 10.1093/molehr/4.12.1116; JONES MH, 1994, GENOMICS, V24, P266, DOI 10.1006/geno.1994.1615; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LAHN BT, SCIENCE, V286, P99; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; QURESHI SJ, 1996, MOL HUM REPROD, V2, P275; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Sargent CA, 1999, J MED GENET, V36, P670; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769	24	262	283	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					429	432		10.1038/70539	http://dx.doi.org/10.1038/70539			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581029				2022-12-27	WOS:000084023900018
J	Hazan, J; Fonknechten, N; Mavel, D; Paternotte, C; Samson, D; Artiguenave, F; Davoine, CS; Cruaud, C; Durr, A; Wincker, P; Brottier, P; Cattolico, L; Barbe, V; Burgunder, JM; Prud'homme, JF; Brice, A; Fontaine, B; Heilig, R; Weissenbach, J				Hazan, J; Fonknechten, N; Mavel, D; Paternotte, C; Samson, D; Artiguenave, F; Davoine, CS; Cruaud, C; Durr, A; Wincker, P; Brottier, P; Cattolico, L; Barbe, V; Burgunder, JM; Prud'homme, JF; Brice, A; Fontaine, B; Heilig, R; Weissenbach, J			Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia	NATURE GENETICS			English	Article							CHROMOSOME 2P; BINDING-PROTEIN; LOCUS; YEAST; SEQUENCES; FAMILY; GENE; LINKAGE; DISEASE; CLASSIFICATION	Autosomal dominant hereditary spastic paraplegia (AD-HSP) is a genetically heterogeneous neurodegenerative disorder characterized by progressive spasticity of the lower limbs. Among the four loci causing AD-HSP identified so far, the SPG4 locus at chromosome 2p21-p22 has been shown to account for 40-50% of all AD-HSP families. Using a positional cloning strategy based on obtaining sequence of the entire SPG4 interval, we identified a candidate gene encoding a new member of the AAA protein family, which we named spastin. Sequence analysis of this gene in seven SPG4-linked pedigrees revealed several DNA modifications, including missense, nonsense and splice-site mutations. Both SPG4 and its mouse orthologue were shown to be expressed early and ubiquitously in fetal and adult tissues. The sequence homologies and putative subcellular localization of spastin suggest that this ATPase is involved in the assembly or function of nuclear protein complexes.	Genoscope, Evry, France; Fac Med Pitie Salpetriere, INSERM, Paris, France; Federat Neurol, Paris, France; INSERM, U289, Paris, France; Grp Hosp Pitie Salpetriere, F-75634 Paris, France; Univ Spital Bern, Neurol Klin & Poliklin, Bern, Switzerland; Genethon, Evry, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Bern; University Hospital of Bern	Hazan, J (corresponding author), Genoscope, Evry, France.		brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009	brice, alexis/0000-0002-0941-3990; Cruaud, Corinne/0000-0002-4752-7278; Steinbach, Delphine/0000-0001-7144-7908; Hazan, Jamile/0000-0001-8119-0325				ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; Beyer A, 1997, PROTEIN SCI, V6, P2043; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Durr A, 1996, BRAIN, V119, P1487, DOI 10.1093/brain/119.5.1487; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FINK JK, 1995, AM J HUM GENET, V56, P188; Fink JK, 1996, NEUROLOGY, V46, P1507, DOI 10.1212/WNL.46.6.1507; HARDING AE, 1983, LANCET, V1, P1151; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Harris NL, 1997, GENOME RES, V7, P754, DOI 10.1101/gr.7.7.754; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HAZAN J, IN PRESS GENOMICS; Hedera P, 1999, AM J HUM GENET, V64, P563, DOI 10.1086/302258; Heinzlef O, 1998, J MED GENET, V35, P89, DOI 10.1136/jmg.35.2.89; HENTATI A, 1994, HUM MOL GENET, V3, P1867, DOI 10.1093/hmg/3.10.1867; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; ICHIDA K, 1993, GENE, V133, P279; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOSAK M, 1996, MAMM GENOME, V7, P563; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; KULP D, 1996, P 4 INT C INT SYST M, P134; Liberzon A, 1996, FEBS LETT, V388, P5, DOI 10.1016/0014-5793(96)00500-5; Neuwald AF, 1999, GENOME RES, V9, P27; Nielsen JE, 1997, HUM MOL GENET, V6, P1811, DOI 10.1093/hmg/6.11.1811; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PERIER F, 1994, FEBS LETT, V351, P286, DOI 10.1016/0014-5793(94)00879-5; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Reid E, 1997, J MED GENET, V34, P499, DOI 10.1136/jmg.34.6.499; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; Scott WK, 1997, NEUROGENETICS, V1, P95, DOI 10.1007/s100480050014; SKRE H, 1974, CLIN GENET, V6, P165; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Swaffield JC, 1997, J MOL EVOL, V45, P549, DOI 10.1007/PL00006259; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WERDERLIN L, 1986, ACTA NEUROL SCA S106, V73, P124; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Xu Y, 1994, Genet Eng (N Y), V16, P241; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	48	483	509	1	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					296	303		10.1038/15472	http://dx.doi.org/10.1038/15472			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610178				2022-12-27	WOS:000083792200017
J	Burley, SK; Almo, SC; Bonanno, JB; Capel, M; Chance, MR; Gaasterland, T; Lin, DW; Sali, A; Studier, FW; Swaminathan, S				Burley, SK; Almo, SC; Bonanno, JB; Capel, M; Chance, MR; Gaasterland, T; Lin, DW; Sali, A; Studier, FW; Swaminathan, S			Structural genomics: beyond the Human Genome Project	NATURE GENETICS			English	Article							MYCOPLASMA-GENITALIUM PROTEINS; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; PREDICTIONS; HEAD; FOLD	With access to whole genome sequences for various organisms and imminent completion of the Human Genome Project, the entire process of discovery in molecular and cellular biology is poised to change. Massively parallel measurement strategies promise to revolutionize how we study and ultimately understand the complex biochemical circuitry responsible for controlling normal development, physiologic homeostasis and disease processes. This information explosion is also providing the foundation for an important new initiative in structural biology. We are about to embark on a program of high-throughput X-ray crystallography aimed at developing a comprehensive mechanistic understanding of normal and abnormal human and microbial physiology at the molecular level. We present the rationale for creation of a structural genomics initiative, recount the efforts of ongoing structural genomics pilot studies, and detail the lofty goals, technical challenges and pitfalls facing structural biologists.	Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA; Albert Einstein Coll Med, Bronx, NY 10461 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Howard Hughes Medical Institute; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; United States Department of Energy (DOE); Brookhaven National Laboratory	Burley, SK (corresponding author), Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.			Burley, Stephen K./0000-0002-2487-9713				Brenner SE, 1997, CURR OPIN STRUC BIOL, V7, P369, DOI 10.1016/S0959-440X(97)80054-1; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Cohen SL, 1996, STRUCTURE, V4, P1013, DOI 10.1016/S0969-2126(96)00108-6; DEO RC, IN PRESS CELL; Fetrow JS, 1998, J MOL BIOL, V282, P703, DOI 10.1006/jmbi.1998.2061; Fischer D, 1997, P NATL ACAD SCI USA, V94, P11929, DOI 10.1073/pnas.94.22.11929; Gaasterland T, 1998, TRENDS GENET, V14, P135, DOI 10.1016/S0168-9525(98)01430-9; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huynen M, 1998, J MOL BIOL, V280, P323, DOI 10.1006/jmbi.1998.1884; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Orengo CA, 1999, NUCLEIC ACIDS RES, V27, P275, DOI 10.1093/nar/27.1.275; Rychlewski L, 1998, FOLD DES, V3, P229, DOI 10.1016/S1359-0278(98)00034-0; Sali Andrej, 1998, Nature Structural Biology, V5, P1029, DOI 10.1038/4136; Sanchez R, 1999, J COMPUT PHYS, V151, P388, DOI 10.1006/jcph.1999.6200; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Wallace AC, 1997, PROTEIN SCI, V6, P2308; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang F, 1998, NAT STRUCT BIOL, V5, P763, DOI 10.1038/1796	21	291	301	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					151	157		10.1038/13783	http://dx.doi.org/10.1038/13783			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508510				2022-12-27	WOS:000082827500013
J	Dealy, MJ; Nguyen, KVT; Lo, J; Gstaiger, M; Krek, W; Elson, D; Arbeit, J; Kipreos, ET; Johnson, RS				Dealy, MJ; Nguyen, KVT; Lo, J; Gstaiger, M; Krek, W; Elson, D; Arbeit, J; Kipreos, ET; Johnson, RS			Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E	NATURE GENETICS			English	Article							F-BOX PROTEIN; UBIQUITIN LIGASE; COMPLEX; DEGRADATION; TRANSITION; PATHWAY; FAMILY; ASSOCIATION; TARGETS; CDC4P	The sequential timing of cell-cycle transitions is primarily governed by the availability and activity of key cell-cycle proteins(1). Recent studies in yeast have identified a class of ubiquitin ligases (E3 enzymes) called SCF complexes, which regulate the abundance of proteins that promote(2-4) and inhibit(4-6) cell-cycle progression at the G1-S phase transition. SCF complexes consist of three invariable components, Skp1, Cul-1 (Cdc53 in yeast) and Rbx1, and a variable F-box protein that recruits a specific cellular protein to the ubquitin pathway for degradation(2,3,5,7-13). To study the role of Cul-1 in mammalian development and cell-cycle regulation, we generated mice deficient for Cul1 and analysed null embryos and heterozygous cell lines. We show that Cul1 is required for early mouse development and that Cul1 mutants fail to regulate the abundance of the G1 cyclin, cyclin E (encoded by Gene), during embryogenesis.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Calif San Francisco, Dept Surg, Ctr Canc, San Francisco, CA 94143 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University of California System; University of California San Diego; Friedrich Miescher Institute for Biomedical Research; University of California System; University of California San Francisco; University System of Georgia; University of Georgia	Johnson, RS (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Johnson, Randall/AAM-1189-2021; Arbeit, Jeffrey/K-6920-2019	Johnson, Randall/0000-0002-4084-6639; 				Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HOGAN B, 1994, MANIPULATING MOUSE E, P61; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Papaioannou V., 1993, Gene targeting: a practical approach., P107; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, GENE DEV, V12, P3144; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Slingerland J, 1998, Results Probl Cell Differ, V22, P133; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, GENE DEV, V13, P1050; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	30	145	148	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					245	248		10.1038/13886	http://dx.doi.org/10.1038/13886			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508527				2022-12-27	WOS:000082827500030
J	Schiaffino, MV; d'Addio, M; Alloni, A; Baschirotto, C; Valetti, C; Cortese, K; Puri, C; Bassi, MT; Colla, C; De Luca, M; Tacchetti, C; Ballabio, A				Schiaffino, MV; d'Addio, M; Alloni, A; Baschirotto, C; Valetti, C; Cortese, K; Puri, C; Bassi, MT; Colla, C; De Luca, M; Tacchetti, C; Ballabio, A			Ocular albinism: evidence for a defect in an intracellular signal transduction system	NATURE GENETICS			English	Article							PROTEIN-COUPLED RECEPTORS; MUTATIONS; ANTIGENS	G protein-coupled receptors (GPCRs) participate in the most common signal transduction system at the plasma membrane(1). The wide distribution of heterotrimeric C proteins in the internal membranes suggests that a similar signalling mechanism might also be used at intracellular locations(2). We provide here structural evidence that the protein product of the ocular albinism type 1 gene (OA1). a pigment cell-specific integral membrane glycopratein(3). represents a novel member of the GPCR superfamily and demonstrate that it binds heterotrimeric G proteins. Moreover, we show that OA1 is not found at the plasma membrane, being instead targeted to specialized intracellular organelles, the melanosomes. Our data suggest that OA1 represents the first example of an exclusively intracellular GPCR and support the hypothesis that GPCR-mediated signal transduction systems also operate at the internal membranes in mamalian cells.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Genoa, Dept Expt Med, Anat Sect, I-16132 Genoa, Italy; Ist Dermopat Immacolata, IRCCS, I-00167 Rome, Italy; Univ Vita Salute San Raffaele, I-20132 Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Genoa; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Vita-Salute San Raffaele University	Schiaffino, MV (corresponding author), Telethon Inst Genet & Med, I-20132 Milan, Italy.	schiaffi@tigem.it	BALLABIO, Andrea/AAL-2672-2020; Bassi, Maria Teresa T/A-3517-2014; Cortese, Katia/AAC-2990-2021; Schiaffino, Maria Vittoria/AAN-3313-2020; De Luca, Michele/N-5883-2014	BALLABIO, Andrea/0000-0003-1381-4604; Bassi, Maria Teresa T/0000-0002-8236-1197; Schiaffino, Maria Vittoria/0000-0001-9744-7025; De Luca, Michele/0000-0002-0850-8445; Cortese, Katia/0000-0001-9218-8933; TACCHETTI, CARLO/0000-0003-4602-000X	Telethon [TGM06S01, TGM97000, A.041, E.0583] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Mironov A. A.  Jr., 1996, Journal of Computer-Assisted Microscopy, V8, P231; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; ODONNELL FE, 1976, ARCH OPHTHALMOL-CHIC, V94, P1883, DOI 10.1001/archopht.1976.03910040593001; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROST B, 1995, PROTEIN SCI, V4, P521; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P2319, DOI 10.1093/hmg/4.12.2319; Schiaffino MV, 1996, P NATL ACAD SCI USA, V93, P9055, DOI 10.1073/pnas.93.17.9055; Schnur RE, 1998, AM J HUM GENET, V62, P800, DOI 10.1086/301776; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WINDER AJ, 1993, J CELL SCI, V106, P153	21	101	107	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					108	112		10.1038/12715	http://dx.doi.org/10.1038/12715			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471510				2022-12-27	WOS:000082337300027
J	Tronche, F; Kellendonk, C; Kretz, O; Gass, P; Anlag, K; Orban, PC; Bock, R; Klein, R; Schutz, G				Tronche, F; Kellendonk, C; Kretz, O; Gass, P; Anlag, K; Orban, PC; Bock, R; Klein, R; Schutz, G			Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety	NATURE GENETICS			English	Article							CORTICOTROPIN-RELEASING-FACTOR; IMPAIRED STRESS-RESPONSE; ELEVATED PLUS-MAZE; ADRENOCORTICAL REGULATION; TRANSGENIC MICE; BEHAVIOR; BRAIN; TRANSCRIPTION; EXPRESSION; SECRETION	The glucocorticoid receptor (Gr, encoded by the gene Grl1) controls transcription of target genes both directly by interaction with DNA regulatory elements and indirectly by cross-talk with other transcription factors(1, 2). In response to various stimuli, including stress, glucocorticoids coordinate metabolic, endocrine, immune and nervous system responses and ensure an adequate profile of transcription. In the brain, Gr has been proposed to modulate emotional behaviour, cognitive functions and addictive states(3-5). Previously, these aspects were not studied in the absence of functional Gr because inactivation of Grl1 in mice causes lethality at birth(6) (F.T., C.K, and G.S., unpublished data), Therefore, we generated tissue-specific mutations of this gene using the Cre/loxP-recombination system(7). This allowed us to generate viable adult mice with loss of Gr function in selected tissues. Loss of Gr function in the nervous system impairs hypothalamus-pituitary-adrenal (HPA)-axis regulation, resulting in increased glucocorticoid (GC) levels that lead to symptoms reminiscent of those observed in Cushing syndrome, Conditional mutagenesis of Gr in the nervous system provides genetic evidence for the importance of Gr signalling in emotional behaviour because mutant animals show an impaired behavioural response to stress and display reduced anxiety.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Saarland, Inst Anat, Homburg, Germany; EMBL, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Saarland University; European Molecular Biology Laboratory (EMBL)	Schutz, G (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		TRONCHE, François/F-3895-2011; Kellendonk, Christoph/O-7229-2018; Klein, Ruediger/C-6147-2008	Kellendonk, Christoph/0000-0003-3302-2188; Klein, Ruediger/0000-0002-3109-0163; Kretz, Oliver/0000-0003-1152-5956				ANDREATINI R, 1994, PROG NEURO-PSYCHOPH, V18, P1333, DOI 10.1016/0278-5846(94)90097-3; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BRITTON KT, 1986, LIFE SCI, V39, P1281, DOI 10.1016/0024-3205(86)90189-X; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; FINK G, 1997, MECHANISM NEGATIVE P, P30; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Heym C, 1997, HISTOL HISTOPATHOL, V12, P567; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; JEFFERYS D, 1987, ENDOCRINOLOGY, V121, P1006, DOI 10.1210/endo-121-3-1006; KORTE SM, 1995, PSYCHONEUROENDOCRINO, V20, P385, DOI 10.1016/0306-4530(94)00069-7; Korte SM, 1996, EUR J PHARMACOL, V301, P19, DOI 10.1016/0014-2999(96)00064-7; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; Miller W.L., 1995, ADRENAL CORTEX, P555; MONTKOWSKI A, 1995, J NEUROENDOCRINOL, V7, P841, DOI 10.1111/j.1365-2826.1995.tb00724.x; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; SHIPSTON MJ, 1995, TRENDS ENDOCRIN MET, V6, P261, DOI 10.1016/1043-2760(95)00149-2; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Smythe JW, 1997, PHARMACOL BIOCHEM BE, V56, P507, DOI 10.1016/S0091-3057(96)00244-4; STENZELPOORE MP, 1994, J NEUROSCI, V14, P2579; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; vanHaarst AD, 1996, ENDOCRINOLOGY, V137, P4935, DOI 10.1210/en.137.11.4935; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	30	1387	1418	2	92	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					99	103		10.1038/12703	http://dx.doi.org/10.1038/12703			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471508				2022-12-27	WOS:000082337300025
J	Pierce, EA; Quinn, T; Meehan, T; McGee, TL; Berson, EL; Dryja, TP				Pierce, EA; Quinn, T; Meehan, T; McGee, TL; Berson, EL; Dryja, TP			Mutations in a gene encoding a new oxygen-regulated photoreceptor protein cause dominant retinitis pigmentosa	NATURE GENETICS			English	Article							MESSENGER-RNA; DIFFERENTIAL DISPLAY; RHODOPSIN GENE; ONE FORM; DNA; LINKAGE; REGION; RP1	The autosomal dominant retinitis pigmentosa (RP) locus, designated RP1, has been mapped through linkage studies to a 4-cM interval at 8q11-13. Here we describe a new photoreceptor-specific gene that maps in this interval and whose expression is modulated by retinal oxygen levels in vivo. This gene consists of at least 4 exons that encode a predicted protein of 2,156 amino acids. A nonsense mutation at codon 677 of this gene is present in approximately 3% of cases of dominant RP in North America. We also detected two deletion mutations that cause frameshifts and introduce premature termination codons in three other families with dominant RP. Our data suggest that mutations in this gene cause dominant RP, and that the encoded protein has an important but unknown role in photoreceptor biology.	Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Stellar Chance Labs 311, Philadelphia, PA 19104 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Pierce, EA (corresponding author), Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Stellar Chance Labs 311, 422 Curie Blvd, Philadelphia, PA 19104 USA.			Pierce, Eric/0000-0002-2354-4102; Meehan, Terrence/0000-0003-1980-3228	NEI NIH HHS [EY00169, EY08689, EY12910] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY000169, R01EY012910, R01EY000169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIELLO LP, 1996, P NATL ACAD SCI USA, P6231; ARCELLANAPANLILIO MY, 1993, METHOD ENZYMOL, V225, P303; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bahri SM, 1997, MOL CELL BIOL, V17, P5521, DOI 10.1128/MCB.17.9.5521; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DRYJA TP, 1992, EYE, V6, P1; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; DRYJA TP, 1998, SEM OPT ISPEN, V10, P25; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; GRUN G, 1982, DEV VERTEBRATE RETIN; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Parminder AH, 1997, INVEST OPHTH VIS SCI, V38, P704; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SPENCE MA, 1977, AM J HUM GENET, V29, P397; SPENCE MA, 1977, AM J HUM GENET, V29, P592; Su MT, 1998, BIOTECHNIQUES, V25, P44, DOI 10.2144/98251bm08; VAITHINATHAN R, 1994, GENOMICS, V21, P461, DOI 10.1006/geno.1994.1301; Xu SY, 1996, HUM GENET, V98, P741, DOI 10.1007/s004390050296	36	152	168	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					248	254		10.1038/10305	http://dx.doi.org/10.1038/10305			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391211				2022-12-27	WOS:000081125900016
J	Zhang, QG; Siebert, R; Yan, MH; Hinzmann, B; Cui, XL; Xue, LQ; Rakestraw, KM; Naeve, CW; Beckmann, G; Weisenburger, DD; Sanger, WG; Nowotny, H; Vesely, M; Callet-Bauchu, E; Salles, G; Dixit, VM; Rosenthal, A; Schlegelberger, B; Morris, SW				Zhang, QG; Siebert, R; Yan, MH; Hinzmann, B; Cui, XL; Xue, LQ; Rakestraw, KM; Naeve, CW; Beckmann, G; Weisenburger, DD; Sanger, WG; Nowotny, H; Vesely, M; Callet-Bauchu, E; Salles, G; Dixit, VM; Rosenthal, A; Schlegelberger, B; Morris, SW			Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)	NATURE GENETICS			English	Article							NF-KAPPA-B; SOMATIC HYPERMUTATION; TRANSCRIPTION FACTORS; CELL LYMPHOMA; ACTIVATION; TRANSFORMATION; REQUIREMENT; APOPTOSIS; DISEASE; CARD	Mucosa-associated lymphoid tissue (MALT) lymphomas most frequently involve the gastrointestinal tract and are the most common subset of extranodal non-Hodgkin lymphoma(1) (NHL). Here we describe overexpression of BCL10, a novel apoptotic signalling gene that encodes an amino-terminal caspase recruitment domain (CARD; ref. 2), in MALT lymphomas due to the recurrent t(1;14)(p22;q32) (ref. 3). BCL10 cDNAs from t(1;14)-positive MALT tumours contained a variety of mutations, most resulting in truncations either in or carboxy terminal to the CARD. Wild-type BCL10 activated NF-kappa B but induced apoptosis of MCF7 and 293 cells. CARD-truncation mutants were unable to induce cell death or activate NF-kappa B, whereas mutants with C-terminal truncations retained NF-kappa B activation but did not induce apoptosis, Mutant BCL10 overexpression might have a twofold lymphomagenic effect: loss of BCL10 pro-apoptosis may confer a survival advantage to MALT B-cells, and constitutive NF-kappa B activation may provide both anti-apoptotic and proliferative signals mediated via its transcriptional targets.	St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Ctr Biotechnol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38163 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; MetaGen Gesell Genomforsch mbH, D-14195 Berlin, Germany; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Ctr Human Genet, Omaha, NE 68198 USA; Hanusch Hosp, Ludwig Boltzmann Inst Leukemia Res & Hematol, A-1140 Vienna, Austria; Lainz Hosp, Jakob Erdheim Inst Pathol, A-1130 Vienna, Austria; Univ Lyon 1, Ctr Hosp Lyon Sud, Hematol Lab, F-69495 Pierre Benite, France; Univ Lyon 1, Ctr Hosp Lyon Sud, Serv Hematol, F-69495 Pierre Benite, France; Univ Kiel, Dept Human Genet, D-24105 Kiel, Germany	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Roche Holding; Genentech; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Ludwig Boltzmann Institute; WGKK - Hanusch Hospital; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Kiel	Morris, SW (corresponding author), St Jude Childrens Res Hosp, Dept Pathol & Lab Med, 332 N Lauderdale St, Memphis, TN 38105 USA.		Siebert, Reiner/A-8049-2010; Salles, Gilles/Z-2336-2019; dixit, vishva m/A-4496-2012	Salles, Gilles/0000-0002-9541-8666; dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA-27165] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Lee H, 1995, Curr Top Microbiol Immunol, V194, P247; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SCHLEGELBERGER B, 1994, LEUKEMIA, V8, P72; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Siebert R, 1998, BLOOD, V91, P984, DOI 10.1182/blood.V91.3.984.984_984_990; Snow EC, 1997, CURR TOP MICROBIOL, V224, P211; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Storb U, 1998, IMMUNOL REV, V162, P5, DOI 10.1111/j.1600-065X.1998.tb01424.x; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; TILLY H, 1994, BLOOD, V84, P1043; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Willis TG, 1997, BLOOD, V90, P2456; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; WOTHERSPOON AC, 1992, CANCER GENET CYTOGEN, V58, P35, DOI 10.1016/0165-4608(92)90130-Z; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zucca E, 1998, BRIT J HAEMATOL, V100, P3, DOI 10.1046/j.1365-2141.1998.00513.x	27	312	326	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					63	68		10.1038/8767	http://dx.doi.org/10.1038/8767			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319863				2022-12-27	WOS:000080096300024
J	Torrents, D; Mykkanen, J; Pineda, M; Feliubadalo, L; Estevez, R; de Cid, R; Sanjurjo, P; Zorzano, A; Nunes, V; Huoponen, K; Reinikainen, A; Simell, O; Savontaus, ML; Aula, P; Palacin, M				Torrents, D; Mykkanen, J; Pineda, M; Feliubadalo, L; Estevez, R; de Cid, R; Sanjurjo, P; Zorzano, A; Nunes, V; Huoponen, K; Reinikainen, A; Simell, O; Savontaus, ML; Aula, P; Palacin, M			Identification of SLC7A7, encoding y(+)LAT-1, as the lysinuric protein intolerance gene	NATURE GENETICS			English	Article							HUMAN ERYTHROCYTES; TRANSPORT; CYSTINURIA; MEMBRANE	Lysinuric protein intolerance (LPI; OMIM 222700) is a rare, recessive disorder with a worldwide distribution, but with a high prevalence in the Finnish population(1); symptoms include failure to thrive, growth retardation, muscle hypotonia and hepatosplenomegaly. A defect in the plasma membrane transport of dibasic amino acids has been demonstrated at the basolateral membrane of epithelial cells in small intestine and in renal tubules(2-4) and in plasma membrane of cultured skin fibroblasts(5) from LPI patients. The gene causing LPI has been assigned by linkage analysis to 14q11-13. Here we report mutations in SLC7A7 cDNA (encoding y(+)L amino acid transporter-1, y(+)LAT-1), which expresses dibasic amino-acid transport activity and is located in the LPI region, in 31 Finnish LPI patients and 1 Spanish patient. The Finnish patients are homozygous for a founder missense mutation leading to a premature stop codon. The Spanish patient is a compound heterozygote with a missense mutation in one allele and a frameshift mutation in the other. The frameshift mutation generates a premature stop codon, eliminating the last one-third of the protein. The missense mutation abolishes y(+)LAT-1 amino-acid transport activity when co-expressed with the heavy chain of the cell-surface antigen 4F2 (4F2hc, also known as CD98) in Xenopus laevis oocytes. Our data establish that mutations in SLC7A7 cause LPI.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Turku Univ, Dept Med Genet, Turku 20520, Finland; Hosp Llobregat, Hosp Duran & Reynolds, IRO, Dept Mol Genet, Barcelona 08907, Spain; Univ Basque Country, Hosp Cruces, Dept Pediat, Baracaldo, Bizcaia, Spain; Univ Turku, Dept Biol, SF-20500 Turku, Finland; Turku Univ, Cent Hosp, Dept Pediat, Turku 20520, Finland; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki 00014, Finland	University of Barcelona; University of Turku; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; Hospital Universitario Cruces; University of Basque Country; University of Turku; University of Turku; University of Helsinki	Palacin, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	mpalacin@porthos.bio.ub.es	Nunes, Virginia/AAD-1014-2019; Feliubadalo, Lidia/G-4577-2016; Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Nunes, Virginia/D-4356-2014; Riu, Marta Pineda/I-1497-2015; de Cid, Rafael/I-4220-2015; Mykkänen, Juha/Q-1663-2015; Sanjurjo, Pablo/E-1647-2012; de cid, rafael/Q-2952-2016; Estevez, Raul/D-8610-2015; Torrents, David/G-5785-2015	Nunes, Virginia/0000-0002-5747-9310; Feliubadalo, Lidia/0000-0002-1736-0112; Nunes, Virginia/0000-0002-5747-9310; Riu, Marta Pineda/0000-0002-5403-5845; Mykkänen, Juha/0000-0001-9898-2660; de cid, rafael/0000-0003-3579-6777; Estevez, Raul/0000-0003-1579-650X; Palacin, Manuel/0000-0002-8670-293X; Torrents, David/0000-0002-6086-9037				ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CHEESEMAN CI, 1983, J PHYSIOL-LONDON, V338, P87, DOI 10.1113/jphysiol.1983.sp014662; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DESJEUX JF, 1980, J CLIN INVEST, V65, P1382, DOI 10.1172/JCI109802; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Deves R., 1998, PHYSIOL REV, V78, P478; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; GOTTESDIENER KM, 1988, MOL CELL BIOL, V8, P3809, DOI 10.1128/MCB.8.9.3809; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Lauteala T, 1998, EUR J HUM GENET, V6, P612, DOI 10.1038/sj.ejhg.5200236; Lauteala T, 1997, AM J HUM GENET, V60, P1479, DOI 10.1086/515457; Lauteala T, 1997, HUM GENET, V100, P80, DOI 10.1007/s004390050469; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peltonen L, 1995, BIOL CHEM H-S, V376, P697; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; RAJANTIE J, 1980, LANCET, V1, P1219; RAJANTIE J, 1981, J CLIN INVEST, V67, P1078, DOI 10.1172/JCI110120; SANJURJO P, 1995, AN ESP PEDIATR, V42, P219; Simell O, 1995, METAB MOL BASES INHE, V1, P3603; SMITH DW, 1987, P NATL ACAD SCI USA, V84, P7711, DOI 10.1073/pnas.84.21.7711; Sperandeo MP, 1998, GENOMICS, V49, P230, DOI 10.1006/geno.1998.5252; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437	27	214	221	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAR	1999	21	3					293	296		10.1038/6809	http://dx.doi.org/10.1038/6809			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	173JR	10080182				2022-12-27	WOS:000078977900023
J	Ueijma, H; Lee, MP; Cui, H; Feinberg, AP				Ueijma, H; Lee, MP; Cui, H; Feinberg, AP			Hot-stop PCR: a simple and general assay for linear quantitation of allele ratios	NATURE GENETICS			English	Article							COLORECTAL-CANCER; RELAXATION; TISSUE		Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Feinberg, AP (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA.		Feinberg, Andrew/AAY-7666-2020; Cui, Hengmi/A-2598-2008	Feinberg, Andrew/0000-0002-8364-1991	NCI NIH HHS [R01 CA054358] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Greenwood AD, 1996, GENOME RES, V6, P336, DOI 10.1101/gr.6.4.336; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Ohlsson R., 1995, GENOMIC IMPRINTING C; Pushnova EA, 1998, ANAL BIOCHEM, V260, P24, DOI 10.1006/abio.1998.2682; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; Yun K, 1999, J PATHOL, V187, P518, DOI 10.1002/(SICI)1096-9896(199904)187:5<518::AID-PATH276>3.0.CO;2-3; 1995, ABI PRISM DNA SEQUEN	13	81	86	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					375	376		10.1038/78040	http://dx.doi.org/10.1038/78040			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932175				2022-12-27	WOS:000088615000007
J	Forsburg, SL; Hodson, JA				Forsburg, SL; Hodson, JA			Mitotic replication initiation proteins are not required for pre-meiotic S phase	NATURE GENETICS			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-POLYMERASE-DELTA; CELL-CYCLE CONTROL; FISSION YEAST; GENE ENCODES; MEIOSIS; MITOSIS; FAMILY; KINASE; CHECKPOINT	Initiation of mitotic DNA replication in eukaryotes requires conserved factors, including Cdc18/CDC6 and minichromosome maintenance (MCM) proteins. We show here that these proteins are not essential for meiotic DNA replication or subsequent meiotic divisions in fission yeast. In addition, vegetative replication checkpoint genes are not required for the arrest of meiotic divisions in response to pre-meiotic S-phase delays. Genes essential for other aspects of vegetative DNA replication, however, including polymerases and DNA ligase, are also required for premeiotic DNA synthesis. Our results indicate that the process of replication initiation and checkpoint control may be fundamentally different in mitotic and meiotic cells.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Forsburg, SL (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	forsburg@salk.edu		Forsburg, Susan L/0000-0002-4895-8598	NIGMS NIH HHS [GM54797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; CALLAN HG, 1972, PROC R SOC SER B-BIO, V181, P19, DOI 10.1098/rspb.1972.0039; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DAYAMAKIN M, 1992, BIOCHEM CELL BIOL, V70, P1088, DOI 10.1139/o92-154; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; DURSO G, 1995, J CELL SCI, V108, P3109; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; FORSBURG SL, 1994, J CELL SCI, V107, P2779; Gould KL, 1998, GENETICS, V149, P1221; GRALLERT B, 1989, CURR GENET, V15, P231, DOI 10.1007/BF00435510; GRALLERT B, 1991, CURR GENET, V20, P199, DOI 10.1007/BF00326233; GRALLERT B, 1990, MOL GEN GENET, V222, P473, DOI 10.1007/BF00633860; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HOLLINGSWORTH RE, 1993, CHROMOSOMA, V102, P415, DOI 10.1007/BF00360406; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1995, GENETICS, V140, P1235; Iino Y, 1997, MOL GEN GENET, V254, P93, DOI 10.1007/s004380050395; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; JOHNSTON LH, 1986, GENE, V41, P321, DOI 10.1016/0378-1119(86)90114-9; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI YF, 1997, GENETICS, V146, P146; Liang DT, 1999, J CELL SCI, V112, P559; LIN YK, 1994, GENETICS, V136, P769; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NIELSEN O, 1990, EMBO J, V9, P1401, DOI 10.1002/j.1460-2075.1990.tb08255.x; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; Parker AE, 1997, MOL CELL BIOL, V17, P2381, DOI 10.1128/MCB.17.5.2381; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Snaith HA, 1999, GENETICS, V152, P839; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; Yamamoto M, 1996, TRENDS BIOCHEM SCI, V21, P18, DOI 10.1016/0968-0004(96)80880-2; You ZY, 1999, MOL CELL BIOL, V19, P8003	50	33	34	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					263	268		10.1038/77015	http://dx.doi.org/10.1038/77015			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888871				2022-12-27	WOS:000087920900011
J	Napirei, M; Karsunky, H; Zevnik, B; Stephan, H; Mannherz, HG; Moroy, T				Napirei, M; Karsunky, H; Zevnik, B; Stephan, H; Mannherz, HG; Moroy, T			Features of systemic lupus erythematosus in Dnase1-deficient mice	NATURE GENETICS			English	Article							DEOXYRIBONUCLEASE-I DNASE; AUTOANTIBODIES; TISSUES; SERUM; NEPHRITIS; APOPTOSIS	Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease that affects over one million people in the United States. SLE is characterized by the presence of anti-nuclear antibodies (ANA) directed against naked DNA and entire nucleosomes. It is thought that the resulting immune complexes accumulate in vessel walls, glomeruli and joints and cause a hypersensitivity reaction type ill, which manifests as glomerulonephritis, arthritis and general vasculitis, The aetiology of SLE is unknown, but several studies suggest that increased liberation or disturbed clearance of nuclear DNA-protein complexes after cell death may initiate and propagate the disease(1-6). Consequently, Dnase1, which is the major nuclease present in serum, urine and secreta, may be responsible for the removal of DNA from nuclear antigens at sites of high cell turnover and thus for the prevention of SLE (refs 7-11). To test this hypothesis, we have generated Dnase1-deficient mice by gene targeting. We report here that these animals show the classical symptoms of SLE. namely the presence of ANA, the deposition of immune complexes in glomeruli and full-blown glomerulonephritis in a Dnasel-dose-dependent manner. Moreover, in agreement with earlier reports(10), we found Dnase1 activities in serum to be lower in SLE patients than in normal subjects. Our findings suggest that lack or reduction of Dnase1 is a critical factor in the initiation of human SLE.	Ruhr Univ Bochum, Fak Med, Abt Anat & Embryol, D-4630 Bochum, Germany; Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-4300 Essen, Germany	Ruhr University Bochum; University of Duisburg Essen	Moroy, T (corresponding author), Ruhr Univ Bochum, Fak Med, Abt Anat & Embryol, Univ Str 150, D-4630 Bochum, Germany.	moeroey@uni-essen.de	Zevnik, Branko/AAB-7853-2020; Mannherz, Hans Georg/HHM-2867-2022; Moroy, Tarik/D-9923-2011; Stephan, Harald/AAT-6802-2021	Zevnik, Branko/0000-0001-7845-9522; Mannherz, Hans Georg/0000-0001-8158-5722				Berden JHM, 1999, CURR OPIN NEPHROL HY, V8, P299, DOI 10.1097/00041552-199905000-00005; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Carroll MC, 1998, NAT GENET, V19, P3, DOI 10.1038/ng0598-3; CHITRABAMRUNG S, 1981, RHEUMATOL INT, V1, P55, DOI 10.1007/BF00541153; Davis JC, 1999, LUPUS, V8, P68, DOI 10.1191/096120399678847380; Eilat D, 1999, IMMUNOL TODAY, V20, P339, DOI 10.1016/S0167-5699(99)01457-7; ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459; LACHMANN PJ, 1961, IMMUNOLOGY, V4, P153; LACKS SA, 1981, J BIOL CHEM, V256, P2644; Macanovic M, 1997, CLIN EXP IMMUNOL, V108, P220, DOI 10.1046/j.1365-2249.1997.3571249.x; Macanovic M, 1996, CLIN EXP IMMUNOL, V106, P243, DOI 10.1046/j.1365-2249.1996.d01-839.x; MOORE TL, 1981, SEMIN ARTHRITIS RHEU, V10, P309, DOI 10.1016/0049-0172(81)90007-X; NADANO D, 1993, CLIN CHEM, V39, P448; Peitsch M C, 1994, Cell Death Differ, V1, P1; PEITSCH MC, 1995, BIOCHEM BIOPH RES CO, V207, P62, DOI 10.1006/bbrc.1995.1153; POLZAR B, 1990, NUCLEIC ACIDS RES, V18, P7151, DOI 10.1093/nar/18.23.7151; POLZAR B, 1994, EUR J CELL BIOL, V64, P200; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; RUMORE PM, 1990, J CLIN INVEST, V86, P69, DOI 10.1172/JCI114716; Shimoda M, 1998, IMMUNOLOGY, V95, P200; Takeshita H, 1997, BIOCHEM MOL BIOL INT, V42, P65; Vanholder R, 1998, EUR J DERMATOL, V8, P4; Verthelyi D, 1998, LUPUS, V7, P223, DOI 10.1191/096120398678920037	24	614	645	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					177	181		10.1038/76032	http://dx.doi.org/10.1038/76032			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835632				2022-12-27	WOS:000087459200016
J	Evans, AL; Muller, U				Evans, AL; Muller, U			Stereocilia defects in the sensory hair cells of the inner ear in mice deficient in integrin alpha 8 beta 1	NATURE GENETICS			English	Article							KIDNEY MORPHOGENESIS; OSTEOPONTIN; EXPRESSION; DEAFNESS; REGENERATION; FIBRONECTIN; ADHESION; RECEPTOR; TENASCIN; GENES	The mammalian inner ear contains organs for the detection of sound and acceleration, the cochlea and the vestibule, respectively. Mechanosensory hair cells within the neuroepithelia of these organs transduce mechanical force generated by sound waves or head movements into neuronal signals. Defects in hair cells lead to deafness and balance defects(1-3). Hair cells have stereocilia that are indispensable for mechanosensation, but the molecular mechanisms regulating stereocilia formation are poorly understood(4-6). We show here that integrin alpha 8 beta 1, its ligand fibronectin and the integrin-regulated focal adhesion kinase (FAK) co-localize to the apical hair-cell surface where stereocilia are forming. In mice homozygous for a targeted mutation of Itga8 (encoding the alpha 8 subunit; ref. 7), this co-localization is perturbed and hair cells in the utricle, a vestibular subcompartment, lack stereocilia or contain malformed stereocilia. Most integrin-alpha 8 beta 1-deficient mice die soon after birth due to kidney defects. Many of the survivors have difficulty balancing, consistent with the structural defects of the inner ear. Our data suggest that integrin alpha 8 beta 1, and potentially other integrins, regulates hair-cell differentiation and stereocilia maturation. Mutations affecting matrix molecules cause inherited forms of inner ear disease(1-3,8) and integrins may mediate some effects of matrix molecules in the ear: thus, mutations in integrin genes may lead to inner-ear diseases as well.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Evans, AL (corresponding author), Friedrich Miescher Inst, CH-4002 Basel, Switzerland.							Corwin JT, 1998, P NATL ACAD SCI USA, V95, P12080, DOI 10.1073/pnas.95.21.12080; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; Cosgrove D, 1996, HEARING RES, V100, P21, DOI 10.1016/0378-5955(96)00114-1; Cremers FPM, 1998, CURR OPIN NEUROL, V11, P11, DOI 10.1097/00019052-199802000-00003; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Legan PK, 1997, SEMIN CELL DEV BIOL, V8, P217, DOI 10.1006/scdb.1997.0145; LIM DJ, 1985, ACTA OTO-LARYNGOL, P1; LOPEZ CA, 1995, HEARING RES, V85, P210, DOI 10.1016/0378-5955(95)00046-7; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; McGuirt WT, 1999, NAT GENET, V23, P413, DOI 10.1038/70516; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; MULLER U, 1995, MOL BIOL CELL, V6, P433; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; TAKEMURA T, 1994, HEARING RES, V79, P99, DOI 10.1016/0378-5955(94)90131-7; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Whitlon DS, 1999, J COMP NEUROL, V406, P361, DOI 10.1002/(SICI)1096-9861(19990412)406:3<361::AID-CNE5>3.0.CO;2-O; Zheng JL, 1997, J NEUROSCI, V17, P8270	26	95	97	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					424	428		10.1038/74286	http://dx.doi.org/10.1038/74286			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742111				2022-12-27	WOS:000086192800026
J	Furukawa, T; Morrow, EM; Li, TS; Davis, FC; Cepko, CL				Furukawa, T; Morrow, EM; Li, TS; Davis, FC; Cepko, CL			Retinopathy and attenuated circadian entrainment in Crx-deficient mice	NATURE GENETICS			English	Article							CONE-ROD DYSTROPHY; RDS MUTANT MICE; HOMEOBOX GENE; RETINITIS-PIGMENTOSA; TRANSGENIC MICE; OUTER SEGMENTS; MUTATIONS; PHOTORECEPTOR; EXPRESSION; DIFFERENTIATION	Crx, an Otx-like homeobox gene, is expressed specifically in the photoreceptors of the retina and the pinealocytes of the pineal gland(1,2). Crx has been proposed to have a role in the regulation of photoreceptor-specific genes in the eye and of pineal-specific genes in the pineal gland. Mutations in human CRX are associated with the retinal diseases, cone-rod dystrophy-2 (adCRD2; refs 3-5), retinitis pigmentosa(5) (RP) and Leber congenital amaurosis(5,6) (LCA), which all lead to loss of vision. We generated mice carrying a targeted disruption of Crx. Crx(-/-) mice do not elaborate photoreceptor outer segments and lacked rod and cone activity as assayed by electroretinogram (ERG). Expression of several photoreceptor- and pineal-specific genes was reduced in Crx mutants. Circadian entrainment was also affected in Crx(-/-) mice.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Northeastern University; Harvard University; Harvard Medical School	Furukawa, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX USA.	furukawa@utsw.swmed.edu; cepko@rascal.med.harvard.edu	Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520				Blackshaw S, 1997, J NEUROSCI, V17, P8074; Boatright J H, 1997, Mol Vis, V3, P15; Bovolenta P, 1997, J NEUROSCI, V17, P4243; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOXMAN SG, 1985, ARCH OPHTHALMOL-CHIC, V103, P1502; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; Grosse D, 1998, J NEUROSCI, V18, P8032; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Morrow EM, 1999, DEVELOPMENT, V126, P23; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; REUTER JH, 1984, NEUROSCI LETT, V48, P231, DOI 10.1016/0304-3940(84)90024-7; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7	27	414	422	2	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					466	470		10.1038/70591	http://dx.doi.org/10.1038/70591			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581037				2022-12-27	WOS:000084023900026
J	de Wind, N; Dekker, M; Claij, N; Jansen, L; van Klink, Y; Radman, M; Riggins, G; van der Valk, M; van 't Wout, K; Riele, HT				de Wind, N; Dekker, M; Claij, N; Jansen, L; van Klink, Y; Radman, M; Riggins, G; van der Valk, M; van 't Wout, K; Riele, HT			HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and MSh6 mismatch-repair protein functions	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; TUMOR-CELLS; GENE; MUTATION; RECOMBINATION; DEFICIENCY; HYPERMUTABILITY; HETERODIMER; HOMOLOG		Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; Univ Paris 05, Fac Med Necker, INSERM, E9916, Paris, France; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Netherlands Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Duke University	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.		jansen, leon/W-9159-2019	Radman, Miroslav/0000-0002-7034-4365				Akiyama Y, 1997, CANCER RES, V57, P3920; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Reitmair AH, 1996, CANCER RES, V56, P3842; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SELVA EM, 1995, GENETICS, V139, P1175; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; Umar A, 1998, GENETICS, V148, P1637; Umar A, 1997, CANCER RES, V57, P3949	28	174	175	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					359	362		10.1038/15544	http://dx.doi.org/10.1038/15544			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545954				2022-12-27	WOS:000083792200029
J	Wallis, DE; Roessler, E; Hehr, U; Nanni, L; Wiltshire, T; Richieri-Costa, A; Gillessen-Kaesbach, G; Zackai, EH; Rommens, J; Muenke, M				Wallis, DE; Roessler, E; Hehr, U; Nanni, L; Wiltshire, T; Richieri-Costa, A; Gillessen-Kaesbach, G; Zackai, EH; Rommens, J; Muenke, M			Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly	NATURE GENETICS			English	Article							SINE OCULIS; VISUAL-SYSTEM; PERSPECTIVES; EXPRESSION	Holoprosencephaly (HPE) is a common, severe malformation of the brain that involves separation of the central nervous system into left and right halves. Mild HPE can consist of signs such as a single central incisor, hypotelorism microcephaly, or other craniofacial findings that can be present with or without associated brain malformations(1-3). The aetiology of HPE is extremely:heterogeneous, with the proposed participation of a minimum of 12 HPE-associated genetic loci as well as the:causal. involvement of specific teratogens acting: at the earliest stages of neurulation(4). The HPE2 locus was recently characterized as a 1-Mb interval on human chromosome 2p21 that contained a gene associated with HPE: A minimal critical region was defined by a set of six overlapping deletions and three clustered translocations in HPE patients(5). We:describe here the isolation and characterization of the human homeobox-containing SIX3 gene from the HPE2 minimal critical region (MCR). We show that at least 2 of the HPE-associated translocation :breakpoints in 2p21 are less than 200 kb from the 5' end of SIX3. Mutational analysis has identified four different mutations in the homeodomain of SIX3 that are predicted to interfere with transcriptional activation and are associated with HPE, We propose that SIX3 is the HPE2 gene, essential for the development of the anterior neural plate and eye in humans.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Halle Wittenberg, Dept Human Genet, Halle, Germany; Univ Sao Paulo, Dept Clin Genet, Bauru, SP, Brazil; Univ Essen Gesamthsch, Dept Human Genet, Essen, Germany; Univ Toronto, Hosp Sick Children, Dept Genet, Program Genet & Genomic Biol, Toronto, ON M5G 1X8, Canada	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Martin Luther University Halle Wittenberg; Universidade de Sao Paulo; University of Duisburg Essen; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Muenke, M (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.	mmuenke@nhgri.nih.gov	Richieri-Costa, Antonio/B-2514-2013	Muenke, Maximilian/0000-0002-7719-6545	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD028732, R01HD029862] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29862, HD28732] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOVOLENTA P, 1996, INT J DEV BIOL S, V1, P738; BUCAN M, 1990, GENOMICS, V6, P1; BURGLIN TR, 1995, BIODIVERSITY EVOLUTI, P291; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; COHEN MM, 1992, J CRAN GENET DEV BIO, V12, P196; COHEN MM, 1989, TERATOLOGY, V40, P211, DOI 10.1002/tera.1420400304; COHEN MM, 1989, AM J MED GENET, V34, P271, DOI 10.1002/ajmg.1320340232; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Loosli F, 1998, MECH DEVELOP, V74, P159, DOI 10.1016/S0925-4773(98)00055-0; Oliver G, 1995, DEVELOPMENT, V121, P4045; Roessler E, 1998, J INHERIT METAB DIS, V21, P481, DOI 10.1023/A:1005406719292; Schell U, 1996, HUM MOL GENET, V5, P223, DOI 10.1093/hmg/5.2.223; Seo HC, 1998, MECH DEVELOP, V73, P45, DOI 10.1016/S0925-4773(98)00028-8; SERIKAKU MA, 1994, GENETICS, V138, P1137; Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; Zuber ME, 1997, DEV BIOL, V186, pB20	20	217	221	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					196	198		10.1038/9718	http://dx.doi.org/10.1038/9718			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369266				2022-12-27	WOS:000080680900029
J	Bi, WM; Deng, JM; Zhang, ZP; Behringer, RR; de Crombrugghe, B				Bi, WM; Deng, JM; Zhang, ZP; Behringer, RR; de Crombrugghe, B			Sox9 is required for cartilage formation	NATURE GENETICS			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CHONDROCYTE-SPECIFIC ENHANCER; COLLAGEN MESSENGER-RNAS; IN-SITU HYBRIDIZATION; CAMPOMELIC DYSPLASIA; SKELETAL DEVELOPMENT; HERITABLE DISEASES; MOLECULAR INSIGHTS; II COLLAGEN	Chondrogenesis results in the formation of cartilages, initial skeletal elements that can serve as templates for endochondral hone formation. Cartilage formation begins with the condensation of mesenchyme cells followed by their differentiation into chondrocytes, Although much is known about the terminal differentiation products that are expressed by chondrocytes(1-3), little is known about the factors that specify the chondrocyte lineage(4-6). SOX9 is a high-mobility-group (HMG) domain transcription factor that is expressed in chondrocytes and other tissues(7-12). In humans, SOX9 haploinsufficiency results in sues campomelic dysplasia, a lethal skeletal malformation syndrome, and XY sex reversal(7,13-16). During embryogenesis, Sox9 is expressed in all cartilage primordia and cartilages, coincident with the expression of the collagen alpha 1(II) gene (Col2a1; refs 8,11,12), Sox9 is also expressed in other tissues, including the central nervous and urogenital systems(8-12). Sox9 binds to essential sequences in the Col2a1 and collagen alpha 2(XI) gene (Col11a2) chondrocyte-specific enhancers and can activate these enhancers in non-chondrocytic cells(17-19). Here, Sox9 is identified as a regulator of the chondrocyte lineage. In mouse chimaeras, Sox9(-/-) cells are excluded from all cartilages but are present as a juxtaposed mesenchyme that does not express the chondrocyte-specific markers Col2a1, Col9a2, Col11a2 and Age. This exclusion occurred cell autonomously at the condensing mesenchyme stage of chondrogenesis, Moreover, no cartilage developed in teratomas derived from Sox9(-/-) embryonic stem (ES) cells. Our results identify Sox9 as the first transcription factor that is essential for chondrocyte differentiation and cartilage formation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	bhr@molgen.mdacc.tmc.edu; benoit_decrombrugghe@molgen.mdacc.tmc.edu			NIAMS NIH HHS [AR42919] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abuin A, 1996, MOL CELL BIOL, V16, P1851; [Anonymous], 1991, CARTILAGE MOL ASPECT; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GLUMOFF V, 1994, BBA-GENE STRUCT EXPR, V1219, P613, DOI 10.1016/0167-4781(94)90220-8; Hogan B, 1994, MANIPULATING MOUSE E; HOVMOLLER ML, 1977, HEREDITAS, V86, P51; Kent J, 1996, DEVELOPMENT, V122, P2813; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; METSARANTA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P241, DOI 10.1016/0167-4781(91)90014-D; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Robertson E. J., 1987, TERATOCARCINOMAS EMB; STOCKWELL RA, 1979, BIOL CARTILAGE CELLS; TAKAHASHI H, 1992, J LARYNGOL OTOL, V106, P361, DOI 10.1017/S0022215100119504; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	30	1300	1350	1	115	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					85	89		10.1038/8792	http://dx.doi.org/10.1038/8792			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319868				2022-12-27	WOS:000080096300029
J	Niederreither, K; Subbarayan, V; Dolle, P; Chambon, P				Niederreither, K; Subbarayan, V; Dolle, P; Chambon, P			Embryonic retinoic acid synthesis is essential for early mouse post-implantation development	NATURE GENETICS			English	Article							HEART DEVELOPMENT; NERVOUS-SYSTEM; HENSEN NODE; EXPRESSION; DEHYDROGENASE; GENE; IDENTIFICATION; RECEPTORS; PATTERNS	A number of studies have suggested that the active derivative of vitamin A, retinoic acid (RA), may be important for early development of mammalian embryos(1,2). Severe vitamin A deprivation in rodents results in maternal infertility(3), precluding a thorough investigation of the role of RA during embryogenesis, Here we show that production of RA by the retinaldehyde dehydrogenase-2 (Raldh2) enzyme(4,5) is required for mouse embryo survival and early morphogenesis. Raldh2 is an HAD-dependent aldehyde dehydrogenase with high substrate specificity for retinaldehyde(4,5). Its pattern of expression during mouse development has suggested that it may be responsible for embryonic RA synthesis(4,6). We generated a targeted disruption of the mouse Raldh2 gene and found that Raldh2(-/-) embryos, which die at midgestation without undergoing axial rotation (body turning), exhibit shortening along the anterioposterior axis and do not form limb buds. Their heart consists of a single, medial, dilated cavity. Their frontonasal region is truncated and their otocysts are severely reduced. These defects result from a block in embryonic RA synthesis, as shown by the lack of activity of RA-responsive transgenes, the altered expression of an RA-target homeobox gene and the near full rescue of the mutant phenotype by maternal RA administration, Our data establish that RA synthesized by the post-implantation mammalian embryo is an essential developmental hormone whose lack leads to early embryo death.	ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090				Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Ang HL, 1997, DEV DYNAM, V208, P536; ANG SL, 1994, DEVELOPMENT, V120, P2979; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Blumberg B, 1997, SEMIN CELL DEV BIOL, V8, P417, DOI 10.1006/scdb.1997.0165; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CONLON RA, 1995, TRENDS GENET, V11, P314, DOI 10.1016/S0168-9525(00)89089-7; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Dierich A, 1997, METHODS IN DEVELOPMENTAL TOXICOLOGY AND BIOLOGY, P111; DUPE V, 1997, DEVELOPMENT, V124, P339; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; Maden M, 1998, DEVELOPMENT, V125, P4133; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Moss JB, 1998, DEV BIOL, V199, P55, DOI 10.1006/dbio.1998.8911; Neela J, 1997, NATL MED J INDIA, V10, P15; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; TWAL W, 1995, DEV BIOL, V168, P225, DOI 10.1006/dbio.1995.1075; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	29	821	848	1	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					444	448		10.1038/7788	http://dx.doi.org/10.1038/7788			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192400				2022-12-27	WOS:000079439700031
J	Yasunaga, S; Grati, M; Cohen-Salmon, M; El-Amraoui, A; Mustapha, M; Salem, N; El-Zir, E; Loiselet, J; Petit, C				Yasunaga, S; Grati, M; Cohen-Salmon, M; El-Amraoui, A; Mustapha, M; Salem, N; El-Zir, E; Loiselet, J; Petit, C			A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness	NATURE GENETICS			English	Article							MYOSIN-VIIA GENE; RECESSIVE DEAFNESS; C-2-DOMAIN PROTEINS; VESICLE FUSION; HAIR-CELLS; C-2 DOMAIN; SYNAPTOTAGMIN; RABPHILIN-3A; JERVELL; BINDING	Using a candidate gene approach, we identified a novel human gene, OTOF, underlying an autosomal recessive, nonsyndromic prelingual deafness, DFNB9. The same nonsense mutation was detected in four unrelated affected families of Lebanese origin. OTOF is the second member of a mammalian gene family related to Caenorhabditis elegans fer-1. It encodes a predicted cytosolic protein (of 1,230 aa) with three C2 domains and a single carboxy-terminal transmembrane domain. The sequence homologies and predicted structure of otoferlin, the protein encoded by OTOF, suggest its involvement in vesicle membrane fusion. In the inner ear, the expression of the orthologous mouse gene, mainly in the sensory hair cells, indicates that such a role could apply to synaptic vesicles.	Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; St Josephs Univ, Fac Med, Biochim Lab, Beyrouth, Lebanon; Hop Sacre Coeur, Clin Audiol, Baabda, Brazilia, Lebanon	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Saint Joseph University Beirut	Petit, C (corresponding author), Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.		Grati, M'hamed/C-9563-2011	EL-AMRAOUI, Aziz/0000-0003-2692-4984; Grati, M'hamed/0000-0002-4490-1682; Cohen-Salmon, Martine/0000-0002-5312-8476; Grati, Mhamed/0000-0001-5149-3245; Petit, Christine/0000-0002-9069-002X				Achanzar WE, 1997, J CELL SCI, V110, P1073; Avraham KB, 1998, NAT MED, V4, P1238, DOI 10.1038/3215; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Chaib H, 1996, HUM MOL GENET, V5, P155, DOI 10.1093/hmg/5.1.155; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Leal SM, 1998, EUR J HUM GENET, V6, P341, DOI 10.1038/sj.ejhg.5200201; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Richardson GP, 1997, J NEUROSCI, V17, P9506; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SAFIEDDINE S, IN PRESS EUR J NEURO; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; SCOTT DA, 1998, MOL BIOL HEARING DEA, P63; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Spicer SS, 1998, HEARING RES, V118, P1, DOI 10.1016/S0378-5955(98)00006-9; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Xiang MQ, 1998, DEVELOPMENT, V125, P3935; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	49	372	409	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	1999	21	4					363	369		10.1038/7693	http://dx.doi.org/10.1038/7693			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	181KC	10192385				2022-12-27	WOS:000079439700016
